element;nb occurence;name of data element;name of the grouping item;name of registry;explanatory description;list of permitted values
12;8;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
12;8;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
12;8;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
12;8;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
12;8;R_PSC_not_in_db312;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
12;8;R_PSC_not_in_db123;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
12;8;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
12;8;R_AIH_not_in_db123;AIH Follow-up Outcome II;Rare Liver (Auto imune);Calculate Nakanuma grading?;calculation
14;3;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
14;3;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
14;3;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
17,2;2;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
17,2;2;Isolated 17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated 17,20 lyase deficiency;
janv-50;1;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
01-fŽvr;1;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
05-aožt;1;EMS 5-8;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;EMS 5-8;
>/=;1;EMS >/= 9;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;EMS >/= 9;
Âµmol/l;1;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
02ml;4;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
02ml;4;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
02ml;4;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
02ml;4;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
11b-hydroxylase;5;11b-hydroxylase def (CYP11B1);ADRENAL;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
11b-hydroxylase;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
11b-hydroxylase;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
11b-hydroxylase;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
11b-hydroxylase;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
11p15;6;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
11p15;6;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
11p15;6;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
11p15;6;Beckwith-Wiedemann syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microduplication;
11p15;6;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
11p15;6;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
12months;1;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
14q32.2;2;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
14q32.2;2;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
15q;7;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
15q;7;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
15q;7;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
15q;7;15q overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;15q overgrowth syndrome;
15q;7;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
15q;7;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
15q;7;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
15q11q13;6;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
15q11q13;6;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
15q11q13;6;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
15q11q13;6;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
15q11q13;6;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
15q11q13;6;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
16p11.2;1;Distal 16p11.2 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Distal 16p11.2 microdeletion syndrome;
16p13.3;1;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
17a-hydroxylase/17,20;1;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
17b-hsd;1;17b-HSD def (HSD17B3);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;17b-HSD def (HSD17B3);
1a;13;21-hydroxylase def (CYP21A);ADRENAL;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
1a;13;P450 scc def (CYP11A1);ADRENAL;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
1a;13;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
1a;13;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
1a;13;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
1a;13;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
1a;13;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
1a;13;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
1a;13;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
1a;13;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
1a;13;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
1a;13;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
1a;13;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
1b;7;11b-hydroxylase def (CYP11B1);ADRENAL;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
1b;7;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
1b;7;HNF1B-MODY5;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1B-MODY5;
1b;7;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
1b;7;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
1b;7;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
1b;7;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
1c;3;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
1c;3;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
1c;3;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
21-hydroxylase;5;21-hydroxylase def (CYP21A);ADRENAL;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
21-hydroxylase;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
21-hydroxylase;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
21-hydroxylase;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
21-hydroxylase;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
24-hr;1;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
24h;1;dia_lab_urine_na_24h;Diagnosis Laboratory data;Rare Liver (Vascular);urine sodium value - 24 hour;numeric
2a;2;EIF2AK3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;EIF2AK3;
2a;2;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
2b;3;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
2b;3;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
2b;3;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
2e;1;(If yes, answer questionÂ 2e);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Tick-box, multiple selection]
2q37;1;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
3-hydroxylacyl-coa;1;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
3b-hsd;4;3b-HSD def (HSD3B2);ADRENAL;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
3b-hsd;4;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
3b-hsd;4;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
3b-hsd;4;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
45,x;2;45,X;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;45,X;
45,x;2;45,X/46,XY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;45,X/46,XY;
45,x/46,xy;1;45,X/46,XY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;45,X/46,XY;
45Â°;3;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
45Â°;3;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
45Â°;3;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
45Â°,;1;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
46,xx/46,xy;1;46,XX/46,XY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;46,XX/46,XY;
47,xxy;1;47,XXY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;47,XXY;
48,xxxy;1;48,XXXY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;48,XXXY;
48,xxyy;1;48,XXYY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;48,XXYY;
49,xxxxy;1;49,XXXXY;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;49,XXXXY;
4d;8;radio_photons_4d;radiotherapy;EURACAN;Photons 4D treatment;1, Yes | 2, No
4d;8;radio_electrons_4d;radiotherapy;EURACAN;Electrons 4D treatment;1, Yes | 2, No
4d;8;radio_protons_4d;radiotherapy;EURACAN;Protons 4D treatment;1, Yes | 2, No
4d;8;radio_carbons_4d;radiotherapy;EURACAN;Carbons 4D treatment;1, Yes | 2, No
4d;8;radio_brachy_4d;radiotherapy;EURACAN;Brachytherapy 4D treatment;1, Yes | 2, No
4d;8;radio_radionuc_4d;radiotherapy;EURACAN;Radionuclide 4D treatment;1, Yes | 2, No
4d;8;radio_boron_4d;radiotherapy;EURACAN;Boron neutron capture therapy 4D treatment;1, Yes | 2, No
4d;8;radio_others_4d;radiotherapy;EURACAN;Others 4D treatment;1, Yes | 2, No
4oz;1;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
5a-reductase;1;5a-reductase def (SRD5A2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;5a-reductase def (SRD5A2);
6mo;115;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
6mo;115;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
6mo;115;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
6mo;115;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
6mo;115;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
6mo;115;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
6mo;115;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
6mo;115;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
6mo;115;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
6mo;115;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
6mo;115;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
6mo;115;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
6mo;115;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
6mo;115;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
6mo;115;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
6mo;115;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
6mo;115;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
6mo;115;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6mo;115;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6mo;115;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
6mo;115;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6mo;115;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6mo;115;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
6mo;115;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6mo;115;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6mo;115;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
6mo;115;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6mo;115;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6mo;115;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
6mo;115;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6mo;115;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6mo;115;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
6mo;115;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6mo;115;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6mo;115;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
6mo;115;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
6mo;115;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
6mo;115;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
6mo;115;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
6mo;115;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
6mo;115;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
6mo;115;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
6mo;115;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
6mo;115;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
6mo;115;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
6mo;115;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
6mo;115;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
6mo;115;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
6mo;115;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
6mo;115;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
6mo;115;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
6mo;115;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
6mo;115;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
6mo;115;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
6mo;115;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
6mo;115;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
6mo;115;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
6mo;115;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
6mo;115;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
6mo;115;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
6mo;115;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
6mo;115;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6mo;115;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
6mo;115;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
6mo;115;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
6mo;115;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
6mo;115;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
6mo;115;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
6mo;115;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
6mo;115;date_check_6mo;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);date_check_6mo;calculation
6mo;115;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
6mo;115;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
6mo;115;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
6mo;115;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
6mo;115;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
6mo;115;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
6mo;115;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
6mo;115;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
6mo;115;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
6mo;115;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
6mo;115;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
6mo;115;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
6mo;115;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
6mo;115;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
6mo;115;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
6mo;115;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
6mo;115;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
6mo;115;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
6mo;115;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
6mo;115;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
6mo;115;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
6mo;115;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
6mo;115;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
6mo;115;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
6mo;115;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
6mo;115;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
6mo;115;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
6mo;115;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
6mo;115;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
6mo;115;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
6mo;115;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
6mo;115;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
6mo;115;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
6mons;1;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
6months;113;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
6months;113;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
6months;113;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
6months;113;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
6months;113;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
6months;113;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
6months;113;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
6months;113;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
6months;113;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
6months;113;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
6months;113;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
6months;113;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
6months;113;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
6months;113;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
6months;113;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
6months;113;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
6months;113;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
6months;113;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6months;113;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6months;113;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
6months;113;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6months;113;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6months;113;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
6months;113;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6months;113;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6months;113;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
6months;113;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6months;113;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6months;113;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
6months;113;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6months;113;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6months;113;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
6months;113;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
6months;113;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
6months;113;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
6months;113;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
6months;113;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
6months;113;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
6months;113;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
6months;113;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
6months;113;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
6months;113;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
6months;113;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
6months;113;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
6months;113;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
6months;113;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
6months;113;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
6months;113;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
6months;113;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
6months;113;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
6months;113;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
6months;113;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
6months;113;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
6months;113;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
6months;113;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
6months;113;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
6months;113;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
6months;113;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
6months;113;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
6months;113;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
6months;113;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
6months;113;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
6months;113;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
6months;113;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
6months;113;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
6months;113;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
6months;113;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
6months;113;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
6months;113;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
6months;113;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
6months;113;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
6months;113;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
6months;113;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
6months;113;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
6months;113;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
6months;113;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
6months;113;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
6months;113;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
6months;113;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
6months;113;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
6months;113;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
6months;113;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
6months;113;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
6months;113;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
6months;113;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
6months;113;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
6months;113;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
6months;113;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
6months;113;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
6months;113;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
6months;113;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
6months;113;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
6months;113;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
6months;113;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
6months;113;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
6months;113;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
6months;113;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
6months;113;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
6months;113;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
6months;113;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
6months;113;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
6q16;2;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
6q16;2;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
6q24;1;6q24;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;6q24;
7p11.2p13;1;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
90Â°;2;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
90Â°;2;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
a.biopsy;1;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
a.cmv;1;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
a.induction;1;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
a.performed;2;a.Performed;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
a.performed;2;a.Performed;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
a.type;11;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
a.type;11;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
a.type;11;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
a.type;11;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
a.type;11;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
a.type;11;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
a.type;11;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
a.type;11;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
a.type;11;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
a.type;11;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
a.type;11;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
abcc8;2;ABCC8;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;ABCC8;
abcc8;2;ABCC8;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;ABCC8;
abd;34;abdominal_pain;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Abdominal pain;radio
abd;34;abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal trauma;radio
abd;34;date_abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal trauma;date
abd;34;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
abd;34;abd_intervention_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of procedure;date
abd;34;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
abd;34;abd_interv_splen;Diagnosis Aetiology;Rare Liver (Vascular);Splenectomy;radio
abd;34;abd_interv_splen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Splenectomy;date
abd;34;abd_interv_chol;Diagnosis Aetiology;Rare Liver (Vascular);Cholecystectomy;radio
abd;34;abd_interv_chol_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Cholecystectomy;date
abd;34;abd_interv_hep;Diagnosis Aetiology;Rare Liver (Vascular);Hepatobiliary Surgery;radio
abd;34;abd_interv_hep_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Hepabiliary Surgery;date
abd;34;abd_interv_tips;Diagnosis Aetiology;Rare Liver (Vascular);TIPS;radio
abd;34;abd_interv_tips_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of TIPS;date
abd;34;abd_interv_sclero;Diagnosis Aetiology;Rare Liver (Vascular);Sclerotherapy;radio
abd;34;abd_interv_sclero_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Sclerotherapy;date
abd;34;abd_interv_ltx;Diagnosis Aetiology;Rare Liver (Vascular);LTx;radio
abd;34;abd_interv_ltx_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of LTx;date
abd;34;abd_interv_other;Diagnosis Aetiology;Rare Liver (Vascular);Other;radio
abd;34;abd_interv_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Intervention;date
abd;34;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
abd;34;abd_inflammation_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal infection/inflamation;date
abd;34;abd_inflammation_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of abdominal infection/inflamation;textarea
abd;34;abdom_infect_panc;Diagnosis Aetiology;Rare Liver (Vascular);Pancreatitis;radio
abd;34;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
abd;34;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
abd;34;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
abd;34;abdom_infect_appen;Diagnosis Aetiology;Rare Liver (Vascular);Appendicitis;radio
abd;34;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
abd;34;abdom_infect_other;Diagnosis Aetiology;Rare Liver (Vascular);Other Infection / Inflammation;radio
abd;34;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
abd;34;extra_abdom_infect_inflam;Diagnosis Aetiology;Rare Liver (Vascular);Extra-abdominal infection/inflamation;radio
abd;34;extra_abd_inflam_date;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
abd;34;extra_abd_inflam_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
abdom;14;abdominal_pain;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Abdominal pain;radio
abdom;14;abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal trauma;radio
abdom;14;date_abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal trauma;date
abdom;14;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
abdom;14;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
abdom;14;abdom_infect_panc;Diagnosis Aetiology;Rare Liver (Vascular);Pancreatitis;radio
abdom;14;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
abdom;14;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
abdom;14;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
abdom;14;abdom_infect_appen;Diagnosis Aetiology;Rare Liver (Vascular);Appendicitis;radio
abdom;14;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
abdom;14;abdom_infect_other;Diagnosis Aetiology;Rare Liver (Vascular);Other Infection / Inflammation;radio
abdom;14;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
abdom;14;extra_abdom_infect_inflam;Diagnosis Aetiology;Rare Liver (Vascular);Extra-abdominal infection/inflamation;radio
abdominal;4;abdominal_pain;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Abdominal pain;radio
abdominal;4;abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal trauma;radio
abdominal;4;date_abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal trauma;date
abdominal;4;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
abnorm;12;EMG abnormality;Diagnosis EMG;EURO-NMD;;single
abnorm;12;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
abnorm;12;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
abnorm;12;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
abnorm;12;hv_abnorm_doppl_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal Doppler flow pattern in more than one large vein;radio
abnorm;12;pc_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time at testing;radio
abnorm;12;ps_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
abnorm;12;at_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
abnorm;12;Phenotypic Abnormality (HPO);;ithaca;;mref
abnorm;12;Molecular abnormalities  ;Pathology;PaedCan;Molecular abnormalities detected in the tumor tissue;yes/no/unknown
abnorm;12;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
abnorm;12;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
abnormal;11;EMG abnormality;Diagnosis EMG;EURO-NMD;;single
abnormal;11;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
abnormal;11;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
abnormal;11;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
abnormal;11;pc_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time at testing;radio
abnormal;11;ps_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
abnormal;11;at_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
abnormal;11;Phenotypic Abnormality (HPO);;ithaca;;mref
abnormal;11;Molecular abnormalities  ;Pathology;PaedCan;Molecular abnormalities detected in the tumor tissue;yes/no/unknown
abnormal;11;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
abnormal;11;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
abnormalities;2;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
abnormalities;2;Molecular abnormalities  ;Pathology;PaedCan;Molecular abnormalities detected in the tumor tissue;yes/no/unknown
abnormality;5;EMG abnormality;Diagnosis EMG;EURO-NMD;;single
abnormality;5;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
abnormality;5;Phenotypic Abnormality (HPO);;ithaca;;mref
abnormality;5;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
abnormality;5;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
abornalities;1;Specify the genetic abornalities found;Patient's history;PaedCan;;String
abortio;1;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
about;1;Please give more details about the treatment of the event;Events;PaedCan;;String
acanthosis;1;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
access;1;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
according;1;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
account;1;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
ace;11;Exacerbation;Diagnosis Fluctuation;EURO-NMD;Exacerbation with infection;yesno
ace;11;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
ace;11;ace_level;Diagnosis Aetiology;Rare Liver (Vascular);Angiotensin-converting enzyme level;numeric
ace;11;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
ace;11;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
ace;11;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
ace;11;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
ace;11;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
ace;11;"e.	Placement: 	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
ace;11;Place of birth;Personal Information;PaedCan;Patient's town of birth;String
ace;11;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
achondroplasia;2;Pseudoachondroplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Pseudoachondroplasia ;
achondroplasia;2;Achondroplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Achondroplasia ;
achr;4;Achromatopsia;Diagnosis ;EURO-NMD;;single
achr;4;Achromatopsia Titer;Diagnosis ;EURO-NMD;;
achr;4;AChR (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
achr;4;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
achromatopsia;2;Achromatopsia;Diagnosis ;EURO-NMD;;single
achromatopsia;2;Achromatopsia Titer;Diagnosis ;EURO-NMD;;
acquired;5;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
acquired;5;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
acquired;5;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
acquired;5;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
acquired;5;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
acroscyphodysplasia;1;Metaphyseal acroscyphodysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal acroscyphodysplasia;
act;92;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
act;92;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
act;92;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
act;92;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
act;92;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
act;92;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
act;92;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
act;92;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
act;92;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
act;92;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
act;92;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
act;92;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
act;92;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
act;92;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
act;92;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
act;92;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
act;92;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
act;92;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
act;92;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
act;92;prot_c_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein C deficiency activity;numeric
act;92;prot_s_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein S decreased activity?;radio
act;92;factor_x;Diagnosis Aetiology;Rare Liver (Vascular);factor X;numeric
act;92;factor_ii;Diagnosis Aetiology;Rare Liver (Vascular);factor II;numeric
act;92;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
act;92;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
act;92;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
act;92;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
act;92;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
act;92;dia_lab_factor_v;Diagnosis Laboratory data;Rare Liver (Vascular);Factor V;numeric
act;92;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
act;92;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
act;92;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
act;92;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
act;92;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
act;92;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
act;92;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
act;92;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
act;92;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
act;92;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
act;92;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
act;92;Phenotypical Characteristics;subject;Genturis;;compound
act;92;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
act;92;ERN/HCP main contact;;ithaca;;mref
act;92;ERN/HCP other contactperson (s);;ithaca;;mref
act;92;Consent to be contacted for research;;ithaca;;bool
act;92;Retractation for biobank use;;ithaca;;bool
act;92;Date of retractation;;ithaca;;date
act;92;Retractation for reuse;;ithaca;;bool
act;92;Date of retractation;;ithaca;;date
act;92;Retractation to be contacted for research;;ithaca;;bool
act;92;Date of retractation;;ithaca;;date
act;92;First Contact date;;ithaca;;date
act;92;Active Ingredient (ATC);;ithaca;;mref
act;92;Active Ingredient (ATC);;ithaca;;mref
act;92;first_contact_date;patient_management_at_the_hospital;EURACAN;Date of first contact with the hospital/registration start;DD-MM-YYYY Format
act;92;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
act;92;radio_photons_fractdose;radiotherapy;EURACAN;Photons dose per fraction;
act;92;radio_photons_nrfract;radiotherapy;EURACAN;Photons number fraction;
act;92;radio_electrons_fractdose;radiotherapy;EURACAN;Electrons dose per fraction;
act;92;radio_electrons_nrfract;radiotherapy;EURACAN;Electrons number fraction;
act;92;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
act;92;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
act;92;radio_carbons_fractdose;radiotherapy;EURACAN;Carbons dose per fraction ;
act;92;radio_carbons_nrfract;radiotherapy;EURACAN;Carbons number fraction ;
act;92;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
act;92;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
act;92;radio_radionuc_fractdose;radiotherapy;EURACAN;Radionuclide dose per fraction ;
act;92;radio_radionuc_nrfract;radiotherapy;EURACAN;Radionuclide number fraction ;
act;92;radio_boron_fractdose;radiotherapy;EURACAN;Boron neutron capture therapy dose per fraction ;
act;92;radio_boron_nrfract;radiotherapy;EURACAN;Boron neutron capture therapy number fraction ;
act;92;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
act;92;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
act;92;To be contacted;Informed consent;PaedCan;Definition whether consent to be contacted was obtained;yes/no
act;92;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
act;92;First Contact with Centre;Care Pathway;EuRR-Bone & EuRRECa;Month and year of first contact with notifying centre;dd/mm/yyyy
act;92;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
act;92;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
act;92;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
act;92;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
act;92;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
act;92;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
act;92;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
act;92;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
act;92;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
act;92;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
act;92;Prolactinoma;PITUITARY;EuRR-Bone & EuRRECa;Prolactinoma;
act;92;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
act;92;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
act;92;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
act;92;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
act;92;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
act;92;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
acth;3;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
acth;3;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
acth;3;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
acth-independent;2;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
acth-independent;2;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
action;4;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
action;4;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
action;4;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
action;4;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
activity;13;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
activity;13;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
activity;13;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
activity;13;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
activity;13;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
activity;13;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
activity;13;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
activity;13;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
activity;13;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
activity;13;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
activity;13;prot_c_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein C deficiency activity;numeric
activity;13;prot_s_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein S decreased activity?;radio
activity;13;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
acute;2;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
acute;2;fu_acute_renal_failure;Follow-up Complications;Rare Liver (Vascular);Acute renal failure;radio
acvhc;1;acvhc;Diagnosis Clinical Manifestations;Rare Liver (Vascular);AC VHC;radio
adalimumab;8;R_PSC_Adalimumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Adalimumab;radio
adalimumab;8;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
adalimumab;8;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
adalimumab;8;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
adalimumab;8;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
adalimumab;8;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
adalimumab;8;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
adalimumab;8;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
adaptive;8;radio_photons_adaptive;radiotherapy;EURACAN;Photons adaptive RT;1, Yes | 2, No
adaptive;8;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
adaptive;8;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
adaptive;8;radio_carbons_adaptive;radiotherapy;EURACAN;Carbons adaptive RT;1, Yes | 2, No
adaptive;8;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
adaptive;8;radio_radionuc_adaptive;radiotherapy;EURACAN;Radionuclide adaptive RT;1, Yes | 2, No
adaptive;8;radio_boron_adaptive;radiotherapy;EURACAN;Boron neutron capture therapy adaptive RT;1, Yes | 2, No
adaptive;8;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
add;26;R_AIH_Additional_nafld;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
add;26;R_AIH_Additional_nash;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
add;26;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
add;26;R_PBC_Additional_nafld;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
add;26;R_PBC_Additional_nash;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
add;26;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
add;26;R_PSC_Additional_nafld;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
add;26;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
add;26;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
add;26;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
add;26;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
add;26;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
add;26;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
add;26;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
add;26;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
add;26;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
add;26;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
add;26;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
add;26;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
add;26;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
add;26;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
add;26;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
add;26;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
add;26;Address;;ithaca;;string
add;26;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
add;26;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
additional;18;R_AIH_Additional_nafld;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
additional;18;R_AIH_Additional_nash;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
additional;18;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
additional;18;R_PBC_Additional_nafld;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
additional;18;R_PBC_Additional_nash;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
additional;18;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
additional;18;R_PSC_Additional_nafld;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
additional;18;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
additional;18;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
additional;18;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
additional;18;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
additional;18;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
additional;18;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
additional;18;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
additional;18;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
additional;18;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
additional;18;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
additional;18;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
adenocarcinoma;1;site_adenocarcinoma;primary_cancer;EURACAN;Adenocarcinoma subtype;1, Intestinal-type adenocarcinoma | 8144/3 | 2, Non-intestinal-type adenocarcinoma  (adk, NOS) | 8140/3 | 3, Nasopharyngeal papillary adenocarcinoma | 8260/3 | 4, Adenoid cystic carcinoma | 8200/3 | 5, Mucoepidermoid carcinoma | 8430/3 | 6, Polymorphous adenocarcinoma | 8525/3 | 7, Acinic cell carcinoma | 8550/3 | 8, Clear cell carcinoma | 8310/3 | 9, Basal cell adenocarcinoma | 8147/3 | 10, Salivary duct carcinoma | 8500/3 | 11, Myoepithelial carcinoma |8982/3 | 12, Epithelial-myoepithelial carcinoma | 8562/3 | 13, Carcinoma ex pleomorphic adenoma | 8941/3 | 14, Secretory carcinoma | 8542/3 | 15, Sebaceous adenocarcinoma | 8410/3 | 16, Carcinosarcoma | 8980/3 | 17, Oncocytic carcinoma | 8290/3 | 18, Adenocarcinoma | 8420/3
adenoma;10;Familial parathyroid adenoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial parathyroid adenoma;
adenoma;10;Pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Pituitary adenoma;
adenoma;10;Familial isolated pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Familial isolated pituitary adenoma;
adenoma;10;Functioning gonadotropic adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning gonadotropic adenoma;
adenoma;10;Functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning pituitary adenoma;
adenoma;10;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
adenoma;10;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
adenoma;10;Null pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Null pituitary adenoma;
adenoma;10;Silent pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Silent pituitary adenoma;
adenoma;10;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
admin;4;immuno_admin;immunotherapy;EURACAN;Number of administrations;
admin;4;immuno_admin_unk;immunotherapy;EURACAN;Unknown;1, Unknown
admin;4;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
admin;4;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
administered;2;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
administered;2;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
admission;1;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
adrenal;9;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
adrenal;9;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
adrenal;9;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
adrenal;9;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
adrenal;9;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
adrenal;9;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
adrenal;9;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
adrenal;9;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
adrenal;9;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
adrenocortical;2;Adrenocortical carcinoma;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma;
adrenocortical;2;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
adrenocorticoid;1;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
adrenoleukodystrophy;2;X-linked adrenoleukodystrophy;ADRENAL;EuRR-Bone & EuRRECa;X-linked adrenoleukodystrophy;
adrenoleukodystrophy;2;Neonatal adrenoleukodystrophy;ADRENAL;EuRR-Bone & EuRRECa;Neonatal adrenoleukodystrophy;
adult;2;Adult hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Adult hypophosphatasia ;
adult;2;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
adverse;2;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
adverse;2;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
ae;75;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
ae;75;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
ae;75;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
ae;75;dia_lab_haemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Haemoglobin;numeric
ae;75;dia_lab_haematocrit;Diagnosis Laboratory data;Rare Liver (Vascular);Haematocrit;numeric
ae;75;ctcae_term;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ae;75;ctcae_spec;adverse_event;EURACAN;Please specify;
ae;75;ae_start;adverse_event;EURACAN;Adverse event starting date;
ae;75;ae_start_mm;adverse_event;EURACAN;Adverse event starting month;
ae;75;ae_start_yyyy;adverse_event;EURACAN;Adverse event starting year;
ae;75;ae_ongoing;adverse_event;EURACAN;Adverse event ongoing;1, Yes | 2, No
ae;75;ae_end;adverse_event;EURACAN;Adverse event end date;
ae;75;ae_end_mm;adverse_event;EURACAN;Adverse event ending month;
ae;75;ae_end_yyyy;adverse_event;EURACAN;Adverse event ending year;
ae;75;ae_grade;adverse_event;EURACAN;Adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
ae;75;ctcae_term_2;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ae;75;ctcae_spec_2;adverse_event;EURACAN;Please specify;
ae;75;ae_start_2;adverse_event;EURACAN;Second adverse event starting date;
ae;75;ae_start_mm_2;adverse_event;EURACAN;Second adverse event starting month;
ae;75;ae_start_yyyy_2;adverse_event;EURACAN;Second adverse event starting year;
ae;75;ae_ongoing_2;adverse_event;EURACAN;Second adverse event ongoing;1, Yes | 2, No
ae;75;ae_end_2;adverse_event;EURACAN;Second adverse event end date;
ae;75;ae_end_mm_2;adverse_event;EURACAN;Second adverse event ending month;
ae;75;ae_end_yyyy_2;adverse_event;EURACAN;Second adverse event ending year;
ae;75;ae_grade_2;adverse_event;EURACAN;Second adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
ae;75;ctcae_term_3;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ae;75;ctcae_spec_3;adverse_event;EURACAN;Please specify;
ae;75;ae_start_3;adverse_event;EURACAN;Third adverse event starting date;
ae;75;ae_start_mm_3;adverse_event;EURACAN;Third adverse event starting month;
ae;75;ae_start_yyyy_3;adverse_event;EURACAN;Third adverse event starting year;
ae;75;ae_ongoing_3;adverse_event;EURACAN;Third adverse event ongoing;1, Yes | 2, No
ae;75;ae_end_3;adverse_event;EURACAN;Third adverse event end date;
ae;75;ae_end_mm_3;adverse_event;EURACAN;Third adverse event ending month;
ae;75;ae_end_yyyy_3;adverse_event;EURACAN;Third adverse event ending year;
ae;75;ae_grade_3;adverse_event;EURACAN;Third adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
ae;75;ctcae_term_4;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ae;75;ctcae_spec_4;adverse_event;EURACAN;Please specify;
ae;75;ae_start_4;adverse_event;EURACAN;Fourth adverse event starting date;
ae;75;ae_start_mm_4;adverse_event;EURACAN;Fourth adverse event starting month;
ae;75;ae_start_yyyy_4;adverse_event;EURACAN;Fourth adverse event starting year;
ae;75;ae_ongoing_4;adverse_event;EURACAN;Fourth adverse event ongoing;1, Yes | 2, No
ae;75;ae_end_4;adverse_event;EURACAN;Fourth adverse event end date;
ae;75;ae_end_mm_4;adverse_event;EURACAN;Fourth adverse event ending month;
ae;75;ae_end_yyyy_4;adverse_event;EURACAN;Fourth adverse event ending year;
ae;75;ae_grade_4;adverse_event;EURACAN;Fourth adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
ae;75;ctcae_term_5;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ae;75;ctcae_spec_5;adverse_event;EURACAN;Please specify;
ae;75;ae_start_5;adverse_event;EURACAN;Fifth adverse event starting date;
ae;75;ae_start_mm_5;adverse_event;EURACAN;Fifth adverse event starting month;
ae;75;ae_start_yyyy_5;adverse_event;EURACAN;Fifth adverse event starting year;
ae;75;ae_ongoing_5;adverse_event;EURACAN;Fifth adverse event ongoing;1, Yes | 2, No
ae;75;ae_end_5;adverse_event;EURACAN;Fifth adverse event end date;
ae;75;ae_end_mm_5;adverse_event;EURACAN;Fifth adverse event ending month;
ae;75;ae_end_yyyy_5;adverse_event;EURACAN;Fifth adverse event ending year;
ae;75;ae_grade_5;adverse_event;EURACAN;Fifth adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
ae;75;biom_faeces;tumour_material_available;EURACAN;Faeces;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
ae;75;Presence of sequelae;Follow up (one form for each follow up visit);PaedCan;;yes/no/unknown
ae;75;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
ae;75;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
ae;75;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
ae;75;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
ae;75;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
ae;75;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
ae;75;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
ae;75;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
ae;75;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
ae;75;Hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypophosphataemic rickets;
ae;75;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
ae;75;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
ae;75;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
ae;75;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
ae;75;X-linked hypophosphataemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;X-linked hypophosphataemia;
ae;75;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
ae;75;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
ae;75;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
aetiological;1;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
affect;5;Affected family members;Diagnosis Family History;EURO-NMD;;multi
affect;5;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
affect;5;closest_degree_affect_rel;Diagnosis Aetiology;Rare Liver (Vascular);Closest degree of affected relatives;radio
affect;5;Gene affected;;ithaca;COSMIC genes (can be replaced by other list of genes);mref
affect;5;Family members affected?;Family history;ERKNet;Â ;fam_affected
affected;3;Affected family members;Diagnosis Family History;EURO-NMD;;multi
affected;3;Gene affected;;ithaca;COSMIC genes (can be replaced by other list of genes);mref
affected;3;Family members affected?;Family history;ERKNet;Â ;fam_affected
affection;1;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
after;5;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
after;5;free_hv_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein After TIPS;numeric
after;5;hv_gradient_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient After TIPS;numeric
after;5;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
after;5;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;Age at visit;Diagnosis Personal Information;EURO-NMD;Calculated age based on Date of Birth and Date of Visit;calculated
age;115;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
age;115;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
age;115;R_AIH_Age_at_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
age;115;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
age;115;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
age;115;R_AIH_Tanner_stage;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
age;115;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
age;115;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_PBC_Age_at_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
age;115;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
age;115;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
age;115;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
age;115;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
age;115;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
age;115;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
age;115;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
age;115;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
age;115;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
age;115;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
age;115;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
age;115;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
age;115;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
age;115;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
age;115;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
age;115;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
age;115;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
age;115;R_AIH_Age_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Age at follow-up;calculation
age;115;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
age;115;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
age;115;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
age;115;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
age;115;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
age;115;R_PBC_Age_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
age;115;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
age;115;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
age;115;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
age;115;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
age;115;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
age;115;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
age;115;esophageal_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophageal varices;radio
age;115;esophageal_varices_grade;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Grade;radio
age;115;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
age;115;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
age;115;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
age;115;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
age;115;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
age;115;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
age;115;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
age;115;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
age;115;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
age;115;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"vesicostomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"openÂ ureterostomies 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"CIC 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;"transplantation 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
age;115;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
age;115;"b. Age at first MCG VUR (in days):		";4. MCG VUR: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
age;115;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
age;115;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
age;115;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
age;115;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
age;115;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
age;115;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
age;115;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
age;115;a. Incontinent for feces (age > 4 years): ;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
age;115;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
age;115;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;"b.	Age at rejection:	";"6.	Rejection";Eurogen (Kid Transplantation);;[Numeric (Integer)]
age;115;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
age;115;Age at diagnosis (benign);benignNeoplasm;Genturis;What was the patient's age (years) at diagnosis of this benign tumour?;int
age;115;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
age;115;Age at diagnosis (malignancy);malignancy;Genturis;At what age (years) was the patient diagnosed with this malignancy?;int
age;115;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
age;115;Age at colonoscopy;subject;Genturis;What was the age (years) of the patient at the last colonoscopy?;int
age;115;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
age;115;Age at first symptoms;subject;Genturis;At what age (years) did the patient have his/her first symptoms?;int
age;115;Age FDR;subject;Genturis;What was the first degree relative(s) age (years) at first diagnosis of the solid malignancy?;categoricalmref
age;115;Age SDR;subject;Genturis;What was the first degree relative(s) age (years) at first diagnosis of the solid malignancy?;categoricalmref
age;115;Consent for usage of biobank material;;ithaca;;bool
age;115;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
age;115;Age at onset;;ithaca;;categorical
age;115;Age at diagnosis;;ithaca;;categorical
age;115;Age when panel opened;;ithaca;;string
age;115;Age at first symptoms onset;;ithaca;;int
age;115;Age at diagnosis;;ithaca;;int
age;115;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
age;115;age;charlson_index;EURACAN;Age;1, 50 - 59 (+1) | 2, 60 - 69 (+2) | 3, 70 - 79 (+3) | 4, 80 - 89 (+4) | 5, 90 - 99 (+5)
age;115;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
age;115;Age at onset;Symptoms and signs;PaedCan;Age at which symptoms/signs first appeared;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
age;115;Age at diagnosis;Care pathway;PaedCan;Age at which diagnosis was made;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
age;115;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
age;115;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
age;115;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
age;115;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
age;115;Smith-Magenis syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Smith-Magenis syndromeÂ ;
age;115;Cartilage-hair hypoplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cartilage-hair hypoplasia ;
age;115;Juvenile Paget disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Juvenile Paget disease ;
age;115;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
age;115;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
agenesis;1;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
aghbs;1;aghbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ag HBs;radio
aho;1;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
aih;536;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
aih;536;R_AIH_Year_of_birth;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
aih;536;R_AIH_Date_of_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
aih;536;R_AIH_Age_at_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
aih;536;R_AIH_Weight;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
aih;536;R_AIH_Height;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
aih;536;R_AIH_BMI;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
aih;536;R_AIH_Sex;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
aih;536;R_AIH_Ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
aih;536;R_AIH_Other_ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
aih;536;R_AIH_Alcohol;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol;radio
aih;536;R_AIH_Smoking;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
aih;536;R_AIH_Smoking_amount;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
aih;536;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
aih;536;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
aih;536;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
aih;536;R_AIH_Simplified_AIH_score;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Simplified AIH score;numeric
aih;536;R_AIH_Liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver biopsy;radio
aih;536;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
aih;536;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
aih;536;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
aih;536;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
aih;536;R_AIH_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Ishak score assessed;radio
aih;536;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
aih;536;R_AIH_mHAI;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);mHAI;numeric
aih;536;R_AIH_Additional_nafld;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
aih;536;R_AIH_Additional_nash;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
aih;536;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
aih;536;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
aih;536;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
aih;536;R_AIH_IQR_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
aih;536;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
aih;536;R_AIH_MRCP_or_ERCP;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Cholangiography (MRCP or ERCP);radio
aih;536;R_AIH_IBD;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);IBD;radio
aih;536;R_AIH_Type_of_IBD;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Type of IBD;radio
aih;536;R_AIH_Tanner_stage;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
aih;536;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
aih;536;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
aih;536;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
aih;536;R_AIH_Ascites;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Ascites;radio
aih;536;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
aih;536;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
aih;536;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
aih;536;R_AIH_HRS_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Hepatorenal syndrome;radio
aih;536;R_AIH_AST;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
aih;536;R_AIH_ALT;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
aih;536;R_AIH_Total_bilirubin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
aih;536;R_AIH_Total_bilirubin_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
aih;536;R_AIH_ALP;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
aih;536;R_AIH_yGT;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);y-GT;numeric
aih;536;R_AIH_Albumin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
aih;536;R_AIH_Creatinine_mgdL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
aih;536;R_AIH_Creatinine_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
aih;536;R_AIH_INR;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
aih;536;R_AIH_Platelets;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
aih;536;R_AIH_IgG;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
aih;536;R_AIH_IgM;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
aih;536;R_AIH_IgA;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
aih;536;R_AIH_yGlobulins;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
aih;536;R_AIH_ANA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
aih;536;R_AIH_ANA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
aih;536;R_AIH_ANA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
aih;536;R_AIH_ANA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
aih;536;R_AIH_AMA_diagnosis;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
aih;536;R_AIH_AMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
aih;536;R_AIH_AMA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
aih;536;R_AIH_AMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
aih;536;R_AIH_SMA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
aih;536;R_AIH_SMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
aih;536;R_AIH_SMA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
aih;536;R_AIH_SMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
aih;536;R_AIH_LKM;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
aih;536;R_AIH_LKM_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
aih;536;R_AIH_LKM_1_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
aih;536;R_AIH_LKM_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
aih;536;R_AIH_SLA_LP;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
aih;536;R_AIH_SLA_LP_value;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
aih;536;R_AIH_SLA_LP_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
aih;536;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
aih;536;R_AIH_Other_antibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
aih;536;R_AIH_DXA;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
aih;536;R_AIH_Date_of_DXA;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
aih;536;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
aih;536;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
aih;536;R_AIH_Biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
aih;536;R_AIH_Liver_tissue;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
aih;536;R_AIH_Serum;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
aih;536;R_AIH_Paxgene;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
aih;536;R_AIH_Other_biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
aih;536;R_AIH_Prednisolone;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_AIH_Prednisolone_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
aih;536;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Budesonide;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_AIH_Budesonide_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
aih;536;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Azathioprine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_AIH_Azathioprine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
aih;536;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_UDCA;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);UDCA;radio
aih;536;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
aih;536;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_MMF;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF;radio
aih;536;R_AIH_MMF_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Infliximab;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Infliximab;radio
aih;536;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Tacrolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_CyclosporinA;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Rituximab;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Everolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Treatment_other;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other;textarea
aih;536;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
aih;536;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
aih;536;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
aih;536;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
aih;536;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_MMF;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
aih;536;R_PBC_AIH_MMF_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Infliximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
aih;536;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Tacrolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_CyclosporinA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Rituximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Everolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
aih;536;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
aih;536;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
aih;536;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
aih;536;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
aih;536;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
aih;536;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_MMF;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
aih;536;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Tacrolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_CyclosporinA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Rituximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
aih;536;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
aih;536;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
aih;536;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
aih;536;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
aih;536;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
aih;536;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
aih;536;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
aih;536;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
aih;536;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
aih;536;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
aih;536;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
aih;536;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
aih;536;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
aih;536;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
aih;536;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
aih;536;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
aih;536;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
aih;536;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
aih;536;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
aih;536;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
aih;536;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
aih;536;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
aih;536;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
aih;536;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
aih;536;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
aih;536;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
aih;536;R_AIH_UDCA_dose;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA dose;numeric
aih;536;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
aih;536;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
aih;536;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
aih;536;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
aih;536;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
aih;536;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
aih;536;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
aih;536;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
aih;536;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
aih;536;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
aih;536;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
aih;536;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
aih;536;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
aih;536;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
aih;536;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
aih;536;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
aih;536;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
aih;536;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
aih;536;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
aih;536;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
aih;536;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
aih;536;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
aih;536;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
aih;536;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
aih;536;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
aih;536;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
aih;536;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
aih;536;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
aih;536;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
aih;536;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
aih;536;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
aih;536;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
aih;536;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
aih;536;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
aih;536;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
aih;536;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
aih;536;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
aih;536;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
aih;536;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
aih;536;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
aih;536;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
aih;536;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
aih;536;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
aih;536;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
aih;536;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
aih;536;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
aih;536;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
aih;536;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
aih;536;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
aih;536;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
aih;536;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
aih;536;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
aih;536;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
aih;536;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
aih;536;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
aih;536;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
aih;536;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
aih;536;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
aih;536;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
aih;536;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
aih;536;R_AIH_AST_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
aih;536;R_AIH_ALT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
aih;536;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
aih;536;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
aih;536;R_AIH_AP_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
aih;536;R_AIH_yGT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);y-GT;numeric
aih;536;R_AIH_Albumin_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
aih;536;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
aih;536;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
aih;536;R_AIH_INR_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
aih;536;R_AIH_Platelets_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
aih;536;R_AIH_IgG_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
aih;536;R_AIH_IgM_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
aih;536;R_AIH_IgA_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
aih;536;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
aih;536;R_AIH_ANA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
aih;536;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
aih;536;R_AIH_ANA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
aih;536;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
aih;536;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
aih;536;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
aih;536;R_AIH_AMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
aih;536;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
aih;536;R_AIH_SMA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
aih;536;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
aih;536;R_AIH_SMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
aih;536;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
aih;536;R_AIH_LKM_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
aih;536;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
aih;536;R_AIH_LKM_1_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
aih;536;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
aih;536;R_AIH_SLA_LP_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
aih;536;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
aih;536;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
aih;536;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
aih;536;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
aih;536;R_AIH_Biosamples_stored;AIH Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
aih;536;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
aih;536;R_AIH_Serum_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
aih;536;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
aih;536;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
aih;536;R_AIH_Date_of_followup_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of follow-up;string
aih;536;R_AIH_Age_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Age at follow-up;calculation
aih;536;R_AIH_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Bone mineral density (DXA);radio
aih;536;R_AIH_Date_of_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of DXA;date
aih;536;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
aih;536;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
aih;536;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
aih;536;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
aih;536;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
aih;536;R_AIH_Spleen_size_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Spleen size (diameter);numeric
aih;536;R_AIH_MRCP_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);MRCP;radio
aih;536;R_AIH_Weight_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Weight;numeric
aih;536;R_AIH_Height_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Height;numeric
aih;536;R_AIH_BMI_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);BMI;calculation
aih;536;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
aih;536;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
aih;536;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
aih;536;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
aih;536;R_AIH_Is_female;AIH Follow-up Outcome I;Rare Liver (Auto imune);Is female;calculation
aih;536;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
aih;536;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
aih;536;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
aih;536;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
aih;536;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
aih;536;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
aih;536;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
aih;536;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
aih;536;R_AIH_mHAI_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);mHAI;numeric
aih;536;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
aih;536;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
aih;536;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
aih;536;R_AIH_not_in_db123;AIH Follow-up Outcome II;Rare Liver (Auto imune);Calculate Nakanuma grading?;calculation
aih;536;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
aih;536;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
aih;536;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
aih;536;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
aih;536;R_AIH_not_in_db;AIH Follow-up Outcome II;Rare Liver (Auto imune);Calculate Nakanuma scoring?;calculation
aih;536;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
aih;536;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
aih;536;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
aih;536;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
aih;536;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
aih;536;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
aih;536;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
aih;536;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
aih;536;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
aih;536;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
aih;536;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
aih;536;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
aih;536;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
aih;536;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
aih;536;R_AIH_HRS_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatorenal syndrome;radio
aih;536;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
aih;536;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
aih;536;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
aih;536;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
aih;536;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
aih;536;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
aih;536;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
aih;536;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
aih;536;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
aih;536;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
aih;536;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
aih;536;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
aih;536;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
aih;536;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
aih;536;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
aih;536;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
aih;536;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
aih;536;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Budesonide_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
aih;536;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
aih;536;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
aih;536;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
aih;536;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
aih;536;R_AIH_MMP_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
aih;536;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
aih;536;R_AIH_UDCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
aih;536;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
aih;536;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_MMF_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
aih;536;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Tacrolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_CyclosporinA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Infliximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
aih;536;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Rituximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
aih;536;aih_pbc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC check;calculation
aih;536;R_AIH_PBC_specific_treament;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC specific treatment;radio
aih;536;R_AIH_PBC_OCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
aih;536;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
aih;536;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
aih;536;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
aih;536;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
aih;536;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
aih;536;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
aih;536;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
aih;536;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
aih;536;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
aih;536;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
aih;536;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
aih;536;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
aih;536;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
aih;536;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
aih;536;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
aih;536;R_PBC_AIH_check;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH check;calculation
aih;536;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
aih;536;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
aih;536;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aih;536;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
aih;536;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
aih;536;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
aih;536;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aih;536;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aih;536;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
aih;536;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
aih;536;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
aih;536;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
aih;536;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
aih;536;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
aih;536;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
aih;536;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
aih;536;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
aih;536;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aih;536;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
alb;17;R_AIH_Albumin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;R_PBC_Albumin;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;R_PSC_Albumin;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;R_AIH_Albumin_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;R_PBC_Albumin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
alb;17;dia_lab_serum_albumin;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin;numeric
alb;17;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
alb;17;dia_lab_ascites_alb;Diagnosis Laboratory data;Rare Liver (Vascular);Albumin;numeric
alb;17;fu_cli_bef_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
alb;17;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
alb;17;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
alb;17;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
alb;17;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
alb;17;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
alb;17;McCune-Albright syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;McCune-Albright syndrome ;
albright;3;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
albright;3;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
albright;3;McCune-Albright syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;McCune-Albright syndrome ;
albumin;13;R_AIH_Albumin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;R_PBC_Albumin;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;R_PSC_Albumin;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;R_AIH_Albumin_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;R_PBC_Albumin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
albumin;13;dia_lab_serum_albumin;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin;numeric
albumin;13;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
albumin;13;fu_cli_bef_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
albumin;13;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
albumin;13;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
albumin;13;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
alcohol;5;R_AIH_Alcohol;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol;radio
alcohol;5;R_PBC_Alcohol;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol;radio
alcohol;5;R_PSC_Alcohol;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol per day;radio
alcohol;5;alcohol_grams_per_week;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Average grams of ethanol per week;radio
alcohol;5;alcohol;patient_management_at_the_hospital;EURACAN;Alcohol;1, Current | 2, Former | 3, Never | 4, History of alcohol dependence
aldosterone;1;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
alfa;6;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
alfa;6;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
alfa;6;fu_cli_bef_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
alfa;6;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
alfa;6;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
alfa;6;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
alfafp;4;fu_cli_bef_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
alfafp;4;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
alfafp;4;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
alfafp;4;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
alk;6;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
alk;6;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
alk;6;fu_cli_bef_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
alk;6;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
alk;6;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
alk;6;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
alkaline;1;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
alkphos;4;fu_cli_bef_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
alkphos;4;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
alkphos;4;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
alkphos;4;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
aloud;1;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
alp;7;R_AIH_ALP;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
alp;7;R_PBC_ALP;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
alp;7;R_PSC_ALP;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
alp;7;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
alp;7;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
alp;7;R_PBC_ALP_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
alp;7;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
alpha;1;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
alstrÃ¶m;1;AlstrÃ¶m syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;AlstrÃ¶m syndromeÂ ;
alt;14;R_AIH_ALT;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;R_PBC_ALT;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;R_PSC_ALT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;R_AIH_ALT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;R_PBC_ALT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
alt;14;dia_lab_alt;Diagnosis Laboratory data;Rare Liver (Vascular);ALT;numeric
alt;14;dia_lab_alt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);ALT normal value;numeric
alt;14;fu_cli_bef_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
alt;14;fu_cli_bef_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
alt;14;fu_cli_last_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
alt;14;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
alt;14;Healthcare Provider (HCP);;ithaca;;xref
ama;25;R_AIH_AMA_diagnosis;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
ama;25;R_AIH_AMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ama;25;R_AIH_AMA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ama;25;R_AIH_AMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ama;25;R_PBC_AMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
ama;25;R_PBC_AMA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ama;25;R_PBC_AMA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ama;25;R_PBC_AMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ama;25;R_PSC_AMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
ama;25;R_PSC_AMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ama;25;R_PSC_AMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ama;25;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ama;25;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
ama;25;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ama;25;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ama;25;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ama;25;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
ama;25;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ama;25;R_AIH_AMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ama;25;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ama;25;R_PBC_AMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
ama;25;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ama;25;R_PBC_AMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ama;25;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ama;25;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
ambulatory;1;Current ambulatory status;Mobility ;EURO-NMD;;single
amh;3;AMH low;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;AMH low;
amh;3;AMH normal;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;AMH normal;
amh;3;AMH not known;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;AMH not known;
amount;4;R_AIH_Smoking_amount;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
amount;4;R_PBC_Smoking_amount;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
amount;4;R_PSC_Smoking_amount;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount (pack years);numeric
amount;4;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ana;35;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
ana;35;R_AIH_ANA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
ana;35;R_AIH_ANA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ana;35;R_AIH_ANA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ana;35;R_AIH_ANA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ana;35;R_PBC_ANA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
ana;35;R_PBC_ANA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ana;35;R_PBC_ANA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ana;35;R_PBC_ANA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ana;35;R_PBC_PBC_specific_ANA_IFT;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
ana;35;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
ana;35;R_PSC_ANA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
ana;35;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ana;35;R_PSC_ANA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ana;35;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ana;35;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
ana;35;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ana;35;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ana;35;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ana;35;R_AIH_ANA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
ana;35;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ana;35;R_AIH_ANA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ana;35;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ana;35;R_PBC_ANA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
ana;35;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ana;35;R_PBC_ANA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ana;35;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ana;35;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
ana;35;portal_recanalization;Follow-up Events;Rare Liver (Vascular);Portal recanalization;radio
ana;35;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
ana;35;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
ana;35;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
ana;35;Metaphyseal anadysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal anadysplasia;
ana;35;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
ana;35;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
anadysplasia;1;Metaphyseal anadysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal anadysplasia;
anaesthetics;1;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
anagen;1;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
analysis;1;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
androgen;6;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
androgen;6;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
androgen;6;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
androgen;6;Disorder of androgen synthesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen synthesis;
androgen;6;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
androgen;6;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
androgens;2;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
androgens;2;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
angio;16;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
angio;16;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
angio;16;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
angio;16;mri_cholangio;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cholangio MRI;radio
angio;16;first_angioplasty;Follow-up Events;Rare Liver (Vascular);First angioplasty/stenting of HV or IVC;radio
angio;16;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
angio;16;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
angio;16;date_of_evaluation_angio;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
angio;16;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
angio;16;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
angio;16;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
angio;16;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
angio;16;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
angio;16;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
angio;16;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
angio;16;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
angioplasty;3;first_angioplasty;Follow-up Events;Rare Liver (Vascular);First angioplasty/stenting of HV or IVC;radio
angioplasty;3;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
angioplasty;3;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
anomalies;3;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
anomalies;3;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
anomalies;3;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
anomaly;3;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
anomaly;3;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
anomaly;3;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
anonymized;2;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
anonymized;2;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
another;2;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
another;2;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
answer;1;(If yes, answer questionÂ 2e);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Tick-box, multiple selection]
anti;31;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
anti;31;R_AIH_Other_antibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
anti;31;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
anti;31;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
anti;31;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
anti;31;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
anti;31;use_anticoagulants;Diagnosis Biobank;Rare Liver (Vascular);Use of anticoagulants;dropdown
anti;31;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
anti;31;use_antiplatlet;Diagnosis Biobank;Rare Liver (Vascular);Use antiplatelet;dropdown
anti;31;pc_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
anti;31;pc_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
anti;31;ps_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
anti;31;ps_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
anti;31;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
anti;31;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
anti;31;jak_2_quantification;Diagnosis Aetiology;Rare Liver (Vascular);% of mutated allele;numeric
anti;31;lupus_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);Lupus anticoagulant antibody;radio
anti;31;anticardio;Diagnosis Aetiology;Rare Liver (Vascular);Anticardiolipin antibody;radio
anti;31;antibeta2gp2;Diagnosis Aetiology;Rare Liver (Vascular);Antibeta2GP1 antibody;radio
anti;31;transglut_antibodies;Diagnosis Aetiology;Rare Liver (Vascular);anti-transglutaminase antibodies;radio
anti;31;dia_lab_antinuclear_antibodies;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies;radio
anti;31;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
anti;31;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
anti;31;anticoag_first_initiated;Follow-up Events;Rare Liver (Vascular);Anticoagulation was first initiated;radio
anti;31;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
anti;31;Semantic type UMLS property (URL);;ithaca;;hyperlink
anti;31;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
anti;31;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
anti;31;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
anti;31;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
anti;31;Infantile hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Infantile hypophosphatasia ;
antibeta2gp2;1;antibeta2gp2;Diagnosis Aetiology;Rare Liver (Vascular);Antibeta2GP1 antibody;radio
antibodies;9;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
antibodies;9;R_AIH_Other_antibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
antibodies;9;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
antibodies;9;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
antibodies;9;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
antibodies;9;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
antibodies;9;transglut_antibodies;Diagnosis Aetiology;Rare Liver (Vascular);anti-transglutaminase antibodies;radio
antibodies;9;dia_lab_antinuclear_antibodies;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies;radio
antibodies;9;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
anticardio;1;anticardio;Diagnosis Aetiology;Rare Liver (Vascular);Anticardiolipin antibody;radio
anticoag;9;use_anticoagulants;Diagnosis Biobank;Rare Liver (Vascular);Use of anticoagulants;dropdown
anticoag;9;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
anticoag;9;pc_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
anticoag;9;pc_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
anticoag;9;ps_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
anticoag;9;ps_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
anticoag;9;lupus_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);Lupus anticoagulant antibody;radio
anticoag;9;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
anticoag;9;anticoag_first_initiated;Follow-up Events;Rare Liver (Vascular);Anticoagulation was first initiated;radio
anticoagulants;2;use_anticoagulants;Diagnosis Biobank;Rare Liver (Vascular);Use of anticoagulants;dropdown
anticoagulants;2;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
antinuclear;2;dia_lab_antinuclear_antibodies;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies;radio
antinuclear;2;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
antiplatlet;1;use_antiplatlet;Diagnosis Biobank;Rare Liver (Vascular);Use antiplatelet;dropdown
antithr;2;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
antithr;2;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
antithromb;1;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
antphospol;1;antphospol_syndrome_tested;Diagnosis Aetiology;Rare Liver (Vascular);Antiphospholipid syndrome tested;radio
ap;102;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
ap;102;Scapular winging;Diagnosis Skeletal;EURO-NMD;;yesno
ap;102;Sudden episodic apnea;Diagnosis Respiratory;EURO-NMD;Episodic apnoea;yesno
ap;102;Vital capacity:;QMG;EURO-NMD;;
ap;102;Thymoma therapy:;Thymoma;EURO-NMD;;
ap;102;If thymoma, relapse?;Thymoma;EURO-NMD;;
ap;102;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
ap;102;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
ap;102;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_PBC_Transient_elastography;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ap;102;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
ap;102;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ap;102;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ap;102;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
ap;102;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ap;102;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ap;102;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ap;102;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_AIH_AP_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
ap;102;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ap;102;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ap;102;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ap;102;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ap;102;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ap;102;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ap;102;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
ap;102;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ap;102;hepatic_venography;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venography;radio
ap;102;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
ap;102;b_fibroscan_cap;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: CAP;numeric
ap;102;apc_resistance;Diagnosis Aetiology;Rare Liver (Vascular);APC resistance;radio
ap;102;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
ap;102;abdom_infect_appen;Diagnosis Aetiology;Rare Liver (Vascular);Appendicitis;radio
ap;102;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
ap;102;fu_last_fibro_cap;Follow-up Imaging data;Rare Liver (Vascular);CAP;numeric
ap;102;medap;Medications Medication;Rare Liver (Vascular);Medication (antiplatelet);radio
ap;102;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
ap;102;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
ap;102;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
ap;102;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ap;102;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
ap;102;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
ap;102;Mammographic density;malignancy;Genturis;What is the mammographic density?;categorical
ap;102;Reference Sequence ID (mapped by NCBI);;ithaca;Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_;string
ap;102;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
ap;102;lymphography_sentinel;surgery;EURACAN;Lymphography and Sentinel node;1, Yes | 2, No | 9, Unknown
ap;102;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
ap;102;radio_photons_adaptive;radiotherapy;EURACAN;Photons adaptive RT;1, Yes | 2, No
ap;102;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
ap;102;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
ap;102;radio_carbons_adaptive;radiotherapy;EURACAN;Carbons adaptive RT;1, Yes | 2, No
ap;102;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
ap;102;radio_radionuc_adaptive;radiotherapy;EURACAN;Radionuclide adaptive RT;1, Yes | 2, No
ap;102;radio_boron_adaptive;radiotherapy;EURACAN;Boron neutron capture therapy adaptive RT;1, Yes | 2, No
ap;102;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
ap;102;National Identifier (if applicable);Identifiers;PaedCan;;String
ap;102;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
ap;102;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
ap;102;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
ap;102;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
ap;102;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
ap;102;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
ap;102;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
ap;102;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
ap;102;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
ap;102;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
ap;102;Papillary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Papillary thyroid carcinoma;
ap;102;Multiple metaphyseal dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple metaphyseal dysplasia;
ap;102;Epimetaphyseal skeletal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Epimetaphyseal skeletal dysplasia ;
ap;102;Metaphyseal anadysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal anadysplasia;
ap;102;Metaphyseal acroscyphodysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal acroscyphodysplasia;
ap;102;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
ap;102;Ulna metaphyseal dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ulna metaphyseal dysplasia syndrome ;
ap;102;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
ap;102;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
ap;102;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
ap;102;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
ap;102;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
ap;102;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
ap;102;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
ap;102;Craniodiaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniodiaphyseal dysplasia ;
ap;102;Craniometaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniometaphyseal dysplasia ;
apc;1;apc_resistance;Diagnosis Aetiology;Rare Liver (Vascular);APC resistance;radio
apnea;1;Sudden episodic apnea;Diagnosis Respiratory;EURO-NMD;Episodic apnoea;yesno
appen;2;abdom_infect_appen;Diagnosis Aetiology;Rare Liver (Vascular);Appendicitis;radio
appen;2;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
applicable;1;National Identifier (if applicable);Identifiers;PaedCan;;String
aps;5;If thymoma, relapse?;Thymoma;EURO-NMD;;
aps;5;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
aps;5;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
aps;5;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
aps;5;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
aq;1;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
area;3;Primary Thematic Area;;ithaca;;categorical
area;3;Secondary Thematic Areas;;ithaca;;categorical
area;3;Target area;Radiotherapy;PaedCan;Report the radiotherapy target;primary tumor/nodes/metastases
arm;5;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
arm;5;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
arm;5;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
arm;5;diff_harm_enlargement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Diffuse harmonious enlargement;radio
arm;5;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
arms/legs;1;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
aromatase;2;Aromatase def (CYP19A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Aromatase def (CYP19A1);
aromatase;2;Aromatase def (CYP19A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Aromatase def (CYP19A1);
art;44;Arthrogryposis;Diagnosis Skeletal;EURO-NMD;;yesno
art;44;Medication Date started;Medication ;EURO-NMD;;date
art;44;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
art;44;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
art;44;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
art;44;heart_rate;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Heart rate;numeric
art;44;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
art;44;hepatic_artery;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery;radio
art;44;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
art;44;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
art;44;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
art;44;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
art;44;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
art;44;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
art;44;Department;;ithaca;;string
art;44;Start date medication;;ithaca;;date
art;44;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
art;44;ae_start;adverse_event;EURACAN;Adverse event starting date;
art;44;ae_start_mm;adverse_event;EURACAN;Adverse event starting month;
art;44;ae_start_yyyy;adverse_event;EURACAN;Adverse event starting year;
art;44;ae_start_2;adverse_event;EURACAN;Second adverse event starting date;
art;44;ae_start_mm_2;adverse_event;EURACAN;Second adverse event starting month;
art;44;ae_start_yyyy_2;adverse_event;EURACAN;Second adverse event starting year;
art;44;ae_start_3;adverse_event;EURACAN;Third adverse event starting date;
art;44;ae_start_mm_3;adverse_event;EURACAN;Third adverse event starting month;
art;44;ae_start_yyyy_3;adverse_event;EURACAN;Third adverse event starting year;
art;44;ae_start_4;adverse_event;EURACAN;Fourth adverse event starting date;
art;44;ae_start_mm_4;adverse_event;EURACAN;Fourth adverse event starting month;
art;44;ae_start_yyyy_4;adverse_event;EURACAN;Fourth adverse event starting year;
art;44;ae_start_5;adverse_event;EURACAN;Fifth adverse event starting date;
art;44;ae_start_mm_5;adverse_event;EURACAN;Fifth adverse event starting month;
art;44;ae_start_yyyy_5;adverse_event;EURACAN;Fifth adverse event starting year;
art;44;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
art;44;Start date;Chemotherapy;PaedCan;First day of chemoterapy;dd/mm/yyyy
art;44;Start date;Radiotherapy;PaedCan;First day of radiotherapy;dd/mm/yyyy
art;44;Start date;Other treatments;PaedCan;Date when therapy was started;dd/mm/yyyy or uk/uk/yyyy
art;44;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
art;44;Heart rate;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Resting heart rate for age;N/Low/High/Not Known
art;44;Familial partial lipodystrophy Type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 1;
art;44;Familial partial lipodystrophy Type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 2;
art;44;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
art;44;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
art;44;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
art;44;Cartilage-hair hypoplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cartilage-hair hypoplasia ;
arterial;1;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
artery;2;hepatic_artery;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery;radio
artery;2;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
arthrogryposis;1;Arthrogryposis;Diagnosis Skeletal;EURO-NMD;;yesno
artrophy;1;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
asc;28;R_AIH_Ascites;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Ascites;radio
asc;28;R_PBC_Ascites;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Ascites;radio
asc;28;R_PSC_Ascites;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Ascites;radio
asc;28;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
asc;28;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
asc;28;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
asc;28;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
asc;28;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
asc;28;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
asc;28;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
asc;28;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
asc;28;vasc_oth;Diagnosis General Information;Rare Liver (Vascular);Specify Other Vascular Disease;string
asc;28;weight_w_o_ascites_oedema;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Estimated weight without ascites and oedema;numeric
asc;28;ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
asc;28;asc_check;Diagnosis Clinical Manifestations;Rare Liver (Vascular);asc_check;calculation
asc;28;ascites_response_diuretics;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites response to diuretics;radio
asc;28;history_of_ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
asc;28;sys_vasculitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Vasculitis;radio
asc;28;ascites_degree;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Ascites degree;radio
asc;28;dia_lab_ascites_alb;Diagnosis Laboratory data;Rare Liver (Vascular);Albumin;numeric
asc;28;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
asc;28;dia_lab_ascites_pmn;Diagnosis Laboratory data;Rare Liver (Vascular);Polymorphonuclear neutrophils;numeric
asc;28;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
asc;28;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
asc;28;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
asc;28;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
asc;28;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
asc;28;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
ascites;25;R_AIH_Ascites;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_PBC_Ascites;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_PSC_Ascites;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
ascites;25;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
ascites;25;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
ascites;25;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
ascites;25;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
ascites;25;weight_w_o_ascites_oedema;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Estimated weight without ascites and oedema;numeric
ascites;25;ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
ascites;25;ascites_response_diuretics;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites response to diuretics;radio
ascites;25;history_of_ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
ascites;25;ascites_degree;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Ascites degree;radio
ascites;25;dia_lab_ascites_alb;Diagnosis Laboratory data;Rare Liver (Vascular);Albumin;numeric
ascites;25;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
ascites;25;dia_lab_ascites_pmn;Diagnosis Laboratory data;Rare Liver (Vascular);Polymorphonuclear neutrophils;numeric
ascites;25;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
ascites;25;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
ascites;25;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
ascites;25;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
ascites;25;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
ascites;25;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
aspect;1;ivc_aspect;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Aspect;radio
assessed;4;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
assessed;4;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
assessed;4;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
assessed;4;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
assist;4;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
assist;4;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
assist;4;med_assist_repro_history;Diagnosis Aetiology;Rare Liver (Vascular);History of medically assisted reproduction;radio
assist;4;med_assist_repro_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of medically assisted reproduction;date
assisted;2;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
assisted;2;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
associated;1;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
ast;130;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
ast;130;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
ast;130;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
ast;130;Gastrostomy tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
ast;130;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
ast;130;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
ast;130;Nasogastric tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
ast;130;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
ast;130;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
ast;130;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
ast;130;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_AIH_AST;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;R_PBC_Transient_elastography;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ast;130;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
ast;130;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_PBC_AST;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ast;130;R_PSC_AST;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
ast;130;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ast;130;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
ast;130;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
ast;130;R_AIH_AST_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
ast;130;R_PBC_AST_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
ast;130;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ast;130;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
ast;130;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
ast;130;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
ast;130;gastric_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastric varices;radio
ast;130;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
ast;130;gastro_intest_bleed_date;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding date;date
ast;130;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
ast;130;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
ast;130;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
ast;130;dia_lab_ast;Diagnosis Laboratory data;Rare Liver (Vascular);AST;numeric
ast;130;dia_lab_ast_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);AST normal value;numeric
ast;130;dia_lab_fasting_glucose_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting Serum Glucose Unit;radio
ast;130;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
ast;130;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
ast;130;dia_lab_fasting_tg_value;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum triglycerides value;numeric
ast;130;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
ast;130;first_angioplasty;Follow-up Events;Rare Liver (Vascular);First angioplasty/stenting of HV or IVC;radio
ast;130;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
ast;130;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
ast;130;fu_cli_bef_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
ast;130;fu_cli_bef_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
ast;130;fu_cli_last_date_eval;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
ast;130;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
ast;130;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
ast;130;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
ast;130;fu_cli_last_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
ast;130;fu_cli_last_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
ast;130;fu_cli_last_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
ast;130;fu_cli_last_platelet_count;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
ast;130;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
ast;130;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
ast;130;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
ast;130;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
ast;130;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
ast;130;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
ast;130;fu_cli_last_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
ast;130;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
ast;130;fu_cli_last_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
ast;130;fu_cli_last_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
ast;130;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
ast;130;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
ast;130;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
ast;130;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
ast;130;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
ast;130;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
ast;130;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
ast;130;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
ast;130;fu_cli_last_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
ast;130;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
ast;130;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
ast;130;fu_cli_last_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
ast;130;fu_cli_last_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
ast;130;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
ast;130;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
ast;130;fu_ima_last_date_eval;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
ast;130;fu_ima_last_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
ast;130;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
ast;130;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
ast;130;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
ast;130;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
ast;130;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
ast;130;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
ast;130;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
ast;130;fu_ima_last_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
ast;130;fu_ima_last_nodules;Follow-up Imaging data;Rare Liver (Vascular);BCS-type, or HNF-like, nodules;radio
ast;130;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
ast;130;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
ast;130;fu_ima_last_fibro_value;Follow-up Imaging data;Rare Liver (Vascular);Liver fibroscan;numeric
ast;130;fu_ima_last_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
ast;130;fu_ima_last_fibro_date;Follow-up Imaging data;Rare Liver (Vascular);Date of fibroscan;date
ast;130;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
ast;130;fu_last_fibro_cap;Follow-up Imaging data;Rare Liver (Vascular);CAP;numeric
ast;130;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
ast;130;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
ast;130;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ast;130;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ast;130;Date of last information;subject;Genturis;What is the date (yyyy-mm-dd) of the last clinical information of the patient?;date
ast;130;Last name;;ithaca;;string
ast;130;Last name;;ithaca;;string
ast;130;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
ast;130;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
ast;130;fu_awd_metastatic;clinical_update;EURACAN;AWD, Metastatic;1, Yes | 2, No | 3, Unknown
ast;130;Metastases (M);Tumor's characteristics;PaedCan;Presence of distant lesions (TNM system);M0/M1/Mx
ast;130;Site of metastases;Tumor's characteristics;PaedCan;Definition of the site of metastases;Skin or soft tissues/CNS/Liver/Bone marrow/Lung/Distant nodes/Peritoneum or omentum/Bone/other/Unknown
ast;130;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
ast;130;Number of metastasis;Tumor's characteristics;PaedCan;Definition of the number of metastases for every site;singular/multiple
ast;130;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
ast;130;Date of metastases biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
ast;130;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
ast;130;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
ast;130;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
ast;130;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
ast;130;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
ast;130;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
ast;130;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
ast;130;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
ast;130;Spondylodysplastic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Spondylodysplastic dysplasia ;
ast;130;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
asymptomatic;1;asymptomatic;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Asymptomatic;radio
atelosteogenesis;1;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
atresia-mandibular;1;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
atrium;1;right_atrium_mm_hg;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right atrium;numeric
atrophy;2;Tongue atrophy;Diagnosis Muscular;EURO-NMD;Tongue wasting;yesno
atrophy;2;Skeletal muscle atrophy;Diagnosis Muscular;EURO-NMD;Muscle wasting;yesno
attainment;1;Educational attainment;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;International Standard Classification of Education (ISCED) 2011;Not Known/0/1/2/3/4/5/6/7/8
attendance;5;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
attendance;5;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
attendance;5;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
attendance;5;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
attendance;5;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
au;44;Cause_of_death;Base information;Rare Liver (Auto imune);Cause of death;radio
au;44;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
au;44;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
au;44;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
au;44;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
au;44;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
au;44;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
au;44;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
au;44;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
au;44;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
au;44;abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal trauma;radio
au;44;date_abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal trauma;date
au;44;eos_death_cause;End of study End of study;Rare Liver (Vascular);Cause of death;radio
au;44;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
au;44;eos_death_autopsy;End of study End of study;Rare Liver (Vascular);Autopsy performed;radio
au;44;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
au;44;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
au;44;Number of Cafe au lait spot;subject;Genturis;What is the maximal number of cafe au lait spots ever observed in the patient?;int
au;44;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
au;44;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
au;44;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
au;44;Cause of death;Follow up (one form for each follow up visit);PaedCan;if the patient is dead specfiy the cause of death;Dead of disease/dead for toxicity/dead for a second tumor/dead for other reason
au;44;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
au;44;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
au;44;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
au;44;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
au;44;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
au;44;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
au;44;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
au;44;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
au;44;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
au;44;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
au;44;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
au;44;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
au;44;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
au;44;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
au;44;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
au;44;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
au;44;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
au;44;Von Hippel-Lindau disease;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Von Hippel-Lindau disease;
au;44;Mazabraud syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mazabraud syndrome ;
au;44;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
au;44;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
au;44;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
augment;1;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
author;2;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
author;2;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
authors;1;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
auto;26;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
auto;26;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
auto;26;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
auto;26;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
auto;26;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
auto;26;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
auto;26;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
auto;26;eos_death_autopsy;End of study End of study;Rare Liver (Vascular);Autopsy performed;radio
auto;26;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
auto;26;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
auto;26;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
auto;26;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
auto;26;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
auto;26;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
auto;26;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
auto;26;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
auto;26;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
auto;26;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
auto;26;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
auto;26;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
auto;26;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
auto;26;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
auto;26;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
auto;26;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
auto;26;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
auto;26;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
autoantibodies;2;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
autoantibodies;2;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
autoimmune;12;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
autoimmune;12;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
autoimmune;12;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
autoimmune;12;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
autoimmune;12;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
autoimmune;12;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
autoimmune;12;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
autoimmune;12;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
autoimmune;12;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
autoimmune;12;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
autoimmune;12;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
autoimmune;12;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
autopsy;1;eos_death_autopsy;End of study End of study;Rare Liver (Vascular);Autopsy performed;radio
autosomal;8;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
autosomal;8;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
autosomal;8;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
autosomal;8;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
autosomal;8;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
autosomal;8;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
autosomal;8;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
autosomal;8;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
availability;2;Data availability;subject;Genturis;What clinical data is locally available for this patient?;categoricalmref
availability;2;Material availability;subject;Genturis;What material is locally available for this patient?;categoricalmref
available;15;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
available;15;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
available;15;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
available;15;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
available;15;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
available;15;Year of birth available?;subject;Genturis;Is the year of birth of the patient known?;enum
available;15;Year of death available?;subject;Genturis;Is the year of death of the patient known?;enum
available;15;Year of lost to follow up available?;subject;Genturis;Is the year of lost to follow up of the patient known?;enum
available;15;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
available;15;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
available;15;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
available;15;Patient's biological sample available for researchÂ ;;ithaca;;bool
available;15;"Other;  what patient Data is available";;ithaca;;categoricalmref
available;15;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
available;15;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
awd;3;fu_awd_local;clinical_update;EURACAN;AWD, Local;1, Yes | 2, No | 3, Unknown
awd;3;fu_awd_regional;clinical_update;EURACAN;AWD, Regional;1, Yes | 2, No | 3, Unknown
awd;3;fu_awd_metastatic;clinical_update;EURACAN;AWD, Metastatic;1, Yes | 2, No | 3, Unknown
aza;39;R_AIH_Azathioprine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_AIH_Azathioprine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
aza;39;R_PBC_Azathioprine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_PBC_Azathioprine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aza;39;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
aza;39;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
aza;39;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
aza;39;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
aza;39;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
aza;39;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aza;39;aza_nodb;PSC Follow-up Treatment;Rare Liver (Auto imune);aza_aih check;calculation
aza;39;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
aza;39;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aza;39;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aza;39;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aza;39;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aza;39;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aza;39;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
aza;39;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
aza;39;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
aza;39;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
aza;39;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
aza;39;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
aza;39;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
aza;39;Mazabraud syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mazabraud syndrome ;
azathioprine;36;R_AIH_Azathioprine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_AIH_Azathioprine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_PBC_Azathioprine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_PBC_Azathioprine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
azathioprine;36;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
azathioprine;36;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
azathioprine;36;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
azathioprine;36;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
azathioprine;36;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
azathioprine;36;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
azathioprine;36;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
azathioprine;36;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
azathioprine;36;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
azathioprine;36;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
azathioprine;36;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
azathioprine;36;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
azathioprine;36;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
b.age;1;"b.	Age at rejection:	";"6.	Rejection";Eurogen (Kid Transplantation);;[Numeric (Integer)]
b.ebv;1;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
b.egfr;1;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
b.previous;1;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
b.specification;1;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
b.type;1;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
bacterial;2;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
bacterial;2;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
bardet-biedl;1;Bardet-Biedl syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Bardet-Biedl syndromeÂ ;
baseline;4;ebv_dna_baseline;primary_cancer;EURACAN;Plasmatic EBV DNA at baseline;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
baseline;4;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
baseline;4;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
baseline;4;copy_number_baseline;primary_cancer;EURACAN;Copy Number;
beam;1;beam_quality;radiotherapy;EURACAN;Beam quality;1, External beam RT Photons | 2, External beam RT Electrons | 3, External beam RT Protons | 4, External beam RT Carbons | 5, Brachytherapy interstitial endocavitary contact | 6, Radionuclide therapy | 7, Boron neutron capture therapy | 8, Others
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome;
beckwith-wiedemann;9;Beckwith-Wiedemann Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann Syndrome;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microduplication;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
beckwith-wiedemann;9;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
bed;1;Transfer from chair to bed;Mobility ;EURO-NMD;;single
bef;53;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
bef;53;free_hv_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein Before TIPS;numeric
bef;53;hv_gradient_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient Before TIPS;numeric
bef;53;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
bef;53;fu_cli_bef_date_evaluation;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
bef;53;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
bef;53;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
bef;53;fu_cli_bef_enceph_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy value;radio
bef;53;fu_cli_bef_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
bef;53;fu_cli_bef_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
bef;53;fu_cli_bef_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
bef;53;fu_cli_bef_platelet_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
bef;53;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
bef;53;fu_cli_bef_pt_normal_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
bef;53;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
bef;53;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
bef;53;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
bef;53;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
bef;53;fu_cli_bef_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
bef;53;fu_cli_bef_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
bef;53;fu_cli_bef_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
bef;53;fu_cli_bef_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
bef;53;fu_cli_bef_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
bef;53;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
bef;53;fu_cli_bef_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
bef;53;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
bef;53;fu_cli_bef_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
bef;53;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bef;53;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bef;53;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
bef;53;fu_cli_bef_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
bef;53;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
bef;53;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
bef;53;fu_cli_bef_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
bef;53;fu_cli_bef_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
bef;53;fu_cli_bef_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
bef;53;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
bef;53;fu_ima_bef_date_evaluation;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
bef;53;fu_ima_bef_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
bef;53;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
bef;53;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
bef;53;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
bef;53;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
bef;53;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
bef;53;fu_ima_bef_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
bef;53;fu_ima_bef_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
bef;53;fu_ima_bef_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
bef;53;fu_ima_bef_nodules;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
bef;53;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
bef;53;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
bef;53;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
bef;53;fu_ima_bef_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
bef;53;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
before;3;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
before;3;free_hv_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein Before TIPS;numeric
before;3;hv_gradient_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient Before TIPS;numeric
behcet;1;behcet_s_disease;Diagnosis Aetiology;Rare Liver (Vascular);Behcet's disease;radio
being;1;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
benign;8;benignNeoplasmLabel;benignNeoplasm;Genturis;;string
benign;8;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
benign;8;Age at diagnosis (benign);benignNeoplasm;Genturis;What was the patient's age (years) at diagnosis of this benign tumour?;int
benign;8;Benign type;benignNeoplasm;Genturis;Where is the benign neoplasm located?;xref
benign;8;Benign diagnosis source;benignNeoplasm;Genturis;What is level of evidence for the diagnosis?;xref
benign;8;Benign neoplasms;subject;Genturis;;compound
benign;8;Benign status;subject;Genturis;Has this patient ever had a benign neoplasm/tumour?;enum
benign;8;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
benignneoplasmlabel;1;benignNeoplasmLabel;benignNeoplasm;Genturis;;string
bening;2;other_hn_bening;previous_cancer_genetic_syndromes;EURACAN;Other head and neck benign tumours;1, Yes | 2, No | 9, Unknown
bening;2;other_hn_bening_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
best;2;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
best;2;Best response;Other treatments;PaedCan;Please record the best response obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
beta;2;antibeta2gp2;Diagnosis Aetiology;Rare Liver (Vascular);Antibeta2GP1 antibody;radio
beta;2;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
bezafibrate;4;R_PBC_Bezafibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Bezafibrate;radio
bezafibrate;4;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
bezafibrate;4;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
bezafibrate;4;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
biallelic;1;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
bifurcation;1;pv_bifurcation;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Longitudinal assessment: portal vein bifurcation;radio
bilateral;1;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
bile;7;R_PBC_Bile_duct_loss_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
bile;7;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
bile;7;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
bile;7;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
bile;7;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
bile;7;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
bile;7;bile_ducts;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Bile ducts;radio
biliary;16;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
biliary;16;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
biliary;16;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
biliary;16;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
biliary;16;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
biliary;16;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
biliary;16;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
biliary;16;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
biliary;16;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
biliary;16;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
biliary;16;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
biliary;16;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
biliary;16;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
biliary;16;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
biliary;16;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
biliary;16;fu_biliary_symptoms;Follow-up Complications;Rare Liver (Vascular);Biliary symptoms;radio
bilirub;23;R_AIH_Total_bilirubin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
bilirub;23;R_AIH_Total_bilirubin_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
bilirub;23;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirub;23;R_PBC_Total_bilirubin_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirub;23;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
bilirub;23;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirub;23;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirub;23;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
bilirub;23;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
bilirub;23;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirub;23;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirub;23;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
bilirub;23;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirub;23;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirub;23;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
bilirub;23;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
bilirub;23;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
bilirub;23;fu_cli_bef_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
bilirub;23;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bilirub;23;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bilirub;23;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
bilirub;23;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bilirub;23;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bilirubin;21;R_AIH_Total_bilirubin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
bilirubin;21;R_AIH_Total_bilirubin_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
bilirubin;21;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirubin;21;R_PBC_Total_bilirubin_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirubin;21;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
bilirubin;21;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirubin;21;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirubin;21;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
bilirubin;21;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
bilirubin;21;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirubin;21;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirubin;21;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
bilirubin;21;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
bilirubin;21;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
bilirubin;21;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
bilirubin;21;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
bilirubin;21;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
bilirubin;21;fu_cli_bef_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
bilirubin;21;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bilirubin;21;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
bilirubin;21;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
bilirubin2;1;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
biobank;6;Consent for usage of biobank material;;ithaca;;bool
biobank;6;Retractation for biobank use;;ithaca;;bool
biobank;6;Biobank;;ithaca;;mref
biobank;6;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
biobank;6;Biobank details;Research;EuRR-Bone & EuRRECa;Details of biobank;String
biobank;6;Biobank Patient ID;Research;EuRR-Bone & EuRRECa;;String
biological;3;Patient's biological sample available for researchÂ ;;ithaca;;bool
biological;3;consent_biological_data;patient_management_at_the_hospital;EURACAN;Consent to use biological data;1, Yes | 2, No
biological;3;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
biom;11;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
biom;11;biom;tumour_material_available;EURACAN;Is tumour material available at the hospital level?;1, Yes | 2, No | 9, Unknown
biom;11;biom_ffpe;tumour_material_available;EURACAN;FFPE;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_frozen;tumour_material_available;EURACAN;Frozen tissue;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_plasma;tumour_material_available;EURACAN;Plasma;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_blood;tumour_material_available;EURACAN;Blood;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_faeces;tumour_material_available;EURACAN;Faeces;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_urine;tumour_material_available;EURACAN;Urine;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_saliva;tumour_material_available;EURACAN;Saliva;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_other;tumour_material_available;EURACAN;Others;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
biom;11;biom_others;tumour_material_available;EURACAN;Others (please specify);
biomaterial;1;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
biopsie;1;biopsie_proven_cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Biopsie proven cirrhosis;radio
biopsy;38;R_AIH_Liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver biopsy;radio
biopsy;38;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
biopsy;38;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
biopsy;38;R_PBC_Liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
biopsy;38;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
biopsy;38;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
biopsy;38;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
biopsy;38;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
biopsy;38;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
biopsy;38;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
biopsy;38;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
biopsy;38;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
biopsy;38;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
biopsy;38;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
biopsy;38;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
biopsy;38;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
biopsy;38;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
biopsy;38;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
biopsy;38;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
biopsy;38;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
biopsy;38;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
biopsy;38;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
biopsy;38;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
biopsy;38;date_liver_biopsy;Diagnosis Biobank;Rare Liver (Vascular);Date of liver biopsy;date
biopsy;38;liver_biopsy_number;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy local number;string
biopsy;38;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
biopsy;38;liver_biopsy_obtained;Diagnosis Biobank;Rare Liver (Vascular);Frozen liver biopsy obtained?;dropdown
biopsy;38;bone_marrow_biopsy;Diagnosis Aetiology;Rare Liver (Vascular);Bone marrow biopsy;radio
biopsy;38;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
biopsy;38;biopsy;primary_cancer;EURACAN;Biopsy;1, Yes | 2, No | 9, Unknown
biopsy;38;biopsy_date;primary_cancer;EURACAN;Biopsy date;
biopsy;38;biopsy_req;primary_cancer;EURACAN;Biopsy done by;1, The hospital | 2, A different hospital | 9, Unknown
biopsy;38;Biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
biopsy;38;Date of biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
biopsy;38;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
biopsy;38;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
biopsy;38;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
biopsy;38;Date of metastases biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
biosamples;12;R_AIH_Biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
biosamples;12;R_AIH_Other_biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
biosamples;12;R_PBC_Biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
biosamples;12;R_PBC_Other_biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
biosamples;12;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
biosamples;12;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
biosamples;12;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
biosamples;12;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
biosamples;12;R_AIH_Biosamples_stored;AIH Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
biosamples;12;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
biosamples;12;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
biosamples;12;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
birth;16;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
birth;16;R_AIH_Year_of_birth;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
birth;16;R_PBC_Year_of_birth;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
birth;16;R_PSC_Year_of_birth;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
birth;16;country_birth;Diagnosis General Information;Rare Liver (Vascular);Country of birth;dropdown
birth;16;Year of birth available?;subject;Genturis;Is the year of birth of the patient known?;enum
birth;16;Year of Birth;subject;Genturis;What is patientâ€™s year of birth? (Specify using 4 digits);int
birth;16;Date of Birth;;ithaca;;date
birth;16;Country of Birth;;ithaca;;xref
birth;16;birth_date;patient_management_at_the_hospital;EURACAN;Date of birth;DD-MM-YYYY Format
birth;16;Date of Birth;Personal Information;PaedCan;Patient's date of birth;dd/mm/yyyy
birth;16;Country of birth;Personal Information;PaedCan;Patient's country of birth;String
birth;16;Place of birth;Personal Information;PaedCan;Patient's town of birth;String
birth;16;Date of Birth;Personal Information;EuRR-Bone & EuRRECa;Patients date of birth;dd/mm/yyyy
birth;16;Sex at birth;Personal Information;EuRR-Bone & EuRRECa;Assigned sex at birth;Male/Female/Other/Unknown
birth;16;Country of birth;Personal Information;EuRR-Bone & EuRRECa;Country of birth;drop down/select
bladder;4;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
bladder;4;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
bladder;4;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
bladder;4;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
bladderneck;1;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
bleed;14;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
bleed;14;R_PSC_Variceal_bleeding;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Variceal bleeding;radio
bleed;14;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
bleed;14;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
bleed;14;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
bleed;14;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
bleed;14;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
bleed;14;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
bleed;14;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
bleed;14;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
bleed;14;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
bleed;14;gastro_intest_bleed_date;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding date;date
bleed;14;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
bleed;14;fu_gi_bleeding;Follow-up Complications;Rare Liver (Vascular);Gastrointestinal bleeding;radio
bleeding;12;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
bleeding;12;R_PSC_Variceal_bleeding;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Variceal bleeding;radio
bleeding;12;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
bleeding;12;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
bleeding;12;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
bleeding;12;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
bleeding;12;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
bleeding;12;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
bleeding;12;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
bleeding;12;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
bleeding;12;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
bleeding;12;fu_gi_bleeding;Follow-up Complications;Rare Liver (Vascular);Gastrointestinal bleeding;radio
blood;3;dia_lab_red_blood_cell_count;Diagnosis Laboratory data;Rare Liver (Vascular);Red blood cell count;numeric
blood;3;biom_blood;tumour_material_available;EURACAN;Blood;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
blood;3;Patient blood;Pathology;PaedCan;;yes/no/unknown
blook;1;Blook pressure;Clinical Status;ERKNet;Â ;bp_sys/bp_dia/bp_sys_sds/bp_dia_sds
blue;1;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
bmi;9;R_AIH_BMI;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
bmi;9;R_PBC_BMI;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
bmi;9;R_PSC_BMI;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
bmi;9;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
bmi;9;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
bmi;9;R_AIH_BMI_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);BMI;calculation
bmi;9;R_PBC_BMI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
bmi;9;bmi_calculated;patient_management_at_the_hospital;EURACAN;BMI;[weight]*10000/([height]*[height])
bmi;9;BMI;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Based on body weight and height ;Not Known/Drop down or autopopulated from Height (cm) and weight (kg)
board;1;Referral to VRT board (national or international) ;Care pathway;PaedCan;The case has been discussed within an official national or international VRT board for diagnosis and/or treatment;no/yes in the EXPERT Virtual consultation system/ yes in another tumor board
body;1;Body side ;Tumor's characteristics;PaedCan;Side of the primary tumor;right/left/bilateral/multifocal/not applicable/unknown
bone;9;bone_marrow_biopsy;Diagnosis Aetiology;Rare Liver (Vascular);Bone marrow biopsy;radio
bone;9;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
bone;9;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
bone;9;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
bone;9;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
bone;9;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
bone;9;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
bone;9;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
bone;9;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
borjeson-forssman-lehmann;1;Borjeson-Forssman-Lehmann syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Borjeson-Forssman-Lehmann syndromeÂ ;
boron;11;boron;radiotherapy;EURACAN;"<div class=""rich-text-field-label""><table style=""border-collapse: collapse; width: auto;"" border=""1""> <tbody> <tr> <td style=""vertical-align: top; text-align: center; width: 629px;"" colspan=""9"">Boron neutron capture therapy</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"">Treatment technique</td> <td style=""width: 100px; vertical-align: top;"">Start date</td> <td style=""width: 100px; vertical-align: top;"">End date</td> <td style=""width: 70px; vertical-align: top;"">Totale dose</td> <td style=""width: 70px; vertical-align: top;"">Dose per fraction</td> <td style=""width: 70px; vertical-align: top;"">Nr of fractions</td> <td style=""width: 60px; vertical-align: top;"">4D treatment</td> <td style=""width: 70px; vertical-align: top;"">Adaptive RT</td> <td style=""width: 70px; vertical-align: top;"">IGRT</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"" rowspan=""2"">{radio_boron_tech}</td> <td style=""width: 100px; vertical-align: top;"">{radio_boron_from}</td> <td style=""width: 100px; vertical-align: top;"">{radio_boron_to}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_boron_totdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_boron_fractdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_boron_nrfract}</td> <td style=""width: 60px; vertical-align: top;"" rowspan=""2"">{radio_boron_4d}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_boron_adaptive}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_boron_igrt}</td> </tr> <tr> <td style=""width: auto; vertical-align: top; text-align: center;"" colspan=""2"">OTT (days) {radio_boron_ott}</td> </tr> </tbody> </table></div>";
boron;11;radio_boron_tech;radiotherapy;EURACAN;Boron neutron capture therapy treatment technique;
boron;11;radio_boron_from;radiotherapy;EURACAN;Boron neutron capture therapy start date;
boron;11;radio_boron_to;radiotherapy;EURACAN;Boron neutron capture therapy end date;
boron;11;radio_boron_totdose;radiotherapy;EURACAN;Boron neutron capture therapy total dose;
boron;11;radio_boron_fractdose;radiotherapy;EURACAN;Boron neutron capture therapy dose per fraction ;
boron;11;radio_boron_nrfract;radiotherapy;EURACAN;Boron neutron capture therapy number fraction ;
boron;11;radio_boron_ott;radiotherapy;EURACAN;Boron neutron capture therapy OTT;"datediff([radio_boron_to],[radio_boron_from],""d"")"
boron;11;radio_boron_4d;radiotherapy;EURACAN;Boron neutron capture therapy 4D treatment;1, Yes | 2, No
boron;11;radio_boron_adaptive;radiotherapy;EURACAN;Boron neutron capture therapy adaptive RT;1, Yes | 2, No
boron;11;radio_boron_igrt;radiotherapy;EURACAN;Boron neutron capture therapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
bowel;1;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
brachy;12;radio_brachy_tech;radiotherapy;EURACAN;Brachytherapy treatment technique;1, Interstitial | 2, Endocavitary | 3, Contact
brachy;12;radio_brachy_from;radiotherapy;EURACAN;Brachytherapy start date;
brachy;12;radio_brachy_to;radiotherapy;EURACAN;Brachytherapy end date;
brachy;12;radio_brachy_totdose;radiotherapy;EURACAN;Brachytherapy total dose;
brachy;12;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
brachy;12;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
brachy;12;radio_brachy_ott;radiotherapy;EURACAN;Brachytherapy OTT;"datediff([radio_brachy_to],[radio_brachy_from],""d"")"
brachy;12;radio_brachy_4d;radiotherapy;EURACAN;Brachytherapy 4D treatment;1, Yes | 2, No
brachy;12;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
brachy;12;radio_brachy_igrt;radiotherapy;EURACAN;Brachytherapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
brachy;12;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
brachy;12;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
braf;1;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
branch;2;right_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein branch;radio
branch;2;left_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein branch;radio
breast;2;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
breast;2;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
brushing;3;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
brushing;3;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
brushing;3;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
budd;3;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
budd;3;budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Budd-Chiari syndrome;radio
budd;3;date_budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
budesonide;33;R_AIH_Budesonide;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_AIH_Budesonide_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_PBC_Budesonide;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_PBC_Budesonide_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_PSC_Budesonide;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_PSC_Budesonide_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
budesonide;33;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
budesonide;33;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
budesonide;33;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
budesonide;33;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
budesonide;33;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
budesonide;33;R_AIH_Budesonide_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_PBC_Budesonide_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
budesonide;33;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
budesonide;33;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
budesonide;33;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
budesonide;33;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
buffy;4;buffy_coat_obtained;Diagnosis Biobank;Rare Liver (Vascular);Buffy coat sample obtained ?;dropdown
buffy;4;buffy_coat_date;Diagnosis Biobank;Rare Liver (Vascular);Buffy coat sample date;date
buffy;4;buffy_coat_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
buffy;4;buffy_coat_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
build;1;Genome build;geneticVariant;Genturis;Genome build;categorical
bulbar;1;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
by;2;Reference Sequence ID (mapped by NCBI);;ithaca;Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_;string
by;2;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
c.amount;1;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
c.cmv;1;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
c.discharge;1;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
c.lowest;9;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
c.lowest;9;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
c.lowest;9;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
c.lowest;9;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
c.lowest;9;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
c.lowest;9;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
c.lowest;9;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
c.lowest;9;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
c.lowest;9;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
c677t;1;homozyg_mthfr_c677t_mut;Diagnosis Aetiology;Rare Liver (Vascular);Homozygous MTHFR-C677T mutation;radio
caci;1;caci_total_sc;charlson_index;EURACAN;Charlson age comorbidity index (CACI) Total points:;if([age]='','',if ([age] =1, 1, 0) + if ([age] =2, 2, 0) + if ([age] =3, 3, 0) + if ([age] =4, 4, 0) + if ([age] =5, 5, 0) + if ([comorbid(1)] =1, 1, 0) + if ([comorbid(2)] =1, 1, 0) + if ([comorbid(3)] =1, 1, 0) + if ([comorbid(4)] =1, 1, 0) + if ([comorbid(5)] =1, 1, 0) + if ([comorbid(6)] =1, 1, 0) + if ([comorbid(7)] =1, 1, 0) + if ([comorbid(8)] =1, 1, 0) + if ([comorbid(9)] =1, 1, 0) + if ([comorbid(10)] =1, 1, 0) + if ([comorbid(11)] =1, 2, 0) + if ([comorbid(12)] =1, 2, 0) + if ([comorbid(13)] =1, 2, 0) + if ([comorbid(14)] =1, 2, 0) + if ([comorbid(15)] =1, 2, 0) + if ([comorbid(16)] =1, 2, 0) + if ([comorbid(17)] =1, 3, 0) + if ([comorbid(18)] =1, 6, 0) + if ([comorbid(19)] =1, 6, 0))
cafe;2;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
cafe;2;Number of Cafe au lait spot;subject;Genturis;What is the maximal number of cafe au lait spots ever observed in the patient?;int
cais;1;CAIS;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CAIS;
calc;12;bmi_calculated;patient_management_at_the_hospital;EURACAN;BMI;[weight]*10000/([height]*[height])
calc;12;smoking_pack_year_calc;patient_management_at_the_hospital;EURACAN;Pack/year;"if ([smoking_habits] = ""1"", ([smoking_per_day]/20)*[smoking_years], ([smoking_per_day]/4)*[smoking_years])"
calc;12;Calcitonin status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Ct < 150 pg/ml;Below/Above
calc;12;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
calc;12;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
calc;12;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
calc;12;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
calc;12;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
calc;12;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
calc;12;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
calc;12;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
calc;12;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
calcinosis/hyperphosphataemic;1;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
calcitonin;1;Calcitonin status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Ct < 150 pg/ml;Below/Above
calculated;1;bmi_calculated;patient_management_at_the_hospital;EURACAN;BMI;[weight]*10000/([height]*[height])
calr;1;calr_mutation;Diagnosis Aetiology;Rare Liver (Vascular);CALR mutation;radio
camurati-engelmann;1;Camurati-Engelmann disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Camurati-Engelmann disease ;
canal;3;portal_recanalization;Follow-up Events;Rare Liver (Vascular);Portal recanalization;radio
canal;3;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
canal;3;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
canc;7;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
canc;7;Cancer Syndrome;;ithaca;;string
canc;7;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
canc;7;other_hn_cancers;previous_cancer_genetic_syndromes;EURACAN;Other head and neck malignant cancers ;1, Yes | 2, No | 9, Unknown
canc;7;prev_pre_canc_lesions_ynu;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Yes | 2, No | 9, Unknown
canc;7;prev_pre_canc_lesions;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Pleomorphic adenoma | 2, Sinonasal papillomas | 3, Oral premalignant lesions
canc;7;new_cancer_idco3;clinical_update;EURACAN;New cancer ICD-O3;for later
cancer;5;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
cancer;5;Cancer Syndrome;;ithaca;;string
cancer;5;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
cancer;5;other_hn_cancers;previous_cancer_genetic_syndromes;EURACAN;Other head and neck malignant cancers ;1, Yes | 2, No | 9, Unknown
cancer;5;new_cancer_idco3;clinical_update;EURACAN;New cancer ICD-O3;for later
cancers;1;other_hn_cancers;previous_cancer_genetic_syndromes;EURACAN;Other head and neck malignant cancers ;1, Yes | 2, No | 9, Unknown
cap;39;Scapular winging;Diagnosis Skeletal;EURO-NMD;;yesno
cap;39;Vital capacity:;QMG;EURO-NMD;;
cap;39;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
cap;39;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
cap;39;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
cap;39;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
cap;39;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
cap;39;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
cap;39;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
cap;39;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
cap;39;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
cap;39;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
cap;39;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
cap;39;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
cap;39;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
cap;39;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
cap;39;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
cap;39;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
cap;39;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
cap;39;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
cap;39;b_fibroscan_cap;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: CAP;numeric
cap;39;fu_last_fibro_cap;Follow-up Imaging data;Rare Liver (Vascular);CAP;numeric
cap;39;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
capacity;1;Vital capacity:;QMG;EURO-NMD;;
capsular;1;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
carbons;10;radio_carbons_tech;radiotherapy;EURACAN;Carbons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
carbons;10;radio_carbons_from;radiotherapy;EURACAN;Carbons start date;
carbons;10;radio_carbons_to;radiotherapy;EURACAN;Carbons end date;
carbons;10;radio_carbons_totdose;radiotherapy;EURACAN;Carbons total dose;
carbons;10;radio_carbons_fractdose;radiotherapy;EURACAN;Carbons dose per fraction ;
carbons;10;radio_carbons_nrfract;radiotherapy;EURACAN;Carbons number fraction ;
carbons;10;radio_carbons_ott;radiotherapy;EURACAN;Carbons OTT;"datediff([radio_carbons_to],[radio_carbons_from],""d"")"
carbons;10;radio_carbons_4d;radiotherapy;EURACAN;Carbons 4D treatment;1, Yes | 2, No
carbons;10;radio_carbons_adaptive;radiotherapy;EURACAN;Carbons adaptive RT;1, Yes | 2, No
carbons;10;radio_carbons_igrt;radiotherapy;EURACAN;Carbons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
carcinoma;7;site_adenocarcinoma;primary_cancer;EURACAN;Adenocarcinoma subtype;1, Intestinal-type adenocarcinoma | 8144/3 | 2, Non-intestinal-type adenocarcinoma  (adk, NOS) | 8140/3 | 3, Nasopharyngeal papillary adenocarcinoma | 8260/3 | 4, Adenoid cystic carcinoma | 8200/3 | 5, Mucoepidermoid carcinoma | 8430/3 | 6, Polymorphous adenocarcinoma | 8525/3 | 7, Acinic cell carcinoma | 8550/3 | 8, Clear cell carcinoma | 8310/3 | 9, Basal cell adenocarcinoma | 8147/3 | 10, Salivary duct carcinoma | 8500/3 | 11, Myoepithelial carcinoma |8982/3 | 12, Epithelial-myoepithelial carcinoma | 8562/3 | 13, Carcinoma ex pleomorphic adenoma | 8941/3 | 14, Secretory carcinoma | 8542/3 | 15, Sebaceous adenocarcinoma | 8410/3 | 16, Carcinosarcoma | 8980/3 | 17, Oncocytic carcinoma | 8290/3 | 18, Adenocarcinoma | 8420/3
carcinoma;7;Adrenocortical carcinoma;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma;
carcinoma;7;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
carcinoma;7;Parathyroid carcinoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Parathyroid carcinoma;
carcinoma;7;Papillary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Papillary thyroid carcinoma;
carcinoma;7;Follicular thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Follicular thyroid carcinoma;
carcinoma;7;Medullary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Medullary thyroid carcinoma;
cardiac;1;cardiac_output;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cardiac output;numeric
care;4;Care path;subject;Genturis;;compound
care;4;Consent for Care;;ithaca;;bool
care;4;Care pathwayÂ ;;ithaca;;compound
care;4;Healthcare Provider (HCP);;ithaca;;xref
carney;2;Carney Complex;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney Complex;
carney;2;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
carpenter;1;Carpenter syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Carpenter syndromeÂ ;
carriers;1;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
cartilage-hair;1;Cartilage-hair hypoplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cartilage-hair hypoplasia ;
case;3;Other cases in the family?;;ithaca;;categorical
case;3;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
case;3;In case of a second tumor please specify the type;Events;PaedCan;;String
catheter;3;hepatic_vein_catheter;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic Vein Catheterization;radio
catheter;3;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
catheter;3;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
catheterisable;1;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
causative;1;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
cause;6;Cause_of_death;Base information;Rare Liver (Auto imune);Cause of death;radio
cause;6;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
cause;6;eos_death_cause;End of study End of study;Rare Liver (Vascular);Cause of death;radio
cause;6;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
cause;6;Cause of death;Follow up (one form for each follow up visit);PaedCan;if the patient is dead specfiy the cause of death;Dead of disease/dead for toxicity/dead for a second tumor/dead for other reason
cause;6;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
cavernoma;3;portoportal_cavernoma;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portoportal cavernoma;radio
cavernoma;3;fu_ima_bef_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
cavernoma;3;fu_ima_last_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
cavity;1;site_nasal_cavity;primary_cancer;EURACAN;Subsite;1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS
cba;4;AChR (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
cba;4;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
cba;4;MuSK (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
cba;4;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
cci;2;cci_total_sc;charlson_index;EURACAN;Charlson comorbidity index (CCI) Total points:;if ([comorbid(1)] =1, 1, '') + if ([comorbid(2)] =1, 1, '') + if ([comorbid(3)] =1, 1, '') + if ([comorbid(4)] =1, 1, '') + if ([comorbid(5)] =1, 1, '') + if ([comorbid(6)] =1, 1, '') + if ([comorbid(7)] =1, 1, '') + if ([comorbid(8)] =1, 1, '') + if ([comorbid(9)] =1, 1, '') + if ([comorbid(10)] =1, 1, '') + if ([comorbid(11)] =1, 2, '') + if ([comorbid(12)] =1, 2, '') + if ([comorbid(13)] =1, 2, '') + if ([comorbid(14)] =1, 2, '') + if ([comorbid(15)] =1, 2, '') + if ([comorbid(16)] =1, 2, '') + if ([comorbid(17)] =1, 3, '') + if ([comorbid(18)] =1, 6, '') + if ([comorbid(19)] =1, 6, '')
cci;2;Maffucci syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Maffucci syndrome ;
cdkn1c;1;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
celiac;1;sys_celiac;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Celiac Disease;radio
cell;3;dia_lab_red_blood_cell_count;Diagnosis Laboratory data;Rare Liver (Vascular);Red blood cell count;numeric
cell;3;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
cell;3;Leydig Cell Hypoplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Leydig Cell Hypoplasia;
center;3;Center;subject;Genturis;;compound
center;3;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
center;3;Center of registration;Personal Information;PaedCan;Center where the patient is registered;String
central;1;Central review;Pathology;PaedCan;no/yes,local diagnosis confirmed/yes,local diagnosis changed;yes/no/unknown
centre;3;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
centre;3;Centre;Care Pathway;EuRR-Bone & EuRRECa;Details of the notifying centre;fixed string
centre;3;First Contact with Centre;Care Pathway;EuRR-Bone & EuRRECa;Month and year of first contact with notifying centre;dd/mm/yyyy
cep19;1;CEP19 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;CEP19 deficiency;
ch;238;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
ch;238;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
ch;238;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
ch;238;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
ch;238;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
ch;238;Chest CT findings;Diagnosis ;EURO-NMD;;single
ch;238;Achromatopsia;Diagnosis ;EURO-NMD;;single
ch;238;Achromatopsia Titer;Diagnosis ;EURO-NMD;;
ch;238;AChR (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
ch;238;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
ch;238;invasive (tracheostomy);Respiratory Myasthenic crisis;EURO-NMD;;yesno
ch;238;Transfer from chair to bed;Mobility ;EURO-NMD;;single
ch;238;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
ch;238;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
ch;238;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
ch;238;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
ch;238;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
ch;238;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
ch;238;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
ch;238;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
ch;238;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
ch;238;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
ch;238;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
ch;238;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
ch;238;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
ch;238;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
ch;238;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
ch;238;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
ch;238;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
ch;238;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
ch;238;R_PSC_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
ch;238;R_PSC_Date_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date CHE;date
ch;238;R_PSC_CHE_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);CHE indication;radio
ch;238;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
ch;238;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
ch;238;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ch;238;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
ch;238;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ch;238;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
ch;238;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ch;238;date_check_6mo;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);date_check_6mo;calculation
ch;238;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
ch;238;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
ch;238;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
ch;238;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
ch;238;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
ch;238;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
ch;238;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
ch;238;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
ch;238;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
ch;238;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
ch;238;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
ch;238;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
ch;238;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ch;238;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ch;238;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ch;238;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ch;238;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ch;238;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ch;238;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
ch;238;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
ch;238;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
ch;238;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
ch;238;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ch;238;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ch;238;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ch;238;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ch;238;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ch;238;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ch;238;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;aih_pbc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC check;calculation
ch;238;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
ch;238;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
ch;238;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
ch;238;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
ch;238;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
ch;238;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
ch;238;R_PBC_AIH_check;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH check;calculation
ch;238;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ch;238;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ch;238;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ch;238;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ch;238;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ch;238;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ch;238;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ch;238;asc_check;Diagnosis Clinical Manifestations;Rare Liver (Vascular);asc_check;calculation
ch;238;mri_cholangio;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cholangio MRI;radio
ch;238;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
ch;238;check_ivc;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);check_ivc;calculation
ch;238;right_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein branch;radio
ch;238;left_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein branch;radio
ch;238;contra_check;Diagnosis Aetiology;Rare Liver (Vascular);contra_check;calculation
ch;238;abd_interv_chol;Diagnosis Aetiology;Rare Liver (Vascular);Cholecystectomy;radio
ch;238;abd_interv_chol_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Cholecystectomy;date
ch;238;budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Budd-Chiari syndrome;radio
ch;238;date_budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
ch;238;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
ch;238;fu_cholesterol_t;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
ch;238;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
ch;238;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
ch;238;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
ch;238;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
ch;238;med_check;Medications Medication;Rare Liver (Vascular);med_check;calculation
ch;238;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ch;238;"d.	HLA-DR mismatches: ";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
ch;238;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ch;238;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ch;238;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ch;238;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ch;238;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
ch;238;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
ch;238;Number of vestibular schwannoma;benignNeoplasm;Genturis;What is the maximal number of vestibular schwannomas ever observed in this patient?;int
ch;238;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
ch;238;Phenotypical Characteristics;subject;Genturis;;compound
ch;238;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
ch;238;Chr Band;;ithaca;;string
ch;238;Region (in chromosome and band/bands);;ithaca;;string
ch;238;Chromosomale Location;;ithaca;Hugo.owl.Chromosome;string
ch;238;Consent for ERN databases/Registries/research;;ithaca;;bool
ch;238;Consent to be contacted for research;;ithaca;;bool
ch;238;Retractation to be contacted for research;;ithaca;;bool
ch;238;ResearchÂ ;;ithaca;;compound
ch;238;Patient's biological sample available for researchÂ ;;ithaca;;bool
ch;238;Other changes:;;ithaca;;text
ch;238;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
ch;238;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
ch;238;chemo;chemotherapy;EURACAN;Chemotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
ch;238;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
ch;238;chemo_date_from;chemotherapy;EURACAN;Start date;
ch;238;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_date_to;chemotherapy;EURACAN;End date;
ch;238;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_cycle;chemotherapy;EURACAN;Number of cycles;
ch;238;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_drug_1;chemotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
ch;238;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_drug_2;chemotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
ch;238;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_drug_3;chemotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
ch;238;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_drug_4;chemotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
ch;238;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_drug_5;chemotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
ch;238;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
ch;238;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
ch;238;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
ch;238;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
ch;238;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
ch;238;end_treatment_chem;chemotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
ch;238;end_treat_res_chem;chemotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
ch;238;radio_photons_tech;radiotherapy;EURACAN;Photons treatment technique;1, 2D | 2, 3D | 3, IMRT conventional | 4, VMAT | 5, Thomotherapy | 6, SBRT
ch;238;radio_electrons_tech;radiotherapy;EURACAN;Electrons treatment technique;1, FLASH  therapy
ch;238;radio_protons_tech;radiotherapy;EURACAN;Protons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
ch;238;radio_carbons_tech;radiotherapy;EURACAN;Carbons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
ch;238;radio_brachy_tech;radiotherapy;EURACAN;Brachytherapy treatment technique;1, Interstitial | 2, Endocavitary | 3, Contact
ch;238;radio_brachy_from;radiotherapy;EURACAN;Brachytherapy start date;
ch;238;radio_brachy_to;radiotherapy;EURACAN;Brachytherapy end date;
ch;238;radio_brachy_totdose;radiotherapy;EURACAN;Brachytherapy total dose;
ch;238;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
ch;238;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
ch;238;radio_brachy_ott;radiotherapy;EURACAN;Brachytherapy OTT;"datediff([radio_brachy_to],[radio_brachy_from],""d"")"
ch;238;radio_brachy_4d;radiotherapy;EURACAN;Brachytherapy 4D treatment;1, Yes | 2, No
ch;238;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
ch;238;radio_brachy_igrt;radiotherapy;EURACAN;Brachytherapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
ch;238;radio_radionuc_tech;radiotherapy;EURACAN;Radionuclide treatment technique;
ch;238;radio_boron_tech;radiotherapy;EURACAN;Boron neutron capture therapy treatment technique;
ch;238;radio_others_tech;radiotherapy;EURACAN;Others treatment technique;
ch;238;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
ch;238;Specify which malignancy;Patient's history;PaedCan;Description of any previous malignancy;ICCC3
ch;238;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
ch;238;Specify which syndrome;Patient's history;PaedCan;Definition of the syndrome affecting the patient;String
ch;238;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
ch;238;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
ch;238;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
ch;238;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
ch;238;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
ch;238;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
ch;238;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
ch;238;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
ch;238;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
ch;238;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
ch;238;Learning support at school;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Requiring extra help at school with learning;Y/N/Not Known
ch;238;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
ch;238;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
ch;238;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
ch;238;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
ch;238;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
ch;238;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
ch;238;Other syndromic form of CH;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other syndromic form of CH;
ch;238;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
ch;238;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
ch;238;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
ch;238;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
ch;238;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
ch;238;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
ch;238;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
ch;238;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
ch;238;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
ch;238;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
ch;238;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
ch;238;Multiple osteochondroma;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple osteochondroma;
ch;238;Pseudoachondroplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Pseudoachondroplasia ;
ch;238;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
ch;238;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
ch;238;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
ch;238;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
ch;238;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
ch;238;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
ch;238;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
ch;238;LÃ©ri-Weill dyschondrosteosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;LÃ©ri-Weill dyschondrosteosis ;
ch;238;Dyschondrosteosis-nephritis syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dyschondrosteosis-nephritis syndrome ;
ch;238;Fibrochondrogenesis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrochondrogenesis ;
ch;238;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
ch;238;Childhood-onset hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Childhood-onset hypophosphatasia ;
ch;238;Achondroplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Achondroplasia ;
ch;238;Hypochondroplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Hypochondroplasia;
ch;238;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
chain;1;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
chair;1;Transfer from chair to bed;Mobility ;EURO-NMD;;single
change;54;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
change;54;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
change;54;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
change;54;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
change;54;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
change;54;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
change;54;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
change;54;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
change;54;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
change;54;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
change;54;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
change;54;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
change;54;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
change;54;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
change;54;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
change;54;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
change;54;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
change;54;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
change;54;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
change;54;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
change;54;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
change;54;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
change;54;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
change;54;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
change;54;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
change;54;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
change;54;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
change;54;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
change;54;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
change;54;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
change;54;Other changes:;;ithaca;;text
changes;2;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
changes;2;Other changes:;;ithaca;;text
characteristics;2;Phenotypical Characteristics;subject;Genturis;;compound
characteristics;2;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
che;70;Chest CT findings;Diagnosis ;EURO-NMD;;single
che;70;invasive (tracheostomy);Respiratory Myasthenic crisis;EURO-NMD;;yesno
che;70;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
che;70;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
che;70;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
che;70;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
che;70;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
che;70;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
che;70;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
che;70;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
che;70;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
che;70;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
che;70;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
che;70;R_PSC_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
che;70;R_PSC_Date_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date CHE;date
che;70;R_PSC_CHE_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);CHE indication;radio
che;70;date_check_6mo;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);date_check_6mo;calculation
che;70;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
che;70;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
che;70;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
che;70;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
che;70;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
che;70;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
che;70;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
che;70;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
che;70;aih_pbc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC check;calculation
che;70;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
che;70;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
che;70;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
che;70;R_PBC_AIH_check;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH check;calculation
che;70;asc_check;Diagnosis Clinical Manifestations;Rare Liver (Vascular);asc_check;calculation
che;70;check_ivc;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);check_ivc;calculation
che;70;contra_check;Diagnosis Aetiology;Rare Liver (Vascular);contra_check;calculation
che;70;med_check;Medications Medication;Rare Liver (Vascular);med_check;calculation
che;70;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
che;70;"d.	HLA-DR mismatches: ";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
che;70;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
che;70;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
che;70;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
che;70;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
che;70;chemo;chemotherapy;EURACAN;Chemotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
che;70;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
che;70;chemo_date_from;chemotherapy;EURACAN;Start date;
che;70;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_date_to;chemotherapy;EURACAN;End date;
che;70;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_cycle;chemotherapy;EURACAN;Number of cycles;
che;70;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_drug_1;chemotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
che;70;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_drug_2;chemotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
che;70;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_drug_3;chemotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
che;70;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_drug_4;chemotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
che;70;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_drug_5;chemotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
che;70;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
che;70;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
che;70;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
che;70;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
che;70;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
che;70;end_treatment_chem;chemotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
che;70;end_treat_res_chem;chemotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
che;70;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
che;70;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
che;70;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
che;70;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
che;70;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
che;70;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
check;10;date_check_6mo;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);date_check_6mo;calculation
check;10;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
check;10;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
check;10;aih_pbc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC check;calculation
check;10;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
check;10;R_PBC_AIH_check;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH check;calculation
check;10;asc_check;Diagnosis Clinical Manifestations;Rare Liver (Vascular);asc_check;calculation
check;10;check_ivc;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);check_ivc;calculation
check;10;contra_check;Diagnosis Aetiology;Rare Liver (Vascular);contra_check;calculation
check;10;med_check;Medications Medication;Rare Liver (Vascular);med_check;calculation
chect;1;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
chem;32;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
chem;32;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
chem;32;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
chem;32;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
chem;32;chemo;chemotherapy;EURACAN;Chemotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
chem;32;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
chem;32;chemo_date_from;chemotherapy;EURACAN;Start date;
chem;32;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_date_to;chemotherapy;EURACAN;End date;
chem;32;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_cycle;chemotherapy;EURACAN;Number of cycles;
chem;32;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_drug_1;chemotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
chem;32;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_drug_2;chemotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
chem;32;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_drug_3;chemotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
chem;32;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_drug_4;chemotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
chem;32;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_drug_5;chemotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
chem;32;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chem;32;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
chem;32;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
chem;32;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
chem;32;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
chem;32;end_treatment_chem;chemotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
chem;32;end_treat_res_chem;chemotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
chem;32;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
chem;32;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
chem;32;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
chem;32;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
chemo;28;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
chemo;28;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
chemo;28;chemo;chemotherapy;EURACAN;Chemotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
chemo;28;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
chemo;28;chemo_date_from;chemotherapy;EURACAN;Start date;
chemo;28;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_date_to;chemotherapy;EURACAN;End date;
chemo;28;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_cycle;chemotherapy;EURACAN;Number of cycles;
chemo;28;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_drug_1;chemotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
chemo;28;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_drug_2;chemotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
chemo;28;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_drug_3;chemotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
chemo;28;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_drug_4;chemotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
chemo;28;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_drug_5;chemotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
chemo;28;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
chemo;28;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
chemo;28;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
chemo;28;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
chemo;28;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
chemo;28;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
chemo;28;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
chemo;28;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
chemo;28;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
chemotherapy;4;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
chemotherapy;4;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
chemotherapy;4;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
chemotherapy;4;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
chest;1;Chest CT findings;Diagnosis ;EURO-NMD;;single
chiari;3;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
chiari;3;budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Budd-Chiari syndrome;radio
chiari;3;date_budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
childbirth;1;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
childhood-onset;1;Childhood-onset hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Childhood-onset hypophosphatasia ;
chol;20;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
chol;20;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
chol;20;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
chol;20;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
chol;20;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
chol;20;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
chol;20;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
chol;20;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
chol;20;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
chol;20;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
chol;20;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
chol;20;mri_cholangio;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cholangio MRI;radio
chol;20;abd_interv_chol;Diagnosis Aetiology;Rare Liver (Vascular);Cholecystectomy;radio
chol;20;abd_interv_chol_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Cholecystectomy;date
chol;20;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
chol;20;fu_cholesterol_t;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
chol;20;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
chol;20;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
chol;20;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
chol;20;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
cholangio;6;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
cholangio;6;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
cholangio;6;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
cholangio;6;mri_cholangio;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cholangio MRI;radio
cholangio;6;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
cholangio;6;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
cholangiopathy;2;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
cholangiopathy;2;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
cholangioscopy;3;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
cholangioscopy;3;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
cholangioscopy;3;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
cholangitis;8;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
cholangitis;8;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
cholangitis;8;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
cholangitis;8;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
cholangitis;8;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
cholangitis;8;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
cholangitis;8;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
cholangitis;8;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
cholesterol;4;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
cholesterol;4;fu_cholesterol_t;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
cholesterol;4;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
cholesterol;4;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
chondrodysplasia-retinitis;1;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
chondrodysplasia,;4;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
chondrodysplasia,;4;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
chondrodysplasia,;4;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
chondrodysplasia,;4;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
chromosomal;2;Chromosomale Location;;ithaca;Hugo.owl.Chromosome;string
chromosomal;2;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
chromosome;8;Region (in chromosome and band/bands);;ithaca;;string
chromosome;8;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
chromosome;8;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
chromosome;8;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
chromosome;8;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
chromosome;8;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
chromosome;8;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
chromosome;8;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
chronic;3;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
chronic;3;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
chronic;3;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
cic;1;"CIC 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
cid;2;cid_of_drugs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);CID of drug(s);textarea
cid;2;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
cirrhosis;13;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_PBC_Signs_of_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver-related complications;radio
cirrhosis;13;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
cirrhosis;13;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
cirrhosis;13;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cirrhosis;13;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
cirrhosis;13;cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Cirrhosis;radio
cirrhosis;13;biopsie_proven_cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Biopsie proven cirrhosis;radio
city;12;Vital capacity:;QMG;EURO-NMD;;
city;12;R_AIH_Ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
city;12;R_AIH_Other_ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
city;12;R_PBC_Ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
city;12;R_PBC_Other_ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
city;12;R_PSC_Ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
city;12;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
city;12;City;;ithaca;;string
city;12;City;;ithaca;;string
city;12;ethnicity;patient_management_at_the_hospital;EURACAN;Ethnicity;1, White | 2, Black | 3, Asians/Pacific Islanders | 4, Hispanic | 5, American Indian/Alaska Native
city;12;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
city;12;City of HCP;Care Pathway;EuRR-Bone & EuRRECa;City where the notifying centre is based;fixed string
class;12;If thymoma, WHO Classification:;Thymoma;EURO-NMD;;
class;12;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
class;12;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
class;12;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
class;12;Variant classification;geneticVariant;Genturis;What is the class of the variant?;xref
class;12;Class ID;hpo;ithaca;;string
class;12;URL to treeview HPO class;;ithaca;;hyperlink
class;12;classID;OMIM (Online Mendelian Inheritance in Man);ithaca;;string
class;12;Class ID;OrphanetÂ Rare Disease Ontology;ithaca;;string
class;12;classid;Patient's disability profile according to International Classification of Functioning and Disability (ICF);ithaca;;string
class;12;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
class;12;Class of variant;;ithaca;Clinical interperation for variant;mref
classid;2;classID;OMIM (Online Mendelian Inheritance in Man);ithaca;;string
classid;2;classid;Patient's disability profile according to International Classification of Functioning and Disability (ICF);ithaca;;string
classification;6;If thymoma, WHO Classification:;Thymoma;EURO-NMD;;
classification;6;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
classification;6;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
classification;6;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
classification;6;Variant classification;geneticVariant;Genturis;What is the class of the variant?;xref
classification;6;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
cleidorhizomelic;1;Cleidorhizomelic syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cleidorhizomelic syndrome ;
cli;85;Climbing stairs;Mobility ;EURO-NMD;;single
cli;85;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
cli;85;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
cli;85;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
cli;85;fu_cli_bef_date_evaluation;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
cli;85;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
cli;85;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
cli;85;fu_cli_bef_enceph_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy value;radio
cli;85;fu_cli_bef_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
cli;85;fu_cli_bef_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
cli;85;fu_cli_bef_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
cli;85;fu_cli_bef_platelet_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
cli;85;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
cli;85;fu_cli_bef_pt_normal_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
cli;85;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
cli;85;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
cli;85;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
cli;85;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
cli;85;fu_cli_bef_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
cli;85;fu_cli_bef_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
cli;85;fu_cli_bef_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
cli;85;fu_cli_bef_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
cli;85;fu_cli_bef_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
cli;85;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
cli;85;fu_cli_bef_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
cli;85;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
cli;85;fu_cli_bef_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
cli;85;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
cli;85;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
cli;85;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
cli;85;fu_cli_bef_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
cli;85;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
cli;85;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
cli;85;fu_cli_bef_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
cli;85;fu_cli_bef_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
cli;85;fu_cli_bef_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
cli;85;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
cli;85;fu_cli_last_date_eval;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
cli;85;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
cli;85;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
cli;85;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
cli;85;fu_cli_last_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
cli;85;fu_cli_last_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
cli;85;fu_cli_last_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
cli;85;fu_cli_last_platelet_count;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
cli;85;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
cli;85;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
cli;85;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
cli;85;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
cli;85;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
cli;85;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
cli;85;fu_cli_last_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
cli;85;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
cli;85;fu_cli_last_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
cli;85;fu_cli_last_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
cli;85;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
cli;85;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
cli;85;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
cli;85;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
cli;85;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
cli;85;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
cli;85;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
cli;85;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
cli;85;fu_cli_last_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
cli;85;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
cli;85;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
cli;85;fu_cli_last_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
cli;85;fu_cli_last_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
cli;85;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
cli;85;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
cli;85;Clinical diagnosis;;ithaca;;compound
cli;85;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
cli;85;ct_clin;stage_procedures;EURACAN;cT;1, Tx | 2, T0 | 3, Tis | 4, T1 | 5, T2 | 6, T3 | 7, T4 | 8, T4a | 9, T4b
cli;85;cn_clin;stage_procedures;EURACAN;cN;1, Nx | 2, N0 | 3, N1 | 4, N2 | 5, N2a | 6, N2b | 7, N2c | 8, N3 | 9, N3a | 10, N3b
cli;85;cm_clin;stage_procedures;EURACAN;cM;1, M0 | 2, M1
cli;85;ene_clin;stage_procedures;EURACAN;Extranodal extension (ENE);1, ENE- | 2, ENE+
cli;85;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
cli;85;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
cli;85;tnm_unk_clin;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
cli;85;staging_def_clin;stage_procedures;EURACAN;Clinical staging defined by;1, the hospital | 2, a different hospital
cli;85;clinical_trial;patient_included_in_clinical_trial;EURACAN;Patient included in a clinical trial;1, Yes | 2, No | 9, Unknown
cli;85;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
cli;85;oth_clinical_trial;other_type_of_treatment;EURACAN;Patient included in a clinical trial;1, Yes | 2, No
cli;85;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
cli;85;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
climbing;1;Climbing stairs;Mobility ;EURO-NMD;;single
clin;18;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
clin;18;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
clin;18;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
clin;18;Clinical diagnosis;;ithaca;;compound
clin;18;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
clin;18;ct_clin;stage_procedures;EURACAN;cT;1, Tx | 2, T0 | 3, Tis | 4, T1 | 5, T2 | 6, T3 | 7, T4 | 8, T4a | 9, T4b
clin;18;cn_clin;stage_procedures;EURACAN;cN;1, Nx | 2, N0 | 3, N1 | 4, N2 | 5, N2a | 6, N2b | 7, N2c | 8, N3 | 9, N3a | 10, N3b
clin;18;cm_clin;stage_procedures;EURACAN;cM;1, M0 | 2, M1
clin;18;ene_clin;stage_procedures;EURACAN;Extranodal extension (ENE);1, ENE- | 2, ENE+
clin;18;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
clin;18;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
clin;18;tnm_unk_clin;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
clin;18;staging_def_clin;stage_procedures;EURACAN;Clinical staging defined by;1, the hospital | 2, a different hospital
clin;18;clinical_trial;patient_included_in_clinical_trial;EURACAN;Patient included in a clinical trial;1, Yes | 2, No | 9, Unknown
clin;18;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
clin;18;oth_clinical_trial;other_type_of_treatment;EURACAN;Patient included in a clinical trial;1, Yes | 2, No
clin;18;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
clin;18;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
clinical;10;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
clinical;10;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
clinical;10;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
clinical;10;Clinical diagnosis;;ithaca;;compound
clinical;10;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
clinical;10;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
clinical;10;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
clinical;10;clinical_trial;patient_included_in_clinical_trial;EURACAN;Patient included in a clinical trial;1, Yes | 2, No | 9, Unknown
clinical;10;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
clinical;10;oth_clinical_trial;other_type_of_treatment;EURACAN;Patient included in a clinical trial;1, Yes | 2, No
clinician;2;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
clinician;2;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
cloacal;2;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
cloacal;2;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
closest;1;closest_degree_affect_rel;Diagnosis Aetiology;Rare Liver (Vascular);Closest degree of affected relatives;radio
cloves;1;CLOVES syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;CLOVES syndrome;
cm;9;igm_cmv;Diagnosis Aetiology;Rare Liver (Vascular);IgM CMV;radio
cm;9;pcr_cmv;Diagnosis Aetiology;Rare Liver (Vascular);PCR CMV;radio
cm;9;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cm;9;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cm;9;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cm;9;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cm;9;cm_clin;stage_procedures;EURACAN;cM;1, M0 | 2, M1
cm;9;cm;stage_procedures;EURACAN;cM;1, M0 | 2, M1
cm;9;Height (cm);Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Height in cm;Not Known/number. To one decimal point
cmv;6;igm_cmv;Diagnosis Aetiology;Rare Liver (Vascular);IgM CMV;radio
cmv;6;pcr_cmv;Diagnosis Aetiology;Rare Liver (Vascular);PCR CMV;radio
cmv;6;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cmv;6;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cmv;6;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cmv;6;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cn;6;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
cn;6;Full caryotype (if not inferred from CNV report);;ithaca;;string
cn;6;cn_clin;stage_procedures;EURACAN;cN;1, Nx | 2, N0 | 3, N1 | 4, N2 | 5, N2a | 6, N2b | 7, N2c | 8, N3 | 9, N3a | 10, N3b
cn;6;cn;stage_procedures;EURACAN;cN;1, Nx | 2, N0 | 3, N1 | 4, N2 | 5, N2a | 6, N2b | 7, N2c | 8, N3 | 9, N3a | 10, N3b
cn;6;KCNJ11;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;KCNJ11;
cn;6;KCNJ11;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;KCNJ11;
coag;10;use_anticoagulants;Diagnosis Biobank;Rare Liver (Vascular);Use of anticoagulants;dropdown
coag;10;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
coag;10;pc_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
coag;10;pc_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
coag;10;ps_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
coag;10;ps_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
coag;10;lupus_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);Lupus anticoagulant antibody;radio
coag;10;dia_lab_dev_coag_dt;Diagnosis Laboratory data;Rare Liver (Vascular);Deviant Laboratory Date;date
coag;10;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
coag;10;anticoag_first_initiated;Follow-up Events;Rare Liver (Vascular);Anticoagulation was first initiated;radio
coat;4;buffy_coat_obtained;Diagnosis Biobank;Rare Liver (Vascular);Buffy coat sample obtained ?;dropdown
coat;4;buffy_coat_date;Diagnosis Biobank;Rare Liver (Vascular);Buffy coat sample date;date
coat;4;buffy_coat_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
coat;4;buffy_coat_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
code;11;Codesystem;Anatomical Therapeutic Chemical Classification;ithaca;;string
code;11;Code;Anatomical Therapeutic Chemical Classification;ithaca;;string
code;11;Description of code;Anatomical Therapeutic Chemical Classification;ithaca;;string
code;11;Codesystem;;ithaca;;string
code;11;Code;;ithaca;;string
code;11;Description of code;;ithaca;;hyperlink
code;11;Parents (link to other OMIM code);;ithaca;;mref
code;11;Allelic variant of (link to other OMIM code);;ithaca;;xref
code;11;Postal code;;ithaca;;string
code;11;OMIM Code;;ithaca;;mref
code;11;All codes;;ithaca;;string
codesystem;2;Codesystem;Anatomical Therapeutic Chemical Classification;ithaca;;string
codesystem;2;Codesystem;;ithaca;;string
coding;4;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
coding;4;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
coding;4;Diagnosis Coding System;;ithaca;;mref
coding;4;Diagnosis Coding System;;ithaca;;mref
coffin-lowry;2;Coffin-Lowry syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Coffin-Lowry syndromeÂ ;
coffin-lowry;2;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
cognitive;1;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
cohen;1;Cohen syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cohen syndromeÂ ;
colectomy;5;R_PSC_Colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Colectomy;radio
colectomy;5;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
colectomy;5;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
colectomy;5;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
colectomy;5;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
coleectomy;1;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
colesterol;2;dia_lab_colesterol_t;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
colesterol;2;dia_lab_colesterol_hdl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
collat;2;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
collat;2;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
collaterals;1;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
collecting;1;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
colobomatous;2;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
colobomatous;2;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
colon;10;R_PSC_Colonoscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Colonoscopy;radio
colon;10;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
colon;10;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
colon;10;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
colon;10;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
colon;10;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
colon;10;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
colon;10;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
colon;10;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
colon;10;Age at colonoscopy;subject;Genturis;What was the age (years) of the patient at the last colonoscopy?;int
colonoscopy;7;R_PSC_Colonoscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Colonoscopy;radio
colonoscopy;7;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
colonoscopy;7;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
colonoscopy;7;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
colonoscopy;7;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
colonoscopy;7;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
colonoscopy;7;Age at colonoscopy;subject;Genturis;What was the age (years) of the patient at the last colonoscopy?;int
com;39;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
com;39;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
com;39;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
com;39;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
com;39;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
com;39;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
com;39;patient_comments;Diagnosis General Information;Rare Liver (Vascular);Comments;textarea
com;39;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
com;39;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
com;39;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
com;39;comments_pregnancy;Diagnosis Aetiology;Rare Liver (Vascular);Comments;textarea
com;39;com_topic;Comments Comments;Rare Liver (Vascular);Topic of Comment;radio
com;39;com_txt;Comments Comments;Rare Liver (Vascular);Comment;textarea
com;39;Comorbidities;;ithaca;;compound
com;39;Other comorbidities;;ithaca;;text
com;39;General comments;;ithaca;;text
com;39;comorbid_ynu;charlson_index;EURACAN;Comorbidity;1, Yes | 2, No | 9, Unknown
com;39;comorbid;charlson_index;EURACAN;Choose all present comorbidities;1, Myocardial infarct (+1) | 2, Congestive heart failure (+1) | 3, Peripheral vascular disease (+1) | 4, Cerebrovascular disease (except hemiplegia) (+1) | 5, Dementia (+1) | 6, Chronic pulmonary disease (+1) | 7, Connective tissue disease (+1) | 8, Ulcer disease (+1) | 9, Mild liver disease (+1) | 17, Moderate or severe liver disease (+3) | 10, Diabetes (without complications) (+1) | 11, Diabetes with end organ damage (+2) | 12, Hemiplegia (+2) | 13, Moderate or severe renal disease (+2) | 14, Solid tumor (non metastatic) (+2) | 18, Metastatic solid tumor (+6) | 15, Leukemia (+2) | 16, Lymphoma, Multiple myeloma (+2) | 19, AIDS (+6)
com;39;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
com;39;Concomitant disease;Patient's history;PaedCan;Presence or absence of any disease which might be related or not to current malignancy;yes/no/unknown
com;39;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
com;39;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
com;39;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
com;39;Specify complications;Surgery;PaedCan;Definition of complication;String
com;39;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
com;39;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
com;39;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
com;39;Dahlberg-Borer-Newcomer syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dahlberg-Borer-Newcomer syndrome;
com;39;Carney Complex;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney Complex;
com;39;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
com;39;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
com;39;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
com;39;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
com;39;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
com;39;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
com;39;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
com;39;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
com;39;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
com;39;Further comments;Genetic diagnosis;ERKNet;Â ;gen_comment
combined;4;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
combined;4;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
combined;4;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
combined;4;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
comments;4;patient_comments;Diagnosis General Information;Rare Liver (Vascular);Comments;textarea
comments;4;comments_pregnancy;Diagnosis Aetiology;Rare Liver (Vascular);Comments;textarea
comments;4;General comments;;ithaca;;text
comments;4;Further comments;Genetic diagnosis;ERKNet;Â ;gen_comment
comorb;6;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
comorb;6;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
comorb;6;Comorbidities;;ithaca;;compound
comorb;6;Other comorbidities;;ithaca;;text
comorb;6;comorbid_ynu;charlson_index;EURACAN;Comorbidity;1, Yes | 2, No | 9, Unknown
comorb;6;comorbid;charlson_index;EURACAN;Choose all present comorbidities;1, Myocardial infarct (+1) | 2, Congestive heart failure (+1) | 3, Peripheral vascular disease (+1) | 4, Cerebrovascular disease (except hemiplegia) (+1) | 5, Dementia (+1) | 6, Chronic pulmonary disease (+1) | 7, Connective tissue disease (+1) | 8, Ulcer disease (+1) | 9, Mild liver disease (+1) | 17, Moderate or severe liver disease (+3) | 10, Diabetes (without complications) (+1) | 11, Diabetes with end organ damage (+2) | 12, Hemiplegia (+2) | 13, Moderate or severe renal disease (+2) | 14, Solid tumor (non metastatic) (+2) | 18, Metastatic solid tumor (+6) | 15, Leukemia (+2) | 16, Lymphoma, Multiple myeloma (+2) | 19, AIDS (+6)
comorbid;5;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
comorbid;5;Comorbidities;;ithaca;;compound
comorbid;5;Other comorbidities;;ithaca;;text
comorbid;5;comorbid_ynu;charlson_index;EURACAN;Comorbidity;1, Yes | 2, No | 9, Unknown
comorbid;5;comorbid;charlson_index;EURACAN;Choose all present comorbidities;1, Myocardial infarct (+1) | 2, Congestive heart failure (+1) | 3, Peripheral vascular disease (+1) | 4, Cerebrovascular disease (except hemiplegia) (+1) | 5, Dementia (+1) | 6, Chronic pulmonary disease (+1) | 7, Connective tissue disease (+1) | 8, Ulcer disease (+1) | 9, Mild liver disease (+1) | 17, Moderate or severe liver disease (+3) | 10, Diabetes (without complications) (+1) | 11, Diabetes with end organ damage (+2) | 12, Hemiplegia (+2) | 13, Moderate or severe renal disease (+2) | 14, Solid tumor (non metastatic) (+2) | 18, Metastatic solid tumor (+6) | 15, Leukemia (+2) | 16, Lymphoma, Multiple myeloma (+2) | 19, AIDS (+6)
comorbidity;1;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
compl;14;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
compl;14;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
compl;14;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
compl;14;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
compl;14;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
compl;14;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
compl;14;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
compl;14;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
compl;14;Specify complications;Surgery;PaedCan;Definition of complication;String
compl;14;Carney Complex;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney Complex;
compl;14;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
compl;14;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
compl;14;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
compl;14;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
complete;2;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
complete;2;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
complex;3;Carney Complex;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney Complex;
complex;3;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
complex;3;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
complex-trismus-pseudocamptodactyly;1;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
complication;8;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
complication;8;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
complication;8;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
complication;8;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
complication;8;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
complication;8;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
complication;8;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
complication;8;Specify complications;Surgery;PaedCan;Definition of complication;String
complications;7;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
complications;7;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
complications;7;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
complications;7;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
complications;7;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
complications;7;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
complications;7;Specify complications;Surgery;PaedCan;Definition of complication;String
components;1;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
con;96;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
con;96;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
con;96;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
con;96;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
con;96;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
con;96;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
con;96;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
con;96;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
con;96;cons_form;Diagnosis General Information;Rare Liver (Vascular);Informed consent form approved and signed;radio
con;96;sys_con_tissue;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Connective Tissue Disease;radio
con;96;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
con;96;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
con;96;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
con;96;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
con;96;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
con;96;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
con;96;contra_check;Diagnosis Aetiology;Rare Liver (Vascular);contra_check;calculation
con;96;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
con;96;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
con;96;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
con;96;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
con;96;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
con;96;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
con;96;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
con;96;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
con;96;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
con;96;"b. Constipation is treated with: 		";5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
con;96;a. Incontinent for feces (age > 4 years): ;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
con;96;b. Severity of incontinence:;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
con;96;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
con;96;Informed consent;subject;Genturis;;compound
con;96;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
con;96;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
con;96;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
con;96;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
con;96;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
con;96;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
con;96;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
con;96;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
con;96;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
con;96;ERN/HCP main contact;;ithaca;;mref
con;96;ERN/HCP other contactperson (s);;ithaca;;mref
con;96;Consent;;ithaca;;compound
con;96;Consent for Care;;ithaca;;bool
con;96;Date of consent;;ithaca;;date
con;96;Consent for ERN databases/Registries/research;;ithaca;;bool
con;96;Date of consent;;ithaca;;date
con;96;Consent to be contacted for research;;ithaca;;bool
con;96;Date of consent;;ithaca;;date
con;96;Consent for usage of biobank material;;ithaca;;bool
con;96;Date of consent;;ithaca;;date
con;96;Retractation to be contacted for research;;ithaca;;bool
con;96;First Contact date;;ithaca;;date
con;96;Consultation Request;;ithaca;;compound
con;96;Consultation Request Reason;;ithaca;;categorical
con;96;Consultation Request Reason Description;;ithaca;;text
con;96;Secondary Thematic Areas;;ithaca;;categorical
con;96;first_contact_date;patient_management_at_the_hospital;EURACAN;Date of first contact with the hospital/registration start;DD-MM-YYYY Format
con;96;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
con;96;consent_biological_data;patient_management_at_the_hospital;EURACAN;Consent to use biological data;1, Yes | 2, No
con;96;reconstruction;surgery;EURACAN;Reconstruction;1, Yes | 2, No | 3, Not required | 9, Unknown
con;96;To be contacted;Informed consent;PaedCan;Definition whether consent to be contacted was obtained;yes/no
con;96;Concomitant disease;Patient's history;PaedCan;Presence or absence of any disease which might be related or not to current malignancy;yes/no/unknown
con;96;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
con;96;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
con;96;In case of a second tumor please specify the type;Events;PaedCan;;String
con;96;Consent for Core Registry;Consent;EuRR-Bone & EuRRECa;Consent to add patients details to the Core Registry;String
con;96;First Contact with Centre;Care Pathway;EuRR-Bone & EuRRECa;Month and year of first contact with notifying centre;dd/mm/yyyy
con;96;Condition Group;Disease History;EuRR-Bone & EuRRECa;One of eight MTGs of Endo-ERN;boxes
con;96;Date of Condition Onset;Disease History;EuRR-Bone & EuRRECa;Approximate date at which symptoms and signs first appeared;dd/mm/yyyy
con;96;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
con;96;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
con;96;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
con;96;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
con;96;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
con;96;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
con;96;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
con;96;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
con;96;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
con;96;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
con;96;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
con;96;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
con;96;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
con;96;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
con;96;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
con;96;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
con;96;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
con;96;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
con;96;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
con;96;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
conclusive;1;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
concomitant;2;Concomitant disease;Patient's history;PaedCan;Presence or absence of any disease which might be related or not to current malignancy;yes/no/unknown
concomitant;2;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
condition;4;Condition Group;Disease History;EuRR-Bone & EuRRECa;One of eight MTGs of Endo-ERN;boxes
condition;4;Date of Condition Onset;Disease History;EuRR-Bone & EuRRECa;Approximate date at which symptoms and signs first appeared;dd/mm/yyyy
condition;4;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
condition;4;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
condition-specific;1;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
confirmed;1;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
congenital;13;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
congenital;13;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
congenital;13;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
congenital;13;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
congenital;13;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
congenital;13;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
congenital;13;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
congenital;13;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
congenital;13;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
congenital;13;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
congenital;13;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
congenital;13;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
congenital;13;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
congenital-generalized;1;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
cons;40;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
cons;40;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
cons;40;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
cons;40;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
cons;40;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
cons;40;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
cons;40;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
cons;40;cons_form;Diagnosis General Information;Rare Liver (Vascular);Informed consent form approved and signed;radio
cons;40;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
cons;40;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
cons;40;"b. Constipation is treated with: 		";5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
cons;40;Informed consent;subject;Genturis;;compound
cons;40;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
cons;40;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
cons;40;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
cons;40;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
cons;40;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
cons;40;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
cons;40;Consent;;ithaca;;compound
cons;40;Consent for Care;;ithaca;;bool
cons;40;Date of consent;;ithaca;;date
cons;40;Consent for ERN databases/Registries/research;;ithaca;;bool
cons;40;Date of consent;;ithaca;;date
cons;40;Consent to be contacted for research;;ithaca;;bool
cons;40;Date of consent;;ithaca;;date
cons;40;Consent for usage of biobank material;;ithaca;;bool
cons;40;Date of consent;;ithaca;;date
cons;40;Consultation Request;;ithaca;;compound
cons;40;Consultation Request Reason;;ithaca;;categorical
cons;40;Consultation Request Reason Description;;ithaca;;text
cons;40;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
cons;40;consent_biological_data;patient_management_at_the_hospital;EURACAN;Consent to use biological data;1, Yes | 2, No
cons;40;reconstruction;surgery;EURACAN;Reconstruction;1, Yes | 2, No | 3, Not required | 9, Unknown
cons;40;Consent for Core Registry;Consent;EuRR-Bone & EuRRECa;Consent to add patients details to the Core Registry;String
consent;23;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
consent;23;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
consent;23;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
consent;23;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
consent;23;Informed consent;subject;Genturis;;compound
consent;23;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
consent;23;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
consent;23;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
consent;23;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
consent;23;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
consent;23;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
consent;23;Consent;;ithaca;;compound
consent;23;Consent for Care;;ithaca;;bool
consent;23;Date of consent;;ithaca;;date
consent;23;Consent for ERN databases/Registries/research;;ithaca;;bool
consent;23;Date of consent;;ithaca;;date
consent;23;Consent to be contacted for research;;ithaca;;bool
consent;23;Date of consent;;ithaca;;date
consent;23;Consent for usage of biobank material;;ithaca;;bool
consent;23;Date of consent;;ithaca;;date
consent;23;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
consent;23;consent_biological_data;patient_management_at_the_hospital;EURACAN;Consent to use biological data;1, Yes | 2, No
consent;23;Consent for Core Registry;Consent;EuRR-Bone & EuRRECa;Consent to add patients details to the Core Registry;String
consistent;10;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
consistent;10;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
consistent;10;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
consistent;10;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
constipation;1;"b. Constipation is treated with: 		";5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
constructed;1;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
contact;20;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
contact;20;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
contact;20;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
contact;20;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
contact;20;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
contact;20;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
contact;20;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
contact;20;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
contact;20;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
contact;20;ERN/HCP main contact;;ithaca;;mref
contact;20;ERN/HCP other contactperson (s);;ithaca;;mref
contact;20;Consent to be contacted for research;;ithaca;;bool
contact;20;Retractation to be contacted for research;;ithaca;;bool
contact;20;First Contact date;;ithaca;;date
contact;20;first_contact_date;patient_management_at_the_hospital;EURACAN;Date of first contact with the hospital/registration start;DD-MM-YYYY Format
contact;20;To be contacted;Informed consent;PaedCan;Definition whether consent to be contacted was obtained;yes/no
contact;20;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
contact;20;First Contact with Centre;Care Pathway;EuRR-Bone & EuRRECa;Month and year of first contact with notifying centre;dd/mm/yyyy
contact;20;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
contact;20;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
contacted;5;Consent to be contacted for research;;ithaca;;bool
contacted;5;Retractation to be contacted for research;;ithaca;;bool
contacted;5;To be contacted;Informed consent;PaedCan;Definition whether consent to be contacted was obtained;yes/no
contacted;5;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
contacted;5;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
contra;9;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
contra;9;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
contra;9;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
contra;9;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
contra;9;contra_check;Diagnosis Aetiology;Rare Liver (Vascular);contra_check;calculation
contra;9;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
contra;9;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
contra;9;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
contra;9;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
contrac;8;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
contrac;8;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
contrac;8;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
contrac;8;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
contrac;8;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
contrac;8;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
contrac;8;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
contrac;8;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
contracept;6;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
contracept;6;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
contracept;6;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
contracept;6;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
contracept;6;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
contracept;6;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
contraceptive;5;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
contraceptive;5;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
contraceptive;5;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
contraceptive;5;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
contraceptive;5;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
contraceptives;4;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
contraceptives;4;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
contraceptives;4;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
contraceptives;4;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
contractures;1;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
control;3;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
control;3;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
control;3;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
convertase;1;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
copy;18;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
copy;18;R_PSC_Colonoscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Colonoscopy;radio
copy;18;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
copy;18;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
copy;18;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
copy;18;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
copy;18;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
copy;18;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
copy;18;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
copy;18;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
copy;18;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
copy;18;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
copy;18;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
copy;18;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
copy;18;Age at colonoscopy;subject;Genturis;What was the age (years) of the patient at the last colonoscopy?;int
copy;18;copy_number_baseline;primary_cancer;EURACAN;Copy Number;
copy;18;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
copy;18;copy_number_radio;radiotherapy;EURACAN;Copy Number;
core;46;MG-ADL total score;QoL;EURO-NMD;;int
core;46;Total QMG score if done;QMG;EURO-NMD;;
core;46;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
core;46;R_AIH_Simplified_AIH_score;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Simplified AIH score;numeric
core;46;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
core;46;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
core;46;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
core;46;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
core;46;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
core;46;R_PBC_Nakanuma_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed?;radio
core;46;R_PBC_nakanuma_grading_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
core;46;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
core;46;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
core;46;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
core;46;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
core;46;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
core;46;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
core;46;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
core;46;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
core;46;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
core;46;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
core;46;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
core;46;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
core;46;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
core;46;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
core;46;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
core;46;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
core;46;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
core;46;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
core;46;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
core;46;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
core;46;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
core;46;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
core;46;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
core;46;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
core;46;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
core;46;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
core;46;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
core;46;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
core;46;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
core;46;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
core;46;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
core;46;WHODAS 2.0 Score (%);;ithaca;;int
core;46;Consent for Core Registry;Consent;EuRR-Bone & EuRRECa;Consent to add patients details to the Core Registry;String
core;46;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
core;46;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
cortisol-producing;1;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
count;21;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
count;21;country_birth;Diagnosis General Information;Rare Liver (Vascular);Country of birth;dropdown
count;21;country_study;Diagnosis General Information;Rare Liver (Vascular);Country of study;dropdown
count;21;dia_lab_red_blood_cell_count;Diagnosis Laboratory data;Rare Liver (Vascular);Red blood cell count;numeric
count;21;dia_lab_platelet_count;Diagnosis Laboratory data;Rare Liver (Vascular);Platelet count;numeric
count;21;fu_cli_last_platelet_count;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
count;21;Country;subject;Genturis;What is the patient's country of residence?;xref
count;21;country;;ithaca;;xref
count;21;Country;;ithaca;;categorical
count;21;Country;;ithaca;;categorical
count;21;Country of residence;;ithaca;;xref
count;21;Country of Birth;;ithaca;;xref
count;21;residence_country;patient_management_at_the_hospital;EURACAN;Country of residence;1, Afghanistan | 2, Albania | 3, Algeria | 4, Andorra | 5, Angola | 6, Antigua and Barbuda | 7, Argentina | 8, Armenia | 9, Australia | 10, Austria | 11, Azerbaijan | 12, The Bahamas | 13, Bahrain | 14, Bangladesh | 15, Barbados | 16, Belarus | 17, Belgium | 18, Belize | 19, Benin | 20, Bhutan | 21, Bolivia | 22, Bosnia and Herzegovina | 23, Botswana | 24, Brazil | 25, Brunei | 26, Bulgaria | 27, Burkina Faso | 28, Burundi | 29, Cambodia | 30, Cameroon | 31, Canada | 32, Cape Verde | 33, Central African Republic | 34, Chad | 35, Chile | 36, China | 37, Colombia | 38, Comoros | 39, Congo | 40, Costa Rica | 41, Cote d'Ivoire | 42, Croatia | 43, Cuba | 44, Cyprus | 45, Czech Republic | 46, Denmark | 47, Djibouti | 48, Dominica | 49, Dominican Republic | 50, East Timor (Timor-Leste) | 51, Ecuador | 52, Egypt | 53, El Salvador | 54, Equatorial Guinea | 55, Eritrea | 56, Estonia | 57, Ethiopia | 58, Fiji | 59, Finland | 60, France | 61, Gabon | 62, The Gambia | 63, Georgia | 64, Germany | 65, Ghana | 66, Greece | 67, Grenada | 68, Guatemala | 69, Guinea | 70, Guinea-Bissau | 71, Guyana | 72, Haiti | 73, Honduras | 74, Hungary | 75, Iceland | 76, India | 77, Indonesia | 78, Iran | 79, Iraq | 80, Ireland | 81, Israel | 82, Italy | 83, Jamaica | 84, Japan | 85, Jordan | 86, Kazakhstan | 87, Kenya | 88, Kiribati | 89, Korea (North) | 90, Korea (South) | 91, Kosovo | 92, Kuwait | 93, Kyrgyzstan | 94, Laos | 95, Latvia | 96, Lebanon | 97, Lesotho | 98, Liberia | 99, Libya | 100, Liechtenstein | 101, Lithuania | 102, Luxembourg | 103, Macedonia | 104, Madagascar | 105, Malawi | 106, Malaysia | 107, Maldives | 108, Mali | 109, Malta | 110, Marshall Islands | 111, Mauritania | 112, Mauritius | 113, Mexico | 114, Micronesia | 115, Moldova | 116, Monaco | 117, Mongolia | 118, Montenegro | 119, Morocco | 120, Mozambique | 121, Myanmar (Burma) | 122, Namibia | 123, Nauru | 124, Nepal | 125, Netherlands | 126, New Zealand | 127, Nicaragua | 128, Niger | 129, Nigeria | 130, Norway | 131, Oman | 132, Pakistan | 133, Palau | 134, Panama | 135, Papua New Guinea | 136, Paraguay | 137, Peru | 138, Philippines | 139, Poland | 140, Portugal | 141, Qatar | 142, Romania | 143, Russia | 144, Rwanda | 145, Saint Kitts and Nevis | 146, Saint Lucia | 147, Saint Vincent and the Grenadines | 148, Samoa | 149, San Marino | 150, Sao Tome and Principe | 151, Saudi Arabia | 152, Senegal | 153, Serbia | 154, Seychelles | 155, Sierra Leone | 156, Singapore | 157, Slovakia | 158, Slovenia | 159, Solomon Islands | 160, Somalia | 161, South Africa | 162, South Sudan | 163, Spain | 164, Sri Lanka | 165, Sudan | 166, Suriname | 167, Swaziland | 168, Sweden | 169, Switzerland | 170, Syria | 171, Taiwan | 172, Tajikistan | 173, Tanzania | 174, Thailand | 175, Togo | 176, Tonga | 177, Trinidad and Tobago | 178, Tunisia | 179, Turkey | 180, Turkmenistan | 181, Tuvalu | 182, Uganda | 183, Ukraine | 184, United Arab Emirates | 185, United Kingdom | 186, United States of America | 187, Uruguay | 188, Uzbekistan | 189, Vanuatu | 190, Vatican City | 191, Venezuela | 192, Vietnam | 193, Yemen | 194, Zambia | 195, Zimbabwe
count;21;Country of registration;Personal Information;PaedCan;Country where the patient is registered;String
count;21;Country of birth;Personal Information;PaedCan;Patient's country of birth;String
count;21;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
count;21;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
count;21;Country of birth;Personal Information;EuRR-Bone & EuRRECa;Country of birth;drop down/select
count;21;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
count;21;Country of HCP ;Care Pathway;EuRR-Bone & EuRRECa;Country where the notifying centre is based;fixed string
count;21;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
counting;1;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
country;16;country_birth;Diagnosis General Information;Rare Liver (Vascular);Country of birth;dropdown
country;16;country_study;Diagnosis General Information;Rare Liver (Vascular);Country of study;dropdown
country;16;Country;subject;Genturis;What is the patient's country of residence?;xref
country;16;country;;ithaca;;xref
country;16;Country;;ithaca;;categorical
country;16;Country;;ithaca;;categorical
country;16;Country of residence;;ithaca;;xref
country;16;Country of Birth;;ithaca;;xref
country;16;residence_country;patient_management_at_the_hospital;EURACAN;Country of residence;1, Afghanistan | 2, Albania | 3, Algeria | 4, Andorra | 5, Angola | 6, Antigua and Barbuda | 7, Argentina | 8, Armenia | 9, Australia | 10, Austria | 11, Azerbaijan | 12, The Bahamas | 13, Bahrain | 14, Bangladesh | 15, Barbados | 16, Belarus | 17, Belgium | 18, Belize | 19, Benin | 20, Bhutan | 21, Bolivia | 22, Bosnia and Herzegovina | 23, Botswana | 24, Brazil | 25, Brunei | 26, Bulgaria | 27, Burkina Faso | 28, Burundi | 29, Cambodia | 30, Cameroon | 31, Canada | 32, Cape Verde | 33, Central African Republic | 34, Chad | 35, Chile | 36, China | 37, Colombia | 38, Comoros | 39, Congo | 40, Costa Rica | 41, Cote d'Ivoire | 42, Croatia | 43, Cuba | 44, Cyprus | 45, Czech Republic | 46, Denmark | 47, Djibouti | 48, Dominica | 49, Dominican Republic | 50, East Timor (Timor-Leste) | 51, Ecuador | 52, Egypt | 53, El Salvador | 54, Equatorial Guinea | 55, Eritrea | 56, Estonia | 57, Ethiopia | 58, Fiji | 59, Finland | 60, France | 61, Gabon | 62, The Gambia | 63, Georgia | 64, Germany | 65, Ghana | 66, Greece | 67, Grenada | 68, Guatemala | 69, Guinea | 70, Guinea-Bissau | 71, Guyana | 72, Haiti | 73, Honduras | 74, Hungary | 75, Iceland | 76, India | 77, Indonesia | 78, Iran | 79, Iraq | 80, Ireland | 81, Israel | 82, Italy | 83, Jamaica | 84, Japan | 85, Jordan | 86, Kazakhstan | 87, Kenya | 88, Kiribati | 89, Korea (North) | 90, Korea (South) | 91, Kosovo | 92, Kuwait | 93, Kyrgyzstan | 94, Laos | 95, Latvia | 96, Lebanon | 97, Lesotho | 98, Liberia | 99, Libya | 100, Liechtenstein | 101, Lithuania | 102, Luxembourg | 103, Macedonia | 104, Madagascar | 105, Malawi | 106, Malaysia | 107, Maldives | 108, Mali | 109, Malta | 110, Marshall Islands | 111, Mauritania | 112, Mauritius | 113, Mexico | 114, Micronesia | 115, Moldova | 116, Monaco | 117, Mongolia | 118, Montenegro | 119, Morocco | 120, Mozambique | 121, Myanmar (Burma) | 122, Namibia | 123, Nauru | 124, Nepal | 125, Netherlands | 126, New Zealand | 127, Nicaragua | 128, Niger | 129, Nigeria | 130, Norway | 131, Oman | 132, Pakistan | 133, Palau | 134, Panama | 135, Papua New Guinea | 136, Paraguay | 137, Peru | 138, Philippines | 139, Poland | 140, Portugal | 141, Qatar | 142, Romania | 143, Russia | 144, Rwanda | 145, Saint Kitts and Nevis | 146, Saint Lucia | 147, Saint Vincent and the Grenadines | 148, Samoa | 149, San Marino | 150, Sao Tome and Principe | 151, Saudi Arabia | 152, Senegal | 153, Serbia | 154, Seychelles | 155, Sierra Leone | 156, Singapore | 157, Slovakia | 158, Slovenia | 159, Solomon Islands | 160, Somalia | 161, South Africa | 162, South Sudan | 163, Spain | 164, Sri Lanka | 165, Sudan | 166, Suriname | 167, Swaziland | 168, Sweden | 169, Switzerland | 170, Syria | 171, Taiwan | 172, Tajikistan | 173, Tanzania | 174, Thailand | 175, Togo | 176, Tonga | 177, Trinidad and Tobago | 178, Tunisia | 179, Turkey | 180, Turkmenistan | 181, Tuvalu | 182, Uganda | 183, Ukraine | 184, United Arab Emirates | 185, United Kingdom | 186, United States of America | 187, Uruguay | 188, Uzbekistan | 189, Vanuatu | 190, Vatican City | 191, Venezuela | 192, Vietnam | 193, Yemen | 194, Zambia | 195, Zimbabwe
country;16;Country of registration;Personal Information;PaedCan;Country where the patient is registered;String
country;16;Country of birth;Personal Information;PaedCan;Patient's country of birth;String
country;16;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
country;16;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
country;16;Country of birth;Personal Information;EuRR-Bone & EuRRECa;Country of birth;drop down/select
country;16;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
country;16;Country of HCP ;Care Pathway;EuRR-Bone & EuRRECa;Country where the notifying centre is based;fixed string
cramps-acral;1;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
craniodiaphyseal;1;Craniodiaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniodiaphyseal dysplasia ;
craniometaphyseal;1;Craniometaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniometaphyseal dysplasia ;
crb;3;buffy_coat_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
crb;3;dna_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
crb;3;plasma_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
creat;31;R_AIH_Creatinine_mgdL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
creat;31;R_AIH_Creatinine_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
creat;31;R_PBC_Creatinine_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_PBC_Creatinine_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
creat;31;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
creat;31;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
creat;31;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
creat;31;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creat;31;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
creat;31;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
creat;31;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
creat;31;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
creat;31;fu_cli_bef_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
creat;31;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
creat;31;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
creat;31;fu_cli_last_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
creat;31;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
creat;31;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
creat;31;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
creat;31;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
creat;31;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
creat;31;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
creat;31;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
creat;31;Serum creatinine;Biochemistry;ERKNet;Â ;screa
creat;31;Protein/Creatinine;Biochemistry;ERKNet;if 2;protur_protcrea
creating;1;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
creatinine;22;R_AIH_Creatinine_mgdL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
creatinine;22;R_AIH_Creatinine_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
creatinine;22;R_PBC_Creatinine_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_PBC_Creatinine_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
creatinine;22;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
creatinine;22;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
creatinine;22;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
creatinine;22;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
creatinine;22;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
creatinine;22;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
creatinine;22;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
creatinine;22;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
creatinine;22;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
creatinine;22;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
creatinine;22;Serum creatinine;Biochemistry;ERKNet;Â ;screa
creatinine;22;Protein/Creatinine;Biochemistry;ERKNet;if 2;protur_protcrea
creatinine2;1;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
creation;1;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
crebbp;1;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
crit;6;incl_crit;Diagnosis General Information;Rare Liver (Vascular);Inclusion criteria;checkbox
crit;6;excl_crit;Diagnosis General Information;Rare Liver (Vascular);Exclusion criteria;checkbox
crit;6;dia_lab_haematocrit;Diagnosis Laboratory data;Rare Liver (Vascular);Haematocrit;numeric
crit;6;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
crit;6;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
crit;6;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
criteria;3;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
criteria;3;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
criteria;3;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
crp;2;fu_cli_bef_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
crp;2;fu_cli_last_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
cryptorchidism;1;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
ct;231;Affected family members;Diagnosis Family History;EURO-NMD;;multi
ct;231;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
ct;231;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
ct;231;Symptom fluctuation;Diagnosis Fluctuation;EURO-NMD;;yesno
ct;231;Chest CT findings;Diagnosis ;EURO-NMD;;single
ct;231;Thymectomy?;Diagnosis ;EURO-NMD;;single
ct;231;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
ct;231;Medication Effect;Medication ;EURO-NMD;;single
ct;231;Thymectomy?;Thymoma;EURO-NMD;;yesno
ct;231;Â­ Thymectomy date;Thymoma;EURO-NMD;;date
ct;231;Time from onset to thymectomy:;Thymoma;EURO-NMD;;
ct;231;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
ct;231;R_AIH_Contact_consent;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
ct;231;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
ct;231;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
ct;231;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
ct;231;R_PBC_Bile_duct_loss_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
ct;231;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
ct;231;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
ct;231;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
ct;231;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
ct;231;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
ct;231;R_PSC_Colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Colectomy;radio
ct;231;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
ct;231;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
ct;231;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
ct;231;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
ct;231;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
ct;231;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
ct;231;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
ct;231;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
ct;231;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
ct;231;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
ct;231;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
ct;231;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
ct;231;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
ct;231;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
ct;231;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
ct;231;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
ct;231;cto;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);CT;radio
ct;231;bile_ducts;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Bile ducts;radio
ct;231;ivc_aspect;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Aspect;radio
ct;231;ivc_obstructed_or_stenosed;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Level of obstruction;radio
ct;231;pv_direction_of_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Direction of flow;radio
ct;231;splenectomy;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenectomy;radio
ct;231;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
ct;231;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
ct;231;prot_c_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein C deficiency activity;numeric
ct;231;prot_s_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein S decreased activity?;radio
ct;231;factor_x;Diagnosis Aetiology;Rare Liver (Vascular);factor X;numeric
ct;231;factor_ii;Diagnosis Aetiology;Rare Liver (Vascular);factor II;numeric
ct;231;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
ct;231;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
ct;231;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
ct;231;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
ct;231;abdom_infect_panc;Diagnosis Aetiology;Rare Liver (Vascular);Pancreatitis;radio
ct;231;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
ct;231;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
ct;231;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
ct;231;abdom_infect_appen;Diagnosis Aetiology;Rare Liver (Vascular);Appendicitis;radio
ct;231;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
ct;231;abdom_infect_other;Diagnosis Aetiology;Rare Liver (Vascular);Other Infection / Inflammation;radio
ct;231;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
ct;231;extra_abdom_infect_inflam;Diagnosis Aetiology;Rare Liver (Vascular);Extra-abdominal infection/inflamation;radio
ct;231;closest_degree_affect_rel;Diagnosis Aetiology;Rare Liver (Vascular);Closest degree of affected relatives;radio
ct;231;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
ct;231;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
ct;231;dia_lab_factor_v;Diagnosis Laboratory data;Rare Liver (Vascular);Factor V;numeric
ct;231;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
ct;231;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
ct;231;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
ct;231;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
ct;231;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
ct;231;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
ct;231;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
ct;231;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
ct;231;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
ct;231;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
ct;231;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
ct;231;fu_ima_bef_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
ct;231;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
ct;231;fu_ima_last_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
ct;231;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
ct;231;fu_end_mesenteric_infarct;Follow-up Endpoints;Rare Liver (Vascular);Mesenteric infarction;radio
ct;231;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
ct;231;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
ct;231;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
ct;231;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
ct;231;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
ct;231;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
ct;231;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
ct;231;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ct;231;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ct;231;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
ct;231;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
ct;231;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ct;231;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ct;231;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ct;231;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ct;231;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
ct;231;"b.	Age at rejection:	";"6.	Rejection";Eurogen (Kid Transplantation);;[Numeric (Integer)]
ct;231;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
ct;231;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
ct;231;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
ct;231;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
ct;231;Phenotypical Characteristics;subject;Genturis;;compound
ct;231;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
ct;231;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
ct;231;ERN/HCP main contact;;ithaca;;mref
ct;231;ERN/HCP other contactperson (s);;ithaca;;mref
ct;231;Consent to be contacted for research;;ithaca;;bool
ct;231;Retractation for biobank use;;ithaca;;bool
ct;231;Date of retractation;;ithaca;;date
ct;231;Retractation for reuse;;ithaca;;bool
ct;231;Date of retractation;;ithaca;;date
ct;231;Retractation to be contacted for research;;ithaca;;bool
ct;231;Date of retractation;;ithaca;;date
ct;231;First Contact date;;ithaca;;date
ct;231;Functional Status and or Disability;;ithaca;;mref
ct;231;Active Ingredient (ATC);;ithaca;;mref
ct;231;Active Ingredient (ATC);;ithaca;;mref
ct;231;Gene affected;;ithaca;COSMIC genes (can be replaced by other list of genes);mref
ct;231;first_contact_date;patient_management_at_the_hospital;EURACAN;Date of first contact with the hospital/registration start;DD-MM-YYYY Format
ct;231;ct_primary;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
ct;231;ct_pet_primary;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
ct;231;ct_neck;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
ct;231;ct_pet_neck;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
ct;231;ct_meta;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
ct;231;ct_pet_meta;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
ct;231;ct_clin;stage_procedures;EURACAN;cT;1, Tx | 2, T0 | 3, Tis | 4, T1 | 5, T2 | 6, T3 | 7, T4 | 8, T4a | 9, T4b
ct;231;ct;stage_procedures;EURACAN;cT;1, Tx | 2, Tis | 3, T1 | 4, T2 | 5, T3 | 6, T4 | 7, T4a | 8, T4b
ct;231;ctcae_term;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ct;231;ctcae_spec;adverse_event;EURACAN;Please specify;
ct;231;ctcae_term_2;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ct;231;ctcae_spec_2;adverse_event;EURACAN;Please specify;
ct;231;ctcae_term_3;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ct;231;ctcae_spec_3;adverse_event;EURACAN;Please specify;
ct;231;ctcae_term_4;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ct;231;ctcae_spec_4;adverse_event;EURACAN;Please specify;
ct;231;ctcae_term_5;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ct;231;ctcae_spec_5;adverse_event;EURACAN;Please specify;
ct;231;neck_dissection;surgery;EURACAN;Neck dissection;1, Yes | 2, No | 9, Unknown
ct;231;reconstruction;surgery;EURACAN;Reconstruction;1, Yes | 2, No | 3, Not required | 9, Unknown
ct;231;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
ct;231;radio_photons_fractdose;radiotherapy;EURACAN;Photons dose per fraction;
ct;231;radio_photons_nrfract;radiotherapy;EURACAN;Photons number fraction;
ct;231;radio_electrons_tech;radiotherapy;EURACAN;Electrons treatment technique;1, FLASH  therapy
ct;231;radio_electrons_from;radiotherapy;EURACAN;Electrons start date;
ct;231;radio_electrons_to;radiotherapy;EURACAN;Electrons end date;
ct;231;radio_electrons_totdose;radiotherapy;EURACAN;Electrons total dose;
ct;231;radio_electrons_fractdose;radiotherapy;EURACAN;Electrons dose per fraction;
ct;231;radio_electrons_nrfract;radiotherapy;EURACAN;Electrons number fraction;
ct;231;radio_electrons_ott;radiotherapy;EURACAN;Electrons OTT;"datediff([radio_electrons_to],[radio_electrons_from],""d"")"
ct;231;radio_electrons_4d;radiotherapy;EURACAN;Electrons 4D treatment;1, Yes | 2, No
ct;231;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
ct;231;radio_electrons_igrt;radiotherapy;EURACAN;Electrons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
ct;231;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
ct;231;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
ct;231;radio_carbons_fractdose;radiotherapy;EURACAN;Carbons dose per fraction ;
ct;231;radio_carbons_nrfract;radiotherapy;EURACAN;Carbons number fraction ;
ct;231;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
ct;231;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
ct;231;radio_radionuc_fractdose;radiotherapy;EURACAN;Radionuclide dose per fraction ;
ct;231;radio_radionuc_nrfract;radiotherapy;EURACAN;Radionuclide number fraction ;
ct;231;radio_boron_fractdose;radiotherapy;EURACAN;Boron neutron capture therapy dose per fraction ;
ct;231;radio_boron_nrfract;radiotherapy;EURACAN;Boron neutron capture therapy number fraction ;
ct;231;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
ct;231;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
ct;231;end_treatment_ct;imaging_available;EURACAN;CT;1, Baseline | 2, After treatment
ct;231;end_treatment_ctpet;imaging_available;EURACAN;CT/PET;1, Baseline | 2, After treatment
ct;231;To be contacted;Informed consent;PaedCan;Definition whether consent to be contacted was obtained;yes/no
ct;231;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
ct;231;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
ct;231;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
ct;231;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
ct;231;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
ct;231;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
ct;231;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
ct;231;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
ct;231;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
ct;231;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
ct;231;First Contact with Centre;Care Pathway;EuRR-Bone & EuRRECa;Month and year of first contact with notifying centre;dd/mm/yyyy
ct;231;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
ct;231;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
ct;231;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
ct;231;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
ct;231;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
ct;231;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
ct;231;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
ct;231;CTLA-4;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;CTLA-4;
ct;231;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
ct;231;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
ct;231;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
ct;231;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
ct;231;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
ct;231;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
ct;231;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
ct;231;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
ct;231;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
ct;231;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
ct;231;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
ct;231;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
ct;231;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
ct;231;Functioning gonadotropic adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning gonadotropic adenoma;
ct;231;Functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning pituitary adenoma;
ct;231;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
ct;231;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
ct;231;Prolactinoma;PITUITARY;EuRR-Bone & EuRRECa;Prolactinoma;
ct;231;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
ct;231;Septo-optic dysplasia spectrum;PITUITARY;EuRR-Bone & EuRRECa;Septo-optic dysplasia spectrum;
ct;231;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
ct;231;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
ct;231;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
ct;231;5a-reductase def (SRD5A2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;5a-reductase def (SRD5A2);
ct;231;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
ct;231;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
ct;231;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
ct;231;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
ct;231;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
ct;231;MCT8 deficiency;THYROID;EuRR-Bone & EuRRECa;MCT8 deficiency;
ct;231;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
ct;231;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
ct;231;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
ct;231;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
ct;231;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
ct;231;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
ct;231;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
ct;231;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
ct;231;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
ct;231;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
ct;231;Family members affected?;Family history;ERKNet;Â ;fam_affected
ctcae;10;ctcae_term;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ctcae;10;ctcae_spec;adverse_event;EURACAN;Please specify;
ctcae;10;ctcae_term_2;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ctcae;10;ctcae_spec_2;adverse_event;EURACAN;Please specify;
ctcae;10;ctcae_term_3;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ctcae;10;ctcae_spec_3;adverse_event;EURACAN;Please specify;
ctcae;10;ctcae_term_4;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ctcae;10;ctcae_spec_4;adverse_event;EURACAN;Please specify;
ctcae;10;ctcae_term_5;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
ctcae;10;ctcae_spec_5;adverse_event;EURACAN;Please specify;
ctla-4;1;CTLA-4;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;CTLA-4;
cto;25;Thymectomy?;Diagnosis ;EURO-NMD;;single
cto;25;Thymectomy?;Thymoma;EURO-NMD;;yesno
cto;25;Â­ Thymectomy date;Thymoma;EURO-NMD;;date
cto;25;Time from onset to thymectomy:;Thymoma;EURO-NMD;;
cto;25;R_PSC_Colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Colectomy;radio
cto;25;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
cto;25;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
cto;25;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
cto;25;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
cto;25;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
cto;25;cto;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);CT;radio
cto;25;splenectomy;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenectomy;radio
cto;25;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
cto;25;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
cto;25;factor_x;Diagnosis Aetiology;Rare Liver (Vascular);factor X;numeric
cto;25;factor_ii;Diagnosis Aetiology;Rare Liver (Vascular);factor II;numeric
cto;25;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
cto;25;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
cto;25;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
cto;25;dia_lab_factor_v;Diagnosis Laboratory data;Rare Liver (Vascular);Factor V;numeric
cto;25;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
cto;25;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
cto;25;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
cto;25;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cto;25;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
ctpet;1;end_treatment_ctpet;imaging_available;EURACAN;CT/PET;1, Baseline | 2, After treatment
culture;2;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
culture;2;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
cumulative;1;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
cup;1;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
current;6;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
current;6;Current ambulatory status;Mobility ;EURO-NMD;;single
current;6;Current treatment;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
current;6;Period of current diagnosis;;ithaca;;categorical
current;6;Date of current diagnosis;;ithaca;;date
current;6;Current gender;Personal Information;EuRR-Bone & EuRRECa;Current gender;Male/Female/Non-binary/Other/Asked but Unknown
cushing;3;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
cushing;3;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
cushing;3;Cushing disease;PITUITARY;EuRR-Bone & EuRRECa;Cushing disease;
cycle;5;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
cycle;5;chemo_cycle;chemotherapy;EURACAN;Number of cycles;
cycle;5;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
cycle;5;tt_cycle;target_therapy;EURACAN;Number of cycles;
cycle;5;tt_cycle_unk;target_therapy;EURACAN;Unknown;1, Unknown
cyclosporina;14;R_AIH_CyclosporinA;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
cyclosporina;14;R_PBC_AIH_CyclosporinA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
cyclosporina;14;R_PSC_AIH_CyclosporinA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
cyclosporina;14;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
cyclosporina;14;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
cyclosporina;14;R_AIH_CyclosporinA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
cyclosporina;14;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
cyclosporina;14;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
cyp11a1;4;P450 scc def (CYP11A1);ADRENAL;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
cyp11a1;4;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
cyp11a1;4;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
cyp11a1;4;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
cyp11b1;5;11b-hydroxylase def (CYP11B1);ADRENAL;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
cyp11b1;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
cyp11b1;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
cyp11b1;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
cyp11b1;5;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
cyp17;4;CYP17 def (P450CYP17);ADRENAL;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
cyp17;4;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
cyp17;4;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
cyp17;4;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
cyp19a1;2;Aromatase def (CYP19A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Aromatase def (CYP19A1);
cyp19a1;2;Aromatase def (CYP19A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Aromatase def (CYP19A1);
cyp21a;5;21-hydroxylase def (CYP21A);ADRENAL;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
cyp21a;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
cyp21a;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
cyp21a;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
cyp21a;5;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
cystic;1;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
cystoscopy;3;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
cystoscopy;3;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
cystoscopy;3;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
cystourethrogram;1;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
cysts-overgrowth-wilms;1;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
cytogenetic;1;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
d-dependent;1;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
d-resistant;2;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
d-resistant;2;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
d.age;1;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
d.ebv;1;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
d.hla-dr;1;"d.	HLA-DR mismatches: ";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
d.number;1;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
d.specification;1;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
d620e;1;new_jak_2_mutation_d620e;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Exon-12;radio
dahlberg-borer-newcomer;1;Dahlberg-Borer-Newcomer syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dahlberg-Borer-Newcomer syndrome;
data;11;Data availability;subject;Genturis;What clinical data is locally available for this patient?;categoricalmref
data;11;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
data;11;Date of data entry;subject;Genturis;At what date (yyyy-mm-dd) was the data entered in the registry?;date
data;11;Consent for ERN databases/Registries/research;;ithaca;;bool
data;11;"Other;  what patient Data is available";;ithaca;;categoricalmref
data;11;Identifying data;;ithaca;;compound
data;11;consent_clinical_data;patient_management_at_the_hospital;EURACAN;Consent to use clinical data;1, Yes | 2, No
data;11;consent_biological_data;patient_management_at_the_hospital;EURACAN;Consent to use biological data;1, Yes | 2, No
data;11;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
data;11;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
data;11;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
date;238;Medication Date started;Medication ;EURO-NMD;;date
date;238;Medication Date stopped;Medication ;EURO-NMD;;date
date;238;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
date;238;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
date;238;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
date;238;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
date;238;Â­ Thymectomy date;Thymoma;EURO-NMD;;date
date;238;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
date;238;Date_of_death;Base information;Rare Liver (Auto imune);Date of Death;date
date;238;R_AIH_Date_of_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
date;238;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
date;238;R_AIH_Date_of_DXA;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
date;238;R_PBC_Date_of_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
date;238;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
date;238;R_PBC_Date_of_DXA;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
date;238;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
date;238;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
date;238;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
date;238;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
date;238;R_PSC_Date_of_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
date;238;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
date;238;R_PSC_Date_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date CHE;date
date;238;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
date;238;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
date;238;date_check_6mo;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);date_check_6mo;calculation
date;238;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
date;238;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
date;238;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
date;238;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
date;238;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
date;238;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
date;238;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
date;238;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
date;238;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
date;238;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
date;238;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
date;238;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
date;238;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
date;238;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
date;238;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
date;238;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
date;238;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
date;238;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
date;238;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
date;238;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
date;238;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
date;238;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
date;238;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
date;238;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
date;238;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
date;238;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
date;238;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
date;238;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
date;238;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
date;238;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
date;238;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Date_of_followup_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of follow-up;string
date;238;R_AIH_Date_of_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of DXA;date
date;238;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
date;238;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
date;238;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
date;238;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
date;238;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
date;238;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
date;238;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
date;238;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
date;238;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
date;238;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
date;238;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
date;238;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
date;238;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PBC_Date_of_followup_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of Follow-up;string
date;238;R_PBC_Date_of_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
date;238;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
date;238;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
date;238;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
date;238;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
date;238;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
date;238;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
date;238;R_PBC_Date_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
date;238;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
date;238;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
date;238;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
date;238;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
date;238;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
date;238;date_first_diagnosis;Diagnosis General Information;Rare Liver (Vascular);Date of first diagnosis;date
date;238;incl_date;Diagnosis General Information;Rare Liver (Vascular);Date of inclusion or screen failure;date
date;238;gastro_intest_bleed_date;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding date;date
date;238;date_of_measurement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of measurement;date
date;238;b_fibroscan_date;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of Fibroscan;date
date;238;date_liver_biopsy;Diagnosis Biobank;Rare Liver (Vascular);Date of liver biopsy;date
date;238;edta_sample_date;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample date;date
date;238;buffy_coat_date;Diagnosis Biobank;Rare Liver (Vascular);Buffy coat sample date;date
date;238;dna_date;Diagnosis Biobank;Rare Liver (Vascular);DNA sample date;date
date;238;plasma_date;Diagnosis Biobank;Rare Liver (Vascular);Plasma sample date;date
date;238;serum_date;Diagnosis Biobank;Rare Liver (Vascular);Serum sample date;date
date;238;urin_sample_date;Diagnosis Biobank;Rare Liver (Vascular);Urine sample date;date
date;238;eval_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of evaluation;date
date;238;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
date;238;med_assist_repro_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of medically assisted reproduction;date
date;238;date_abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal trauma;date
date;238;abd_intervention_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of procedure;date
date;238;abd_inflammation_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal infection/inflamation;date
date;238;extra_abd_inflam_date;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
date;238;date_mesenterico_portal;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
date;238;date_budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
date;238;date_nciph;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
date;238;dia_lab_date;Diagnosis Laboratory data;Rare Liver (Vascular);Date of Evaluation;date
date;238;eos_death_date;End of study End of study;Rare Liver (Vascular);Date of death;date
date;238;eos_liver_transplant_date;End of study End of study;Rare Liver (Vascular);Date of liver transplantation;date
date;238;date_follow_up;Follow-up Date;Rare Liver (Vascular);Date of follow-up;date
date;238;date_of_interruption;Follow-up Events;Rare Liver (Vascular);Date of interruption;date
date;238;date_of_initiation;Follow-up Events;Rare Liver (Vascular);Date of initiation;date
date;238;date_of_stenting;Follow-up Events;Rare Liver (Vascular);Date of stenting;date
date;238;date_of_tips;Follow-up Events;Rare Liver (Vascular);Date of TIPS;date
date;238;date_of_transplantation;Follow-up Events;Rare Liver (Vascular);Date of transplantation;date
date;238;date_of_shunt;Follow-up Events;Rare Liver (Vascular);Date of shunt;date
date;238;date_of_revision;Follow-up Events;Rare Liver (Vascular);Date of revision;date
date;238;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
date;238;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
date;238;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
date;238;date_of_evaluation_tips;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
date;238;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
date;238;date_of_evaluation_angio;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
date;238;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
date;238;date_of_evaluation_shunt;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
date;238;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
date;238;fu_cli_bef_date_evaluation;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
date;238;fu_cli_last_date_eval;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
date;238;fu_ima_bef_date_evaluation;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
date;238;fu_ima_last_date_eval;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
date;238;fu_ima_last_fibro_date;Follow-up Imaging data;Rare Liver (Vascular);Date of fibroscan;date
date;238;fu_end_date_evaluation;Follow-up Endpoints;Rare Liver (Vascular);Date of evaluation;date
date;238;Date of last information;subject;Genturis;What is the date (yyyy-mm-dd) of the last clinical information of the patient?;date
date;238;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
date;238;Date of data entry;subject;Genturis;At what date (yyyy-mm-dd) was the data entered in the registry?;date
date;238;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
date;238;Date enrolled;;ithaca;;date
date;238;Date of consent;;ithaca;;date
date;238;Date of consent;;ithaca;;date
date;238;Date of consent;;ithaca;;date
date;238;Date of consent;;ithaca;;date
date;238;Date of retractation;;ithaca;;date
date;238;Date of retractation;;ithaca;;date
date;238;Date of retractation;;ithaca;;date
date;238;Date of death;;ithaca;;date
date;238;First Contact date;;ithaca;;date
date;238;Date of onset;;ithaca;;date
date;238;Date of diagnose;;ithaca;;date
date;238;Date of Birth;;ithaca;;date
date;238;Date of first symptoms onset;;ithaca;;date
date;238;Date of current diagnosis;;ithaca;;date
date;238;Date of diagnosis;;ithaca;;date
date;238;Start date medication;;ithaca;;date
date;238;End date medication;;ithaca;;date
date;238;first_contact_date;patient_management_at_the_hospital;EURACAN;Date of first contact with the hospital/registration start;DD-MM-YYYY Format
date;238;birth_date;patient_management_at_the_hospital;EURACAN;Date of birth;DD-MM-YYYY Format
date;238;biopsy_date;primary_cancer;EURACAN;Biopsy date;
date;238;fu_date;clinical_update;EURACAN;Clinical update date;DD-MM-YYYY Format
date;238;fu_date_mm;clinical_update;EURACAN;Month of clinical update;
date;238;fu_date_yyyy;clinical_update;EURACAN;Year of clinical update;
date;238;surgery_date;surgery;EURACAN;Surgery date;
date;238;surgery_date_mm;surgery;EURACAN;Month of surgery;
date;238;surgery_date_yyyy;surgery;EURACAN;Year of surgery;
date;238;chemo_date_from;chemotherapy;EURACAN;Start date;
date;238;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
date;238;chemo_date_to;chemotherapy;EURACAN;End date;
date;238;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
date;238;immuno_date_from;immunotherapy;EURACAN;Start date;
date;238;immuno_date_from_unk;immunotherapy;EURACAN;Unknown;1, Unknown
date;238;immuno_date_to;immunotherapy;EURACAN;End date;
date;238;immuno_date_to_unk;immunotherapy;EURACAN;Unknown;1, Unknown
date;238;tt_date_from;target_therapy;EURACAN;Start date;
date;238;tt_date_from_unk;target_therapy;EURACAN;Unknown;1, Unknown
date;238;tt_date_to;target_therapy;EURACAN;End date;
date;238;tt_date_to_unk;target_therapy;EURACAN;Unknown;1, Unknown
date;238;other_treatment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of other treatment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{other_treatment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{other_treatment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{other_treatment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
date;238;other_treatment_date;other_type_of_treatment;EURACAN;Date;
date;238;other_treatment_date_mm;other_type_of_treatment;EURACAN;Month of other treatment;
date;238;other_treatment_date_yyyy;other_type_of_treatment;EURACAN;Year of other treatment;
date;238;oth_enrolment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of enrolment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{oth_enrolment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{oth_enrolment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{oth_enrolment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
date;238;oth_enrolment_date;other_type_of_treatment;EURACAN;Date of enrolment;
date;238;oth_enrolment_date_mm;other_type_of_treatment;EURACAN;Month of enrolment;
date;238;oth_enrolment_date_yyyy;other_type_of_treatment;EURACAN;Year of enrolment;
date;238;Date of Birth;Personal Information;PaedCan;Patient's date of birth;dd/mm/yyyy
date;238;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
date;238;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
date;238;Date of referral;Care pathway;PaedCan;Date of referral to a Very rare Tumor board;dd/mm/yyyy
date;238;Date of diagnosis;Pathology;PaedCan;"Date of diagnostic surgery; if no surgery performed please record the start of treatment date";dd/mm/yyyy
date;238;Date of biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
date;238;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
date;238;Date of delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
date;238;Date of further surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
date;238;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
date;238;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
date;238;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
date;238;Date of metastases biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
date;238;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
date;238;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
date;238;Start date;Chemotherapy;PaedCan;First day of chemoterapy;dd/mm/yyyy
date;238;End date;Chemotherapy;PaedCan;Last day of chemoterapy;dd/mm/yyyy
date;238;Start date;Radiotherapy;PaedCan;First day of radiotherapy;dd/mm/yyyy
date;238;End date;Radiotherapy;PaedCan;Last day of radiotherapy;dd/mm/yyyy
date;238;Start date;Other treatments;PaedCan;Date when therapy was started;dd/mm/yyyy or uk/uk/yyyy
date;238;End date;Other treatments;PaedCan;Date when therapy was ended;dd/mm/yyyy or uk/uk/yyyy
date;238;End of treatment date;End of treatment;PaedCan;Date of the last chemotherapy cycle or the last surgical procedure or the last day of radiotherapy or the last day of any other treatment whichever come last.;dd/mm/yyyy
date;238;Date of follow up;Follow up (one form for each follow up visit);PaedCan;Date of the last contact with the patient including visit and telephone call;dd/mm/yyyy
date;238;Date of death;Follow up (one form for each follow up visit);PaedCan;Date when the patient died;dd/mm/yyyy
date;238;Date of event;Events;PaedCan;Date when the event occurred;dd/mm/yyyy
date;238;Date of Birth;Personal Information;EuRR-Bone & EuRRECa;Patients date of birth;dd/mm/yyyy
date;238;Date of death;Patient Status;EuRR-Bone & EuRRECa;Patient's year of death;dd/mm/yyyy
date;238;Date of Condition Onset;Disease History;EuRR-Bone & EuRRECa;Approximate date at which symptoms and signs first appeared;dd/mm/yyyy
date;238;Date of Diagnosis;Disease History;EuRR-Bone & EuRRECa;Date when diagnosis is suspected;dd/mm/yyyy
date;238;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
date;238;Date of measurement;Biochemistry;ERKNet;If 1,2,3;protur_date
date;238;Date of screening;Genetic diagnosis;ERKNet;Â ;gen_scr_date
date;238;Date of diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes|no;Â 
day;27;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
day;27;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
day;27;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"vesicostomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"openÂ ureterostomies 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"CIC 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;"transplantation 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
day;27;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
day;27;"b. Age at first MCG VUR (in days):		";4. MCG VUR: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
day;27;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
day;27;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
day;27;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
day;27;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
day;27;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
day;27;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
day;27;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
day;27;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
day;27;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
day;27;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
day;27;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
day;27;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
day;27;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
day;27;smoking_per_day;patient_management_at_the_hospital;EURACAN;Cigarettes/cigars smoked per day;
days;26;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
days;26;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
days;26;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"vesicostomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"openÂ ureterostomies 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"CIC 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;"transplantation 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
days;26;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
days;26;"b. Age at first MCG VUR (in days):		";4. MCG VUR: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
days;26;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
days;26;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
days;26;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
days;26;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
days;26;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
days;26;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
days;26;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
days;26;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
days;26;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
days;26;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
days;26;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
days;26;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
days;26;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
db;13;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
db;13;R_PBC_not_in_db22;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate naknuma grading;calculation
db;13;R_PBC_not_in_db;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate naknuma staging;calculation
db;13;R_PSC_not_in_db4;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma grade;calculation
db;13;R_PSC_not_in_db42;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma score;calculation
db;13;R_PSC_not_in_db312;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
db;13;R_PSC_not_in_db123;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
db;13;aza_nodb;PSC Follow-up Treatment;Rare Liver (Auto imune);aza_aih check;calculation
db;13;R_AIH_not_in_db123;AIH Follow-up Outcome II;Rare Liver (Auto imune);Calculate Nakanuma grading?;calculation
db;13;R_AIH_not_in_db;AIH Follow-up Outcome II;Rare Liver (Auto imune);Calculate Nakanuma scoring?;calculation
db;13;R_PBC_not_in_db_3;PBC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
db;13;R_PBC_not_in_db5;PBC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
db;13;medb;Medications Medication;Rare Liver (Vascular);Medication (blocker);radio
db123;2;R_PSC_not_in_db123;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
db123;2;R_AIH_not_in_db123;AIH Follow-up Outcome II;Rare Liver (Auto imune);Calculate Nakanuma grading?;calculation
db22;1;R_PBC_not_in_db22;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate naknuma grading;calculation
db312;1;R_PSC_not_in_db312;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
db4;2;R_PSC_not_in_db4;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma grade;calculation
db4;2;R_PSC_not_in_db42;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma score;calculation
db42;1;R_PSC_not_in_db42;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma score;calculation
db5;1;R_PBC_not_in_db5;PBC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
dead;2;eos_dead;End of study End of study;Rare Liver (Vascular);Dead?;radio
dead;2;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
deafness;3;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
deafness;3;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
deafness;3;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
deafness-renal;1;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
death;16;Date_of_death;Base information;Rare Liver (Auto imune);Date of Death;date
death;16;Cause_of_death;Base information;Rare Liver (Auto imune);Cause of death;radio
death;16;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
death;16;eos_death;End of study End of study;Rare Liver (Vascular);Did death occur?;calculation
death;16;eos_death_date;End of study End of study;Rare Liver (Vascular);Date of death;date
death;16;eos_death_cause;End of study End of study;Rare Liver (Vascular);Cause of death;radio
death;16;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
death;16;eos_death_autopsy;End of study End of study;Rare Liver (Vascular);Autopsy performed;radio
death;16;eos_liver_transplant_death;End of study End of study;Rare Liver (Vascular);Death after liver transplantation?;calculation
death;16;Year of death available?;subject;Genturis;Is the year of death of the patient known?;enum
death;16;Year of death;subject;Genturis;In what year did the patient die?;int
death;16;Date of death;;ithaca;;date
death;16;Cause of death;Follow up (one form for each follow up visit);PaedCan;if the patient is dead specfiy the cause of death;Dead of disease/dead for toxicity/dead for a second tumor/dead for other reason
death;16;Date of death;Follow up (one form for each follow up visit);PaedCan;Date when the patient died;dd/mm/yyyy
death;16;Date of death;Patient Status;EuRR-Bone & EuRRECa;Patient's year of death;dd/mm/yyyy
death;16;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
decreased;3;prot_c_decreased;Diagnosis Aetiology;Rare Liver (Vascular);Protein C activity decreased?;radio
decreased;3;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
decreased;3;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
def;89;protein_s_deficiency;Diagnosis Aetiology;Rare Liver (Vascular);Protein S deficiency activity (%);numeric
def;89;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
def;89;vitamin_deficiency_excl;Diagnosis Aetiology;Rare Liver (Vascular);Vitamin deficiency/ folic acid excluded;radio
def;89;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
def;89;Definitions;;ithaca;;text
def;89;Definitions;;ithaca;;text
def;89;staging_def_clin;stage_procedures;EURACAN;Clinical staging defined by;1, the hospital | 2, a different hospital
def;89;end_treat_res_def_other;other_type_of_treatment;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
def;89;overall_treat_res_def;overall_treatment_response;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
def;89;Familial glucocorticoid deficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial glucocorticoid deficiency;
def;89;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
def;89;21-hydroxylase def (CYP21A);ADRENAL;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
def;89;11b-hydroxylase def (CYP11B1);ADRENAL;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
def;89;3b-HSD def (HSD3B2);ADRENAL;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
def;89;CYP17 def (P450CYP17);ADRENAL;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
def;89;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
def;89;P450 scc def (CYP11A1);ADRENAL;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
def;89;StAR def;ADRENAL;EuRR-Bone & EuRRECa;StAR def;
def;89;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
def;89;INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;INSR deficiency;
def;89;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
def;89;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
def;89;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
def;89;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
def;89;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
def;89;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
def;89;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
def;89;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
def;89;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
def;89;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
def;89;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
def;89;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
def;89;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
def;89;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
def;89;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
def;89;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
def;89;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
def;89;Melanocortin 4 receptor deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Melanocortin 4 receptor deficiency;
def;89;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
def;89;Pro-opiomelanocortin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pro-opiomelanocortin deficiency;
def;89;CEP19 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;CEP19 deficiency;
def;89;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
def;89;SIM1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1 deficiency;
def;89;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
def;89;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
def;89;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
def;89;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
def;89;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
def;89;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
def;89;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
def;89;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
def;89;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
def;89;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
def;89;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
def;89;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
def;89;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
def;89;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
def;89;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
def;89;StAR def;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;StAR def;
def;89;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
def;89;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
def;89;Aromatase def (CYP19A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Aromatase def (CYP19A1);
def;89;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
def;89;StAR def;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;StAR def;
def;89;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
def;89;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
def;89;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
def;89;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
def;89;Isolated 17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated 17,20 lyase deficiency;
def;89;17b-HSD def (HSD17B3);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;17b-HSD def (HSD17B3);
def;89;5a-reductase def (SRD5A2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;5a-reductase def (SRD5A2);
def;89;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
def;89;LH deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;LH deficiency;
def;89;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
def;89;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
def;89;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
def;89;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
def;89;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
def;89;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
def;89;StAR def;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;StAR def;
def;89;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
def;89;21-hydroxylase def (CYP21A);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;21-hydroxylase def (CYP21A);
def;89;11b-hydroxylase def (CYP11B1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;11b-hydroxylase def (CYP11B1);
def;89;Aromatase def (CYP19A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Aromatase def (CYP19A1);
def;89;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
def;89;MCT8 deficiency;THYROID;EuRR-Bone & EuRRECa;MCT8 deficiency;
def;89;SBP2 deficiency;THYROID;EuRR-Bone & EuRRECa;SBP2 deficiency;
def;89;Madelung deformity ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Madelung deformity ;
def;89;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
defect;7;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
defect;7;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
defect;7;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
defect;7;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
defect;7;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
defect;7;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
defect;7;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
defective;1;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
defects;4;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
defects;4;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
defects;4;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
defects;4;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
defects-obesity-pulmonary;1;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
deficiencies,;1;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
deficiency;38;protein_s_deficiency;Diagnosis Aetiology;Rare Liver (Vascular);Protein S deficiency activity (%);numeric
deficiency;38;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
deficiency;38;vitamin_deficiency_excl;Diagnosis Aetiology;Rare Liver (Vascular);Vitamin deficiency/ folic acid excluded;radio
deficiency;38;Familial glucocorticoid deficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial glucocorticoid deficiency;
deficiency;38;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
deficiency;38;INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;INSR deficiency;
deficiency;38;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
deficiency;38;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
deficiency;38;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
deficiency;38;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
deficiency;38;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
deficiency;38;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
deficiency;38;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
deficiency;38;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
deficiency;38;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
deficiency;38;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
deficiency;38;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
deficiency;38;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
deficiency;38;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
deficiency;38;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
deficiency;38;Melanocortin 4 receptor deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Melanocortin 4 receptor deficiency;
deficiency;38;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
deficiency;38;Pro-opiomelanocortin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pro-opiomelanocortin deficiency;
deficiency;38;CEP19 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;CEP19 deficiency;
deficiency;38;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
deficiency;38;SIM1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1 deficiency;
deficiency;38;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
deficiency;38;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
deficiency;38;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
deficiency;38;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
deficiency;38;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
deficiency;38;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
deficiency;38;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
deficiency;38;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
deficiency;38;Isolated 17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated 17,20 lyase deficiency;
deficiency;38;LH deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;LH deficiency;
deficiency;38;MCT8 deficiency;THYROID;EuRR-Bone & EuRRECa;MCT8 deficiency;
deficiency;38;SBP2 deficiency;THYROID;EuRR-Bone & EuRRECa;SBP2 deficiency;
definitive;1;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
deformity;1;Madelung deformity ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Madelung deformity ;
degree;2;ascites_degree;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Ascites degree;radio
degree;2;closest_degree_affect_rel;Diagnosis Aetiology;Rare Liver (Vascular);Closest degree of affected relatives;radio
dehydrogenase;1;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
delay;11;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
delay;11;Delayed motor milestones;Diagnosis Developmental;EURO-NMD;;yesno
delay;11;Delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
delay;11;Date of delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
delay;11;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
delay;11;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
delay;11;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
delay;11;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
delay;11;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
delay;11;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
delay;11;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
delay-lung;1;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
delayed;8;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
delayed;8;Delayed motor milestones;Diagnosis Developmental;EURO-NMD;;yesno
delayed;8;Delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
delayed;8;Date of delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
delayed;8;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
delayed;8;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
delayed;8;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
delayed;8;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
deletion;13;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
deletion;13;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
deletion;13;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
deletion;13;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
deletion;13;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
deletion;13;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
deletion;13;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
deletion;13;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
deletion;13;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
deletion;13;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
deletion;13;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
deletion;13;Distal 16p11.2 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Distal 16p11.2 microdeletion syndrome;
deletion;13;Xq21 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Xq21 microdeletion syndrome;
delivered;2;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
delivered;2;Please describe the treatment delivered;Other treatments;PaedCan;;String
delivery;2;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
delivery;2;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
density;3;Mammographic density;malignancy;Genturis;What is the mammographic density?;categorical
density;3;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
density;3;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
dent;13;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
dent;13;Patient identifiers;subject;Genturis;;compound
dent;13;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
dent;13;Identifying data;;ithaca;;compound
dent;13;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
dent;13;National Identifier (if applicable);Identifiers;PaedCan;;String
dent;13;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
dent;13;e-REC indentifier;Identifiers;EuRR-Bone & EuRRECa;Identifier forÂ e-REC;String
dent;13;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
dent;13;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
dent;13;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
dent;13;Dent disease;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dent disease;
dent;13;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
deposition;5;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
deposition;5;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
deposition;5;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
deposition;5;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
deposition;5;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
describe;1;Please describe the treatment delivered;Other treatments;PaedCan;;String
description;17;Description (English);Anatomical Therapeutic Chemical Classification;ithaca;;text
description;17;Description of code;Anatomical Therapeutic Chemical Classification;ithaca;;string
description;17;description;;ithaca;;text
description;17;Description;;ithaca;;string
description;17;Description (English);;ithaca;;text
description;17;Description of code;;ithaca;;hyperlink
description;17;Description;;ithaca;;text
description;17;description;;ithaca;;text
description;17;Description;;ithaca;;text
description;17;Description;;ithaca;;text
description;17;Description;;ithaca;;text
description;17;Description;;ithaca;;text
description;17;Consultation Request Reason Description;;ithaca;;text
description;17;Medication for Rare Disease Description;;ithaca;;text
description;17;Description;;ithaca;;text
description;17;Nucleotide variant description;;ithaca;;text
description;17;Protein variant description;;ithaca;;text
desmet;7;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
desmet;7;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
desmet;7;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
desmet;7;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
desmet;7;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
desmet;7;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
desmet;7;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
detailed;3;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
detailed;3;Detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Name;String
detailed;3;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
details;2;Please give more details about the treatment of the event;Events;PaedCan;;String
details;2;Biobank details;Research;EuRR-Bone & EuRRECa;Details of biobank;String
dev;8;dia_lab_dev_coag_dt;Diagnosis Laboratory data;Rare Liver (Vascular);Deviant Laboratory Date;date
dev;8;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
dev;8;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
dev;8;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
dev;8;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
dev;8;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
dev;8;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
dev;8;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
development;7;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
development;7;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
development;7;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
development;7;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
development;7;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
development;7;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
development;7;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
developmental;2;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
developmental;2;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
dia;180;Initial_diagnosis;Base information;Rare Liver (Auto imune);Initial diagnosis;radio
dia;180;R_AIH_Date_of_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
dia;180;R_AIH_Age_at_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
dia;180;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
dia;180;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
dia;180;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
dia;180;R_AIH_HRS_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Hepatorenal syndrome;radio
dia;180;R_AIH_AMA_diagnosis;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
dia;180;R_PBC_Date_of_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
dia;180;R_PBC_Age_at_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
dia;180;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
dia;180;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
dia;180;R_PBC_Variceal_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Variceal bleeding;radio
dia;180;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
dia;180;R_PBC_HRS_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Hepatorenal syndrome;radio
dia;180;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
dia;180;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
dia;180;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
dia;180;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
dia;180;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
dia;180;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
dia;180;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
dia;180;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
dia;180;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
dia;180;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
dia;180;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
dia;180;psc_pbc_diag;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);psc pbc diag;calculation
dia;180;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
dia;180;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
dia;180;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
dia;180;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
dia;180;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
dia;180;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
dia;180;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
dia;180;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
dia;180;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
dia;180;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
dia;180;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
dia;180;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
dia;180;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
dia;180;date_first_diagnosis;Diagnosis General Information;Rare Liver (Vascular);Date of first diagnosis;date
dia;180;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
dia;180;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
dia;180;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
dia;180;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
dia;180;diabetes;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diabetes;radio
dia;180;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
dia;180;cardiac_output;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cardiac output;numeric
dia;180;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
dia;180;dia_lab_date;Diagnosis Laboratory data;Rare Liver (Vascular);Date of Evaluation;date
dia;180;dia_lab_red_blood_cell_count;Diagnosis Laboratory data;Rare Liver (Vascular);Red blood cell count;numeric
dia;180;dia_lab_haemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Haemoglobin;numeric
dia;180;dia_lab_haematocrit;Diagnosis Laboratory data;Rare Liver (Vascular);Haematocrit;numeric
dia;180;dia_lab_leucocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Leukocytes;numeric
dia;180;dia_lab_neutrophils;Diagnosis Laboratory data;Rare Liver (Vascular);Neutrophils;numeric
dia;180;dia_lab_eosinophils;Diagnosis Laboratory data;Rare Liver (Vascular);Eosinophils;numeric
dia;180;dia_lab_lymphocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Lymphocytes;numeric
dia;180;dia_lab_platelet_count;Diagnosis Laboratory data;Rare Liver (Vascular);Platelet count;numeric
dia;180;dia_lab_dev_coag_dt;Diagnosis Laboratory data;Rare Liver (Vascular);Deviant Laboratory Date;date
dia;180;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
dia;180;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
dia;180;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
dia;180;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
dia;180;dia_lab_antinuclear_antibodies;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies;radio
dia;180;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
dia;180;dia_lab_alt;Diagnosis Laboratory data;Rare Liver (Vascular);ALT;numeric
dia;180;dia_lab_alt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);ALT normal value;numeric
dia;180;dia_lab_ast;Diagnosis Laboratory data;Rare Liver (Vascular);AST;numeric
dia;180;dia_lab_ast_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);AST normal value;numeric
dia;180;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
dia;180;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
dia;180;dia_lab_ggt;Diagnosis Laboratory data;Rare Liver (Vascular);GGT;numeric
dia;180;dia_lab_ggt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);GGT normal value;numeric
dia;180;dia_lab_serum_albumin;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin;numeric
dia;180;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
dia;180;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
dia;180;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
dia;180;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
dia;180;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
dia;180;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
dia;180;dia_lab_serum_ferritine;Diagnosis Laboratory data;Rare Liver (Vascular);Serum ferritin;numeric
dia;180;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
dia;180;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
dia;180;dia_lab_factor_v;Diagnosis Laboratory data;Rare Liver (Vascular);Factor V;numeric
dia;180;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
dia;180;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
dia;180;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
dia;180;dia_lab_sodium_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
dia;180;dia_lab_fasting_glucose_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting Serum Glucose Unit;radio
dia;180;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
dia;180;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
dia;180;dia_lab_fasting_tg_value;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum triglycerides value;numeric
dia;180;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
dia;180;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
dia;180;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
dia;180;dia_lab_colesterol_t;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
dia;180;dia_lab_colesterol_hdl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
dia;180;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
dia;180;dia_lab_insulinemia;Diagnosis Laboratory data;Rare Liver (Vascular);Insulinemia;numeric
dia;180;dia_lab_glycated_hemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
dia;180;dia_lab_urine_na_24h;Diagnosis Laboratory data;Rare Liver (Vascular);urine sodium value - 24 hour;numeric
dia;180;dia_lab_ascites_alb;Diagnosis Laboratory data;Rare Liver (Vascular);Albumin;numeric
dia;180;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
dia;180;dia_lab_ascites_pmn;Diagnosis Laboratory data;Rare Liver (Vascular);Polymorphonuclear neutrophils;numeric
dia;180;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
dia;180;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
dia;180;Age at diagnosis (benign);benignNeoplasm;Genturis;What was the patient's age (years) at diagnosis of this benign tumour?;int
dia;180;Benign diagnosis source;benignNeoplasm;Genturis;What is level of evidence for the diagnosis?;xref
dia;180;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
dia;180;Age at diagnosis (malignancy);malignancy;Genturis;At what age (years) was the patient diagnosed with this malignancy?;int
dia;180;Diagnosis source;malignancy;Genturis;What is the level of evidence for the diagnosis?;xref
dia;180;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
dia;180;Diagnosis;subject;Genturis;;compound
dia;180;Diagnosis;subject;Genturis;Multiple malignancy diagnoses can be entered;mref
dia;180;Diagnosis;subject;Genturis;Multiple benign neoplasms diagnoses can be entered;mref
dia;180;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
dia;180;Age at diagnosis;;ithaca;;categorical
dia;180;Date of diagnose;;ithaca;;date
dia;180;Clinical diagnosis;;ithaca;;compound
dia;180;Diagnosis Coding System;;ithaca;;mref
dia;180;Period of current diagnosis;;ithaca;;categorical
dia;180;Date of current diagnosis;;ithaca;;date
dia;180;Age at diagnosis;;ithaca;;int
dia;180;Biologic diagnosis;;ithaca;;compound
dia;180;Biologic diagnosis;;ithaca;;categorical
dia;180;Diagnosis Coding System;;ithaca;;mref
dia;180;Date of diagnosis;;ithaca;;date
dia;180;Status of diagnosis;;ithaca;;categorical
dia;180;Other status of diagnosis;;ithaca;;text
dia;180;other_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
dia;180;other_hn_bening_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
dia;180;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
dia;180;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
dia;180;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
dia;180;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
dia;180;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
dia;180;prev_not_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
dia;180;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
dia;180;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
dia;180;Age at diagnosis;Care pathway;PaedCan;Age at which diagnosis was made;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
dia;180;Diagnosis;Pathology;PaedCan;Final diagnosis ;ICCC3
dia;180;Date of diagnosis;Pathology;PaedCan;"Date of diagnostic surgery; if no surgery performed please record the start of treatment date";dd/mm/yyyy
dia;180;Biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
dia;180;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
dia;180;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
dia;180;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
dia;180;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
dia;180;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
dia;180;Specific diagnosis;Disease History;EuRR-Bone & EuRRECa;Orphacode for condition entered in 6.3;Drop down category
dia;180;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
dia;180;Date of Diagnosis;Disease History;EuRR-Bone & EuRRECa;Date when diagnosis is suspected;dd/mm/yyyy
dia;180;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
dia;180;Diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus;
dia;180;Diabetes mellitus type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 1;
dia;180;Diabetes mellitus type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 2;
dia;180;Other diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other diabetes mellitus;
dia;180;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
dia;180;Neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes;
dia;180;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
dia;180;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
dia;180;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
dia;180;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
dia;180;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
dia;180;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
dia;180;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
dia;180;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
dia;180;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
dia;180;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
dia;180;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
dia;180;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
dia;180;Isolated hypospadias;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated hypospadias;
dia;180;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
dia;180;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
dia;180;Craniodiaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniodiaphyseal dysplasia ;
dia;180;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
dia;180;Date of diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes|no;Â 
dia;180;(Diagnosis) Method;Genetic diagnosis;ERKNet;If gen_diagnosis != result pending;"`-  individual gene testing
-  NGS gene panel screening
-  exome sequencing"
dia;180;Diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes;genes_ar | genes_ad | genes_x | genes_mt | genes_di
dia;180;Diagnosis - Mutation;Genetic diagnosis;ERKNet;Â ;Â 
dia;180;Diagnosis - Zygosity;Genetic diagnosis;ERKNet;From Wiki: the degree to which both copies of a chromosome or gene have the same genetic sequence.;homozygous, heterozygous, hemizygous
diabetes;11;diabetes;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diabetes;radio
diabetes;11;Diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus;
diabetes;11;Diabetes mellitus type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 1;
diabetes;11;Diabetes mellitus type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 2;
diabetes;11;Other diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other diabetes mellitus;
diabetes;11;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
diabetes;11;Neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes;
diabetes;11;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
diabetes;11;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
diabetes;11;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
diabetes;11;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
diag;97;Initial_diagnosis;Base information;Rare Liver (Auto imune);Initial diagnosis;radio
diag;97;R_AIH_Date_of_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diag;97;R_AIH_Age_at_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diag;97;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
diag;97;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
diag;97;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
diag;97;R_AIH_HRS_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Hepatorenal syndrome;radio
diag;97;R_AIH_AMA_diagnosis;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
diag;97;R_PBC_Date_of_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diag;97;R_PBC_Age_at_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diag;97;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diag;97;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
diag;97;R_PBC_Variceal_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Variceal bleeding;radio
diag;97;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
diag;97;R_PBC_HRS_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Hepatorenal syndrome;radio
diag;97;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diag;97;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diag;97;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diag;97;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
diag;97;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
diag;97;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
diag;97;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
diag;97;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
diag;97;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
diag;97;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
diag;97;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
diag;97;psc_pbc_diag;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);psc pbc diag;calculation
diag;97;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
diag;97;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
diag;97;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
diag;97;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
diag;97;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
diag;97;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
diag;97;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
diag;97;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
diag;97;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
diag;97;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
diag;97;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
diag;97;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diag;97;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
diag;97;date_first_diagnosis;Diagnosis General Information;Rare Liver (Vascular);Date of first diagnosis;date
diag;97;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
diag;97;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
diag;97;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
diag;97;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
diag;97;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
diag;97;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
diag;97;Age at diagnosis (benign);benignNeoplasm;Genturis;What was the patient's age (years) at diagnosis of this benign tumour?;int
diag;97;Benign diagnosis source;benignNeoplasm;Genturis;What is level of evidence for the diagnosis?;xref
diag;97;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
diag;97;Age at diagnosis (malignancy);malignancy;Genturis;At what age (years) was the patient diagnosed with this malignancy?;int
diag;97;Diagnosis source;malignancy;Genturis;What is the level of evidence for the diagnosis?;xref
diag;97;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
diag;97;Diagnosis;subject;Genturis;;compound
diag;97;Diagnosis;subject;Genturis;Multiple malignancy diagnoses can be entered;mref
diag;97;Diagnosis;subject;Genturis;Multiple benign neoplasms diagnoses can be entered;mref
diag;97;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
diag;97;Age at diagnosis;;ithaca;;categorical
diag;97;Date of diagnose;;ithaca;;date
diag;97;Clinical diagnosis;;ithaca;;compound
diag;97;Diagnosis Coding System;;ithaca;;mref
diag;97;Period of current diagnosis;;ithaca;;categorical
diag;97;Date of current diagnosis;;ithaca;;date
diag;97;Age at diagnosis;;ithaca;;int
diag;97;Biologic diagnosis;;ithaca;;compound
diag;97;Biologic diagnosis;;ithaca;;categorical
diag;97;Diagnosis Coding System;;ithaca;;mref
diag;97;Date of diagnosis;;ithaca;;date
diag;97;Status of diagnosis;;ithaca;;categorical
diag;97;Other status of diagnosis;;ithaca;;text
diag;97;other_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
diag;97;other_hn_bening_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
diag;97;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
diag;97;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
diag;97;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
diag;97;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
diag;97;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
diag;97;prev_not_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
diag;97;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
diag;97;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
diag;97;Age at diagnosis;Care pathway;PaedCan;Age at which diagnosis was made;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
diag;97;Diagnosis;Pathology;PaedCan;Final diagnosis ;ICCC3
diag;97;Date of diagnosis;Pathology;PaedCan;"Date of diagnostic surgery; if no surgery performed please record the start of treatment date";dd/mm/yyyy
diag;97;Biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diag;97;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
diag;97;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diag;97;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
diag;97;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diag;97;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
diag;97;Specific diagnosis;Disease History;EuRR-Bone & EuRRECa;Orphacode for condition entered in 6.3;Drop down category
diag;97;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
diag;97;Date of Diagnosis;Disease History;EuRR-Bone & EuRRECa;Date when diagnosis is suspected;dd/mm/yyyy
diag;97;Date of diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes|no;Â 
diag;97;(Diagnosis) Method;Genetic diagnosis;ERKNet;If gen_diagnosis != result pending;"`-  individual gene testing
-  NGS gene panel screening
-  exome sequencing"
diag;97;Diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes;genes_ar | genes_ad | genes_x | genes_mt | genes_di
diag;97;Diagnosis - Mutation;Genetic diagnosis;ERKNet;Â ;Â 
diag;97;Diagnosis - Zygosity;Genetic diagnosis;ERKNet;From Wiki: the degree to which both copies of a chromosome or gene have the same genetic sequence.;homozygous, heterozygous, hemizygous
diagn;87;Initial_diagnosis;Base information;Rare Liver (Auto imune);Initial diagnosis;radio
diagn;87;R_AIH_Date_of_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diagn;87;R_AIH_Age_at_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diagn;87;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
diagn;87;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
diagn;87;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
diagn;87;R_AIH_HRS_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Hepatorenal syndrome;radio
diagn;87;R_AIH_AMA_diagnosis;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
diagn;87;R_PBC_Date_of_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diagn;87;R_PBC_Age_at_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diagn;87;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diagn;87;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
diagn;87;R_PBC_Variceal_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Variceal bleeding;radio
diagn;87;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
diagn;87;R_PBC_HRS_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Hepatorenal syndrome;radio
diagn;87;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diagn;87;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diagn;87;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diagn;87;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
diagn;87;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
diagn;87;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
diagn;87;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
diagn;87;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
diagn;87;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
diagn;87;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
diagn;87;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
diagn;87;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
diagn;87;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
diagn;87;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
diagn;87;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
diagn;87;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
diagn;87;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
diagn;87;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
diagn;87;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
diagn;87;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
diagn;87;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
diagn;87;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
diagn;87;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diagn;87;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
diagn;87;date_first_diagnosis;Diagnosis General Information;Rare Liver (Vascular);Date of first diagnosis;date
diagn;87;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
diagn;87;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
diagn;87;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
diagn;87;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
diagn;87;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
diagn;87;Age at diagnosis (benign);benignNeoplasm;Genturis;What was the patient's age (years) at diagnosis of this benign tumour?;int
diagn;87;Benign diagnosis source;benignNeoplasm;Genturis;What is level of evidence for the diagnosis?;xref
diagn;87;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
diagn;87;Age at diagnosis (malignancy);malignancy;Genturis;At what age (years) was the patient diagnosed with this malignancy?;int
diagn;87;Diagnosis source;malignancy;Genturis;What is the level of evidence for the diagnosis?;xref
diagn;87;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
diagn;87;Diagnosis;subject;Genturis;;compound
diagn;87;Diagnosis;subject;Genturis;Multiple malignancy diagnoses can be entered;mref
diagn;87;Diagnosis;subject;Genturis;Multiple benign neoplasms diagnoses can be entered;mref
diagn;87;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
diagn;87;Age at diagnosis;;ithaca;;categorical
diagn;87;Date of diagnose;;ithaca;;date
diagn;87;Clinical diagnosis;;ithaca;;compound
diagn;87;Diagnosis Coding System;;ithaca;;mref
diagn;87;Period of current diagnosis;;ithaca;;categorical
diagn;87;Date of current diagnosis;;ithaca;;date
diagn;87;Age at diagnosis;;ithaca;;int
diagn;87;Biologic diagnosis;;ithaca;;compound
diagn;87;Biologic diagnosis;;ithaca;;categorical
diagn;87;Diagnosis Coding System;;ithaca;;mref
diagn;87;Date of diagnosis;;ithaca;;date
diagn;87;Status of diagnosis;;ithaca;;categorical
diagn;87;Other status of diagnosis;;ithaca;;text
diagn;87;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
diagn;87;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
diagn;87;Age at diagnosis;Care pathway;PaedCan;Age at which diagnosis was made;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
diagn;87;Diagnosis;Pathology;PaedCan;Final diagnosis ;ICCC3
diagn;87;Date of diagnosis;Pathology;PaedCan;"Date of diagnostic surgery; if no surgery performed please record the start of treatment date";dd/mm/yyyy
diagn;87;Biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diagn;87;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
diagn;87;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diagn;87;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
diagn;87;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diagn;87;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
diagn;87;Specific diagnosis;Disease History;EuRR-Bone & EuRRECa;Orphacode for condition entered in 6.3;Drop down category
diagn;87;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
diagn;87;Date of Diagnosis;Disease History;EuRR-Bone & EuRRECa;Date when diagnosis is suspected;dd/mm/yyyy
diagn;87;Date of diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes|no;Â 
diagn;87;(Diagnosis) Method;Genetic diagnosis;ERKNet;If gen_diagnosis != result pending;"`-  individual gene testing
-  NGS gene panel screening
-  exome sequencing"
diagn;87;Diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes;genes_ar | genes_ad | genes_x | genes_mt | genes_di
diagn;87;Diagnosis - Mutation;Genetic diagnosis;ERKNet;Â ;Â 
diagn;87;Diagnosis - Zygosity;Genetic diagnosis;ERKNet;From Wiki: the degree to which both copies of a chromosome or gene have the same genetic sequence.;homozygous, heterozygous, hemizygous
diagnosis;84;Initial_diagnosis;Base information;Rare Liver (Auto imune);Initial diagnosis;radio
diagnosis;84;R_AIH_Date_of_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diagnosis;84;R_AIH_Age_at_diagnosis;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diagnosis;84;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
diagnosis;84;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
diagnosis;84;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
diagnosis;84;R_AIH_HRS_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Hepatorenal syndrome;radio
diagnosis;84;R_AIH_AMA_diagnosis;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
diagnosis;84;R_PBC_Date_of_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diagnosis;84;R_PBC_Age_at_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diagnosis;84;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diagnosis;84;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
diagnosis;84;R_PBC_Variceal_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Variceal bleeding;radio
diagnosis;84;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
diagnosis;84;R_PBC_HRS_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Hepatorenal syndrome;radio
diagnosis;84;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
diagnosis;84;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
diagnosis;84;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diagnosis;84;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
diagnosis;84;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
diagnosis;84;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
diagnosis;84;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
diagnosis;84;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
diagnosis;84;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
diagnosis;84;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
diagnosis;84;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
diagnosis;84;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
diagnosis;84;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
diagnosis;84;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
diagnosis;84;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
diagnosis;84;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
diagnosis;84;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
diagnosis;84;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
diagnosis;84;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
diagnosis;84;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
diagnosis;84;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
diagnosis;84;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
diagnosis;84;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
diagnosis;84;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
diagnosis;84;date_first_diagnosis;Diagnosis General Information;Rare Liver (Vascular);Date of first diagnosis;date
diagnosis;84;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
diagnosis;84;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
diagnosis;84;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
diagnosis;84;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
diagnosis;84;Age at diagnosis (benign);benignNeoplasm;Genturis;What was the patient's age (years) at diagnosis of this benign tumour?;int
diagnosis;84;Benign diagnosis source;benignNeoplasm;Genturis;What is level of evidence for the diagnosis?;xref
diagnosis;84;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
diagnosis;84;Age at diagnosis (malignancy);malignancy;Genturis;At what age (years) was the patient diagnosed with this malignancy?;int
diagnosis;84;Diagnosis source;malignancy;Genturis;What is the level of evidence for the diagnosis?;xref
diagnosis;84;Diagnosis;subject;Genturis;;compound
diagnosis;84;Diagnosis;subject;Genturis;Multiple malignancy diagnoses can be entered;mref
diagnosis;84;Diagnosis;subject;Genturis;Multiple benign neoplasms diagnoses can be entered;mref
diagnosis;84;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
diagnosis;84;Age at diagnosis;;ithaca;;categorical
diagnosis;84;Clinical diagnosis;;ithaca;;compound
diagnosis;84;Diagnosis Coding System;;ithaca;;mref
diagnosis;84;Period of current diagnosis;;ithaca;;categorical
diagnosis;84;Date of current diagnosis;;ithaca;;date
diagnosis;84;Age at diagnosis;;ithaca;;int
diagnosis;84;Biologic diagnosis;;ithaca;;compound
diagnosis;84;Biologic diagnosis;;ithaca;;categorical
diagnosis;84;Diagnosis Coding System;;ithaca;;mref
diagnosis;84;Date of diagnosis;;ithaca;;date
diagnosis;84;Status of diagnosis;;ithaca;;categorical
diagnosis;84;Other status of diagnosis;;ithaca;;text
diagnosis;84;age_diagnosis_auto;primary_cancer;EURACAN;Age at diagnosis (automatic);"rounddown(datediff([date_diagnosis],[birth_date],""y""))"
diagnosis;84;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
diagnosis;84;Age at diagnosis;Care pathway;PaedCan;Age at which diagnosis was made;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
diagnosis;84;Diagnosis;Pathology;PaedCan;Final diagnosis ;ICCC3
diagnosis;84;Date of diagnosis;Pathology;PaedCan;"Date of diagnostic surgery; if no surgery performed please record the start of treatment date";dd/mm/yyyy
diagnosis;84;Biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diagnosis;84;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
diagnosis;84;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diagnosis;84;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
diagnosis;84;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
diagnosis;84;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
diagnosis;84;Specific diagnosis;Disease History;EuRR-Bone & EuRRECa;Orphacode for condition entered in 6.3;Drop down category
diagnosis;84;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
diagnosis;84;Date of Diagnosis;Disease History;EuRR-Bone & EuRRECa;Date when diagnosis is suspected;dd/mm/yyyy
diagnosis;84;Date of diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes|no;Â 
diagnosis;84;(Diagnosis) Method;Genetic diagnosis;ERKNet;If gen_diagnosis != result pending;"`-  individual gene testing
-  NGS gene panel screening
-  exome sequencing"
diagnosis;84;Diagnosis;Genetic diagnosis;ERKNet;if gen_diagnosis=yes;genes_ar | genes_ad | genes_x | genes_mt | genes_di
diagnosis;84;Diagnosis - Mutation;Genetic diagnosis;ERKNet;Â ;Â 
diagnosis;84;Diagnosis - Zygosity;Genetic diagnosis;ERKNet;From Wiki: the degree to which both copies of a chromosome or gene have the same genetic sequence.;homozygous, heterozygous, hemizygous
diagnostics;1;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
dialysis;1;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
diaper;1;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
diast;1;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
diazoxide-resistant;5;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
diazoxide-resistant;5;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
diazoxide-resistant;5;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
diazoxide-resistant;5;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
diazoxide-resistant;5;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
diazoxide-sensitive;1;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
did;2;Link to PubmedID;;ithaca;Hugo.owl.Pubmed_IDs;string
did;2;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
diff;6;Swallowing difficulties;Bulbar/Gi ;EURO-NMD;;single
diff;6;diff_harm_enlargement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Diffuse harmonious enlargement;radio
diff;6;Learning difficulty;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;It takes your child longer than other people to get his or her school work done in past 4 weeks - severity;Not at all/A little bit/somewhat/quite a bit/very much/not applicable
diff;6;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
diff;6;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
diff;6;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
different;1;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
difficulties;1;Swallowing difficulties;Bulbar/Gi ;EURO-NMD;;single
difficulty;1;Learning difficulty;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;It takes your child longer than other people to get his or her school work done in past 4 weeks - severity;Not at all/A little bit/somewhat/quite a bit/very much/not applicable
diffuse;2;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
diffuse;2;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
dilatation;1;ha_dilatation;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Dilatation;radio
dilation;3;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
dilation;3;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
dilation;3;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
diplopia;1;Diplopia;Diagnosis Eye;EURO-NMD;;yesno
dipstick;1;Dipstick result;Biochemistry;ERKNet;if 3;protur_dipstick
direction;3;pv_direction_of_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Direction of flow;radio
direction;3;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
direction;3;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
dis;101;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
dis;101;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
dis;101;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
dis;101;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
dis;101;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
dis;101;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
dis;101;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
dis;101;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
dis;101;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
dis;101;behcet_s_disease;Diagnosis Aetiology;Rare Liver (Vascular);Behcet's disease;radio
dis;101;other_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
dis;101;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
dis;101;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
dis;101;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
dis;101;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
dis;101;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
dis;101;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
dis;101;Rare disease  syndrome;subject;Genturis;What is the classification (Orphanet) of the rare disease of the patients?;xref
dis;101;Disease historyÂ ;;ithaca;;compound
dis;101;Functional Status and or Disability;;ithaca;;mref
dis;101;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
dis;101;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
dis;101;Medication for Rare Disease Description;;ithaca;;text
dis;101;neck_dissection;surgery;EURACAN;Neck dissection;1, Yes | 2, No | 9, Unknown
dis;101;Concomitant disease;Patient's history;PaedCan;Presence or absence of any disease which might be related or not to current malignancy;yes/no/unknown
dis;101;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
dis;101;Specify the disease;Family's history;PaedCan;Definition of disease affecting the patient's first degree relative;String
dis;101;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
dis;101;Disease status;Follow up (one form for each follow up visit);PaedCan;If the patient is alive reports the status of the disease;on treatment/ in 1st complete remission/in 2nd complete remission/alive in 3rd or more complete remission/ alive with disease/unknown
dis;101;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
dis;101;Detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Name;String
dis;101;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
dis;101;No evidence of disease;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Using biochemical and/or imaging tests according (international) guidelines;Y/N/Not Known
dis;101;Hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism;
dis;101;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
dis;101;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
dis;101;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
dis;101;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
dis;101;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
dis;101;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
dis;101;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
dis;101;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
dis;101;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
dis;101;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
dis;101;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
dis;101;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
dis;101;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
dis;101;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
dis;101;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
dis;101;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
dis;101;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
dis;101;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
dis;101;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
dis;101;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
dis;101;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
dis;101;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
dis;101;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
dis;101;Dent disease;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dent disease;
dis;101;Von Hippel-Lindau disease;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Von Hippel-Lindau disease;
dis;101;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
dis;101;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
dis;101;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
dis;101;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
dis;101;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
dis;101;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
dis;101;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
dis;101;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
dis;101;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
dis;101;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
dis;101;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
dis;101;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
dis;101;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
dis;101;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
dis;101;Distal 16p11.2 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Distal 16p11.2 microdeletion syndrome;
dis;101;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
dis;101;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
dis;101;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
dis;101;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
dis;101;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
dis;101;Cushing disease;PITUITARY;EuRR-Bone & EuRRECa;Cushing disease;
dis;101;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
dis;101;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
dis;101;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
dis;101;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
dis;101;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
dis;101;Disorder of androgen synthesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen synthesis;
dis;101;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
dis;101;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
dis;101;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
dis;101;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
dis;101;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
dis;101;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
dis;101;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
dis;101;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
dis;101;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
dis;101;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
dis;101;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
dis;101;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
dis;101;Juvenile Paget disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Juvenile Paget disease ;
dis;101;Camurati-Engelmann disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Camurati-Engelmann disease ;
dis;101;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
disability;9;Functional Status and or Disability;;ithaca;;mref
disability;9;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
disability;9;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
disability;9;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
disability;9;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
disability;9;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
disability;9;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
disability;9;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
disability;9;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
disability-conductive;1;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
disability-facial;1;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
disability-nystagmus-obesity;1;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
disability-obesity-brain;1;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
disability-obesity-prognathism-eye;1;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
disability-seizures-macrocephaly-obesity;1;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
discharge;4;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
discharge;4;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
discharge;4;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
discharge;4;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
diseaese;1;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
disease;33;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
disease;33;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
disease;33;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
disease;33;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
disease;33;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
disease;33;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
disease;33;behcet_s_disease;Diagnosis Aetiology;Rare Liver (Vascular);Behcet's disease;radio
disease;33;other_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
disease;33;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
disease;33;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
disease;33;Rare disease  syndrome;subject;Genturis;What is the classification (Orphanet) of the rare disease of the patients?;xref
disease;33;Disease historyÂ ;;ithaca;;compound
disease;33;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
disease;33;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
disease;33;Medication for Rare Disease Description;;ithaca;;text
disease;33;Concomitant disease;Patient's history;PaedCan;Presence or absence of any disease which might be related or not to current malignancy;yes/no/unknown
disease;33;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
disease;33;Specify the disease;Family's history;PaedCan;Definition of disease affecting the patient's first degree relative;String
disease;33;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
disease;33;Disease status;Follow up (one form for each follow up visit);PaedCan;If the patient is alive reports the status of the disease;on treatment/ in 1st complete remission/in 2nd complete remission/alive in 3rd or more complete remission/ alive with disease/unknown
disease;33;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
disease;33;Detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Name;String
disease;33;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
disease;33;No evidence of disease;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Using biochemical and/or imaging tests according (international) guidelines;Y/N/Not Known
disease;33;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
disease;33;Dent disease;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dent disease;
disease;33;Von Hippel-Lindau disease;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Von Hippel-Lindau disease;
disease;33;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
disease;33;Cushing disease;PITUITARY;EuRR-Bone & EuRRECa;Cushing disease;
disease;33;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
disease;33;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
disease;33;Juvenile Paget disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Juvenile Paget disease ;
disease;33;Camurati-Engelmann disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Camurati-Engelmann disease ;
diseases;4;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
diseases;4;other_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
diseases;4;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
diseases;4;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
disomy;6;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
disomy;6;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
disomy;6;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
disomy;6;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
disomy;6;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
disomy;6;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
disorder;10;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
disorder;10;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
disorder;10;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
disorder;10;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
disorder;10;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
disorder;10;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
disorder;10;Disorder of androgen synthesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen synthesis;
disorder;10;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
disorder;10;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
disorder;10;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
disorders;1;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
disorganized;1;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
dissection;1;neck_dissection;surgery;EURACAN;Neck dissection;1, Yes | 2, No | 9, Unknown
distal;1;Distal 16p11.2 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Distal 16p11.2 microdeletion syndrome;
diuretics;1;ascites_response_diuretics;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites response to diuretics;radio
divert;2;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
divert;2;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
dl;24;MG-ADL total score;QoL;EURO-NMD;;int
dl;24;R_AIH_Creatinine_mgdL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
dl;24;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
dl;24;R_PBC_Creatinine_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
dl;24;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
dl;24;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
dl;24;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
dl;24;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
dl;24;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
dl;24;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
dl;24;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
dl;24;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
dl;24;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
dl;24;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
dl;24;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
dl;24;dia_lab_colesterol_hdl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
dl;24;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
dl;24;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
dl;24;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
dl;24;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
dl;24;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
dl;24;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
dl;24;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
dl;24;Bardet-Biedl syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Bardet-Biedl syndromeÂ ;
dna;8;dna_obtained;Diagnosis Biobank;Rare Liver (Vascular);DNA sample obtained?;dropdown
dna;8;dna_date;Diagnosis Biobank;Rare Liver (Vascular);DNA sample date;date
dna;8;dna_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
dna;8;dna_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
dna;8;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
dna;8;ebv_dna_baseline;primary_cancer;EURACAN;Plasmatic EBV DNA at baseline;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
dna;8;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
dna;8;ebv_dna_radio;radiotherapy;EURACAN;Plasmatic EBV DNA during/after radiotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
dob;1;dob;Diagnosis General Information;Rare Liver (Vascular);Birth date;date
dominant;5;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
dominant;5;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
dominant;5;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
dominant;5;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
dominant;5;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
done;1;Total QMG score if done;QMG;EURO-NMD;;
donor;2;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
donor;2;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
doppl;2;doppler;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Doppler;radio
doppl;2;hv_abnorm_doppl_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal Doppler flow pattern in more than one large vein;radio
doppler;1;doppler;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Doppler;radio
dose;64;Medication Dose;Medication ;EURO-NMD;;float
dose;64;R_AIH_Prednisolone_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_AIH_Budesonide_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_AIH_Azathioprine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_AIH_MMF_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF dose;numeric
dose;64;R_PBC_UDCA_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
dose;64;R_PBC_UDCA_dose_per_kg;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose mg / kg;calculation
dose;64;R_PBC_OCA_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);OCA dose;numeric
dose;64;R_PBC_Prednisolone_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_PBC_Budesonide_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_PBC_Azathioprine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_PBC_AIH_MMF_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
dose;64;R_PSC_UDCA_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
dose;64;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_PSC_Budesonide_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
dose;64;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_AIH_UDCA_dose;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA dose;numeric
dose;64;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
dose;64;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
dose;64;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
dose;64;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
dose;64;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
dose;64;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
dose;64;R_PBC_UDCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
dose;64;R_PBC_OCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
dose;64;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
dose;64;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
dose;64;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
dose;64;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
dose;64;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
dose;64;meddose;Medications Medication;Rare Liver (Vascular);Daily Dose;numeric
dose;64;radio_photons_totdose;radiotherapy;EURACAN;Photons total dose;
dose;64;radio_photons_fractdose;radiotherapy;EURACAN;Photons dose per fraction;
dose;64;radio_electrons_totdose;radiotherapy;EURACAN;Electrons total dose;
dose;64;radio_electrons_fractdose;radiotherapy;EURACAN;Electrons dose per fraction;
dose;64;radio_protons_totdose;radiotherapy;EURACAN;Protons total dose;
dose;64;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
dose;64;radio_carbons_totdose;radiotherapy;EURACAN;Carbons total dose;
dose;64;radio_carbons_fractdose;radiotherapy;EURACAN;Carbons dose per fraction ;
dose;64;radio_brachy_totdose;radiotherapy;EURACAN;Brachytherapy total dose;
dose;64;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
dose;64;radio_radionuc_totdose;radiotherapy;EURACAN;Radionuclide total dose;
dose;64;radio_radionuc_fractdose;radiotherapy;EURACAN;Radionuclide dose per fraction ;
dose;64;radio_boron_totdose;radiotherapy;EURACAN;Boron neutron capture therapy total dose;
dose;64;radio_boron_fractdose;radiotherapy;EURACAN;Boron neutron capture therapy dose per fraction ;
dose;64;radio_others_totdose;radiotherapy;EURACAN;Others total dose;
dose;64;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
dose;64;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
double;2;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
double;2;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
drainage;5;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
drainage;5;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
drainage;5;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
drainage;5;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
drainage;5;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
drug;33;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
drug;33;cid_of_drugs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);CID of drug(s);textarea
drug;33;chemo_drug_1;chemotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
drug;33;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
drug;33;chemo_drug_2;chemotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
drug;33;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
drug;33;chemo_drug_3;chemotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
drug;33;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
drug;33;chemo_drug_4;chemotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
drug;33;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
drug;33;chemo_drug_5;chemotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
drug;33;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
drug;33;immuno_drug_1;immunotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
drug;33;immuno_drug_1_unk;immunotherapy;EURACAN;Unknown;1, Unknown
drug;33;immuno_drug_2;immunotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
drug;33;immuno_drug_2_unk;immunotherapy;EURACAN;Unknown;1, Unknown
drug;33;immuno_drug_3;immunotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
drug;33;immuno_drug_3_unk;immunotherapy;EURACAN;Unknown;1, Unknown
drug;33;immuno_drug_4;immunotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
drug;33;immuno_drug_4_unk;immunotherapy;EURACAN;Unknown;1, Unknown
drug;33;immuno_drug_5;immunotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
drug;33;immuno_drug_5_unk;immunotherapy;EURACAN;Unknown;1, Unknown
drug;33;tt_drug_1;target_therapy;EURACAN;Drug 1;BIOPORTAL:ATC
drug;33;tt_drug_1_unk;target_therapy;EURACAN;Unknown;1, Unknown
drug;33;tt_drug_2;target_therapy;EURACAN;Drug 2;BIOPORTAL:ATC
drug;33;tt_drug_2_unk;target_therapy;EURACAN;Unknown;1, Unknown
drug;33;tt_drug_3;target_therapy;EURACAN;Drug 3;BIOPORTAL:ATC
drug;33;tt_drug_3_unk;target_therapy;EURACAN;Unknown;1, Unknown
drug;33;tt_drug_4;target_therapy;EURACAN;Drug 4;BIOPORTAL:ATC
drug;33;tt_drug_4_unk;target_therapy;EURACAN;Unknown;1, Unknown
drug;33;tt_drug_5;target_therapy;EURACAN;Drug 5;BIOPORTAL:ATC
drug;33;tt_drug_5_unk;target_therapy;EURACAN;Unknown;1, Unknown
drug;33;if yes specify the drugs used;Chemotherapy;PaedCan;;String
drugs;3;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
drugs;3;cid_of_drugs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);CID of drug(s);textarea
drugs;3;if yes specify the drugs used;Chemotherapy;PaedCan;;String
dsd;4;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
dsd;4;Testicular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Testicular DSD;
dsd;4;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
dsd;4;Testicular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Testicular DSD;
dt;17;vis_dt;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Date of visit;date
dt;17;edta_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample obtained?;radio
dt;17;edta_sample_date;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample date;date
dt;17;stool_dt;Diagnosis Biobank;Rare Liver (Vascular);Stool sample date;date
dt;17;abd_interv_splen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Splenectomy;date
dt;17;abd_interv_chol_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Cholecystectomy;date
dt;17;abd_interv_hep_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Hepabiliary Surgery;date
dt;17;abd_interv_tips_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of TIPS;date
dt;17;abd_interv_sclero_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Sclerotherapy;date
dt;17;abd_interv_ltx_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of LTx;date
dt;17;abd_interv_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Intervention;date
dt;17;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
dt;17;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
dt;17;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
dt;17;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
dt;17;dia_lab_dev_coag_dt;Diagnosis Laboratory data;Rare Liver (Vascular);Deviant Laboratory Date;date
dt;17;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
duct;18;R_PBC_Bile_duct_loss_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
duct;18;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
duct;18;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
duct;18;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
duct;18;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
duct;18;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
duct;18;bile_ducts;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Bile ducts;radio
duct;18;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
duct;18;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
duct;18;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
duct;18;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
duct;18;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
duct;18;5a-reductase def (SRD5A2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;5a-reductase def (SRD5A2);
duct;18;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
duct;18;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
duct;18;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
duct;18;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
duct;18;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
ducts;1;bile_ducts;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Bile ducts;radio
due;57;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
due;57;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
due;57;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
due;57;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
due;57;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
due;57;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
due;57;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
due;57;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
due;57;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
due;57;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
due;57;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
due;57;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
due;57;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
due;57;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
due;57;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
due;57;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
due;57;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
due;57;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
due;57;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
due;57;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
due;57;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
due;57;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
due;57;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
due;57;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
due;57;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
due;57;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
due;57;Beckwith-Wiedemann syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microduplication;
due;57;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
due;57;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
due;57;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
due;57;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
due;57;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
due;57;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
due;57;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
due;57;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
due;57;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
due;57;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
due;57;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
due;57;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
due;57;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
due;57;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
due;57;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
due;57;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
due;57;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
due;57;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
due;57;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
due;57;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
due;57;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
due;57;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
due;57;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
due;57;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
due;57;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
due;57;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
due;57;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
due;57;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
due;57;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
due;57;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
duration;7;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
duration;7;Duration;Respiratory Apneic Episodes;EURO-NMD;Apneic episodes in last 12 months;int
duration;7;Duration;Respiratory Myasthenic crisis;EURO-NMD;Myasthenic crisis in last 12 months;int
duration;7;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
duration;7;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
duration;7;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
duration;7;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
during;18;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
during;18;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
during;18;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
during;18;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
during;18;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
during;18;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
during;18;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
during;18;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
during;18;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
during;18;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
during;18;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
during;18;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
during;18;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
during;18;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
during;18;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
during;18;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
during;18;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
during;18;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
dwarfism;5;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
dwarfism;5;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
dwarfism;5;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
dwarfism;5;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
dwarfism;5;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
dwarfism-cleft;1;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
dwarfism-insulin;1;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
dwarfism,;2;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
dwarfism,;2;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
dxa;12;R_AIH_DXA;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
dxa;12;R_AIH_Date_of_DXA;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
dxa;12;R_PBC_DXA;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
dxa;12;R_PBC_Date_of_DXA;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
dxa;12;R_PSC_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
dxa;12;R_PSC_Date_of_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
dxa;12;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
dxa;12;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
dxa;12;R_AIH_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Bone mineral density (DXA);radio
dxa;12;R_AIH_Date_of_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of DXA;date
dxa;12;R_PBC_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
dxa;12;R_PBC_Date_of_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
dysarthria;1;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
dyschondrosteosis;2;LÃ©ri-Weill dyschondrosteosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;LÃ©ri-Weill dyschondrosteosis ;
dyschondrosteosis;2;Dyschondrosteosis-nephritis syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dyschondrosteosis-nephritis syndrome ;
dyschondrosteosis-nephritis;1;Dyschondrosteosis-nephritis syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dyschondrosteosis-nephritis syndrome ;
dysfunc;9;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunc;9;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
dysfunc;9;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
dysfunc;9;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunc;9;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
dysfunc;9;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
dysfunc;9;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunc;9;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
dysfunc;9;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
dysfunct;5;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunct;5;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunct;5;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunct;5;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
dysfunct;5;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
dysfunction;3;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunction;3;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysfunction;3;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
dysgenesis;4;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
dysgenesis;4;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
dysgenesis;4;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
dysgenesis;4;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
dysmorphism;4;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
dysmorphism;4;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
dysmorphism;4;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
dysmorphism;4;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
dysmorphism-hyperelastic;1;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
dysostosis;2;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
dysostosis;2;Dysostosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dysostosis ;
dysostosis-intellectual;1;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
dysplasia;36;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
dysplasia;36;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
dysplasia;36;Septo-optic dysplasia spectrum;PITUITARY;EuRR-Bone & EuRRECa;Septo-optic dysplasia spectrum;
dysplasia;36;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
dysplasia;36;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
dysplasia;36;Polyostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Polyostotic fibrous dysplasia ;
dysplasia;36;Monostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Monostotic fibrous dysplasia ;
dysplasia;36;Multiple metaphyseal dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple metaphyseal dysplasia;
dysplasia;36;Epimetaphyseal skeletal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Epimetaphyseal skeletal dysplasia ;
dysplasia;36;Metaphyseal anadysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal anadysplasia;
dysplasia;36;Metaphyseal acroscyphodysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal acroscyphodysplasia;
dysplasia;36;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
dysplasia;36;Ulna metaphyseal dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ulna metaphyseal dysplasia syndrome ;
dysplasia;36;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
dysplasia;36;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
dysplasia;36;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
dysplasia;36;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
dysplasia;36;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
dysplasia;36;Spondylodysplastic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Spondylodysplastic dysplasia ;
dysplasia;36;Mesomelic and rhizo-mesomelic dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic and rhizo-mesomelic dysplasia;
dysplasia;36;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
dysplasia;36;Upper limb mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Upper limb mesomelic dysplasia ;
dysplasia;36;Langer mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Langer mesomelic dysplasia ;
dysplasia;36;Omodysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Omodysplasia ;
dysplasia;36;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
dysplasia;36;Mesomelic dysplasia, Savarirayan type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Savarirayan type ;
dysplasia;36;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
dysplasia;36;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
dysplasia;36;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
dysplasia;36;Craniodiaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniodiaphyseal dysplasia ;
dysplasia;36;Craniometaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniometaphyseal dysplasia ;
dysplasia;36;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
dysplasia;36;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
dysplasia;36;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
dysplasia;36;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
dysplasia;36; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
dysplasia-maxillary;1;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
dysplasia,;7;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
dysplasia,;7;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
dysplasia,;7;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
dysplasia,;7;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
dysplasia,;7;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
dysplasia,;7;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
dysplasia,;7;Mesomelic dysplasia, Savarirayan type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Savarirayan type ;
e-rec;1;e-REC indentifier;Identifiers;EuRR-Bone & EuRRECa;Identifier forÂ e-REC;String
e.ebv;1;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
e.egfr;1;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
e.placement;1;"e.	Placement: 	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
early-onset;2;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
early-onset;2;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
ebv;7;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ebv;7;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ebv;7;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ebv;7;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ebv;7;ebv_dna_baseline;primary_cancer;EURACAN;Plasmatic EBV DNA at baseline;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
ebv;7;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
ebv;7;ebv_dna_radio;radiotherapy;EURACAN;Plasmatic EBV DNA during/after radiotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
edta;2;edta_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample obtained?;radio
edta;2;edta_sample_date;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample date;date
education;2;education;patient_management_at_the_hospital;EURACAN;Education (ISCED classification);1, University (ISCED 4-6) | 2, Upper secondary school (ISCED 3A-3B) | 3, Lower secondary and vocational school (ISCED 2, 3C) | 4, Primary school (ISCED 1) | 5, No education (ISCED 0)
education;2;Educational attainment;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;International Standard Classification of Education (ISCED) 2011;Not Known/0/1/2/3/4/5/6/7/8
educational;1;Educational attainment;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;International Standard Classification of Education (ISCED) 2011;Not Known/0/1/2/3/4/5/6/7/8
effect;3;Medication Effect;Medication ;EURO-NMD;;single
effect;3;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
effect;3;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
effects;1;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
effraction;1;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
effusion;1;pleural_effusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Pleural effusion;radio
egfr;4;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
egfr;4;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
egfr;4;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
egfr;4;eGFR;Biochemistry;ERKNet;Â ;egfr
ehlers-danlos/osteogenesis;1;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
eif2ak3;1;EIF2AK3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;EIF2AK3;
elastography;4;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
elastography;4;R_PBC_Transient_elastography;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
elastography;4;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
elastography;4;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
electrons;10;radio_electrons_tech;radiotherapy;EURACAN;Electrons treatment technique;1, FLASH  therapy
electrons;10;radio_electrons_from;radiotherapy;EURACAN;Electrons start date;
electrons;10;radio_electrons_to;radiotherapy;EURACAN;Electrons end date;
electrons;10;radio_electrons_totdose;radiotherapy;EURACAN;Electrons total dose;
electrons;10;radio_electrons_fractdose;radiotherapy;EURACAN;Electrons dose per fraction;
electrons;10;radio_electrons_nrfract;radiotherapy;EURACAN;Electrons number fraction;
electrons;10;radio_electrons_ott;radiotherapy;EURACAN;Electrons OTT;"datediff([radio_electrons_to],[radio_electrons_from],""d"")"
electrons;10;radio_electrons_4d;radiotherapy;EURACAN;Electrons 4D treatment;1, Yes | 2, No
electrons;10;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
electrons;10;radio_electrons_igrt;radiotherapy;EURACAN;Electrons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
elisa;25;R_AIH_ANA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
elisa;25;R_AIH_AMA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
elisa;25;R_AIH_SMA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
elisa;25;R_AIH_LKM_1_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
elisa;25;R_PBC_ANA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
elisa;25;R_PBC_SMA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
elisa;25;R_PBC_LKM1_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
elisa;25;R_PBC_AMA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
elisa;25;R_PBC_gp210_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
elisa;25;R_PSC_ANA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
elisa;25;R_PSC_SMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
elisa;25;R_PSC_LKM1_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
elisa;25;R_PSC_AMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
elisa;25;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
elisa;25;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
elisa;25;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
elisa;25;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
elisa;25;R_AIH_ANA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
elisa;25;R_AIH_AMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
elisa;25;R_AIH_SMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
elisa;25;R_AIH_LKM_1_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
elisa;25;R_PBC_ANA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
elisa;25;R_PBC_SMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
elisa;25;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
elisa;25;R_PBC_AMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
else;1;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
emb;5;Affected family members;Diagnosis Family History;EURO-NMD;;multi
emb;5;Link to Ensembl Gene ID;;ithaca;Hugo.owl.Ensembl_ID__mapped_data_supplied_by_Ensembl_;string
emb;5;other_treatment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of other treatment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{other_treatment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{other_treatment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{other_treatment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
emb;5;oth_enrolment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of enrolment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{oth_enrolment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{oth_enrolment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{oth_enrolment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
emb;5;Family members affected?;Family history;ERKNet;Â ;fam_affected
emg;6;EMG result;Diagnosis EMG;EURO-NMD;EMG result;single
emg;6;EMG abnormality;Diagnosis EMG;EURO-NMD;;single
emg;6;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
emg;6;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
emg;6;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
emg;6;SF EMG result;Diagnosis EMG;EURO-NMD;;
ems;3;EMS < 5;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;EMS < 5;
ems;3;EMS 5-8;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;EMS 5-8;
ems;3;EMS >/= 9;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;EMS >/= 9;
enceph;17;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
enceph;17;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
enceph;17;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
enceph;17;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
enceph;17;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
enceph;17;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
enceph;17;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
enceph;17;fu_encephalopathy;Follow-up Complications;Rare Liver (Vascular);Encephalopathy;radio
enceph;17;fu_cli_bef_enceph_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy value;radio
enceph;17;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
enceph;17;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
encephalopahty;1;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
encephalopathy;13;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
encephalopathy;13;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
encephalopathy;13;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
encephalopathy;13;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
encephalopathy;13;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
encephalopathy;13;fu_encephalopathy;Follow-up Complications;Rare Liver (Vascular);Encephalopathy;radio
encephalopathy;13;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
encephaolopathy;1;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
end;75;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
end;75;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
end;75;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
end;75;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
end;75;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
end;75;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
end;75;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
end;75;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
end;75;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
end;75;fu_end_date_evaluation;Follow-up Endpoints;Rare Liver (Vascular);Date of evaluation;date
end;75;fu_end_mesenteric_infarct;Follow-up Endpoints;Rare Liver (Vascular);Mesenteric infarction;radio
end;75;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
end;75;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
end;75;Number of ependymomas;benignNeoplasm;Genturis;What is the maximal number of ependymomas ever observed in this patient?;int
end;75;Gender;;ithaca;;categorical
end;75;End date medication;;ithaca;;date
end;75;gender;patient_management_at_the_hospital;EURACAN;Gender;1, Male | 2, Female | 9, Unknown
end;75;site_neuroendocrine;primary_cancer;EURACAN;Neuroendocrine subtype;1, Small cell neuroendocrine carcinoma (SmCC) | 8041/3 | 2, Large cell neuroendocrine carcinoma (LCNEC) | 8013/3 | 3, Well-differentiated neuroendocrine carcinoma | 8240/3 | 4, Moderately differentiated neuroendocrine carcinoma | 8249/3 | 5, Sinonasal undifferentiated carcinoma | 8020/3
end;75;site_neuroend_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
end;75;ae_end;adverse_event;EURACAN;Adverse event end date;
end;75;ae_end_mm;adverse_event;EURACAN;Adverse event ending month;
end;75;ae_end_yyyy;adverse_event;EURACAN;Adverse event ending year;
end;75;ae_end_2;adverse_event;EURACAN;Second adverse event end date;
end;75;ae_end_mm_2;adverse_event;EURACAN;Second adverse event ending month;
end;75;ae_end_yyyy_2;adverse_event;EURACAN;Second adverse event ending year;
end;75;ae_end_3;adverse_event;EURACAN;Third adverse event end date;
end;75;ae_end_mm_3;adverse_event;EURACAN;Third adverse event ending month;
end;75;ae_end_yyyy_3;adverse_event;EURACAN;Third adverse event ending year;
end;75;ae_end_4;adverse_event;EURACAN;Fourth adverse event end date;
end;75;ae_end_mm_4;adverse_event;EURACAN;Fourth adverse event ending month;
end;75;ae_end_yyyy_4;adverse_event;EURACAN;Fourth adverse event ending year;
end;75;ae_end_5;adverse_event;EURACAN;Fifth adverse event end date;
end;75;ae_end_mm_5;adverse_event;EURACAN;Fifth adverse event ending month;
end;75;ae_end_yyyy_5;adverse_event;EURACAN;Fifth adverse event ending year;
end;75;end_treatment_chem;chemotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
end;75;end_treat_res_chem;chemotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
end;75;end_treatment_immuno;immunotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
end;75;end_treat_res_immuno;immunotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
end;75;end_treatment_tt;target_therapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
end;75;end_treat_res_tt;target_therapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
end;75;end_treatment_radio;radiotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
end;75;end_treat_res_radio;radiotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
end;75;end_treatment_other;other_type_of_treatment;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
end;75;end_treat_res_other;other_type_of_treatment;EURACAN;Treatment response (based on imaging no defined criteria);1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
end;75;end_treat_res_def_other;other_type_of_treatment;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
end;75;end_treatment_note;imaging_available;EURACAN;Imaging after treatment available at the hospital?;
end;75;end_treatment_us;imaging_available;EURACAN;US;1, Baseline | 2, After treatment
end;75;end_treatment_ct;imaging_available;EURACAN;CT;1, Baseline | 2, After treatment
end;75;end_treatment_mri;imaging_available;EURACAN;MRI;1, Baseline | 2, After treatment
end;75;end_treatment_pet;imaging_available;EURACAN;PET;1, Baseline | 2, After treatment
end;75;end_treatment_optical;imaging_available;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Baseline | 2, After treatment
end;75;end_treatment_ctpet;imaging_available;EURACAN;CT/PET;1, Baseline | 2, After treatment
end;75;End date;Chemotherapy;PaedCan;Last day of chemoterapy;dd/mm/yyyy
end;75;End date;Radiotherapy;PaedCan;Last day of radiotherapy;dd/mm/yyyy
end;75;End date;Other treatments;PaedCan;Date when therapy was ended;dd/mm/yyyy or uk/uk/yyyy
end;75;End of treatment date;End of treatment;PaedCan;Date of the last chemotherapy cycle or the last surgical procedure or the last day of radiotherapy or the last day of any other treatment whichever come last.;dd/mm/yyyy
end;75;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
end;75;Current gender;Personal Information;EuRR-Bone & EuRRECa;Current gender;Male/Female/Non-binary/Other/Asked but Unknown
end;75;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
end;75;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
end;75;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
end;75;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
end;75;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
end;75;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
end;75;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
end;75;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
end;75;Multiple endocrine neoplasia;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia;
end;75;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
end;75;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
end;75;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
end;75;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
end;75;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
end;75;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
end;75;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
end;75;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
endocrine;8;site_neuroendocrine;primary_cancer;EURACAN;Neuroendocrine subtype;1, Small cell neuroendocrine carcinoma (SmCC) | 8041/3 | 2, Large cell neuroendocrine carcinoma (LCNEC) | 8013/3 | 3, Well-differentiated neuroendocrine carcinoma | 8240/3 | 4, Moderately differentiated neuroendocrine carcinoma | 8249/3 | 5, Sinonasal undifferentiated carcinoma | 8020/3
endocrine;8;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
endocrine;8;Multiple endocrine neoplasia;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia;
endocrine;8;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
endocrine;8;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
endocrine;8;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
endocrine;8;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
endocrine;8;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
endoscopy;2;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
endoscopy;2;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
ene;59;R_AIH_Paxgene;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
ene;59;R_PBC_Paxgene;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
ene;59;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
ene;59;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
ene;59;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
ene;59;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
ene;59;splenectomy;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenectomy;radio
ene;59;geneticVariantLabel;geneticVariant;Genturis;;string
ene;59;Name of the gene;geneticVariant;Genturis;Gene (cosmic);xref
ene;59;Genetics  (germline);subject;Genturis;;compound
ene;59;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
ene;59;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
ene;59;Genetic variants;subject;Genturis;Genetic variants;mref
ene;59;Extra gene information COSMIC;;ithaca;;xref
ene;59;Link to Ensembl Gene ID;;ithaca;Hugo.owl.Ensembl_ID__mapped_data_supplied_by_Ensembl_;string
ene;59;Gene Locus;;ithaca;;string
ene;59;Gene Symbol;;ithaca;;string
ene;59;Age when panel opened;;ithaca;;string
ene;59;General comments;;ithaca;;text
ene;59;Gene affected;;ithaca;COSMIC genes (can be replaced by other list of genes);mref
ene;59;genetic_syndrome_ynu;previous_cancer_genetic_syndromes;EURACAN;Genetic syndrome;1, Yes | 2, No | 9, Unknown
ene;59;ene_clin;stage_procedures;EURACAN;Extranodal extension (ENE);1, ENE- | 2, ENE+
ene;59;ene_pat;stage_procedures;EURACAN;Extranodal extension (ENE);1, ENE- | 2, ENE+
ene;59;Specify the genetic abornalities found;Patient's history;PaedCan;;String
ene;59;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
ene;59;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
ene;59;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
ene;59;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
ene;59;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
ene;59;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
ene;59;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
ene;59;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
ene;59;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
ene;59;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
ene;59;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
ene;59;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
ene;59;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
ene;59;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
ene;59;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
ene;59;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
ene;59;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
ene;59;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
ene;59;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
ene;59;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
ene;59;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
ene;59;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
ene;59;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
ene;59;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
ene;59;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
ene;59;Fibrochondrogenesis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrochondrogenesis ;
ene;59;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
ene;59;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
ene;59;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
ene;59;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
ene;59;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
ene;59;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
ene;59;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
ene;59;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
ene;59;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
english;4;Value (English);Anatomical Therapeutic Chemical Classification;ithaca;;string
english;4;Description (English);Anatomical Therapeutic Chemical Classification;ithaca;;text
english;4;Value (English);ICD-10: International Classification of Diseases and Related Health Problems;ithaca;;string
english;4;Description (English);;ithaca;;text
enlargement;2;diff_harm_enlargement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Diffuse harmonious enlargement;radio
enlargement;2;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
enrol;7;Patient enrolment;;ithaca;;compound
enrol;7;Date enrolled;;ithaca;;date
enrol;7;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
enrol;7;oth_enrolment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of enrolment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{oth_enrolment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{oth_enrolment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{oth_enrolment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
enrol;7;oth_enrolment_date;other_type_of_treatment;EURACAN;Date of enrolment;
enrol;7;oth_enrolment_date_mm;other_type_of_treatment;EURACAN;Month of enrolment;
enrol;7;oth_enrolment_date_yyyy;other_type_of_treatment;EURACAN;Year of enrolment;
enrolment;5;Patient enrolment;;ithaca;;compound
enrolment;5;oth_enrolment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of enrolment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{oth_enrolment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{oth_enrolment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{oth_enrolment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
enrolment;5;oth_enrolment_date;other_type_of_treatment;EURACAN;Date of enrolment;
enrolment;5;oth_enrolment_date_mm;other_type_of_treatment;EURACAN;Month of enrolment;
enrolment;5;oth_enrolment_date_yyyy;other_type_of_treatment;EURACAN;Year of enrolment;
entry;1;Date of data entry;subject;Genturis;At what date (yyyy-mm-dd) was the data entered in the registry?;date
eos;19;invasive (tracheostomy);Respiratory Myasthenic crisis;EURO-NMD;;yesno
eos;19;dia_lab_eosinophils;Diagnosis Laboratory data;Rare Liver (Vascular);Eosinophils;numeric
eos;19;eos_termination_reason;End of study End of study;Rare Liver (Vascular);Reason for Study Termination;radio
eos;19;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
eos;19;eos_dead;End of study End of study;Rare Liver (Vascular);Dead?;radio
eos;19;eos_death;End of study End of study;Rare Liver (Vascular);Did death occur?;calculation
eos;19;eos_death_date;End of study End of study;Rare Liver (Vascular);Date of death;date
eos;19;eos_death_cause;End of study End of study;Rare Liver (Vascular);Cause of death;radio
eos;19;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
eos;19;eos_death_autopsy;End of study End of study;Rare Liver (Vascular);Autopsy performed;radio
eos;19;eos_liver_transplant;End of study End of study;Rare Liver (Vascular);Was a liver transplantation performed?;radio
eos;19;eos_liver_transplant_date;End of study End of study;Rare Liver (Vascular);Date of liver transplantation;date
eos;19;eos_liver_transplant_reason;End of study End of study;Rare Liver (Vascular);Why was no liver transplantation performed?;radio
eos;19;eos_liver_transplant_other;End of study End of study;Rare Liver (Vascular);Other reason:;string
eos;19;eos_liver_transplant_death;End of study End of study;Rare Liver (Vascular);Death after liver transplantation?;calculation
eos;19;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
eos;19;LÃ©ri-Weill dyschondrosteosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;LÃ©ri-Weill dyschondrosteosis ;
eos;19;Dyschondrosteosis-nephritis syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dyschondrosteosis-nephritis syndrome ;
eos;19;MelorheostosisÂ withÂ osteopoikilosisÂ ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;MelorheostosisÂ withÂ osteopoikilosisÂ ;
eosinophils;1;dia_lab_eosinophils;Diagnosis Laboratory data;Rare Liver (Vascular);Eosinophils;numeric
ep300;1;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
ependymomas;1;Number of ependymomas;benignNeoplasm;Genturis;What is the maximal number of ependymomas ever observed in this patient?;int
epimetaphyseal;1;Epimetaphyseal skeletal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Epimetaphyseal skeletal dysplasia ;
episodic;1;Sudden episodic apnea;Diagnosis Respiratory;EURO-NMD;Episodic apnoea;yesno
epo;12;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
epo;12;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
epo;12;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
epo;12;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
epo;12;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
epo;12;epo_value;Diagnosis Aetiology;Rare Liver (Vascular);EPO Value;numeric
epo;12;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
epo;12;Full caryotype (if not inferred from CNV report);;ithaca;;string
epo;12;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
epo;12;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
epo;12;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
epo;12;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
er;719;Affected family members;Diagnosis Family History;EURO-NMD;;multi
er;719;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
er;719;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
er;719;Exacerbation;Diagnosis Fluctuation;EURO-NMD;Exacerbation with infection;yesno
er;719;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
er;719;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
er;719;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
er;719;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
er;719;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
er;719;Achromatopsia Titer;Diagnosis ;EURO-NMD;;
er;719;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
er;719;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
er;719;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
er;719;Titin Titer;Diagnosis ;EURO-NMD;;
er;719;RYR1 Titer;Diagnosis ;EURO-NMD;;
er;719;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
er;719;Medication Other;Medication ;EURO-NMD;;text
er;719;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
er;719;Transfer from chair to bed;Mobility ;EURO-NMD;;single
er;719;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
er;719;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
er;719;Thymoma therapy:;Thymoma;EURO-NMD;;
er;719;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
er;719;External_institute_HUDEB;Base information;Rare Liver (Auto imune);External Institute;dropdown
er;719;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
er;719;R_AIH_Other_ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
er;719;is_smoker;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
er;719;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
er;719;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
er;719;R_AIH_Liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver biopsy;radio
er;719;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
er;719;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
er;719;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
er;719;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
er;719;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
er;719;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
er;719;R_AIH_MRCP_or_ERCP;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Cholangiography (MRCP or ERCP);radio
er;719;R_AIH_Tanner_stage;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
er;719;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
er;719;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
er;719;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
er;719;R_AIH_ANA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
er;719;R_AIH_AMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
er;719;R_AIH_SMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
er;719;R_AIH_LKM_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
er;719;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
er;719;R_AIH_Other_antibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
er;719;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
er;719;R_AIH_Liver_tissue;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
er;719;R_AIH_Serum;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
er;719;R_AIH_Other_biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
er;719;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
er;719;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
er;719;R_AIH_Everolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Everolimus;radio
er;719;R_AIH_Treatment_other;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other;textarea
er;719;R_PBC_Other_ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
er;719;PBC_is_smoker;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
er;719;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
er;719;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
er;719;R_PBC_Liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
er;719;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
er;719;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
er;719;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
er;719;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
er;719;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
er;719;R_PBC_Liver_stiffness;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
er;719;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
er;719;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
er;719;R_PBC_ANA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
er;719;R_PBC_Titer_SMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
er;719;R_PBC_LKM_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
er;719;R_PBC_AMA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
er;719;R_PBC_IFT_pattern;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
er;719;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
er;719;R_PBC_Liver_tissue;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
er;719;R_PBC_Serum;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
er;719;R_PBC_Other_biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
er;719;R_PBC_UDCA_dose_per_kg;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose mg / kg;calculation
er;719;R_PBC_Other_treatment;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
er;719;R_PBC_Treatment_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
er;719;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
er;719;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PBC_AIH_Everolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
er;719;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
er;719;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
er;719;PSC_is_smoker;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
er;719;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
er;719;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
er;719;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
er;719;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
er;719;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
er;719;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
er;719;R_PSC_ERCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP;radio
er;719;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
er;719;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
er;719;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
er;719;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
er;719;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
er;719;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
er;719;R_PSC_SMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
er;719;R_PSC_LKM_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
er;719;R_PSC_AMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
er;719;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
er;719;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
er;719;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
er;719;R_PSC_Serum;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
er;719;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
er;719;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
er;719;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
er;719;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
er;719;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
er;719;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
er;719;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
er;719;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
er;719;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
er;719;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
er;719;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
er;719;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
er;719;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
er;719;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
er;719;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
er;719;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
er;719;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
er;719;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
er;719;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
er;719;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
er;719;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
er;719;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
er;719;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
er;719;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
er;719;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
er;719;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
er;719;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
er;719;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
er;719;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
er;719;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
er;719;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
er;719;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
er;719;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
er;719;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
er;719;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
er;719;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
er;719;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
er;719;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
er;719;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
er;719;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
er;719;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
er;719;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
er;719;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
er;719;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
er;719;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
er;719;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
er;719;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
er;719;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
er;719;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
er;719;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
er;719;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
er;719;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
er;719;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
er;719;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
er;719;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
er;719;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
er;719;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
er;719;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
er;719;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
er;719;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
er;719;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
er;719;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
er;719;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
er;719;R_AIH_Serum_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
er;719;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
er;719;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
er;719;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
er;719;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
er;719;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
er;719;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
er;719;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
er;719;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
er;719;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
er;719;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
er;719;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
er;719;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
er;719;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
er;719;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
er;719;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
er;719;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
er;719;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
er;719;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
er;719;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
er;719;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
er;719;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
er;719;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
er;719;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
er;719;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
er;719;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
er;719;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
er;719;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
er;719;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
er;719;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
er;719;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
er;719;R_PBC_Serum_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
er;719;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
er;719;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
er;719;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
er;719;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
er;719;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
er;719;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
er;719;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
er;719;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
er;719;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
er;719;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
er;719;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
er;719;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
er;719;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
er;719;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
er;719;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
er;719;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
er;719;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
er;719;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
er;719;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
er;719;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
er;719;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
er;719;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
er;719;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
er;719;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
er;719;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
er;719;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
er;719;fever;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Fever 38Ã‚Â°C;radio
er;719;oedema_lower_limbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Oedema of lower limbs;radio
er;719;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
er;719;other_symptoms;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other symptoms;textarea
er;719;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
er;719;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
er;719;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
er;719;alcohol_grams_per_week;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Average grams of ethanol per week;radio
er;719;smoker;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Smoker;radio
er;719;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
er;719;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
er;719;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
er;719;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
er;719;doppler;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Doppler;radio
er;719;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
er;719;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
er;719;number_of_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of nodules;radio
er;719;superior_mesenteric_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Superior mesenteric vein;radio
er;719;portoportal_cavernoma;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portoportal cavernoma;radio
er;719;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
er;719;hepatic_artery;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery;radio
er;719;hepatic_vein_catheter;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic Vein Catheterization;radio
er;719;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
er;719;free_hv_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein After TIPS;numeric
er;719;hv_gradient_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient After TIPS;numeric
er;719;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
er;719;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
er;719;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
er;719;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
er;719;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
er;719;date_liver_biopsy;Diagnosis Biobank;Rare Liver (Vascular);Date of liver biopsy;date
er;719;liver_biopsy_number;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy local number;string
er;719;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
er;719;liver_biopsy_obtained;Diagnosis Biobank;Rare Liver (Vascular);Frozen liver biopsy obtained?;dropdown
er;719;buffy_coat_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
er;719;dna_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
er;719;plasma_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
er;719;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
er;719;serum_obtained;Diagnosis Biobank;Rare Liver (Vascular);Serum sample obtained?;dropdown
er;719;serum_date;Diagnosis Biobank;Rare Liver (Vascular);Serum sample date;date
er;719;serum_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
er;719;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
er;719;methionine_tolerance_test;Diagnosis Aetiology;Rare Liver (Vascular);Methionine tolerance test;radio
er;719;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
er;719;pathergy_test;Diagnosis Aetiology;Rare Liver (Vascular);Pathergy test;radio
er;719;telomeropathy;Diagnosis Aetiology;Rare Liver (Vascular);Telomeropathy;radio
er;719;telomeropathy_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of telomeropathy;string
er;719;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
er;719;number_miscarriagies;Diagnosis Aetiology;Rare Liver (Vascular);Number of miscarriages;radio
er;719;other_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
er;719;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
er;719;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
er;719;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
er;719;abd_intervention_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of procedure;date
er;719;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
er;719;abd_interv_splen;Diagnosis Aetiology;Rare Liver (Vascular);Splenectomy;radio
er;719;abd_interv_splen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Splenectomy;date
er;719;abd_interv_chol;Diagnosis Aetiology;Rare Liver (Vascular);Cholecystectomy;radio
er;719;abd_interv_chol_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Cholecystectomy;date
er;719;abd_interv_hep;Diagnosis Aetiology;Rare Liver (Vascular);Hepatobiliary Surgery;radio
er;719;abd_interv_hep_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Hepabiliary Surgery;date
er;719;abd_interv_tips;Diagnosis Aetiology;Rare Liver (Vascular);TIPS;radio
er;719;abd_interv_tips_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of TIPS;date
er;719;abd_interv_sclero;Diagnosis Aetiology;Rare Liver (Vascular);Sclerotherapy;radio
er;719;abd_interv_sclero_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Sclerotherapy;date
er;719;abd_interv_ltx;Diagnosis Aetiology;Rare Liver (Vascular);LTx;radio
er;719;abd_interv_ltx_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of LTx;date
er;719;abd_interv_other;Diagnosis Aetiology;Rare Liver (Vascular);Other;radio
er;719;abd_interv_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Intervention;date
er;719;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
er;719;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
er;719;abdom_infect_other;Diagnosis Aetiology;Rare Liver (Vascular);Other Infection / Inflammation;radio
er;719;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
er;719;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
er;719;date_mesenterico_portal;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
er;719;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
er;719;dia_lab_serum_albumin;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin;numeric
er;719;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
er;719;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
er;719;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
er;719;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
er;719;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
er;719;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
er;719;dia_lab_serum_ferritine;Diagnosis Laboratory data;Rare Liver (Vascular);Serum ferritin;numeric
er;719;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
er;719;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
er;719;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
er;719;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
er;719;dia_lab_colesterol_t;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
er;719;dia_lab_colesterol_hdl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
er;719;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
er;719;eos_termination_reason;End of study End of study;Rare Liver (Vascular);Reason for Study Termination;radio
er;719;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
er;719;eos_liver_transplant;End of study End of study;Rare Liver (Vascular);Was a liver transplantation performed?;radio
er;719;eos_liver_transplant_date;End of study End of study;Rare Liver (Vascular);Date of liver transplantation;date
er;719;eos_liver_transplant_reason;End of study End of study;Rare Liver (Vascular);Why was no liver transplantation performed?;radio
er;719;eos_liver_transplant_other;End of study End of study;Rare Liver (Vascular);Other reason:;string
er;719;eos_liver_transplant_death;End of study End of study;Rare Liver (Vascular);Death after liver transplantation?;calculation
er;719;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
er;719;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
er;719;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
er;719;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
er;719;date_of_interruption;Follow-up Events;Rare Liver (Vascular);Date of interruption;date
er;719;first_liver_transplant;Follow-up Events;Rare Liver (Vascular);First liver transplantation;radio
er;719;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
er;719;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
er;719;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
er;719;fu_cholesterol_t;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
er;719;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
er;719;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
er;719;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
er;719;fu_ima_bef_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
er;719;fu_ima_last_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
er;719;fu_end_mesenteric_infarct;Follow-up Endpoints;Rare Liver (Vascular);Mesenteric infarction;radio
er;719;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
er;719;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
er;719;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
er;719;(If yes, answer questionÂ 2e);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Tick-box, multiple selection]
er;719;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
er;719;"openÂ ureterostomies 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
er;719;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
er;719;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
er;719;"bladder augment 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
er;719;a.Performed;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
er;719;a.Performed;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
er;719;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
er;719;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
er;719;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
er;719;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
er;719;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
er;719;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
er;719;e. Vesicoureteral reflux:;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
er;719;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
er;719;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
er;719;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
er;719;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
er;719;b. Severity of incontinence:;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
er;719;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
er;719;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
er;719;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
er;719;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
er;719;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
er;719;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
er;719;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
er;719;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
er;719;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
er;719;Number of polyps;benignNeoplasm;Genturis;What is the maximal number of these polyps ever observed in this patient?;int
er;719;Number of vestibular schwannoma;benignNeoplasm;Genturis;What is the maximal number of vestibular schwannomas ever observed in this patient?;int
er;719;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
er;719;Number of meningioma;benignNeoplasm;Genturis;What is the maximal number of meningiomas ever observed in this patient?;int
er;719;Number of ependymomas;benignNeoplasm;Genturis;What is the maximal number of ependymomas ever observed in this patient?;int
er;719;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
er;719;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
er;719;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
er;719;ER receptor status;malignancy;Genturis;What is the Estrogen receptor status of the breast cancer?;categorical
er;719;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
er;719;Laterality;malignancy;Genturis;What is the laterality of the breast cancer?;categorical
er;719;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
er;719;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
er;719;Patient identifiers;subject;Genturis;;compound
er;719;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
er;719;Material availability;subject;Genturis;What material is locally available for this patient?;categoricalmref
er;719;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
er;719;Center;subject;Genturis;;compound
er;719;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
er;719;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
er;719;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
er;719;Phenotypical Characteristics;subject;Genturis;;compound
er;719;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
er;719;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
er;719;Number of Cafe au lait spot;subject;Genturis;What is the maximal number of cafe au lait spots ever observed in the patient?;int
er;719;Genetics  (germline);subject;Genturis;;compound
er;719;Tumour Types(Germline);;ithaca;;string
er;719;Cancer Syndrome;;ithaca;;string
er;719;Reference genome;;ithaca;;categorical
er;719;Number of copies / UPD;;ithaca;;categorical
er;719;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
er;719;Full caryotype (if not inferred from CNV report);;ithaca;;string
er;719;Reference Sequence ID (mapped by NCBI);;ithaca;Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_;string
er;719;Parents (link to other OMIM code);;ithaca;;mref
er;719;Allelic variant of (link to other OMIM code);;ithaca;;xref
er;719;Semantic type UMLS property (URL);;ithaca;;hyperlink
er;719;ERN/HCP number;Organisations;ithaca;;string
er;719;Institution name ERN/HCP;;ithaca;;string
er;719;ERN/HCP main contact;;ithaca;;mref
er;719;ERN/HCP other contactperson (s);;ithaca;;mref
er;719;Website ERN/HCP;;ithaca;;hyperlink
er;719;Phone number;;ithaca;;string
er;719;EUPID/ Person ID;;ithaca;;string
er;719;Consent for ERN databases/Registries/research;;ithaca;;bool
er;719;Consent for usage of biobank material;;ithaca;;bool
er;719;"Other;  what patient Data is available";;ithaca;;categoricalmref
er;719;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
er;719;Healthcare Provider (HCP);;ithaca;;xref
er;719;ERN;;ithaca;;categoricalmref
er;719;Gender;;ithaca;;categorical
er;719;Other Remarks;;ithaca;;text
er;719;Period of first symptom onset;;ithaca;;categorical
er;719;Period of current diagnosis;;ithaca;;categorical
er;719;Other cases in the family?;;ithaca;;categorical
er;719;If Yes â€“ kinship of Carrier;;ithaca;;xref
er;719;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
er;719;Other comorbidities;;ithaca;;text
er;719;Other status of diagnosis;;ithaca;;text
er;719;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
er;719;Is the patient following any other medication?;;ithaca;;bool
er;719;General comments;;ithaca;;text
er;719;Nucleotide reference sequence (RefSeq id/LRG id);;ithaca;;string
er;719;Other changes:;;ithaca;;text
er;719;gender;patient_management_at_the_hospital;EURACAN;Gender;1, Male | 2, Female | 9, Unknown
er;719;smoking_per_day;patient_management_at_the_hospital;EURACAN;Cigarettes/cigars smoked per day;
er;719;exposure_other;patient_management_at_the_hospital;EURACAN;Please specify;
er;719;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
er;719;other_hn_cancers;previous_cancer_genetic_syndromes;EURACAN;Other head and neck malignant cancers ;1, Yes | 2, No | 9, Unknown
er;719;other_hn_site;previous_cancer_genetic_syndromes;EURACAN;Site;999, Unknown | 1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS | 9, C11 nasopharynx | 10, C11.0  Superior wall of nasopharynx | 11, C11.1  Posterior wall of nasopharynx | 12, C11.2  Lateral wall of nasopharynx | 13, C11.3  Anterior wall of nasopharynx | 14, C11.8  Overlapping lesion of nasopharynx | 15, C11.9  Nasopharynx, NOS | 16, C12.9  Pyriform sinus | 17, C13 Hypopharynx | 18, C13.0  Postcricoid region | 19, C13.1  Hypopharyngeal aspect of aryepiglottic fold | 20, C13.2  Posterior wall of hypopharynx | 21, C13.8  Overlapping lesion of hypopharynx | 22, C13.9  Hypopharynx, NOS | 23, C01.9  Base of tongue, NOS | 24, C02.4  Lingual tonsil | 25, C05.1  Soft palate, NOS | 26, C05.2  Uvula | 27, C09 tonsil | 28, C09.0  Tonsillar fossa | 29, C09.1  Tonsillar pillar | 30, C09.8  Overlapping lesion of tonsil | 31, C09.9  Tonsil, NOS | 32, C10 oropharynx | 33, C10.0  Vallecula | 34, C10.2 Lateral wall of oropharynx | 35, C10.3 Posterior Pharyngeal wall | 36, C10.8 Overlapping lesions of oropharynx | 37, C10.9 Oropharynx, NOS | 38, C11.1 Pharyngeal tonsils | 39, C01.9  Base of tongue, NOS | 40, C02.4  Lingual tonsil | 41, C05.1  Soft palate, NOS | 42, C05.2  Uvula | 43, C09 tonsil | 44, C09.0  Tonsillar fossa | 45, C09.1  Tonsillar pillar | 46, C09.8  Overlapping lesion of tonsil | 47, C09.9  Tonsil, NOS | 48, C10 oropharynx | 49, C10.0  Vallecula | 50, C10.2 Lateral wall of oropharynx | 51, C10.3 Posterior Pharyngeal wall | 52, C10.8 Overlapping lesions of oropharynx | 53, C10.9 Oropharynx, NOS | 54, C11.1 Pharyngeal tonsils | 55, C10.1 Anterior (lingual) surface of epiglottis | 56, C32 Larynx | 57, C32.0  Glottis | 58, C32.1  Supraglottis | 59, C32.2  Subglottis | 60, C32.3  Laryngeal cartilage | 61, C32.8  Overlapping lesion of larynx | 62, C32.9  Larynx, NOS | 63, C02.0  Dorsal surface of tongue, NOS | 64, C02.1  Border of tongue | 65, C02.2  Ventral surface of tongue, NOS | 66, C02.3  Anterior 2/3 of tongue, NOS | 67, C02.8 Overlapping lesion of tongue | 68, C02.9  Tongue, NOS | 69, C03 gum | 70, C03.0  Upper gum | 71, C03.1  Lower gum | 72, C03.9  Gum, NOS | 73, C04 floor of mouth | 74, C04.0  Anterior floor of mouth | 75, C04.1  Lateral floor of mouth | 76, C04.8  Overlapping lesion of floor of mouth | 77, C04.9  Floor of mouth, NOS | 78, C05 palate | 79, C05.0  Hard palate | 80, C05.8  Overlapping lesion of palate | 81, C05.9  Palate, NOS | 82, C06 other and unspecified parts of mouth | 83, C06.0  Cheek mucosa | 84, C06.1  Vestibule of mouth | 85, C06.2  Retromolar area | 86, C06.8  Overlapping lesion of other  and unspecified parts of mouth | 87, C06.9  Mouth, NOS | 88, C00 lip (excludes skin of lip C44.0) | 89, C00.0  External upper lip | 90, C00.1  External lower lip | 91, C00.2  External lip, NOS | 92, C00.3  Mucosa of upper lip | 93, C00.4  Mucosa of lower lip | 94, C00.5  Mucosa of lip, NOS | 95, C00.6  Commissure of lip | 96, C00.8  Overlapping lesion of lip | 97, C00.9  Lip, NOS | 98, C30.1  Middle ear | 99, C07.9  Parotid gland | 100, C08 other and unspecified major salivary glands | 101, C08.0  Submandibular gland | 102, C08.1  Sublingual gland | 103, C08.8  Overlapping lesion of major salivary glands | 104, C08.9  Major salivary gland, NOS | 105, Minor salivary gland of the head & neck
er;719;other_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
er;719;other_hn_bening;previous_cancer_genetic_syndromes;EURACAN;Other head and neck benign tumours;1, Yes | 2, No | 9, Unknown
er;719;other_hn_bening_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
er;719;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
er;719;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
er;719;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
er;719;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
er;719;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
er;719;copy_number_baseline;primary_cancer;EURACAN;Copy Number;
er;719;new_cancer_idco3;clinical_update;EURACAN;New cancer ICD-O3;for later
er;719;ctcae_term;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
er;719;ctcae_term_2;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
er;719;ctcae_term_3;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
er;719;ctcae_term_4;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
er;719;ctcae_term_5;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
er;719;surgery;surgery;EURACAN;Surgery performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done
er;719;surgery_date;surgery;EURACAN;Surgery date;
er;719;surgery_date_mm;surgery;EURACAN;Month of surgery;
er;719;surgery_date_yyyy;surgery;EURACAN;Year of surgery;
er;719;surgery_type;surgery;EURACAN;Tumor site, type of  surgery;1, External | 2, Endoscopic | 3, Robotic | 9, Unknown
er;719;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
er;719;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
er;719;surgery_margins;surgery;EURACAN;Margins after surgery;0, R0 (microscopic negative) | 1, R1 (microscopic positive) | 2, R2 (macroscopic positive) | 9, Unknown
er;719;surgery_nr_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
er;719;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
er;719;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
er;719;surgery_fu_site;surgery;EURACAN;Surgery site;1, T | 2, N | 3, M
er;719;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
er;719;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
er;719;others;radiotherapy;EURACAN;"<div class=""rich-text-field-label""><p>Â </p> <table style=""border-collapse: collapse; width: auto;"" border=""1""> <tbody> <tr> <td style=""vertical-align: top; text-align: center; width: 629px;"" colspan=""9"">Others</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"">Treatment technique</td> <td style=""width: 100px; vertical-align: top;"">Start date</td> <td style=""width: 100px; vertical-align: top;"">End date</td> <td style=""width: 70px; vertical-align: top;"">Totale dose</td> <td style=""width: 70px; vertical-align: top;"">Dose per fraction</td> <td style=""width: 70px; vertical-align: top;"">Nr of fractions</td> <td style=""width: 60px; vertical-align: top;"">4D treatment</td> <td style=""width: 70px; vertical-align: top;"">Adaptive RT</td> <td style=""width: 70px; vertical-align: top;"">IGRT</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"" rowspan=""2"">{radio_others_tech}</td> <td style=""width: 100px; vertical-align: top;"">{radio_others_from}</td> <td style=""width: 100px; vertical-align: top;"">{radio_others_to}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_totdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_fractdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_nrfract}</td> <td style=""width: 60px; vertical-align: top;"" rowspan=""2"">{radio_others_4d}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_adaptive}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_igrt}</td> </tr> <tr> <td style=""width: auto; vertical-align: top; text-align: center;"" colspan=""2"">OTT (days) {radio_others_ott}</td> </tr> </tbody> </table></div>";
er;719;radio_others_tech;radiotherapy;EURACAN;Others treatment technique;
er;719;radio_others_from;radiotherapy;EURACAN;Others start date;
er;719;radio_others_to;radiotherapy;EURACAN;Others end date;
er;719;radio_others_totdose;radiotherapy;EURACAN;Others total dose;
er;719;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
er;719;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
er;719;radio_others_ott;radiotherapy;EURACAN;Others OTT;"datediff([radio_others_to],[radio_others_from],""d"")"
er;719;radio_others_4d;radiotherapy;EURACAN;Others 4D treatment;1, Yes | 2, No
er;719;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
er;719;radio_others_igrt;radiotherapy;EURACAN;Others IGRT  (imagine guide radiotherapy);1, Yes | 2, No
er;719;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
er;719;copy_number_radio;radiotherapy;EURACAN;Copy Number;
er;719;other_treatment;other_type_of_treatment;EURACAN;Other treatment performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
er;719;other_treatment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of other treatment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{other_treatment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{other_treatment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{other_treatment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
er;719;other_treatment_date;other_type_of_treatment;EURACAN;Date;
er;719;other_treatment_date_mm;other_type_of_treatment;EURACAN;Month of other treatment;
er;719;other_treatment_date_yyyy;other_type_of_treatment;EURACAN;Year of other treatment;
er;719;other_treatment_type;other_type_of_treatment;EURACAN;Type;1, Local | 2, Systemic | 9, Unknown
er;719;end_treatment_other;other_type_of_treatment;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
er;719;end_treat_res_other;other_type_of_treatment;EURACAN;Treatment response (based on imaging no defined criteria);1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
er;719;end_treat_res_def_other;other_type_of_treatment;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
er;719;biom_other;tumour_material_available;EURACAN;Others;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
er;719;biom_others;tumour_material_available;EURACAN;Others (please specify);
er;719;overall_treat_res;overall_treatment_response;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
er;719;overall_treat_res_def;overall_treatment_response;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
er;719;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
er;719;National Identifier (if applicable);Identifiers;PaedCan;;String
er;719;Center of registration;Personal Information;PaedCan;Center where the patient is registered;String
er;719;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
er;719;If other specify;Patient's history;PaedCan;;String
er;719;Germline mutations;Patient's history;PaedCan;Report if any specific genetic abnormallitis have been detected in the patient;yes/no/unknown
er;719;Referral to VRT board (national or international) ;Care pathway;PaedCan;The case has been discussed within an official national or international VRT board for diagnosis and/or treatment;no/yes in the EXPERT Virtual consultation system/ yes in another tumor board
er;719;Date of referral;Care pathway;PaedCan;Date of referral to a Very rare Tumor board;dd/mm/yyyy
er;719;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
er;719;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
er;719;Number of metastasis;Tumor's characteristics;PaedCan;Definition of the number of metastases for every site;singular/multiple
er;719;Delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
er;719;Date of delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
er;719;Further surgery;Surgery;PaedCan;A form to be completed if additional surgery has been perfomed;yes/no/unknown
er;719;Date of further surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
er;719;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
er;719;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
er;719;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
er;719;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
er;719;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
er;719;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
er;719;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
er;719;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
er;719;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
er;719;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
er;719;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
er;719;If other please specify;Radiotherapy;PaedCan;;String
er;719;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
er;719;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
er;719;Please describe the treatment delivered;Other treatments;PaedCan;;String
er;719;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
er;719;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
er;719;e-REC indentifier;Identifiers;EuRR-Bone & EuRRECa;Identifier forÂ e-REC;String
er;719;Current gender;Personal Information;EuRR-Bone & EuRRECa;Current gender;Male/Female/Non-binary/Other/Asked but Unknown
er;719;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
er;719;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
er;719;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
er;719;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
er;719;Familial hyperaldosteronism;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism;
er;719;Familial hyperaldosteronism type I;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type I;
er;719;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
er;719;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
er;719;Dahlberg-Borer-Newcomer syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dahlberg-Borer-Newcomer syndrome;
er;719;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
er;719;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
er;719;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
er;719;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
er;719;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
er;719;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
er;719;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
er;719;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
er;719;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
er;719;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
er;719;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
er;719;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
er;719;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
er;719;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
er;719;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
er;719;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
er;719;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
er;719;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
er;719;Other diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other diabetes mellitus;
er;719;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
er;719;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
er;719;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
er;719;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
er;719;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
er;719;Familial hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial hyperinsulinism;
er;719;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
er;719;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
er;719;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
er;719;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
er;719;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
er;719;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
er;719;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
er;719;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
er;719;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
er;719;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
er;719;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
er;719;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
er;719;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
er;719;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
er;719;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
er;719;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
er;719;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
er;719;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
er;719;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
er;719;Other syndromic form of CH;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other syndromic form of CH;
er;719;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
er;719;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
er;719;Silver-Russell Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell Syndrome;
er;719;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
er;719;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
er;719;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
er;719;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
er;719;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
er;719;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
er;719;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
er;719;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
er;719;Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi Syndrome;
er;719;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
er;719;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
er;719;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
er;719;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
er;719;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
er;719;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
er;719;Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome;
er;719;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
er;719;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
er;719;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
er;719;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
er;719;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
er;719;Overgrowth Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth Syndrome;
er;719;15q overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;15q overgrowth syndrome;
er;719;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
er;719;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
er;719;Malan overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Malan overgrowth syndrome;
er;719;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
er;719;Non syndromic limb overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non syndromic limb overgrowth;
er;719;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
er;719;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
er;719;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
er;719;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
er;719;Overgrowth/obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth/obesity syndrome;
er;719;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
er;719;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
er;719;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
er;719;Weaver syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Weaver syndrome;
er;719;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
er;719;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
er;719;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
er;719;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
er;719;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
er;719;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
er;719;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
er;719;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
er;719;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
er;719;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
er;719;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
er;719;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
er;719;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
er;719;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
er;719;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
er;719;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
er;719;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
er;719;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
er;719;Carpenter syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Carpenter syndromeÂ ;
er;719;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
er;719;Wilson-Turner syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Wilson-Turner syndrome;
er;719;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
er;719;Other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Other;
er;719;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
er;719;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
er;719;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
er;719;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
er;719;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
er;719;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
er;719;Disorder of androgen synthesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen synthesis;
er;719;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
er;719;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
er;719;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
er;719;Other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Other;
er;719;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
er;719;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
er;719;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
er;719;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
er;719;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
er;719;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
er;719;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
er;719;Other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Other;
er;719;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
er;719;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
er;719;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
er;719;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
er;719;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
er;719;Upper limb mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Upper limb mesomelic dysplasia ;
er;719;Langer mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Langer mesomelic dysplasia ;
er;719;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
er;719;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
er;719;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
er;719;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
er;719;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
er;719;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
er;719;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
er;719;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
er;719;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
er;719;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
er;719; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
er;719;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
er;719;Serum creatinine;Biochemistry;ERKNet;Â ;screa
er;719;Family members affected?;Family history;ERKNet;Â ;fam_affected
er;719;Further comments;Genetic diagnosis;ERKNet;Â ;gen_comment
er;719;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
ercp;6;R_AIH_MRCP_or_ERCP;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Cholangiography (MRCP or ERCP);radio
ercp;6;R_PSC_ERCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP;radio
ercp;6;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
ercp;6;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
ercp;6;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
ercp;6;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
ern/hcp;5;ERN/HCP number;Organisations;ithaca;;string
ern/hcp;5;Institution name ERN/HCP;;ithaca;;string
ern/hcp;5;ERN/HCP main contact;;ithaca;;mref
ern/hcp;5;ERN/HCP other contactperson (s);;ithaca;;mref
ern/hcp;5;Website ERN/HCP;;ithaca;;hyperlink
erythroid;1;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
esoph;13;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
esoph;13;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
esoph;13;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esoph;13;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
esoph;13;esophageal_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophageal varices;radio
esoph;13;esophageal_varices_grade;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Grade;radio
esoph;13;esoph_varices_red_signs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophagel varices red color signs;radio
esophageal;12;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
esophageal;12;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
esophageal;12;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
esophageal;12;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
esophageal;12;esophageal_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophageal varices;radio
esophageal;12;esophageal_varices_grade;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Grade;radio
espghan;2;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
espghan;2;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
ethnicity;7;R_AIH_Ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
ethnicity;7;R_AIH_Other_ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
ethnicity;7;R_PBC_Ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
ethnicity;7;R_PBC_Other_ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
ethnicity;7;R_PSC_Ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
ethnicity;7;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
ethnicity;7;ethnicity;patient_management_at_the_hospital;EURACAN;Ethnicity;1, White | 2, Black | 3, Asians/Pacific Islanders | 4, Hispanic | 5, American Indian/Alaska Native
etiology;1;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
eupid;3;EUPID;subject;Genturis;What is the patient's European patient identifier (EUPID)?;string
eupid;3;EUPID/ Person ID;;ithaca;;string
eupid;3;EUPID (European Patient ID);Identifiers;EuRR-Bone & EuRRECa;Patients Pseudonym;String
european;1;EUPID (European Patient ID);Identifiers;EuRR-Bone & EuRRECa;Patients Pseudonym;String
eval;9;eval_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of evaluation;date
eval;9;date_of_evaluation_tips;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
eval;9;date_of_evaluation_angio;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
eval;9;date_of_evaluation_shunt;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
eval;9;fu_cli_bef_date_evaluation;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
eval;9;fu_cli_last_date_eval;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
eval;9;fu_ima_bef_date_evaluation;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
eval;9;fu_ima_last_date_eval;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
eval;9;fu_end_date_evaluation;Follow-up Endpoints;Rare Liver (Vascular);Date of evaluation;date
evaluation;6;date_of_evaluation_tips;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
evaluation;6;date_of_evaluation_angio;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
evaluation;6;date_of_evaluation_shunt;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
evaluation;6;fu_cli_bef_date_evaluation;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
evaluation;6;fu_ima_bef_date_evaluation;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
evaluation;6;fu_end_date_evaluation;Follow-up Endpoints;Rare Liver (Vascular);Date of evaluation;date
event;8;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
event;8;fu_thrombotic_event;Follow-up Complications;Rare Liver (Vascular);Thrombotic event;radio
event;8;An event has occurred;Events;PaedCan;If any event has occurred ;yes/no/unknown
event;8;Type of event;Events;PaedCan;Definition of the type of event that has occured;local relapse/local relapse combined with regional nodal relapse/local relapse combined with metastatic relapse/regional nodal relapse/nodal relapse combined with metastatic relapse/metastatic relapse/progressive disease/second tumor/death for toxicity/death for other causes
event;8;Date of event;Events;PaedCan;Date when the event occurred;dd/mm/yyyy
event;8;Treatment of the event;Events;PaedCan;Event treated or not;yes,with curative intent/yes,with palliative intent/no/unknown
event;8;Type of treatment of the event;Events;PaedCan;;surgery/chemotherapy/radiotherapy/other treatment/unknown
event;8;Please give more details about the treatment of the event;Events;PaedCan;;String
events;1;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
everolimus;13;R_AIH_Everolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_PBC_AIH_Everolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
everolimus;13;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
everolimus;13;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
everolimus;13;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
everolimus;13;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
everolimus;13;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
everolimus;13;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
evidence;2;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
evidence;2;No evidence of disease;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Using biochemical and/or imaging tests according (international) guidelines;Y/N/Not Known
exacerbation;1;Exacerbation;Diagnosis Fluctuation;EURO-NMD;Exacerbation with infection;yesno
excess;2;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
excess;2;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
excl;2;excl_crit;Diagnosis General Information;Rare Liver (Vascular);Exclusion criteria;checkbox
excl;2;vitamin_deficiency_excl;Diagnosis Aetiology;Rare Liver (Vascular);Vitamin deficiency/ folic acid excluded;radio
exercise-induced;1;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
exposure;2;exposure;patient_management_at_the_hospital;EURACAN;Exposure to carcinogens (IARC);1, X-radiation, gamma-radiation | 2, Formaldehyde | 3, Salted fish | 4, Wood dust | 5, Others | 6, None | 9, Unknown
exposure;2;exposure_other;patient_management_at_the_hospital;EURACAN;Please specify;
exstrophy;2;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
exstrophy;2;Bladder Exstrophy;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Bladder Exstrophy;
external;2;External_institute_HUDEB;Base information;Rare Liver (Auto imune);External Institute;dropdown
external;2;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
extra;4;extra_abdom_infect_inflam;Diagnosis Aetiology;Rare Liver (Vascular);Extra-abdominal infection/inflamation;radio
extra;4;extra_abd_inflam_date;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
extra;4;extra_abd_inflam_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
extra;4;Extra gene information COSMIC;;ithaca;;xref
eye;4;eye_lesions;Diagnosis Aetiology;Rare Liver (Vascular);Eye lesions;radio
eye;4;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
eye;4;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
eye;4;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
f.ebv;1;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
f.warm;1;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
facial;7;Weakness of facial musculature;Diagnosis Muscular;EURO-NMD;Facial weakness;yesno
facial;7;Facial Muscles;QMG;EURO-NMD;;
facial;7;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
facial;7;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
facial;7;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
facial;7;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
facial;7;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
facies-heart;1;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
factor;11;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
factor;11;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
factor;11;factor_x;Diagnosis Aetiology;Rare Liver (Vascular);factor X;numeric
factor;11;factor_ii;Diagnosis Aetiology;Rare Liver (Vascular);factor II;numeric
factor;11;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
factor;11;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
factor;11;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
factor;11;dia_lab_factor_v;Diagnosis Laboratory data;Rare Liver (Vascular);Factor V;numeric
factor;11;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
factor;11;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
factor;11;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
factors;1;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
faeces;1;biom_faeces;tumour_material_available;EURACAN;Faeces;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
failure;3;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
failure;3;fu_acute_renal_failure;Follow-up Complications;Rare Liver (Vascular);Acute renal failure;radio
failure;3;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
familial;23;Familial glucocorticoid deficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial glucocorticoid deficiency;
familial;23;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
familial;23;Familial hyperaldosteronism;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism;
familial;23;Familial hyperaldosteronism type I;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type I;
familial;23;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
familial;23;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
familial;23;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
familial;23;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
familial;23;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
familial;23;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
familial;23;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
familial;23;Familial parathyroid adenoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial parathyroid adenoma;
familial;23;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
familial;23;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
familial;23;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
familial;23;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
familial;23;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
familial;23;Familial partial lipodystrophy Type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 1;
familial;23;Familial partial lipodystrophy Type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 2;
familial;23;Familial hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial hyperinsulinism;
familial;23;Familial isolated pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Familial isolated pituitary adenoma;
familial;23;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
familial;23;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
family;10;Affected family members;Diagnosis Family History;EURO-NMD;;multi
family;10;Family ID;subject;Genturis;What is the local family pseudonym?;string
family;10;Family history ;subject;Genturis;;compound
family;10;Family history FDR;subject;Genturis;Has any first degree relative ever had a solid malignancy?;enum
family;10;Family history SDR;subject;Genturis;Has any second degree relative(s) ever had a solid malignancy?;enum
family;10;Family ID;Families;ithaca;;string
family;10;Family History;;ithaca;;compound
family;10;Other cases in the family?;;ithaca;;categorical
family;10;Family ;Family's history;PaedCan;Presence or abscence of relevant disease in the patient's first degree relatives;father/mother/sister/brother
family;10;Family members affected?;Family history;ERKNet;Â ;fam_affected
fasting;5;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
fasting;5;dia_lab_fasting_glucose_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting Serum Glucose Unit;radio
fasting;5;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
fasting;5;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
fasting;5;dia_lab_fasting_tg_value;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum triglycerides value;numeric
fatigable;2;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
fatigable;2;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
fdg;3;fdg_pet_primary;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
fdg;3;fdg_pet_neck;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
fdg;3;fdg_pet_meta;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
fdr;8;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
fdr;8;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
fdr;8;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
fdr;8;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
fdr;8;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
fdr;8;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
fdr;8;Family history FDR;subject;Genturis;Has any first degree relative ever had a solid malignancy?;enum
fdr;8;Age FDR;subject;Genturis;What was the first degree relative(s) age (years) at first diagnosis of the solid malignancy?;categoricalmref
feces;1;a. Incontinent for feces (age > 4 years): ;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
feeding;7;Gastrostomy tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
feeding;7;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
feeding;7;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
feeding;7;Nasogastric tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
feeding;7;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
feeding;7;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
feeding;7;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
feedingÂ­;4;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
feedingÂ­;4;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
feedingÂ­;4;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
feedingÂ­;4;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
female;6;R_PSC_Is_female;PSC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
female;6;R_AIH_Is_female;AIH Follow-up Outcome I;Rare Liver (Auto imune);Is female;calculation
female;6;R_PBC_is_female;PBC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
female;6;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
female;6;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
female;6;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
femur;5;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
femur;5;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
femur;5;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
femur;5;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
femur;5;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
fenofibrate;4;R_PBC_Fenofibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fenofibrate;radio
fenofibrate;4;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
fenofibrate;4;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
fenofibrate;4;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
ferritine;1;dia_lab_serum_ferritine;Diagnosis Laboratory data;Rare Liver (Vascular);Serum ferritin;numeric
fetal;2;Fetal ultrasound ;Imaging;ERKNet;Â ;Â 
fetal;2;Fetal MRI ;Imaging;ERKNet;Â ;Â 
fever;2;fever;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Fever 38Ã‚Â°C;radio
fever;2;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ffpe;1;biom_ffpe;tumour_material_available;EURACAN;FFPE;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
fibrate;12;R_PBC_Fibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fibrate;radio
fibrate;12;R_PBC_Fenofibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fenofibrate;radio
fibrate;12;R_PBC_Bezafibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Bezafibrate;radio
fibrate;12;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
fibrate;12;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
fibrate;12;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
fibrate;12;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
fibrate;12;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
fibrate;12;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
fibrate;12;R_PBC_Fibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
fibrate;12;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
fibrate;12;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
fibro;47;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibro;47;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibro;47;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
fibro;47;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
fibro;47;R_AIH_IQR_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibro;47;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibro;47;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibro;47;R_PBC_Fibrosis_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
fibro;47;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibro;47;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibro;47;R_PSC_Fibrosis_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
fibro;47;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibro;47;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibro;47;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibro;47;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibro;47;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
fibro;47;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
fibro;47;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibro;47;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibro;47;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibro;47;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
fibro;47;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
fibro;47;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibro;47;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibro;47;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
fibro;47;b_fibroscan;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan at diagnosis;numeric
fibro;47;b_fibroscan_date;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of Fibroscan;date
fibro;47;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
fibro;47;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
fibro;47;b_fibroscan_cap;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: CAP;numeric
fibro;47;b_fibroscan_iqr;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);IQR;numeric
fibro;47;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
fibro;47;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
fibro;47;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
fibro;47;fu_ima_last_fibro_value;Follow-up Imaging data;Rare Liver (Vascular);Liver fibroscan;numeric
fibro;47;fu_ima_last_fibro_date;Follow-up Imaging data;Rare Liver (Vascular);Date of fibroscan;date
fibro;47;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
fibro;47;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
fibro;47;fu_last_fibro_cap;Follow-up Imaging data;Rare Liver (Vascular);CAP;numeric
fibro;47;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
fibro;47;Neurofibromatosis-Noonan syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Neurofibromatosis-Noonan syndrome;
fibro;47;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
fibro;47;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
fibro;47;Polyostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Polyostotic fibrous dysplasia ;
fibro;47;Monostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Monostotic fibrous dysplasia ;
fibro;47;Fibrochondrogenesis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrochondrogenesis ;
fibro;47; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
fibroadipose;1;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
fibrochondrogenesis;1;Fibrochondrogenesis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrochondrogenesis ;
fibrodysplasia;1; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
fibroscan;17;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
fibroscan;17;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
fibroscan;17;R_AIH_IQR_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibroscan;17;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibroscan;17;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibroscan;17;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
fibroscan;17;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
fibroscan;17;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
fibroscan;17;b_fibroscan;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan at diagnosis;numeric
fibroscan;17;b_fibroscan_date;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of Fibroscan;date
fibroscan;17;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
fibroscan;17;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
fibroscan;17;b_fibroscan_cap;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: CAP;numeric
fibroscan;17;b_fibroscan_iqr;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);IQR;numeric
fibroscan;17;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
fibroscan;17;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
fibroscan;17;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
fibrosis;18;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibrosis;18;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibrosis;18;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibrosis;18;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibrosis;18;R_PBC_Fibrosis_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
fibrosis;18;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibrosis;18;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibrosis;18;R_PSC_Fibrosis_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
fibrosis;18;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibrosis;18;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibrosis;18;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
fibrosis;18;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibrosis;18;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibrosis;18;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
fibrosis;18;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
fibrosis;18;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
fibrosis;18;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
fibrosis;18;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
fibrosis-related;1;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
fibrous;3;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
fibrous;3;Polyostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Polyostotic fibrous dysplasia ;
fibrous;3;Monostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Monostotic fibrous dysplasia ;
fifth;1;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
findings;2;Chest CT findings;Diagnosis ;EURO-NMD;;single
findings;2;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
first;32;date_first_diagnosis;Diagnosis General Information;Rare Liver (Vascular);Date of first diagnosis;date
first;32;anticoag_first_initiated;Follow-up Events;Rare Liver (Vascular);Anticoagulation was first initiated;radio
first;32;first_angioplasty;Follow-up Events;Rare Liver (Vascular);First angioplasty/stenting of HV or IVC;radio
first;32;first_tipps;Follow-up Events;Rare Liver (Vascular);First TIPS;radio
first;32;first_liver_transplant;Follow-up Events;Rare Liver (Vascular);First liver transplantation;radio
first;32;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
first;32;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
first;32;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
first;32;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
first;32;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
first;32;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
first;32;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
first;32;"b. Age at first MCG VUR (in days):		";4. MCG VUR: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
first;32;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
first;32;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
first;32;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
first;32;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
first;32;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
first;32;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
first;32;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
first;32;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
first;32;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
first;32;Age at first symptoms;subject;Genturis;At what age (years) did the patient have his/her first symptoms?;int
first;32;First name;;ithaca;;string
first;32;First name;;ithaca;;string
first;32;First Contact date;;ithaca;;date
first;32;Period of first symptom onset;;ithaca;;categorical
first;32;Date of first symptoms onset;;ithaca;;date
first;32;Age at first symptoms onset;;ithaca;;int
first;32;first_contact_date;patient_management_at_the_hospital;EURACAN;Date of first contact with the hospital/registration start;DD-MM-YYYY Format
first;32;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
first;32;First Contact with Centre;Care Pathway;EuRR-Bone & EuRRECa;Month and year of first contact with notifying centre;dd/mm/yyyy
fistula;1;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
floor;1;Rise from the floor;Mobility ;EURO-NMD;;single
flow;6;hv_abnorm_doppl_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal Doppler flow pattern in more than one large vein;radio
flow;6;pv_direction_of_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Direction of flow;radio
flow;6;pv_flow_right;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein direction of flow;radio
flow;6;pv_flow_left;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein direction of flow;radio
flow;6;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
flow;6;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
fluctuacting;1;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
fluctuation;1;Symptom fluctuation;Diagnosis Fluctuation;EURO-NMD;;yesno
focal;3;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
focal;3;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
focal;3;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
foetal;1;Reduced foetal movements;Diagnosis Developmental;EURO-NMD;;yesno
foetoprotein;2;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
foetoprotein;2;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
follicular;1;Follicular thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Follicular thyroid carcinoma;
follow;543;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
follow;543;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
follow;543;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
follow;543;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
follow;543;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
follow;543;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
follow;543;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
follow;543;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
follow;543;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
follow;543;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
follow;543;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
follow;543;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
follow;543;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
follow;543;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
follow;543;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
follow;543;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
follow;543;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
follow;543;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
follow;543;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
follow;543;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
follow;543;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
follow;543;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
follow;543;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
follow;543;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
follow;543;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
follow;543;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
follow;543;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
follow;543;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
follow;543;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
follow;543;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
follow;543;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
follow;543;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
follow;543;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
follow;543;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
follow;543;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
follow;543;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
follow;543;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
follow;543;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
follow;543;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
follow;543;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
follow;543;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
follow;543;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
follow;543;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
follow;543;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
follow;543;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
follow;543;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
follow;543;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
follow;543;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
follow;543;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
follow;543;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
follow;543;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
follow;543;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
follow;543;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
follow;543;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
follow;543;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
follow;543;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
follow;543;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
follow;543;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
follow;543;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
follow;543;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
follow;543;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
follow;543;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
follow;543;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
follow;543;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
follow;543;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
follow;543;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
follow;543;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
follow;543;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
follow;543;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
follow;543;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
follow;543;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
follow;543;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
follow;543;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
follow;543;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
follow;543;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
follow;543;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
follow;543;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
follow;543;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
follow;543;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
follow;543;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
follow;543;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
follow;543;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
follow;543;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
follow;543;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
follow;543;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
follow;543;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
follow;543;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
follow;543;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
follow;543;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
follow;543;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
follow;543;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
follow;543;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
follow;543;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
follow;543;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
follow;543;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
follow;543;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
follow;543;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
follow;543;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
follow;543;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
follow;543;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
follow;543;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
follow;543;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
follow;543;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
follow;543;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
follow;543;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
follow;543;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
follow;543;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
follow;543;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
follow;543;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
follow;543;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
follow;543;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
follow;543;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
follow;543;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
follow;543;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
follow;543;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
follow;543;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
follow;543;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
follow;543;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
follow;543;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
follow;543;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
follow;543;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
follow;543;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
follow;543;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
follow;543;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
follow;543;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
follow;543;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
follow;543;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
follow;543;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
follow;543;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
follow;543;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
follow;543;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
follow;543;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
follow;543;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
follow;543;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
follow;543;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
follow;543;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
follow;543;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
follow;543;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
follow;543;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
follow;543;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
follow;543;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
follow;543;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
follow;543;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
follow;543;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
follow;543;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
follow;543;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
follow;543;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
follow;543;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
follow;543;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
follow;543;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
follow;543;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
follow;543;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
follow;543;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
follow;543;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
follow;543;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
follow;543;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
follow;543;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
follow;543;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
follow;543;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
follow;543;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
follow;543;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
follow;543;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
follow;543;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
follow;543;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
follow;543;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
follow;543;R_AIH_AST_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
follow;543;R_AIH_ALT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
follow;543;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
follow;543;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
follow;543;R_AIH_AP_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
follow;543;R_AIH_yGT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);y-GT;numeric
follow;543;R_AIH_Albumin_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
follow;543;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
follow;543;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
follow;543;R_AIH_INR_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
follow;543;R_AIH_Platelets_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
follow;543;R_AIH_IgG_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
follow;543;R_AIH_IgM_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
follow;543;R_AIH_IgA_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
follow;543;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
follow;543;R_AIH_ANA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
follow;543;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
follow;543;R_AIH_ANA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
follow;543;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
follow;543;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
follow;543;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
follow;543;R_AIH_AMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
follow;543;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
follow;543;R_AIH_SMA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
follow;543;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
follow;543;R_AIH_SMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
follow;543;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
follow;543;R_AIH_LKM_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
follow;543;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
follow;543;R_AIH_LKM_1_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
follow;543;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
follow;543;R_AIH_SLA_LP_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
follow;543;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
follow;543;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
follow;543;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
follow;543;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
follow;543;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
follow;543;R_AIH_Serum_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
follow;543;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
follow;543;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
follow;543;R_AIH_Date_of_followup_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of follow-up;string
follow;543;R_AIH_Age_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Age at follow-up;calculation
follow;543;R_AIH_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Bone mineral density (DXA);radio
follow;543;R_AIH_Date_of_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of DXA;date
follow;543;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
follow;543;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
follow;543;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
follow;543;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
follow;543;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
follow;543;R_AIH_Spleen_size_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Spleen size (diameter);numeric
follow;543;R_AIH_MRCP_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);MRCP;radio
follow;543;R_AIH_Weight_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Weight;numeric
follow;543;R_AIH_Height_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Height;numeric
follow;543;R_AIH_BMI_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);BMI;calculation
follow;543;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
follow;543;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
follow;543;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
follow;543;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
follow;543;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
follow;543;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
follow;543;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
follow;543;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
follow;543;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
follow;543;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
follow;543;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
follow;543;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
follow;543;R_AIH_mHAI_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);mHAI;numeric
follow;543;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
follow;543;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
follow;543;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
follow;543;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
follow;543;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
follow;543;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
follow;543;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
follow;543;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
follow;543;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
follow;543;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
follow;543;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
follow;543;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
follow;543;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
follow;543;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
follow;543;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
follow;543;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
follow;543;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
follow;543;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
follow;543;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
follow;543;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
follow;543;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
follow;543;R_AIH_HRS_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatorenal syndrome;radio
follow;543;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
follow;543;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
follow;543;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
follow;543;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
follow;543;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
follow;543;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
follow;543;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
follow;543;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
follow;543;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
follow;543;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
follow;543;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
follow;543;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
follow;543;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
follow;543;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
follow;543;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
follow;543;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
follow;543;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
follow;543;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
follow;543;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
follow;543;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
follow;543;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
follow;543;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
follow;543;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
follow;543;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Budesonide_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
follow;543;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
follow;543;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
follow;543;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
follow;543;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
follow;543;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
follow;543;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
follow;543;R_AIH_MMP_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
follow;543;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
follow;543;R_AIH_UDCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
follow;543;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
follow;543;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
follow;543;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
follow;543;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_MMF_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
follow;543;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
follow;543;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Tacrolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
follow;543;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_CyclosporinA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
follow;543;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Infliximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
follow;543;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Rituximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
follow;543;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
follow;543;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
follow;543;R_AIH_PBC_OCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
follow;543;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
follow;543;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
follow;543;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
follow;543;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
follow;543;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
follow;543;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
follow;543;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
follow;543;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
follow;543;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
follow;543;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
follow;543;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
follow;543;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
follow;543;R_PBC_AST_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
follow;543;R_PBC_ALT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
follow;543;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
follow;543;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
follow;543;R_PBC_ALP_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
follow;543;R_PBC_yGT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
follow;543;R_PBC_Albumin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
follow;543;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
follow;543;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
follow;543;R_PBC_INR_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
follow;543;R_PBC_Platelets_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
follow;543;R_PBC_IgG_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
follow;543;R_PBC_IgM_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
follow;543;R_PBC_IgA_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
follow;543;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
follow;543;R_PBC_ANA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
follow;543;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
follow;543;R_PBC_ANA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
follow;543;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
follow;543;R_PBC_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
follow;543;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
follow;543;R_PBC_SMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
follow;543;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
follow;543;R_PBC_LKM_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
follow;543;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
follow;543;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
follow;543;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
follow;543;R_PBC_SLA_LP_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
follow;543;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
follow;543;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
follow;543;R_PBC_AMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
follow;543;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
follow;543;R_PBC_AMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
follow;543;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
follow;543;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
follow;543;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
follow;543;R_PBC_gp210_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
follow;543;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
follow;543;R_PBC_SP100_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
follow;543;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
follow;543;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
follow;543;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
follow;543;R_PBC_Serum_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
follow;543;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
follow;543;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
follow;543;R_PBC_Date_of_followup_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of Follow-up;string
follow;543;R_PBC_Age_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
follow;543;R_PBC_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
follow;543;R_PBC_Date_of_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
follow;543;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
follow;543;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
follow;543;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
follow;543;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
follow;543;R_PBC_IQR_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
follow;543;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
follow;543;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
follow;543;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
follow;543;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
follow;543;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
follow;543;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
follow;543;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
follow;543;R_PBC_mHAI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
follow;543;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
follow;543;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
follow;543;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
follow;543;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
follow;543;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
follow;543;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
follow;543;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
follow;543;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
follow;543;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
follow;543;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
follow;543;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
follow;543;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
follow;543;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
follow;543;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
follow;543;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
follow;543;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
follow;543;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
follow;543;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
follow;543;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
follow;543;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
follow;543;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
follow;543;R_PBC_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
follow;543;R_PBC_Date_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
follow;543;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
follow;543;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
follow;543;R_PBC_Indication_LTx_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Indication for liver transplantation;radio
follow;543;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
follow;543;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
follow;543;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
follow;543;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
follow;543;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
follow;543;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
follow;543;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
follow;543;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
follow;543;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
follow;543;R_PBC_Weight_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
follow;543;R_PBC_Height_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
follow;543;R_PBC_BMI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
follow;543;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
follow;543;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
follow;543;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
follow;543;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
follow;543;R_PBC_UDCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
follow;543;R_PBC_UDCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
follow;543;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
follow;543;R_PBC_OCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
follow;543;R_PBC_OCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
follow;543;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
follow;543;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
follow;543;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_Budesonide_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
follow;543;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
follow;543;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
follow;543;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
follow;543;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
follow;543;R_PBC_TGN_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
follow;543;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
follow;543;R_PBC_MMP_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
follow;543;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
follow;543;R_PBC_Fibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
follow;543;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
follow;543;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
follow;543;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
follow;543;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
follow;543;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
follow;543;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
follow;543;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
follow;543;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
follow;543;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
follow;543;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
follow;543;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
follow;543;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
follow;543;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
follow;543;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
follow;543;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
follow;543;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
follow;543;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
follow;543;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
follow;543;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
follow;543;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
follow;543;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
follow;543;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
follow;543;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
follow;543;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
follow;543;date_follow_up;Follow-up Date;Rare Liver (Vascular);Date of follow-up;date
follow;543;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
follow;543;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
follow;543;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
follow;543;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow;543;Follow-up status;subject;Genturis;What is the patient's follow-up status?;categorical
follow;543;Year of lost to follow up available?;subject;Genturis;Is the year of lost to follow up of the patient known?;enum
follow;543;Year of lost to follow up;subject;Genturis;In what year was the patient lost to follow up?;int
follow;543;Is the patient following any other medication?;;ithaca;;bool
follow;543;Date of follow up;Follow up (one form for each follow up visit);PaedCan;Date of the last contact with the patient including visit and telephone call;dd/mm/yyyy
follow;543;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
follow;543;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
follow-up;13;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
follow-up;13;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
follow-up;13;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
follow-up;13;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
follow-up;13;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
follow-up;13;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
follow-up;13;Follow-up status;subject;Genturis;What is the patient's follow-up status?;categorical
following;2;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
following;2;Is the patient following any other medication?;;ithaca;;bool
followp;1;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
followup;520;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
followup;520;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
followup;520;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
followup;520;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
followup;520;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
followup;520;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
followup;520;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
followup;520;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
followup;520;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
followup;520;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
followup;520;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
followup;520;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
followup;520;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
followup;520;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
followup;520;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
followup;520;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
followup;520;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
followup;520;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
followup;520;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
followup;520;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
followup;520;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
followup;520;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
followup;520;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
followup;520;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
followup;520;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
followup;520;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
followup;520;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
followup;520;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
followup;520;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
followup;520;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
followup;520;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
followup;520;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
followup;520;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
followup;520;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
followup;520;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
followup;520;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
followup;520;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
followup;520;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
followup;520;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
followup;520;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
followup;520;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
followup;520;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
followup;520;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
followup;520;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
followup;520;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
followup;520;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
followup;520;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
followup;520;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
followup;520;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
followup;520;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
followup;520;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
followup;520;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
followup;520;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
followup;520;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
followup;520;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
followup;520;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
followup;520;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
followup;520;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
followup;520;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
followup;520;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
followup;520;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
followup;520;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
followup;520;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
followup;520;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
followup;520;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
followup;520;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
followup;520;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
followup;520;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
followup;520;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
followup;520;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
followup;520;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
followup;520;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
followup;520;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
followup;520;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
followup;520;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
followup;520;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
followup;520;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
followup;520;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
followup;520;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
followup;520;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
followup;520;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
followup;520;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
followup;520;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
followup;520;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
followup;520;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
followup;520;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
followup;520;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
followup;520;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
followup;520;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
followup;520;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
followup;520;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
followup;520;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
followup;520;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
followup;520;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
followup;520;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
followup;520;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
followup;520;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
followup;520;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
followup;520;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
followup;520;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
followup;520;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
followup;520;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
followup;520;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
followup;520;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
followup;520;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
followup;520;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
followup;520;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
followup;520;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
followup;520;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
followup;520;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
followup;520;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
followup;520;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
followup;520;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
followup;520;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
followup;520;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
followup;520;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
followup;520;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
followup;520;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
followup;520;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
followup;520;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
followup;520;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
followup;520;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
followup;520;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
followup;520;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
followup;520;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
followup;520;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
followup;520;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
followup;520;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
followup;520;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
followup;520;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
followup;520;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
followup;520;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
followup;520;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
followup;520;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
followup;520;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
followup;520;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
followup;520;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
followup;520;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
followup;520;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
followup;520;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
followup;520;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
followup;520;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
followup;520;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
followup;520;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
followup;520;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
followup;520;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
followup;520;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
followup;520;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
followup;520;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
followup;520;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
followup;520;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
followup;520;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
followup;520;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
followup;520;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
followup;520;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
followup;520;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
followup;520;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
followup;520;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
followup;520;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
followup;520;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
followup;520;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
followup;520;R_AIH_AST_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
followup;520;R_AIH_ALT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
followup;520;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
followup;520;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
followup;520;R_AIH_AP_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
followup;520;R_AIH_yGT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);y-GT;numeric
followup;520;R_AIH_Albumin_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
followup;520;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
followup;520;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
followup;520;R_AIH_INR_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
followup;520;R_AIH_Platelets_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
followup;520;R_AIH_IgG_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
followup;520;R_AIH_IgM_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
followup;520;R_AIH_IgA_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
followup;520;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
followup;520;R_AIH_ANA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
followup;520;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
followup;520;R_AIH_ANA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
followup;520;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
followup;520;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
followup;520;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
followup;520;R_AIH_AMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
followup;520;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
followup;520;R_AIH_SMA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
followup;520;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
followup;520;R_AIH_SMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
followup;520;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
followup;520;R_AIH_LKM_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
followup;520;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
followup;520;R_AIH_LKM_1_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
followup;520;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
followup;520;R_AIH_SLA_LP_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
followup;520;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
followup;520;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
followup;520;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
followup;520;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
followup;520;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
followup;520;R_AIH_Serum_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
followup;520;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
followup;520;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
followup;520;R_AIH_Date_of_followup_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of follow-up;string
followup;520;R_AIH_Age_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Age at follow-up;calculation
followup;520;R_AIH_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Bone mineral density (DXA);radio
followup;520;R_AIH_Date_of_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of DXA;date
followup;520;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
followup;520;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
followup;520;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
followup;520;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
followup;520;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
followup;520;R_AIH_Spleen_size_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Spleen size (diameter);numeric
followup;520;R_AIH_MRCP_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);MRCP;radio
followup;520;R_AIH_Weight_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Weight;numeric
followup;520;R_AIH_Height_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Height;numeric
followup;520;R_AIH_BMI_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);BMI;calculation
followup;520;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
followup;520;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
followup;520;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
followup;520;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
followup;520;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
followup;520;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
followup;520;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
followup;520;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
followup;520;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
followup;520;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
followup;520;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
followup;520;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
followup;520;R_AIH_mHAI_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);mHAI;numeric
followup;520;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
followup;520;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
followup;520;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
followup;520;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
followup;520;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
followup;520;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
followup;520;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
followup;520;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
followup;520;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
followup;520;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
followup;520;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
followup;520;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
followup;520;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
followup;520;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
followup;520;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
followup;520;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
followup;520;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
followup;520;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
followup;520;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
followup;520;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
followup;520;R_AIH_HRS_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatorenal syndrome;radio
followup;520;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
followup;520;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
followup;520;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
followup;520;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
followup;520;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
followup;520;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
followup;520;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
followup;520;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
followup;520;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
followup;520;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
followup;520;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
followup;520;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
followup;520;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
followup;520;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
followup;520;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
followup;520;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
followup;520;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
followup;520;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
followup;520;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
followup;520;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
followup;520;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
followup;520;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
followup;520;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
followup;520;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Budesonide_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
followup;520;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
followup;520;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
followup;520;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
followup;520;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
followup;520;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
followup;520;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
followup;520;R_AIH_MMP_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
followup;520;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
followup;520;R_AIH_UDCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
followup;520;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
followup;520;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
followup;520;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
followup;520;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_MMF_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
followup;520;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
followup;520;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Tacrolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
followup;520;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_CyclosporinA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
followup;520;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Infliximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
followup;520;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Rituximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
followup;520;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
followup;520;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
followup;520;R_AIH_PBC_OCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
followup;520;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
followup;520;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
followup;520;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
followup;520;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
followup;520;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
followup;520;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
followup;520;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
followup;520;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
followup;520;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
followup;520;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
followup;520;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
followup;520;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
followup;520;R_PBC_AST_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
followup;520;R_PBC_ALT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
followup;520;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
followup;520;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
followup;520;R_PBC_ALP_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
followup;520;R_PBC_yGT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
followup;520;R_PBC_Albumin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
followup;520;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
followup;520;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
followup;520;R_PBC_INR_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
followup;520;R_PBC_Platelets_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
followup;520;R_PBC_IgG_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
followup;520;R_PBC_IgM_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
followup;520;R_PBC_IgA_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
followup;520;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
followup;520;R_PBC_ANA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
followup;520;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
followup;520;R_PBC_ANA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
followup;520;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
followup;520;R_PBC_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
followup;520;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
followup;520;R_PBC_SMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
followup;520;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
followup;520;R_PBC_LKM_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
followup;520;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
followup;520;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
followup;520;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
followup;520;R_PBC_SLA_LP_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
followup;520;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
followup;520;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
followup;520;R_PBC_AMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
followup;520;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
followup;520;R_PBC_AMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
followup;520;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
followup;520;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
followup;520;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
followup;520;R_PBC_gp210_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
followup;520;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
followup;520;R_PBC_SP100_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
followup;520;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
followup;520;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
followup;520;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
followup;520;R_PBC_Serum_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
followup;520;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
followup;520;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
followup;520;R_PBC_Date_of_followup_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of Follow-up;string
followup;520;R_PBC_Age_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
followup;520;R_PBC_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
followup;520;R_PBC_Date_of_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
followup;520;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
followup;520;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
followup;520;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
followup;520;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
followup;520;R_PBC_IQR_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
followup;520;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
followup;520;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
followup;520;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
followup;520;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
followup;520;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
followup;520;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
followup;520;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
followup;520;R_PBC_mHAI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
followup;520;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
followup;520;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
followup;520;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
followup;520;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
followup;520;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
followup;520;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
followup;520;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
followup;520;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
followup;520;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
followup;520;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
followup;520;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
followup;520;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
followup;520;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
followup;520;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
followup;520;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
followup;520;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
followup;520;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
followup;520;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
followup;520;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
followup;520;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
followup;520;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
followup;520;R_PBC_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
followup;520;R_PBC_Date_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
followup;520;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
followup;520;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
followup;520;R_PBC_Indication_LTx_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Indication for liver transplantation;radio
followup;520;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
followup;520;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
followup;520;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
followup;520;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
followup;520;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
followup;520;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
followup;520;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
followup;520;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
followup;520;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
followup;520;R_PBC_Weight_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
followup;520;R_PBC_Height_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
followup;520;R_PBC_BMI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
followup;520;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
followup;520;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
followup;520;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
followup;520;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
followup;520;R_PBC_UDCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
followup;520;R_PBC_UDCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
followup;520;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
followup;520;R_PBC_OCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
followup;520;R_PBC_OCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
followup;520;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
followup;520;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
followup;520;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_Budesonide_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
followup;520;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
followup;520;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
followup;520;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
followup;520;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
followup;520;R_PBC_TGN_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
followup;520;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
followup;520;R_PBC_MMP_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
followup;520;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
followup;520;R_PBC_Fibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
followup;520;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
followup;520;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
followup;520;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
followup;520;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
followup;520;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
followup;520;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
followup;520;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
followup;520;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
followup;520;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
followup;520;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
followup;520;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
followup;520;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
followup;520;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
followup;520;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
followup;520;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
followup;520;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
followup;520;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
followup;520;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
followup;520;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
followup;520;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
followup;520;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
followup;520;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
followup;520;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
followup;520;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
fop;1; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
form;32;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
form;32;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
form;32;cons_form;Diagnosis General Information;Rare Liver (Vascular);Informed consent form approved and signed;radio
form;32;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
form;32;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
form;32;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
form;32;a.Performed;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
form;32;a.Performed;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
form;32;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
form;32;a. Type of malformation:;1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
form;32;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
form;32;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
form;32;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
form;32;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
form;32;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
form;32;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
form;32;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
form;32;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
form;32;Patient information;subject;Genturis;;compound
form;32;Date of last information;subject;Genturis;What is the date (yyyy-mm-dd) of the last clinical information of the patient?;date
form;32;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
form;32;Informed consent;subject;Genturis;;compound
form;32;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
form;32;Extra gene information COSMIC;;ithaca;;xref
form;32;Patient Information;;ithaca;;compound
form;32;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
form;32;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
form;32;Other syndromic form of CH;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other syndromic form of CH;
form;32;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
form;32;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
form;32;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
form;32;Madelung deformity ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Madelung deformity ;
forms;2;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
forms;2;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
found;1;Specify the genetic abornalities found;Patient's history;PaedCan;;String
foxp3;1;FOXP3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;FOXP3;
fractdose;8;radio_photons_fractdose;radiotherapy;EURACAN;Photons dose per fraction;
fractdose;8;radio_electrons_fractdose;radiotherapy;EURACAN;Electrons dose per fraction;
fractdose;8;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
fractdose;8;radio_carbons_fractdose;radiotherapy;EURACAN;Carbons dose per fraction ;
fractdose;8;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
fractdose;8;radio_radionuc_fractdose;radiotherapy;EURACAN;Radionuclide dose per fraction ;
fractdose;8;radio_boron_fractdose;radiotherapy;EURACAN;Boron neutron capture therapy dose per fraction ;
fractdose;8;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
fractures;1;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
fragile;1;Fragile X syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Fragile X syndrome;
free;3;free_hv_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein Before TIPS;numeric
free;3;free_hv_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein After TIPS;numeric
free;3;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
frequency;2;Frequency;Respiratory Apneic Episodes;EURO-NMD;;int
frequency;2;Frequency;Respiratory Myasthenic crisis;EURO-NMD;;int
frozen;2;biom_frozen;tumour_material_available;EURACAN;Frozen tissue;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
frozen;2;Frozen tumor ;Pathology;PaedCan;;yes/no/unknown
fu;157;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
fu;157;pv_bifurcation;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Longitudinal assessment: portal vein bifurcation;radio
fu;157;pleural_effusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Pleural effusion;radio
fu;157;fu_gi_bleeding;Follow-up Complications;Rare Liver (Vascular);Gastrointestinal bleeding;radio
fu;157;fu_encephalopathy;Follow-up Complications;Rare Liver (Vascular);Encephalopathy;radio
fu;157;fu_acute_renal_failure;Follow-up Complications;Rare Liver (Vascular);Acute renal failure;radio
fu;157;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
fu;157;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
fu;157;fu_thrombotic_event;Follow-up Complications;Rare Liver (Vascular);Thrombotic event;radio
fu;157;fu_biliary_symptoms;Follow-up Complications;Rare Liver (Vascular);Biliary symptoms;radio
fu;157;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
fu;157;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
fu;157;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
fu;157;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
fu;157;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
fu;157;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
fu;157;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
fu;157;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
fu;157;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
fu;157;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
fu;157;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
fu;157;fu_cli_bef_date_evaluation;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
fu;157;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
fu;157;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
fu;157;fu_cli_bef_enceph_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy value;radio
fu;157;fu_cli_bef_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
fu;157;fu_cli_bef_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
fu;157;fu_cli_bef_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
fu;157;fu_cli_bef_platelet_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
fu;157;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
fu;157;fu_cli_bef_pt_normal_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
fu;157;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
fu;157;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
fu;157;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
fu;157;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
fu;157;fu_cli_bef_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
fu;157;fu_cli_bef_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
fu;157;fu_cli_bef_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
fu;157;fu_cli_bef_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
fu;157;fu_cli_bef_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
fu;157;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
fu;157;fu_cli_bef_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
fu;157;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
fu;157;fu_cli_bef_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
fu;157;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
fu;157;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
fu;157;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
fu;157;fu_cli_bef_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
fu;157;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
fu;157;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
fu;157;fu_cli_bef_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
fu;157;fu_cli_bef_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
fu;157;fu_cli_bef_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
fu;157;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
fu;157;fu_cholesterol_t;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
fu;157;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
fu;157;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
fu;157;fu_insulinemia;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Insulinemia;numeric
fu;157;fu_glycated_hemoglobin;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
fu;157;fu_cli_last_date_eval;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
fu;157;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
fu;157;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
fu;157;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
fu;157;fu_cli_last_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
fu;157;fu_cli_last_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
fu;157;fu_cli_last_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
fu;157;fu_cli_last_platelet_count;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
fu;157;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
fu;157;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
fu;157;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
fu;157;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
fu;157;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
fu;157;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
fu;157;fu_cli_last_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
fu;157;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
fu;157;fu_cli_last_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
fu;157;fu_cli_last_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
fu;157;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
fu;157;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
fu;157;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
fu;157;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
fu;157;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
fu;157;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
fu;157;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
fu;157;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
fu;157;fu_cli_last_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
fu;157;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
fu;157;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
fu;157;fu_cli_last_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
fu;157;fu_cli_last_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
fu;157;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
fu;157;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
fu;157;fu_ima_bef_date_evaluation;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
fu;157;fu_ima_bef_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
fu;157;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
fu;157;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
fu;157;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
fu;157;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
fu;157;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
fu;157;fu_ima_bef_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
fu;157;fu_ima_bef_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
fu;157;fu_ima_bef_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
fu;157;fu_ima_bef_nodules;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
fu;157;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
fu;157;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
fu;157;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
fu;157;fu_ima_bef_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
fu;157;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
fu;157;fu_ima_last_date_eval;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
fu;157;fu_ima_last_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
fu;157;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
fu;157;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
fu;157;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
fu;157;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
fu;157;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
fu;157;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
fu;157;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
fu;157;fu_ima_last_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
fu;157;fu_ima_last_nodules;Follow-up Imaging data;Rare Liver (Vascular);BCS-type, or HNF-like, nodules;radio
fu;157;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
fu;157;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
fu;157;fu_ima_last_fibro_value;Follow-up Imaging data;Rare Liver (Vascular);Liver fibroscan;numeric
fu;157;fu_ima_last_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
fu;157;fu_ima_last_fibro_date;Follow-up Imaging data;Rare Liver (Vascular);Date of fibroscan;date
fu;157;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
fu;157;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
fu;157;fu_last_fibro_cap;Follow-up Imaging data;Rare Liver (Vascular);CAP;numeric
fu;157;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
fu;157;fu_end_date_evaluation;Follow-up Endpoints;Rare Liver (Vascular);Date of evaluation;date
fu;157;fu_end_mesenteric_infarct;Follow-up Endpoints;Rare Liver (Vascular);Mesenteric infarction;radio
fu;157;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
fu;157;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
fu;157;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
fu;157;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
fu;157;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
fu;157;Full caryotype (if not inferred from CNV report);;ithaca;;string
fu;157;Full name;;ithaca;;string
fu;157;Functional Status and or Disability;;ithaca;;mref
fu;157;fu;clinical_update;EURACAN;Clinical update;1, Done at the hospital | 2, Done at a different hospital
fu;157;fu_date;clinical_update;EURACAN;Clinical update date;DD-MM-YYYY Format
fu;157;fu_date_mm;clinical_update;EURACAN;Month of clinical update;
fu;157;fu_date_yyyy;clinical_update;EURACAN;Year of clinical update;
fu;157;fu_status;clinical_update;EURACAN;Status at last clinical update;1, Alive, No Evidence of Disease (NED) | 2, Alive, With Disease (AWD) | 3, Dead of Disease (DOD) | 4, Dead of Other Cause (DOC) | 5, Dead of Unknown Cause (DUC) | 6, Unknown status | 7, Patients lost to follow-up | 8, New cancer diagnosis
fu;157;fu_awd_local;clinical_update;EURACAN;AWD, Local;1, Yes | 2, No | 3, Unknown
fu;157;fu_awd_regional;clinical_update;EURACAN;AWD, Regional;1, Yes | 2, No | 3, Unknown
fu;157;fu_awd_metastatic;clinical_update;EURACAN;AWD, Metastatic;1, Yes | 2, No | 3, Unknown
fu;157;surgery_fu_site;surgery;EURACAN;Surgery site;1, T | 2, N | 3, M
fu;157;Further surgery;Surgery;PaedCan;A form to be completed if additional surgery has been perfomed;yes/no/unknown
fu;157;Date of further surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
fu;157;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
fu;157;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
fu;157;Functioning gonadotropic adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning gonadotropic adenoma;
fu;157;Functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning pituitary adenoma;
fu;157;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
fu;157;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
fu;157;Maffucci syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Maffucci syndrome ;
fu;157;Further comments;Genetic diagnosis;ERKNet;Â ;gen_comment
function;11;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
function;11;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
function;11;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
function;11;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
function;11;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
function;11;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
function;11;Functional Status and or Disability;;ithaca;;mref
function;11;Functioning gonadotropic adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning gonadotropic adenoma;
function;11;Functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning pituitary adenoma;
function;11;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
function;11;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
functioning;4;Functioning gonadotropic adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning gonadotropic adenoma;
functioning;4;Functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning pituitary adenoma;
functioning;4;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
functioning;4;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
further;3;Further surgery;Surgery;PaedCan;A form to be completed if additional surgery has been perfomed;yes/no/unknown
further;3;Date of further surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
further;3;Further comments;Genetic diagnosis;ERKNet;Â ;gen_comment
g.cmv;1;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
g.cold;1;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
g20210a;1;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
gamma;2;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
gamma;2;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
gastric;14;Nasogastric tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
gastric;14;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
gastric;14;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
gastric;14;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
gastric;14;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
gastric;14;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
gastric;14;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
gastric;14;gastric_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastric varices;radio
gastro;6;Gastrostomy tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
gastro;6;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
gastro;6;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
gastro;6;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
gastro;6;gastro_intest_bleed_date;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding date;date
gastro;6;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
gastrostomy;3;Gastrostomy tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
gastrostomy;3;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
gastrostomy;3;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
gata4;1;GATA4;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;GATA4;
gata6;1;GATA6;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;GATA6;
gaze;2;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
gaze;2;Ptosis (upward gaze) Sec.;QMG;EURO-NMD;;
gck-mody2;1;GCK-MODY2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;GCK-MODY2;
gen;95;R_AIH_Paxgene;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
gen;95;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
gen;95;R_PBC_Paxgene;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
gen;95;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
gen;95;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
gen;95;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
gen;95;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
gen;95;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
gen;95;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
gen;95;rec_gen_ulc;Diagnosis Aetiology;Rare Liver (Vascular);Recurrent genital ulceration;radio
gen;95;geneticVariantLabel;geneticVariant;Genturis;;string
gen;95;Name of the gene;geneticVariant;Genturis;Gene (cosmic);xref
gen;95;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
gen;95;Genome build;geneticVariant;Genturis;Genome build;categorical
gen;95;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
gen;95;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
gen;95;Genetics  (germline);subject;Genturis;;compound
gen;95;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
gen;95;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
gen;95;Genetic variants;subject;Genturis;Genetic variants;mref
gen;95;Genome Location;;ithaca;;string
gen;95;Extra gene information COSMIC;;ithaca;;xref
gen;95;Reference genome;;ithaca;;categorical
gen;95;Region (in genomic coodinates < array);;ithaca;;string
gen;95;Genname;;ithaca;Hugo.owl.Approved_Symbol;string
gen;95;Link to Ensembl Gene ID;;ithaca;Hugo.owl.Ensembl_ID__mapped_data_supplied_by_Ensembl_;string
gen;95;Gene Locus;;ithaca;;string
gen;95;Gene Symbol;;ithaca;;string
gen;95;Is urgency required for this panel?;;ithaca;;bool
gen;95;Gender;;ithaca;;categorical
gen;95;Link to Genomic variant;;ithaca;;mref
gen;95;General comments;;ithaca;;text
gen;95;Gene affected;;ithaca;COSMIC genes (can be replaced by other list of genes);mref
gen;95;gender;patient_management_at_the_hospital;EURACAN;Gender;1, Male | 2, Female | 9, Unknown
gen;95;genetic_syndrome_ynu;previous_cancer_genetic_syndromes;EURACAN;Genetic syndrome;1, Yes | 2, No | 9, Unknown
gen;95;Specify the genetic abornalities found;Patient's history;PaedCan;;String
gen;95;Current gender;Personal Information;EuRR-Bone & EuRRECa;Current gender;Male/Female/Non-binary/Other/Asked but Unknown
gen;95;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
gen;95;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
gen;95;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
gen;95;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
gen;95;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
gen;95;Oncogenic osteomalacia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Oncogenic osteomalacia;
gen;95;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
gen;95;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
gen;95;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
gen;95;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
gen;95;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
gen;95;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
gen;95;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
gen;95;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
gen;95;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
gen;95;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
gen;95;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
gen;95;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
gen;95;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
gen;95;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
gen;95;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
gen;95;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
gen;95;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
gen;95;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
gen;95;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
gen;95;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
gen;95;Smith-Magenis syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Smith-Magenis syndromeÂ ;
gen;95;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
gen;95;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
gen;95;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
gen;95;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
gen;95;Disorder of androgen action;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen action;
gen;95;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
gen;95;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
gen;95;Disorder of androgen synthesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen synthesis;
gen;95;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
gen;95;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
gen;95;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
gen;95;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
gen;95;Disorder of Androgen Excess;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of Androgen Excess;
gen;95;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
gen;95;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
gen;95;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
gen;95;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
gen;95;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
gen;95;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
gen;95;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
gen;95;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
gen;95;Fibrochondrogenesis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrochondrogenesis ;
gen;95;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
gen;95;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
gen;95;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
gen;95;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
gen;95;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
gen;95;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
gen;95;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
gen;95;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
gen;95;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
gender;5;Gender;;ithaca;;categorical
gender;5;gender;patient_management_at_the_hospital;EURACAN;Gender;1, Male | 2, Female | 9, Unknown
gender;5;Current gender;Personal Information;EuRR-Bone & EuRRECa;Current gender;Male/Female/Non-binary/Other/Asked but Unknown
gender;5;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
gender;5;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
gene;54;R_AIH_Paxgene;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
gene;54;R_PBC_Paxgene;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
gene;54;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
gene;54;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
gene;54;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
gene;54;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
gene;54;geneticVariantLabel;geneticVariant;Genturis;;string
gene;54;Name of the gene;geneticVariant;Genturis;Gene (cosmic);xref
gene;54;Genetics  (germline);subject;Genturis;;compound
gene;54;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
gene;54;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
gene;54;Genetic variants;subject;Genturis;Genetic variants;mref
gene;54;Extra gene information COSMIC;;ithaca;;xref
gene;54;Link to Ensembl Gene ID;;ithaca;Hugo.owl.Ensembl_ID__mapped_data_supplied_by_Ensembl_;string
gene;54;Gene Locus;;ithaca;;string
gene;54;Gene Symbol;;ithaca;;string
gene;54;General comments;;ithaca;;text
gene;54;Gene affected;;ithaca;COSMIC genes (can be replaced by other list of genes);mref
gene;54;genetic_syndrome_ynu;previous_cancer_genetic_syndromes;EURACAN;Genetic syndrome;1, Yes | 2, No | 9, Unknown
gene;54;Specify the genetic abornalities found;Patient's history;PaedCan;;String
gene;54;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
gene;54;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
gene;54;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
gene;54;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
gene;54;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
gene;54;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
gene;54;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
gene;54;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
gene;54;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
gene;54;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
gene;54;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
gene;54;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
gene;54;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
gene;54;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
gene;54;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
gene;54;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
gene;54;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
gene;54;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
gene;54;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
gene;54;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
gene;54;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
gene;54;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
gene;54;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
gene;54;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
gene;54;Fibrochondrogenesis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrochondrogenesis ;
gene;54;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
gene;54;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
gene;54;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
gene;54;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
gene;54;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
gene;54;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
gene;54;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
gene;54;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
gene;54;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
genetic;26;geneticVariantLabel;geneticVariant;Genturis;;string
genetic;26;Genetics  (germline);subject;Genturis;;compound
genetic;26;Genetic diagnosis;subject;Genturis;Is a genetic test performed?;enum
genetic;26;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
genetic;26;Genetic variants;subject;Genturis;Genetic variants;mref
genetic;26;genetic_syndrome_ynu;previous_cancer_genetic_syndromes;EURACAN;Genetic syndrome;1, Yes | 2, No | 9, Unknown
genetic;26;Specify the genetic abornalities found;Patient's history;PaedCan;;String
genetic;26;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
genetic;26;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
genetic;26;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
genetic;26;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
genetic;26;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
genetic;26;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
genetic;26;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
genetic;26;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
genetic;26;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
genetic;26;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
genetic;26;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
genetic;26;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
genetic;26;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
genetic;26;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
genetic;26;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
genetic;26;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
genetic;26;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
genetic;26;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
genetic;26;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
genetically;2;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
genetically;2;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
genetics;1;Genetics  (germline);subject;Genturis;;compound
geneticvariantlabel;1;geneticVariantLabel;geneticVariant;Genturis;;string
genital;17;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
genital;17;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
genital;17;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
genital;17;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
genital;17;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
genital;17;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
genital;17;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
genital;17;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
genital;17;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
genital;17;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
genital;17;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
genital;17;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
genital;17;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
genital;17;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
genital;17;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
genital;17;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
genital;17;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
genome;3;Genome build;geneticVariant;Genturis;Genome build;categorical
genome;3;Genome Location;;ithaca;;string
genome;3;Reference genome;;ithaca;;categorical
genomic;3;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
genomic;3;Region (in genomic coodinates < array);;ithaca;;string
genomic;3;Link to Genomic variant;;ithaca;;mref
genturis;2;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
genturis;2;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
germline;3;Genetics  (germline);subject;Genturis;;compound
germline;3;Tumour Types(Germline);;ithaca;;string
germline;3;Germline mutations;Patient's history;PaedCan;Report if any specific genetic abnormallitis have been detected in the patient;yes/no/unknown
gestational;1;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
ggt;2;dia_lab_ggt;Diagnosis Laboratory data;Rare Liver (Vascular);GGT;numeric
ggt;2;dia_lab_ggt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);GGT normal value;numeric
gi;99;Spinal rigidity;Diagnosis Skeletal;EURO-NMD;;yesno
gi;99;Scapular winging;Diagnosis Skeletal;EURO-NMD;;yesno
gi;99;Nasal regurgitation;Bulbar/Gi ;EURO-NMD;;single
gi;99;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
gi;99;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
gi;99;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
gi;99;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
gi;99;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
gi;99;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
gi;99;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
gi;99;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
gi;99;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
gi;99;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
gi;99;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
gi;99;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
gi;99;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
gi;99;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
gi;99;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
gi;99;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
gi;99;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
gi;99;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
gi;99;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
gi;99;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
gi;99;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
gi;99;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
gi;99;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
gi;99;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
gi;99;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
gi;99;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
gi;99;mri_cholangio;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cholangio MRI;radio
gi;99;pv_origin;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Longitudinal assessment: portal vein origin;radio
gi;99;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
gi;99;number_miscarriagies;Diagnosis Aetiology;Rare Liver (Vascular);Number of miscarriages;radio
gi;99;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
gi;99;fu_gi_bleeding;Follow-up Complications;Rare Liver (Vascular);Gastrointestinal bleeding;radio
gi;99;first_angioplasty;Follow-up Events;Rare Liver (Vascular);First angioplasty/stenting of HV or IVC;radio
gi;99;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
gi;99;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
gi;99;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
gi;99;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
gi;99;date_of_evaluation_angio;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
gi;99;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
gi;99;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
gi;99;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
gi;99;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
gi;99;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
gi;99;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
gi;99;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
gi;99;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
gi;99;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
gi;99;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
gi;99;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
gi;99;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
gi;99;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
gi;99;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
gi;99;Number of meningioma;benignNeoplasm;Genturis;What is the maximal number of meningiomas ever observed in this patient?;int
gi;99;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
gi;99;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
gi;99;Region (in chromosome and band/bands);;ithaca;;string
gi;99;Region (in genomic coodinates < array);;ithaca;;string
gi;99;Consent for ERN databases/Registries/research;;ithaca;;bool
gi;99;Patient's biological sample available for researchÂ ;;ithaca;;bool
gi;99;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
gi;99;Biologic diagnosis;;ithaca;;compound
gi;99;Biologic diagnosis;;ithaca;;categorical
gi;99;consent_biological_data;patient_management_at_the_hospital;EURACAN;Consent to use biological data;1, Yes | 2, No
gi;99;staging_proc_req;stage_procedures;EURACAN;Staging procedures done/requested by;1, the hospital | 2, a different hospital
gi;99;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
gi;99;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
gi;99;staging_def_clin;stage_procedures;EURACAN;Clinical staging defined by;1, the hospital | 2, a different hospital
gi;99;pathological_na;stage_procedures;EURACAN;Pathological T, N, M;1, Not applicable
gi;99;fu_awd_regional;clinical_update;EURACAN;AWD, Regional;1, Yes | 2, No | 3, Unknown
gi;99;surgery_margins;surgery;EURACAN;Margins after surgery;0, R0 (microscopic negative) | 1, R1 (microscopic positive) | 2, R2 (macroscopic positive) | 9, Unknown
gi;99;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
gi;99;Country of registration;Personal Information;PaedCan;Country where the patient is registered;String
gi;99;Center of registration;Personal Information;PaedCan;Center where the patient is registered;String
gi;99;To be included in the registry;Informed consent;PaedCan;Definition whether consent for patient's registration was obtained;yes/no
gi;99;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
gi;99;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
gi;99;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
gi;99;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
gi;99;Please give more details about the treatment of the event;Events;PaedCan;;String
gi;99;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
gi;99;Consent for Core Registry;Consent;EuRR-Bone & EuRRECa;Consent to add patients details to the Core Registry;String
gi;99;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
gi;99;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
gi;99;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
gi;99;Detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Name;String
gi;99;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
gi;99;Noonan syndrome with multiple lentigines;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome with multiple lentigines;
gi;99;Fragile X syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Fragile X syndrome;
gi;99;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
gi;99;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
give;2;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
give;2;Please give more details about the treatment of the event;Events;PaedCan;;String
given;1;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
gland;3;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
gland;3;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
gland;3;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
global;2;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
global;2;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
globulins;9;R_AIH_yGlobulins;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;R_PBC_yGlobulins;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;R_PSC_yGlobulins;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
globulins;9;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
globulins;9;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
glucocorticoid;1;Familial glucocorticoid deficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial glucocorticoid deficiency;
glucokinase;1;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
glucose;3;dia_lab_fasting_glucose_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting Serum Glucose Unit;radio
glucose;3;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
glucose;3;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
glycated;2;dia_lab_glycated_hemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
glycated;2;fu_glycated_hemoglobin;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
gonadal;8;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
gonadal;8;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
gonadal;8;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
gonadal;8;Gonadal regression;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Gonadal regression;
gonadal;8;Disorder of gonadal development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of gonadal development;
gonadal;8;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
gonadal;8;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
gonadal;8;Gonadal regression;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Gonadal regression;
gonadotropic;3;Functioning gonadotropic adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning gonadotropic adenoma;
gonadotropic;3;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
gonadotropic;3;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
gp210;4;R_PBC_gp210_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
gp210;4;R_PBC_gp210_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
gp210;4;R_PBC_gp210_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
gp210;4;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
grade;10;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
grade;10;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
grade;10;esophageal_varices_grade;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Grade;radio
grade;10;ae_grade;adverse_event;EURACAN;Adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
grade;10;ae_grade_2;adverse_event;EURACAN;Second adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
grade;10;ae_grade_3;adverse_event;EURACAN;Third adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
grade;10;ae_grade_4;adverse_event;EURACAN;Fourth adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
grade;10;ae_grade_5;adverse_event;EURACAN;Fifth adverse events grade (CTCAE v5);1, Grade 1 | 2, Grade 2 | 3, Grade 3 | 4, Grade 4 | 5, Grade 5
grade;10;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
grade;10;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
gradient;2;hv_gradient_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient Before TIPS;numeric
gradient;2;hv_gradient_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient After TIPS;numeric
grading;9;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
grading;9;R_PBC_nakanuma_grading_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
grading;9;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
grading;9;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
grading;9;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
grading;9;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
grading;9;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
grading;9;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
grading;9;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
grams;1;alcohol_grams_per_week;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Average grams of ethanol per week;radio
granules;5;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
granules;5;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
granules;5;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
granules;5;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
granules;5;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
graves;1;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
grip;2;Right hand grip (KgW):;QMG;EURO-NMD;;
grip;2;Left hand grip (KgW):;QMG;EURO-NMD;;
group;1;Condition Group;Disease History;EuRR-Bone & EuRRECa;One of eight MTGs of Endo-ERN;boxes
growth;16;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
growth;16;Overgrowth Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth Syndrome;
growth;16;15q overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;15q overgrowth syndrome;
growth;16;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
growth;16;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
growth;16;Malan overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Malan overgrowth syndrome;
growth;16;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
growth;16;Non syndromic limb overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non syndromic limb overgrowth;
growth;16;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
growth;16;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
growth;16;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
growth;16;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
growth;16;Overgrowth/obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth/obesity syndrome;
growth;16;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
growth;16;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
growth;16;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
guidelines;1;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
h.cmv;1;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
h.post-operative;1;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
ha;166;Ophthalmoparesis;Diagnosis Eye;EURO-NMD;;yesno
ha;166;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
ha;166;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
ha;166;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
ha;166;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
ha;166;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
ha;166;Transfer from chair to bed;Mobility ;EURO-NMD;;single
ha;166;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
ha;166;Right hand grip (KgW):;QMG;EURO-NMD;;
ha;166;Left hand grip (KgW):;QMG;EURO-NMD;;
ha;166;R_AIH_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Ishak score assessed;radio
ha;166;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ha;166;R_AIH_mHAI;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);mHAI;numeric
ha;166;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
ha;166;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
ha;166;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ha;166;R_PBC_mHAI;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
ha;166;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
ha;166;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
ha;166;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ha;166;R_PSC_mHAI;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
ha;166;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
ha;166;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
ha;166;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
ha;166;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ha;166;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
ha;166;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ha;166;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
ha;166;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
ha;166;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
ha;166;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
ha;166;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
ha;166;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ha;166;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
ha;166;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
ha;166;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
ha;166;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
ha;166;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
ha;166;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ha;166;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ha;166;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ha;166;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ha;166;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ha;166;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ha;166;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
ha;166;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
ha;166;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
ha;166;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ha;166;R_AIH_mHAI_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);mHAI;numeric
ha;166;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
ha;166;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
ha;166;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ha;166;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ha;166;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ha;166;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ha;166;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ha;166;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ha;166;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
ha;166;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ha;166;R_PBC_mHAI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
ha;166;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ha;166;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
ha;166;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
ha;166;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
ha;166;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
ha;166;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ha;166;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ha;166;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ha;166;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ha;166;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ha;166;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ha;166;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ha;166;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
ha;166;esophageal_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophageal varices;radio
ha;166;esophageal_varices_grade;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Grade;radio
ha;166;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
ha;166;diff_harm_enlargement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Diffuse harmonious enlargement;radio
ha;166;ha_dilatation;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Dilatation;radio
ha;166;ha_resistance_index;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery resistance index;numeric
ha;166;dia_lab_haemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Haemoglobin;numeric
ha;166;dia_lab_haematocrit;Diagnosis Laboratory data;Rare Liver (Vascular);Haematocrit;numeric
ha;166;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
ha;166;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
ha;166;fu_encephalopathy;Follow-up Complications;Rare Liver (Vascular);Encephalopathy;radio
ha;166;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
ha;166;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ha;166;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ha;166;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
ha;166;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
ha;166;Phenotypical Characteristics;subject;Genturis;;compound
ha;166;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
ha;166;"Other;  what patient Data is available";;ithaca;;categoricalmref
ha;166;Orphanet nomenclature;;ithaca;;mref
ha;166;Orphanet nomenclature;;ithaca;;mref
ha;166;Other changes:;;ithaca;;text
ha;166;smoking_habits;patient_management_at_the_hospital;EURACAN;Smoking habits;1, Cigarettes | 2, Cigar
ha;166;site_nasopharynx;primary_cancer;EURACAN;Subsite;1, C11 nasopharynx | 2, C11.0  Superior wall of nasopharynx | 3, C11.1  Posterior wall of nasopharynx | 4, C11.2  Lateral wall of nasopharynx | 5, C11.3  Anterior wall of nasopharynx | 6, C11.8  Overlapping lesion of nasopharynx | 7, C11.9  Nasopharynx, NOS
ha;166;An event has occurred;Events;PaedCan;If any event has occurred ;yes/no/unknown
ha;166;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
ha;166;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
ha;166;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
ha;166;Hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypophosphataemic rickets;
ha;166;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
ha;166;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
ha;166;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
ha;166;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
ha;166;X-linked hypophosphataemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;X-linked hypophosphataemia;
ha;166;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
ha;166;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
ha;166;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
ha;166;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
ha;166;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
ha;166;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
ha;166;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
ha;166;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
ha;166;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
ha;166;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
ha;166;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
ha;166;ROHHAD syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;ROHHAD syndrome;
ha;166;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
ha;166;Cartilage-hair hypoplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cartilage-hair hypoplasia ;
ha;166;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
ha;166;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
ha;166;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
ha;166;Hypophosphatasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Hypophosphatasia;
ha;166;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
ha;166;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
ha;166;Infantile hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Infantile hypophosphatasia ;
ha;166;Childhood-onset hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Childhood-onset hypophosphatasia ;
ha;166;Adult hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Adult hypophosphatasia ;
ha;166;Odontohypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Odontohypophosphatasia ;
habits;1;smoking_habits;patient_management_at_the_hospital;EURACAN;Smoking habits;1, Cigarettes | 2, Cigar
haematocrit;1;dia_lab_haematocrit;Diagnosis Laboratory data;Rare Liver (Vascular);Haematocrit;numeric
haemoglobin;1;dia_lab_haemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Haemoglobin;numeric
hair;10;Transfer from chair to bed;Mobility ;EURO-NMD;;single
hair;10;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
hair;10;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
hair;10;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
hair;10;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
hair;10;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
hair;10;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
hair;10;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
hair;10;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
hair;10;Cartilage-hair hypoplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cartilage-hair hypoplasia ;
hand;3;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
hand;3;Right hand grip (KgW):;QMG;EURO-NMD;;
hand;3;Left hand grip (KgW):;QMG;EURO-NMD;;
haploinsufficiency;1;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
harm;1;diff_harm_enlargement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Diffuse harmonious enlargement;radio
has;1;An event has occurred;Events;PaedCan;If any event has occurred ;yes/no/unknown
hb;3;aghbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ag HBs;radio
hb;3;fu_cli_bef_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
hb;3;fu_cli_last_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
hcp;11;Responsible HCP;subject;Genturis;What is the responsible HCP?;xref
hcp;11;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
hcp;11;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
hcp;11;ERN/HCP number;Organisations;ithaca;;string
hcp;11;Institution name ERN/HCP;;ithaca;;string
hcp;11;ERN/HCP main contact;;ithaca;;mref
hcp;11;ERN/HCP other contactperson (s);;ithaca;;mref
hcp;11;Website ERN/HCP;;ithaca;;hyperlink
hcp;11;Healthcare Provider (HCP);;ithaca;;xref
hcp;11;Country of HCP ;Care Pathway;EuRR-Bone & EuRRECa;Country where the notifying centre is based;fixed string
hcp;11;City of HCP;Care Pathway;EuRR-Bone & EuRRECa;City where the notifying centre is based;fixed string
hdl;2;dia_lab_colesterol_hdl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
hdl;2;fu_cholesterol_hdl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
head,;1;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
hearing;1;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
heart;3;heart_rate;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Heart rate;numeric
heart;3;Heart rate;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Resting heart rate for age;N/Low/High/Not Known
heart;3;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
height;13;Height;Diagnosis General;EURO-NMD;;float
height;13;R_AIH_Height;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
height;13;R_PBC_Height;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
height;13;R_PSC_Height;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
height;13;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
height;13;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
height;13;R_AIH_Height_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Height;numeric
height;13;R_PBC_Height_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
height;13;Height;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Height;numeric
height;13;height;patient_management_at_the_hospital;EURACAN;Height (cm);
height;13;Height;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Height SDS to one decimal point;Not Known/number
height;13;Height (cm);Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Height in cm;Not Known/number. To one decimal point
height;13;Height;Clinical Status;ERKNet;Â ;height/height_age/height_sds/bmi/bmi_sds
hemodynamic;3;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
hemodynamic;3;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
hemodynamic;3;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
hemoglobin;2;dia_lab_glycated_hemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
hemoglobin;2;fu_glycated_hemoglobin;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
hep;39;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
hep;39;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
hep;39;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hep;39;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
hep;39;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
hep;39;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
hep;39;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
hep;39;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hep;39;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
hep;39;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hep;39;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
hep;39;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
hep;39;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
hep;39;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hep;39;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hep;39;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
hep;39;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
hep;39;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
hep;39;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
hep;39;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
hep;39;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hep;39;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
hep;39;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
hep;39;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
hep;39;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hep;39;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
hep;39;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
hep;39;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
hep;39;hepatorenal_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatorenal syndrome;radio
hep;39;hepatopulmonary_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatopulmonary syndrome;radio
hep;39;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
hep;39;hepatic_venography;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venography;radio
hep;39;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
hep;39;hepatic_artery;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery;radio
hep;39;hepatic_vein_catheter;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic Vein Catheterization;radio
hep;39;infrahep_vci;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Infrahepatic IVC;numeric
hep;39;wedged_hepatic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged hepatic vein;numeric
hep;39;abd_interv_hep;Diagnosis Aetiology;Rare Liver (Vascular);Hepatobiliary Surgery;radio
hep;39;abd_interv_hep_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Hepabiliary Surgery;date
hepatic;8;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
hepatic;8;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
hepatic;8;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
hepatic;8;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
hepatic;8;hepatic_venography;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venography;radio
hepatic;8;hepatic_artery;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery;radio
hepatic;8;hepatic_vein_catheter;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic Vein Catheterization;radio
hepatic;8;wedged_hepatic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged hepatic vein;numeric
hepatitis;5;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
hepatitis;5;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
hepatitis;5;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
hepatitis;5;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
hepatitis;5;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
hepatobiliary;13;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
hepatobiliary;13;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
hepatobiliary;13;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
hepatobiliary;13;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
hepatobiliary;13;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
hepatobiliary;13;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hepatobiliary;13;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
hepatobiliary;13;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
hepatobiliary;13;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
hepatobiliary;13;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
hepatobiliary;13;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hepatobiliary;13;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
hepatobiliary;13;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
hepatobillary;2;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hepatobillary;2;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
hepatopulmonary;1;hepatopulmonary_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatopulmonary syndrome;radio
hepatorenal;6;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hepatorenal;6;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hepatorenal;6;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
hepatorenal;6;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hepatorenal;6;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
hepatorenal;6;hepatorenal_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatorenal syndrome;radio
her2neu;1;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
hereditary;4;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
hereditary;4;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
hereditary;4;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
hereditary;4;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
heteroplasia;1; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
hg;3;right_atrium_mm_hg;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right atrium;numeric
hg;3;HGNC_ID;HUGO Gene Nomenclature Committe (genes);ithaca;Hugo.owl.HGNC_ID;string
hg;3;HGNC symbols;;ithaca;;mref
hgnc;2;HGNC_ID;HUGO Gene Nomenclature Committe (genes);ithaca;Hugo.owl.HGNC_ID;string
hgnc;2;HGNC symbols;;ithaca;;mref
high;2;High palate;Diagnosis Skeletal;EURO-NMD;;yesno
high;2;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
hippel-lindau;1;Von Hippel-Lindau disease;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Von Hippel-Lindau disease;
his;26;Thymus histology:;Thymoma;EURO-NMD;;
his;26;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
his;26;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
his;26;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
his;26;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
his;26;history_of_ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
his;26;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
his;26;med_assist_repro_history;Diagnosis Aetiology;Rare Liver (Vascular);History of medically assisted reproduction;radio
his;26;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
his;26;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
his;26;Family history ;subject;Genturis;;compound
his;26;Family history FDR;subject;Genturis;Has any first degree relative ever had a solid malignancy?;enum
his;26;Family history SDR;subject;Genturis;Has any second degree relative(s) ever had a solid malignancy?;enum
his;26;Is urgency required for this panel?;;ithaca;;bool
his;26;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
his;26;Disease historyÂ ;;ithaca;;compound
his;26;Family History;;ithaca;;compound
his;26;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
his;26;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
his;26;histology;primary_cancer;EURACAN;Histology (WHO 2017);1, Squamous (S) | 2, Adenocarcinoma (A) | 3, Neuroendocrine (N) | 4, Adenosquamous carcinoma | 5, Teratocarcinosarcoma | 6, NUT carcinoma | 7, HPV-related Multiphenotypic Sinonasal Carcinoma
his;26;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
his;26;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
his;26;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
his;26;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
his;26;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
his;26;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
histological;1;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
histology;4;Thymus histology:;Thymoma;EURO-NMD;;
histology;4;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
histology;4;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
histology;4;histology;primary_cancer;EURACAN;Histology (WHO 2017);1, Squamous (S) | 2, Adenocarcinoma (A) | 3, Neuroendocrine (N) | 4, Adenosquamous carcinoma | 5, Teratocarcinosarcoma | 6, NUT carcinoma | 7, HPV-related Multiphenotypic Sinonasal Carcinoma
history;12;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
history;12;history_of_ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
history;12;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
history;12;med_assist_repro_history;Diagnosis Aetiology;Rare Liver (Vascular);History of medically assisted reproduction;radio
history;12;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
history;12;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
history;12;Family history ;subject;Genturis;;compound
history;12;Family history FDR;subject;Genturis;Has any first degree relative ever had a solid malignancy?;enum
history;12;Family history SDR;subject;Genturis;Has any second degree relative(s) ever had a solid malignancy?;enum
history;12;Disease historyÂ ;;ithaca;;compound
history;12;Family History;;ithaca;;compound
history;12;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
hla;2;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
hla;2;"d.	HLA-DR mismatches: ";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
hn;39;R_AIH_Ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
hn;39;R_AIH_Other_ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
hn;39;R_PBC_Ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
hn;39;R_PBC_Other_ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
hn;39;R_PSC_Ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
hn;39;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
hn;39;ethnicity;patient_management_at_the_hospital;EURACAN;Ethnicity;1, White | 2, Black | 3, Asians/Pacific Islanders | 4, Hispanic | 5, American Indian/Alaska Native
hn;39;other_hn_cancers;previous_cancer_genetic_syndromes;EURACAN;Other head and neck malignant cancers ;1, Yes | 2, No | 9, Unknown
hn;39;other_hn_site;previous_cancer_genetic_syndromes;EURACAN;Site;999, Unknown | 1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS | 9, C11 nasopharynx | 10, C11.0  Superior wall of nasopharynx | 11, C11.1  Posterior wall of nasopharynx | 12, C11.2  Lateral wall of nasopharynx | 13, C11.3  Anterior wall of nasopharynx | 14, C11.8  Overlapping lesion of nasopharynx | 15, C11.9  Nasopharynx, NOS | 16, C12.9  Pyriform sinus | 17, C13 Hypopharynx | 18, C13.0  Postcricoid region | 19, C13.1  Hypopharyngeal aspect of aryepiglottic fold | 20, C13.2  Posterior wall of hypopharynx | 21, C13.8  Overlapping lesion of hypopharynx | 22, C13.9  Hypopharynx, NOS | 23, C01.9  Base of tongue, NOS | 24, C02.4  Lingual tonsil | 25, C05.1  Soft palate, NOS | 26, C05.2  Uvula | 27, C09 tonsil | 28, C09.0  Tonsillar fossa | 29, C09.1  Tonsillar pillar | 30, C09.8  Overlapping lesion of tonsil | 31, C09.9  Tonsil, NOS | 32, C10 oropharynx | 33, C10.0  Vallecula | 34, C10.2 Lateral wall of oropharynx | 35, C10.3 Posterior Pharyngeal wall | 36, C10.8 Overlapping lesions of oropharynx | 37, C10.9 Oropharynx, NOS | 38, C11.1 Pharyngeal tonsils | 39, C01.9  Base of tongue, NOS | 40, C02.4  Lingual tonsil | 41, C05.1  Soft palate, NOS | 42, C05.2  Uvula | 43, C09 tonsil | 44, C09.0  Tonsillar fossa | 45, C09.1  Tonsillar pillar | 46, C09.8  Overlapping lesion of tonsil | 47, C09.9  Tonsil, NOS | 48, C10 oropharynx | 49, C10.0  Vallecula | 50, C10.2 Lateral wall of oropharynx | 51, C10.3 Posterior Pharyngeal wall | 52, C10.8 Overlapping lesions of oropharynx | 53, C10.9 Oropharynx, NOS | 54, C11.1 Pharyngeal tonsils | 55, C10.1 Anterior (lingual) surface of epiglottis | 56, C32 Larynx | 57, C32.0  Glottis | 58, C32.1  Supraglottis | 59, C32.2  Subglottis | 60, C32.3  Laryngeal cartilage | 61, C32.8  Overlapping lesion of larynx | 62, C32.9  Larynx, NOS | 63, C02.0  Dorsal surface of tongue, NOS | 64, C02.1  Border of tongue | 65, C02.2  Ventral surface of tongue, NOS | 66, C02.3  Anterior 2/3 of tongue, NOS | 67, C02.8 Overlapping lesion of tongue | 68, C02.9  Tongue, NOS | 69, C03 gum | 70, C03.0  Upper gum | 71, C03.1  Lower gum | 72, C03.9  Gum, NOS | 73, C04 floor of mouth | 74, C04.0  Anterior floor of mouth | 75, C04.1  Lateral floor of mouth | 76, C04.8  Overlapping lesion of floor of mouth | 77, C04.9  Floor of mouth, NOS | 78, C05 palate | 79, C05.0  Hard palate | 80, C05.8  Overlapping lesion of palate | 81, C05.9  Palate, NOS | 82, C06 other and unspecified parts of mouth | 83, C06.0  Cheek mucosa | 84, C06.1  Vestibule of mouth | 85, C06.2  Retromolar area | 86, C06.8  Overlapping lesion of other  and unspecified parts of mouth | 87, C06.9  Mouth, NOS | 88, C00 lip (excludes skin of lip C44.0) | 89, C00.0  External upper lip | 90, C00.1  External lower lip | 91, C00.2  External lip, NOS | 92, C00.3  Mucosa of upper lip | 93, C00.4  Mucosa of lower lip | 94, C00.5  Mucosa of lip, NOS | 95, C00.6  Commissure of lip | 96, C00.8  Overlapping lesion of lip | 97, C00.9  Lip, NOS | 98, C30.1  Middle ear | 99, C07.9  Parotid gland | 100, C08 other and unspecified major salivary glands | 101, C08.0  Submandibular gland | 102, C08.1  Sublingual gland | 103, C08.8  Overlapping lesion of major salivary glands | 104, C08.9  Major salivary gland, NOS | 105, Minor salivary gland of the head & neck
hn;39;other_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
hn;39;other_hn_bening;previous_cancer_genetic_syndromes;EURACAN;Other head and neck benign tumours;1, Yes | 2, No | 9, Unknown
hn;39;other_hn_bening_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
hn;39;prev_hn_radio;previous_cancer_genetic_syndromes;EURACAN;Previous radiotherapy at head and neck site;1, Yes | 2, No | 9, Unknown
hn;39;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
hn;39;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
hn;39;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
hn;39;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
hn;39;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
hn;39;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
hn;39;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
hn;39;prev_not_hn;previous_cancer_genetic_syndromes;EURACAN;Other malignant cancers different from cancers of head and neck;1, Yes | 2, No | 9, Unknown
hn;39;prev_not_hn_spec;previous_cancer_genetic_syndromes;EURACAN;Please select the malignant cancers different from cancers of head and neck;99, Unknown | 1, Adrenal Glands | 2, Anal Canal & Anus | 3, Appendix | 4, Bones & Joints (Excl Skull And Face, Mandible) | 5, Bones Of Skull And Face | 6, Brain, & Cranial Nerves, & Spinal Cord, (Excl. Ventricle, Cerebellum) | 7, Breast | 8, Cerebellum | 9, Cervix Uteri | 10, Corpus Uteri | 11, Craniopharyngeal Duct | 12, Esophagus | 13, Eyeball | 14, Fallopian Tube | 15, Gallbladder & Extrahepatic Bile Ducts | 16, Heart | 17, Intrahepatic Bile Ducts | 18, Kidney | 19, Large Intestine (Excl. Appendix) | 20, Liver | 21, Lung & Bronchus | 22, Mandible | 23, Mediastinum | 24, Melanoma Skin | 25, Meninges (Cerebral, Spinal | 26, Orbit & Lacrimal Gland (Excl Ret, Eye, Nos) | 27, Ovary | 28, Pancreas | 29, Parathyroid Gland | 30, Penis | 31, Peripheral Nerves | 32, Peritoneum | 33, Pineal Gland | 34, Pituitary Gland | 35, Placenta | 36, Pleura | 37, Prostate Gland | 38, Rectum | 39, Renal Pelvis | 40, Retina | 41, Retroperitoneum | 42, Sarcoma | 43, Scrotum | 44, Small Intestine | 45, Stomach | 46, Testis | 47, Thymus | 48, Thyroid Gland | 49, Trachea | 50, Ureter | 51, Urinary Bladder | 52, Vagina & Labia | 53, Ventricle | 54, Vulva
hn;39;prev_not_hn_sarc;previous_cancer_genetic_syndromes;EURACAN;Please specify;1, Soft Tissue | 2, Viscera | 3, Bone
hn;39;prev_not_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
hn;39;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
hn;39;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
hn;39;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
hn;39;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
hn;39;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
hn;39;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
hn;39;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
hn;39;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
hn;39;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
hn;39;HNF4A-MODY1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A-MODY1;
hn;39;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
hn;39;HNF1B-MODY5;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1B-MODY5;
hn;39;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
hn;39;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
hn;39;HNF4A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A;
hnf1a;2;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
hnf1a;2;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
hnf1a-mody3;1;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
hnf1b-mody5;1;HNF1B-MODY5;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1B-MODY5;
hnf4a;3;HNF4A-MODY1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A-MODY1;
hnf4a;3;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
hnf4a;3;HNF4A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A;
hnf4a-mody1;1;HNF4A-MODY1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A-MODY1;
homocy;2;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
homocy;2;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
homozyg;1;homozyg_mthfr_c677t_mut;Diagnosis Aetiology;Rare Liver (Vascular);Homozygous MTHFR-C677T mutation;radio
hormonal;1;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
hormone;10;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
hormone;10;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
hormone;10;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
hormone;10;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
hormone;10;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
hormone;10;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
hormone;10;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
hormone;10;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
hormone;10;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
hormone;10;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
hospital;7;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
hospital;7;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
hospital;7;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
hospital;7;Hospitalization required;Respiratory Apneic Episodes;EURO-NMD;;yesno
hospital;7;Hospitalization required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
hospital;7;Hospital patient ID;patient_management_at_the_hospital;EURACAN;;
hospital;7;hospital;patient_management_at_the_hospital;EURACAN;Hospital Name [user-dag-label];
hospitalization;5;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
hospitalization;5;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
hospitalization;5;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
hospitalization;5;Hospitalization required;Respiratory Apneic Episodes;EURO-NMD;;yesno
hospitalization;5;Hospitalization required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
hours;1;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
how;1;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
hpv;2;hpv_status;primary_cancer;EURACAN;HPV status;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
hpv;2;hpv_status_type;primary_cancer;EURACAN;HPV status detected by;1, FISH | 2, PCR | 9, Unknown
hrs;6;R_AIH_HRS_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hrs;6;R_PBC_HRS_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hrs;6;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
hrs;6;R_AIH_HRS_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hrs;6;R_PBC_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
hrs;6;R_PBC_Date_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
hsd17b3;1;17b-HSD def (HSD17B3);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;17b-HSD def (HSD17B3);
hsd3b2;4;3b-HSD def (HSD3B2);ADRENAL;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
hsd3b2;4;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
hsd3b2;4;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
hsd3b2;4;3b-HSD def (HSD3B2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;3b-HSD def (HSD3B2);
hta;1;hta;Diagnosis Clinical Manifestations;Rare Liver (Vascular);HTA;radio
hto;2;fu_cli_bef_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
hto;2;fu_cli_last_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
hudeb;1;External_institute_HUDEB;Base information;Rare Liver (Auto imune);External Institute;dropdown
hv;9;hv_patent;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of veins seen fully patent and normal;radio
hv;9;hv_short_length_stenosis;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Short length stenosis (;radio
hv;9;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
hv;9;hv_abnorm_doppl_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal Doppler flow pattern in more than one large vein;radio
hv;9;free_hv_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein Before TIPS;numeric
hv;9;free_hv_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein After TIPS;numeric
hv;9;hv_gradient_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient Before TIPS;numeric
hv;9;hv_gradient_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient After TIPS;numeric
hv;9;hv_upstream;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic vein upstream from a short-length stenosis;numeric
hydrocephalus-obesity-hypogonadism;1;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
hyperaldosteronism;4;Familial hyperaldosteronism;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism;
hyperaldosteronism;4;Familial hyperaldosteronism type I;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type I;
hyperaldosteronism;4;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
hyperaldosteronism;4;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
hypercalcaemia;5;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
hypercalcaemia;5;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
hypercalcaemia;5;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
hypercalcaemia;5;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
hypercalcaemia;5;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
hypercalciuria;1;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
hyperhomocyste;1;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
hyperinsulinism;20;Familial hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial hyperinsulinism;
hyperinsulinism;20;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
hyperinsulinism;20;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
hyperinsulinism;20;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
hyperinsulinism;20;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
hyperinsulinism;20;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
hyperinsulinism;20;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
hyperinsulinism;20;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
hyperinsulinism;20;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
hyperinsulinism;20;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
hyperinsulinism;20;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
hyperinsulinism;20;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
hyperinsulinism;20;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
hyperinsulinism;20;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
hyperinsulinism;20;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
hyperinsulinism;20;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
hyperinsulinism;20;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
hyperinsulinism;20;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
hyperinsulinism;20;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
hyperinsulinism;20;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
hyperinsulinism-hyperammonaemia;1;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
hypermethylation;1;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
hyperostosis;1;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
hyperparathyroidism;7;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
hyperparathyroidism;7;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
hyperparathyroidism;7;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
hyperparathyroidism;7;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
hyperparathyroidism;7;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
hyperparathyroidism;7;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
hyperparathyroidism;7;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
hyperparathyroidism-jaw;1;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
hyperphosphataemic;1;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
hyperplasia;5;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
hyperplasia;5;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
hyperplasia;5;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
hyperplasia;5;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
hyperplasia;5;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
hypersecretion;1;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
hypertension;1;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
hyperthyroidism;2;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
hyperthyroidism;2;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
hypertrophy;1;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
hypocalcaemic;2;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
hypocalcaemic;2;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
hypocalciuric;4;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
hypocalciuric;4;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
hypocalciuric;4;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
hypocalciuric;4;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
hypochondroplasia;1;Hypochondroplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Hypochondroplasia;
hypogonadism;3;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
hypogonadism;3;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
hypogonadism;3;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
hypogonadotropic;2;Congenital hypogonadotropic hypogonadism;PITUITARY;EuRR-Bone & EuRRECa;Congenital hypogonadotropic hypogonadism;
hypogonadotropic;2;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
hypomethylation;1;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
hypoparathyroidism;20;Hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism;
hypoparathyroidism;20;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
hypoparathyroidism;20;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
hypoparathyroidism;20;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
hypoparathyroidism;20;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
hypoparathyroidism;20;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
hypoparathyroidism;20;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
hypoparathyroidism;20;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
hypoparathyroidism;20;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
hypoparathyroidism;20;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
hypoparathyroidism;20;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
hypoparathyroidism;20;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
hypoparathyroidism;20;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
hypoparathyroidism;20;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
hypoparathyroidism;20;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
hypoparathyroidism;20;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
hypoparathyroidism;20;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
hypoparathyroidism;20;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
hypoparathyroidism;20;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
hypoparathyroidism;20;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
hypoparathyroidism-sensorineural;1;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
hypophosphataemia;2;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
hypophosphataemia;2;X-linked hypophosphataemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;X-linked hypophosphataemia;
hypophosphataemic;4;Hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypophosphataemic rickets;
hypophosphataemic;4;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
hypophosphataemic;4;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
hypophosphataemic;4;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
hypophosphatasia;7;Hypophosphatasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Hypophosphatasia;
hypophosphatasia;7;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
hypophosphatasia;7;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
hypophosphatasia;7;Infantile hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Infantile hypophosphatasia ;
hypophosphatasia;7;Childhood-onset hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Childhood-onset hypophosphatasia ;
hypophosphatasia;7;Adult hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Adult hypophosphatasia ;
hypophosphatasia;7;Odontohypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Odontohypophosphatasia ;
hypoplasia;4;Leydig Cell Hypoplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Leydig Cell Hypoplasia;
hypoplasia;4;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
hypoplasia;4;Cartilage-hair hypoplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cartilage-hair hypoplasia ;
hypoplasia;4;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
hypoplasia-brachydacty;1;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
hypoplasia-skeletal;1;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
hypospadias;1;Isolated hypospadias;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated hypospadias;
hypothyroidism;2;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
hypothyroidism;2;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
i.bkv;1;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ibd;7;R_AIH_IBD;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);IBD;radio
ibd;7;R_AIH_Type_of_IBD;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Type of IBD;radio
ibd;7;R_PSC_IBD_status;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD Status;radio
ibd;7;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
ibd;7;R_PSC_IBD_remission;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD in histological remission;radio
ibd;7;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
ibd;7;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
id;198;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
id;198;Spinal rigidity;Diagnosis Skeletal;EURO-NMD;;yesno
id;198;Stridor;Diagnosis Respiratory;EURO-NMD;;yesno
id;198;R_AIH_Budesonide;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide;radio
id;198;R_AIH_Budesonide_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
id;198;R_PBC_Budesonide;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
id;198;R_PBC_Budesonide_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
id;198;R_PSC_Budesonide;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
id;198;R_PSC_Budesonide_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
id;198;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
id;198;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
id;198;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
id;198;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
id;198;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
id;198;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
id;198;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
id;198;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
id;198;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
id;198;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
id;198;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
id;198;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
id;198;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
id;198;R_AIH_Budesonide_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
id;198;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
id;198;R_PBC_Budesonide_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
id;198;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
id;198;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
id;198;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
id;198;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
id;198;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
id;198;cid_of_drugs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);CID of drug(s);textarea
id;198;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
id;198;sys_sarcoidosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Sarcoidosis;radio
id;198;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
id;198;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
id;198;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
id;198;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
id;198;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
id;198;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
id;198;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
id;198;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
id;198;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
id;198;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
id;198;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
id;198;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
id;198;id;benignNeoplasm;Genturis;;string
id;198;id;geneticVariant;Genturis;;string
id;198;id;malignancy;Genturis;;string
id;198;Patient identifiers;subject;Genturis;;compound
id;198;Patient ID;subject;Genturis;What is the local patient pseudonym?;string
id;198;Family ID;subject;Genturis;What is the local family pseudonym?;string
id;198;EUPID;subject;Genturis;What is the patient's European patient identifier (EUPID)?;string
id;198;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
id;198;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
id;198;id;Allelic State;ithaca;;string
id;198;id;Biobanks;ithaca;;string
id;198;id;Biologic diagnosis;ithaca;;string
id;198;id;Class of Variant;ithaca;;string
id;198;id;Consultation Request Reason;ithaca;;string
id;198;id;Countries;ithaca;;string
id;198;id;Data available;ithaca;;string
id;198;id;Diagnosis status;ithaca;;string
id;198;id;diseasehis;ithaca;;string
id;198;id;extra_gene;ithaca;;string
id;198;Family ID;Families;ithaca;;string
id;198;id;Gender;ithaca;;string
id;198;id;Gene;ithaca;;string
id;198;id;Genetic cause identified;ithaca;;string
id;198;id;Genetic diagnostics performed;ithaca;;string
id;198;id;genomeVariant;ithaca;something recognizable;string
id;198;Class ID;hpo;ithaca;;string
id;198;HGNC_ID;HUGO Gene Nomenclature Committe (genes);ithaca;Hugo.owl.HGNC_ID;string
id;198;Reference Sequence ID (mapped by NCBI);;ithaca;Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_;string
id;198;Link to PubmedID;;ithaca;Hugo.owl.Pubmed_IDs;string
id;198;Link to Ensembl Gene ID;;ithaca;Hugo.owl.Ensembl_ID__mapped_data_supplied_by_Ensembl_;string
id;198;id;International Classification of Diseases for Oncology (M and T);ithaca;;string
id;198;id;laterality;ithaca;;string
id;198;id;Lists that needs to be provided;ithaca;;string
id;198;id;Locus Type;ithaca;;string
id;198;id;Material types;ithaca;;string
id;198;id;Mode of diagnosis;ithaca;;string
id;198;id;Number of copies / UPD;ithaca;;string
id;198;classID;OMIM (Online Mendelian Inheritance in Man);ithaca;;string
id;198;id;OMIM type;ithaca;;string
id;198;id;onset;ithaca;;string
id;198;Class ID;OrphanetÂ Rare Disease Ontology;ithaca;;string
id;198;id;Patient recall;ithaca;;string
id;198;classid;Patient's disability profile according to International Classification of Functioning and Disability (ICF);ithaca;;string
id;198;id;Patient status;ithaca;;string
id;198;ID;Persons;ithaca;;string
id;198;id;Positive Family History;ithaca;;string
id;198;id;progression;ithaca;;string
id;198;id;Reference genome;ithaca;;string
id;198;id;severe;ithaca;;string
id;198;id;spatial;ithaca;;string
id;198;id;Structural anomaly (if not inferred from CNV report);ithaca;;string
id;198;EUPID/ Person ID;;ithaca;;string
id;198;Patient ID;;ithaca;;string
id;198;Identifying data;;ithaca;;compound
id;198;Healthcare Provider (HCP);;ithaca;;xref
id;198;Panel ID;;ithaca;;string
id;198;Country of residence;;ithaca;;xref
id;198;Comorbidities;;ithaca;;compound
id;198;Other comorbidities;;ithaca;;text
id;198;id;temporal;ithaca;;string
id;198;id;tissueType;ithaca;;string
id;198;id;Type of genetic diagnostics;ithaca;;string
id;198;id;Type of mutation;ithaca;;string
id;198;id;Type of Relative;ithaca;;string
id;198;id;variant;ithaca;;string
id;198;Nucleotide reference sequence (RefSeq id/LRG id);;ithaca;;string
id;198;Nucleotide variant description;;ithaca;;text
id;198;Protein sequence (RefSeq id/LRG id);;ithaca;;string
id;198;record_id;patient_management_at_the_hospital;EURACAN;Record ID;
id;198;Hospital patient ID;patient_management_at_the_hospital;EURACAN;;
id;198;residence_country;patient_management_at_the_hospital;EURACAN;Country of residence;1, Afghanistan | 2, Albania | 3, Algeria | 4, Andorra | 5, Angola | 6, Antigua and Barbuda | 7, Argentina | 8, Armenia | 9, Australia | 10, Austria | 11, Azerbaijan | 12, The Bahamas | 13, Bahrain | 14, Bangladesh | 15, Barbados | 16, Belarus | 17, Belgium | 18, Belize | 19, Benin | 20, Bhutan | 21, Bolivia | 22, Bosnia and Herzegovina | 23, Botswana | 24, Brazil | 25, Brunei | 26, Bulgaria | 27, Burkina Faso | 28, Burundi | 29, Cambodia | 30, Cameroon | 31, Canada | 32, Cape Verde | 33, Central African Republic | 34, Chad | 35, Chile | 36, China | 37, Colombia | 38, Comoros | 39, Congo | 40, Costa Rica | 41, Cote d'Ivoire | 42, Croatia | 43, Cuba | 44, Cyprus | 45, Czech Republic | 46, Denmark | 47, Djibouti | 48, Dominica | 49, Dominican Republic | 50, East Timor (Timor-Leste) | 51, Ecuador | 52, Egypt | 53, El Salvador | 54, Equatorial Guinea | 55, Eritrea | 56, Estonia | 57, Ethiopia | 58, Fiji | 59, Finland | 60, France | 61, Gabon | 62, The Gambia | 63, Georgia | 64, Germany | 65, Ghana | 66, Greece | 67, Grenada | 68, Guatemala | 69, Guinea | 70, Guinea-Bissau | 71, Guyana | 72, Haiti | 73, Honduras | 74, Hungary | 75, Iceland | 76, India | 77, Indonesia | 78, Iran | 79, Iraq | 80, Ireland | 81, Israel | 82, Italy | 83, Jamaica | 84, Japan | 85, Jordan | 86, Kazakhstan | 87, Kenya | 88, Kiribati | 89, Korea (North) | 90, Korea (South) | 91, Kosovo | 92, Kuwait | 93, Kyrgyzstan | 94, Laos | 95, Latvia | 96, Lebanon | 97, Lesotho | 98, Liberia | 99, Libya | 100, Liechtenstein | 101, Lithuania | 102, Luxembourg | 103, Macedonia | 104, Madagascar | 105, Malawi | 106, Malaysia | 107, Maldives | 108, Mali | 109, Malta | 110, Marshall Islands | 111, Mauritania | 112, Mauritius | 113, Mexico | 114, Micronesia | 115, Moldova | 116, Monaco | 117, Mongolia | 118, Montenegro | 119, Morocco | 120, Mozambique | 121, Myanmar (Burma) | 122, Namibia | 123, Nauru | 124, Nepal | 125, Netherlands | 126, New Zealand | 127, Nicaragua | 128, Niger | 129, Nigeria | 130, Norway | 131, Oman | 132, Pakistan | 133, Palau | 134, Panama | 135, Papua New Guinea | 136, Paraguay | 137, Peru | 138, Philippines | 139, Poland | 140, Portugal | 141, Qatar | 142, Romania | 143, Russia | 144, Rwanda | 145, Saint Kitts and Nevis | 146, Saint Lucia | 147, Saint Vincent and the Grenadines | 148, Samoa | 149, San Marino | 150, Sao Tome and Principe | 151, Saudi Arabia | 152, Senegal | 153, Serbia | 154, Seychelles | 155, Sierra Leone | 156, Singapore | 157, Slovakia | 158, Slovenia | 159, Solomon Islands | 160, Somalia | 161, South Africa | 162, South Sudan | 163, Spain | 164, Sri Lanka | 165, Sudan | 166, Suriname | 167, Swaziland | 168, Sweden | 169, Switzerland | 170, Syria | 171, Taiwan | 172, Tajikistan | 173, Tanzania | 174, Thailand | 175, Togo | 176, Tonga | 177, Trinidad and Tobago | 178, Tunisia | 179, Turkey | 180, Turkmenistan | 181, Tuvalu | 182, Uganda | 183, Ukraine | 184, United Arab Emirates | 185, United Kingdom | 186, United States of America | 187, Uruguay | 188, Uzbekistan | 189, Vanuatu | 190, Vatican City | 191, Venezuela | 192, Vietnam | 193, Yemen | 194, Zambia | 195, Zimbabwe
id;198;comorbid_ynu;charlson_index;EURACAN;Comorbidity;1, Yes | 2, No | 9, Unknown
id;198;comorbid;charlson_index;EURACAN;Choose all present comorbidities;1, Myocardial infarct (+1) | 2, Congestive heart failure (+1) | 3, Peripheral vascular disease (+1) | 4, Cerebrovascular disease (except hemiplegia) (+1) | 5, Dementia (+1) | 6, Chronic pulmonary disease (+1) | 7, Connective tissue disease (+1) | 8, Ulcer disease (+1) | 9, Mild liver disease (+1) | 17, Moderate or severe liver disease (+3) | 10, Diabetes (without complications) (+1) | 11, Diabetes with end organ damage (+2) | 12, Hemiplegia (+2) | 13, Moderate or severe renal disease (+2) | 14, Solid tumor (non metastatic) (+2) | 18, Metastatic solid tumor (+6) | 15, Leukemia (+2) | 16, Lymphoma, Multiple myeloma (+2) | 19, AIDS (+6)
id;198;new_cancer_idco3;clinical_update;EURACAN;New cancer ICD-O3;for later
id;198;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
id;198;National Identifier (if applicable);Identifiers;PaedCan;;String
id;198;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
id;198;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
id;198;Body side ;Tumor's characteristics;PaedCan;Side of the primary tumor;right/left/bilateral/multifocal/not applicable/unknown
id;198;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
id;198;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
id;198;EUPID (European Patient ID);Identifiers;EuRR-Bone & EuRRECa;Patients Pseudonym;String
id;198;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
id;198;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
id;198;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
id;198;Biobank Patient ID;Research;EuRR-Bone & EuRRECa;;String
id;198;No evidence of disease;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Using biochemical and/or imaging tests according (international) guidelines;Y/N/Not Known
id;198;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
id;198;Familial glucocorticoid deficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial glucocorticoid deficiency;
id;198;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
id;198;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
id;198;Hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism;
id;198;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
id;198;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
id;198;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
id;198;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
id;198;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
id;198;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
id;198;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
id;198;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
id;198;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
id;198;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
id;198;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
id;198;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
id;198;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
id;198;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
id;198;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
id;198;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
id;198;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
id;198;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
id;198;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
id;198;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
id;198;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
id;198;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
id;198;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
id;198;Parathyroid carcinoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Parathyroid carcinoma;
id;198;Familial parathyroid adenoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial parathyroid adenoma;
id;198;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
id;198;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
id;198;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
id;198;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
id;198;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
id;198;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
id;198;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
id;198;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
id;198;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
id;198;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
id;198;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
id;198;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
id;198;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
id;198;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
id;198;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
id;198;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
id;198;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
id;198;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
id;198;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
id;198;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
id;198;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
id;198;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
id;198;Papillary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Papillary thyroid carcinoma;
id;198;Follicular thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Follicular thyroid carcinoma;
id;198;Medullary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Medullary thyroid carcinoma;
id;198;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
id;198;Cleidorhizomelic syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cleidorhizomelic syndrome ;
id;198;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
id;198;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
id;198;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
idco3;1;new_cancer_idco3;clinical_update;EURACAN;New cancer ICD-O3;for later
identified;1;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
identifier;4;Patient identifiers;subject;Genturis;;compound
identifier;4;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
identifier;4;National Identifier (if applicable);Identifiers;PaedCan;;String
identifier;4;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
identifiers;1;Patient identifiers;subject;Genturis;;compound
idiopathic;1;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
ift;14;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
ift;14;R_PBC_ANA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ift;14;R_PBC_LKM_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
ift;14;R_PBC_AMA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ift;14;R_PBC_PBC_specific_ANA_IFT;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
ift;14;R_PBC_IFT_pattern;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
ift;14;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ift;14;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ift;14;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ift;14;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
ift;14;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ift;14;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
ift;14;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
ift;14;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
iga;9;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
iga;9;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
iga;9;R_AIH_IgA;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
iga;9;R_PBC_IgA;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
iga;9;R_PSC_IgA;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
iga;9;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
iga;9;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
iga;9;R_AIH_IgA_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
iga;9;R_PBC_IgA_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
igg;8;R_AIH_IgG;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
igg;8;R_PBC_IgG;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
igg;8;R_PSC_IgG;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
igg;8;R_PSC_IgG4;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG4;numeric
igg;8;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
igg;8;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
igg;8;R_AIH_IgG_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
igg;8;R_PBC_IgG_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
igg4;1;R_PSC_IgG4;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG4;numeric
igm;11;Tensilon/Prostigmine test response;Diagnosis ;EURO-NMD;;single
igm;11;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
igm;11;R_AIH_IgM;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;R_PBC_IgM;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;R_PSC_IgM;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;R_AIH_IgM_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;R_PBC_IgM_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
igm;11;igm_cmv;Diagnosis Aetiology;Rare Liver (Vascular);IgM CMV;radio
igm;11;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
igrt;8;radio_photons_igrt;radiotherapy;EURACAN;Photons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_electrons_igrt;radiotherapy;EURACAN;Electrons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_protons_igrt;radiotherapy;EURACAN;Protons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_carbons_igrt;radiotherapy;EURACAN;Carbons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_brachy_igrt;radiotherapy;EURACAN;Brachytherapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_radionuc_igrt;radiotherapy;EURACAN;Radionuclide IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_boron_igrt;radiotherapy;EURACAN;Boron neutron capture therapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
igrt;8;radio_others_igrt;radiotherapy;EURACAN;Others IGRT  (imagine guide radiotherapy);1, Yes | 2, No
ihc;1;MMR IHC status;malignancy;Genturis;What are the results of the IHC of the MMR proteins?;enum
ii;8;factor_ii;Diagnosis Aetiology;Rare Liver (Vascular);factor II;numeric
ii;8;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
ii;8;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
ii;8;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
ii;8;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
ii;8;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
ii;8;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
ii;8;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
iii;2;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
iii;2;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
ima;176;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Infliximab;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Rituximab;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Infliximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Rituximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Infliximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Rituximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
ima;176;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
ima;176;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Infliximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Rituximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ima;176;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
ima;176;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
ima;176;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
ima;176;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ima;176;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
ima;176;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
ima;176;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
ima;176;fu_ima_bef_date_evaluation;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
ima;176;fu_ima_bef_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
ima;176;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
ima;176;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
ima;176;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
ima;176;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
ima;176;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
ima;176;fu_ima_bef_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
ima;176;fu_ima_bef_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
ima;176;fu_ima_bef_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
ima;176;fu_ima_bef_nodules;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
ima;176;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
ima;176;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
ima;176;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
ima;176;fu_ima_bef_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
ima;176;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
ima;176;fu_ima_last_date_eval;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
ima;176;fu_ima_last_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
ima;176;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
ima;176;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
ima;176;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
ima;176;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
ima;176;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
ima;176;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
ima;176;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
ima;176;fu_ima_last_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
ima;176;fu_ima_last_nodules;Follow-up Imaging data;Rare Liver (Vascular);BCS-type, or HNF-like, nodules;radio
ima;176;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
ima;176;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
ima;176;fu_ima_last_fibro_value;Follow-up Imaging data;Rare Liver (Vascular);Liver fibroscan;numeric
ima;176;fu_ima_last_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
ima;176;fu_ima_last_fibro_date;Follow-up Imaging data;Rare Liver (Vascular);Date of fibroscan;date
ima;176;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
ima;176;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
ima;176;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
ima;176;Primary Thematic Area;;ithaca;;categorical
ima;176;imag_primary;stage_procedures;EURACAN;Imaging for primary site;1, Yes | 2, No | 3, Unknown
ima;176;ct_primary;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
ima;176;mri_primary;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
ima;176;us_primary;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
ima;176;fdg_pet_primary;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
ima;176;pet_oth_primary;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
ima;176;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
ima;176;ct_pet_primary;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
ima;176;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
ima;176;imag_primary_oth;stage_procedures;EURACAN;Other imaging for primary site;
ima;176;imag_neck;stage_procedures;EURACAN;Imaging for neck;1, Yes | 2, No | 9, Unknown
ima;176;imag_neck_oth;stage_procedures;EURACAN;Other imaging for neck;
ima;176;imag_meta;stage_procedures;EURACAN;Imaging for metastatic disease;1, Yes | 2, No | 3, Unknown
ima;176;imag_meta_oth;stage_procedures;EURACAN;Other imaging for metastatic disease;
ima;176;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
ima;176;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
ima;176;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
ima;176;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
ima;176;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
ima;176;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
ima;176;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
ima;176;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
ima;176;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
ima;176;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
ima;176;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
ima;176;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
ima;176;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
ima;176;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
ima;176;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
ima;176;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
ima;176;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
imag;19;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
imag;19;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
imag;19;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imag;19;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
imag;19;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
imag;19;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
imag;19;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
imag;19;imag_primary;stage_procedures;EURACAN;Imaging for primary site;1, Yes | 2, No | 3, Unknown
imag;19;imag_primary_oth;stage_procedures;EURACAN;Other imaging for primary site;
imag;19;imag_neck;stage_procedures;EURACAN;Imaging for neck;1, Yes | 2, No | 9, Unknown
imag;19;imag_neck_oth;stage_procedures;EURACAN;Other imaging for neck;
imag;19;imag_meta;stage_procedures;EURACAN;Imaging for metastatic disease;1, Yes | 2, No | 3, Unknown
imag;19;imag_meta_oth;stage_procedures;EURACAN;Other imaging for metastatic disease;
imaging;13;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
imaging;13;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
imaging;13;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
imaging;13;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
imaging;13;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
imaging;13;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
imaging;13;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
immune;13;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
immune;13;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
immune;13;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
immune;13;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
immune;13;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
immune;13;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
immune;13;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
immune;13;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
immune;13;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
immune;13;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
immune;13;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
immune;13;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
immune;13;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
immuno;67;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
immuno;67;R_AIH_ANA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immuno;67;R_AIH_AMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immuno;67;R_AIH_SMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immuno;67;R_AIH_LKM_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immuno;67;R_AIH_SLA_LP_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immuno;67;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
immuno;67;R_PBC_ANA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immuno;67;R_PBC_SMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immuno;67;R_PBC_LKM_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immuno;67;R_PBC_SLA_LP_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immuno;67;R_PBC_AMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immuno;67;R_PBC_gp210_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
immuno;67;R_PBC_SP100_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
immuno;67;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
immuno;67;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
immuno;67;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immuno;67;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immuno;67;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immuno;67;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immuno;67;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immuno;67;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
immuno;67;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
immuno;67;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immuno;67;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immuno;67;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immuno;67;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immuno;67;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immuno;67;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
immuno;67;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immuno;67;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immuno;67;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immuno;67;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immuno;67;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immuno;67;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
immuno;67;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immuno;67;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immuno;67;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immuno;67;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immuno;67;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immuno;67;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
immuno;67;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
immuno;67;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
immuno;67;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
immuno;67;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
immuno;67;immuno;immunotherapy;EURACAN;Immunotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
immuno;67;immuno_setting;immunotherapy;EURACAN;Setting;1, neo-adjuvant | 2, concomitant | 3, adjuvant | 4, palliative | 9, unknown
immuno;67;immuno_date_from;immunotherapy;EURACAN;Start date;
immuno;67;immuno_date_from_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_date_to;immunotherapy;EURACAN;End date;
immuno;67;immuno_date_to_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_admin;immunotherapy;EURACAN;Number of administrations;
immuno;67;immuno_admin_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_drug_1;immunotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
immuno;67;immuno_drug_1_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_drug_2;immunotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
immuno;67;immuno_drug_2_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_drug_3;immunotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
immuno;67;immuno_drug_3_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_drug_4;immunotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
immuno;67;immuno_drug_4_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;immuno_drug_5;immunotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
immuno;67;immuno_drug_5_unk;immunotherapy;EURACAN;Unknown;1, Unknown
immuno;67;end_treatment_immuno;immunotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
immuno;67;end_treat_res_immuno;immunotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
immuno;67;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
immuno;67;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
immunoblot;34;R_AIH_ANA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immunoblot;34;R_AIH_AMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immunoblot;34;R_AIH_SMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immunoblot;34;R_AIH_LKM_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immunoblot;34;R_AIH_SLA_LP_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immunoblot;34;R_PBC_ANA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immunoblot;34;R_PBC_SMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immunoblot;34;R_PBC_LKM_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immunoblot;34;R_PBC_SLA_LP_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immunoblot;34;R_PBC_AMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immunoblot;34;R_PBC_gp210_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
immunoblot;34;R_PBC_SP100_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
immunoblot;34;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immunoblot;34;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immunoblot;34;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immunoblot;34;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immunoblot;34;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immunoblot;34;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immunoblot;34;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immunoblot;34;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immunoblot;34;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immunoblot;34;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immunoblot;34;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immunoblot;34;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immunoblot;34;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immunoblot;34;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immunoblot;34;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immunoblot;34;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
immunoblot;34;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
immunoblot;34;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
immunoblot;34;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
immunoblot;34;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
immunoblot;34;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
immunoblot;34;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
immunodeficiency;1;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
immunomarkers;1;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
immunosuppressants;2;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
immunosuppressants;2;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
immunosuppression;6;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
immunosuppression;6;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
immunosuppression;6;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
immunosuppression;6;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
immunosuppression;6;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
immunosuppression;6;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
immunosuppressive;3;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
immunosuppressive;3;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
immunosuppressive;3;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
impaired;2;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
impaired;2;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
impairment-coarse;1;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
imperfecta;5;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
imperfecta;5;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
imperfecta;5;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
imperfecta;5;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
imperfecta;5;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
imperfecta-microcephaly-cataracts;1;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
imperfecta-retinopathy-seizures-intellectual;1;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
imprinting;4;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
imprinting;4;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
imprinting;4;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
imprinting;4;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
incidental;1;Consent for incidental findings;subject;Genturis;Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES);enum
incl;10;incl_crit;Diagnosis General Information;Rare Liver (Vascular);Inclusion criteria;checkbox
incl;10;incl;Diagnosis General Information;Rare Liver (Vascular);Inclusion in the study;calculation
incl;10;incl_date;Diagnosis General Information;Rare Liver (Vascular);Date of inclusion or screen failure;date
incl;10;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
incl;10;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
incl;10;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
incl;10;Somatic Mutation as included in COSMIC;;ithaca;;text
incl;10;To be included in the registry;Informed consent;PaedCan;Definition whether consent for patient's registration was obtained;yes/no
incl;10;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
incl;10;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
included;2;Somatic Mutation as included in COSMIC;;ithaca;;text
included;2;To be included in the registry;Informed consent;PaedCan;Definition whether consent for patient's registration was obtained;yes/no
inclusion;4;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
inclusion;4;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
inclusion;4;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
inclusion;4;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
incontinence;1;b. Severity of incontinence:;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
incontinent;1;a. Incontinent for feces (age > 4 years): ;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
increased;1;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
indentifier;1;e-REC indentifier;Identifiers;EuRR-Bone & EuRRECa;Identifier forÂ e-REC;String
independent;3;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
independent;3;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
independent;3;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
index;1;ha_resistance_index;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery resistance index;numeric
indication;89;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_CHE_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);CHE indication;radio
indication;89;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
indication;89;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
indication;89;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
indication;89;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
indication;89;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
indication;89;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_Indication_LTx_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Indication for liver transplantation;radio
indication;89;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indication;89;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
indiction;1;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
induced;2;radio_induced;primary_cancer;EURACAN;Radiotherapy induced;1, Yes | 2, No | 9, Unknown
induced;2;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
induction;2;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
induction;2;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
infantile;2;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
infantile;2;Infantile hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Infantile hypophosphatasia ;
infarct;2;fu_end_mesenteric_infarct;Follow-up Endpoints;Rare Liver (Vascular);Mesenteric infarction;radio
infarct;2;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
infarction;1;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
infect;16;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
infect;16;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
infect;16;abdom_infect_panc;Diagnosis Aetiology;Rare Liver (Vascular);Pancreatitis;radio
infect;16;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
infect;16;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
infect;16;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
infect;16;abdom_infect_appen;Diagnosis Aetiology;Rare Liver (Vascular);Appendicitis;radio
infect;16;abdom_infect_appen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Appendicitis;date
infect;16;abdom_infect_other;Diagnosis Aetiology;Rare Liver (Vascular);Other Infection / Inflammation;radio
infect;16;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
infect;16;extra_abdom_infect_inflam;Diagnosis Aetiology;Rare Liver (Vascular);Extra-abdominal infection/inflamation;radio
infect;16;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
infect;16;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infect;16;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infect;16;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infect;16;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infection;5;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
infection;5;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infection;5;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infection;5;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
infection;5;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
inflam;6;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
inflam;6;abd_inflammation_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal infection/inflamation;date
inflam;6;abd_inflammation_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of abdominal infection/inflamation;textarea
inflam;6;extra_abdom_infect_inflam;Diagnosis Aetiology;Rare Liver (Vascular);Extra-abdominal infection/inflamation;radio
inflam;6;extra_abd_inflam_date;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
inflam;6;extra_abd_inflam_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
inflamation;1;abdom_infect_inflamation;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal infection/inflamation;radio
inflammation;2;abd_inflammation_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal infection/inflamation;date
inflammation;2;abd_inflammation_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of abdominal infection/inflamation;textarea
infliximab;13;R_AIH_Infliximab;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_PBC_AIH_Infliximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
infliximab;13;R_PSC_Infliximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
infliximab;13;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
infliximab;13;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
infliximab;13;R_AIH_Infliximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
infliximab;13;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
infliximab;13;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
infliximap;1;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
information;6;Patient information;subject;Genturis;;compound
information;6;Date of last information;subject;Genturis;What is the date (yyyy-mm-dd) of the last clinical information of the patient?;date
information;6;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
information;6;Extra gene information COSMIC;;ithaca;;xref
information;6;Patient Information;;ithaca;;compound
information;6;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
informed;1;Informed consent;subject;Genturis;;compound
infrahep;1;infrahep_vci;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Infrahepatic IVC;numeric
initial;3;Initial_diagnosis;Base information;Rare Liver (Auto imune);Initial diagnosis;radio
initial;3;initials;Diagnosis General Information;Rare Liver (Vascular);Initials;string
initial;3;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
initials;1;initials;Diagnosis General Information;Rare Liver (Vascular);Initials;string
initiated;1;anticoag_first_initiated;Follow-up Events;Rare Liver (Vascular);Anticoagulation was first initiated;radio
initiation;1;date_of_initiation;Follow-up Events;Rare Liver (Vascular);Date of initiation;date
inr;12;R_AIH_INR;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;R_PBC_INR;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;R_PSC_INR;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;R_AIH_INR_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;R_PBC_INR_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
inr;12;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
inr;12;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
inr;12;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
inr;12;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
inr;12;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
ins;60;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
ins;60;inst;Base information;Rare Liver (Auto imune);inst;calculation
ins;60;External_institute_HUDEB;Base information;Rare Liver (Auto imune);External Institute;dropdown
ins;60;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
ins;60;R_AIH_yGlobulins;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;R_PBC_yGlobulins;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;R_PSC_yGlobulins;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ins;60;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
ins;60;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
ins;60;dia_lab_insulinemia;Diagnosis Laboratory data;Rare Liver (Vascular);Insulinemia;numeric
ins;60;fu_insulinemia;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Insulinemia;numeric
ins;60;Institution name ERN/HCP;;ithaca;;string
ins;60;If Yes â€“ kinship of Carrier;;ithaca;;xref
ins;60;surgery_margins;surgery;EURACAN;Margins after surgery;0, R0 (microscopic negative) | 1, R1 (microscopic positive) | 2, R2 (macroscopic positive) | 9, Unknown
ins;60;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
ins;60;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
ins;60;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
ins;60;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
ins;60;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
ins;60;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
ins;60;INS;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;INS;
ins;60;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
ins;60;INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;INSR deficiency;
ins;60;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
ins;60;Familial hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial hyperinsulinism;
ins;60;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
ins;60;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
ins;60;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
ins;60;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
ins;60;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
ins;60;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
ins;60;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
ins;60;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
ins;60;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
ins;60;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
ins;60;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
ins;60;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
ins;60;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
ins;60;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
ins;60;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
ins;60;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
ins;60;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
ins;60;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
ins;60;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
ins;60;Insulin-resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome;
ins;60;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
ins;60;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
ins;60;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
ins;60;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
ins;60;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
ins;60;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
ins;60;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
ins;60;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
ins;60;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
ins;60;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
ins;60;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
insr;2;INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;INSR deficiency;
insr;2;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
inst;7;inst;Base information;Rare Liver (Auto imune);inst;calculation
inst;7;External_institute_HUDEB;Base information;Rare Liver (Auto imune);External Institute;dropdown
inst;7;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
inst;7;Institution name ERN/HCP;;ithaca;;string
inst;7;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
inst;7;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
inst;7;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
institute;2;External_institute_HUDEB;Base information;Rare Liver (Auto imune);External Institute;dropdown
institute;2;External_institute_CHECT;Base information;Rare Liver (Auto imune);External Institute;dropdown
insufficiency;8;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
insufficiency;8;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
insufficiency;8;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
insufficiency;8;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
insufficiency;8;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
insufficiency;8;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
insufficiency;8;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
insufficiency;8;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
insulin;33;dia_lab_insulinemia;Diagnosis Laboratory data;Rare Liver (Vascular);Insulinemia;numeric
insulin;33;fu_insulinemia;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Insulinemia;numeric
insulin;33;Genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic defects in insulin action;
insulin;33;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
insulin;33;Familial hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial hyperinsulinism;
insulin;33;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
insulin;33;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
insulin;33;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
insulin;33;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
insulin;33;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
insulin;33;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
insulin;33;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
insulin;33;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
insulin;33;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
insulin;33;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
insulin;33;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
insulin;33;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
insulin;33;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
insulin;33;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
insulin;33;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
insulin;33;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
insulin;33;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
insulin;33;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
insulin;33;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
insulin;33;Insulin-resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome;
insulin;33;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
insulin;33;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
insulin;33;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
insulin;33;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
insulin;33;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
insulin;33;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
insulin;33;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
insulin;33;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
insulin-like;1;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
insulin-resistance;3;Insulin-resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome;
insulin-resistance;3;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
insulin-resistance;3;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
insulinemia;2;dia_lab_insulinemia;Diagnosis Laboratory data;Rare Liver (Vascular);Insulinemia;numeric
insulinemia;2;fu_insulinemia;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Insulinemia;numeric
intellectual;8;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
intellectual;8;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
intellectual;8;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
intellectual;8;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
intellectual;8;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
intellectual;8;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
intellectual;8;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
intellectual;8;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
intent;1;radio_intent;radiotherapy;EURACAN;Intent;1, Curative | 2, Palliative | 9, Unknown
international;3;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
international;3;Referral to VRT board (national or international) ;Care pathway;PaedCan;The case has been discussed within an official national or international VRT board for diagnosis and/or treatment;no/yes in the EXPERT Virtual consultation system/ yes in another tumor board
international;3;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
interruption;1;date_of_interruption;Follow-up Events;Rare Liver (Vascular);Date of interruption;date
interv;18;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
interv;18;abd_intervention_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of procedure;date
interv;18;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
interv;18;abd_interv_splen;Diagnosis Aetiology;Rare Liver (Vascular);Splenectomy;radio
interv;18;abd_interv_splen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Splenectomy;date
interv;18;abd_interv_chol;Diagnosis Aetiology;Rare Liver (Vascular);Cholecystectomy;radio
interv;18;abd_interv_chol_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Cholecystectomy;date
interv;18;abd_interv_hep;Diagnosis Aetiology;Rare Liver (Vascular);Hepatobiliary Surgery;radio
interv;18;abd_interv_hep_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Hepabiliary Surgery;date
interv;18;abd_interv_tips;Diagnosis Aetiology;Rare Liver (Vascular);TIPS;radio
interv;18;abd_interv_tips_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of TIPS;date
interv;18;abd_interv_sclero;Diagnosis Aetiology;Rare Liver (Vascular);Sclerotherapy;radio
interv;18;abd_interv_sclero_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Sclerotherapy;date
interv;18;abd_interv_ltx;Diagnosis Aetiology;Rare Liver (Vascular);LTx;radio
interv;18;abd_interv_ltx_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of LTx;date
interv;18;abd_interv_other;Diagnosis Aetiology;Rare Liver (Vascular);Other;radio
interv;18;abd_interv_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Intervention;date
interv;18;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
intervention;4;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
intervention;4;abd_intervention_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of procedure;date
intervention;4;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
intervention;4;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
interventions;1;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
intest;3;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
intest;3;gastro_intest_bleed_date;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding date;date
intest;3;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
intestinal;1;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
intrahep;1;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
invasive;4;invasive (tracheostomy);Respiratory Myasthenic crisis;EURO-NMD;;yesno
invasive;4;non-invasive ventilation;Respiratory Myasthenic crisis;EURO-NMD;;single
invasive;4;Malignancies (invasive/ in situ);subject;Genturis;;compound
invasive;4;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
invasive/;1;Malignancies (invasive/ in situ);subject;Genturis;;compound
invasiveness;1;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
involvement;3;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
involvement;3;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
involvement;3;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
involvement-short;1;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
iqr;9;R_AIH_IQR_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
iqr;9;R_PBC_IQR;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
iqr;9;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
iqr;9;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
iqr;9;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
iqr;9;R_PBC_IQR_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
iqr;9;b_fibroscan_iqr;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);IQR;numeric
iqr;9;fu_ima_bef_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
iqr;9;fu_ima_last_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
irm;4;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
irm;4;fu_ima_bef_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
irm;4;fu_ima_last_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
irm;4;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
ischemia;2;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ischemia;2;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ishak;12;R_AIH_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Ishak score assessed;radio
ishak;12;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ishak;12;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
ishak;12;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ishak;12;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
ishak;12;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ishak;12;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
ishak;12;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ishak;12;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
ishak;12;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ishak;12;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
ishak;12;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
isolated;11;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
isolated;11;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
isolated;11;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
isolated;11;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
isolated;11;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
isolated;11;Familial isolated pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Familial isolated pituitary adenoma;
isolated;11;Congenital isolated ACTH deficiency;PITUITARY;EuRR-Bone & EuRRECa;Congenital isolated ACTH deficiency;
isolated;11;Isolated 17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated 17,20 lyase deficiency;
isolated;11;Isolated hypospadias;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated hypospadias;
isolated;11;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
isolated;11;Isolated micropenis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated micropenis;
isotope;1;Nuclear isotope scan;Imaging;ERKNet;Â ;Â 
iv;155;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
iv;155;invasive (tracheostomy);Respiratory Myasthenic crisis;EURO-NMD;;yesno
iv;155;non-invasive ventilation;Respiratory Myasthenic crisis;EURO-NMD;;single
iv;155;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
iv;155;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
iv;155;R_AIH_Liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver biopsy;radio
iv;155;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
iv;155;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
iv;155;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
iv;155;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
iv;155;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
iv;155;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
iv;155;R_AIH_Liver_tissue;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
iv;155;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
iv;155;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
iv;155;R_PBC_Liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
iv;155;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
iv;155;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
iv;155;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
iv;155;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
iv;155;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
iv;155;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
iv;155;R_PBC_Liver_stiffness;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
iv;155;R_PBC_Liver_tissue;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
iv;155;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
iv;155;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
iv;155;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
iv;155;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
iv;155;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
iv;155;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
iv;155;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
iv;155;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
iv;155;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
iv;155;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
iv;155;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
iv;155;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
iv;155;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
iv;155;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
iv;155;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
iv;155;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
iv;155;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
iv;155;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
iv;155;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
iv;155;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
iv;155;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
iv;155;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
iv;155;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
iv;155;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
iv;155;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
iv;155;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
iv;155;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
iv;155;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
iv;155;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
iv;155;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
iv;155;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
iv;155;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
iv;155;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
iv;155;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
iv;155;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
iv;155;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
iv;155;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
iv;155;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
iv;155;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
iv;155;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
iv;155;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
iv;155;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
iv;155;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
iv;155;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
iv;155;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
iv;155;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
iv;155;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
iv;155;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
iv;155;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
iv;155;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
iv;155;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
iv;155;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
iv;155;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
iv;155;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
iv;155;ivc_aspect;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Aspect;radio
iv;155;check_ivc;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);check_ivc;calculation
iv;155;ivc_obstructed_or_stenosed;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Level of obstruction;radio
iv;155;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
iv;155;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
iv;155;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
iv;155;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
iv;155;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
iv;155;date_liver_biopsy;Diagnosis Biobank;Rare Liver (Vascular);Date of liver biopsy;date
iv;155;liver_biopsy_number;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy local number;string
iv;155;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
iv;155;liver_biopsy_obtained;Diagnosis Biobank;Rare Liver (Vascular);Frozen liver biopsy obtained?;dropdown
iv;155;prot_c_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein C deficiency activity;numeric
iv;155;prot_s_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein S decreased activity?;radio
iv;155;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
iv;155;decreased_activity_antithr;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin decreased activity;radio
iv;155;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
iv;155;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
iv;155;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
iv;155;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
iv;155;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
iv;155;abdom_infect_divert;Diagnosis Aetiology;Rare Liver (Vascular);Diverticulitis;radio
iv;155;abdom_infect_divert_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Diverticulitis;date
iv;155;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
iv;155;eos_liver_transplant;End of study End of study;Rare Liver (Vascular);Was a liver transplantation performed?;radio
iv;155;eos_liver_transplant_date;End of study End of study;Rare Liver (Vascular);Date of liver transplantation;date
iv;155;eos_liver_transplant_reason;End of study End of study;Rare Liver (Vascular);Why was no liver transplantation performed?;radio
iv;155;eos_liver_transplant_other;End of study End of study;Rare Liver (Vascular);Other reason:;string
iv;155;eos_liver_transplant_death;End of study End of study;Rare Liver (Vascular);Death after liver transplantation?;calculation
iv;155;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
iv;155;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
iv;155;first_liver_transplant;Follow-up Events;Rare Liver (Vascular);First liver transplantation;radio
iv;155;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
iv;155;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
iv;155;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
iv;155;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
iv;155;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
iv;155;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
iv;155;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
iv;155;Malignancies (invasive/ in situ);subject;Genturis;;compound
iv;155;NF1 relative;subject;Genturis;"Has the patient a first degree relative with NF1 who has been diagnosed according to the following criteria: Presence of two or more of the following diagnostic criteria in the first degree relative:
1) Six or more cafÃ© au lait spots (> 5mm in greatest diameter in prepuberal patient  and >15mm in greatest diameter in postpuberal patient)
2) Two or more neurofibromas or one plexiform neurofibromas
3) Axillary or inguinal freckling
4) Optic glioma
5) Two or more lisch nodules (iris hamartomas)
6) A distinct osseous lesion";enum
iv;155;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
iv;155;Active Ingredient (ATC);;ithaca;;mref
iv;155;Active Ingredient (ATC);;ithaca;;mref
iv;155;site_maj_salivary;primary_cancer;EURACAN;Subsite;1, C07.9  Parotid gland | 2, C08 other and unspecified major salivary glands | 3, C08.0  Submandibular gland | 4, C08.1  Sublingual gland | 5, C08.8  Overlapping lesion of major salivary glands | 6, C08.9  Major salivary gland, NOS
iv;155;site_salivary;primary_cancer;EURACAN;Subsite;1, nasal cavity and paranasal sinuses | 2, nasopharynx | 3, major salivary glands | 4, hypopharynx | 5, Oropharynx | 6, larynx | 7, oral cavity | 8, lip
iv;155;radio_photons_adaptive;radiotherapy;EURACAN;Photons adaptive RT;1, Yes | 2, No
iv;155;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
iv;155;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
iv;155;radio_carbons_adaptive;radiotherapy;EURACAN;Carbons adaptive RT;1, Yes | 2, No
iv;155;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
iv;155;radio_radionuc_adaptive;radiotherapy;EURACAN;Radionuclide adaptive RT;1, Yes | 2, No
iv;155;radio_boron_adaptive;radiotherapy;EURACAN;Boron neutron capture therapy adaptive RT;1, Yes | 2, No
iv;155;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
iv;155;biom_saliva;tumour_material_available;EURACAN;Saliva;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
iv;155;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
iv;155;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
iv;155;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
iv;155;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
iv;155;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
iv;155;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
iv;155;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
iv;155;Please describe the treatment delivered;Other treatments;PaedCan;;String
iv;155;Please give more details about the treatment of the event;Events;PaedCan;;String
iv;155;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
iv;155;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
iv;155;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
iv;155;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
iv;155;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
iv;155;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
iv;155;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
iv;155;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
iv;155;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
iv;155;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
iv;155; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
iv;155; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
iv;155;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
ivc;7;ivc_aspect;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Aspect;radio
ivc;7;check_ivc;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);check_ivc;calculation
ivc;7;ivc_obstructed_or_stenosed;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Level of obstruction;radio
ivc;7;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
ivc;7;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
ivc;7;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
ivc;7;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
j.culture-proven;1;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
jak;3;jak_2_mutation_v617f;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Mutation (V617F);radio
jak;3;new_jak_2_mutation_d620e;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Exon-12;radio
jak;3;jak_2_quantification;Diagnosis Aetiology;Rare Liver (Vascular);% of mutated allele;numeric
jansen;1;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
joint;1;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
juvenile;3;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
juvenile;3;Juvenile Paget disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Juvenile Paget disease ;
juvenile;3;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
kabuki;1;Kabuki syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Kabuki syndrome;
kaitila;1;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
kallmann;1;Kallmann Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Kallmann Syndrome;
kantaputra;1;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
kcnj11;2;KCNJ11;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;KCNJ11;
kcnj11;2;KCNJ11;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;KCNJ11;
kearns-sayre;1;Kearns-Sayre syndrome;ADRENAL;EuRR-Bone & EuRRECa;Kearns-Sayre syndrome;
kg;4;Right hand grip (KgW):;QMG;EURO-NMD;;
kg;4;Left hand grip (KgW):;QMG;EURO-NMD;;
kg;4;R_PBC_UDCA_dose_per_kg;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose mg / kg;calculation
kg;4;Weight (kg);Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Weight in kg;Not Known/number to one decimal point
kgw;2;Right hand grip (KgW):;QMG;EURO-NMD;;
kgw;2;Left hand grip (KgW):;QMG;EURO-NMD;;
kidney;5;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
kidney;5;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
kidney;5;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
kidney;5;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
kidney;5;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
kidneys;1;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
kir6.2;3;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
kir6.2;3;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
kir6.2;3;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
known;6;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
known;6;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
known;6;unknown_pet;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
known;6;unknown_meta;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
known;6;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
known;6;AMH not known;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;AMH not known;
kyphoscoliosis-overgrowth;1;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
lÃ©ri-weill;1;LÃ©ri-Weill dyschondrosteosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;LÃ©ri-Weill dyschondrosteosis ;
lab;109;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
lab;109;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
lab;109;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
lab;109;dia_lab_date;Diagnosis Laboratory data;Rare Liver (Vascular);Date of Evaluation;date
lab;109;dia_lab_red_blood_cell_count;Diagnosis Laboratory data;Rare Liver (Vascular);Red blood cell count;numeric
lab;109;dia_lab_haemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Haemoglobin;numeric
lab;109;dia_lab_haematocrit;Diagnosis Laboratory data;Rare Liver (Vascular);Haematocrit;numeric
lab;109;dia_lab_leucocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Leukocytes;numeric
lab;109;dia_lab_neutrophils;Diagnosis Laboratory data;Rare Liver (Vascular);Neutrophils;numeric
lab;109;dia_lab_eosinophils;Diagnosis Laboratory data;Rare Liver (Vascular);Eosinophils;numeric
lab;109;dia_lab_lymphocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Lymphocytes;numeric
lab;109;dia_lab_platelet_count;Diagnosis Laboratory data;Rare Liver (Vascular);Platelet count;numeric
lab;109;dia_lab_dev_coag_dt;Diagnosis Laboratory data;Rare Liver (Vascular);Deviant Laboratory Date;date
lab;109;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
lab;109;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
lab;109;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
lab;109;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
lab;109;dia_lab_antinuclear_antibodies;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies;radio
lab;109;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
lab;109;dia_lab_alt;Diagnosis Laboratory data;Rare Liver (Vascular);ALT;numeric
lab;109;dia_lab_alt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);ALT normal value;numeric
lab;109;dia_lab_ast;Diagnosis Laboratory data;Rare Liver (Vascular);AST;numeric
lab;109;dia_lab_ast_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);AST normal value;numeric
lab;109;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
lab;109;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
lab;109;dia_lab_ggt;Diagnosis Laboratory data;Rare Liver (Vascular);GGT;numeric
lab;109;dia_lab_ggt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);GGT normal value;numeric
lab;109;dia_lab_serum_albumin;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin;numeric
lab;109;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
lab;109;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
lab;109;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
lab;109;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
lab;109;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
lab;109;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
lab;109;dia_lab_serum_ferritine;Diagnosis Laboratory data;Rare Liver (Vascular);Serum ferritin;numeric
lab;109;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
lab;109;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
lab;109;dia_lab_factor_v;Diagnosis Laboratory data;Rare Liver (Vascular);Factor V;numeric
lab;109;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
lab;109;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
lab;109;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
lab;109;dia_lab_sodium_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
lab;109;dia_lab_fasting_glucose_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting Serum Glucose Unit;radio
lab;109;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
lab;109;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
lab;109;dia_lab_fasting_tg_value;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum triglycerides value;numeric
lab;109;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
lab;109;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
lab;109;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
lab;109;dia_lab_colesterol_t;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol T;numeric
lab;109;dia_lab_colesterol_hdl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol HDL;numeric
lab;109;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
lab;109;dia_lab_insulinemia;Diagnosis Laboratory data;Rare Liver (Vascular);Insulinemia;numeric
lab;109;dia_lab_glycated_hemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
lab;109;dia_lab_urine_na_24h;Diagnosis Laboratory data;Rare Liver (Vascular);urine sodium value - 24 hour;numeric
lab;109;dia_lab_ascites_alb;Diagnosis Laboratory data;Rare Liver (Vascular);Albumin;numeric
lab;109;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
lab;109;dia_lab_ascites_pmn;Diagnosis Laboratory data;Rare Liver (Vascular);Polymorphonuclear neutrophils;numeric
lab;109;benignNeoplasmLabel;benignNeoplasm;Genturis;;string
lab;109;Age at diagnosis (benign) available?;benignNeoplasm;Genturis;Is the age (years) at which the patient was diagnosed with this benign tumour known?;enum
lab;109;geneticVariantLabel;geneticVariant;Genturis;;string
lab;109;malignancyLabel;malignancy;Genturis;;string
lab;109;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
lab;109;Year of birth available?;subject;Genturis;Is the year of birth of the patient known?;enum
lab;109;Year of death available?;subject;Genturis;Is the year of death of the patient known?;enum
lab;109;Year of lost to follow up available?;subject;Genturis;Is the year of lost to follow up of the patient known?;enum
lab;109;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
lab;109;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
lab;109;Data availability;subject;Genturis;What clinical data is locally available for this patient?;categoricalmref
lab;109;Material availability;subject;Genturis;What material is locally available for this patient?;categoricalmref
lab;109;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
lab;109;Medical laboratory;subject;Genturis;Which medical laboratory is in charge of the genetic analysis;string
lab;109;label;Allelic State;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;Label;;ithaca;;string
lab;109;Label;;ithaca;Hugo.owl.Approved_Name;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;Label;;ithaca;;text
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;Label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;Label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;Patient's biological sample available for researchÂ ;;ithaca;;bool
lab;109;"Other;  what patient Data is available";;ithaca;;categoricalmref
lab;109;Record Label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;label;;ithaca;;string
lab;109;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
lab;109;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
label;36;benignNeoplasmLabel;benignNeoplasm;Genturis;;string
label;36;geneticVariantLabel;geneticVariant;Genturis;;string
label;36;malignancyLabel;malignancy;Genturis;;string
label;36;label;Allelic State;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;Label;;ithaca;;string
label;36;Label;;ithaca;Hugo.owl.Approved_Name;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;Label;;ithaca;;text
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;Label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;Label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;Record Label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
label;36;label;;ithaca;;string
laboratory;1;Medical laboratory;subject;Genturis;Which medical laboratory is in charge of the genetic analysis;string
lait;2;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
lait;2;Number of Cafe au lait spot;subject;Genturis;What is the maximal number of cafe au lait spots ever observed in the patient?;int
langer;1;Langer mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Langer mesomelic dysplasia ;
largest;1;largest_nodule_size;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Largest nodule size;numeric
laron;1;Laron syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Laron syndrome;
last;78;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
last;78;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
last;78;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
last;78;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
last;78;R_PBC_Transient_elastography;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
last;78;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
last;78;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
last;78;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
last;78;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
last;78;eos_last_contact;End of study End of study;Rare Liver (Vascular);Date of Last Contact;date
last;78;first_angioplasty;Follow-up Events;Rare Liver (Vascular);First angioplasty/stenting of HV or IVC;radio
last;78;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
last;78;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
last;78;fu_cli_last_date_eval;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Date of evaluation;date
last;78;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
last;78;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
last;78;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
last;78;fu_cli_last_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
last;78;fu_cli_last_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
last;78;fu_cli_last_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
last;78;fu_cli_last_platelet_count;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
last;78;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
last;78;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
last;78;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
last;78;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
last;78;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
last;78;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
last;78;fu_cli_last_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
last;78;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
last;78;fu_cli_last_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
last;78;fu_cli_last_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
last;78;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
last;78;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
last;78;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
last;78;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
last;78;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
last;78;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
last;78;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
last;78;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
last;78;fu_cli_last_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
last;78;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
last;78;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
last;78;fu_cli_last_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
last;78;fu_cli_last_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
last;78;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
last;78;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
last;78;fu_ima_last_date_eval;Follow-up Imaging data;Rare Liver (Vascular);Date of evaluation;date
last;78;fu_ima_last_ct_irm;Follow-up Imaging data;Rare Liver (Vascular);CT or IRM;radio
last;78;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
last;78;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
last;78;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
last;78;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
last;78;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
last;78;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
last;78;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
last;78;fu_ima_last_cavernoma;Follow-up Imaging data;Rare Liver (Vascular);Cavernoma;radio
last;78;fu_ima_last_nodules;Follow-up Imaging data;Rare Liver (Vascular);BCS-type, or HNF-like, nodules;radio
last;78;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
last;78;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
last;78;fu_ima_last_fibro_value;Follow-up Imaging data;Rare Liver (Vascular);Liver fibroscan;numeric
last;78;fu_ima_last_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
last;78;fu_ima_last_fibro_date;Follow-up Imaging data;Rare Liver (Vascular);Date of fibroscan;date
last;78;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
last;78;fu_last_fibro_cap;Follow-up Imaging data;Rare Liver (Vascular);CAP;numeric
last;78;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
last;78;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
last;78;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
last;78;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
last;78;Date of last information;subject;Genturis;What is the date (yyyy-mm-dd) of the last clinical information of the patient?;date
last;78;Last name;;ithaca;;string
last;78;Last name;;ithaca;;string
last;78;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
last;78;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
last;78;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
last;78;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
last;78;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
last;78;Spondylodysplastic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Spondylodysplastic dysplasia ;
last;78;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
lateral;5;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
lateral;5;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
lateral;5;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
lateral;5;Laterality;malignancy;Genturis;What is the laterality of the breast cancer?;categorical
lateral;5;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
laterality;2;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
laterality;2;Laterality;malignancy;Genturis;What is the laterality of the breast cancer?;categorical
ldl;2;dia_lab_cholesterol_ldl;Diagnosis Laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
ldl;2;fu_cholesterol_ldl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Cholesterol LDL;numeric
learning;2;Learning support at school;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Requiring extra help at school with learning;Y/N/Not Known
learning;2;Learning difficulty;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;It takes your child longer than other people to get his or her school work done in past 4 weeks - severity;Not at all/A little bit/somewhat/quite a bit/very much/not applicable
left;8;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
left;8;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
left;8;Left hand grip (KgW):;QMG;EURO-NMD;;
left;8;left_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein branch;radio
left;8;pv_flow_left;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein direction of flow;radio
left;8;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
left;8;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
left;8;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
leg;4;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
leg;4;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
leg;4;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
leg;4;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
leiden;2;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
leiden;2;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
lemli;3;Smith-Lemli-Opitz syndrome;ADRENAL;EuRR-Bone & EuRRECa;Smith-Lemli-Opitz syndrome;
lemli;3;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
lemli;3;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
length;2;hv_short_length_stenosis;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Short length stenosis (;radio
length;2;spleen_length;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Maximal spleen length;numeric
lentigines;1;Noonan syndrome with multiple lentigines;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome with multiple lentigines;
leptin;3;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
leptin;3;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
leptin;3;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
lesions;5;eye_lesions;Diagnosis Aetiology;Rare Liver (Vascular);Eye lesions;radio
lesions;5;skin_lesions;Diagnosis Aetiology;Rare Liver (Vascular);Skin lesions;radio
lesions;5;prev_pre_canc_lesions_ynu;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Yes | 2, No | 9, Unknown
lesions;5;prev_pre_canc_lesions;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Pleomorphic adenoma | 2, Sinonasal papillomas | 3, Oral premalignant lesions
lesions;5;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
lethal;1;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
leuco;3;dia_lab_leucocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Leukocytes;numeric
leuco;3;fu_cli_bef_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
leuco;3;fu_cli_last_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
leucocytes;1;dia_lab_leucocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Leukocytes;numeric
leukemia;1;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
level;2;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
level;2;ace_level;Diagnosis Aetiology;Rare Liver (Vascular);Angiotensin-converting enzyme level;numeric
leydig;1;Leydig Cell Hypoplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Leydig Cell Hypoplasia;
lh;2;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
lh;2;LH deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;LH deficiency;
life;2;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
life;2;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
lifespan;1;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
lifted;1;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
like;11;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
like;11;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
like;11;Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome;
like;11;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
like;11;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
like;11;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
like;11;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
like;11;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
like;11;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
like;11;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
like;11;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
limb;10;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
limb;10;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
limb;10;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
limb;10;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
limb;10;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
limb;10;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
limb;10;Climbing stairs;Mobility ;EURO-NMD;;single
limb;10;oedema_lower_limbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Oedema of lower limbs;radio
limb;10;Non syndromic limb overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non syndromic limb overgrowth;
limb;10;Upper limb mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Upper limb mesomelic dysplasia ;
limbs;1;oedema_lower_limbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Oedema of lower limbs;radio
line;12;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
line;12;dia_lab_insulinemia;Diagnosis Laboratory data;Rare Liver (Vascular);Insulinemia;numeric
line;12;fu_insulinemia;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Insulinemia;numeric
line;12;Genetics  (germline);subject;Genturis;;compound
line;12;Tumour Types(Germline);;ithaca;;string
line;12;ebv_dna_baseline;primary_cancer;EURACAN;Plasmatic EBV DNA at baseline;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
line;12;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
line;12;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
line;12;copy_number_baseline;primary_cancer;EURACAN;Copy Number;
line;12;Germline mutations;Patient's history;PaedCan;Report if any specific genetic abnormallitis have been detected in the patient;yes/no/unknown
line;12;Treatment line;Therapy;PaedCan;Please specifiy if this treatment has been given as first line treatment or after relapse or progression;1st line/2nd line/3rd line
line;12;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
lipodystrophy;3;Congenital-generalized lipodystrophy;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital-generalized lipodystrophy;
lipodystrophy;3;Familial partial lipodystrophy Type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 1;
lipodystrophy;3;Familial partial lipodystrophy Type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 2;
liver;75;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
liver;75;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
liver;75;R_AIH_Liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver biopsy;radio
liver;75;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
liver;75;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
liver;75;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
liver;75;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
liver;75;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
liver;75;R_AIH_Liver_imaging_consistent_cirrhosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
liver;75;R_AIH_Liver_tissue;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
liver;75;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
liver;75;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
liver;75;R_PBC_Liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
liver;75;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
liver;75;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
liver;75;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
liver;75;R_PBC_Liver_stiffness;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
liver;75;R_PBC_Liver_tissue;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
liver;75;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
liver;75;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
liver;75;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
liver;75;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
liver;75;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
liver;75;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
liver;75;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
liver;75;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
liver;75;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
liver;75;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
liver;75;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
liver;75;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
liver;75;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
liver;75;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
liver;75;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
liver;75;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
liver;75;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
liver;75;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
liver;75;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
liver;75;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
liver;75;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
liver;75;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
liver;75;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
liver;75;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
liver;75;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
liver;75;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
liver;75;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
liver;75;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
liver;75;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
liver;75;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
liver;75;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
liver;75;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
liver;75;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
liver;75;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
liver;75;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
liver;75;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
liver;75;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
liver;75;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
liver;75;history_of_liver_diseases;Diagnosis Clinical Manifestations;Rare Liver (Vascular);If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?;radio
liver;75;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
liver;75;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
liver;75;date_liver_biopsy;Diagnosis Biobank;Rare Liver (Vascular);Date of liver biopsy;date
liver;75;liver_biopsy_number;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy local number;string
liver;75;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
liver;75;liver_biopsy_obtained;Diagnosis Biobank;Rare Liver (Vascular);Frozen liver biopsy obtained?;dropdown
liver;75;date_last_delivery_abortio;Diagnosis Aetiology;Rare Liver (Vascular);Date of last delivery/abortion;date
liver;75;eos_liver_transplant;End of study End of study;Rare Liver (Vascular);Was a liver transplantation performed?;radio
liver;75;eos_liver_transplant_date;End of study End of study;Rare Liver (Vascular);Date of liver transplantation;date
liver;75;eos_liver_transplant_reason;End of study End of study;Rare Liver (Vascular);Why was no liver transplantation performed?;radio
liver;75;eos_liver_transplant_other;End of study End of study;Rare Liver (Vascular);Other reason:;string
liver;75;eos_liver_transplant_death;End of study End of study;Rare Liver (Vascular);Death after liver transplantation?;calculation
liver;75;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
liver;75;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
liver;75;first_liver_transplant;Follow-up Events;Rare Liver (Vascular);First liver transplantation;radio
liver;75;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
liver;75;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
liver;75;Please describe the treatment delivered;Other treatments;PaedCan;;String
lkm;24;R_AIH_LKM;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
lkm;24;R_AIH_LKM_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
lkm;24;R_AIH_LKM_1_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm;24;R_AIH_LKM_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
lkm;24;R_PBC_LKM;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
lkm;24;R_PBC_LKM_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
lkm;24;R_PBC_LKM1_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm;24;R_PBC_LKM_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
lkm;24;R_PSC_LKM;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
lkm;24;R_PSC_LKM_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
lkm;24;R_PSC_LKM1_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm;24;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
lkm;24;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
lkm;24;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
lkm;24;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm;24;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
lkm;24;R_AIH_LKM_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
lkm;24;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
lkm;24;R_AIH_LKM_1_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm;24;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
lkm;24;R_PBC_LKM_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
lkm;24;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
lkm;24;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm;24;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
lkm1;4;R_PBC_LKM1_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm1;4;R_PSC_LKM1_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm1;4;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lkm1;4;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
lnr;1;lnr_ratio;surgery;EURACAN;LNR (Lymph node ratio);([surgery_nr_pos_lymphnodes]/[surgery_nr_lymphnodes])
local;2;fu_awd_local;clinical_update;EURACAN;AWD, Local;1, Yes | 2, No | 3, Unknown
local;2;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
location;7;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
location;7;Genome Location;;ithaca;;string
location;7;Chromosomale Location;;ithaca;Hugo.owl.Chromosome;string
location;7;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
location;7;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
location;7;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
location;7;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
loose;1;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
loss;6;R_PBC_Bile_duct_loss_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
loss;6;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
loss;6;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
loss;6;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
loss;6;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
loss;6;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
loss-rhizomelic;1;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
lost;3;Year of lost to follow up available?;subject;Genturis;Is the year of lost to follow up of the patient known?;enum
lost;3;Year of lost to follow up;subject;Genturis;In what year was the patient lost to follow up?;int
lost;3;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
low;569;AChR (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
low;569;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
low;569;MuSK (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
low;569;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
low;569;Swallowing difficulties;Bulbar/Gi ;EURO-NMD;;single
low;569;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
low;569;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
low;569;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
low;569;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
low;569;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
low;569;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
low;569;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
low;569;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
low;569;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
low;569;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
low;569;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
low;569;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
low;569;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
low;569;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
low;569;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
low;569;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
low;569;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
low;569;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
low;569;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
low;569;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
low;569;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
low;569;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
low;569;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
low;569;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
low;569;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
low;569;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
low;569;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
low;569;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
low;569;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
low;569;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
low;569;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
low;569;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
low;569;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
low;569;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
low;569;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
low;569;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
low;569;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
low;569;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
low;569;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
low;569;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
low;569;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
low;569;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
low;569;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
low;569;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
low;569;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
low;569;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
low;569;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
low;569;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
low;569;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
low;569;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
low;569;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
low;569;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
low;569;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
low;569;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
low;569;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
low;569;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
low;569;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
low;569;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
low;569;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
low;569;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
low;569;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
low;569;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
low;569;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
low;569;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
low;569;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
low;569;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
low;569;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
low;569;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
low;569;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
low;569;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
low;569;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
low;569;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
low;569;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
low;569;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
low;569;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
low;569;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
low;569;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
low;569;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
low;569;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
low;569;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
low;569;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
low;569;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
low;569;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
low;569;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
low;569;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
low;569;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
low;569;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
low;569;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
low;569;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
low;569;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
low;569;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
low;569;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
low;569;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
low;569;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
low;569;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
low;569;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
low;569;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
low;569;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
low;569;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
low;569;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
low;569;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
low;569;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
low;569;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
low;569;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
low;569;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
low;569;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
low;569;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
low;569;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
low;569;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
low;569;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
low;569;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
low;569;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
low;569;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
low;569;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
low;569;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
low;569;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
low;569;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
low;569;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
low;569;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
low;569;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
low;569;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
low;569;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
low;569;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
low;569;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
low;569;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
low;569;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
low;569;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
low;569;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
low;569;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
low;569;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
low;569;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
low;569;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
low;569;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
low;569;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
low;569;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
low;569;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
low;569;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
low;569;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
low;569;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
low;569;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
low;569;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
low;569;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
low;569;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
low;569;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
low;569;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
low;569;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
low;569;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
low;569;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
low;569;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
low;569;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
low;569;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
low;569;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
low;569;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
low;569;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
low;569;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
low;569;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
low;569;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
low;569;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
low;569;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
low;569;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_Budesonide_change_followup_1;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
low;569;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
low;569;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
low;569;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
low;569;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
low;569;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
low;569;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
low;569;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
low;569;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
low;569;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
low;569;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
low;569;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
low;569;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
low;569;R_AIH_AST_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
low;569;R_AIH_ALT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
low;569;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
low;569;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
low;569;R_AIH_AP_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
low;569;R_AIH_yGT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);y-GT;numeric
low;569;R_AIH_Albumin_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
low;569;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
low;569;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
low;569;R_AIH_INR_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
low;569;R_AIH_Platelets_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
low;569;R_AIH_IgG_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
low;569;R_AIH_IgM_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
low;569;R_AIH_IgA_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
low;569;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
low;569;R_AIH_ANA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
low;569;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
low;569;R_AIH_ANA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
low;569;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
low;569;R_AIH_AMA_diagnosis_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
low;569;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
low;569;R_AIH_AMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
low;569;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
low;569;R_AIH_SMA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
low;569;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
low;569;R_AIH_SMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
low;569;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
low;569;R_AIH_LKM_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
low;569;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
low;569;R_AIH_LKM_1_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
low;569;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
low;569;R_AIH_SLA_LP_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
low;569;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
low;569;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
low;569;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
low;569;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
low;569;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
low;569;R_AIH_Serum_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
low;569;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
low;569;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
low;569;R_AIH_Date_of_followup_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of follow-up;string
low;569;R_AIH_Age_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Age at follow-up;calculation
low;569;R_AIH_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Bone mineral density (DXA);radio
low;569;R_AIH_Date_of_DXA_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Date of DXA;date
low;569;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
low;569;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
low;569;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
low;569;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
low;569;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
low;569;R_AIH_Spleen_size_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Spleen size (diameter);numeric
low;569;R_AIH_MRCP_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);MRCP;radio
low;569;R_AIH_Weight_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Weight;numeric
low;569;R_AIH_Height_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Height;numeric
low;569;R_AIH_BMI_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);BMI;calculation
low;569;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
low;569;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
low;569;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
low;569;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
low;569;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
low;569;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
low;569;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
low;569;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
low;569;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
low;569;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
low;569;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
low;569;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
low;569;R_AIH_mHAI_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);mHAI;numeric
low;569;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
low;569;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
low;569;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
low;569;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
low;569;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
low;569;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
low;569;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
low;569;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
low;569;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
low;569;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
low;569;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
low;569;R_AIH_Liver_imaging_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
low;569;R_AIH_Date_consistent_cirrhosis_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date imaging consistent with cirrhosis;date
low;569;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
low;569;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
low;569;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
low;569;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
low;569;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
low;569;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
low;569;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
low;569;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
low;569;R_AIH_HRS_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatorenal syndrome;radio
low;569;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
low;569;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
low;569;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
low;569;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
low;569;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
low;569;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
low;569;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
low;569;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
low;569;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
low;569;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
low;569;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
low;569;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
low;569;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
low;569;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
low;569;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
low;569;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
low;569;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
low;569;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_Budesonide_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
low;569;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
low;569;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
low;569;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
low;569;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
low;569;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
low;569;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Budesonide_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
low;569;R_AIH_Budesonide_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
low;569;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
low;569;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
low;569;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
low;569;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
low;569;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
low;569;R_AIH_MMP_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
low;569;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
low;569;R_AIH_UDCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
low;569;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
low;569;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
low;569;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
low;569;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_MMF_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
low;569;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
low;569;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Tacrolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
low;569;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_CyclosporinA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
low;569;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Infliximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
low;569;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Rituximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
low;569;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
low;569;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
low;569;R_AIH_PBC_OCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
low;569;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
low;569;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
low;569;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
low;569;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
low;569;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
low;569;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
low;569;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
low;569;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
low;569;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
low;569;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
low;569;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
low;569;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
low;569;R_PBC_AST_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
low;569;R_PBC_ALT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
low;569;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
low;569;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
low;569;R_PBC_ALP_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
low;569;R_PBC_yGT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
low;569;R_PBC_Albumin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
low;569;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
low;569;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
low;569;R_PBC_INR_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
low;569;R_PBC_Platelets_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
low;569;R_PBC_IgG_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
low;569;R_PBC_IgM_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
low;569;R_PBC_IgA_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
low;569;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
low;569;R_PBC_ANA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
low;569;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
low;569;R_PBC_ANA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
low;569;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
low;569;R_PBC_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
low;569;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
low;569;R_PBC_SMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
low;569;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
low;569;R_PBC_LKM_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
low;569;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
low;569;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
low;569;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
low;569;R_PBC_SLA_LP_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
low;569;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
low;569;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
low;569;R_PBC_AMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
low;569;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
low;569;R_PBC_AMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
low;569;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
low;569;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
low;569;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
low;569;R_PBC_gp210_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
low;569;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
low;569;R_PBC_SP100_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
low;569;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
low;569;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
low;569;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
low;569;R_PBC_Serum_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
low;569;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
low;569;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
low;569;R_PBC_Date_of_followup_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of Follow-up;string
low;569;R_PBC_Age_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
low;569;R_PBC_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
low;569;R_PBC_Date_of_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
low;569;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
low;569;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
low;569;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
low;569;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
low;569;R_PBC_IQR_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
low;569;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
low;569;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
low;569;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
low;569;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
low;569;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
low;569;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
low;569;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
low;569;R_PBC_mHAI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
low;569;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
low;569;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
low;569;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
low;569;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
low;569;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
low;569;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
low;569;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
low;569;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
low;569;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
low;569;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
low;569;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
low;569;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
low;569;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
low;569;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
low;569;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
low;569;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
low;569;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
low;569;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
low;569;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
low;569;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
low;569;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
low;569;R_PBC_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
low;569;R_PBC_Date_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
low;569;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
low;569;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
low;569;R_PBC_Indication_LTx_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Indication for liver transplantation;radio
low;569;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
low;569;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
low;569;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
low;569;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
low;569;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
low;569;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
low;569;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
low;569;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
low;569;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
low;569;R_PBC_Weight_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
low;569;R_PBC_Height_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
low;569;R_PBC_BMI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
low;569;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
low;569;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
low;569;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
low;569;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
low;569;R_PBC_UDCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
low;569;R_PBC_UDCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
low;569;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
low;569;R_PBC_OCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
low;569;R_PBC_OCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
low;569;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
low;569;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
low;569;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_Budesonide_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
low;569;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
low;569;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
low;569;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
low;569;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
low;569;R_PBC_TGN_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
low;569;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
low;569;R_PBC_MMP_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
low;569;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
low;569;R_PBC_Fibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
low;569;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
low;569;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
low;569;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
low;569;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
low;569;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
low;569;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
low;569;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
low;569;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
low;569;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
low;569;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
low;569;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
low;569;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
low;569;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
low;569;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
low;569;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
low;569;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
low;569;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
low;569;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
low;569;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
low;569;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
low;569;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
low;569;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
low;569;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
low;569;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
low;569;oedema_lower_limbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Oedema of lower limbs;radio
low;569;hv_abnorm_doppl_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal Doppler flow pattern in more than one large vein;radio
low;569;pv_direction_of_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Direction of flow;radio
low;569;pv_flow_right;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein direction of flow;radio
low;569;pv_flow_left;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein direction of flow;radio
low;569;date_follow_up;Follow-up Date;Rare Liver (Vascular);Date of follow-up;date
low;569;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
low;569;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
low;569;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
low;569;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
low;569;Age at last follow up (in days):;6. Age at last follow up (in days):;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
low;569;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
low;569;"d.	Age at last follow-up contact:		";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
low;569;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
low;569;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
low;569;Follow-up status;subject;Genturis;What is the patient's follow-up status?;categorical
low;569;Year of lost to follow up available?;subject;Genturis;Is the year of lost to follow up of the patient known?;enum
low;569;Year of lost to follow up;subject;Genturis;In what year was the patient lost to follow up?;int
low;569;Is the patient following any other medication?;;ithaca;;bool
low;569;Date of follow up;Follow up (one form for each follow up visit);PaedCan;Date of the last contact with the patient including visit and telephone call;dd/mm/yyyy
low;569;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
low;569;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
low;569;Coffin-Lowry syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Coffin-Lowry syndromeÂ ;
low;569;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
low;569;AMH low;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;AMH low;
low;569;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
low-affinity,;4;AChR (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
low-affinity,;4;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
low-affinity,;4;MuSK (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
low-affinity,;4;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
lower;1;oedema_lower_limbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Oedema of lower limbs;radio
lowest;13;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
lowest;13;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lowest;13;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
lowest;13;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lowest;13;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
lowest;13;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lowest;13;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
lowest;13;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lowest;13;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
lowest;13;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lowest;13;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
lowest;13;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
lowest;13;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
lp;27;R_AIH_ALP;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
lp;27;R_AIH_SLA_LP;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
lp;27;R_AIH_SLA_LP_value;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
lp;27;R_AIH_SLA_LP_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
lp;27;R_PBC_ALP;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
lp;27;R_PBC_SLA_LP;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
lp;27;R_PBC_SLA_LP_units;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
lp;27;R_PBC_SLA_LP_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
lp;27;R_PSC_ALP;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
lp;27;R_PSC_SLA_LP;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
lp;27;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
lp;27;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
lp;27;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
lp;27;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
lp;27;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
lp;27;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
lp;27;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
lp;27;R_AIH_SLA_LP_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
lp;27;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
lp;27;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
lp;27;R_PBC_ALP_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
lp;27;R_PBC_SLA_LP_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
lp;27;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
lp;27;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
lp;27;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
lp;27;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
lp;27;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
lpv;2;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
lpv;2;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
lrba;1;LRBA;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;LRBA;
ltx;3;R_PBC_Indication_LTx_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Indication for liver transplantation;radio
ltx;3;abd_interv_ltx;Diagnosis Aetiology;Rare Liver (Vascular);LTx;radio
ltx;3;abd_interv_ltx_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of LTx;date
lumber;6;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lumber;6;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lumber;6;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lumber;6;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lumber;6;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
lumber;6;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
lupus;1;lupus_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);Lupus anticoagulant antibody;radio
lyase;2;Combined 17a-hydroxylase/17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Combined 17a-hydroxylase/17,20 lyase deficiency;
lyase;2;Isolated 17,20 lyase deficiency;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated 17,20 lyase deficiency;
lymph;13;dia_lab_lymphocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Lymphocytes;numeric
lymph;13;lymphography_sentinel;surgery;EURACAN;Lymphography and Sentinel node;1, Yes | 2, No | 9, Unknown
lymph;13;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
lymph;13;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
lymph;13;surgery_nr_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
lymph;13;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
lymph;13;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
lymph;13;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
lymph;13;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
lymph;13;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
lymph;13;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
lymph;13;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
lymph;13;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
lymphnodes;9;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
lymphnodes;9;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
lymphnodes;9;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
lymphnodes;9;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
lymphnodes;9;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
lymphnodes;9;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
lymphnodes;9;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
lymphnodes;9;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
lymphnodes;9;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
lymphocytes;1;dia_lab_lymphocytes;Diagnosis Laboratory data;Rare Liver (Vascular);Lymphocytes;numeric
lymphography;1;lymphography_sentinel;surgery;EURACAN;Lymphography and Sentinel node;1, Yes | 2, No | 9, Unknown
madelung;1;Madelung deformity ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Madelung deformity ;
maffucci;1;Maffucci syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Maffucci syndrome ;
magel2;2;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
magel2;2;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
maj;3;site_maj_salivary;primary_cancer;EURACAN;Subsite;1, C07.9  Parotid gland | 2, C08 other and unspecified major salivary glands | 3, C08.0  Submandibular gland | 4, C08.1  Sublingual gland | 5, C08.8  Overlapping lesion of major salivary glands | 6, C08.9  Major salivary gland, NOS
maj;3;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
maj;3;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
major;2;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
major;2;Major adverse effect (grade IV);Radiotherapy;PaedCan;Describe any adverse effect related  to radiotherapy if any;yes/no/unknown
malan;1;Malan overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Malan overgrowth syndrome;
male;8;R_PSC_Is_female;PSC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
male;8;R_AIH_Is_female;AIH Follow-up Outcome I;Rare Liver (Auto imune);Is female;calculation
male;8;R_PBC_is_female;PBC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
male;8;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
male;8;Chromosomale Location;;ithaca;Hugo.owl.Chromosome;string
male;8;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
male;8;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
male;8;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
malformation;2;a. Type of malformation:;1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
malformation;2;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
malformations-facial;1;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
malignancies;1;Malignancies (invasive/ in situ);subject;Genturis;;compound
malignancy;37;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
malignancy;37;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
malignancy;37;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
malignancy;37;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
malignancy;37;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
malignancy;37;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
malignancy;37;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
malignancy;37;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
malignancy;37;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
malignancy;37;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
malignancy;37;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
malignancy;37;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
malignancy;37;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
malignancy;37;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
malignancy;37;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
malignancy;37;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
malignancy;37;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
malignancy;37;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
malignancy;37;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
malignancy;37;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
malignancy;37;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
malignancy;37;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
malignancy;37;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
malignancy;37;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
malignancy;37;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
malignancy;37;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
malignancy;37;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
malignancy;37;malignancyLabel;malignancy;Genturis;;string
malignancy;37;Age at diagnosis (malignancy) available?;malignancy;Genturis;Is the age (years) at which the patient was diagnosed with this malignancy known?;enum
malignancy;37;Age at diagnosis (malignancy);malignancy;Genturis;At what age (years) was the patient diagnosed with this malignancy?;int
malignancy;37;Malignancy type;malignancy;Genturis;Where is the malignancy located?;xref
malignancy;37;Malignancy morphology;malignancy;Genturis;What is the morphology of this malignancy?;xref
malignancy;37;Malignancy status;subject;Genturis;Has this patient ever had a (invasive or in situ) malignancy?;enum
malignancy;37;Previous malignancy;Patient's history;PaedCan;Did the patient suffer from any malignancy before?;yes/no/unknown
malignancy;37;Specify which malignancy;Patient's history;PaedCan;Description of any previous malignancy;ICCC3
malignancy;37;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
malignancy;37;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
malignancylabel;1;malignancyLabel;malignancy;Genturis;;string
mammographic;1;Mammographic density;malignancy;Genturis;What is the mammographic density?;categorical
man;19;woman_still_menstruated;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Is she still menstruated?;radio
man;19;Semantic type UMLS property (URL);;ithaca;;hyperlink
man;19;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
man;19;smoking_pack_year_man;patient_management_at_the_hospital;EURACAN;Pack/year (manual);
man;19;Beckwith-Wiedemann syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome;
man;19;Beckwith-Wiedemann Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann Syndrome;
man;19;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
man;19;Beckwith-Wiedemann syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microduplication;
man;19;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
man;19;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
man;19;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
man;19;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
man;19;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
man;19;Borjeson-Forssman-Lehmann syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Borjeson-Forssman-Lehmann syndromeÂ ;
man;19;Kallmann Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Kallmann Syndrome;
man;19;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
man;19;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
man;19;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
man;19;Camurati-Engelmann disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Camurati-Engelmann disease ;
management;1;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
margins;1;surgery_margins;surgery;EURACAN;Margins after surgery;0, R0 (microscopic negative) | 1, R1 (microscopic positive) | 2, R2 (macroscopic positive) | 9, Unknown
marital;1;marital_status;patient_management_at_the_hospital;EURACAN;Marital status;1, Married | 2, Not married | 3, Divorced | 4, Widowed/Widower | 5, Single
marrow;1;bone_marrow_biopsy;Diagnosis Aetiology;Rare Liver (Vascular);Bone marrow biopsy;radio
mas;4;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
mas;4;Number of ependymomas;benignNeoplasm;Genturis;What is the maximal number of ependymomas ever observed in this patient?;int
mas;4;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
mas;4;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
masaoka;1;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
mass;1;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
material;3;Material availability;subject;Genturis;What material is locally available for this patient?;categoricalmref
material;3;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
material;3;Consent for usage of biobank material;;ithaca;;bool
maternal;7;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
maternal;7;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
maternal;7;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
maternal;7;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
maternal;7;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
maternal;7;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
maternal;7;Maternal Androgens;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Maternal Androgens;
matter;1;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
mazabraud;1;Mazabraud syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mazabraud syndrome ;
mccune-albright;1;McCune-Albright syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;McCune-Albright syndrome ;
mcg;3;"b. Age at first MCG VUR (in days):		";4. MCG VUR: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
mcg;3;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
mcg;3;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
mct8;1;MCT8 deficiency;THYROID;EuRR-Bone & EuRRECa;MCT8 deficiency;
mcug;1;MCUG ;Imaging;ERKNet;Â ;Â 
measured;1;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
measurement;3;date_of_measurement;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of measurement;date
measurement;3;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
measurement;3;Date of measurement;Biochemistry;ERKNet;If 1,2,3;protur_date
measurements;1;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
measures;4;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
measures;4;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
measures;4;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
measures;4;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
med;48;Medication;Medication ;EURO-NMD;;single
med;48;Medication Other;Medication ;EURO-NMD;;text
med;48;Medication Dose;Medication ;EURO-NMD;;float
med;48;Medication Date started;Medication ;EURO-NMD;;date
med;48;Medication Date stopped;Medication ;EURO-NMD;;date
med;48;Medication Effect;Medication ;EURO-NMD;;single
med;48;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
med;48;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
med;48;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
med;48;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
med;48;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
med;48;med_assist_repro_history;Diagnosis Aetiology;Rare Liver (Vascular);History of medically assisted reproduction;radio
med;48;med_assist_repro_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of medically assisted reproduction;date
med;48;med_typ;Medications Medication;Rare Liver (Vascular);Type of medication;radio
med;48;med_typ_oth;Medications Medication;Rare Liver (Vascular);Other, please specify type of medication;string
med;48;medac;Medications Medication;Rare Liver (Vascular);Medication (anticoagulation);radio
med;48;medd;Medications Medication;Rare Liver (Vascular);Medication (diuretic);radio
med;48;medap;Medications Medication;Rare Liver (Vascular);Medication (antiplatelet);radio
med;48;medb;Medications Medication;Rare Liver (Vascular);Medication (blocker);radio
med;48;med_check;Medications Medication;Rare Liver (Vascular);med_check;calculation
med;48;med_oth;Medications Medication;Rare Liver (Vascular);Medication (generic name);string
med;48;meddose;Medications Medication;Rare Liver (Vascular);Daily Dose;numeric
med;48;med_unit;Medications Medication;Rare Liver (Vascular);Unit;radio
med;48;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
med;48;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
med;48;a.Performed;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
med;48;a.Performed;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
med;48;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
med;48;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
med;48;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
med;48;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
med;48;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
med;48;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
med;48;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
med;48;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
med;48;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
med;48;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
med;48;Informed consent;subject;Genturis;;compound
med;48;Medical laboratory;subject;Genturis;Which medical laboratory is in charge of the genetic analysis;string
med;48;Link to PubmedID;;ithaca;Hugo.owl.Pubmed_IDs;string
med;48;Medication;;ithaca;;compound
med;48;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
med;48;Medication for Rare Disease Description;;ithaca;;text
med;48;Start date medication;;ithaca;;date
med;48;End date medication;;ithaca;;date
med;48;Is the patient following any other medication?;;ithaca;;bool
med;48;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
med;48;Medullary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Medullary thyroid carcinoma;
medac;1;medac;Medications Medication;Rare Liver (Vascular);Medication (anticoagulation);radio
medap;1;medap;Medications Medication;Rare Liver (Vascular);Medication (antiplatelet);radio
medb;1;medb;Medications Medication;Rare Liver (Vascular);Medication (blocker);radio
medd;2;medd;Medications Medication;Rare Liver (Vascular);Medication (diuretic);radio
medd;2;meddose;Medications Medication;Rare Liver (Vascular);Daily Dose;numeric
meddose;1;meddose;Medications Medication;Rare Liver (Vascular);Daily Dose;numeric
mediated;1;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
medical;1;Medical laboratory;subject;Genturis;Which medical laboratory is in charge of the genetic analysis;string
medication;12;Medication;Medication ;EURO-NMD;;single
medication;12;Medication Other;Medication ;EURO-NMD;;text
medication;12;Medication Dose;Medication ;EURO-NMD;;float
medication;12;Medication Date started;Medication ;EURO-NMD;;date
medication;12;Medication Date stopped;Medication ;EURO-NMD;;date
medication;12;Medication Effect;Medication ;EURO-NMD;;single
medication;12;Medication;;ithaca;;compound
medication;12;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
medication;12;Medication for Rare Disease Description;;ithaca;;text
medication;12;Start date medication;;ithaca;;date
medication;12;End date medication;;ithaca;;date
medication;12;Is the patient following any other medication?;;ithaca;;bool
medics;1;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
medullary;1;Medullary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Medullary thyroid carcinoma;
megalencephaly-severe;1;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
mehmo;1;MEHMO syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MEHMO syndrome;
melanocortin;2;Melanocortin 4 receptor deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Melanocortin 4 receptor deficiency;
melanocortin;2;Pro-opiomelanocortin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pro-opiomelanocortin deficiency;
mellitus;5;Diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus;
mellitus;5;Diabetes mellitus type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 1;
mellitus;5;Diabetes mellitus type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 2;
mellitus;5;Other diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other diabetes mellitus;
mellitus;5;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
melorheostosis;1;MelorheostosisÂ withÂ osteopoikilosisÂ ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;MelorheostosisÂ withÂ osteopoikilosisÂ ;
members;2;Affected family members;Diagnosis Family History;EURO-NMD;;multi
members;2;Family members affected?;Family history;ERKNet;Â ;fam_affected
menarche;1;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
meningeal;1;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
meningioma;1;Number of meningioma;benignNeoplasm;Genturis;What is the maximal number of meningiomas ever observed in this patient?;int
menstrual;1;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
menstruated;1;woman_still_menstruated;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Is she still menstruated?;radio
mercaptopurine;31;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
mercaptopurine;31;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
mercaptopurine;31;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
mercaptopurine;31;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mercaptopurine;31;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mercaptopurine;31;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
mercaptopurine;31;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
mercaptopurine;31;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mercaptopurine;31;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mercaptopurine;31;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mercaptopurine;31;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
mercaptopurine;31;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mercaptopurine;31;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mercaptopurine;31;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mercaptopurine;31;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mercaptopurine;31;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
mercaptopurine;31;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mercaptourine;2;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
mercaptourine;2;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
mesenteric;4;superior_mesenteric_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Superior mesenteric vein;radio
mesenteric;4;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
mesenteric;4;date_mesenterico_portal;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
mesenteric;4;fu_end_mesenteric_infarct;Follow-up Endpoints;Rare Liver (Vascular);Mesenteric infarction;radio
mesenterico;2;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
mesenterico;2;date_mesenterico_portal;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
mesomelic;8;Mesomelic and rhizo-mesomelic dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic and rhizo-mesomelic dysplasia;
mesomelic;8;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
mesomelic;8;Upper limb mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Upper limb mesomelic dysplasia ;
mesomelic;8;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
mesomelic;8;Langer mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Langer mesomelic dysplasia ;
mesomelic;8;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
mesomelic;8;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
mesomelic;8;Mesomelic dysplasia, Savarirayan type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Savarirayan type ;
meta;39;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
meta;39;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
meta;39;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
meta;39;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
meta;39;imag_meta;stage_procedures;EURACAN;Imaging for metastatic disease;1, Yes | 2, No | 3, Unknown
meta;39;ct_meta;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
meta;39;mri_meta;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
meta;39;us_meta;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
meta;39;fdg_pet_meta;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
meta;39;pet_oth_meta;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
meta;39;ct_pet_meta;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
meta;39;unknown_meta;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
meta;39;imag_meta_oth;stage_procedures;EURACAN;Other imaging for metastatic disease;
meta;39;fu_awd_metastatic;clinical_update;EURACAN;AWD, Metastatic;1, Yes | 2, No | 3, Unknown
meta;39;Metastases (M);Tumor's characteristics;PaedCan;Presence of distant lesions (TNM system);M0/M1/Mx
meta;39;Site of metastases;Tumor's characteristics;PaedCan;Definition of the site of metastases;Skin or soft tissues/CNS/Liver/Bone marrow/Lung/Distant nodes/Peritoneum or omentum/Bone/other/Unknown
meta;39;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
meta;39;Number of metastasis;Tumor's characteristics;PaedCan;Definition of the number of metastases for every site;singular/multiple
meta;39;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
meta;39;Date of metastases biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
meta;39;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
meta;39;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
meta;39;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
meta;39;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
meta;39;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
meta;39;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
meta;39;Multiple metaphyseal dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple metaphyseal dysplasia;
meta;39;Epimetaphyseal skeletal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Epimetaphyseal skeletal dysplasia ;
meta;39;Metaphyseal anadysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal anadysplasia;
meta;39;Metaphyseal acroscyphodysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal acroscyphodysplasia;
meta;39;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
meta;39;Ulna metaphyseal dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ulna metaphyseal dysplasia syndrome ;
meta;39;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
meta;39;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
meta;39;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
meta;39;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
meta;39;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
meta;39;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
meta;39;Craniometaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniometaphyseal dysplasia ;
metabolites;4;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
metabolites;4;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
metabolites;4;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
metabolites;4;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
metacarpals-insulin;1;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
metaphyseal;14;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
metaphyseal;14;Multiple metaphyseal dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple metaphyseal dysplasia;
metaphyseal;14;Epimetaphyseal skeletal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Epimetaphyseal skeletal dysplasia ;
metaphyseal;14;Metaphyseal anadysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal anadysplasia;
metaphyseal;14;Metaphyseal acroscyphodysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal acroscyphodysplasia;
metaphyseal;14;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
metaphyseal;14;Ulna metaphyseal dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ulna metaphyseal dysplasia syndrome ;
metaphyseal;14;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
metaphyseal;14;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
metaphyseal;14;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
metaphyseal;14;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
metaphyseal;14;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
metaphyseal;14;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
metaphyseal;14;Craniometaphyseal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Craniometaphyseal dysplasia ;
metastases;9;Metastases (M);Tumor's characteristics;PaedCan;Presence of distant lesions (TNM system);M0/M1/Mx
metastases;9;Site of metastases;Tumor's characteristics;PaedCan;Definition of the site of metastases;Skin or soft tissues/CNS/Liver/Bone marrow/Lung/Distant nodes/Peritoneum or omentum/Bone/other/Unknown
metastases;9;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
metastases;9;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
metastases;9;Date of metastases biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
metastases;9;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
metastases;9;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
metastases;9;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
metastases;9;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
metastases,;1;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
metastasis;1;Number of metastasis;Tumor's characteristics;PaedCan;Definition of the number of metastases for every site;singular/multiple
metastatic;1;fu_awd_metastatic;clinical_update;EURACAN;AWD, Metastatic;1, Yes | 2, No | 3, Unknown
methionine;1;methionine_tolerance_test;Diagnosis Aetiology;Rare Liver (Vascular);Methionine tolerance test;radio
method;3;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
method;3;optical_methods_neck;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
method;3;(Diagnosis) Method;Genetic diagnosis;ERKNet;If gen_diagnosis != result pending;"`-  individual gene testing
-  NGS gene panel screening
-  exome sequencing"
methods;2;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
methods;2;optical_methods_neck;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
mg;26;EMG result;Diagnosis EMG;EURO-NMD;EMG result;single
mg;26;EMG abnormality;Diagnosis EMG;EURO-NMD;;single
mg;26;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
mg;26;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
mg;26;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
mg;26;SF EMG result;Diagnosis EMG;EURO-NMD;;
mg;26;MG-ADL total score;QoL;EURO-NMD;;int
mg;26;Total QMG score if done;QMG;EURO-NMD;;
mg;26;R_AIH_Creatinine_mgdL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mg;26;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mg;26;R_PBC_Creatinine_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
mg;26;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
mg;26;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
mg;26;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mg;26;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mg;26;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
mg;26;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mg;26;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mg;26;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
mg;26;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
mg;26;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
mg;26;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
mg;26;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
mg;26;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
mg;26;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
mg;26;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
mg-adl;1;MG-ADL total score;QoL;EURO-NMD;;int
mgdl;11;R_AIH_Creatinine_mgdL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mgdl;11;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mgdl;11;R_PBC_Creatinine_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
mgdl;11;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
mgdl;11;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
mgdl;11;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mgdl;11;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mgdl;11;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
mgdl;11;R_AIH_Bilirubin_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mgdl;11;R_AIH_Creatinine_mgdL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mgdl;11;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
mhai;6;R_AIH_mHAI;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);mHAI;numeric
mhai;6;R_PBC_mHAI;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
mhai;6;R_PSC_mHAI;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
mhai;6;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
mhai;6;R_AIH_mHAI_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);mHAI;numeric
mhai;6;R_PBC_mHAI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
microcephalic;2;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
microcephalic;2;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
microdeletion;7;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
microdeletion;7;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
microdeletion;7;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
microdeletion;7;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
microdeletion;7;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
microdeletion;7;Distal 16p11.2 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Distal 16p11.2 microdeletion syndrome;
microdeletion;7;Xq21 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Xq21 microdeletion syndrome;
microduplication;3;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
microduplication;3;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
microduplication;3;Beckwith-Wiedemann syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microduplication;
micromelia;1;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
micropenis;1;Isolated micropenis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated micropenis;
microphthalmia-obesity-hypogenitalism-intellectual;1;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
microphthalmia-rhizomelic;1;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
milestones;1;Delayed motor milestones;Diagnosis Developmental;EURO-NMD;;yesno
mineralization;1;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
minutes;2;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
minutes;2;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
miscarriagies;1;number_miscarriagies;Diagnosis Aetiology;Rare Liver (Vascular);Number of miscarriages;radio
mismatches;2;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
mismatches;2;"d.	HLA-DR mismatches: ";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
mixed;1;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
ml/min/1.73m2;3;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ml/min/1.73m2;3;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ml/min/1.73m2;3;"e.	eGFR at last follow-up (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
mlh1;1;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
mm;152;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
mm;152;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
mm;152;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
mm;152;R_AIH_ANA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
mm;152;R_AIH_AMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
mm;152;R_AIH_SMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
mm;152;R_AIH_LKM_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
mm;152;R_AIH_SLA_LP_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
mm;152;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
mm;152;R_AIH_MMF;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF;radio
mm;152;R_AIH_MMF_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
mm;152;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
mm;152;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
mm;152;R_PBC_ANA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
mm;152;R_PBC_SMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
mm;152;R_PBC_LKM_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
mm;152;R_PBC_SLA_LP_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
mm;152;R_PBC_AMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
mm;152;R_PBC_gp210_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
mm;152;R_PBC_SP100_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
mm;152;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
mm;152;R_PBC_AIH_MMF;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
mm;152;R_PBC_AIH_MMF_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
mm;152;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
mm;152;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
mm;152;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
mm;152;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
mm;152;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
mm;152;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
mm;152;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
mm;152;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
mm;152;R_PSC_AIH_MMF;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
mm;152;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
mm;152;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
mm;152;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
mm;152;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mm;152;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mm;152;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
mm;152;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mm;152;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
mm;152;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mm;152;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
mm;152;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
mm;152;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
mm;152;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
mm;152;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
mm;152;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
mm;152;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mm;152;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
mm;152;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mm;152;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mm;152;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mm;152;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mm;152;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mm;152;R_AIH_ANA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
mm;152;R_AIH_AMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
mm;152;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
mm;152;R_AIH_LKM_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
mm;152;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
mm;152;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
mm;152;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mm;152;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mm;152;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mm;152;R_AIH_MMP_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
mm;152;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mm;152;R_AIH_MMF_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mm;152;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mm;152;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
mm;152;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
mm;152;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
mm;152;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
mm;152;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
mm;152;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
mm;152;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
mm;152;R_PBC_MMP_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
mm;152;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mm;152;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
mm;152;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mm;152;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mm;152;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mm;152;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mm;152;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
mm;152;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mm;152;patient_comments;Diagnosis General Information;Rare Liver (Vascular);Comments;textarea
mm;152;right_atrium_mm_hg;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right atrium;numeric
mm;152;comments_pregnancy;Diagnosis Aetiology;Rare Liver (Vascular);Comments;textarea
mm;152;abd_inflammation_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal infection/inflamation;date
mm;152;abd_inflammation_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of abdominal infection/inflamation;textarea
mm;152;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
mm;152;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
mm;152;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
mm;152;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
mm;152;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
mm;152;Mammographic density;malignancy;Genturis;What is the mammographic density?;categorical
mm;152;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
mm;152;MMR IHC status;malignancy;Genturis;What are the results of the IHC of the MMR proteins?;enum
mm;152;MMR MSA status;malignancy;Genturis;What are the results of the MSA of the tumour DNA?;enum
mm;152;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
mm;152;General comments;;ithaca;;text
mm;152;fu_date_mm;clinical_update;EURACAN;Month of clinical update;
mm;152;ae_start_mm;adverse_event;EURACAN;Adverse event starting month;
mm;152;ae_end_mm;adverse_event;EURACAN;Adverse event ending month;
mm;152;ae_start_mm_2;adverse_event;EURACAN;Second adverse event starting month;
mm;152;ae_end_mm_2;adverse_event;EURACAN;Second adverse event ending month;
mm;152;ae_start_mm_3;adverse_event;EURACAN;Third adverse event starting month;
mm;152;ae_end_mm_3;adverse_event;EURACAN;Third adverse event ending month;
mm;152;ae_start_mm_4;adverse_event;EURACAN;Fourth adverse event starting month;
mm;152;ae_end_mm_4;adverse_event;EURACAN;Fourth adverse event ending month;
mm;152;ae_start_mm_5;adverse_event;EURACAN;Fifth adverse event starting month;
mm;152;ae_end_mm_5;adverse_event;EURACAN;Fifth adverse event ending month;
mm;152;surgery_date_mm;surgery;EURACAN;Month of surgery;
mm;152;immuno;immunotherapy;EURACAN;Immunotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
mm;152;immuno_setting;immunotherapy;EURACAN;Setting;1, neo-adjuvant | 2, concomitant | 3, adjuvant | 4, palliative | 9, unknown
mm;152;immuno_date_from;immunotherapy;EURACAN;Start date;
mm;152;immuno_date_from_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_date_to;immunotherapy;EURACAN;End date;
mm;152;immuno_date_to_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_admin;immunotherapy;EURACAN;Number of administrations;
mm;152;immuno_admin_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_drug_1;immunotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
mm;152;immuno_drug_1_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_drug_2;immunotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
mm;152;immuno_drug_2_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_drug_3;immunotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
mm;152;immuno_drug_3_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_drug_4;immunotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
mm;152;immuno_drug_4_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;immuno_drug_5;immunotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
mm;152;immuno_drug_5_unk;immunotherapy;EURACAN;Unknown;1, Unknown
mm;152;end_treatment_immuno;immunotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
mm;152;end_treat_res_immuno;immunotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
mm;152;other_treatment_date_mm;other_type_of_treatment;EURACAN;Month of other treatment;
mm;152;oth_enrolment_date_mm;other_type_of_treatment;EURACAN;Month of enrolment;
mm;152;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
mm;152;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
mm;152;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
mm;152;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
mm;152;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
mm;152;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
mm;152;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
mm;152;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
mm;152;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
mm;152;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
mm;152;Somatomammotropinoma;PITUITARY;EuRR-Bone & EuRRECa;Somatomammotropinoma;
mm;152;Further comments;Genetic diagnosis;ERKNet;Â ;gen_comment
mm;152;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
mmf;33;R_AIH_MMF;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF;radio
mmf;33;R_AIH_MMF_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
mmf;33;R_PBC_AIH_MMF;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
mmf;33;R_PBC_AIH_MMF_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
mmf;33;R_PSC_AIH_MMF;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
mmf;33;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
mmf;33;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
mmf;33;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mmf;33;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mmf;33;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
mmf;33;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mmf;33;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mmf;33;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mmf;33;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mmf;33;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mmf;33;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mmf;33;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mmf;33;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mmf;33;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mmf;33;R_AIH_MMF_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mmf;33;R_AIH_MMF_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mmf;33;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mmf;33;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
mmf;33;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
mmf;33;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
mmf;33;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
mmf;33;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
mmol;1;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
mmp;8;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
mmp;8;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mmp;8;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
mmp;8;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mmp;8;R_AIH_MMP_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
mmp;8;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mmp;8;R_PBC_MMP_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
mmp;8;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mmr;4;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
mmr;4;MMR IHC status;malignancy;Genturis;What are the results of the IHC of the MMR proteins?;enum
mmr;4;MMR MSA status;malignancy;Genturis;What are the results of the MSA of the tumour DNA?;enum
mmr;4;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
mo;297;Ophthalmoparesis;Diagnosis Eye;EURO-NMD;;yesno
mo;297;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
mo;297;Reduced foetal movements;Diagnosis Developmental;EURO-NMD;;yesno
mo;297;Delayed motor milestones;Diagnosis Developmental;EURO-NMD;;yesno
mo;297;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
mo;297;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
mo;297;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
mo;297;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
mo;297;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
mo;297;If thymoma, WHO Classification:;Thymoma;EURO-NMD;;
mo;297;Thymoma therapy:;Thymoma;EURO-NMD;;
mo;297;If thymoma, relapse?;Thymoma;EURO-NMD;;
mo;297;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
mo;297;R_AIH_Smoking;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
mo;297;is_smoker;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
mo;297;R_AIH_Smoking_amount;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
mo;297;R_AIH_Total_bilirubin_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
mo;297;R_AIH_Creatinine_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
mo;297;R_PBC_Smoking;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
mo;297;PBC_is_smoker;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
mo;297;R_PBC_Smoking_amount;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
mo;297;R_PBC_Total_bilirubin_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
mo;297;R_PBC_Creatinine_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
mo;297;R_PSC_Smoking;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
mo;297;PSC_is_smoker;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
mo;297;R_PSC_Smoking_amount;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount (pack years);numeric
mo;297;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
mo;297;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
mo;297;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
mo;297;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
mo;297;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
mo;297;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
mo;297;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
mo;297;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
mo;297;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
mo;297;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
mo;297;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
mo;297;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
mo;297;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
mo;297;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
mo;297;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
mo;297;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
mo;297;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
mo;297;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
mo;297;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
mo;297;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
mo;297;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mo;297;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mo;297;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
mo;297;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mo;297;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mo;297;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
mo;297;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mo;297;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mo;297;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mo;297;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mo;297;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mo;297;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
mo;297;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mo;297;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mo;297;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
mo;297;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
mo;297;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
mo;297;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
mo;297;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
mo;297;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
mo;297;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
mo;297;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
mo;297;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
mo;297;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
mo;297;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
mo;297;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
mo;297;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
mo;297;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mo;297;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
mo;297;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
mo;297;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
mo;297;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
mo;297;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
mo;297;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
mo;297;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
mo;297;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
mo;297;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
mo;297;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
mo;297;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
mo;297;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
mo;297;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
mo;297;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
mo;297;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
mo;297;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
mo;297;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
mo;297;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
mo;297;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
mo;297;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
mo;297;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
mo;297;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
mo;297;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
mo;297;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
mo;297;date_check_6mo;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);date_check_6mo;calculation
mo;297;date_check_6mons;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date check;calculation
mo;297;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
mo;297;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
mo;297;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
mo;297;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
mo;297;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
mo;297;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
mo;297;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
mo;297;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
mo;297;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
mo;297;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
mo;297;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
mo;297;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
mo;297;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
mo;297;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
mo;297;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
mo;297;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
mo;297;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
mo;297;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
mo;297;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
mo;297;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
mo;297;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
mo;297;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
mo;297;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
mo;297;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
mo;297;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
mo;297;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
mo;297;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
mo;297;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
mo;297;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
mo;297;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
mo;297;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
mo;297;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
mo;297;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
mo;297;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
mo;297;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
mo;297;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
mo;297;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mo;297;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
mo;297;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
mo;297;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
mo;297;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mo;297;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
mo;297;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
mo;297;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
mo;297;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
mo;297;hepatopulmonary_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatopulmonary syndrome;radio
mo;297;smoker;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Smoker;radio
mo;297;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
mo;297;comorbidity_at_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Comorbidity at time of diagnosis;radio
mo;297;comorb_disorders_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other comorbidity disorders;textarea
mo;297;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
mo;297;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
mo;297;homozyg_mthfr_c677t_mut;Diagnosis Aetiology;Rare Liver (Vascular);Homozygous MTHFR-C677T mutation;radio
mo;297;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
mo;297;dia_lab_haemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Haemoglobin;numeric
mo;297;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
mo;297;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
mo;297;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
mo;297;dia_lab_glycated_hemoglobin;Diagnosis Laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
mo;297;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
mo;297;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
mo;297;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
mo;297;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
mo;297;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
mo;297;fu_glycated_hemoglobin;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Glycated hemoglobin;numeric
mo;297;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
mo;297;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
mo;297;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
mo;297;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
mo;297;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
mo;297;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
mo;297;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
mo;297;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
mo;297;Number of ependymomas;benignNeoplasm;Genturis;What is the maximal number of ependymomas ever observed in this patient?;int
mo;297;Malignancy morphology;malignancy;Genturis;What is the morphology of this malignancy?;xref
mo;297;Mammographic density;malignancy;Genturis;What is the mammographic density?;categorical
mo;297;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
mo;297;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
mo;297;Tumour Types(Somatic);;ithaca;;string
mo;297;Tumour Types(Germline);;ithaca;;string
mo;297;Region (in chromosome and band/bands);;ithaca;;string
mo;297;Mosaic;;ithaca;;bool
mo;297;Chromosomale Location;;ithaca;Hugo.owl.Chromosome;string
mo;297;Comorbidities;;ithaca;;compound
mo;297;Other comorbidities;;ithaca;;text
mo;297;smoking_status;patient_management_at_the_hospital;EURACAN;Smoking;1, Current tobacco smoker | 2, Former smoker | 3, Never smoker | 4, Unknown
mo;297;smoking_habits;patient_management_at_the_hospital;EURACAN;Smoking habits;1, Cigarettes | 2, Cigar
mo;297;smoking_per_day;patient_management_at_the_hospital;EURACAN;Cigarettes/cigars smoked per day;
mo;297;smoking_years;patient_management_at_the_hospital;EURACAN;Number of years as a smoker;
mo;297;smoking_pack_year_calc;patient_management_at_the_hospital;EURACAN;Pack/year;"if ([smoking_habits] = ""1"", ([smoking_per_day]/20)*[smoking_years], ([smoking_per_day]/4)*[smoking_years])"
mo;297;smoking_pack_year_man;patient_management_at_the_hospital;EURACAN;Pack/year (manual);
mo;297;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
mo;297;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
mo;297;comorbid_ynu;charlson_index;EURACAN;Comorbidity;1, Yes | 2, No | 9, Unknown
mo;297;comorbid;charlson_index;EURACAN;Choose all present comorbidities;1, Myocardial infarct (+1) | 2, Congestive heart failure (+1) | 3, Peripheral vascular disease (+1) | 4, Cerebrovascular disease (except hemiplegia) (+1) | 5, Dementia (+1) | 6, Chronic pulmonary disease (+1) | 7, Connective tissue disease (+1) | 8, Ulcer disease (+1) | 9, Mild liver disease (+1) | 17, Moderate or severe liver disease (+3) | 10, Diabetes (without complications) (+1) | 11, Diabetes with end organ damage (+2) | 12, Hemiplegia (+2) | 13, Moderate or severe renal disease (+2) | 14, Solid tumor (non metastatic) (+2) | 18, Metastatic solid tumor (+6) | 15, Leukemia (+2) | 16, Lymphoma, Multiple myeloma (+2) | 19, AIDS (+6)
mo;297;site_squamous;primary_cancer;EURACAN;Squamous subtype;1, Keratinizing squamous cell carcinoma | 8071/3 | 2, Non-keratinizing squamous cell carcinoma | 8072/3 | 3, Spindle cell (sarcomatoid) squamous cell carcinoma | 8074/3 | 4, Lymphoepithelial carcinoma | 8082/3 | 5, Basaloid squamous cell carcinoma | 8083/3 | 6, Conventional squamous cell carcinoma | 8070/3 | 7, Verrucous squamous cell carcinoma | 8051/3 | 8, Papillary squamous cell carcinoma | 8052/3 | 9, Squamous cell carcinoma, HPV-positive | 8085/3 | 10, Squamous cell carcinoma, HPV-negative | 8086/3
mo;297;site_squamous_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
mo;297;chemo;chemotherapy;EURACAN;Chemotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
mo;297;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
mo;297;chemo_date_from;chemotherapy;EURACAN;Start date;
mo;297;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_date_to;chemotherapy;EURACAN;End date;
mo;297;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_cycle;chemotherapy;EURACAN;Number of cycles;
mo;297;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_drug_1;chemotherapy;EURACAN;Drug 1;BIOPORTAL:ATC
mo;297;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_drug_2;chemotherapy;EURACAN;Drug 2;BIOPORTAL:ATC
mo;297;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_drug_3;chemotherapy;EURACAN;Drug 3;BIOPORTAL:ATC
mo;297;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_drug_4;chemotherapy;EURACAN;Drug 4;BIOPORTAL:ATC
mo;297;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_drug_5;chemotherapy;EURACAN;Drug 5;BIOPORTAL:ATC
mo;297;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
mo;297;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
mo;297;ebv_dna_chemo;chemotherapy;EURACAN;Plasmatic EBV DNA during/after chemotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
mo;297;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
mo;297;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
mo;297;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
mo;297;Paraffin tumor tissue;Pathology;PaedCan;;yes/no/unknown
mo;297;Frozen tumor ;Pathology;PaedCan;;yes/no/unknown
mo;297;Molecular abnormalities  ;Pathology;PaedCan;Molecular abnormalities detected in the tumor tissue;yes/no/unknown
mo;297;I yes, specify the most relevant;Pathology;PaedCan;;String
mo;297;Tumor size;Tumor's characteristics;PaedCan;Maximum diameter of the tumor;a/b/x
mo;297;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
mo;297;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
mo;297;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
mo;297;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
mo;297;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
mo;297;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
mo;297;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
mo;297;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
mo;297;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
mo;297;In case of a second tumor please specify the type;Events;PaedCan;;String
mo;297;Please give more details about the treatment of the event;Events;PaedCan;;String
mo;297;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
mo;297;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
mo;297;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
mo;297;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
mo;297;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
mo;297;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
mo;297;MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;MODY;
mo;297;HNF4A-MODY1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A-MODY1;
mo;297;GCK-MODY2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;GCK-MODY2;
mo;297;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
mo;297;HNF1B-MODY5;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1B-MODY5;
mo;297;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
mo;297;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
mo;297;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
mo;297;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
mo;297;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
mo;297;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
mo;297;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
mo;297;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
mo;297;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
mo;297;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
mo;297;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
mo;297;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
mo;297;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
mo;297;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
mo;297;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
mo;297;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
mo;297;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
mo;297;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
mo;297;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
mo;297;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
mo;297;MEHMO syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MEHMO syndrome;
mo;297;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
mo;297;MOMO syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MOMO syndrome;
mo;297;MORM syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MORM syndrome;
mo;297;Somatomammotropinoma;PITUITARY;EuRR-Bone & EuRRECa;Somatomammotropinoma;
mo;297;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
mo;297;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
mo;297;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
mo;297;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
mo;297;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
mo;297;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
mo;297;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
mo;297;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
mo;297;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
mo;297;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
mo;297;Monostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Monostotic fibrous dysplasia ;
mo;297;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
mo;297;Omodysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Omodysplasia ;
mody;10;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
mody;10;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
mody;10;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
mody;10;MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;MODY;
mody;10;HNF4A-MODY1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF4A-MODY1;
mody;10;GCK-MODY2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;GCK-MODY2;
mody;10;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
mody;10;HNF1B-MODY5;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1B-MODY5;
mody;10;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
mody;10;Omodysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Omodysplasia ;
molecular;1;Molecular abnormalities  ;Pathology;PaedCan;Molecular abnormalities detected in the tumor tissue;yes/no/unknown
momo;1;MOMO syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MOMO syndrome;
monostotic;1;Monostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Monostotic fibrous dysplasia ;
month;120;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
month;120;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
month;120;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
month;120;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
month;120;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
month;120;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
month;120;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
month;120;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
month;120;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
month;120;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
month;120;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
month;120;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
month;120;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
month;120;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
month;120;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
month;120;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
month;120;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
month;120;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
month;120;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
month;120;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
month;120;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
month;120;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
month;120;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
month;120;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
month;120;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
month;120;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
month;120;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
month;120;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
month;120;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
month;120;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
month;120;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
month;120;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
month;120;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
month;120;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
month;120;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
month;120;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
month;120;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
month;120;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
month;120;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
month;120;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
month;120;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
month;120;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
month;120;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
month;120;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
month;120;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
month;120;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
month;120;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
month;120;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
month;120;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
month;120;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
month;120;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
month;120;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
month;120;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
month;120;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
month;120;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
month;120;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
month;120;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
month;120;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
month;120;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
month;120;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
month;120;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
month;120;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
month;120;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
month;120;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
month;120;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
month;120;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
month;120;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
month;120;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
month;120;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
month;120;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
month;120;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
month;120;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
month;120;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
month;120;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
month;120;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
month;120;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
month;120;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
month;120;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
month;120;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
month;120;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
month;120;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
month;120;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
month;120;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
month;120;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
month;120;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
month;120;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
month;120;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
month;120;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
month;120;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
month;120;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
month;120;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
month;120;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
month;120;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
month;120;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
month;120;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
month;120;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
month;120;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
month;120;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
month;120;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
month;120;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
month;120;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
month;120;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
month;120;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
month;120;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
month;120;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
month;120;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
month;120;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
month;120;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
months;117;R_AIH_AST_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);AST;numeric
months;117;R_AIH_ALT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);ALT;numeric
months;117;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
months;117;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
months;117;R_AIH_ALP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
months;117;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
months;117;R_AIH_Albumin_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Albumin;numeric
months;117;R_AIH_Creatinine_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (mg/dL);numeric
months;117;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
months;117;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
months;117;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
months;117;R_AIH_IgG_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgG;numeric
months;117;R_AIH_IgM_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgM;numeric
months;117;R_AIH_IgA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);IgA;numeric
months;117;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
months;117;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
months;117;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
months;117;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
months;117;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
months;117;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
months;117;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
months;117;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
months;117;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
months;117;R_AIH_Budesonide_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
months;117;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
months;117;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
months;117;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
months;117;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
months;117;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
months;117;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
months;117;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
months;117;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
months;117;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
months;117;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
months;117;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
months;117;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
months;117;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
months;117;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Budesonide_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide;radio
months;117;R_AIH_Budesonide_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Budesonide dose;numeric
months;117;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
months;117;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
months;117;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
months;117;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
months;117;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
months;117;R_AIH_MMP_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP;numeric
months;117;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
months;117;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
months;117;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
months;117;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
months;117;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
months;117;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_MMF_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
months;117;R_AIH_MMF_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF dose;numeric
months;117;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
months;117;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
months;117;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Infliximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Infliximab;radio
months;117;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
months;117;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
months;117;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
months;117;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
months;117;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
months;117;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
months;117;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
months;117;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
months;117;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
months;117;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
months;117;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
months;117;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
months;117;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
months;117;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
months;117;R_AIH_Date_of_followup_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of follow-up;string
months;117;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
months;117;R_AIH_Liver_imaging_consistent_with_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
months;117;R_AIH_Date_imaging_consistent_cirrhosis_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date liver imaging consistent with cirrhosis;date
months;117;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
months;117;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
months;117;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
months;117;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
months;117;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
months;117;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
months;117;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
months;117;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
months;117;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
months;117;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
months;117;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
months;117;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
months;117;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
months;117;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
months;117;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
months;117;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
months;117;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
months;117;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
months;117;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
months;117;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
months;117;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
months;117;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
months;117;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
months;117;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
months;117;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
months;117;R_AIH_Height_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Height;numeric
months;117;R_AIH_BMI_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);BMI;calculation
months;117;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
months;117;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
months;117;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
months;117;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
months;117;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
more;1;Please give more details about the treatment of the event;Events;PaedCan;;String
morm;1;MORM syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MORM syndrome;
morphology;1;Malignancy morphology;malignancy;Genturis;What is the morphology of this malignancy?;xref
most;3;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
most;3;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
most;3;I yes, specify the most relevant;Pathology;PaedCan;;String
motor;1;Delayed motor milestones;Diagnosis Developmental;EURO-NMD;;yesno
mouth;1;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
move;2;Reduced foetal movements;Diagnosis Developmental;EURO-NMD;;yesno
move;2;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
movements;1;Reduced foetal movements;Diagnosis Developmental;EURO-NMD;;yesno
mpd;1;type_of_mpd;Diagnosis Aetiology;Rare Liver (Vascular);Type of MPD;radio
mpl;44;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
mpl;44;R_AIH_Simplified_AIH_score;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Simplified AIH score;numeric
mpl;44;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
mpl;44;R_AIH_Biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
mpl;44;R_AIH_Other_biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
mpl;44;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
mpl;44;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
mpl;44;R_PBC_Biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
mpl;44;R_PBC_Other_biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
mpl;44;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
mpl;44;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
mpl;44;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
mpl;44;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
mpl;44;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
mpl;44;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
mpl;44;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
mpl;44;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
mpl;44;R_AIH_Biosamples_stored;AIH Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
mpl;44;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
mpl;44;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
mpl;44;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
mpl;44;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
mpl;44;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
mpl;44;edta_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample obtained?;radio
mpl;44;edta_sample_date;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample date;date
mpl;44;urine_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);Urine sample obtained?;dropdown
mpl;44;urin_sample_date;Diagnosis Biobank;Rare Liver (Vascular);Urine sample date;date
mpl;44;mpl_mutation;Diagnosis Aetiology;Rare Liver (Vascular);MPL mutation (myeloproliferative leukemia);radio
mpl;44;Patient's biological sample available for researchÂ ;;ithaca;;bool
mpl;44;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
mpl;44;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
mpl;44;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
mpl;44;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
mpl;44;Specify complications;Surgery;PaedCan;Definition of complication;String
mpl;44;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
mpl;44;Carney Complex;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney Complex;
mpl;44;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
mpl;44;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
mpl;44;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
mpl;44;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
mpl;44;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
mpl;44;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
mpl;44;Complex genital anomalies;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complex genital anomalies;
mpl;44;Complete gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Complete gonadal dysgenesis;
mpv;2;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
mpv;2;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
mrcp;4;R_AIH_MRCP_or_ERCP;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Cholangiography (MRCP or ERCP);radio
mrcp;4;R_PSC_MRCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);MRCP;radio
mrcp;4;R_AIH_MRCP_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);MRCP;radio
mrcp;4;R_AIH_MRCP_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);MRCP;radio
mri;9;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
mri;9;mri;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);MRI;radio
mri;9;mri_cholangio;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cholangio MRI;radio
mri;9;mri_primary;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
mri;9;mri_neck;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
mri;9;mri_meta;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
mri;9;end_treatment_mri;imaging_available;EURACAN;MRI;1, Baseline | 2, After treatment
mri;9;Fetal MRI ;Imaging;ERKNet;Â ;Â 
mri;9;(postnatal) MRI ;Imaging;ERKNet;Â ;Â 
mrks;1;MRKS;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;MRKS;
msa;1;MMR MSA status;malignancy;Genturis;What are the results of the MSA of the tumour DNA?;enum
mthfr;1;homozyg_mthfr_c677t_mut;Diagnosis Aetiology;Rare Liver (Vascular);Homozygous MTHFR-C677T mutation;radio
mullerian;2;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
mullerian;2;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
multiple;9;Multiple endocrine neoplasia;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia;
multiple;9;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
multiple;9;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
multiple;9;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
multiple;9;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
multiple;9;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
multiple;9;Noonan syndrome with multiple lentigines;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome with multiple lentigines;
multiple;9;Multiple osteochondroma;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple osteochondroma;
multiple;9;Multiple metaphyseal dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple metaphyseal dysplasia;
murcs;1;MURCS;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;MURCS;
muscle;13;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
muscle;13;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
muscle;13;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
muscle;13;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
muscle;13;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
muscle;13;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
muscle;13;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
muscle;13;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
muscle;13;Neck muscle weakness;Diagnosis Muscular;EURO-NMD;Neck weakness;yesno
muscle;13;Skeletal muscle atrophy;Diagnosis Muscular;EURO-NMD;Muscle wasting;yesno
muscle;13;Facial Muscles;QMG;EURO-NMD;;
muscle;13;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
muscle;13;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
muscles;2;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
muscles;2;Facial Muscles;QMG;EURO-NMD;;
musculature;1;Weakness of facial musculature;Diagnosis Muscular;EURO-NMD;Facial weakness;yesno
musk;4;MuSK (standard, RIA);Diagnosis ;EURO-NMD;;single
musk;4;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
musk;4;MuSK (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
musk;4;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
mut;27;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
mut;27;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
mut;27;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
mut;27;prot_c_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein C mutation;radio
mut;27;prot_s1_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein S mutation;radio
mut;27;at_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin mutation;radio
mut;27;jak_2_mutation_v617f;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Mutation (V617F);radio
mut;27;new_jak_2_mutation_d620e;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Exon-12;radio
mut;27;calr_mutation;Diagnosis Aetiology;Rare Liver (Vascular);CALR mutation;radio
mut;27;mpl_mutation;Diagnosis Aetiology;Rare Liver (Vascular);MPL mutation (myeloproliferative leukemia);radio
mut;27;homozyg_mthfr_c677t_mut;Diagnosis Aetiology;Rare Liver (Vascular);Homozygous MTHFR-C677T mutation;radio
mut;27;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
mut;27;Somatic Mutation as included in COSMIC;;ithaca;;text
mut;27;Type of mutation;;ithaca;;mref
mut;27;Germline mutations;Patient's history;PaedCan;Report if any specific genetic abnormallitis have been detected in the patient;yes/no/unknown
mut;27;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
mut;27;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
mut;27;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
mut;27;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
mut;27;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
mut;27;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
mut;27;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
mut;27;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
mut;27;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
mut;27;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
mut;27;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
mut;27;Diagnosis - Mutation;Genetic diagnosis;ERKNet;Â ;Â 
mutation;26;factor_v_leiden_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Factor V leiden mutation;radio
mutation;26;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
mutation;26;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
mutation;26;prot_c_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein C mutation;radio
mutation;26;prot_s1_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein S mutation;radio
mutation;26;at_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin mutation;radio
mutation;26;jak_2_mutation_v617f;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Mutation (V617F);radio
mutation;26;new_jak_2_mutation_d620e;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Exon-12;radio
mutation;26;calr_mutation;Diagnosis Aetiology;Rare Liver (Vascular);CALR mutation;radio
mutation;26;mpl_mutation;Diagnosis Aetiology;Rare Liver (Vascular);MPL mutation (myeloproliferative leukemia);radio
mutation;26;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
mutation;26;Somatic Mutation as included in COSMIC;;ithaca;;text
mutation;26;Type of mutation;;ithaca;;mref
mutation;26;Germline mutations;Patient's history;PaedCan;Report if any specific genetic abnormallitis have been detected in the patient;yes/no/unknown
mutation;26;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
mutation;26;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
mutation;26;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
mutation;26;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
mutation;26;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
mutation;26;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
mutation;26;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
mutation;26;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
mutation;26;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
mutation;26;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
mutation;26;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
mutation;26;Diagnosis - Mutation;Genetic diagnosis;ERKNet;Â ;Â 
mutations;3;Germline mutations;Patient's history;PaedCan;Report if any specific genetic abnormallitis have been detected in the patient;yes/no/unknown
mutations;3;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
mutations;3;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
myelomonocytic;1;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
mymol;6;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
mymol;6;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
mymol;6;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
mymol;6;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
mymol;6;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
mymol;6;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
myopathic;1;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
myopia-midfacial;1;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
nafld;6;R_AIH_Additional_nafld;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
nafld;6;R_PBC_Additional_nafld;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
nafld;6;R_PSC_Additional_nafld;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
nafld;6;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
nafld;6;R_AIH_Additional_nafld_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
nafld;6;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
nakanamuma;1;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
nakanuma;39;R_PBC_Nakanuma_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed?;radio
nakanuma;39;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
nakanuma;39;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
nakanuma;39;R_PBC_nakanuma_grading_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
nakanuma;39;R_PBC_Fibrosis_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
nakanuma;39;R_PBC_Bile_duct_loss_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
nakanuma;39;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
nakanuma;39;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
nakanuma;39;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
nakanuma;39;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
nakanuma;39;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
nakanuma;39;R_PSC_Fibrosis_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
nakanuma;39;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
nakanuma;39;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
nakanuma;39;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
nakanuma;39;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
nakanuma;39;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
nakanuma;39;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
nakanuma;39;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
nakanuma;39;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
nakanuma;39;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
nakanuma;39;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
nakanuma;39;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
nakanuma;39;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
nakanuma;39;R_AIH_Cholangitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Cholangitis activity;numeric
nakanuma;39;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
nakanuma;39;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
nakanuma;39;R_AIH_Fibrosis_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis;numeric
nakanuma;39;R_AIH_Bile_duct_loss_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Bile duct loss;numeric
nakanuma;39;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
nakanuma;39;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
nakanuma;39;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
nakanuma;39;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
nakanuma;39;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
nakanuma;39;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
nakanuma;39;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
nakanuma;39;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
nakanuma;39;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
nakanuma;39;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
name;12;Name of the gene;geneticVariant;Genturis;Gene (cosmic);xref
name;12;name;;ithaca;;string
name;12;Genname;;ithaca;Hugo.owl.Approved_Symbol;string
name;12;Institution name ERN/HCP;;ithaca;;string
name;12;First name;;ithaca;;string
name;12;Last name;;ithaca;;string
name;12;Full name;;ithaca;;string
name;12;First name;;ithaca;;string
name;12;Last name;;ithaca;;string
name;12;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
name;12;name;;ithaca;hgvs notation for this allele. Format (NM_004006.2:c.4375C>T);string
name;12;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
names;1;Names of different Immunomarkers;Immunological evaluation;ERKNet;Â ;"99=Not tested, 0=normal, 1=low, 2=elevated ;
99=Not tested, 0=negative, 1=positive / low;
â€¦"
nasal;2;Nasal regurgitation;Bulbar/Gi ;EURO-NMD;;single
nasal;2;site_nasal_cavity;primary_cancer;EURACAN;Subsite;1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS
nash;6;R_AIH_Additional_nash;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
nash;6;R_PBC_Additional_nash;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
nash;6;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
nash;6;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
nash;6;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
nash;6;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
nasogastric;3;Nasogastric tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
nasogastric;3;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
nasogastric;3;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
nasopharynx;1;site_nasopharynx;primary_cancer;EURACAN;Subsite;1, C11 nasopharynx | 2, C11.0  Superior wall of nasopharynx | 3, C11.1  Posterior wall of nasopharynx | 4, C11.2  Lateral wall of nasopharynx | 5, C11.3  Anterior wall of nasopharynx | 6, C11.8  Overlapping lesion of nasopharynx | 7, C11.9  Nasopharynx, NOS
national;4;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
national;4;National Identifier (if applicable);Identifiers;PaedCan;;String
national;4;Referral to VRT board (national or international) ;Care pathway;PaedCan;The case has been discussed within an official national or international VRT board for diagnosis and/or treatment;no/yes in the EXPERT Virtual consultation system/ yes in another tumor board
national;4;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
native;1;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
natural-killer;1;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
nciph;2;nciph;Diagnosis Aetiology;Rare Liver (Vascular);Non cirrhotic idiopathic portal hypertension;radio
nciph;2;date_nciph;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
neck;12;Neck muscle weakness;Diagnosis Muscular;EURO-NMD;Neck weakness;yesno
neck;12;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
neck;12;ct_neck;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
neck;12;mri_neck;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
neck;12;imag_neck;stage_procedures;EURACAN;Imaging for neck;1, Yes | 2, No | 9, Unknown
neck;12;us_neck;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
neck;12;fdg_pet_neck;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
neck;12;pet_oth_neck;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
neck;12;optical_methods_neck;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
neck;12;ct_pet_neck;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
neck;12;imag_neck_oth;stage_procedures;EURACAN;Other imaging for neck;
neck;12;neck_dissection;surgery;EURACAN;Neck dissection;1, Yes | 2, No | 9, Unknown
neonatal;5;Neonatal adrenoleukodystrophy;ADRENAL;EuRR-Bone & EuRRECa;Neonatal adrenoleukodystrophy;
neonatal;5;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
neonatal;5;Neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes;
neonatal;5;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
neonatal;5;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
neopl;11;benignNeoplasmLabel;benignNeoplasm;Genturis;;string
neopl;11;Benign neoplasms;subject;Genturis;;compound
neopl;11;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
neopl;11;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
neopl;11;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
neopl;11;Multiple endocrine neoplasia;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia;
neopl;11;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
neopl;11;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
neopl;11;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
neopl;11;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
neopl;11;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
neoplasia;6;Multiple endocrine neoplasia;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia;
neoplasia;6;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
neoplasia;6;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
neoplasia;6;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
neoplasia;6;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
neoplasia;6;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
neoplasms;1;Benign neoplasms;subject;Genturis;;compound
neoplastic;2;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
neoplastic;2;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
nephrectomy;1;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
nephrolithiasis;1;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
nephropathy-deafness-hyperparathyroidism;1;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
nephrotic;1;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
neprectomy;1;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
nerve;1;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
neuroend;2;site_neuroendocrine;primary_cancer;EURACAN;Neuroendocrine subtype;1, Small cell neuroendocrine carcinoma (SmCC) | 8041/3 | 2, Large cell neuroendocrine carcinoma (LCNEC) | 8013/3 | 3, Well-differentiated neuroendocrine carcinoma | 8240/3 | 4, Moderately differentiated neuroendocrine carcinoma | 8249/3 | 5, Sinonasal undifferentiated carcinoma | 8020/3
neuroend;2;site_neuroend_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
neuroendocrine;1;site_neuroendocrine;primary_cancer;EURACAN;Neuroendocrine subtype;1, Small cell neuroendocrine carcinoma (SmCC) | 8041/3 | 2, Large cell neuroendocrine carcinoma (LCNEC) | 8013/3 | 3, Well-differentiated neuroendocrine carcinoma | 8240/3 | 4, Moderately differentiated neuroendocrine carcinoma | 8249/3 | 5, Sinonasal undifferentiated carcinoma | 8020/3
neurofibromatosis-noonan;1;Neurofibromatosis-Noonan syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Neurofibromatosis-Noonan syndrome;
neuropathic;1;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
neutrophils;1;dia_lab_neutrophils;Diagnosis Laboratory data;Rare Liver (Vascular);Neutrophils;numeric
new;10;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
new;10;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
new;10;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
new;10;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
new;10;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
new;10;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
new;10;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
new;10;new_jak_2_mutation_d620e;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Exon-12;radio
new;10;new_cancer_idco3;clinical_update;EURACAN;New cancer ICD-O3;for later
new;10;Dahlberg-Borer-Newcomer syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dahlberg-Borer-Newcomer syndrome;
nf1;4;NF1 relative;subject;Genturis;"Has the patient a first degree relative with NF1 who has been diagnosed according to the following criteria: Presence of two or more of the following diagnostic criteria in the first degree relative:
1) Six or more cafÃ© au lait spots (> 5mm in greatest diameter in prepuberal patient  and >15mm in greatest diameter in postpuberal patient)
2) Two or more neurofibromas or one plexiform neurofibromas
3) Axillary or inguinal freckling
4) Optic glioma
5) Two or more lisch nodules (iris hamartomas)
6) A distinct osseous lesion";enum
nf1;4;HNF1A-MODY3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1A-MODY3;
nf1;4;HNF1B-MODY5;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;HNF1B-MODY5;
nf1;4;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
nievergelt;1;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
nigricans-insulin;1;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
nodb;1;aza_nodb;PSC Follow-up Treatment;Rare Liver (Auto imune);aza_aih check;calculation
node;11;node_picking;surgery;EURACAN;Node picking;1, Yes | 2, No | 9, Unknown
node;11;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
node;11;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
node;11;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
node;11;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
node;11;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
node;11;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
node;11;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
node;11;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
node;11;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
node;11;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
nodule;5;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
nodule;5;largest_nodule_size;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Largest nodule size;numeric
nodule;5;number_of_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of nodules;radio
nodule;5;fu_ima_bef_nodules;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
nodule;5;fu_ima_last_nodules;Follow-up Imaging data;Rare Liver (Vascular);BCS-type, or HNF-like, nodules;radio
nodules;4;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
nodules;4;number_of_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of nodules;radio
nodules;4;fu_ima_bef_nodules;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
nodules;4;fu_ima_last_nodules;Follow-up Imaging data;Rare Liver (Vascular);BCS-type, or HNF-like, nodules;radio
non;20;non-invasive ventilation;Respiratory Myasthenic crisis;EURO-NMD;;single
non;20;Synonyms;;ithaca;;string
non;20;Synonyms;;ithaca;;text
non;20;Synonym;;ithaca;Hugo.owl.Aliases;string
non;20;synonyms;;ithaca;;text
non;20;Synonyms;;ithaca;;text
non;20;Synonyms;;ithaca;;text
non;20;synonyms;;ithaca;;string
non;20;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
non;20;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
non;20;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
non;20;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
non;20;Non syndromic limb overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non syndromic limb overgrowth;
non;20;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
non;20;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
non;20;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
non;20;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
non;20;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
non;20;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
non;20;Non-specific;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Non-specific;
non-acquired;3;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
non-acquired;3;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
non-acquired;3;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
non-functioning;1;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
non-invasive;1;non-invasive ventilation;Respiratory Myasthenic crisis;EURO-NMD;;single
non-specific;1;Non-specific;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Non-specific;
non-syndromic;2;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
non-syndromic;2;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
noonan;7;Noonan Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan Syndrome;
noonan;7;Neurofibromatosis-Noonan syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Neurofibromatosis-Noonan syndrome;
noonan;7;Noonan syndrome and Noonan-related syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome and Noonan-related syndrome;
noonan;7;Noonan syndrome with multiple lentigines;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome with multiple lentigines;
noonan;7;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
noonan;7;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
noonan;7;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
noonan-related;1;Noonan syndrome and Noonan-related syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome and Noonan-related syndrome;
normal;21;EMG abnormality;Diagnosis EMG;EURO-NMD;;single
normal;21;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
normal;21;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
normal;21;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
normal;21;pc_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time at testing;radio
normal;21;ps_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
normal;21;at_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
normal;21;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
normal;21;dia_lab_alt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);ALT normal value;numeric
normal;21;dia_lab_ast_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);AST normal value;numeric
normal;21;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
normal;21;dia_lab_ggt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);GGT normal value;numeric
normal;21;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
normal;21;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
normal;21;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
normal;21;fu_cli_bef_pt_normal_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
normal;21;Phenotypic Abnormality (HPO);;ithaca;;mref
normal;21;Molecular abnormalities  ;Pathology;PaedCan;Molecular abnormalities detected in the tumor tissue;yes/no/unknown
normal;21;AMH normal;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;AMH normal;
normal;21;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
normal;21;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
normosmic;1;Normosmic congenital hypogonadotropic hypogonadism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Normosmic congenital hypogonadotropic hypogonadism;
note;1;end_treatment_note;imaging_available;EURACAN;Imaging after treatment available at the hospital?;
nr;32;R_AIH_INR;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;R_PBC_INR;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;R_PSC_INR;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;R_AIH_INR_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;R_AIH_INR_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;R_PBC_INR_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
nr;32;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
nr;32;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
nr;32;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nr;32;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
nr;32;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nr;32;Patient enrolment;;ithaca;;compound
nr;32;Date enrolled;;ithaca;;date
nr;32;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
nr;32;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
nr;32;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
nr;32;lnr_ratio;surgery;EURACAN;LNR (Lymph node ratio);([surgery_nr_pos_lymphnodes]/[surgery_nr_lymphnodes])
nr;32;surgery_nr_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
nr;32;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
nr;32;radio_photons_nrfract;radiotherapy;EURACAN;Photons number fraction;
nr;32;radio_electrons_nrfract;radiotherapy;EURACAN;Electrons number fraction;
nr;32;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
nr;32;radio_carbons_nrfract;radiotherapy;EURACAN;Carbons number fraction ;
nr;32;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
nr;32;radio_radionuc_nrfract;radiotherapy;EURACAN;Radionuclide number fraction ;
nr;32;radio_boron_nrfract;radiotherapy;EURACAN;Boron neutron capture therapy number fraction ;
nr;32;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
nr;32;oth_enrolment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of enrolment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{oth_enrolment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{oth_enrolment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{oth_enrolment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
nr;32;oth_enrolment_date;other_type_of_treatment;EURACAN;Date of enrolment;
nr;32;oth_enrolment_date_mm;other_type_of_treatment;EURACAN;Month of enrolment;
nr;32;oth_enrolment_date_yyyy;other_type_of_treatment;EURACAN;Year of enrolment;
nrfract;8;radio_photons_nrfract;radiotherapy;EURACAN;Photons number fraction;
nrfract;8;radio_electrons_nrfract;radiotherapy;EURACAN;Electrons number fraction;
nrfract;8;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
nrfract;8;radio_carbons_nrfract;radiotherapy;EURACAN;Carbons number fraction ;
nrfract;8;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
nrfract;8;radio_radionuc_nrfract;radiotherapy;EURACAN;Radionuclide number fraction ;
nrfract;8;radio_boron_nrfract;radiotherapy;EURACAN;Boron neutron capture therapy number fraction ;
nrfract;8;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
nsd1;1;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
nuclear;3;dia_lab_antinuclear_antibodies;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies;radio
nuclear;3;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
nuclear;3;Nuclear isotope scan;Imaging;ERKNet;Â ;Â 
null;1;Null pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Null pituitary adenoma;
number;25;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
number;25;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
number;25;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
number;25;number_of_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of nodules;radio
number;25;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
number;25;liver_biopsy_number;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy local number;string
number;25;buffy_coat_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
number;25;dna_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
number;25;plasma_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
number;25;serum_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
number;25;number_miscarriagies;Diagnosis Aetiology;Rare Liver (Vascular);Number of miscarriages;radio
number;25;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
number;25;Number of polyps;benignNeoplasm;Genturis;What is the maximal number of these polyps ever observed in this patient?;int
number;25;Number of vestibular schwannoma;benignNeoplasm;Genturis;What is the maximal number of vestibular schwannomas ever observed in this patient?;int
number;25;Number of meningioma;benignNeoplasm;Genturis;What is the maximal number of meningiomas ever observed in this patient?;int
number;25;Number of ependymomas;benignNeoplasm;Genturis;What is the maximal number of ependymomas ever observed in this patient?;int
number;25;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
number;25;Number of Cafe au lait spot;subject;Genturis;What is the maximal number of cafe au lait spots ever observed in the patient?;int
number;25;Number of copies / UPD;;ithaca;;categorical
number;25;ERN/HCP number;Organisations;ithaca;;string
number;25;Phone number;;ithaca;;string
number;25;copy_number_baseline;primary_cancer;EURACAN;Copy Number;
number;25;copy_number_chemo;chemotherapy;EURACAN;Copy Number;
number;25;copy_number_radio;radiotherapy;EURACAN;Copy Number;
number;25;Number of metastasis;Tumor's characteristics;PaedCan;Definition of the number of metastases for every site;singular/multiple
nvalue;15;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nvalue;15;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nvalue;15;fu_cli_bef_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
nvalue;15;fu_cli_bef_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
nvalue;15;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
nvalue;15;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
nvalue;15;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
nvalue;15;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nvalue;15;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nvalue;15;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
nvalue;15;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
nvalue;15;fu_cli_last_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
nvalue;15;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
nvalue;15;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
nvalue;15;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
obesity;20;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
obesity;20;Overgrowth/obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth/obesity syndrome;
obesity;20;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
obesity;20;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
obesity;20;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
obesity;20;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
obesity;20;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
obesity;20;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
obesity;20;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
obesity;20;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
obesity;20;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
obesity;20;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
obesity;20;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
obesity;20;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
obesity;20;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
obesity;20;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
obesity;20;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
obesity;20;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
obesity;20;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
obesity;20;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
obesity-insulin;2;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
obesity-insulin;2;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
obstructed;1;ivc_obstructed_or_stenosed;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Level of obstruction;radio
obtained;7;liver_biopsy_obtained;Diagnosis Biobank;Rare Liver (Vascular);Frozen liver biopsy obtained?;dropdown
obtained;7;edta_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample obtained?;radio
obtained;7;buffy_coat_obtained;Diagnosis Biobank;Rare Liver (Vascular);Buffy coat sample obtained ?;dropdown
obtained;7;dna_obtained;Diagnosis Biobank;Rare Liver (Vascular);DNA sample obtained?;dropdown
obtained;7;plasma_obtained;Diagnosis Biobank;Rare Liver (Vascular);Plasma sample obtained?;dropdown
obtained;7;serum_obtained;Diagnosis Biobank;Rare Liver (Vascular);Serum sample obtained?;dropdown
obtained;7;urine_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);Urine sample obtained?;dropdown
oca;28;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
oca;28;R_PBC_OCA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
oca;28;R_PBC_OCA_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);OCA dose;numeric
oca;28;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
oca;28;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
oca;28;R_AIH_PBC_OCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
oca;28;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
oca;28;R_PBC_OCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
oca;28;R_PBC_OCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
oca;28;Genome Location;;ithaca;;string
oca;28;Chromosomale Location;;ithaca;Hugo.owl.Chromosome;string
oca;28;site_adenocarcinoma;primary_cancer;EURACAN;Adenocarcinoma subtype;1, Intestinal-type adenocarcinoma | 8144/3 | 2, Non-intestinal-type adenocarcinoma  (adk, NOS) | 8140/3 | 3, Nasopharyngeal papillary adenocarcinoma | 8260/3 | 4, Adenoid cystic carcinoma | 8200/3 | 5, Mucoepidermoid carcinoma | 8430/3 | 6, Polymorphous adenocarcinoma | 8525/3 | 7, Acinic cell carcinoma | 8550/3 | 8, Clear cell carcinoma | 8310/3 | 9, Basal cell adenocarcinoma | 8147/3 | 10, Salivary duct carcinoma | 8500/3 | 11, Myoepithelial carcinoma |8982/3 | 12, Epithelial-myoepithelial carcinoma | 8562/3 | 13, Carcinoma ex pleomorphic adenoma | 8941/3 | 14, Secretory carcinoma | 8542/3 | 15, Sebaceous adenocarcinoma | 8410/3 | 16, Carcinosarcoma | 8980/3 | 17, Oncocytic carcinoma | 8290/3 | 18, Adenocarcinoma | 8420/3
oca;28;fu_awd_local;clinical_update;EURACAN;AWD, Local;1, Yes | 2, No | 3, Unknown
oca;28;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
oca;28;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
oca;28;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
oca;28;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
oca;28;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
oca;28;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
oca;28;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
oca;28;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
oca;28;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
oca;28;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
oca;28;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
oca;28;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
oca;28;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
oca;28;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
oca;28;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
occlusion;2;pv_occlusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion;radio
occlusion;2;pv_occlusion_type;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion type;radio
occurred;1;An event has occurred;Events;PaedCan;If any event has occurred ;yes/no/unknown
odontohypophosphatasia;1;Odontohypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Odontohypophosphatasia ;
oedema;2;weight_w_o_ascites_oedema;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Estimated weight without ascites and oedema;numeric
oedema;2;oedema_lower_limbs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Oedema of lower limbs;radio
oi;75;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
oi;75;R_AIH_FDR_with_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
oi;75;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
oi;75;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
oi;75;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
oi;75;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
oi;75;sys_sarcoidosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Sarcoidosis;radio
oi;75;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
oi;75;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
oi;75;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
oi;75;ae_ongoing;adverse_event;EURACAN;Adverse event ongoing;1, Yes | 2, No
oi;75;ae_ongoing_2;adverse_event;EURACAN;Second adverse event ongoing;1, Yes | 2, No
oi;75;ae_ongoing_3;adverse_event;EURACAN;Third adverse event ongoing;1, Yes | 2, No
oi;75;ae_ongoing_4;adverse_event;EURACAN;Fourth adverse event ongoing;1, Yes | 2, No
oi;75;ae_ongoing_5;adverse_event;EURACAN;Fifth adverse event ongoing;1, Yes | 2, No
oi;75;Chronic adrenocorticoid insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Chronic adrenocorticoid insufficiency;
oi;75;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
oi;75;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
oi;75;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
oi;75;Familial glucocorticoid deficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial glucocorticoid deficiency;
oi;75;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
oi;75;Hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism;
oi;75;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
oi;75;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
oi;75;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
oi;75;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
oi;75;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
oi;75;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
oi;75;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
oi;75;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
oi;75;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
oi;75;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
oi;75;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
oi;75;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
oi;75;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
oi;75;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
oi;75;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
oi;75;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
oi;75;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
oi;75;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
oi;75;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
oi;75;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
oi;75;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
oi;75;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
oi;75;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
oi;75;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
oi;75;Parathyroid carcinoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Parathyroid carcinoma;
oi;75;Familial parathyroid adenoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial parathyroid adenoma;
oi;75;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
oi;75;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
oi;75;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
oi;75;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
oi;75;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
oi;75;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
oi;75;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
oi;75;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
oi;75;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
oi;75;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
oi;75;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
oi;75;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
oi;75;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
oi;75;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
oi;75;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
oi;75;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
oi;75;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
oi;75;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
oi;75;Papillary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Papillary thyroid carcinoma;
oi;75;Follicular thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Follicular thyroid carcinoma;
oi;75;Medullary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Medullary thyroid carcinoma;
oi;75;MelorheostosisÂ withÂ osteopoikilosisÂ ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;MelorheostosisÂ withÂ osteopoikilosisÂ ;
oi;75;OI type 1;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 1;
oi;75;OI type 2;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 2;
oi;75;OI type 3;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 3;
oi;75;OI type 4;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 4;
oi;75;OI type 5;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 5;
omodysplasia;1;Omodysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Omodysplasia ;
onco;7;International Classification of Diseases for Oncology Topography (ICD-O-3-T);;ithaca;;mref
onco;7;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
onco;7;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
onco;7;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
onco;7;Concomitant disease;Patient's history;PaedCan;Presence or absence of any disease which might be related or not to current malignancy;yes/no/unknown
onco;7;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
onco;7;Oncogenic osteomalacia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Oncogenic osteomalacia;
oncogenic;1;Oncogenic osteomalacia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Oncogenic osteomalacia;
ongoing;6;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
ongoing;6;ae_ongoing;adverse_event;EURACAN;Adverse event ongoing;1, Yes | 2, No
ongoing;6;ae_ongoing_2;adverse_event;EURACAN;Second adverse event ongoing;1, Yes | 2, No
ongoing;6;ae_ongoing_3;adverse_event;EURACAN;Third adverse event ongoing;1, Yes | 2, No
ongoing;6;ae_ongoing_4;adverse_event;EURACAN;Fourth adverse event ongoing;1, Yes | 2, No
ongoing;6;ae_ongoing_5;adverse_event;EURACAN;Fifth adverse event ongoing;1, Yes | 2, No
only;1;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
onset;17;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
onset;17;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
onset;17;Time from onset to thymectomy:;Thymoma;EURO-NMD;;
onset;17;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
onset;17;imaging_number_onset;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis;radio
onset;17;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
onset;17;Age at onset;;ithaca;;categorical
onset;17;Date of onset;;ithaca;;date
onset;17;Period of first symptom onset;;ithaca;;categorical
onset;17;Date of first symptoms onset;;ithaca;;date
onset;17;Age at first symptoms onset;;ithaca;;int
onset;17;Age at onset;Symptoms and signs;PaedCan;Age at which symptoms/signs first appeared;Antenatal/At birth/Date (dd/mm/yyyy)/Undetermined
onset;17;Date of Condition Onset;Disease History;EuRR-Bone & EuRRECa;Approximate date at which symptoms and signs first appeared;dd/mm/yyyy
onset;17;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
onset;17;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
onset;17;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
onset;17;Childhood-onset hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Childhood-onset hypophosphatasia ;
open;3;"openÂ ureterostomies 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
open;3;Age when panel opened;;ithaca;;string
open;3;Isolated micropenis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated micropenis;
ophthalmoparesis;1;Ophthalmoparesis;Diagnosis Eye;EURO-NMD;;yesno
opitz;3;Smith-Lemli-Opitz syndrome;ADRENAL;EuRR-Bone & EuRRECa;Smith-Lemli-Opitz syndrome;
opitz;3;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
opitz;3;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
opted;2;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
opted;2;Year of opted out;subject;Genturis;In what year has the patient opted out or revoked the GENTURIS registry consent?;int
opted-out;1;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
optical;3;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
optical;3;optical_methods_neck;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
optical;3;end_treatment_optical;imaging_available;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Baseline | 2, After treatment
oral;2;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
oral;2;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
orcein;5;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
orcein;5;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
orcein;5;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
orcein;5;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
orcein;5;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
origin;3;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
origin;3;pv_origin;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Longitudinal assessment: portal vein origin;radio
origin;3;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
osseous;1; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
ossificans;1; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
ossification;1;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
osteochondroma;1;Multiple osteochondroma;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Multiple osteochondroma;
osteodysplastic;1;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
osteodystrophy;2;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
osteodystrophy;2;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
osteogenesis;6;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
osteogenesis;6;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
osteogenesis;6;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
osteogenesis;6;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
osteogenesis;6;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
osteogenesis;6;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
osteomalacia;1;Oncogenic osteomalacia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Oncogenic osteomalacia;
osteopetrosis;1;Osteopetrosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteopetrosis ;
osteopoikilosis;1;MelorheostosisÂ withÂ osteopoikilosisÂ ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;MelorheostosisÂ withÂ osteopoikilosisÂ ;
osteoporosis;3;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
osteoporosis;3;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
osteoporosis;3;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
oth;147;Medication Other;Medication ;EURO-NMD;;text
oth;147;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
oth;147;R_AIH_Other_ethnicity;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
oth;147;R_AIH_Other_autoantibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
oth;147;R_AIH_Other_antibodies;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
oth;147;R_AIH_Other_biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
oth;147;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
oth;147;R_AIH_Treatment_other;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other;textarea
oth;147;R_PBC_Other_ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
oth;147;R_PBC_Other_biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
oth;147;R_PBC_Other_treatment;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
oth;147;R_PBC_Treatment_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
oth;147;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
oth;147;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
oth;147;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
oth;147;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
oth;147;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
oth;147;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
oth;147;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
oth;147;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
oth;147;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
oth;147;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
oth;147;R_AIH_Other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Other malignancy;radio
oth;147;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
oth;147;R_AIH_Date_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of other malignancy;date
oth;147;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
oth;147;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
oth;147;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
oth;147;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
oth;147;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
oth;147;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
oth;147;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
oth;147;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
oth;147;R_AIH_Other_autoantibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other autoantibodies;radio
oth;147;R_AIH_Other_antibodies_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
oth;147;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
oth;147;R_AIH_Other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Other malignancy;radio
oth;147;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
oth;147;R_AIH_Date_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of other malignancy;date
oth;147;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
oth;147;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
oth;147;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
oth;147;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
oth;147;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
oth;147;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
oth;147;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
oth;147;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
oth;147;vasc_oth;Diagnosis General Information;Rare Liver (Vascular);Specify Other Vascular Disease;string
oth;147;other_symptoms;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other symptoms;textarea
oth;147;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
oth;147;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
oth;147;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
oth;147;other_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
oth;147;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
oth;147;other_aetiological_factors;Diagnosis Aetiology;Rare Liver (Vascular);Other potential aetiological factors Condition(s);textarea
oth;147;abd_interv_other;Diagnosis Aetiology;Rare Liver (Vascular);Other;radio
oth;147;abd_interv_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Intervention;date
oth;147;abdom_infect_other;Diagnosis Aetiology;Rare Liver (Vascular);Other Infection / Inflammation;radio
oth;147;abdom_infect_other_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Other Infection / Inflammation;date
oth;147;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
oth;147;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
oth;147;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
oth;147;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
oth;147;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
oth;147;eos_liver_transplant_other;End of study End of study;Rare Liver (Vascular);Other reason:;string
oth;147;med_typ_oth;Medications Medication;Rare Liver (Vascular);Other, please specify type of medication;string
oth;147;med_oth;Medications Medication;Rare Liver (Vascular);Medication (generic name);string
oth;147;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
oth;147;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
oth;147;Parents (link to other OMIM code);;ithaca;;mref
oth;147;Allelic variant of (link to other OMIM code);;ithaca;;xref
oth;147;ERN/HCP other contactperson (s);;ithaca;;mref
oth;147;"Other;  what patient Data is available";;ithaca;;categoricalmref
oth;147;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
oth;147;Other Remarks;;ithaca;;text
oth;147;Other cases in the family?;;ithaca;;categorical
oth;147;Other comorbidities;;ithaca;;text
oth;147;Other status of diagnosis;;ithaca;;text
oth;147;Is the patient following any other medication?;;ithaca;;bool
oth;147;Other changes:;;ithaca;;text
oth;147;exposure_other;patient_management_at_the_hospital;EURACAN;Please specify;
oth;147;other_hn_cancers;previous_cancer_genetic_syndromes;EURACAN;Other head and neck malignant cancers ;1, Yes | 2, No | 9, Unknown
oth;147;other_hn_site;previous_cancer_genetic_syndromes;EURACAN;Site;999, Unknown | 1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS | 9, C11 nasopharynx | 10, C11.0  Superior wall of nasopharynx | 11, C11.1  Posterior wall of nasopharynx | 12, C11.2  Lateral wall of nasopharynx | 13, C11.3  Anterior wall of nasopharynx | 14, C11.8  Overlapping lesion of nasopharynx | 15, C11.9  Nasopharynx, NOS | 16, C12.9  Pyriform sinus | 17, C13 Hypopharynx | 18, C13.0  Postcricoid region | 19, C13.1  Hypopharyngeal aspect of aryepiglottic fold | 20, C13.2  Posterior wall of hypopharynx | 21, C13.8  Overlapping lesion of hypopharynx | 22, C13.9  Hypopharynx, NOS | 23, C01.9  Base of tongue, NOS | 24, C02.4  Lingual tonsil | 25, C05.1  Soft palate, NOS | 26, C05.2  Uvula | 27, C09 tonsil | 28, C09.0  Tonsillar fossa | 29, C09.1  Tonsillar pillar | 30, C09.8  Overlapping lesion of tonsil | 31, C09.9  Tonsil, NOS | 32, C10 oropharynx | 33, C10.0  Vallecula | 34, C10.2 Lateral wall of oropharynx | 35, C10.3 Posterior Pharyngeal wall | 36, C10.8 Overlapping lesions of oropharynx | 37, C10.9 Oropharynx, NOS | 38, C11.1 Pharyngeal tonsils | 39, C01.9  Base of tongue, NOS | 40, C02.4  Lingual tonsil | 41, C05.1  Soft palate, NOS | 42, C05.2  Uvula | 43, C09 tonsil | 44, C09.0  Tonsillar fossa | 45, C09.1  Tonsillar pillar | 46, C09.8  Overlapping lesion of tonsil | 47, C09.9  Tonsil, NOS | 48, C10 oropharynx | 49, C10.0  Vallecula | 50, C10.2 Lateral wall of oropharynx | 51, C10.3 Posterior Pharyngeal wall | 52, C10.8 Overlapping lesions of oropharynx | 53, C10.9 Oropharynx, NOS | 54, C11.1 Pharyngeal tonsils | 55, C10.1 Anterior (lingual) surface of epiglottis | 56, C32 Larynx | 57, C32.0  Glottis | 58, C32.1  Supraglottis | 59, C32.2  Subglottis | 60, C32.3  Laryngeal cartilage | 61, C32.8  Overlapping lesion of larynx | 62, C32.9  Larynx, NOS | 63, C02.0  Dorsal surface of tongue, NOS | 64, C02.1  Border of tongue | 65, C02.2  Ventral surface of tongue, NOS | 66, C02.3  Anterior 2/3 of tongue, NOS | 67, C02.8 Overlapping lesion of tongue | 68, C02.9  Tongue, NOS | 69, C03 gum | 70, C03.0  Upper gum | 71, C03.1  Lower gum | 72, C03.9  Gum, NOS | 73, C04 floor of mouth | 74, C04.0  Anterior floor of mouth | 75, C04.1  Lateral floor of mouth | 76, C04.8  Overlapping lesion of floor of mouth | 77, C04.9  Floor of mouth, NOS | 78, C05 palate | 79, C05.0  Hard palate | 80, C05.8  Overlapping lesion of palate | 81, C05.9  Palate, NOS | 82, C06 other and unspecified parts of mouth | 83, C06.0  Cheek mucosa | 84, C06.1  Vestibule of mouth | 85, C06.2  Retromolar area | 86, C06.8  Overlapping lesion of other  and unspecified parts of mouth | 87, C06.9  Mouth, NOS | 88, C00 lip (excludes skin of lip C44.0) | 89, C00.0  External upper lip | 90, C00.1  External lower lip | 91, C00.2  External lip, NOS | 92, C00.3  Mucosa of upper lip | 93, C00.4  Mucosa of lower lip | 94, C00.5  Mucosa of lip, NOS | 95, C00.6  Commissure of lip | 96, C00.8  Overlapping lesion of lip | 97, C00.9  Lip, NOS | 98, C30.1  Middle ear | 99, C07.9  Parotid gland | 100, C08 other and unspecified major salivary glands | 101, C08.0  Submandibular gland | 102, C08.1  Sublingual gland | 103, C08.8  Overlapping lesion of major salivary glands | 104, C08.9  Major salivary gland, NOS | 105, Minor salivary gland of the head & neck
oth;147;other_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
oth;147;other_hn_bening;previous_cancer_genetic_syndromes;EURACAN;Other head and neck benign tumours;1, Yes | 2, No | 9, Unknown
oth;147;other_hn_bening_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
oth;147;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
oth;147;pet_oth_primary;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
oth;147;imag_primary_oth;stage_procedures;EURACAN;Other imaging for primary site;
oth;147;pet_oth_neck;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
oth;147;imag_neck_oth;stage_procedures;EURACAN;Other imaging for neck;
oth;147;pet_oth_meta;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
oth;147;imag_meta_oth;stage_procedures;EURACAN;Other imaging for metastatic disease;
oth;147;others;radiotherapy;EURACAN;"<div class=""rich-text-field-label""><p>Â </p> <table style=""border-collapse: collapse; width: auto;"" border=""1""> <tbody> <tr> <td style=""vertical-align: top; text-align: center; width: 629px;"" colspan=""9"">Others</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"">Treatment technique</td> <td style=""width: 100px; vertical-align: top;"">Start date</td> <td style=""width: 100px; vertical-align: top;"">End date</td> <td style=""width: 70px; vertical-align: top;"">Totale dose</td> <td style=""width: 70px; vertical-align: top;"">Dose per fraction</td> <td style=""width: 70px; vertical-align: top;"">Nr of fractions</td> <td style=""width: 60px; vertical-align: top;"">4D treatment</td> <td style=""width: 70px; vertical-align: top;"">Adaptive RT</td> <td style=""width: 70px; vertical-align: top;"">IGRT</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"" rowspan=""2"">{radio_others_tech}</td> <td style=""width: 100px; vertical-align: top;"">{radio_others_from}</td> <td style=""width: 100px; vertical-align: top;"">{radio_others_to}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_totdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_fractdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_nrfract}</td> <td style=""width: 60px; vertical-align: top;"" rowspan=""2"">{radio_others_4d}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_adaptive}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_igrt}</td> </tr> <tr> <td style=""width: auto; vertical-align: top; text-align: center;"" colspan=""2"">OTT (days) {radio_others_ott}</td> </tr> </tbody> </table></div>";
oth;147;radio_others_tech;radiotherapy;EURACAN;Others treatment technique;
oth;147;radio_others_from;radiotherapy;EURACAN;Others start date;
oth;147;radio_others_to;radiotherapy;EURACAN;Others end date;
oth;147;radio_others_totdose;radiotherapy;EURACAN;Others total dose;
oth;147;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
oth;147;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
oth;147;radio_others_ott;radiotherapy;EURACAN;Others OTT;"datediff([radio_others_to],[radio_others_from],""d"")"
oth;147;radio_others_4d;radiotherapy;EURACAN;Others 4D treatment;1, Yes | 2, No
oth;147;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
oth;147;radio_others_igrt;radiotherapy;EURACAN;Others IGRT  (imagine guide radiotherapy);1, Yes | 2, No
oth;147;other_treatment;other_type_of_treatment;EURACAN;Other treatment performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
oth;147;other_treatment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of other treatment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{other_treatment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{other_treatment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{other_treatment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
oth;147;other_treatment_date;other_type_of_treatment;EURACAN;Date;
oth;147;other_treatment_date_mm;other_type_of_treatment;EURACAN;Month of other treatment;
oth;147;other_treatment_date_yyyy;other_type_of_treatment;EURACAN;Year of other treatment;
oth;147;other_treatment_type;other_type_of_treatment;EURACAN;Type;1, Local | 2, Systemic | 9, Unknown
oth;147;end_treatment_other;other_type_of_treatment;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
oth;147;end_treat_res_other;other_type_of_treatment;EURACAN;Treatment response (based on imaging no defined criteria);1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
oth;147;end_treat_res_def_other;other_type_of_treatment;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
oth;147;oth_clinical_trial;other_type_of_treatment;EURACAN;Patient included in a clinical trial;1, Yes | 2, No
oth;147;oth_enrolment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of enrolment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{oth_enrolment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{oth_enrolment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{oth_enrolment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
oth;147;oth_enrolment_date;other_type_of_treatment;EURACAN;Date of enrolment;
oth;147;oth_enrolment_date_mm;other_type_of_treatment;EURACAN;Month of enrolment;
oth;147;oth_enrolment_date_yyyy;other_type_of_treatment;EURACAN;Year of enrolment;
oth;147;biom_other;tumour_material_available;EURACAN;Others;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
oth;147;biom_others;tumour_material_available;EURACAN;Others (please specify);
oth;147;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
oth;147;If other specify;Patient's history;PaedCan;;String
oth;147;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
oth;147;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
oth;147;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
oth;147;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
oth;147;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
oth;147;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
oth;147;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
oth;147;If other please specify;Radiotherapy;PaedCan;;String
oth;147;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
oth;147;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
oth;147;Other diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other diabetes mellitus;
oth;147;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
oth;147;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
oth;147;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
oth;147;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
oth;147;Other syndromic form of CH;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other syndromic form of CH;
oth;147;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
oth;147;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
oth;147;Other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Other;
oth;147;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
oth;147;Other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Other;
oth;147;Cloacal anomaly and other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Cloacal anomaly and other;
oth;147;Other;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Other;
oth;147;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
oth;147;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
others;12;others;radiotherapy;EURACAN;"<div class=""rich-text-field-label""><p>Â </p> <table style=""border-collapse: collapse; width: auto;"" border=""1""> <tbody> <tr> <td style=""vertical-align: top; text-align: center; width: 629px;"" colspan=""9"">Others</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"">Treatment technique</td> <td style=""width: 100px; vertical-align: top;"">Start date</td> <td style=""width: 100px; vertical-align: top;"">End date</td> <td style=""width: 70px; vertical-align: top;"">Totale dose</td> <td style=""width: 70px; vertical-align: top;"">Dose per fraction</td> <td style=""width: 70px; vertical-align: top;"">Nr of fractions</td> <td style=""width: 60px; vertical-align: top;"">4D treatment</td> <td style=""width: 70px; vertical-align: top;"">Adaptive RT</td> <td style=""width: 70px; vertical-align: top;"">IGRT</td> </tr> <tr> <td style=""width: 159px; vertical-align: top;"" rowspan=""2"">{radio_others_tech}</td> <td style=""width: 100px; vertical-align: top;"">{radio_others_from}</td> <td style=""width: 100px; vertical-align: top;"">{radio_others_to}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_totdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_fractdose}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_nrfract}</td> <td style=""width: 60px; vertical-align: top;"" rowspan=""2"">{radio_others_4d}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_adaptive}</td> <td style=""width: 70px; vertical-align: top;"" rowspan=""2"">{radio_others_igrt}</td> </tr> <tr> <td style=""width: auto; vertical-align: top; text-align: center;"" colspan=""2"">OTT (days) {radio_others_ott}</td> </tr> </tbody> </table></div>";
others;12;radio_others_tech;radiotherapy;EURACAN;Others treatment technique;
others;12;radio_others_from;radiotherapy;EURACAN;Others start date;
others;12;radio_others_to;radiotherapy;EURACAN;Others end date;
others;12;radio_others_totdose;radiotherapy;EURACAN;Others total dose;
others;12;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
others;12;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
others;12;radio_others_ott;radiotherapy;EURACAN;Others OTT;"datediff([radio_others_to],[radio_others_from],""d"")"
others;12;radio_others_4d;radiotherapy;EURACAN;Others 4D treatment;1, Yes | 2, No
others;12;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
others;12;radio_others_igrt;radiotherapy;EURACAN;Others IGRT  (imagine guide radiotherapy);1, Yes | 2, No
others;12;biom_others;tumour_material_available;EURACAN;Others (please specify);
ott;8;radio_photons_ott;radiotherapy;EURACAN;Photons OTT;"datediff([radio_photons_to],[radio_photons_from],""d"")"
ott;8;radio_electrons_ott;radiotherapy;EURACAN;Electrons OTT;"datediff([radio_electrons_to],[radio_electrons_from],""d"")"
ott;8;radio_protons_ott;radiotherapy;EURACAN;Protons OTT;"datediff([radio_protons_to],[radio_protons_from],""d"")"
ott;8;radio_carbons_ott;radiotherapy;EURACAN;Carbons OTT;"datediff([radio_carbons_to],[radio_carbons_from],""d"")"
ott;8;radio_brachy_ott;radiotherapy;EURACAN;Brachytherapy OTT;"datediff([radio_brachy_to],[radio_brachy_from],""d"")"
ott;8;radio_radionuc_ott;radiotherapy;EURACAN;Radionuclide OTT;"datediff([radio_radionuc_to],[radio_radionuc_from],""d"")"
ott;8;radio_boron_ott;radiotherapy;EURACAN;Boron neutron capture therapy OTT;"datediff([radio_boron_to],[radio_boron_from],""d"")"
ott;8;radio_others_ott;radiotherapy;EURACAN;Others OTT;"datediff([radio_others_to],[radio_others_from],""d"")"
out;15;Independent feeding (hand to mouth);Mobility ;EURO-NMD;;single
out;15;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
out;15;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
out;15;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
out;15;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
out;15;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
out;15;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
out;15;cardiac_output;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cardiac output;numeric
out;15;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
out;15;Year of opted out;subject;Genturis;In what year has the patient opted out or revoked the GENTURIS registry consent?;int
out;15;Please give more details about the treatment of the event;Events;PaedCan;;String
out;15;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
out;15;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
out;15;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
out;15;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
outcome;5;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
outcome;5;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
outcome;5;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
outcome;5;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
outcome;5;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
outcomes;3;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
outcomes;3;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
outcomes;3;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
output;1;cardiac_output;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Cardiac output;numeric
outstretched;4;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
outstretched;4;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
outstretched;4;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
outstretched;4;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
overall;2;overall_treat_res;overall_treatment_response;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
overall;2;overall_treat_res_def;overall_treatment_response;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
overgrowth;15;Overgrowth Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth Syndrome;
overgrowth;15;15q overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;15q overgrowth syndrome;
overgrowth;15;Chromosomal disease with overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Chromosomal disease with overgrowth;
overgrowth;15;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
overgrowth;15;Malan overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Malan overgrowth syndrome;
overgrowth;15;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
overgrowth;15;Non syndromic limb overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non syndromic limb overgrowth;
overgrowth;15;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
overgrowth;15;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
overgrowth;15;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
overgrowth;15;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
overgrowth;15;Overgrowth/obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth/obesity syndrome;
overgrowth;15;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
overgrowth;15;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
overgrowth;15;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
overgrowth-craniofacial;1;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
overgrowth-macrocephaly-facial;1;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
overgrowth-metaphyseal;1;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
overgrowth/obesity;1;Overgrowth/obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth/obesity syndrome;
overt;1;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
ovotesticular;2;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
ovotesticular;2;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
oxidoreductase;6;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
oxidoreductase;6;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
oxidoreductase;6;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
oxidoreductase;6;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
oxidoreductase;6;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
oxidoreductase;6;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p16;1;p16;primary_cancer;EURACAN;p16;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
p450;14;CYP17 def (P450CYP17);ADRENAL;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450;14;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p450;14;P450 scc def (CYP11A1);ADRENAL;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
p450;14;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450;14;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p450;14;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
p450;14;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p450;14;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
p450;14;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450;14;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p450;14;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450;14;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p450;14;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
p450;14;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
p450cyp17;4;CYP17 def (P450CYP17);ADRENAL;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450cyp17;4;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450cyp17;4;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
p450cyp17;4;CYP17 def (P450CYP17);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;CYP17 def (P450CYP17);
pack;3;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
pack;3;smoking_pack_year_calc;patient_management_at_the_hospital;EURACAN;Pack/year;"if ([smoking_habits] = ""1"", ([smoking_per_day]/20)*[smoking_years], ([smoking_per_day]/4)*[smoking_years])"
pack;3;smoking_pack_year_man;patient_management_at_the_hospital;EURACAN;Pack/year (manual);
paediatric-onset;1;Paediatric-onset Graves disease;THYROID;EuRR-Bone & EuRRECa;Paediatric-onset Graves disease;
paget;1;Juvenile Paget disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Juvenile Paget disease ;
pain;1;abdominal_pain;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Abdominal pain;radio
pais;1;PAIS;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;PAIS;
palate;2;High palate;Diagnosis Skeletal;EURO-NMD;;yesno
palate;2;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
palate-camptodactyly;1;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
panc;2;abdom_infect_panc;Diagnosis Aetiology;Rare Liver (Vascular);Pancreatitis;radio
panc;2;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
pancreat;1;abdom_infect_pancreat_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Pancreatitis;date
panhypopituitarism;1;Panhypopituitarism;PITUITARY;EuRR-Bone & EuRRECa;Panhypopituitarism;
papillary;1;Papillary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Papillary thyroid carcinoma;
paraffin;1;Paraffin tumor tissue;Pathology;PaedCan;;yes/no/unknown
paraganglioma;2;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
paraganglioma;2;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
paraplegia-intellectual;1;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
parathormone;1;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
parathyroid;30;Hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism;
parathyroid;30;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
parathyroid;30;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
parathyroid;30;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
parathyroid;30;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
parathyroid;30;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
parathyroid;30;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
parathyroid;30;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
parathyroid;30;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
parathyroid;30;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
parathyroid;30;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
parathyroid;30;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
parathyroid;30;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
parathyroid;30;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
parathyroid;30;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
parathyroid;30;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
parathyroid;30;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
parathyroid;30;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
parathyroid;30;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
parathyroid;30;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
parathyroid;30;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
parathyroid;30;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
parathyroid;30;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
parathyroid;30;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
parathyroid;30;Parathyroid carcinoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Parathyroid carcinoma;
parathyroid;30;Familial parathyroid adenoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial parathyroid adenoma;
parathyroid;30;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
parathyroid;30;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
parathyroid;30;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
parathyroid;30;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
partial;4;Familial partial lipodystrophy Type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 1;
partial;4;Familial partial lipodystrophy Type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 2;
partial;4;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
partial;4;Partial gonadal dysgenesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Partial gonadal dysgenesis;
participation;1;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
partner;1;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
past;2;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
past;2;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
pat;124;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
pat;124;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
pat;124;Patient_status;Base information;Rare Liver (Auto imune);Patient status;radio
pat;124;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
pat;124;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
pat;124;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
pat;124;R_PBC_IFT_pattern;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
pat;124;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
pat;124;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
pat;124;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
pat;124;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
pat;124;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
pat;124;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
pat;124;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
pat;124;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
pat;124;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
pat;124;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
pat;124;R_AIH_Hepatobillary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
pat;124;R_AIH_Date_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
pat;124;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
pat;124;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
pat;124;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
pat;124;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
pat;124;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
pat;124;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
pat;124;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
pat;124;R_AIH_Hepatitis_activity_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatitis activity;numeric
pat;124;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
pat;124;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
pat;124;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
pat;124;R_AIH_Hepatobillary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
pat;124;R_AIH_Date_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of hepatobiliary malignancy;date
pat;124;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
pat;124;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
pat;124;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
pat;124;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
pat;124;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
pat;124;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
pat;124;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
pat;124;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
pat;124;patient_comments;Diagnosis General Information;Rare Liver (Vascular);Comments;textarea
pat;124;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
pat;124;hepatorenal_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatorenal syndrome;radio
pat;124;hepatopulmonary_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatopulmonary syndrome;radio
pat;124;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
pat;124;hepatic_venography;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venography;radio
pat;124;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
pat;124;hv_patent;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of veins seen fully patent and normal;radio
pat;124;hepatic_artery;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery;radio
pat;124;hepatic_vein_catheter;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic Vein Catheterization;radio
pat;124;wedged_hepatic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged hepatic vein;numeric
pat;124;pathergy_test;Diagnosis Aetiology;Rare Liver (Vascular);Pathergy test;radio
pat;124;telomeropathy;Diagnosis Aetiology;Rare Liver (Vascular);Telomeropathy;radio
pat;124;telomeropathy_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of telomeropathy;string
pat;124;fu_encephalopathy;Follow-up Complications;Rare Liver (Vascular);Encephalopathy;radio
pat;124;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
pat;124;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
pat;124;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
pat;124;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
pat;124;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
pat;124;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
pat;124;fu_ima_bef_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
pat;124;fu_ima_bef_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
pat;124;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
pat;124;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
pat;124;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
pat;124;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
pat;124;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
pat;124;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
pat;124;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
pat;124;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
pat;124;"b. Constipation is treated with: 		";5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
pat;124;Patient identifiers;subject;Genturis;;compound
pat;124;Patient ID;subject;Genturis;What is the local patient pseudonym?;string
pat;124;Patient information;subject;Genturis;;compound
pat;124;Care path;subject;Genturis;;compound
pat;124;Patient enrolment;;ithaca;;compound
pat;124;Patient ID;;ithaca;;string
pat;124;Patient's biological sample available for researchÂ ;;ithaca;;bool
pat;124;"Other;  what patient Data is available";;ithaca;;categoricalmref
pat;124;Patient StatusÂ ;;ithaca;;compound
pat;124;Patient's Status;;ithaca;;categorical
pat;124;Care pathwayÂ ;;ithaca;;compound
pat;124;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
pat;124;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
pat;124;Patient Information;;ithaca;;compound
pat;124;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
pat;124;Is the patient following any other medication?;;ithaca;;bool
pat;124;Hospital patient ID;patient_management_at_the_hospital;EURACAN;;
pat;124;pathological_na;stage_procedures;EURACAN;Pathological T, N, M;1, Not applicable
pat;124;ene_pat;stage_procedures;EURACAN;Extranodal extension (ENE);1, ENE- | 2, ENE+
pat;124;tnm_unk_pat;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
pat;124;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
pat;124;Patient blood;Pathology;PaedCan;;yes/no/unknown
pat;124;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
pat;124;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
pat;124;EUPID (European Patient ID);Identifiers;EuRR-Bone & EuRRECa;Patients Pseudonym;String
pat;124;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
pat;124;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
pat;124;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
pat;124;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
pat;124;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
pat;124;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
pat;124;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
pat;124;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
pat;124;Biobank Patient ID;Research;EuRR-Bone & EuRRECa;;String
pat;124;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
pat;124;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
pat;124;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
pat;124;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
pat;124;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
pat;124;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
pat;124;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
pat;124;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
pat;124;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
pat;124;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
pat;124;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
pat;124;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
pat;124;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
pat;124;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
pat;124;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
pat;124;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
pat;124;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
pat;124;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
patent;13;hv_patent;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of veins seen fully patent and normal;radio
patent;13;fu_ima_bef_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
patent;13;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
patent;13;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
patent;13;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
patent;13;fu_ima_bef_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
patent;13;fu_ima_bef_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
patent;13;fu_ima_last_ivc_patent;Follow-up Imaging data;Rare Liver (Vascular);Inferior vena cava patent;radio
patent;13;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
patent;13;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
patent;13;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
patent;13;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
patent;13;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
paternal;9;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
paternal;9;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
paternal;9;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
paternal;9;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
paternal;9;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
paternal;9;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
paternal;9;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
paternal;9;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
paternal;9;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
path;32;EMG: myopathic abnormalities;Diagnosis EMG;EURO-NMD;myopathic;
path;32;EMG: neuropathic changes;Diagnosis EMG;EURO-NMD;neurogenic;
path;32;R_AIH_Encephalopathy_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Overt encephalopathy;radio
path;32;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
path;32;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
path;32;R_AIH_Hepatic_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Overt encephalopathy;radio
path;32;R_AIH_Date_encephalopathy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date encephalopathy;date
path;32;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
path;32;R_AIH_Hepatic_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Overt encephalopathy;radio
path;32;R_AIH_Date_encephalopathy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date encephalopathy;date
path;32;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
path;32;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
path;32;hepatic_encephaolopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopoathy;radio
path;32;history_of_hepatic_encephalopathy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatic encephalopathy;radio
path;32;pathergy_test;Diagnosis Aetiology;Rare Liver (Vascular);Pathergy test;radio
path;32;telomeropathy;Diagnosis Aetiology;Rare Liver (Vascular);Telomeropathy;radio
path;32;telomeropathy_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of telomeropathy;string
path;32;fu_encephalopathy;Follow-up Complications;Rare Liver (Vascular);Encephalopathy;radio
path;32;fu_cli_last_encephalopathy;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy;radio
path;32;fu_ima_bef_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
path;32;fu_ima_last_cholangiopathy;Follow-up Imaging data;Rare Liver (Vascular);MRI documented cholangiopathy;radio
path;32;Care path;subject;Genturis;;compound
path;32;Care pathwayÂ ;;ithaca;;compound
path;32;pathological_na;stage_procedures;EURACAN;Pathological T, N, M;1, Not applicable
path;32;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
path;32;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
path;32;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
path;32;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
path;32;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
path;32;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
path;32;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
path;32;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
pathergy;1;pathergy_test;Diagnosis Aetiology;Rare Liver (Vascular);Pathergy test;radio
pathological;1;pathological_na;stage_procedures;EURACAN;Pathological T, N, M;1, Not applicable
pathology;1;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
patient;30;Patient_status;Base information;Rare Liver (Auto imune);Patient status;radio
patient;30;patient_comments;Diagnosis General Information;Rare Liver (Vascular);Comments;textarea
patient;30;Patient identifiers;subject;Genturis;;compound
patient;30;Patient ID;subject;Genturis;What is the local patient pseudonym?;string
patient;30;Patient information;subject;Genturis;;compound
patient;30;Patient enrolment;;ithaca;;compound
patient;30;Patient ID;;ithaca;;string
patient;30;Patient's biological sample available for researchÂ ;;ithaca;;bool
patient;30;"Other;  what patient Data is available";;ithaca;;categoricalmref
patient;30;Patient StatusÂ ;;ithaca;;compound
patient;30;Patient's Status;;ithaca;;categorical
patient;30;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
patient;30;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
patient;30;Patient Information;;ithaca;;compound
patient;30;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
patient;30;Is the patient following any other medication?;;ithaca;;bool
patient;30;Hospital patient ID;patient_management_at_the_hospital;EURACAN;;
patient;30;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
patient;30;Patient blood;Pathology;PaedCan;;yes/no/unknown
patient;30;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
patient;30;EUPID (European Patient ID);Identifiers;EuRR-Bone & EuRRECa;Patients Pseudonym;String
patient;30;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
patient;30;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
patient;30;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
patient;30;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
patient;30;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
patient;30;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
patient;30;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
patient;30;Biobank Patient ID;Research;EuRR-Bone & EuRRECa;;String
patient;30;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
patient's;4;Patient's biological sample available for researchÂ ;;ithaca;;bool
patient's;4;Patient's Status;;ithaca;;categorical
patient's;4;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
patient's;4;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
pattern;3;R_PBC_IFT_pattern;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
pattern;3;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
pattern;3;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
patterson-lowry;1;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
paxgene;6;R_AIH_Paxgene;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
paxgene;6;R_PBC_Paxgene;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
paxgene;6;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
paxgene;6;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
paxgene;6;R_AIH_Paxgene_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
paxgene;6;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
pbc;326;R_PBC_Contact_consent;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Contact Consent;radio
pbc;326;R_PBC_Year_of_birth;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
pbc;326;R_PBC_Date_of_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
pbc;326;R_PBC_Age_at_diagnosis;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
pbc;326;R_PBC_Additional_diagnosis_of_AIH;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
pbc;326;R_PBC_Weight;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
pbc;326;R_PBC_Height;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
pbc;326;R_PBC_BMI;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
pbc;326;R_PBC_Sex;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
pbc;326;R_PBC_Ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
pbc;326;R_PBC_Other_ethnicity;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
pbc;326;R_PBC_Alcohol;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol;radio
pbc;326;R_PBC_Smoking;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
pbc;326;PBC_is_smoker;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
pbc;326;R_PBC_Smoking_amount;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
pbc;326;R_PBC_FDR_with_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver disease;radio
pbc;326;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
pbc;326;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
pbc;326;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
pbc;326;R_PBC_Liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
pbc;326;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
pbc;326;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
pbc;326;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
pbc;326;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
pbc;326;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
pbc;326;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
pbc;326;R_PBC_mHAI;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
pbc;326;R_PBC_Nakanuma_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed?;radio
pbc;326;R_PBC_Cholangitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
pbc;326;R_PBC_Hepatitis_activity_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
pbc;326;R_PBC_not_in_db22;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate naknuma grading;calculation
pbc;326;R_PBC_nakanuma_grading_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
pbc;326;R_PBC_Fibrosis_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
pbc;326;R_PBC_Bile_duct_loss_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
pbc;326;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pbc;326;R_PBC_not_in_db;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate naknuma staging;calculation
pbc;326;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
pbc;326;R_PBC_Additional_nafld;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
pbc;326;R_PBC_Additional_nash;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
pbc;326;R_PBC_Transient_elastography;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
pbc;326;R_PBC_Liver_stiffness;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
pbc;326;R_PBC_IQR;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
pbc;326;R_PBC_Spleen_size;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
pbc;326;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
pbc;326;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
pbc;326;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
pbc;326;R_PBC_Signs_of_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver-related complications;radio
pbc;326;R_PBC_Imaging_consistent_with_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
pbc;326;R_PBC_Ascites;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Ascites;radio
pbc;326;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
pbc;326;R_PBC_Variceal_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Variceal bleeding;radio
pbc;326;R_PBC_Encephalopathy_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Overt encephalopathy;radio
pbc;326;R_PBC_HRS_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Hepatorenal syndrome;radio
pbc;326;R_PBC_Pruritus;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Pruritus;radio
pbc;326;R_PBC_AST;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
pbc;326;R_PBC_ALT;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
pbc;326;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
pbc;326;R_PBC_Total_bilirubin_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
pbc;326;R_PBC_ALP;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
pbc;326;R_PBC_yGT;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);y-GT;numeric
pbc;326;R_PBC_Albumin;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
pbc;326;R_PBC_Creatinine_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
pbc;326;R_PBC_Creatinine_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
pbc;326;R_PBC_INR;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
pbc;326;R_PBC_Platelets;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
pbc;326;R_PBC_IgG;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
pbc;326;R_PBC_IgM;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
pbc;326;R_PBC_IgA;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
pbc;326;R_PBC_yGlobulins;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
pbc;326;R_PBC_ANA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
pbc;326;R_PBC_ANA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
pbc;326;R_PBC_ANA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
pbc;326;R_PBC_ANA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
pbc;326;R_PBC_SMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
pbc;326;R_PBC_Titer_SMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
pbc;326;R_PBC_SMA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
pbc;326;R_PBC_SMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
pbc;326;R_PBC_LKM;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
pbc;326;R_PBC_LKM_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
pbc;326;R_PBC_LKM1_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
pbc;326;R_PBC_LKM_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
pbc;326;R_PBC_SLA_LP;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
pbc;326;R_PBC_SLA_LP_units;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
pbc;326;R_PBC_SLA_LP_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
pbc;326;R_PBC_AMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
pbc;326;R_PBC_AMA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
pbc;326;R_PBC_AMA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
pbc;326;R_PBC_AMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
pbc;326;R_PBC_PBC_specific_ANA_IFT;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
pbc;326;R_PBC_IFT_pattern;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
pbc;326;R_PBC_gp210_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
pbc;326;R_PBC_gp210_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
pbc;326;R_PBC_SP100;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
pbc;326;R_PBC_SP100_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
pbc;326;R_PBC_DXA;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
pbc;326;R_PBC_Date_of_DXA;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
pbc;326;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
pbc;326;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
pbc;326;R_PBC_Biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
pbc;326;R_PBC_Liver_tissue;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
pbc;326;R_PBC_Serum;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
pbc;326;R_PBC_Paxgene;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
pbc;326;R_PBC_Other_biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
pbc;326;R_PBC_UDCA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA;radio
pbc;326;R_PBC_UDCA_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
pbc;326;R_PBC_UDCA_dose_per_kg;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose mg / kg;calculation
pbc;326;R_PBC_Other_treatment;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
pbc;326;R_PBC_OCA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
pbc;326;R_PBC_OCA_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);OCA dose;numeric
pbc;326;R_PBC_Prednisolone;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pbc;326;R_PBC_Prednisolone_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pbc;326;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_Budesonide;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
pbc;326;R_PBC_Budesonide_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
pbc;326;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_Azathioprine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pbc;326;R_PBC_Azathioprine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pbc;326;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_Fibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fibrate;radio
pbc;326;R_PBC_Fenofibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fenofibrate;radio
pbc;326;R_PBC_Bezafibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Bezafibrate;radio
pbc;326;R_PBC_Treatment_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
pbc;326;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pbc;326;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pbc;326;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
pbc;326;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_MMF;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
pbc;326;R_PBC_AIH_MMF_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
pbc;326;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Infliximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
pbc;326;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Tacrolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
pbc;326;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_CyclosporinA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
pbc;326;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Rituximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
pbc;326;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Everolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
pbc;326;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
pbc;326;psc_pbc_diag;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);psc pbc diag;calculation
pbc;326;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
pbc;326;R_AIH_PBC_OCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
pbc;326;R_AIH_PBC_OCA_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);OCA dose;numeric
pbc;326;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
pbc;326;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
pbc;326;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
pbc;326;R_AIH_New_diagnosis_of_PBC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PBC;radio
pbc;326;R_AIH_New_diagnosis_of_PBC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
pbc;326;R_AIH_Additional_diagnosis_of_PBC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PBC;radio
pbc;326;R_AIH_New_diagnosis_of_PBC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PBC;date
pbc;326;aih_pbc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC check;calculation
pbc;326;R_AIH_PBC_specific_treament;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC specific treatment;radio
pbc;326;R_AIH_PBC_OCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
pbc;326;R_AIH_PBC_OCA_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
pbc;326;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
pbc;326;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
pbc;326;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
pbc;326;R_PBC_AST_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
pbc;326;R_PBC_ALT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
pbc;326;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
pbc;326;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
pbc;326;R_PBC_ALP_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
pbc;326;R_PBC_yGT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
pbc;326;R_PBC_Albumin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
pbc;326;R_PBC_Creatinine_mgdL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
pbc;326;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
pbc;326;R_PBC_INR_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
pbc;326;R_PBC_Platelets_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
pbc;326;R_PBC_IgG_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
pbc;326;R_PBC_IgM_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
pbc;326;R_PBC_IgA_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
pbc;326;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
pbc;326;R_PBC_ANA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
pbc;326;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
pbc;326;R_PBC_ANA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
pbc;326;R_PBC_ANA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
pbc;326;R_PBC_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
pbc;326;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
pbc;326;R_PBC_SMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
pbc;326;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
pbc;326;R_PBC_LKM_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
pbc;326;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
pbc;326;R_PBC_LKM1_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
pbc;326;R_PBC_LKM_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
pbc;326;R_PBC_SLA_LP_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
pbc;326;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
pbc;326;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
pbc;326;R_PBC_AMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
pbc;326;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
pbc;326;R_PBC_AMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
pbc;326;R_PBC_AMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
pbc;326;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
pbc;326;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
pbc;326;R_PBC_gp210_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (ELISA);radio
pbc;326;R_PBC_gp210_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);gp210 (Immunoblot);radio
pbc;326;R_PBC_SP100_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
pbc;326;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
pbc;326;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
pbc;326;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
pbc;326;R_PBC_Serum_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
pbc;326;R_PBC_Paxgene_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
pbc;326;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
pbc;326;R_PBC_Date_of_followup_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of Follow-up;string
pbc;326;R_PBC_Age_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
pbc;326;R_PBC_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
pbc;326;R_PBC_Date_of_DXA_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
pbc;326;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
pbc;326;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
pbc;326;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
pbc;326;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
pbc;326;R_PBC_IQR_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
pbc;326;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
pbc;326;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
pbc;326;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
pbc;326;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
pbc;326;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
pbc;326;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
pbc;326;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
pbc;326;R_PBC_mHAI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
pbc;326;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
pbc;326;R_PBC_Cholangitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
pbc;326;R_PBC_Hepatitis_activity_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
pbc;326;R_PBC_not_in_db_3;PBC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
pbc;326;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
pbc;326;R_PBC_Fibrosis_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
pbc;326;R_PBC_Bile_duct_loss_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
pbc;326;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pbc;326;R_PBC_not_in_db5;PBC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
pbc;326;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
pbc;326;R_PBC_Additional_nafld_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
pbc;326;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
pbc;326;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
pbc;326;R_PBC_Liver_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
pbc;326;R_PBC_Date_imaging_consistent_with_cirrhosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of imaging consistent with cirrhosis;date
pbc;326;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
pbc;326;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
pbc;326;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
pbc;326;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
pbc;326;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
pbc;326;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
pbc;326;R_PBC_Encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
pbc;326;R_PBC_Date_encephalopathy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date encephalopathy;date
pbc;326;R_PBC_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
pbc;326;R_PBC_Date_HRS_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
pbc;326;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
pbc;326;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
pbc;326;R_PBC_Indication_LTx_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Indication for liver transplantation;radio
pbc;326;R_PBC_Hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
pbc;326;R_PBC_Date_hepatobiliary_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
pbc;326;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
pbc;326;R_PBC_Other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
pbc;326;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
pbc;326;R_PBC_Date_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
pbc;326;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
pbc;326;R_PBC_Additional_diagnosis_of_AIH_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
pbc;326;R_PBC_Date_AIH_diagnosis_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of new diagnosis AIH;date
pbc;326;R_PBC_Weight_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
pbc;326;R_PBC_Height_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
pbc;326;R_PBC_BMI_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
pbc;326;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
pbc;326;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
pbc;326;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
pbc;326;R_PBC_is_female;PBC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
pbc;326;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pbc;326;R_PBC_UDCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
pbc;326;R_PBC_UDCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
pbc;326;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
pbc;326;R_PBC_OCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Obeticholic acid (OCA);radio
pbc;326;R_PBC_OCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);OCA dose;numeric
pbc;326;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pbc;326;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pbc;326;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_Budesonide_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
pbc;326;R_PBC_Budesonide_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
pbc;326;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pbc;326;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pbc;326;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_Aza_metabolites_assessed_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
pbc;326;R_PBC_TGN_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
pbc;326;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pbc;326;R_PBC_MMP_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
pbc;326;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pbc;326;R_PBC_Fibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
pbc;326;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
pbc;326;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
pbc;326;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
pbc;326;R_PBC_AIH_check;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH check;calculation
pbc;326;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
pbc;326;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pbc;326;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pbc;326;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pbc;326;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pbc;326;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pbc;326;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pbc;326;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pbc;326;R_PBC_AIH_Budesonide_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
pbc;326;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pbc;326;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pbc;326;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pbc;326;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pbc;326;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pbc;326;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
pbc;326;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pbc;326;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pbc;326;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
pbc;326;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pbc;326;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pbc;326;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pbc;326;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
pbc;326;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_MMF_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
pbc;326;R_PBC_AIH_MMF_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
pbc;326;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
pbc;326;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
pbc;326;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Infliximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
pbc;326;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
pbc;326;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
pbc;326;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pbc;326;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
pc;6;apc_resistance;Diagnosis Aetiology;Rare Liver (Vascular);APC resistance;radio
pc;6;pc_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time at testing;radio
pc;6;pc_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
pc;6;pc_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
pc;6;pcr_cmv;Diagnosis Aetiology;Rare Liver (Vascular);PCR CMV;radio
pc;6;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
pcr;1;pcr_cmv;Diagnosis Aetiology;Rare Liver (Vascular);PCR CMV;radio
pediatric/adult;1;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
per;97;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
per;97;R_PBC_UDCA_dose_per_kg;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose mg / kg;calculation
per;97;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
per;97;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
per;97;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
per;97;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
per;97;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
per;97;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
per;97;alcohol_grams_per_week;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Average grams of ethanol per week;radio
per;97;artrophy_hypertrophy_compl;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Atrophy / hypertrophy complex;radio
per;97;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
per;97;superior_mesenteric_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Superior mesenteric vein;radio
per;97;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
per;97;evidence_hyperhomocyste;Diagnosis Aetiology;Rare Liver (Vascular);Evidence for hyperhomocysteinemia;radio
per;97;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
per;97;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
per;97;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
per;97;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
per;97;a.Performed;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
per;97;a.Performed;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
per;97;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
per;97;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
per;97;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
per;97;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
per;97;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
per;97;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
per;97;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
per;97;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
per;97;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
per;97;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
per;97;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
per;97;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
per;97;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
per;97;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
per;97;Semantic type UMLS property (URL);;ithaca;;hyperlink
per;97;ERN/HCP other contactperson (s);;ithaca;;mref
per;97;EUPID/ Person ID;;ithaca;;string
per;97;Period of first symptom onset;;ithaca;;categorical
per;97;Period of current diagnosis;;ithaca;;categorical
per;97;smoking_per_day;patient_management_at_the_hospital;EURACAN;Cigarettes/cigars smoked per day;
per;97;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
per;97;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
per;97;Familial hyperaldosteronism;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism;
per;97;Familial hyperaldosteronism type I;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type I;
per;97;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
per;97;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
per;97;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
per;97;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
per;97;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
per;97;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
per;97;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
per;97;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
per;97;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
per;97;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
per;97;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
per;97;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
per;97;Familial hypocalciuric hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia;
per;97;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
per;97;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
per;97;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
per;97;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
per;97;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
per;97;Familial hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial hyperinsulinism;
per;97;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
per;97;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
per;97;Exercise-induced hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Exercise-induced hyperinsulinism;
per;97;Hyperinsulinism due to HNF4A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF4A deficiency;
per;97;Hyperinsulinism due to INSR deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to INSR deficiency;
per;97;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
per;97;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
per;97;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to Kir6.2 deficiency;
per;97;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
per;97;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
per;97;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
per;97;Hyperinsulinism due to HNF1A deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to HNF1A deficiency;
per;97;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
per;97;Congenital isolated hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Congenital isolated hyperinsulinism;
per;97;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
per;97;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
per;97;Hyperinsulinism due to glucokinase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to glucokinase deficiency;
per;97;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
per;97;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
per;97;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
per;97;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
per;97;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
per;97;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
per;97;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
per;97;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
per;97;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
per;97;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
per;97;Upper limb mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Upper limb mesomelic dysplasia ;
per;97;High bone mass osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;High bone mass osteogenesis imperfecta ;
per;97;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
per;97;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
per;97;Osteogenesis imperfecta ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta ;
per;97;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
per;97;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
performed;17;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
performed;17;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
performed;17;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
performed;17;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
performed;17;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
performed;17;a.Performed;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
performed;17;a.Performed;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
performed;17;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
performed;17;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
performed;17;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
performed;17;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
performed;17;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
performed;17;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
performed;17;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
performed;17;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
performed;17;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
performed;17;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
perfusion;1;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
perinatal;1;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
period;5;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
period;5;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
period;5;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
period;5;Period of first symptom onset;;ithaca;;categorical
period;5;Period of current diagnosis;;ithaca;;categorical
peritonitis;1;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
perm;3;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
perm;3;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
perm;3;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
permanent;1;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
persistent;1;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
person;4;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
person;4;Contact information HCP contact person;subject;Genturis;What is the e-mail address of the HCP contact person;email
person;4;ERN/HCP other contactperson (s);;ithaca;;mref
person;4;EUPID/ Person ID;;ithaca;;string
pet;14;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
pet;14;fdg_pet_primary;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
pet;14;pet_oth_primary;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
pet;14;ct_pet_primary;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
pet;14;fdg_pet_neck;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
pet;14;pet_oth_neck;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
pet;14;ct_pet_neck;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
pet;14;unknown_pet;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
pet;14;fdg_pet_meta;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
pet;14;pet_oth_meta;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
pet;14;ct_pet_meta;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
pet;14;end_treatment_pet;imaging_available;EURACAN;PET;1, Baseline | 2, After treatment
pet;14;end_treatment_ctpet;imaging_available;EURACAN;CT/PET;1, Baseline | 2, After treatment
pet;14;Osteopetrosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteopetrosis ;
phaeochromocytoma;2;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
phaeochromocytoma;2;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
phaeochromocytoma/secreting;1;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
phenotypes;1;Phenotypes;subject;Genturis;Multiple phenotypes can be entered;mref
phenotypical;2;Phenotypical Characteristics;subject;Genturis;;compound
phenotypical;2;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
pheochromocytoma-paraganglioma;1;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
phosphat;16;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
phosphat;16;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
phosphat;16;Hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypophosphataemic rickets;
phosphat;16;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
phosphat;16;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
phosphat;16;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
phosphat;16;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
phosphat;16;X-linked hypophosphataemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;X-linked hypophosphataemia;
phosphat;16;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
phosphat;16;Hypophosphatasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Hypophosphatasia;
phosphat;16;Perinatal lethal hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Perinatal lethal hypophosphatasia ;
phosphat;16;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
phosphat;16;Infantile hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Infantile hypophosphatasia ;
phosphat;16;Childhood-onset hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Childhood-onset hypophosphatasia ;
phosphat;16;Adult hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Adult hypophosphatasia ;
phosphat;16;Odontohypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Odontohypophosphatasia ;
phosphatase;1;dia_lab_alkaline_phosphatase;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase;numeric
photons;10;radio_photons_tech;radiotherapy;EURACAN;Photons treatment technique;1, 2D | 2, 3D | 3, IMRT conventional | 4, VMAT | 5, Thomotherapy | 6, SBRT
photons;10;radio_photons_from;radiotherapy;EURACAN;Photons start date;
photons;10;radio_photons_to;radiotherapy;EURACAN;Photons end date;
photons;10;radio_photons_totdose;radiotherapy;EURACAN;Photons total dose;
photons;10;radio_photons_fractdose;radiotherapy;EURACAN;Photons dose per fraction;
photons;10;radio_photons_nrfract;radiotherapy;EURACAN;Photons number fraction;
photons;10;radio_photons_ott;radiotherapy;EURACAN;Photons OTT;"datediff([radio_photons_to],[radio_photons_from],""d"")"
photons;10;radio_photons_4d;radiotherapy;EURACAN;Photons 4D treatment;1, Yes | 2, No
photons;10;radio_photons_adaptive;radiotherapy;EURACAN;Photons adaptive RT;1, Yes | 2, No
photons;10;radio_photons_igrt;radiotherapy;EURACAN;Photons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
php;1;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
picking;1;node_picking;surgery;EURACAN;Node picking;1, Yes | 2, No | 9, Unknown
pigmentosa;1;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
pik3ca-related;1;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
pik3r1;1;PIK3R1 (Short Syndrome);GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;PIK3R1 (Short Syndrome);
pituitary;14;Pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Pituitary adenoma;
pituitary;14;Familial isolated pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Familial isolated pituitary adenoma;
pituitary;14;Functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Functioning pituitary adenoma;
pituitary;14;Mixed functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Mixed functioning pituitary adenoma;
pituitary;14;Non-functioning pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Non-functioning pituitary adenoma;
pituitary;14;Null pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Null pituitary adenoma;
pituitary;14;Silent pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Silent pituitary adenoma;
pituitary;14;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
pituitary;14;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
pituitary;14;Combined pituitary hormone deficiencies, genetic forms;PITUITARY;EuRR-Bone & EuRRECa;Combined pituitary hormone deficiencies, genetic forms;
pituitary;14;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
pituitary;14;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
pituitary;14;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
pituitary;14;Pituitary hormone deficiency from meningeal origin;PITUITARY;EuRR-Bone & EuRRECa;Pituitary hormone deficiency from meningeal origin;
place;3;"e.	Placement: 	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
place;3;Place of birth;Personal Information;PaedCan;Patient's town of birth;String
place;3;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
plasma;6;plasma_obtained;Diagnosis Biobank;Rare Liver (Vascular);Plasma sample obtained?;dropdown
plasma;6;plasma_date;Diagnosis Biobank;Rare Liver (Vascular);Plasma sample date;date
plasma;6;plasma_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
plasma;6;plasma_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
plasma;6;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
plasma;6;biom_plasma;tumour_material_available;EURACAN;Plasma;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
plasmalevel;1;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
platelet;10;R_AIH_Platelets;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;R_PBC_Platelets;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;R_PSC_Platelets;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;R_AIH_Platelets_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;R_PBC_Platelets_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
platelet;10;dia_lab_platelet_count;Diagnosis Laboratory data;Rare Liver (Vascular);Platelet count;numeric
platelet;10;fu_cli_bef_platelet_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
platelet;10;fu_cli_last_platelet_count;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
platelets;7;R_AIH_Platelets;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelets;7;R_PBC_Platelets;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelets;7;R_PSC_Platelets;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelets;7;R_AIH_Platelets_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Platelets;numeric
platelets;7;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
platelets;7;R_AIH_Platelets_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
platelets;7;R_PBC_Platelets_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
pleural;1;pleural_effusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Pleural effusion;radio
pmn;1;dia_lab_ascites_pmn;Diagnosis Laboratory data;Rare Liver (Vascular);Polymorphonuclear neutrophils;numeric
pmol;8;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmol;8;R_AIH_MMP_pmol_02ml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmol;8;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmol;8;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmol;8;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmol;8;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmol;8;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmol;8;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmol02ml;3;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmol02ml;3;R_AIH_MMP_pmol02ml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmol02ml;3;R_PBC_MMP_pmol02ml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
pmolml;4;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmolml;4;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmolml;4;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pmolml;4;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
pnh;1;pnh;Diagnosis Aetiology;Rare Liver (Vascular);Paroxysmal nocturnal hemoglobinuria: CD55 and CD59 deficient clone at flow cytometry;radio
poh;1; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
point;5;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
point;5;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
point;5;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
point;5;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
point;5;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
polyendocrinopathy;4;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
polyendocrinopathy;4;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
polyendocrinopathy;4;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
polyendocrinopathy;4;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
polyglandular;2;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
polyglandular;2;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
polyhydramnios;1;Polyhydramnios;Diagnosis Developmental;EURO-NMD;;yesno
polyostotic;1;Polyostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Polyostotic fibrous dysplasia ;
polyposis;1;Polyposis syndrome;benignNeoplasm;Genturis;What is the dominant polyp type?;xref
polyps;1;Number of polyps;benignNeoplasm;Genturis;What is the maximal number of these polyps ever observed in this patient?;int
por;45;R_AIH_CyclosporinA;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
por;45;R_PBC_AIH_CyclosporinA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
por;45;R_PSC_AIH_CyclosporinA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
por;45;R_AIH_CyclosporinA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
por;45;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
por;45;R_AIH_CyclosporinA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
por;45;R_PBC_AIH_CyclosporinA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
por;45;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
por;45;portal_vein_thromb;Diagnosis General Information;Rare Liver (Vascular);For Portal vein thrombosis;radio
por;45;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
por;45;right_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein branch;radio
por;45;left_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein branch;radio
por;45;portoportal_cavernoma;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portoportal cavernoma;radio
por;45;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
por;45;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
por;45;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
por;45;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
por;45;date_mesenterico_portal;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
por;45;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
por;45;portal_recanalization;Follow-up Events;Rare Liver (Vascular);Portal recanalization;radio
por;45;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
por;45;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
por;45;Full caryotype (if not inferred from CNV report);;ithaca;;string
por;45;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
por;45;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
por;45;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
por;45;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
por;45;Learning support at school;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Requiring extra help at school with learning;Y/N/Not Known
por;45;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
por;45;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
por;45;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
por;45;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dominant hypophosphataemia with nephrolithiasis or osteoporosis;
por;45;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
por;45;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
por;45;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
por;45;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
por;45;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
por;45;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
por;45;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
portal;10;portal_vein_thromb;Diagnosis General Information;Rare Liver (Vascular);For Portal vein thrombosis;radio
portal;10;right_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein branch;radio
portal;10;left_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein branch;radio
portal;10;portoportal_cavernoma;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portoportal cavernoma;radio
portal;10;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
portal;10;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
portal;10;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
portal;10;date_mesenterico_portal;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
portal;10;portal_recanalization;Follow-up Events;Rare Liver (Vascular);Portal recanalization;radio
portal;10;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
porto;4;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
porto;4;portoportal_cavernoma;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portoportal cavernoma;radio
porto;4;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
porto;4;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
portoportal;1;portoportal_cavernoma;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portoportal cavernoma;radio
portopulm;1;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
portosystemic;1;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
pos;19;Arthrogryposis;Diagnosis Skeletal;EURO-NMD;;yesno
pos;19;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pos;19;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pos;19;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pos;19;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pos;19;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
pos;19;"h.	Post-operative drainage:	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Tickbox, multipleÂ selection]
pos;19;Polyposis syndrome;benignNeoplasm;Genturis;What is the dominant polyp type?;xref
pos;19;Postal code;;ithaca;;string
pos;19;exposure;patient_management_at_the_hospital;EURACAN;Exposure to carcinogens (IARC);1, X-radiation, gamma-radiation | 2, Formaldehyde | 3, Salted fish | 4, Wood dust | 5, Others | 6, None | 9, Unknown
pos;19;exposure_other;patient_management_at_the_hospital;EURACAN;Please specify;
pos;19;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
pos;19;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
pos;19;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
pos;19;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
pos;19;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
pos;19;Isolated hypospadias;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated hypospadias;
pos;19;(postnatal) ultrasound ;Imaging;ERKNet;Â ;Â 
pos;19;(postnatal) MRI ;Imaging;ERKNet;Â ;Â 
positive;5;R_PBC_Deposition_orcein_positive_granules_nakanuma;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
positive;5;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
positive;5;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
positive;5;R_AIH_Deposition_orcein_positive_granules_nakanuma_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
positive;5;R_PBC_Deposition_orcein_positive_granules_nakanuma_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
postnatal;2;(postnatal) ultrasound ;Imaging;ERKNet;Â ;Â 
postnatal;2;(postnatal) MRI ;Imaging;ERKNet;Â ;Â 
pr;331;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
pr;331;Tensilon/Prostigmine test response;Diagnosis ;EURO-NMD;;single
pr;331;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
pr;331;R_AIH_Prednisolone;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_AIH_Prednisolone_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Azathioprine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_AIH_Azathioprine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pr;331;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_Pruritus;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Pruritus;radio
pr;331;R_PBC_Prednisolone;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_PBC_Prednisolone_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_Azathioprine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_PBC_Azathioprine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pr;331;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
pr;331;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pr;331;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
pr;331;R_PSC_Pruritus;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Pruritus;radio
pr;331;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
pr;331;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
pr;331;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pr;331;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
pr;331;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pr;331;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pr;331;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pr;331;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
pr;331;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
pr;331;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pr;331;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pr;331;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pr;331;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pr;331;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pr;331;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pr;331;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pr;331;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pr;331;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pr;331;syst_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systolic blood pressue;numeric
pr;331;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
pr;331;biopsie_proven_cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Biopsie proven cirrhosis;radio
pr;331;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
pr;331;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
pr;331;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
pr;331;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
pr;331;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
pr;331;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
pr;331;prot_c_decreased;Diagnosis Aetiology;Rare Liver (Vascular);Protein C activity decreased?;radio
pr;331;prot_c_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein C deficiency activity;numeric
pr;331;prot_c_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein C mutation;radio
pr;331;prot_s_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein S decreased activity?;radio
pr;331;prot_s1_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein S mutation;radio
pr;331;protein_s_deficiency;Diagnosis Aetiology;Rare Liver (Vascular);Protein S deficiency activity (%);numeric
pr;331;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
pr;331;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
pr;331;comments_pregnancy;Diagnosis Aetiology;Rare Liver (Vascular);Comments;textarea
pr;331;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
pr;331;med_assist_repro_history;Diagnosis Aetiology;Rare Liver (Vascular);History of medically assisted reproduction;radio
pr;331;med_assist_repro_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of medically assisted reproduction;date
pr;331;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
pr;331;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
pr;331;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
pr;331;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
pr;331;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
pr;331;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
pr;331;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
pr;331;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
pr;331;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
pr;331;pregnancy;Follow-up Events;Rare Liver (Vascular);Pregnancy;radio
pr;331;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
pr;331;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
pr;331;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
pr;331;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
pr;331;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
pr;331;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
pr;331;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
pr;331;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
pr;331;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
pr;331;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
pr;331;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
pr;331;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
pr;331;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
pr;331;b. Procedure;1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pr;331;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
pr;331;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pr;331;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pr;331;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pr;331;a. Procedure:Â ;2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[Tickbox, multipleÂ selection]
pr;331;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
pr;331;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pr;331;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pr;331;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
pr;331;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
pr;331;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pr;331;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pr;331;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pr;331;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
pr;331;PR receptor status;malignancy;Genturis;What is the Progesteron receptor status of the breast cancer?;categorical
pr;331;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
pr;331;Proband status;subject;Genturis;Is this a proband patient or relative?;enum
pr;331;Relation to proband;subject;Genturis;What is the relation of this patient to the proband?;xref
pr;331;Semantic type UMLS property (URL);;ithaca;;hyperlink
pr;331;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
pr;331;Healthcare Provider (HCP);;ithaca;;xref
pr;331;Primary Thematic Area;;ithaca;;categorical
pr;331;Pregnancy;;ithaca;;bool
pr;331;Protein sequence (RefSeq id/LRG id);;ithaca;;string
pr;331;Protein variant description;;ithaca;;text
pr;331;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
pr;331;prev_hn_radio;previous_cancer_genetic_syndromes;EURACAN;Previous radiotherapy at head and neck site;1, Yes | 2, No | 9, Unknown
pr;331;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
pr;331;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
pr;331;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
pr;331;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
pr;331;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
pr;331;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
pr;331;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
pr;331;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
pr;331;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
pr;331;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
pr;331;prev_not_hn;previous_cancer_genetic_syndromes;EURACAN;Other malignant cancers different from cancers of head and neck;1, Yes | 2, No | 9, Unknown
pr;331;prev_not_hn_spec;previous_cancer_genetic_syndromes;EURACAN;Please select the malignant cancers different from cancers of head and neck;99, Unknown | 1, Adrenal Glands | 2, Anal Canal & Anus | 3, Appendix | 4, Bones & Joints (Excl Skull And Face, Mandible) | 5, Bones Of Skull And Face | 6, Brain, & Cranial Nerves, & Spinal Cord, (Excl. Ventricle, Cerebellum) | 7, Breast | 8, Cerebellum | 9, Cervix Uteri | 10, Corpus Uteri | 11, Craniopharyngeal Duct | 12, Esophagus | 13, Eyeball | 14, Fallopian Tube | 15, Gallbladder & Extrahepatic Bile Ducts | 16, Heart | 17, Intrahepatic Bile Ducts | 18, Kidney | 19, Large Intestine (Excl. Appendix) | 20, Liver | 21, Lung & Bronchus | 22, Mandible | 23, Mediastinum | 24, Melanoma Skin | 25, Meninges (Cerebral, Spinal | 26, Orbit & Lacrimal Gland (Excl Ret, Eye, Nos) | 27, Ovary | 28, Pancreas | 29, Parathyroid Gland | 30, Penis | 31, Peripheral Nerves | 32, Peritoneum | 33, Pineal Gland | 34, Pituitary Gland | 35, Placenta | 36, Pleura | 37, Prostate Gland | 38, Rectum | 39, Renal Pelvis | 40, Retina | 41, Retroperitoneum | 42, Sarcoma | 43, Scrotum | 44, Small Intestine | 45, Stomach | 46, Testis | 47, Thymus | 48, Thyroid Gland | 49, Trachea | 50, Ureter | 51, Urinary Bladder | 52, Vagina & Labia | 53, Ventricle | 54, Vulva
pr;331;prev_not_hn_sarc;previous_cancer_genetic_syndromes;EURACAN;Please specify;1, Soft Tissue | 2, Viscera | 3, Bone
pr;331;prev_not_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
pr;331;prev_pre_canc_lesions_ynu;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Yes | 2, No | 9, Unknown
pr;331;prev_pre_canc_lesions;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Pleomorphic adenoma | 2, Sinonasal papillomas | 3, Oral premalignant lesions
pr;331;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
pr;331;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
pr;331;staging_proc_req;stage_procedures;EURACAN;Staging procedures done/requested by;1, the hospital | 2, a different hospital
pr;331;imag_primary;stage_procedures;EURACAN;Imaging for primary site;1, Yes | 2, No | 3, Unknown
pr;331;ct_primary;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
pr;331;mri_primary;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
pr;331;us_primary;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
pr;331;fdg_pet_primary;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
pr;331;pet_oth_primary;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
pr;331;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
pr;331;ct_pet_primary;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
pr;331;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
pr;331;imag_primary_oth;stage_procedures;EURACAN;Other imaging for primary site;
pr;331;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
pr;331;radio_protons_tech;radiotherapy;EURACAN;Protons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
pr;331;radio_protons_from;radiotherapy;EURACAN;Protons start date;
pr;331;radio_protons_totdose;radiotherapy;EURACAN;Protons total dose;
pr;331;radio_protons_to;radiotherapy;EURACAN;Protons end date;
pr;331;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
pr;331;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
pr;331;radio_protons_ott;radiotherapy;EURACAN;Protons OTT;"datediff([radio_protons_to],[radio_protons_from],""d"")"
pr;331;radio_protons_4d;radiotherapy;EURACAN;Protons 4D treatment;1, Yes | 2, No
pr;331;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
pr;331;radio_protons_igrt;radiotherapy;EURACAN;Protons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
pr;331;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
pr;331;Previous malignancy;Patient's history;PaedCan;Did the patient suffer from any malignancy before?;yes/no/unknown
pr;331;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
pr;331;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
pr;331;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
pr;331;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
pr;331;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
pr;331;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
pr;331;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
pr;331;Presence of sequelae;Follow up (one form for each follow up visit);PaedCan;;yes/no/unknown
pr;331;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
pr;331;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
pr;331;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
pr;331;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
pr;331;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
pr;331;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
pr;331;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
pr;331;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
pr;331;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
pr;331;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
pr;331;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
pr;331;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
pr;331;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
pr;331;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
pr;331;Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi Syndrome;
pr;331;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
pr;331;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
pr;331;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
pr;331;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
pr;331;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
pr;331;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
pr;331;Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome;
pr;331;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
pr;331;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
pr;331;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
pr;331;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
pr;331;Pro-opiomelanocortin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pro-opiomelanocortin deficiency;
pr;331;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
pr;331;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
pr;331;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
pr;331;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
pr;331;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
pr;331;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
pr;331;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
pr;331;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
pr;331;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
pr;331;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
pr;331;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
pr;331;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
pr;331;Prolactinoma;PITUITARY;EuRR-Bone & EuRRECa;Prolactinoma;
pr;331;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
pr;331;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
pr;331;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
pr;331;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
pr;331;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
pr;331;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
pr;331;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
pr;331; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
pr;331; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
pr;331;Blook pressure;Clinical Status;ERKNet;Â ;bp_sys/bp_dia/bp_sys_sds/bp_dia_sds
pr;331;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
pr;331;Proteinuria ;Biochemistry;ERKNet;Â ;protur
pr;331;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
pr;331;Protein/Creatinine;Biochemistry;ERKNet;if 2;protur_protcrea
prader-willi;20;Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi Syndrome;
prader-willi;20;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
prader-willi;20;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
prader-willi;20;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
prader-willi;20;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
prader-willi;20;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
prader-willi;20;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
prader-willi;20;Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome;
prader-willi;20;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
prader-willi;20;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
prader-willi;20;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
prader-willi;20;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
prader-willi;20;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
prader-willi;20;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
prader-willi;20;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
prader-willi;20;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
prader-willi;20;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
prader-willi;20;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
prader-willi;20;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
prader-willi;20;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
prader-willi-like;6;Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome;
prader-willi-like;6;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
prader-willi-like;6;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
prader-willi-like;6;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
prader-willi-like;6;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
prader-willi-like;6;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
pre;92;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
pre;92;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
pre;92;R_AIH_Prednisolone;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_AIH_Prednisolone_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pre;92;R_PBC_Prednisolone;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_PBC_Prednisolone_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pre;92;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
pre;92;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
pre;92;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
pre;92;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
pre;92;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
pre;92;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pre;92;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pre;92;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pre;92;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pre;92;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pre;92;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pre;92;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pre;92;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pre;92;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pre;92;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
pre;92;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pre;92;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
pre;92;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pre;92;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pre;92;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pre;92;syst_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systolic blood pressue;numeric
pre;92;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
pre;92;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
pre;92;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
pre;92;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
pre;92;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
pre;92;comments_pregnancy;Diagnosis Aetiology;Rare Liver (Vascular);Comments;textarea
pre;92;pregnancy;Follow-up Events;Rare Liver (Vascular);Pregnancy;radio
pre;92;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
pre;92;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
pre;92;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
pre;92;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
pre;92;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pre;92;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pre;92;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
pre;92;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pre;92;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
pre;92;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
pre;92;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
pre;92;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
pre;92;Pregnancy;;ithaca;;bool
pre;92;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
pre;92;prev_hn_radio;previous_cancer_genetic_syndromes;EURACAN;Previous radiotherapy at head and neck site;1, Yes | 2, No | 9, Unknown
pre;92;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
pre;92;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
pre;92;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
pre;92;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
pre;92;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
pre;92;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
pre;92;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
pre;92;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
pre;92;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
pre;92;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
pre;92;prev_not_hn;previous_cancer_genetic_syndromes;EURACAN;Other malignant cancers different from cancers of head and neck;1, Yes | 2, No | 9, Unknown
pre;92;prev_not_hn_spec;previous_cancer_genetic_syndromes;EURACAN;Please select the malignant cancers different from cancers of head and neck;99, Unknown | 1, Adrenal Glands | 2, Anal Canal & Anus | 3, Appendix | 4, Bones & Joints (Excl Skull And Face, Mandible) | 5, Bones Of Skull And Face | 6, Brain, & Cranial Nerves, & Spinal Cord, (Excl. Ventricle, Cerebellum) | 7, Breast | 8, Cerebellum | 9, Cervix Uteri | 10, Corpus Uteri | 11, Craniopharyngeal Duct | 12, Esophagus | 13, Eyeball | 14, Fallopian Tube | 15, Gallbladder & Extrahepatic Bile Ducts | 16, Heart | 17, Intrahepatic Bile Ducts | 18, Kidney | 19, Large Intestine (Excl. Appendix) | 20, Liver | 21, Lung & Bronchus | 22, Mandible | 23, Mediastinum | 24, Melanoma Skin | 25, Meninges (Cerebral, Spinal | 26, Orbit & Lacrimal Gland (Excl Ret, Eye, Nos) | 27, Ovary | 28, Pancreas | 29, Parathyroid Gland | 30, Penis | 31, Peripheral Nerves | 32, Peritoneum | 33, Pineal Gland | 34, Pituitary Gland | 35, Placenta | 36, Pleura | 37, Prostate Gland | 38, Rectum | 39, Renal Pelvis | 40, Retina | 41, Retroperitoneum | 42, Sarcoma | 43, Scrotum | 44, Small Intestine | 45, Stomach | 46, Testis | 47, Thymus | 48, Thyroid Gland | 49, Trachea | 50, Ureter | 51, Urinary Bladder | 52, Vagina & Labia | 53, Ventricle | 54, Vulva
pre;92;prev_not_hn_sarc;previous_cancer_genetic_syndromes;EURACAN;Please specify;1, Soft Tissue | 2, Viscera | 3, Bone
pre;92;prev_not_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
pre;92;prev_pre_canc_lesions_ynu;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Yes | 2, No | 9, Unknown
pre;92;prev_pre_canc_lesions;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Pleomorphic adenoma | 2, Sinonasal papillomas | 3, Oral premalignant lesions
pre;92;Previous malignancy;Patient's history;PaedCan;Did the patient suffer from any malignancy before?;yes/no/unknown
pre;92;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
pre;92;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
pre;92;Presence of sequelae;Follow up (one form for each follow up visit);PaedCan;;yes/no/unknown
pre;92;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
pre;92;Blook pressure;Clinical Status;ERKNet;Â ;bp_sys/bp_dia/bp_sys_sds/bp_dia_sds
pre;92;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
prednisolone;33;R_AIH_Prednisolone;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_AIH_Prednisolone_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_PBC_Prednisolone;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_PBC_Prednisolone_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
prednisolone;33;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
prednisolone;33;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
prednisolone;33;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
prednisolone;33;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
prednisolone;33;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
prednisolone;33;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
prednisolone;33;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
prednisolone;33;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
prednisolone;33;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
prednisolone;33;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
prednisone;1;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
pregnancy;9;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
pregnancy;9;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pregnancy;9;R_AIH_Pregnancy_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pregnancy;9;R_PBC_Pregnancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
pregnancy;9;comments_pregnancy;Diagnosis Aetiology;Rare Liver (Vascular);Comments;textarea
pregnancy;9;pregnancy;Follow-up Events;Rare Liver (Vascular);Pregnancy;radio
pregnancy;9;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
pregnancy;9;pregnancy_delivery_date;Follow-up Events;Rare Liver (Vascular);Date of delivery;date
pregnancy;9;Pregnancy;;ithaca;;bool
premenarcheal;1;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
prenatal;1;Prenatal benign hypophosphatasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Prenatal benign hypophosphatasia ;
presence;1;Presence of sequelae;Follow up (one form for each follow up visit);PaedCan;;yes/no/unknown
present;3;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
present;3;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
present;3;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
press;18;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
press;18;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
press;18;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
press;18;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
press;18;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
press;18;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
press;18;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
press;18;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
press;18;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
press;18;syst_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systolic blood pressue;numeric
press;18;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
press;18;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
press;18;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
press;18;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
press;18;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
press;18;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
press;18;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
press;18;Blook pressure;Clinical Status;ERKNet;Â ;bp_sys/bp_dia/bp_sys_sds/bp_dia_sds
pressure;3;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
pressure;3;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
pressure;3;Blook pressure;Clinical Status;ERKNet;Â ;bp_sys/bp_dia/bp_sys_sds/bp_dia_sds
prev;25;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
prev;25;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
prev;25;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
prev;25;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
prev;25;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
prev;25;prev_hn_radio;previous_cancer_genetic_syndromes;EURACAN;Previous radiotherapy at head and neck site;1, Yes | 2, No | 9, Unknown
prev;25;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
prev;25;prev_hn_chemo;previous_cancer_genetic_syndromes;EURACAN;Previous chemotherapy for head and neck cancer;1, Yes | 2, No | 9, Unknown
prev;25;prev_hn_chemo_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of chemotherapy;
prev;25;prev_anti_neoplastic;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents for head and neck cancer;1, Yes | 2, No | 9, Unknown
prev;25;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
prev;25;prev_anti_neopl_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of anti neoplastic agents;
prev;25;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
prev;25;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
prev;25;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
prev;25;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
prev;25;prev_not_hn;previous_cancer_genetic_syndromes;EURACAN;Other malignant cancers different from cancers of head and neck;1, Yes | 2, No | 9, Unknown
prev;25;prev_not_hn_spec;previous_cancer_genetic_syndromes;EURACAN;Please select the malignant cancers different from cancers of head and neck;99, Unknown | 1, Adrenal Glands | 2, Anal Canal & Anus | 3, Appendix | 4, Bones & Joints (Excl Skull And Face, Mandible) | 5, Bones Of Skull And Face | 6, Brain, & Cranial Nerves, & Spinal Cord, (Excl. Ventricle, Cerebellum) | 7, Breast | 8, Cerebellum | 9, Cervix Uteri | 10, Corpus Uteri | 11, Craniopharyngeal Duct | 12, Esophagus | 13, Eyeball | 14, Fallopian Tube | 15, Gallbladder & Extrahepatic Bile Ducts | 16, Heart | 17, Intrahepatic Bile Ducts | 18, Kidney | 19, Large Intestine (Excl. Appendix) | 20, Liver | 21, Lung & Bronchus | 22, Mandible | 23, Mediastinum | 24, Melanoma Skin | 25, Meninges (Cerebral, Spinal | 26, Orbit & Lacrimal Gland (Excl Ret, Eye, Nos) | 27, Ovary | 28, Pancreas | 29, Parathyroid Gland | 30, Penis | 31, Peripheral Nerves | 32, Peritoneum | 33, Pineal Gland | 34, Pituitary Gland | 35, Placenta | 36, Pleura | 37, Prostate Gland | 38, Rectum | 39, Renal Pelvis | 40, Retina | 41, Retroperitoneum | 42, Sarcoma | 43, Scrotum | 44, Small Intestine | 45, Stomach | 46, Testis | 47, Thymus | 48, Thyroid Gland | 49, Trachea | 50, Ureter | 51, Urinary Bladder | 52, Vagina & Labia | 53, Ventricle | 54, Vulva
prev;25;prev_not_hn_sarc;previous_cancer_genetic_syndromes;EURACAN;Please specify;1, Soft Tissue | 2, Viscera | 3, Bone
prev;25;prev_not_hn_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of diagnosis;
prev;25;prev_pre_canc_lesions_ynu;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Yes | 2, No | 9, Unknown
prev;25;prev_pre_canc_lesions;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Pleomorphic adenoma | 2, Sinonasal papillomas | 3, Oral premalignant lesions
prev;25;Previous malignancy;Patient's history;PaedCan;Did the patient suffer from any malignancy before?;yes/no/unknown
prev;25;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
prev;25;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
previous;8;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
previous;8;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
previous;8;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
previous;8;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
previous;8;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
previous;8;Previous malignancy;Patient's history;PaedCan;Did the patient suffer from any malignancy before?;yes/no/unknown
previous;8;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
previous;8;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
pri;153;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_AIH_Azathioprine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_Azathioprine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_PBC_Azathioprine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
pri;153;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
pri;153;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_AIH_Azathioprine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine_metabolites_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Azathioprine metabolites;radio
pri;153;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
pri;153;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pri;153;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pri;153;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pri;153;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pri;153;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_AIH_Azathioprine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Azathioprine_metabolites_assessed_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
pri;153;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_Azathioprine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_PBC_Azathioprine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
pri;153;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Azathioprine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
pri;153;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pri;153;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pri;153;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pri;153;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
pri;153;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
pri;153;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
pri;153;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pri;153;Primary Thematic Area;;ithaca;;categorical
pri;153;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
pri;153;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
pri;153;imag_primary;stage_procedures;EURACAN;Imaging for primary site;1, Yes | 2, No | 3, Unknown
pri;153;ct_primary;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
pri;153;mri_primary;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
pri;153;us_primary;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
pri;153;fdg_pet_primary;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
pri;153;pet_oth_primary;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
pri;153;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
pri;153;ct_pet_primary;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
pri;153;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
pri;153;imag_primary_oth;stage_procedures;EURACAN;Other imaging for primary site;
pri;153;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
pri;153;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
pri;153;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
pri;153;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
pri;153;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
pri;153;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
pri;153;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
pri;153;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
pri;153;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
pri;153;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
pri;153;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
pri;153;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
pri;153;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
pri;153;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
pri;153;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
pri;153;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
pri;153;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
pri;153;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
pri;153;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
pri;153;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
pri;153;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
pri;153;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
pri;153;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
pri;153;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
pri;153;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
primary;111;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Budesonide_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Azathioprine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_MMF_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Infliximap_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_cyclosporinA_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Budesonide_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Azathioprine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_MMF_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Infliximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_CyclosporinA_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Budesonide_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Azathioprine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_MMF_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_CyclosporinA_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Infliximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Budesonide_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Azathioprine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_MMF_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_CyclosporinA_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Infliximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_Budesonide_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_Azathioprine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_MMF_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_CyclosporinA_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Infliximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
primary;111;fu_primary_liver_cancer;Follow-up Complications;Rare Liver (Vascular);Primary liver cancer;radio
primary;111;Primary Thematic Area;;ithaca;;categorical
primary;111;imag_primary;stage_procedures;EURACAN;Imaging for primary site;1, Yes | 2, No | 3, Unknown
primary;111;ct_primary;stage_procedures;EURACAN;CT;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
primary;111;mri_primary;stage_procedures;EURACAN;MRI;1, Yes, with contrast | 2, Yes, without contrast | 3, No | 9, Unknown
primary;111;us_primary;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
primary;111;fdg_pet_primary;stage_procedures;EURACAN;FDG PET;1, Yes | 2, No | 9, Unknown
primary;111;pet_oth_primary;stage_procedures;EURACAN;PET with other tracers;1, Yes | 2, No | 9, Unknown
primary;111;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
primary;111;ct_pet_primary;stage_procedures;EURACAN;CT/PET;1, Yes | 2, No | 9, Unknown
primary;111;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
primary;111;imag_primary_oth;stage_procedures;EURACAN;Other imaging for primary site;
primary;111;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
primary;111;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
primary;111;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
primary;111;Primary Endocrine Condition;Disease History;EuRR-Bone & EuRRECa;Conditions covered within each Condition Group;Drop down category
primary;111;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
primary;111;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
primary;111;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
primary;111;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
primary;111;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
primary;111;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
primary;111;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
primary;111;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
primary;111;Primary bone dysplasia with increased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with increased bone density;
primary;111;Primary bone dysplasia with decreased bone density;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with decreased bone density;
primary;111;Primary bone dysplasia with defective bone mineralization;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with defective bone mineralization;
primary;111;Primary bone dysplasia with micromelia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with micromelia;
primary;111;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
primer;4;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
primer;4;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
primer;4;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
primer;4;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
primordial;2;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
primordial;2;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
prior;2;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
prior;2;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
pro-opiomelanocortin;1;Pro-opiomelanocortin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pro-opiomelanocortin deficiency;
proband;2;Proband status;subject;Genturis;Is this a proband patient or relative?;enum
proband;2;Relation to proband;subject;Genturis;What is the relation of this patient to the proband?;xref
proc;13;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
proc;13;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
proc;13;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
proc;13;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
proc;13;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
proc;13;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
proc;13;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
proc;13;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
proc;13;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
proc;13;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
proc;13;b. Procedure;1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
proc;13;a. Procedure:Â ;2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[Tickbox, multipleÂ selection]
proc;13;staging_proc_req;stage_procedures;EURACAN;Staging procedures done/requested by;1, the hospital | 2, a different hospital
procedure;6;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
procedure;6;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
procedure;6;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
procedure;6;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
procedure;6;b. Procedure;1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
procedure;6;a. Procedure:Â ;2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[Tickbox, multipleÂ selection]
progenit;1;culture_erythroid_progenit;Diagnosis Aetiology;Rare Liver (Vascular);Culture of erythroid progenitors;radio
progressiva;1; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
progressive;3;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
progressive;3;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
progressive;3; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
prohormone;1;Prohormone convertase I deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prohormone convertase I deficiency;
prolactinoma;1;Prolactinoma;PITUITARY;EuRR-Bone & EuRRECa;Prolactinoma;
promoter;1;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
prophylaxis;2;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
prophylaxis;2;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
prot;34;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
prot;34;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
prot;34;prot_c_decreased;Diagnosis Aetiology;Rare Liver (Vascular);Protein C activity decreased?;radio
prot;34;prot_c_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein C deficiency activity;numeric
prot;34;prot_c_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein C mutation;radio
prot;34;prot_s_activity;Diagnosis Aetiology;Rare Liver (Vascular);Protein S decreased activity?;radio
prot;34;prot_s1_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein S mutation;radio
prot;34;protein_s_deficiency;Diagnosis Aetiology;Rare Liver (Vascular);Protein S deficiency activity (%);numeric
prot;34;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prot;34;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
prot;34;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prot;34;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prot;34;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
prot;34;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
prot;34;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
prot;34;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
prot;34;Protein sequence (RefSeq id/LRG id);;ithaca;;string
prot;34;Protein variant description;;ithaca;;text
prot;34;radio_protons_tech;radiotherapy;EURACAN;Protons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
prot;34;radio_protons_from;radiotherapy;EURACAN;Protons start date;
prot;34;radio_protons_totdose;radiotherapy;EURACAN;Protons total dose;
prot;34;radio_protons_to;radiotherapy;EURACAN;Protons end date;
prot;34;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
prot;34;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
prot;34;radio_protons_ott;radiotherapy;EURACAN;Protons OTT;"datediff([radio_protons_to],[radio_protons_from],""d"")"
prot;34;radio_protons_4d;radiotherapy;EURACAN;Protons 4D treatment;1, Yes | 2, No
prot;34;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
prot;34;radio_protons_igrt;radiotherapy;EURACAN;Protons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
prot;34;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
prot;34;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
prot;34;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
prot;34;Proteinuria ;Biochemistry;ERKNet;Â ;protur
prot;34;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
prot;34;Protein/Creatinine;Biochemistry;ERKNet;if 2;protur_protcrea
protein;9;protein_s_deficiency;Diagnosis Aetiology;Rare Liver (Vascular);Protein S deficiency activity (%);numeric
protein;9;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
protein;9;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
protein;9;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
protein;9;Protein sequence (RefSeq id/LRG id);;ithaca;;string
protein;9;Protein variant description;;ithaca;;text
protein;9;Proteinuria ;Biochemistry;ERKNet;Â ;protur
protein;9;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
protein;9;Protein/Creatinine;Biochemistry;ERKNet;if 2;protur_protcrea
protein/creatinine;1;Protein/Creatinine;Biochemistry;ERKNet;if 2;protur_protcrea
proteinuria;2;Proteinuria ;Biochemistry;ERKNet;Â ;protur
proteinuria;2;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
proth;6;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
proth;6;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
proth;6;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
proth;6;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
proth;6;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
proth;6;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prothrom;5;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
prothrom;5;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prothrom;5;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
prothrom;5;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prothrom;5;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prothrombin;4;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prothrombin;4;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
prothrombin;4;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
prothrombin;4;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
protocol;3;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
protocol;3;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
protocol;3;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
protons;10;radio_protons_tech;radiotherapy;EURACAN;Protons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
protons;10;radio_protons_from;radiotherapy;EURACAN;Protons start date;
protons;10;radio_protons_totdose;radiotherapy;EURACAN;Protons total dose;
protons;10;radio_protons_to;radiotherapy;EURACAN;Protons end date;
protons;10;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
protons;10;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
protons;10;radio_protons_ott;radiotherapy;EURACAN;Protons OTT;"datediff([radio_protons_to],[radio_protons_from],""d"")"
protons;10;radio_protons_4d;radiotherapy;EURACAN;Protons 4D treatment;1, Yes | 2, No
protons;10;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
protons;10;radio_protons_igrt;radiotherapy;EURACAN;Protons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
proven;3;biopsie_proven_cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Biopsie proven cirrhosis;radio
proven;3;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
proven;3;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
provided;1;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
pruritus;4;R_PBC_Pruritus;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Pruritus;radio
pruritus;4;R_PSC_Pruritus;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Pruritus;radio
pruritus;4;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
pruritus;4;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
ps;452;Achromatopsia;Diagnosis ;EURO-NMD;;single
ps;452;Achromatopsia Titer;Diagnosis ;EURO-NMD;;
ps;452;If thymoma, relapse?;Thymoma;EURO-NMD;;
ps;452;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
ps;452;pseudonym;Base information;Rare Liver (Auto imune);Pseudonym;calculation
ps;452;R_AIH_Liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver biopsy;radio
ps;452;R_AIH_Date_liver_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Date of liver biopsy;date
ps;452;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
ps;452;R_PBC_Liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
ps;452;R_PBC_Date_liver_biopsy;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
ps;452;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
ps;452;R_PSC_Year_of_birth;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
ps;452;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
ps;452;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
ps;452;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
ps;452;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
ps;452;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
ps;452;R_PSC_Weight;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
ps;452;R_PSC_Height;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
ps;452;R_PSC_BMI;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
ps;452;R_PSC_Sex;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
ps;452;R_PSC_Ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
ps;452;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
ps;452;R_PSC_Alcohol;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol per day;radio
ps;452;R_PSC_Smoking;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
ps;452;PSC_is_smoker;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
ps;452;R_PSC_Smoking_amount;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount (pack years);numeric
ps;452;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
ps;452;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
ps;452;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
ps;452;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
ps;452;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
ps;452;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
ps;452;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
ps;452;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
ps;452;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
ps;452;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
ps;452;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ps;452;R_PSC_mHAI;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
ps;452;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
ps;452;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
ps;452;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
ps;452;R_PSC_not_in_db4;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma grade;calculation
ps;452;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
ps;452;R_PSC_Fibrosis_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
ps;452;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
ps;452;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
ps;452;R_PSC_not_in_db42;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma score;calculation
ps;452;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
ps;452;R_PSC_Additional_nafld;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
ps;452;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
ps;452;R_PSC_MRCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);MRCP;radio
ps;452;R_PSC_ERCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP;radio
ps;452;R_PSC_PTCD;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);PTCD;radio
ps;452;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
ps;452;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
ps;452;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
ps;452;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
ps;452;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ps;452;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
ps;452;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
ps;452;R_PSC_Spleen_size;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size;numeric
ps;452;R_PSC_Colonoscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Colonoscopy;radio
ps;452;R_PSC_IBD_status;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD Status;radio
ps;452;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
ps;452;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
ps;452;R_PSC_IBD_remission;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD in histological remission;radio
ps;452;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
ps;452;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
ps;452;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
ps;452;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
ps;452;R_PSC_AST;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
ps;452;R_PSC_ALT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
ps;452;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
ps;452;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
ps;452;R_PSC_ALP;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
ps;452;R_PSC_yGT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGT;numeric
ps;452;R_PSC_Albumin;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
ps;452;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
ps;452;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
ps;452;R_PSC_INR;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
ps;452;R_PSC_Platelets;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
ps;452;R_PSC_IgG;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
ps;452;R_PSC_IgM;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
ps;452;R_PSC_IgA;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
ps;452;R_PSC_yGlobulins;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ps;452;R_PSC_IgG4;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG4;numeric
ps;452;R_PSC_ANA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
ps;452;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ps;452;R_PSC_ANA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ps;452;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ps;452;R_PSC_SMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
ps;452;R_PSC_SMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
ps;452;R_PSC_SMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
ps;452;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
ps;452;R_PSC_LKM;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
ps;452;R_PSC_LKM_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
ps;452;R_PSC_LKM1_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
ps;452;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
ps;452;R_PSC_SLA_LP;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
ps;452;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
ps;452;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
ps;452;R_PSC_AMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
ps;452;R_PSC_AMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ps;452;R_PSC_AMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ps;452;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ps;452;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
ps;452;R_PSC_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
ps;452;R_PSC_Date_of_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
ps;452;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
ps;452;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
ps;452;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
ps;452;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
ps;452;R_PSC_Serum;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
ps;452;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
ps;452;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
ps;452;R_PSC_UDCA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA;radio
ps;452;R_PSC_UDCA_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
ps;452;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
ps;452;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ps;452;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
ps;452;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Budesonide;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
ps;452;R_PSC_Budesonide_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
ps;452;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
ps;452;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
ps;452;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Infliximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
ps;452;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Adalimumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Adalimumab;radio
ps;452;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Vedolizumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Vedolizumab;radio
ps;452;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Ustekinumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Ustekinumab;radio
ps;452;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
ps;452;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
ps;452;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ps;452;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
ps;452;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_MMF;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
ps;452;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
ps;452;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Tacrolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
ps;452;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_CyclosporinA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
ps;452;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Rituximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
ps;452;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
ps;452;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
ps;452;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
ps;452;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ps;452;R_PSC_Ascites;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Ascites;radio
ps;452;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ps;452;R_PSC_Variceal_bleeding;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Variceal bleeding;radio
ps;452;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
ps;452;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
ps;452;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
ps;452;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
ps;452;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
ps;452;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
ps;452;R_PSC_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
ps;452;R_PSC_Date_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date CHE;date
ps;452;R_PSC_CHE_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);CHE indication;radio
ps;452;R_PSC_Colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Colectomy;radio
ps;452;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
ps;452;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
ps;452;R_PSC_Pruritus;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Pruritus;radio
ps;452;psc_pbc_diag;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);psc pbc diag;calculation
ps;452;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
ps;452;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
ps;452;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
ps;452;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
ps;452;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
ps;452;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
ps;452;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
ps;452;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
ps;452;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
ps;452;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
ps;452;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
ps;452;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
ps;452;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
ps;452;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
ps;452;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
ps;452;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
ps;452;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
ps;452;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
ps;452;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
ps;452;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
ps;452;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ps;452;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
ps;452;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
ps;452;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
ps;452;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
ps;452;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
ps;452;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
ps;452;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
ps;452;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
ps;452;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
ps;452;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
ps;452;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
ps;452;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
ps;452;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
ps;452;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
ps;452;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
ps;452;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
ps;452;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
ps;452;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
ps;452;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
ps;452;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
ps;452;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
ps;452;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
ps;452;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
ps;452;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
ps;452;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
ps;452;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
ps;452;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
ps;452;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
ps;452;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
ps;452;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
ps;452;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
ps;452;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
ps;452;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
ps;452;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
ps;452;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
ps;452;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
ps;452;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
ps;452;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
ps;452;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
ps;452;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
ps;452;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
ps;452;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
ps;452;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
ps;452;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
ps;452;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
ps;452;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
ps;452;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
ps;452;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
ps;452;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
ps;452;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
ps;452;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
ps;452;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
ps;452;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
ps;452;R_PSC_not_in_db312;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
ps;452;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
ps;452;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
ps;452;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
ps;452;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
ps;452;R_PSC_not_in_db123;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
ps;452;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
ps;452;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
ps;452;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
ps;452;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
ps;452;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
ps;452;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
ps;452;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
ps;452;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
ps;452;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
ps;452;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
ps;452;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
ps;452;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
ps;452;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
ps;452;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
ps;452;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
ps;452;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
ps;452;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
ps;452;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
ps;452;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
ps;452;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
ps;452;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
ps;452;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
ps;452;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
ps;452;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
ps;452;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
ps;452;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
ps;452;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
ps;452;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
ps;452;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
ps;452;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
ps;452;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
ps;452;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
ps;452;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
ps;452;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
ps;452;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
ps;452;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
ps;452;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
ps;452;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
ps;452;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
ps;452;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
ps;452;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
ps;452;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
ps;452;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
ps;452;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
ps;452;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
ps;452;R_PSC_Is_female;PSC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
ps;452;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
ps;452;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
ps;452;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
ps;452;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
ps;452;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
ps;452;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ps;452;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
ps;452;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
ps;452;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
ps;452;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ps;452;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
ps;452;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
ps;452;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
ps;452;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
ps;452;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
ps;452;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
ps;452;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
ps;452;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
ps;452;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
ps;452;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
ps;452;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
ps;452;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
ps;452;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
ps;452;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
ps;452;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
ps;452;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
ps;452;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
ps;452;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
ps;452;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
ps;452;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
ps;452;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ps;452;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ps;452;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
ps;452;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ps;452;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ps;452;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ps;452;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ps;452;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ps;452;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ps;452;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ps;452;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ps;452;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ps;452;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ps;452;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
ps;452;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
ps;452;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
ps;452;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
ps;452;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
ps;452;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
ps;452;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
ps;452;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
ps;452;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
ps;452;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
ps;452;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
ps;452;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
ps;452;R_AIH_Liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Follow-up liver biopsy;radio
ps;452;R_AIH_Date_liver_biopsy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date follow-up biopsy;date
ps;452;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
ps;452;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
ps;452;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
ps;452;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
ps;452;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
ps;452;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
ps;452;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
ps;452;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ps;452;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
ps;452;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
ps;452;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
ps;452;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
ps;452;R_PBC_Liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
ps;452;R_PBC_Date_liver_biopsy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
ps;452;biopsie_proven_cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Biopsie proven cirrhosis;radio
ps;452;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
ps;452;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
ps;452;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
ps;452;free_hv_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein Before TIPS;numeric
ps;452;free_hv_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein After TIPS;numeric
ps;452;hv_gradient_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient Before TIPS;numeric
ps;452;hv_gradient_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient After TIPS;numeric
ps;452;hv_upstream;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic vein upstream from a short-length stenosis;numeric
ps;452;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
ps;452;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
ps;452;liver_biopsy_performed;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy performed;radio
ps;452;liver_biopsy_consent;Diagnosis Biobank;Rare Liver (Vascular);Consentment obtained using remnant biopsy;radio
ps;452;date_liver_biopsy;Diagnosis Biobank;Rare Liver (Vascular);Date of liver biopsy;date
ps;452;liver_biopsy_number;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy local number;string
ps;452;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
ps;452;liver_biopsy_obtained;Diagnosis Biobank;Rare Liver (Vascular);Frozen liver biopsy obtained?;dropdown
ps;452;ps_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
ps;452;ps_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);use of anticoagulation at testing;radio
ps;452;ps_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
ps;452;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
ps;452;bone_marrow_biopsy;Diagnosis Aetiology;Rare Liver (Vascular);Bone marrow biopsy;radio
ps;452;confirmed_aps;Diagnosis Aetiology;Rare Liver (Vascular);Confirmed APS;radio
ps;452;abd_interv_tips;Diagnosis Aetiology;Rare Liver (Vascular);TIPS;radio
ps;452;abd_interv_tips_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of TIPS;date
ps;452;eos_death_autopsy;End of study End of study;Rare Liver (Vascular);Autopsy performed;radio
ps;452;first_tipps;Follow-up Events;Rare Liver (Vascular);First TIPS;radio
ps;452;date_of_tips;Follow-up Events;Rare Liver (Vascular);Date of TIPS;date
ps;452;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
ps;452;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
ps;452;date_of_evaluation_tips;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
ps;452;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
ps;452;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
ps;452;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
ps;452;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
ps;452;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
ps;452;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
ps;452;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
ps;452;Number of polyps;benignNeoplasm;Genturis;What is the maximal number of these polyps ever observed in this patient?;int
ps;452;PseudonymÂ ;Subjects;ithaca;;compound
ps;452;biopsy;primary_cancer;EURACAN;Biopsy;1, Yes | 2, No | 9, Unknown
ps;452;biopsy_date;primary_cancer;EURACAN;Biopsy date;
ps;452;biopsy_req;primary_cancer;EURACAN;Biopsy done by;1, The hospital | 2, A different hospital | 9, Unknown
ps;452;capsular_effraction;surgery;EURACAN;Capsular effraction;1, Yes | 2, No | 3, Unknown
ps;452;Biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
ps;452;Date of biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
ps;452;Lymphnodes biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
ps;452;Date of lymphnodes biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
ps;452;Metastases biopsy at diagnosis;Surgery;PaedCan;Report if a biopsy has been perfomed before starting any medical treatment;yes/no/unknown
ps;452;Date of metastases biopsy;Surgery;PaedCan;Date of biopsy;dd/mm/yyyy
ps;452;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
ps;452;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
ps;452;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
ps;452;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
ps;452;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
ps;452;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
ps;452;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
ps;452;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
ps;452;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
ps;452;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
ps;452;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
ps;452;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
ps;452;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
ps;452;Pseudoachondroplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Pseudoachondroplasia ;
ps;452;Dipstick result;Biochemistry;ERKNet;if 3;protur_dipstick
psc;373;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
psc;373;R_PSC_Year_of_birth;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
psc;373;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
psc;373;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
psc;373;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
psc;373;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
psc;373;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
psc;373;R_PSC_Weight;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
psc;373;R_PSC_Height;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
psc;373;R_PSC_BMI;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
psc;373;R_PSC_Sex;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
psc;373;R_PSC_Ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
psc;373;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
psc;373;R_PSC_Alcohol;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol per day;radio
psc;373;R_PSC_Smoking;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
psc;373;PSC_is_smoker;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
psc;373;R_PSC_Smoking_amount;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount (pack years);numeric
psc;373;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
psc;373;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
psc;373;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
psc;373;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
psc;373;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
psc;373;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
psc;373;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
psc;373;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
psc;373;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
psc;373;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
psc;373;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
psc;373;R_PSC_mHAI;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
psc;373;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
psc;373;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
psc;373;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
psc;373;R_PSC_not_in_db4;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma grade;calculation
psc;373;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
psc;373;R_PSC_Fibrosis_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
psc;373;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
psc;373;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
psc;373;R_PSC_not_in_db42;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma score;calculation
psc;373;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
psc;373;R_PSC_Additional_nafld;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
psc;373;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
psc;373;R_PSC_MRCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);MRCP;radio
psc;373;R_PSC_ERCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP;radio
psc;373;R_PSC_PTCD;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);PTCD;radio
psc;373;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
psc;373;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
psc;373;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
psc;373;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
psc;373;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
psc;373;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
psc;373;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
psc;373;R_PSC_Spleen_size;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size;numeric
psc;373;R_PSC_Colonoscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Colonoscopy;radio
psc;373;R_PSC_IBD_status;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD Status;radio
psc;373;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
psc;373;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
psc;373;R_PSC_IBD_remission;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD in histological remission;radio
psc;373;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
psc;373;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
psc;373;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
psc;373;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
psc;373;R_PSC_AST;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
psc;373;R_PSC_ALT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
psc;373;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
psc;373;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
psc;373;R_PSC_ALP;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
psc;373;R_PSC_yGT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGT;numeric
psc;373;R_PSC_Albumin;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
psc;373;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
psc;373;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
psc;373;R_PSC_INR;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
psc;373;R_PSC_Platelets;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
psc;373;R_PSC_IgG;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
psc;373;R_PSC_IgM;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
psc;373;R_PSC_IgA;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
psc;373;R_PSC_yGlobulins;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
psc;373;R_PSC_IgG4;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG4;numeric
psc;373;R_PSC_ANA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
psc;373;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
psc;373;R_PSC_ANA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
psc;373;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
psc;373;R_PSC_SMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
psc;373;R_PSC_SMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
psc;373;R_PSC_SMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
psc;373;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
psc;373;R_PSC_LKM;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
psc;373;R_PSC_LKM_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
psc;373;R_PSC_LKM1_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
psc;373;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
psc;373;R_PSC_SLA_LP;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
psc;373;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
psc;373;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
psc;373;R_PSC_AMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
psc;373;R_PSC_AMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
psc;373;R_PSC_AMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
psc;373;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
psc;373;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
psc;373;R_PSC_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
psc;373;R_PSC_Date_of_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
psc;373;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
psc;373;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
psc;373;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
psc;373;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
psc;373;R_PSC_Serum;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
psc;373;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
psc;373;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
psc;373;R_PSC_UDCA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA;radio
psc;373;R_PSC_UDCA_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
psc;373;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
psc;373;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
psc;373;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
psc;373;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Budesonide;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
psc;373;R_PSC_Budesonide_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
psc;373;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
psc;373;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
psc;373;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Infliximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
psc;373;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Adalimumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Adalimumab;radio
psc;373;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Vedolizumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Vedolizumab;radio
psc;373;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Ustekinumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Ustekinumab;radio
psc;373;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
psc;373;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
psc;373;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
psc;373;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
psc;373;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_MMF;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
psc;373;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
psc;373;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Tacrolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
psc;373;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_CyclosporinA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
psc;373;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Rituximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
psc;373;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
psc;373;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
psc;373;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
psc;373;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
psc;373;R_PSC_Ascites;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Ascites;radio
psc;373;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
psc;373;R_PSC_Variceal_bleeding;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Variceal bleeding;radio
psc;373;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
psc;373;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
psc;373;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
psc;373;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
psc;373;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
psc;373;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
psc;373;R_PSC_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
psc;373;R_PSC_Date_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date CHE;date
psc;373;R_PSC_CHE_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);CHE indication;radio
psc;373;R_PSC_Colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Colectomy;radio
psc;373;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
psc;373;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
psc;373;R_PSC_Pruritus;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Pruritus;radio
psc;373;psc_pbc_diag;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);psc pbc diag;calculation
psc;373;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
psc;373;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
psc;373;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
psc;373;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
psc;373;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
psc;373;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
psc;373;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
psc;373;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
psc;373;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
psc;373;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
psc;373;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
psc;373;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
psc;373;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
psc;373;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
psc;373;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
psc;373;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
psc;373;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
psc;373;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
psc;373;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
psc;373;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
psc;373;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
psc;373;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
psc;373;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
psc;373;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
psc;373;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
psc;373;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
psc;373;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
psc;373;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
psc;373;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
psc;373;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
psc;373;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
psc;373;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
psc;373;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
psc;373;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
psc;373;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
psc;373;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
psc;373;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
psc;373;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
psc;373;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
psc;373;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
psc;373;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
psc;373;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
psc;373;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
psc;373;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
psc;373;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
psc;373;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
psc;373;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
psc;373;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
psc;373;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
psc;373;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
psc;373;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
psc;373;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
psc;373;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
psc;373;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
psc;373;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
psc;373;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
psc;373;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
psc;373;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
psc;373;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
psc;373;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
psc;373;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
psc;373;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
psc;373;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
psc;373;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
psc;373;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
psc;373;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
psc;373;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
psc;373;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
psc;373;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
psc;373;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
psc;373;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
psc;373;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
psc;373;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
psc;373;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
psc;373;R_PSC_not_in_db312;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
psc;373;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
psc;373;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
psc;373;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
psc;373;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
psc;373;R_PSC_not_in_db123;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
psc;373;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
psc;373;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
psc;373;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
psc;373;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
psc;373;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
psc;373;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
psc;373;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
psc;373;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
psc;373;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
psc;373;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
psc;373;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
psc;373;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
psc;373;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
psc;373;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
psc;373;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
psc;373;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
psc;373;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
psc;373;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
psc;373;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
psc;373;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
psc;373;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
psc;373;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
psc;373;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
psc;373;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
psc;373;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
psc;373;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
psc;373;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
psc;373;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
psc;373;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
psc;373;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
psc;373;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
psc;373;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
psc;373;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
psc;373;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
psc;373;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
psc;373;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
psc;373;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
psc;373;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
psc;373;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
psc;373;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
psc;373;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
psc;373;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
psc;373;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
psc;373;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
psc;373;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
psc;373;R_PSC_Is_female;PSC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
psc;373;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
psc;373;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
psc;373;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
psc;373;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
psc;373;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
psc;373;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
psc;373;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
psc;373;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
psc;373;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
psc;373;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
psc;373;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
psc;373;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
psc;373;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
psc;373;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
psc;373;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
psc;373;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
psc;373;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
psc;373;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
psc;373;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
psc;373;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
psc;373;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
psc;373;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
psc;373;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
psc;373;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
psc;373;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
psc;373;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
psc;373;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
psc;373;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
psc;373;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
psc;373;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
psc;373;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
psc;373;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
psc;373;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
psc;373;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
psc;373;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
psc;373;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
psc;373;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
psc;373;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
psc;373;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
psc;373;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
psc;373;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
psc;373;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
psc;373;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
psc;373;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
psc;373;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
psc;373;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
psc;373;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
psc;373;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
psc;373;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
psc;373;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
psc;373;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
psc;373;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
psc;373;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
psc;373;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
psc;373;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
psc;373;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
psc;373;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
psc;373;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
psc;373;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
psc;373;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
psc;373;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
psc;373;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
psc;373;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
psc;373;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
psc;373;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
psc;373;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
psc;373;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
pseudoachondroplasia;1;Pseudoachondroplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Pseudoachondroplasia ;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
pseudohypoparathyroidism;11;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
pseudohypoparathyroidism;11;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
pseudohypoparathyroidism;11;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
pseudonym;2;pseudonym;Base information;Rare Liver (Auto imune);Pseudonym;calculation
pseudonym;2;PseudonymÂ ;Subjects;ithaca;;compound
pseudopseudohypoparathyroidism;2;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
pseudopseudohypoparathyroidism;2;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
pt;118;Ptosis;Diagnosis Eye;EURO-NMD;;yesno
pt;118;Symptom fluctuation;Diagnosis Fluctuation;EURO-NMD;;yesno
pt;118;Ptosis (upward gaze) Sec.;QMG;EURO-NMD;;
pt;118;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
pt;118;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pt;118;R_PSC_PTCD;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);PTCD;radio
pt;118;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
pt;118;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
pt;118;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
pt;118;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
pt;118;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
pt;118;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
pt;118;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
pt;118;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pt;118;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pt;118;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pt;118;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pt;118;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pt;118;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pt;118;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
pt;118;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
pt;118;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
pt;118;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
pt;118;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
pt;118;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
pt;118;asymptomatic;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Asymptomatic;radio
pt;118;other_symptoms;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other symptoms;textarea
pt;118;pc_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time at testing;radio
pt;118;ps_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
pt;118;ps_oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives at testing;radio
pt;118;at_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
pt;118;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
pt;118;oral_contraceptives;Diagnosis Aetiology;Rare Liver (Vascular);Use of oral contraceptives prior to diagnosis;radio
pt;118;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
pt;118;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
pt;118;contracept_ongoing;Diagnosis Aetiology;Rare Liver (Vascular);Ongoing;radio
pt;118;contraceptives_end;Diagnosis Aetiology;Rare Liver (Vascular);Date end of use;date
pt;118;fu_biliary_symptoms;Follow-up Complications;Rare Liver (Vascular);Biliary symptoms;radio
pt;118;date_of_interruption;Follow-up Events;Rare Liver (Vascular);Date of interruption;date
pt;118;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
pt;118;fu_cli_bef_pt_normal_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
pt;118;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
pt;118;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
pt;118;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
pt;118;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
pt;118;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
pt;118;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
pt;118;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
pt;118;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
pt;118;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
pt;118;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
pt;118;Transcript;geneticVariant;Genturis;What is the transcript belonging to the cDNA variant? (HGVS nomenclature);string
pt;118;ER receptor status;malignancy;Genturis;What is the Estrogen receptor status of the breast cancer?;categorical
pt;118;PR receptor status;malignancy;Genturis;What is the Progesteron receptor status of the breast cancer?;categorical
pt;118;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
pt;118;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
pt;118;Year of opted out;subject;Genturis;In what year has the patient opted out or revoked the GENTURIS registry consent?;int
pt;118;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
pt;118;Age at first symptoms;subject;Genturis;At what age (years) did the patient have his/her first symptoms?;int
pt;118;Description (English);Anatomical Therapeutic Chemical Classification;ithaca;;text
pt;118;Description of code;Anatomical Therapeutic Chemical Classification;ithaca;;string
pt;118;description;;ithaca;;text
pt;118;Description;;ithaca;;string
pt;118;Description (English);;ithaca;;text
pt;118;Description of code;;ithaca;;hyperlink
pt;118;Description;;ithaca;;text
pt;118;description;;ithaca;;text
pt;118;Description;;ithaca;;text
pt;118;Description;;ithaca;;text
pt;118;Description;;ithaca;;text
pt;118;Description;;ithaca;;text
pt;118;Consultation Request Reason Description;;ithaca;;text
pt;118;Period of first symptom onset;;ithaca;;categorical
pt;118;Date of first symptoms onset;;ithaca;;date
pt;118;Age at first symptoms onset;;ithaca;;int
pt;118;Medication for Rare Disease Description;;ithaca;;text
pt;118;Description;;ithaca;;text
pt;118;Nucleotide variant description;;ithaca;;text
pt;118;Protein variant description;;ithaca;;text
pt;118;optical_methods_primary;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
pt;118;optical_methods_neck;stage_procedures;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Yes | 2, No | 9, Unknown
pt;118;radio_photons_adaptive;radiotherapy;EURACAN;Photons adaptive RT;1, Yes | 2, No
pt;118;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
pt;118;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
pt;118;radio_carbons_adaptive;radiotherapy;EURACAN;Carbons adaptive RT;1, Yes | 2, No
pt;118;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
pt;118;radio_radionuc_adaptive;radiotherapy;EURACAN;Radionuclide adaptive RT;1, Yes | 2, No
pt;118;radio_boron_adaptive;radiotherapy;EURACAN;Boron neutron capture therapy adaptive RT;1, Yes | 2, No
pt;118;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
pt;118;end_treatment_optical;imaging_available;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Baseline | 2, After treatment
pt;118;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
pt;118;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
pt;118;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
pt;118;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
pt;118;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
pt;118;Melanocortin 4 receptor deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Melanocortin 4 receptor deficiency;
pt;118;Obesity due to congenital leptin deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Obesity due to congenital leptin deficiency;
pt;118;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
pt;118;Septo-optic dysplasia spectrum;PITUITARY;EuRR-Bone & EuRRECa;Septo-optic dysplasia spectrum;
pt;118;Isolated bilateral cryptorchidism;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Isolated bilateral cryptorchidism;
pt;118;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
pt;118;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
ptcd;5;R_PSC_PTCD;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);PTCD;radio
ptcd;5;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
ptcd;5;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
ptcd;5;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
ptcd;5;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
pth;1;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
ptosis;2;Ptosis;Diagnosis Eye;EURO-NMD;;yesno
ptosis;2;Ptosis (upward gaze) Sec.;QMG;EURO-NMD;;
pubertal;1;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
puberty;1;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
pubic;6;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
pubic;6;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
pubic;6;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
pubic;6;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
pubic;6;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
pubic;6;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
pulm;5;hepatopulmonary_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatopulmonary syndrome;radio
pulm;5;portopulm_hypertension;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Portopulmonary hypertension;radio
pulm;5;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
pulm;5;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
pulm;5;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
pure;1;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
purposes;2;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
purposes;2;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
pv;15;pv_occlusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion;radio
pv;15;pv_occlusion_type;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion type;radio
pv;15;pv_bifurcation;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Longitudinal assessment: portal vein bifurcation;radio
pv;15;pv_origin;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Longitudinal assessment: portal vein origin;radio
pv;15;pv_direction_of_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Direction of flow;radio
pv;15;pv_flow_right;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein direction of flow;radio
pv;15;pv_flow_left;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein direction of flow;radio
pv;15;fu_ima_bef_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
pv;15;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
pv;15;fu_ima_bef_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
pv;15;fu_ima_last_mpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Main portal vein patent;radio
pv;15;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
pv;15;fu_ima_last_lpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Left portal vein branch patent;radio
pv;15;hpv_status;primary_cancer;EURACAN;HPV status;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
pv;15;hpv_status_type;primary_cancer;EURACAN;HPV status detected by;1, FISH | 2, PCR | 9, Unknown
pws;1;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
pyridostigmine;1;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
qmg;1;Total QMG score if done;QMG;EURO-NMD;;
quality;1;beam_quality;radiotherapy;EURACAN;Beam quality;1, External beam RT Photons | 2, External beam RT Electrons | 3, External beam RT Protons | 4, External beam RT Carbons | 5, Brachytherapy interstitial endocavitary contact | 6, Radionuclide therapy | 7, Boron neutron capture therapy | 8, Others
quantification;1;jak_2_quantification;Diagnosis Aetiology;Rare Liver (Vascular);% of mutated allele;numeric
question;1;(If yes, answer questionÂ 2e);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Tick-box, multiple selection]
quic;5;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
quic;5;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
quic;5;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
quic;5;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
quic;5;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
quick;4;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
quick;4;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
quick;4;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
quick;4;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
radio;99;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radio;99;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radio;99;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radio;99;prev_hn_radio;previous_cancer_genetic_syndromes;EURACAN;Previous radiotherapy at head and neck site;1, Yes | 2, No | 9, Unknown
radio;99;prev_hn_radio_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of radiotherapy;
radio;99;radio_induced;primary_cancer;EURACAN;Radiotherapy induced;1, Yes | 2, No | 9, Unknown
radio;99;radio;radiotherapy;EURACAN;Radiotherapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
radio;99;radio_intent;radiotherapy;EURACAN;Intent;1, Curative | 2, Palliative | 9, Unknown
radio;99;radio_t;radiotherapy;EURACAN;Site, T;1, yes | 2, no
radio;99;radio_n;radiotherapy;EURACAN;Site, N;1, yes | 2, no | 9, unknown
radio;99;radio_m;radiotherapy;EURACAN;Site, M;1, yes | 2, no | 9, unknown
radio;99;radio_photons_tech;radiotherapy;EURACAN;Photons treatment technique;1, 2D | 2, 3D | 3, IMRT conventional | 4, VMAT | 5, Thomotherapy | 6, SBRT
radio;99;radio_photons_from;radiotherapy;EURACAN;Photons start date;
radio;99;radio_photons_to;radiotherapy;EURACAN;Photons end date;
radio;99;radio_photons_totdose;radiotherapy;EURACAN;Photons total dose;
radio;99;radio_photons_fractdose;radiotherapy;EURACAN;Photons dose per fraction;
radio;99;radio_photons_nrfract;radiotherapy;EURACAN;Photons number fraction;
radio;99;radio_photons_ott;radiotherapy;EURACAN;Photons OTT;"datediff([radio_photons_to],[radio_photons_from],""d"")"
radio;99;radio_photons_4d;radiotherapy;EURACAN;Photons 4D treatment;1, Yes | 2, No
radio;99;radio_photons_adaptive;radiotherapy;EURACAN;Photons adaptive RT;1, Yes | 2, No
radio;99;radio_photons_igrt;radiotherapy;EURACAN;Photons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_electrons_tech;radiotherapy;EURACAN;Electrons treatment technique;1, FLASH  therapy
radio;99;radio_electrons_from;radiotherapy;EURACAN;Electrons start date;
radio;99;radio_electrons_to;radiotherapy;EURACAN;Electrons end date;
radio;99;radio_electrons_totdose;radiotherapy;EURACAN;Electrons total dose;
radio;99;radio_electrons_fractdose;radiotherapy;EURACAN;Electrons dose per fraction;
radio;99;radio_electrons_nrfract;radiotherapy;EURACAN;Electrons number fraction;
radio;99;radio_electrons_ott;radiotherapy;EURACAN;Electrons OTT;"datediff([radio_electrons_to],[radio_electrons_from],""d"")"
radio;99;radio_electrons_4d;radiotherapy;EURACAN;Electrons 4D treatment;1, Yes | 2, No
radio;99;radio_electrons_adaptive;radiotherapy;EURACAN;Electrons  adaptive RT;1, Yes | 2, No
radio;99;radio_electrons_igrt;radiotherapy;EURACAN;Electrons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_protons_tech;radiotherapy;EURACAN;Protons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
radio;99;radio_protons_from;radiotherapy;EURACAN;Protons start date;
radio;99;radio_protons_totdose;radiotherapy;EURACAN;Protons total dose;
radio;99;radio_protons_to;radiotherapy;EURACAN;Protons end date;
radio;99;radio_protons_fractdose;radiotherapy;EURACAN;Protons dose per fraction;
radio;99;radio_protons_nrfract;radiotherapy;EURACAN;Protons nr fraction;
radio;99;radio_protons_ott;radiotherapy;EURACAN;Protons OTT;"datediff([radio_protons_to],[radio_protons_from],""d"")"
radio;99;radio_protons_4d;radiotherapy;EURACAN;Protons 4D treatment;1, Yes | 2, No
radio;99;radio_protons_adaptive;radiotherapy;EURACAN;Protons adaptive RT;1, Yes | 2, No
radio;99;radio_protons_igrt;radiotherapy;EURACAN;Protons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_carbons_tech;radiotherapy;EURACAN;Carbons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
radio;99;radio_carbons_from;radiotherapy;EURACAN;Carbons start date;
radio;99;radio_carbons_to;radiotherapy;EURACAN;Carbons end date;
radio;99;radio_carbons_totdose;radiotherapy;EURACAN;Carbons total dose;
radio;99;radio_carbons_fractdose;radiotherapy;EURACAN;Carbons dose per fraction ;
radio;99;radio_carbons_nrfract;radiotherapy;EURACAN;Carbons number fraction ;
radio;99;radio_carbons_ott;radiotherapy;EURACAN;Carbons OTT;"datediff([radio_carbons_to],[radio_carbons_from],""d"")"
radio;99;radio_carbons_4d;radiotherapy;EURACAN;Carbons 4D treatment;1, Yes | 2, No
radio;99;radio_carbons_adaptive;radiotherapy;EURACAN;Carbons adaptive RT;1, Yes | 2, No
radio;99;radio_carbons_igrt;radiotherapy;EURACAN;Carbons IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_brachy_tech;radiotherapy;EURACAN;Brachytherapy treatment technique;1, Interstitial | 2, Endocavitary | 3, Contact
radio;99;radio_brachy_from;radiotherapy;EURACAN;Brachytherapy start date;
radio;99;radio_brachy_to;radiotherapy;EURACAN;Brachytherapy end date;
radio;99;radio_brachy_totdose;radiotherapy;EURACAN;Brachytherapy total dose;
radio;99;radio_brachy_fractdose;radiotherapy;EURACAN;Brachytherapy dose per fraction ;
radio;99;radio_brachy_nrfract;radiotherapy;EURACAN;Brachytherapy number fraction ;
radio;99;radio_brachy_ott;radiotherapy;EURACAN;Brachytherapy OTT;"datediff([radio_brachy_to],[radio_brachy_from],""d"")"
radio;99;radio_brachy_4d;radiotherapy;EURACAN;Brachytherapy 4D treatment;1, Yes | 2, No
radio;99;radio_brachy_adaptive;radiotherapy;EURACAN;Brachytherapy adaptive RT;1, Yes | 2, No
radio;99;radio_brachy_igrt;radiotherapy;EURACAN;Brachytherapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_radionuc_tech;radiotherapy;EURACAN;Radionuclide treatment technique;
radio;99;radio_radionuc_from;radiotherapy;EURACAN;Radionuclide start date;
radio;99;radio_radionuc_to;radiotherapy;EURACAN;Radionuclide end date;
radio;99;radio_radionuc_totdose;radiotherapy;EURACAN;Radionuclide total dose;
radio;99;radio_radionuc_fractdose;radiotherapy;EURACAN;Radionuclide dose per fraction ;
radio;99;radio_radionuc_nrfract;radiotherapy;EURACAN;Radionuclide number fraction ;
radio;99;radio_radionuc_ott;radiotherapy;EURACAN;Radionuclide OTT;"datediff([radio_radionuc_to],[radio_radionuc_from],""d"")"
radio;99;radio_radionuc_4d;radiotherapy;EURACAN;Radionuclide 4D treatment;1, Yes | 2, No
radio;99;radio_radionuc_adaptive;radiotherapy;EURACAN;Radionuclide adaptive RT;1, Yes | 2, No
radio;99;radio_radionuc_igrt;radiotherapy;EURACAN;Radionuclide IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_boron_tech;radiotherapy;EURACAN;Boron neutron capture therapy treatment technique;
radio;99;radio_boron_from;radiotherapy;EURACAN;Boron neutron capture therapy start date;
radio;99;radio_boron_to;radiotherapy;EURACAN;Boron neutron capture therapy end date;
radio;99;radio_boron_totdose;radiotherapy;EURACAN;Boron neutron capture therapy total dose;
radio;99;radio_boron_fractdose;radiotherapy;EURACAN;Boron neutron capture therapy dose per fraction ;
radio;99;radio_boron_nrfract;radiotherapy;EURACAN;Boron neutron capture therapy number fraction ;
radio;99;radio_boron_ott;radiotherapy;EURACAN;Boron neutron capture therapy OTT;"datediff([radio_boron_to],[radio_boron_from],""d"")"
radio;99;radio_boron_4d;radiotherapy;EURACAN;Boron neutron capture therapy 4D treatment;1, Yes | 2, No
radio;99;radio_boron_adaptive;radiotherapy;EURACAN;Boron neutron capture therapy adaptive RT;1, Yes | 2, No
radio;99;radio_boron_igrt;radiotherapy;EURACAN;Boron neutron capture therapy IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;radio_others_tech;radiotherapy;EURACAN;Others treatment technique;
radio;99;radio_others_from;radiotherapy;EURACAN;Others start date;
radio;99;radio_others_to;radiotherapy;EURACAN;Others end date;
radio;99;radio_others_totdose;radiotherapy;EURACAN;Others total dose;
radio;99;radio_others_fractdose;radiotherapy;EURACAN;Others dose per fraction ;
radio;99;radio_others_nrfract;radiotherapy;EURACAN;Others number fraction ;
radio;99;radio_others_ott;radiotherapy;EURACAN;Others OTT;"datediff([radio_others_to],[radio_others_from],""d"")"
radio;99;radio_others_4d;radiotherapy;EURACAN;Others 4D treatment;1, Yes | 2, No
radio;99;radio_others_adaptive;radiotherapy;EURACAN;Others adaptive RT;1, Yes | 2, No
radio;99;radio_others_igrt;radiotherapy;EURACAN;Others IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radio;99;ebv_dna_radio;radiotherapy;EURACAN;Plasmatic EBV DNA during/after radiotherapy;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
radio;99;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
radio;99;copy_number_radio;radiotherapy;EURACAN;Copy Number;
radio;99;end_treatment_radio;radiotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
radio;99;end_treat_res_radio;radiotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
radio;99;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
radio;99;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
radio;99;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
radiologic;3;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radiologic;3;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radiologic;3;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radiological;2;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radiological;2;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
radiology;1;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
radionuc;10;radio_radionuc_tech;radiotherapy;EURACAN;Radionuclide treatment technique;
radionuc;10;radio_radionuc_from;radiotherapy;EURACAN;Radionuclide start date;
radionuc;10;radio_radionuc_to;radiotherapy;EURACAN;Radionuclide end date;
radionuc;10;radio_radionuc_totdose;radiotherapy;EURACAN;Radionuclide total dose;
radionuc;10;radio_radionuc_fractdose;radiotherapy;EURACAN;Radionuclide dose per fraction ;
radionuc;10;radio_radionuc_nrfract;radiotherapy;EURACAN;Radionuclide number fraction ;
radionuc;10;radio_radionuc_ott;radiotherapy;EURACAN;Radionuclide OTT;"datediff([radio_radionuc_to],[radio_radionuc_from],""d"")"
radionuc;10;radio_radionuc_4d;radiotherapy;EURACAN;Radionuclide 4D treatment;1, Yes | 2, No
radionuc;10;radio_radionuc_adaptive;radiotherapy;EURACAN;Radionuclide adaptive RT;1, Yes | 2, No
radionuc;10;radio_radionuc_igrt;radiotherapy;EURACAN;Radionuclide IGRT  (imagine guide radiotherapy);1, Yes | 2, No
radiotherapy;2;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
radiotherapy;2;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
rare;4;Rare disease  syndrome;subject;Genturis;What is the classification (Orphanet) of the rare disease of the patients?;xref
rare;4;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
rare;4;Medication for Rare Disease Description;;ithaca;;text
rare;4;Other rare forms of immune mediated diabetes ;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other rare forms of immune mediated diabetes ;
rate;14;R_PBC_Fibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fibrate;radio
rate;14;R_PBC_Fenofibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Fenofibrate;radio
rate;14;R_PBC_Bezafibrate;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Bezafibrate;radio
rate;14;R_AIH_PBC_Fibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fibrate;radio
rate;14;R_AIH_PBC_Fenofibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Fenofibrate;radio
rate;14;R_AIH_PBC_Bezafibrate_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Bezafibrate;radio
rate;14;R_AIH_PBC_Fibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
rate;14;R_AIH_PBC_Fenofibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
rate;14;R_AIH_PBC_Bezafibrate_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
rate;14;R_PBC_Fibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fibrate;radio
rate;14;R_PBC_Fenofibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Fenofibrate;radio
rate;14;R_PBC_Bezafibrate_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Bezafibrate;radio
rate;14;heart_rate;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Heart rate;numeric
rate;14;Heart rate;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Resting heart rate for age;N/Low/High/Not Known
ratio;10;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
ratio;10;Duration;Respiratory Apneic Episodes;EURO-NMD;Apneic episodes in last 12 months;int
ratio;10;Duration;Respiratory Myasthenic crisis;EURO-NMD;Myasthenic crisis in last 12 months;int
ratio;10;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ratio;10;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ratio;10;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ratio;10;Double J catheter Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ratio;10;lnr_ratio;surgery;EURACAN;LNR (Lymph node ratio);([surgery_nr_pos_lymphnodes]/[surgery_nr_lymphnodes])
ratio;10;Country of registration;Personal Information;PaedCan;Country where the patient is registered;String
ratio;10;Center of registration;Personal Information;PaedCan;Center where the patient is registered;String
re-contact;1;Consent for re-contact;subject;Genturis;Has the patient signed consent for re-contacting for research purposes?;enum
re-excision;1;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
re-use;1;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
reached;1;How was diagnosis reached;Disease History;EuRR-Bone & EuRRECa;Select all modalities that were used to reach the diagnosis;"1-Clinical 2-Biochemistry, 3-Genetic 4-Histology, 5- CT, 6-MRI 7- PET; 8- USS, 9-Other, 10-NK"
reactive;1;dia_lab_reactive_c_protein;Diagnosis Laboratory data;Rare Liver (Vascular);C-Reactive protein;numeric
reason;29;R_AIH_Azathioprine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Budesonide_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_MMF_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Azathioprine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Budesonide_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_AIH_MMF_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PBC_AIH_Azathioprine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PBC_AIH_Budesonide_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;R_PBC_AIH_MMF_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
reason;29;eos_termination_reason;End of study End of study;Rare Liver (Vascular);Reason for Study Termination;radio
reason;29;eos_liver_transplant_reason;End of study End of study;Rare Liver (Vascular);Why was no liver transplantation performed?;radio
reason;29;Consultation Request Reason;;ithaca;;categorical
reason;29;Consultation Request Reason Description;;ithaca;;text
reason;29;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
reasons;1;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
rec;33;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
rec;33;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
rec;33;pv_direction_of_flow;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Direction of flow;radio
rec;33;rec_gen_ulc;Diagnosis Aetiology;Rare Liver (Vascular);Recurrent genital ulceration;radio
rec;33;portal_recanalization;Follow-up Events;Rare Liver (Vascular);Portal recanalization;radio
rec;33;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
rec;33;fu_ima_bef_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
rec;33;fu_ima_last_flow_direction;Follow-up Imaging data;Rare Liver (Vascular);Direction of portal flow;radio
rec;33;"neprectomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
rec;33;c. History of nephrectomy of native kidneys:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
rec;33;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
rec;33;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
rec;33;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
rec;33;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
rec;33;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
rec;33;ER receptor status;malignancy;Genturis;What is the Estrogen receptor status of the breast cancer?;categorical
rec;33;PR receptor status;malignancy;Genturis;What is the Progesteron receptor status of the breast cancer?;categorical
rec;33;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
rec;33;Record Label;;ithaca;;string
rec;33;Is the patient receiving medication for his/her rare disease?;;ithaca;;bool
rec;33;record_id;patient_management_at_the_hospital;EURACAN;Record ID;
rec;33;reconstruction;surgery;EURACAN;Reconstruction;1, Yes | 2, No | 3, Not required | 9, Unknown
rec;33;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
rec;33;e-REC indentifier;Identifiers;EuRR-Bone & EuRRECa;Identifier forÂ e-REC;String
rec;33;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
rec;33;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
rec;33;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
rec;33;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
rec;33;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
rec;33;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
rec;33;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
rec;33;Melanocortin 4 receptor deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Melanocortin 4 receptor deficiency;
rec;33;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
recanalization;2;portal_recanalization;Follow-up Events;Rare Liver (Vascular);Portal recanalization;radio
recanalization;2;portal_recanalization_date;Follow-up Events;Rare Liver (Vascular);Date of portal recanalization;date
receive;2;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
receive;2;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
received;1;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
recent;2;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
recent;2;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
receptor;6;ER receptor status;malignancy;Genturis;What is the Estrogen receptor status of the breast cancer?;categorical
receptor;6;PR receptor status;malignancy;Genturis;What is the Progesteron receptor status of the breast cancer?;categorical
receptor;6;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
receptor;6;Leptin receptor gene deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Leptin receptor gene deficiency;
receptor;6;Melanocortin 4 receptor deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Melanocortin 4 receptor deficiency;
receptor;6;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
recessive;4;Autosomal recessive infantile hypercalcaemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive infantile hypercalcaemia;
recessive;4;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
recessive;4;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
recessive;4;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to Kir6.2 deficiency;
recipient;2;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
recipient;2;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
reconstruction;1;reconstruction;surgery;EURACAN;Reconstruction;1, Yes | 2, No | 3, Not required | 9, Unknown
record;4;Record Label;;ithaca;;string
record;4;record_id;patient_management_at_the_hospital;EURACAN;Record ID;
record;4;Date of initial creation of record ( author);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
record;4;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
recovery;1;Delayed recovery from anaesthetics;Diagnosis Fluctuation;EURO-NMD;;yesno
recurrent;1;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
red;72;Reduced foetal movements;Diagnosis Developmental;EURO-NMD;;yesno
red;72;Hospitalization required;Respiratory Apneic Episodes;EURO-NMD;;yesno
red;72;Hospitalization required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
red;72;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
red;72;R_AIH_Prednisolone;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_AIH_Prednisolone_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_AIH_Prednisolone_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
red;72;R_PBC_Prednisolone;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_PBC_Prednisolone_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_PBC_AIH_Prednisolone_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
red;72;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
red;72;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
red;72;R_AIH_Prednisolone_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_AIH_Prednisolone_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
red;72;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
red;72;R_AIH_Prednisolone_Prednisone_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_AIH_Prednisolone_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_AIH_Prednisolone_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
red;72;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
red;72;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
red;72;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
red;72;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
red;72;R_AIH_Biosamples_stored;AIH Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
red;72;R_AIH_Prednisolone_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_AIH_Prednisolone_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
red;72;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
red;72;R_AIH_Prednisolone_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_AIH_Prednisolone_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_AIH_Prednisolone_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
red;72;R_PBC_Prednisolone_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_PBC_Prednisolone_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
red;72;R_PBC_Prednisolone_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
red;72;R_PBC_AIH_Prednisolone_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
red;72;R_PBC_AIH_Prednisolone_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
red;72;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
red;72;esoph_varices_red_signs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophagel varices red color signs;radio
red;72;dia_lab_red_blood_cell_count;Diagnosis Laboratory data;Rare Liver (Vascular);Red blood cell count;numeric
red;72;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
red;72;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
red;72;Full caryotype (if not inferred from CNV report);;ithaca;;string
red;72;Is urgency required for this panel?;;ithaca;;bool
red;72;Active Ingredient (ATC);;ithaca;;mref
red;72;Active Ingredient (ATC);;ithaca;;mref
red;72;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
red;72;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
red;72;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
red;72;Please describe the treatment delivered;Other treatments;PaedCan;;String
red;72;An event has occurred;Events;PaedCan;If any event has occurred ;yes/no/unknown
red;72;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
red;72;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
red;72;P450 oxidoreductase def (POR);ADRENAL;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
red;72;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
red;72;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
red;72;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
red;72;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
red;72;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
red;72;Hereditary pheochromocytoma-paraganglioma;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Hereditary pheochromocytoma-paraganglioma;
red;72;Non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired combined pituitary hormone deficiency;
red;72;Disease associated with non-acquired combined pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Disease associated with non-acquired combined pituitary hormone deficiency;
red;72;Non-acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Non-acquired pituitary hormone deficiency;
red;72;Acquired pituitary hormone deficiency;PITUITARY;EuRR-Bone & EuRRECa;Acquired pituitary hormone deficiency;
red;72;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
red;72;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
red;72;5a-reductase def (SRD5A2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;5a-reductase def (SRD5A2);
red;72;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
red;72;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
red;72;P450 oxidoreductase def (POR);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 oxidoreductase def (POR);
reduced;1;Reduced foetal movements;Diagnosis Developmental;EURO-NMD;;yesno
reference;5;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
reference;5;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
reference;5;Reference genome;;ithaca;;categorical
reference;5;Reference Sequence ID (mapped by NCBI);;ithaca;Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_;string
reference;5;Nucleotide reference sequence (RefSeq id/LRG id);;ithaca;;string
referral;2;Referral to VRT board (national or international) ;Care pathway;PaedCan;The case has been discussed within an official national or international VRT board for diagnosis and/or treatment;no/yes in the EXPERT Virtual consultation system/ yes in another tumor board
referral;2;Date of referral;Care pathway;PaedCan;Date of referral to a Very rare Tumor board;dd/mm/yyyy
reflux;2;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
reflux;2;e. Vesicoureteral reflux:;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
regimen;4;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
regimen;4;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
regimen;4;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
regimen;4;chemo_regimen;chemotherapy;EURACAN;Regimen;1, 5-FU / Hydroxyurea | 2, 5-FU, 2nd line | 3, Capecitabine | 4, Capecitabine, 2nd line | 5, Carboplatin | 6, CE, 1st line | 7, Cetuximab | 8, Cetuximab, 2nd line | 9, Cetuximab-based chemotherapy, 1st line | 10, CF | 11, Cisplatin, 2nd line | 12, CP | 13, CP, 1st line | 14, Docetaxel | 15, Docetaxel, 2nd line | 16, Gemcitabine | 17, GP | 18, High-dose cisplatin | 19, Methotrexate, 2nd line | 20, Nivolumab, 2nd line | 21, Paclitaxel | 22, Paclitaxel, 2nd line | 23, Pembrolizumab, 2nd line | 24, PF | 25, PF or CF | 26, PF, 1st line | 27, TC | 28, TC, 1st line | 29, TP | 30, TP, 1st line | 31, TPEx, 1st line | 32, TPF | 33, Vinorelbine, 2nd line | 34, Weekly cisplatin
regional;2;fu_awd_regional;clinical_update;EURACAN;AWD, Regional;1, Yes | 2, No | 3, Unknown
regional;2;Regional lymphnodes involvement (N);Tumor's characteristics;PaedCan;Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system);N0/N1/Nx
registration;2;Country of registration;Personal Information;PaedCan;Country where the patient is registered;String
registration;2;Center of registration;Personal Information;PaedCan;Center where the patient is registered;String
registry;11;Consent for GENTURIS registry;subject;Genturis;Has the patient signed consent for the GENTURIS registry?;enum
registry;11;Date GENTURIS registry consent;subject;Genturis;At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?;date
registry;11;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
registry;11;To be included in the registry;Informed consent;PaedCan;Definition whether consent for patient's registration was obtained;yes/no
registry;11;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
registry;11;Consent for Core Registry;Consent;EuRR-Bone & EuRRECa;Consent to add patients details to the Core Registry;String
registry;11;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
registry;11;Information provided on creating a patient account in Core Registry;Research;EuRR-Bone & EuRRECa;Information will be provided when obtaining consent on how to create an account and access data on Core Registry;Y/N/NK
registry;11;Participation in detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Involvement in detailed disease registries;Y/N/NK
registry;11;Detailed Disease Registry;Research;EuRR-Bone & EuRRECa;Name;String
registry;11;Detailed Disease Registry patient ID;Research;EuRR-Bone & EuRRECa;;String
regression;2;Gonadal regression;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Gonadal regression;
regression;2;Gonadal regression;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Gonadal regression;
regurgitation;1;Nasal regurgitation;Bulbar/Gi ;EURO-NMD;;single
reinhardt-pfeiffer;1;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
rejection;2;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
rejection;2;"b.	Age at rejection:	";"6.	Rejection";Eurogen (Kid Transplantation);;[Numeric (Integer)]
rel;19;If thymoma, relapse?;Thymoma;EURO-NMD;;
rel;19;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
rel;19;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
rel;19;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
rel;19;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
rel;19;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
rel;19;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
rel;19;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
rel;19;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
rel;19;closest_degree_affect_rel;Diagnosis Aetiology;Rare Liver (Vascular);Closest degree of affected relatives;radio
rel;19;Relation to proband;subject;Genturis;What is the relation of this patient to the proband?;xref
rel;19;NF1 relative;subject;Genturis;"Has the patient a first degree relative with NF1 who has been diagnosed according to the following criteria: Presence of two or more of the following diagnostic criteria in the first degree relative:
1) Six or more cafÃ© au lait spots (> 5mm in greatest diameter in prepuberal patient  and >15mm in greatest diameter in postpuberal patient)
2) Two or more neurofibromas or one plexiform neurofibromas
3) Axillary or inguinal freckling
4) Optic glioma
5) Two or more lisch nodules (iris hamartomas)
6) A distinct osseous lesion";enum
rel;19;I yes, specify the most relevant;Pathology;PaedCan;;String
rel;19;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
rel;19;Noonan syndrome and Noonan-related syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome and Noonan-related syndrome;
rel;19;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
rel;19;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
rel;19;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
rel;19;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
relapse;2;If thymoma, relapse?;Thymoma;EURO-NMD;;
relapse;2;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
relat;14;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
relat;14;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
relat;14;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
relat;14;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
relat;14;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
relat;14;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
relat;14;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
relat;14;Relation to proband;subject;Genturis;What is the relation of this patient to the proband?;xref
relat;14;NF1 relative;subject;Genturis;"Has the patient a first degree relative with NF1 who has been diagnosed according to the following criteria: Presence of two or more of the following diagnostic criteria in the first degree relative:
1) Six or more cafÃ© au lait spots (> 5mm in greatest diameter in prepuberal patient  and >15mm in greatest diameter in postpuberal patient)
2) Two or more neurofibromas or one plexiform neurofibromas
3) Axillary or inguinal freckling
4) Optic glioma
5) Two or more lisch nodules (iris hamartomas)
6) A distinct osseous lesion";enum
relat;14;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
relat;14;Noonan syndrome and Noonan-related syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome and Noonan-related syndrome;
relat;14;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
relat;14;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
relat;14;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
related;11;R_AIH_Liver_related_complications;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Liver-related complications or signs of cirrhosis;radio
related;11;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
related;11;R_AIH_Liver_related_complications_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
related;11;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
related;11;R_AIH_Liver_related_outcome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
related;11;R_PBC_Liver_related_complications_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
related;11;Cystic fibrosis-related diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Cystic fibrosis-related diabetes;
related;11;Noonan syndrome and Noonan-related syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome and Noonan-related syndrome;
related;11;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
related;11;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
related;11;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
relation;1;Relation to proband;subject;Genturis;What is the relation of this patient to the proband?;xref
relative;1;NF1 relative;subject;Genturis;"Has the patient a first degree relative with NF1 who has been diagnosed according to the following criteria: Presence of two or more of the following diagnostic criteria in the first degree relative:
1) Six or more cafÃ© au lait spots (> 5mm in greatest diameter in prepuberal patient  and >15mm in greatest diameter in postpuberal patient)
2) Two or more neurofibromas or one plexiform neurofibromas
3) Axillary or inguinal freckling
4) Optic glioma
5) Two or more lisch nodules (iris hamartomas)
6) A distinct osseous lesion";enum
relevant;1;I yes, specify the most relevant;Pathology;PaedCan;;String
remission;2;R_PSC_IBD_remission;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD in histological remission;radio
remission;2;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
renal;17;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
renal;17;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
renal;17;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
renal;17;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
renal;17;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
renal;17;hepatorenal_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatorenal syndrome;radio
renal;17;fu_acute_renal_failure;Follow-up Complications;Rare Liver (Vascular);Acute renal failure;radio
renal;17;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
renal;17;Primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary adrenal insufficiency;
renal;17;Acquired chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Acquired chronic primary adrenal insufficiency;
renal;17;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
renal;17;Genetic chronic primary adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Genetic chronic primary adrenal insufficiency;
renal;17;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency;
renal;17;Congenital Adrenal Hyperplasia;ADRENAL;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
renal;17;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
renal;17;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
renal;17;Congenital Adrenal Hyperplasia;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Congenital Adrenal Hyperplasia;
renography;3;b. Age at first function renography (in days);3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
renography;3;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
renography;3;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
repair;1;"b. Age definitive repair (in days):	";2. Definitive repair:Â ;Eurogen (Anorectal Malformations);;[NumericÂ (Integer)]
repetitive;1;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
report;6;Structural anomaly (if not inferred from CNV report);;ithaca;;categoricalmref
report;6;Full caryotype (if not inferred from CNV report);;ithaca;;string
report;6;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
report;6;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
report;6;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
report;6;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
reported;2;Can be contacted for collecting Patient Reported Outcomes;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5);Y/N/NK
reported;2;Patient Reported Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Generic Patient Reported Outcomes using Euroqol EQ-5D ;"Questionnaire
"
repro;2;med_assist_repro_history;Diagnosis Aetiology;Rare Liver (Vascular);History of medically assisted reproduction;radio
repro;2;med_assist_repro_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of medically assisted reproduction;date
req;12;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
req;12;Frequency;Respiratory Apneic Episodes;EURO-NMD;;int
req;12;Hospitalization required;Respiratory Apneic Episodes;EURO-NMD;;yesno
req;12;Frequency;Respiratory Myasthenic crisis;EURO-NMD;;int
req;12;Hospitalization required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
req;12;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
req;12;Consultation Request;;ithaca;;compound
req;12;Is urgency required for this panel?;;ithaca;;bool
req;12;Consultation Request Reason;;ithaca;;categorical
req;12;Consultation Request Reason Description;;ithaca;;text
req;12;biopsy_req;primary_cancer;EURACAN;Biopsy done by;1, The hospital | 2, A different hospital | 9, Unknown
req;12;staging_proc_req;stage_procedures;EURACAN;Staging procedures done/requested by;1, the hospital | 2, a different hospital
required;4;Hospitalization required;Respiratory Apneic Episodes;EURO-NMD;;yesno
required;4;Hospitalization required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
required;4;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
required;4;Is urgency required for this panel?;;ithaca;;bool
requiring;1;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
reresection;1;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
res;108;Ophthalmoparesis;Diagnosis Eye;EURO-NMD;;yesno
res;108;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
res;108;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
res;108;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
res;108;EMG result;Diagnosis EMG;EURO-NMD;EMG result;single
res;108;SF EMG result;Diagnosis EMG;EURO-NMD;;
res;108;Tensilon/Prostigmine test response;Diagnosis ;EURO-NMD;;single
res;108;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
res;108;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
res;108;R_AIH_Immunosuppression_at_biopsy;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Immunosuppression at biopsy (if more than 7 days);radio
res;108;R_AIH_Other_immunosuppression;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
res;108;R_PBC_AIH_Other_immunosuppression;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
res;108;R_PBC_AIH_Immunosuppression_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
res;108;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
res;108;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
res;108;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
res;108;R_AIH_Change_of_immunosuppressive_regimen_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
res;108;R_PBC_AIH_Change_of_immunosuppressive_regimen_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
res;108;syst_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systolic blood pressue;numeric
res;108;diast_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Diastolic pressue;numeric
res;108;ascites_response_diuretics;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites response to diuretics;radio
res;108;ha_resistance_index;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery resistance index;numeric
res;108;free_pulm_artery_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free pulmonary artery pressure;numeric
res;108;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
res;108;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
res;108;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
res;108;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
res;108;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
res;108;apc_resistance;Diagnosis Aetiology;Rare Liver (Vascular);APC resistance;radio
res;108;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
res;108;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
res;108;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
res;108;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
res;108;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
res;108;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
res;108;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
res;108;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
res;108;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
res;108;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
res;108;Responsible HCP;subject;Genturis;What is the responsible HCP?;xref
res;108;Address;;ithaca;;string
res;108;Consent for ERN databases/Registries/research;;ithaca;;bool
res;108;Consent to be contacted for research;;ithaca;;bool
res;108;Retractation to be contacted for research;;ithaca;;bool
res;108;ResearchÂ ;;ithaca;;compound
res;108;Patient's biological sample available for researchÂ ;;ithaca;;bool
res;108;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
res;108;Country of residence;;ithaca;;xref
res;108;residence_country;patient_management_at_the_hospital;EURACAN;Country of residence;1, Afghanistan | 2, Albania | 3, Algeria | 4, Andorra | 5, Angola | 6, Antigua and Barbuda | 7, Argentina | 8, Armenia | 9, Australia | 10, Austria | 11, Azerbaijan | 12, The Bahamas | 13, Bahrain | 14, Bangladesh | 15, Barbados | 16, Belarus | 17, Belgium | 18, Belize | 19, Benin | 20, Bhutan | 21, Bolivia | 22, Bosnia and Herzegovina | 23, Botswana | 24, Brazil | 25, Brunei | 26, Bulgaria | 27, Burkina Faso | 28, Burundi | 29, Cambodia | 30, Cameroon | 31, Canada | 32, Cape Verde | 33, Central African Republic | 34, Chad | 35, Chile | 36, China | 37, Colombia | 38, Comoros | 39, Congo | 40, Costa Rica | 41, Cote d'Ivoire | 42, Croatia | 43, Cuba | 44, Cyprus | 45, Czech Republic | 46, Denmark | 47, Djibouti | 48, Dominica | 49, Dominican Republic | 50, East Timor (Timor-Leste) | 51, Ecuador | 52, Egypt | 53, El Salvador | 54, Equatorial Guinea | 55, Eritrea | 56, Estonia | 57, Ethiopia | 58, Fiji | 59, Finland | 60, France | 61, Gabon | 62, The Gambia | 63, Georgia | 64, Germany | 65, Ghana | 66, Greece | 67, Grenada | 68, Guatemala | 69, Guinea | 70, Guinea-Bissau | 71, Guyana | 72, Haiti | 73, Honduras | 74, Hungary | 75, Iceland | 76, India | 77, Indonesia | 78, Iran | 79, Iraq | 80, Ireland | 81, Israel | 82, Italy | 83, Jamaica | 84, Japan | 85, Jordan | 86, Kazakhstan | 87, Kenya | 88, Kiribati | 89, Korea (North) | 90, Korea (South) | 91, Kosovo | 92, Kuwait | 93, Kyrgyzstan | 94, Laos | 95, Latvia | 96, Lebanon | 97, Lesotho | 98, Liberia | 99, Libya | 100, Liechtenstein | 101, Lithuania | 102, Luxembourg | 103, Macedonia | 104, Madagascar | 105, Malawi | 106, Malaysia | 107, Maldives | 108, Mali | 109, Malta | 110, Marshall Islands | 111, Mauritania | 112, Mauritius | 113, Mexico | 114, Micronesia | 115, Moldova | 116, Monaco | 117, Mongolia | 118, Montenegro | 119, Morocco | 120, Mozambique | 121, Myanmar (Burma) | 122, Namibia | 123, Nauru | 124, Nepal | 125, Netherlands | 126, New Zealand | 127, Nicaragua | 128, Niger | 129, Nigeria | 130, Norway | 131, Oman | 132, Pakistan | 133, Palau | 134, Panama | 135, Papua New Guinea | 136, Paraguay | 137, Peru | 138, Philippines | 139, Poland | 140, Portugal | 141, Qatar | 142, Romania | 143, Russia | 144, Rwanda | 145, Saint Kitts and Nevis | 146, Saint Lucia | 147, Saint Vincent and the Grenadines | 148, Samoa | 149, San Marino | 150, Sao Tome and Principe | 151, Saudi Arabia | 152, Senegal | 153, Serbia | 154, Seychelles | 155, Sierra Leone | 156, Singapore | 157, Slovakia | 158, Slovenia | 159, Solomon Islands | 160, Somalia | 161, South Africa | 162, South Sudan | 163, Spain | 164, Sri Lanka | 165, Sudan | 166, Suriname | 167, Swaziland | 168, Sweden | 169, Switzerland | 170, Syria | 171, Taiwan | 172, Tajikistan | 173, Tanzania | 174, Thailand | 175, Togo | 176, Tonga | 177, Trinidad and Tobago | 178, Tunisia | 179, Turkey | 180, Turkmenistan | 181, Tuvalu | 182, Uganda | 183, Ukraine | 184, United Arab Emirates | 185, United Kingdom | 186, United States of America | 187, Uruguay | 188, Uzbekistan | 189, Vanuatu | 190, Vatican City | 191, Venezuela | 192, Vietnam | 193, Yemen | 194, Zambia | 195, Zimbabwe
res;108;end_treat_res_chem;chemotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
res;108;end_treat_res_immuno;immunotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
res;108;end_treat_res_tt;target_therapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
res;108;end_treat_res_radio;radiotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
res;108;end_treat_res_other;other_type_of_treatment;EURACAN;Treatment response (based on imaging no defined criteria);1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
res;108;end_treat_res_def_other;other_type_of_treatment;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
res;108;overall_treat_res;overall_treatment_response;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
res;108;overall_treat_res_def;overall_treatment_response;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
res;108;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
res;108;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
res;108;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
res;108;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
res;108;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
res;108;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
res;108;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
res;108;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
res;108;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
res;108;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
res;108;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
res;108;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
res;108;Best response;Other treatments;PaedCan;Please record the best response obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
res;108;Presence of sequelae;Follow up (one form for each follow up visit);PaedCan;;yes/no/unknown
res;108;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
res;108;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
res;108;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
res;108;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
res;108;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
res;108;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
res;108;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
res;108;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
res;108;Diazoxide-resistant hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant hyperinsulinism;
res;108;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
res;108;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency;
res;108;Diazoxide-resistant focal hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism;
res;108;Insulin-resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome;
res;108;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
res;108;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
res;108;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
res;108;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
res;108;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
res;108;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
res;108;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
res;108;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
res;108;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
res;108;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
res;108;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
res;108;Gonadal regression;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Gonadal regression;
res;108;Gonadal regression;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Gonadal regression;
res;108;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
res;108;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
res;108;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
res;108;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
res;108;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
res;108;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
res;108; Fibrodysplasia ossificans progressiva (FOP);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Fibrodysplasia ossificans progressiva (FOP);
res;108; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
res;108;Blook pressure;Clinical Status;ERKNet;Â ;bp_sys/bp_dia/bp_sys_sds/bp_dia_sds
res;108;Dipstick result;Biochemistry;ERKNet;if 3;protur_dipstick
res;108;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
research;10;Consent for ERN databases/Registries/research;;ithaca;;bool
research;10;Consent to be contacted for research;;ithaca;;bool
research;10;Retractation to be contacted for research;;ithaca;;bool
research;10;ResearchÂ ;;ithaca;;compound
research;10;Patient's biological sample available for researchÂ ;;ithaca;;bool
research;10;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
research;10;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
research;10;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
research;10;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
research;10;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
resection;9;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
resection;9;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
resection;9;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
resection;9;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
resection;9;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
resection;9;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
resection;9;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
resection;9;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
resection;9;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
residence;5;Country of residence;;ithaca;;xref
residence;5;residence_country;patient_management_at_the_hospital;EURACAN;Country of residence;1, Afghanistan | 2, Albania | 3, Algeria | 4, Andorra | 5, Angola | 6, Antigua and Barbuda | 7, Argentina | 8, Armenia | 9, Australia | 10, Austria | 11, Azerbaijan | 12, The Bahamas | 13, Bahrain | 14, Bangladesh | 15, Barbados | 16, Belarus | 17, Belgium | 18, Belize | 19, Benin | 20, Bhutan | 21, Bolivia | 22, Bosnia and Herzegovina | 23, Botswana | 24, Brazil | 25, Brunei | 26, Bulgaria | 27, Burkina Faso | 28, Burundi | 29, Cambodia | 30, Cameroon | 31, Canada | 32, Cape Verde | 33, Central African Republic | 34, Chad | 35, Chile | 36, China | 37, Colombia | 38, Comoros | 39, Congo | 40, Costa Rica | 41, Cote d'Ivoire | 42, Croatia | 43, Cuba | 44, Cyprus | 45, Czech Republic | 46, Denmark | 47, Djibouti | 48, Dominica | 49, Dominican Republic | 50, East Timor (Timor-Leste) | 51, Ecuador | 52, Egypt | 53, El Salvador | 54, Equatorial Guinea | 55, Eritrea | 56, Estonia | 57, Ethiopia | 58, Fiji | 59, Finland | 60, France | 61, Gabon | 62, The Gambia | 63, Georgia | 64, Germany | 65, Ghana | 66, Greece | 67, Grenada | 68, Guatemala | 69, Guinea | 70, Guinea-Bissau | 71, Guyana | 72, Haiti | 73, Honduras | 74, Hungary | 75, Iceland | 76, India | 77, Indonesia | 78, Iran | 79, Iraq | 80, Ireland | 81, Israel | 82, Italy | 83, Jamaica | 84, Japan | 85, Jordan | 86, Kazakhstan | 87, Kenya | 88, Kiribati | 89, Korea (North) | 90, Korea (South) | 91, Kosovo | 92, Kuwait | 93, Kyrgyzstan | 94, Laos | 95, Latvia | 96, Lebanon | 97, Lesotho | 98, Liberia | 99, Libya | 100, Liechtenstein | 101, Lithuania | 102, Luxembourg | 103, Macedonia | 104, Madagascar | 105, Malawi | 106, Malaysia | 107, Maldives | 108, Mali | 109, Malta | 110, Marshall Islands | 111, Mauritania | 112, Mauritius | 113, Mexico | 114, Micronesia | 115, Moldova | 116, Monaco | 117, Mongolia | 118, Montenegro | 119, Morocco | 120, Mozambique | 121, Myanmar (Burma) | 122, Namibia | 123, Nauru | 124, Nepal | 125, Netherlands | 126, New Zealand | 127, Nicaragua | 128, Niger | 129, Nigeria | 130, Norway | 131, Oman | 132, Pakistan | 133, Palau | 134, Panama | 135, Papua New Guinea | 136, Paraguay | 137, Peru | 138, Philippines | 139, Poland | 140, Portugal | 141, Qatar | 142, Romania | 143, Russia | 144, Rwanda | 145, Saint Kitts and Nevis | 146, Saint Lucia | 147, Saint Vincent and the Grenadines | 148, Samoa | 149, San Marino | 150, Sao Tome and Principe | 151, Saudi Arabia | 152, Senegal | 153, Serbia | 154, Seychelles | 155, Sierra Leone | 156, Singapore | 157, Slovakia | 158, Slovenia | 159, Solomon Islands | 160, Somalia | 161, South Africa | 162, South Sudan | 163, Spain | 164, Sri Lanka | 165, Sudan | 166, Suriname | 167, Swaziland | 168, Sweden | 169, Switzerland | 170, Syria | 171, Taiwan | 172, Tajikistan | 173, Tanzania | 174, Thailand | 175, Togo | 176, Tonga | 177, Trinidad and Tobago | 178, Tunisia | 179, Turkey | 180, Turkmenistan | 181, Tuvalu | 182, Uganda | 183, Ukraine | 184, United Arab Emirates | 185, United Kingdom | 186, United States of America | 187, Uruguay | 188, Uzbekistan | 189, Vanuatu | 190, Vatican City | 191, Venezuela | 192, Vietnam | 193, Yemen | 194, Zambia | 195, Zimbabwe
residence;5;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
residence;5;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
residence;5;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
residual;1;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
resistance;14;ha_resistance_index;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic artery resistance index;numeric
resistance;14;apc_resistance;Diagnosis Aetiology;Rare Liver (Vascular);APC resistance;radio
resistance;14;Insulin-resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome;
resistance;14;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
resistance;14;Growth delay due to insulin-like growth factor I resistance;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Growth delay due to insulin-like growth factor I resistance;
resistance;14;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
resistance;14;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
resistance;14;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
resistance;14;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
resistance;14;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
resistance;14;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
resistance;14;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
resistance;14;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
resistance;14;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
resistance-muscle;1;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
respiratory;3;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
respiratory;3;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
respiratory;3;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
response;5;Tensilon/Prostigmine test response;Diagnosis ;EURO-NMD;;single
response;5;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
response;5;ascites_response_diuretics;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites response to diuretics;radio
response;5;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
response;5;Best response;Other treatments;PaedCan;Please record the best response obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
responsible;4;Responsible HCP;subject;Genturis;What is the responsible HCP?;xref
responsible;4;Name of the physician responsible for patient coding in the registry;;ithaca;;xref
responsible;4;Clinician Responsible for Patient;Care Pathway;EuRR-Bone & EuRRECa;Senior endocrine clinician responsible for case for clinical care and data governance;Drop down/Not assigned
responsible;4;Can be contacted for research purposes by clinician responsible for patient;Research;EuRR-Bone & EuRRECa;Patient's permission to be contacted for research purpose through local clinician (5.5);Y/N/NK - LOINC Code: 83930-8Â 
result;4;EMG result;Diagnosis EMG;EURO-NMD;EMG result;single
result;4;SF EMG result;Diagnosis EMG;EURO-NMD;;
result;4;Dipstick result;Biochemistry;ERKNet;if 3;protur_dipstick
result;4;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
retrusion-sensorineural;1;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
reuse;2;Retractation for reuse;;ithaca;;bool
reuse;2;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
review;1;Central review;Pathology;PaedCan;no/yes,local diagnosis confirmed/yes,local diagnosis changed;yes/no/unknown
revision;3;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
revision;3;date_of_revision;Follow-up Events;Rare Liver (Vascular);Date of revision;date
revision;3;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
rhizo-mesomelic;1;Mesomelic and rhizo-mesomelic dysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic and rhizo-mesomelic dysplasia;
rhizomelic;5;Cleidorhizomelic syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cleidorhizomelic syndrome ;
rhizomelic;5;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
rhizomelic;5;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
rhizomelic;5;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
rhizomelic;5;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
rhyns;1;RHYNS syndrome;PITUITARY;EuRR-Bone & EuRRECa;RHYNS syndrome;
ria;37;MuSK (standard, RIA);Diagnosis ;EURO-NMD;;single
ria;37;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
ria;37;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
ria;37;bacterial_peritonitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Spontaneous bacterial peritonitis;radio
ria;37;number_miscarriagies;Diagnosis Aetiology;Rare Liver (Vascular);Number of miscarriages;radio
ria;37;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
ria;37;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
ria;37;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
ria;37;geneticVariantLabel;geneticVariant;Genturis;;string
ria;37;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
ria;37;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
ria;37;Variant type;geneticVariant;Genturis;What is the type of mutation?;xref
ria;37;Zygosity of variant;geneticVariant;Genturis;What is the zygosity of the germline variant?;enum
ria;37;Variant classification;geneticVariant;Genturis;What is the class of the variant?;xref
ria;37;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
ria;37;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
ria;37;Material availability;subject;Genturis;What material is locally available for this patient?;categoricalmref
ria;37;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
ria;37;Variant status;subject;Genturis;Has any class 3, 4 of 5 variant been found?;enum
ria;37;Genetic variants;subject;Genturis;Genetic variants;mref
ria;37;Allelic variant of (link to other OMIM code);;ithaca;;xref
ria;37;Consent for usage of biobank material;;ithaca;;bool
ria;37;Link to variant;;ithaca;;mref
ria;37;Link to Genomic variant;;ithaca;;mref
ria;37;Nucleotide variant description;;ithaca;;text
ria;37;Protein variant description;;ithaca;;text
ria;37;Class of variant;;ithaca;Clinical interperation for variant;mref
ria;37;clinical_trial;patient_included_in_clinical_trial;EURACAN;Patient included in a clinical trial;1, Yes | 2, No | 9, Unknown
ria;37;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
ria;37;oth_clinical_trial;other_type_of_treatment;EURACAN;Patient included in a clinical trial;1, Yes | 2, No
ria;37;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
ria;37;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
ria;37;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
ria;37;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
ria;37;Defects of mullerian development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Defects of mullerian development;
ria;37;Proteinuria ;Biochemistry;ERKNet;Â ;protur
ria;37;proteinuria (pediatric/adult);Biochemistry;ERKNet;If 1;protur_24h
rib-polydactyly;1;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
rickets;6;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
rickets;6;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
rickets;6;Hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypophosphataemic rickets;
rickets;6;Autosomal dominant hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal dominant hypophosphataemic rickets;
rickets;6;Autosomal recessive hypophosphataemic rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autosomal recessive hypophosphataemic rickets;
rickets;6;Hereditary hypophosphataemic rickets with hypercalciuria;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hereditary hypophosphataemic rickets with hypercalciuria;
right;11;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
right;11;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
right;11;Right hand grip (KgW):;QMG;EURO-NMD;;
right;11;right_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein branch;radio
right;11;pv_flow_right;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein direction of flow;radio
right;11;right_atrium_mm_hg;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right atrium;numeric
right;11;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
right;11;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
right;11;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
right;11;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
right;11;McCune-Albright syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;McCune-Albright syndrome ;
rigidity;1;Spinal rigidity;Diagnosis Skeletal;EURO-NMD;;yesno
rise;1;Rise from the floor;Mobility ;EURO-NMD;;single
rituximab;15;R_AIH_Rituximab;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_AIH_Rituximab_primary_indication_1;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_AIH_Rituximab_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_PBC_AIH_Rituximab;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_PBC_AIH_Rituximab_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_PSC_AIH_Rituximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_AIH_Rituximab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_AIH_Rituximab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_AIH_Rituximab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_AIH_Rituximab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
rituximab;15;R_PBC_AIH_Rituximab_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
rituximab;15;R_PBC_AIH_Rituximab_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
robinow;1;Robinow syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Robinow syndrome ;
rohhad;1;ROHHAD syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;ROHHAD syndrome;
rpv;2;fu_ima_bef_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
rpv;2;fu_ima_last_rpv_patent;Follow-up Imaging data;Rare Liver (Vascular);Right portal vein branch patent;radio
rubenstein;1;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
rubinstein-taybi;3;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
rubinstein-taybi;3;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
rubinstein-taybi;3;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
ryr1;2;RYR1;Diagnosis ;EURO-NMD;;single
ryr1;2;RYR1 Titer;Diagnosis ;EURO-NMD;;
s1;1;prot_s1_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Protein S mutation;radio
sacrum;2;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
sacrum;2;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
saldino-noonan;1;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
saliva;3;site_maj_salivary;primary_cancer;EURACAN;Subsite;1, C07.9  Parotid gland | 2, C08 other and unspecified major salivary glands | 3, C08.0  Submandibular gland | 4, C08.1  Sublingual gland | 5, C08.8  Overlapping lesion of major salivary glands | 6, C08.9  Major salivary gland, NOS
saliva;3;site_salivary;primary_cancer;EURACAN;Subsite;1, nasal cavity and paranasal sinuses | 2, nasopharynx | 3, major salivary glands | 4, hypopharynx | 5, Oropharynx | 6, larynx | 7, oral cavity | 8, lip
saliva;3;biom_saliva;tumour_material_available;EURACAN;Saliva;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
salivary;2;site_maj_salivary;primary_cancer;EURACAN;Subsite;1, C07.9  Parotid gland | 2, C08 other and unspecified major salivary glands | 3, C08.0  Submandibular gland | 4, C08.1  Sublingual gland | 5, C08.8  Overlapping lesion of major salivary glands | 6, C08.9  Major salivary gland, NOS
salivary;2;site_salivary;primary_cancer;EURACAN;Subsite;1, nasal cavity and paranasal sinuses | 2, nasopharynx | 3, major salivary glands | 4, hypopharynx | 5, Oropharynx | 6, larynx | 7, oral cavity | 8, lip
salvage;7;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
salvage;7;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
salvage;7;salvage_procedure_angio;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
salvage;7;date_salvage_proc_angio;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
salvage;7;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
salvage;7;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
salvage;7;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
sample;19;R_AIH_Biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sample;19;R_AIH_Other_biosamples;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sample;19;R_PBC_Biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sample;19;R_PBC_Other_biosamples;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sample;19;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sample;19;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sample;19;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sample;19;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sample;19;R_AIH_Biosamples_stored;AIH Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sample;19;R_AIH_Other_biosamples_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sample;19;R_PBC_Biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sample;19;R_PBC_Other_biosamples_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sample;19;edta_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample obtained?;radio
sample;19;edta_sample_date;Diagnosis Biobank;Rare Liver (Vascular);EDTA sample date;date
sample;19;urine_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);Urine sample obtained?;dropdown
sample;19;urin_sample_date;Diagnosis Biobank;Rare Liver (Vascular);Urine sample date;date
sample;19;Patient's biological sample available for researchÂ ;;ithaca;;bool
sample;19;Biological sample available for research;Pathology;PaedCan;Patientâ€™s biological sample available;yes/no
sample;19;Biobank sample available for researchÂ ;Research;EuRR-Bone & EuRRECa;Patient has a sample stored in a biobank for research to be used subject to further ethics approval;Y/N/NK - LOINC Code: 75520-7
sanjad-sakati;1;Sanjad-Sakati syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Sanjad-Sakati syndrome;
sarc;2;sys_sarcoidosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Sarcoidosis;radio
sarc;2;prev_not_hn_sarc;previous_cancer_genetic_syndromes;EURACAN;Please specify;1, Soft Tissue | 2, Viscera | 3, Bone
sarcoidosis;1;sys_sarcoidosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Sarcoidosis;radio
savarirayan;1;Mesomelic dysplasia, Savarirayan type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Savarirayan type ;
sbp2;1;SBP2 deficiency;THYROID;EuRR-Bone & EuRRECa;SBP2 deficiency;
sc;522;Weakness of facial musculature;Diagnosis Muscular;EURO-NMD;Facial weakness;yesno
sc;522;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
sc;522;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
sc;522;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
sc;522;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
sc;522;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
sc;522;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
sc;522;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
sc;522;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
sc;522;Neck muscle weakness;Diagnosis Muscular;EURO-NMD;Neck weakness;yesno
sc;522;Skeletal muscle atrophy;Diagnosis Muscular;EURO-NMD;Muscle wasting;yesno
sc;522;Scoliosis;Diagnosis Skeletal;EURO-NMD;;yesno
sc;522;Scapular winging;Diagnosis Skeletal;EURO-NMD;;yesno
sc;522;MG-ADL total score;QoL;EURO-NMD;;int
sc;522;Total QMG score if done;QMG;EURO-NMD;;
sc;522;Facial Muscles;QMG;EURO-NMD;;
sc;522;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
sc;522;R_AIH_Simplified_AIH_score;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Simplified AIH score;numeric
sc;522;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
sc;522;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
sc;522;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
sc;522;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
sc;522;R_AIH_IQR_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
sc;522;R_AIH_Ascites;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Ascites;radio
sc;522;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
sc;522;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
sc;522;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
sc;522;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
sc;522;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
sc;522;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
sc;522;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
sc;522;R_PBC_Nakanuma_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed?;radio
sc;522;R_PBC_nakanuma_grading_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
sc;522;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
sc;522;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
sc;522;R_PBC_Ascites;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Ascites;radio
sc;522;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
sc;522;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
sc;522;R_PSC_Contact_consent;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Contact consent;radio
sc;522;R_PSC_Year_of_birth;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
sc;522;R_PSC_Date_of_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of diagnosis;string
sc;522;R_PSC_Age_at_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Age at diagnosis;calculation
sc;522;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
sc;522;R_PSC_Additional_diagnosis_of_AIH;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Additional diagnosis of AIH;radio
sc;522;R_PSC_Date_AIH_diagnosis;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Date of AIH diagnosis;date
sc;522;R_PSC_Weight;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
sc;522;R_PSC_Height;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Height;numeric
sc;522;R_PSC_BMI;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);BMI;calculation
sc;522;R_PSC_Sex;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
sc;522;R_PSC_Ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Ethnicity;radio
sc;522;R_PSC_Other_ethnicity;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Other ethnicity;string
sc;522;R_PSC_Alcohol;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Alcohol per day;radio
sc;522;R_PSC_Smoking;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
sc;522;PSC_is_smoker;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
sc;522;R_PSC_Smoking_amount;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount (pack years);numeric
sc;522;R_PSC_FDR_autoimmune_liver_diseaese;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);First degree relative with autoimmune liver diseases;radio
sc;522;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
sc;522;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
sc;522;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
sc;522;R_PSC_Liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver biopsy;radio
sc;522;R_PSC_Date_liver_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of liver biopsy;date
sc;522;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
sc;522;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
sc;522;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
sc;522;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
sc;522;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sc;522;R_PSC_mHAI;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);mHAI;numeric
sc;522;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
sc;522;R_PSC_Cholangitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangitis activity;numeric
sc;522;R_PSC_Hepatitis_activity_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Hepatitis activity;numeric
sc;522;R_PSC_not_in_db4;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma grade;calculation
sc;522;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
sc;522;R_PSC_Fibrosis_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis;numeric
sc;522;R_PSC_Bile_duct_loss_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Bile duct loss;numeric
sc;522;R_PSC_Deposition_orcein_positive_granules_nakanuma;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
sc;522;R_PSC_not_in_db42;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Calculate nakanuma score;calculation
sc;522;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
sc;522;R_PSC_Additional_nafld;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
sc;522;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
sc;522;R_PSC_MRCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);MRCP;radio
sc;522;R_PSC_ERCP;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP;radio
sc;522;R_PSC_PTCD;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);PTCD;radio
sc;522;R_PSC_ERCP_PTCD_performed;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
sc;522;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
sc;522;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
sc;522;R_PSC_Cholangioscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Cholangioscopy;radio
sc;522;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
sc;522;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
sc;522;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
sc;522;R_PSC_Spleen_size;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size;numeric
sc;522;R_PSC_Colonoscopy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Colonoscopy;radio
sc;522;R_PSC_IBD_status;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD Status;radio
sc;522;R_PSC_Colonoscopy_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Biopsy performed?;radio
sc;522;R_PSC_Date_of_IBD_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Date of IBD diagnosis;date
sc;522;R_PSC_IBD_remission;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD in histological remission;radio
sc;522;R_PSC_Histology_colon_biopsy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Histology colon biopsy;radio
sc;522;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
sc;522;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
sc;522;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
sc;522;R_PSC_AST;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);AST;numeric
sc;522;R_PSC_ALT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);ALT;numeric
sc;522;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
sc;522;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
sc;522;R_PSC_ALP;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
sc;522;R_PSC_yGT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGT;numeric
sc;522;R_PSC_Albumin;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Albumin;numeric
sc;522;R_PSC_Creatinine_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
sc;522;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
sc;522;R_PSC_INR;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);INR;numeric
sc;522;R_PSC_Platelets;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Platelets;numeric
sc;522;R_PSC_IgG;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG;numeric
sc;522;R_PSC_IgM;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgM;numeric
sc;522;R_PSC_IgA;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgA;numeric
sc;522;R_PSC_yGlobulins;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
sc;522;R_PSC_IgG4;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);IgG4;numeric
sc;522;R_PSC_ANA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA;radio
sc;522;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
sc;522;R_PSC_ANA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
sc;522;R_PSC_ANA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
sc;522;R_PSC_SMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
sc;522;R_PSC_SMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sc;522;R_PSC_SMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sc;522;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sc;522;R_PSC_LKM;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM;radio
sc;522;R_PSC_LKM_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
sc;522;R_PSC_LKM1_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
sc;522;R_PSC_LKM_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
sc;522;R_PSC_SLA_LP;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sc;522;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
sc;522;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sc;522;R_PSC_AMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA;radio
sc;522;R_PSC_AMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
sc;522;R_PSC_AMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
sc;522;R_PSC_AMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
sc;522;R_PSC_Other_antibodies;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
sc;522;R_PSC_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Bone Mineral Density (DXA);radio
sc;522;R_PSC_Date_of_DXA;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Date of DXA;date
sc;522;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
sc;522;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
sc;522;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sc;522;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
sc;522;R_PSC_Serum;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
sc;522;R_PSC_Paxgene;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Paxgene;radio
sc;522;R_PSC_Other_biosamples;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sc;522;R_PSC_UDCA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA;radio
sc;522;R_PSC_UDCA_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
sc;522;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
sc;522;R_PSC_Prednisolone;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
sc;522;R_PSC_Prednisolone_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
sc;522;R_PSC_Prednisolone_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Budesonide;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide;radio
sc;522;R_PSC_Budesonide_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Budesonide dose;numeric
sc;522;R_PSC_Budesonide_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Azathioprine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine;radio
sc;522;R_PSC_Azathioprine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Azathioprine dose;numeric
sc;522;R_PSC_Azathioprine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Infliximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Infliximab;radio
sc;522;R_PSC_Infliximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Adalimumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Adalimumab;radio
sc;522;R_PSC_Adalimumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Vedolizumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Vedolizumab;radio
sc;522;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Ustekinumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Ustekinumab;radio
sc;522;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
sc;522;R_PSC_AIH_Other_immunosuppression;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other immunosuppression;radio
sc;522;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
sc;522;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
sc;522;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_MMF;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF;radio
sc;522;R_PSC_AIH_MMF_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);MMF dose;numeric
sc;522;R_PSC_AIH_MMF_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Tacrolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
sc;522;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_CyclosporinA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Cyclosporin A;radio
sc;522;R_PSC_AIH_CyclosporinA_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Rituximab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Rituximab;radio
sc;522;R_PSC_AIH_Rituximab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
sc;522;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Immunosuppression_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other;textarea
sc;522;R_PSC_Liver_related_complications;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver-related complications / signs of cirrhosis;radio
sc;522;R_PSC_Imaging_consistent_cirrhosis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
sc;522;R_PSC_Ascites;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Ascites;radio
sc;522;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
sc;522;R_PSC_Variceal_bleeding;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Variceal bleeding;radio
sc;522;R_PSC_Overt_encephalopathy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
sc;522;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
sc;522;R_PSC_Cholangitis;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholangitis (Clinical diagnosis requires antibiotic use);radio
sc;522;R_PSC_Hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary Malignancy;radio
sc;522;R_PSC_Date_hepatobiliary_malignancy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
sc;522;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
sc;522;R_PSC_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
sc;522;R_PSC_Date_CHE;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date CHE;date
sc;522;R_PSC_CHE_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);CHE indication;radio
sc;522;R_PSC_Colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Colectomy;radio
sc;522;R_PSC_Date_colectomy;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Date colectomy;date
sc;522;R_PSC_Colectomy_indication;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
sc;522;R_PSC_Pruritus;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Pruritus;radio
sc;522;psc_pbc_diag;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);psc pbc diag;calculation
sc;522;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
sc;522;R_AIH_PSC_Adalimumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Adalimumab;radio
sc;522;R_AIH_PSC_Adalimumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
sc;522;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
sc;522;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_AIH_Ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Ascites;radio
sc;522;R_AIH_Date_ascites_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date ascites;date
sc;522;R_AIH_Date_endoscopy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of endoscopy;date
sc;522;R_AIH_New_diagnosis_of_PSC_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);New diagnosis of PSC;radio
sc;522;R_AIH_New_diagnosis_of_PSC_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
sc;522;R_PSC_AST_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);AST;numeric
sc;522;R_PSC_ALT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);ALT;numeric
sc;522;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
sc;522;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
sc;522;R_PSC_ALP_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Alkaline Phosphatase;numeric
sc;522;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
sc;522;R_PSC_Albumin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Albumin;numeric
sc;522;R_PSC_Creatinine_mgdL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
sc;522;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
sc;522;R_PSC_INR_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);INR;numeric
sc;522;R_PSC_Platelets_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Platelets;numeric
sc;522;R_PSC_IgG_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgG;numeric
sc;522;R_PSC_IgM_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgM;numeric
sc;522;R_PSC_IgA_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);IgA;numeric
sc;522;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
sc;522;R_PSC_ANA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA;radio
sc;522;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
sc;522;R_PSC_ANA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (ELISA);numeric
sc;522;R_PSC_ANA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (Immunoblot);radio
sc;522;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
sc;522;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sc;522;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sc;522;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sc;522;R_PSC_LKM_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM;radio
sc;522;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
sc;522;R_PSC_LKM1_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM-1 (ELISA);numeric
sc;522;R_PSC_LKM_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (Immunoblot);radio
sc;522;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sc;522;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
sc;522;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sc;522;R_PSC_AMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA;radio
sc;522;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
sc;522;R_PSC_AMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (ELISA);numeric
sc;522;R_PSC_AMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (Immunoblot);radio
sc;522;R_PSC_Other_antibodies_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);Other antibodies:;string
sc;522;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
sc;522;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
sc;522;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
sc;522;R_PSC_Paxgene_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Paxgene;radio
sc;522;R_PSC_Other_biosamples_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Other biosamples:;textarea
sc;522;R_PSC_Colonoscopy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Colonoscopy;radio
sc;522;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
sc;522;R_PSC_Colonoscopy_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Biopsy performed?;radio
sc;522;R_PSC_Date_of_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Date of biopsy;date
sc;522;R_PSC_Histology_colon_biopsy_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Histology colon biopsy;radio
sc;522;R_PSC_IBD_histological_remission_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD in histological remission;radio
sc;522;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
sc;522;R_PSC_MRI_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);MRI;radio
sc;522;R_PSC_Date_of_followup_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of follow-up;string
sc;522;R_PSC_Age_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Age at follow-up;calculation
sc;522;R_PSC_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bone mineral density (DXA);radio
sc;522;R_PSC_Date_of_DXA_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of DXA;date
sc;522;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
sc;522;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
sc;522;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
sc;522;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
sc;522;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
sc;522;R_PSC_Liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver biopsy;radio
sc;522;R_PSC_Date_liver_biopsy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver biopsy;date
sc;522;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
sc;522;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
sc;522;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
sc;522;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
sc;522;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sc;522;R_PSC_mHAI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);mHAI;numeric
sc;522;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
sc;522;R_PSC_Cholangitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis activity;numeric
sc;522;R_PSC_Hepatitis_activity_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatitis activity;numeric
sc;522;R_PSC_not_in_db312;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma grading;calculation
sc;522;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
sc;522;R_PSC_Fibrosis_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis;numeric
sc;522;R_PSC_Bile_duct_loss_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Bile duct loss;numeric
sc;522;R_PSC_Deposition_orcein_positive_granules_nakanuma_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Deposition of orcein positive granules;numeric
sc;522;R_PSC_not_in_db123;PSC Follow-up Outcome;Rare Liver (Auto imune);Calculate nakanuma staging;calculation
sc;522;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
sc;522;R_PSC_Additional_nafld_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NAFLD?;radio
sc;522;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
sc;522;R_PSC_Liver_related_outcome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver-related outcome / complications;radio
sc;522;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
sc;522;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
sc;522;R_PSC_Imaging_consistent_cirrhosis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver imaging consistent with cirrhosis;radio
sc;522;R_PSC_Date_liver_imaging_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date liver imaging;date
sc;522;R_PSC_Ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
sc;522;R_PSC_Date_ascites_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
sc;522;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
sc;522;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
sc;522;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
sc;522;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
sc;522;R_PSC_Encephalopahty_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Overt encephalopathy;radio
sc;522;R_PSC_Date_encephalopathy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date encephallopathy;date
sc;522;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
sc;522;R_PSC_Date_HRS_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatorenal syndrome;date
sc;522;R_PSC_Cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholangitis (clinical diagnosis requires antibiotics);radio
sc;522;R_PSC_Date_cholangitis_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date cholangitis;date
sc;522;R_PSC_Hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy;radio
sc;522;R_PSC_Date_hepatobiliary_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date hepatobiliary malignancy;date
sc;522;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
sc;522;R_PSC_Other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Other malignancy;radio
sc;522;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
sc;522;R_PSC_Date_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of other malignancy;date
sc;522;R_PSC_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Cholecystectomy (CHE);radio
sc;522;R_PSC_Date_CHE_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date CHE;date
sc;522;R_PSC_Indiction_CHE_12months_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication CHE;radio
sc;522;R_PSC_Colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Colectomy;radio
sc;522;R_PSC_Date_coleectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date colectomy;date
sc;522;R_PSC_Indication_colectomy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Main indication for colectomy;radio
sc;522;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
sc;522;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
sc;522;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
sc;522;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
sc;522;R_PSC_New_diagnosis_of_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);New diagnosis of AIH;radio
sc;522;R_PSC_Date_diagnosis_AIH_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date new diagnosis of AIH;date
sc;522;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
sc;522;R_PSC_Height_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Height;numeric
sc;522;R_PSC_BMI_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);BMI;calculation
sc;522;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
sc;522;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
sc;522;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
sc;522;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
sc;522;R_PSC_Is_female;PSC Follow-up Outcome;Rare Liver (Auto imune);Is female;calculation
sc;522;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
sc;522;R_PSC_AIH_check;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH_check;calculation
sc;522;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
sc;522;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
sc;522;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
sc;522;R_PSC_Prednisolone_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
sc;522;R_PSC_Prednisolone_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone dose;numeric
sc;522;R_PSC_Prednisolone_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Budesonide_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide;radio
sc;522;R_PSC_Budesonide_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Budesonide dose;numeric
sc;522;R_PSC_Budesonide_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Azathioprine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
sc;522;R_PSC_Azathioprine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine dose;numeric
sc;522;R_PSC_Azathioprine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Azathioprine_metabolites_assessed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine metabolites assessed;radio
sc;522;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
sc;522;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
sc;522;R_PSC_AIH_MMP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP;numeric
sc;522;R_PSC_AIH_MMP_pmol02ml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMP (pmol/0.2ml);numeric
sc;522;R_PSC_Infliximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Infliximab;radio
sc;522;R_PSC_Infliximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Adalimumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
sc;522;R_PSC_Adalimumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
sc;522;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
sc;522;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
sc;522;R_PSC_ERCP_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP within last 12 months;radio
sc;522;R_PSC_PTCD_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);PTCD within last 12 months;radio
sc;522;R_PSC_ERCP_PTCD_performed_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);ERCP/PTCD performed;calculation
sc;522;R_PSC_Biliary_dilation_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
sc;522;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
sc;522;R_PSC_Cholangioscopy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
sc;522;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
sc;522;R_PSC_AIH_Change_of_immunosuppressive_regimen_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Change of immunosuppressive regimen (other than dose change);radio
sc;522;R_PSC_AIH_Azathioprine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Azathioprine;radio
sc;522;R_PSC_AIH_Azathioprine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
sc;522;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
sc;522;R_PSC_AIH_Prednisolone_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Prednisolone/Prednisone;radio
sc;522;R_PSC_AIH_Prednisolone_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
sc;522;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
sc;522;R_PSC_AIH_Budesonide_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
sc;522;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
sc;522;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
sc;522;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
sc;522;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
sc;522;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
sc;522;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
sc;522;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
sc;522;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
sc;522;R_PSC_AIH_MMF_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
sc;522;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
sc;522;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
sc;522;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
sc;522;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_MMF_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
sc;522;R_PSC_AIH_MMF_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF dose;numeric
sc;522;R_PSC_AIH_MMF_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
sc;522;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_CyclosporinA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Cyclosporin A;radio
sc;522;R_PSC_AIH_CyclosporinA_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Rituximab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Rituximab;radio
sc;522;R_PSC_AIH_Rituximab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
sc;522;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
sc;522;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
sc;522;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
sc;522;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
sc;522;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
sc;522;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
sc;522;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
sc;522;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
sc;522;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
sc;522;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
sc;522;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
sc;522;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
sc;522;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
sc;522;R_AIH_Ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ascites;radio
sc;522;R_AIH_Date_ascites_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date Ascites;date
sc;522;R_AIH_Additional_diagnosis_of_PSC_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional diagnosis of PSC;radio
sc;522;R_AIH_New_diagnosis_of_PSC_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of new diagnosis of PSC;date
sc;522;aih_psc_check;AIH Follow-up Treatment;Rare Liver (Auto imune);psc check;calculation
sc;522;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
sc;522;R_AIH_PSC_Adalimumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Adalimumab;radio
sc;522;R_AIH_PSC_Adalimumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
sc;522;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
sc;522;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
sc;522;R_AIH_PSC_ERCP_PTCD_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);ERCP or PTCD within last 12 months;radio
sc;522;R_AIH_PSC_Biliary_dilation_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Dilation therapy;radio
sc;522;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
sc;522;R_AIH_PSC_Cholangioscopy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Cholangioscopy;radio
sc;522;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
sc;522;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
sc;522;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
sc;522;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
sc;522;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
sc;522;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
sc;522;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
sc;522;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
sc;522;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
sc;522;R_PBC_Ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ascites;radio
sc;522;R_PBC_Date_ascites_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date ascites;date
sc;522;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
sc;522;vasc_oth;Diagnosis General Information;Rare Liver (Vascular);Specify Other Vascular Disease;string
sc;522;weight_w_o_ascites_oedema;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Estimated weight without ascites and oedema;numeric
sc;522;ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
sc;522;asc_check;Diagnosis Clinical Manifestations;Rare Liver (Vascular);asc_check;calculation
sc;522;ascites_response_diuretics;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites response to diuretics;radio
sc;522;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
sc;522;history_of_ascites;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Ascites;radio
sc;522;sys_vasculitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Vasculitis;radio
sc;522;ascites_degree;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Ascites degree;radio
sc;522;b_fibroscan;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan at diagnosis;numeric
sc;522;b_fibroscan_date;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of Fibroscan;date
sc;522;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
sc;522;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
sc;522;b_fibroscan_cap;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: CAP;numeric
sc;522;b_fibroscan_iqr;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);IQR;numeric
sc;522;number_miscarriagies;Diagnosis Aetiology;Rare Liver (Vascular);Number of miscarriages;radio
sc;522;abd_interv_sclero;Diagnosis Aetiology;Rare Liver (Vascular);Sclerotherapy;radio
sc;522;abd_interv_sclero_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Sclerotherapy;date
sc;522;dia_lab_ascites_alb;Diagnosis Laboratory data;Rare Liver (Vascular);Albumin;numeric
sc;522;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
sc;522;dia_lab_ascites_pmn;Diagnosis Laboratory data;Rare Liver (Vascular);Polymorphonuclear neutrophils;numeric
sc;522;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
sc;522;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
sc;522;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
sc;522;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
sc;522;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
sc;522;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
sc;522;fu_ima_bef_imaging_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
sc;522;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
sc;522;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
sc;522;fu_ima_last_ima_ascites;Follow-up Imaging data;Rare Liver (Vascular);Ascites;radio
sc;522;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
sc;522;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
sc;522;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
sc;522;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
sc;522;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
sc;522;"a.	Age at discharge (in days):	";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
sc;522;"b.	eGFR at discharge (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
sc;522;"c.	Discharge with immunosuppressants:";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
sc;522;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
sc;522;Number of vestibular schwannoma;benignNeoplasm;Genturis;What is the maximal number of vestibular schwannomas ever observed in this patient?;int
sc;522;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
sc;522;Transcript;geneticVariant;Genturis;What is the transcript belonging to the cDNA variant? (HGVS nomenclature);string
sc;522;Colonoscopy performed?;subject;Genturis;Has the patient ever had a colonoscopy?;enum
sc;522;Age at colonoscopy available?;subject;Genturis;Is the age (years) at which the patient had the last colonoscopy known?;enum
sc;522;Age at colonoscopy;subject;Genturis;What was the age (years) of the patient at the last colonoscopy?;int
sc;522;Description (English);Anatomical Therapeutic Chemical Classification;ithaca;;text
sc;522;Description of code;Anatomical Therapeutic Chemical Classification;ithaca;;string
sc;522;description;;ithaca;;text
sc;522;Description;;ithaca;;string
sc;522;Description (English);;ithaca;;text
sc;522;Description of code;;ithaca;;hyperlink
sc;522;Description;;ithaca;;text
sc;522;description;;ithaca;;text
sc;522;Description;;ithaca;;text
sc;522;Description;;ithaca;;text
sc;522;Description;;ithaca;;text
sc;522;Description;;ithaca;;text
sc;522;Consultation Request Reason Description;;ithaca;;text
sc;522;WHODAS 2.0 Score (%);;ithaca;;int
sc;522;Medication for Rare Disease Description;;ithaca;;text
sc;522;Description;;ithaca;;text
sc;522;Nucleotide variant description;;ithaca;;text
sc;522;Protein variant description;;ithaca;;text
sc;522;cci_total_sc;charlson_index;EURACAN;Charlson comorbidity index (CCI) Total points:;if ([comorbid(1)] =1, 1, '') + if ([comorbid(2)] =1, 1, '') + if ([comorbid(3)] =1, 1, '') + if ([comorbid(4)] =1, 1, '') + if ([comorbid(5)] =1, 1, '') + if ([comorbid(6)] =1, 1, '') + if ([comorbid(7)] =1, 1, '') + if ([comorbid(8)] =1, 1, '') + if ([comorbid(9)] =1, 1, '') + if ([comorbid(10)] =1, 1, '') + if ([comorbid(11)] =1, 2, '') + if ([comorbid(12)] =1, 2, '') + if ([comorbid(13)] =1, 2, '') + if ([comorbid(14)] =1, 2, '') + if ([comorbid(15)] =1, 2, '') + if ([comorbid(16)] =1, 2, '') + if ([comorbid(17)] =1, 3, '') + if ([comorbid(18)] =1, 6, '') + if ([comorbid(19)] =1, 6, '')
sc;522;caci_total_sc;charlson_index;EURACAN;Charlson age comorbidity index (CACI) Total points:;if([age]='','',if ([age] =1, 1, 0) + if ([age] =2, 2, 0) + if ([age] =3, 3, 0) + if ([age] =4, 4, 0) + if ([age] =5, 5, 0) + if ([comorbid(1)] =1, 1, 0) + if ([comorbid(2)] =1, 1, 0) + if ([comorbid(3)] =1, 1, 0) + if ([comorbid(4)] =1, 1, 0) + if ([comorbid(5)] =1, 1, 0) + if ([comorbid(6)] =1, 1, 0) + if ([comorbid(7)] =1, 1, 0) + if ([comorbid(8)] =1, 1, 0) + if ([comorbid(9)] =1, 1, 0) + if ([comorbid(10)] =1, 1, 0) + if ([comorbid(11)] =1, 2, 0) + if ([comorbid(12)] =1, 2, 0) + if ([comorbid(13)] =1, 2, 0) + if ([comorbid(14)] =1, 2, 0) + if ([comorbid(15)] =1, 2, 0) + if ([comorbid(16)] =1, 2, 0) + if ([comorbid(17)] =1, 3, 0) + if ([comorbid(18)] =1, 6, 0) + if ([comorbid(19)] =1, 6, 0))
sc;522;Please describe the treatment delivered;Other treatments;PaedCan;;String
sc;522;Learning support at school;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Requiring extra help at school with learning;Y/N/Not Known
sc;522;P450 scc def (CYP11A1);ADRENAL;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
sc;522;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
sc;522;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
sc;522;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
sc;522;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
sc;522;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
sc;522;Metaphyseal acroscyphodysplasia;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal acroscyphodysplasia;
sc;522;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
sc;522;LÃ©ri-Weill dyschondrosteosis ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;LÃ©ri-Weill dyschondrosteosis ;
sc;522;Dyschondrosteosis-nephritis syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dyschondrosteosis-nephritis syndrome ;
sc;522;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
sc;522;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
sc;522;Date of screening;Genetic diagnosis;ERKNet;Â ;gen_scr_date
sc;522;Nuclear isotope scan;Imaging;ERKNet;Â ;Â 
scale;1;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
scan;19;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
scan;19;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
scan;19;R_AIH_IQR_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
scan;19;R_PSC_IQR_Fibroscan;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Interquartile range (IQR);numeric
scan;19;R_PSC_IQR_fibroscan_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Interquartile range (IQR);numeric
scan;19;R_AIH_Fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
scan;19;R_AIH_IQR_fibroscan_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Interquartile range (IQR);numeric
scan;19;R_PBC_Fibroscan_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
scan;19;b_fibroscan;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan at diagnosis;numeric
scan;19;b_fibroscan_date;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Date of Fibroscan;date
scan;19;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
scan;19;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
scan;19;b_fibroscan_cap;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: CAP;numeric
scan;19;b_fibroscan_iqr;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);IQR;numeric
scan;19;fu_ima_bef_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan value;radio
scan;19;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
scan;19;fu_ima_last_fibroscan;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan;radio
scan;19;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
scan;19;Nuclear isotope scan;Imaging;ERKNet;Â ;Â 
scapular;1;Scapular winging;Diagnosis Skeletal;EURO-NMD;;yesno
scc;4;P450 scc def (CYP11A1);ADRENAL;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
scc;4;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
scc;4;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
scc;4;P450 scc def (CYP11A1);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;P450 scc def (CYP11A1);
schauer;1;R_PSC_Desmet_and_Schauer_classification_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
scheuer;11;R_AIH_Desmet_and_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
scheuer;11;R_AIH_Grade_Scheuer;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Grade (Scheuer);numeric
scheuer;11;R_PBC_Desmet_scheuer;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
scheuer;11;R_PBC_Grading_scheuer_diagnosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
scheuer;11;R_PSC_Desmet_Scheuer_classification_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Desmet and Scheuer classification assessed;radio
scheuer;11;R_PSC_Grading_scheuer;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Grading (Scheuer);numeric
scheuer;11;R_PSC_Grading_scheuer_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Grading (Scheuer);numeric
scheuer;11;R_AIH_Desmet_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
scheuer;11;R_AIH_Grade_scheuer_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Grade (Scheuer);numeric
scheuer;11;R_PBC_Desmet_and_Scheuer_classification_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Desmet and Scheuer classification assessed?;radio
scheuer;11;R_PBC_Grading_scheuer_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Grade (Scheuer);numeric
schmid;1;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
school;6;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
school;6;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
school;6;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
school;6;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
school;6;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
school;6;Learning support at school;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Requiring extra help at school with learning;Y/N/Not Known
schwannoma;2;Number of vestibular schwannoma;benignNeoplasm;Genturis;What is the maximal number of vestibular schwannomas ever observed in this patient?;int
schwannoma;2;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
sclero;2;abd_interv_sclero;Diagnosis Aetiology;Rare Liver (Vascular);Sclerotherapy;radio
sclero;2;abd_interv_sclero_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Sclerotherapy;date
scoliosis;2;Scoliosis;Diagnosis Skeletal;EURO-NMD;;yesno
scoliosis;2;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
score;43;MG-ADL total score;QoL;EURO-NMD;;int
score;43;Total QMG score if done;QMG;EURO-NMD;;
score;43;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
score;43;R_AIH_Simplified_AIH_score;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Simplified AIH score;numeric
score;43;R_AIH_Lowest_T_Score_femur;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
score;43;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
score;43;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
score;43;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
score;43;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
score;43;R_PBC_Nakanuma_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed?;radio
score;43;R_PBC_nakanuma_grading_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
score;43;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
score;43;R_PBC_Lowest_T_score_femur;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
score;43;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
score;43;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
score;43;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
score;43;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
score;43;R_PSC_Nakanamuma_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma score assessed;radio
score;43;R_PSC_Nakanuma_grading_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
score;43;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
score;43;R_PSC_Lowest_T_Score_femur;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
score;43;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
score;43;R_PSC_Lowest_T_Score_femur_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus, in case of negative value);numeric
score;43;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
score;43;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
score;43;R_PSC_Nakanuma_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed;radio
score;43;R_PSC_Nakanuma_grading_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
score;43;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
score;43;R_PSC_espghan_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);ESPGHAN Score;numeric
score;43;R_AIH_T_Score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (right or left femur, please add minus in case of negative value);numeric
score;43;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
score;43;R_AIH_espghan_score_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);ESPGHAN Score;numeric
score;43;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
score;43;R_AIH_Nakanuma_score_followp;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma score assessed?;radio
score;43;R_AIH_Nakanuma_grading_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma grading score;calculation
score;43;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
score;43;R_PBC_Lowest_T_Score_femur_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (right or left femur, please add minus in case of negative value);numeric
score;43;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
score;43;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
score;43;R_PBC_Nakanuma_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma score assessed?;radio
score;43;R_PBC_Nakanuma_grading_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma grading score;calculation
score;43;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
score;43;WHODAS 2.0 Score (%);;ithaca;;int
screening;1;Date of screening;Genetic diagnosis;ERKNet;Â ;gen_scr_date
sdr;2;Family history SDR;subject;Genturis;Has any second degree relative(s) ever had a solid malignancy?;enum
sdr;2;Age SDR;subject;Genturis;What was the first degree relative(s) age (years) at first diagnosis of the solid malignancy?;categoricalmref
sec;27;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
sec;27;Ptosis (upward gaze) Sec.;QMG;EURO-NMD;;
sec;27;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
sec;27;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
sec;27;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
sec;27;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
sec;27;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
sec;27;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
sec;27;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
sec;27;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
sec;27;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
sec;27;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
sec;27;Secondary Thematic Areas;;ithaca;;categorical
sec;27;neck_dissection;surgery;EURACAN;Neck dissection;1, Yes | 2, No | 9, Unknown
sec;27;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
sec;27;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
sec;27;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
sec;27;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
sec;27;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
sec;27;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
sec;27;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
sec;27;In case of a second tumor please specify the type;Events;PaedCan;;String
sec;27;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
sec;27;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
sec;27;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
sec;27;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
sec;27;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
sec.;26;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
sec.;26;Ptosis (upward gaze) Sec.;QMG;EURO-NMD;;
sec.;26;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
sec.;26;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
sec.;26;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
sec.;26;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
sec.;26;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
sec.;26;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
sec.;26;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
sec.;26;fu_end_bowel_resection;Follow-up Endpoints;Rare Liver (Vascular);Bowel resection;radio
sec.;26;reresection Age (inÂ days);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
sec.;26;Secondary Thematic Areas;;ithaca;;categorical
sec.;26;neck_dissection;surgery;EURACAN;Neck dissection;1, Yes | 2, No | 9, Unknown
sec.;26;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
sec.;26;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
sec.;26;Resection of lymphnodes at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/sampling/lymphadenectomy/unknown
sec.;26;Date of lymphnodes resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
sec.;26;Resection of metastases at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment) if perfomed ;not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
sec.;26;Date of metastases resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
sec.;26;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
sec.;26;In case of a second tumor please specify the type;Events;PaedCan;;String
sec.;26;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
sec.;26;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
sec.;26;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
sec.;26;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
sec.;26;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
second;3;Secondary Thematic Areas;;ithaca;;categorical
second;3;In case of a second tumor please specify the type;Events;PaedCan;;String
second;3;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
secondary;2;Secondary Thematic Areas;;ithaca;;categorical
secondary;2;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
secretion;3;Adrenocortical carcinoma with pure aldosterone hypersecretion;ADRENAL;EuRR-Bone & EuRRECa;Adrenocortical carcinoma with pure aldosterone hypersecretion;
secretion;3;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
secretion;3;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
segmental;1;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
sentinel;1;lymphography_sentinel;surgery;EURACAN;Lymphography and Sentinel node;1, Yes | 2, No | 9, Unknown
septo-optic;1;Septo-optic dysplasia spectrum;PITUITARY;EuRR-Bone & EuRRECa;Septo-optic dysplasia spectrum;
sequelae;1;Presence of sequelae;Follow up (one form for each follow up visit);PaedCan;;yes/no/unknown
sequence;5;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
sequence;5;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
sequence;5;Reference Sequence ID (mapped by NCBI);;ithaca;Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_;string
sequence;5;Nucleotide reference sequence (RefSeq id/LRG id);;ithaca;;string
sequence;5;Protein sequence (RefSeq id/LRG id);;ithaca;;string
serological;4;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
serological;4;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
serological;4;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
serological;4;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
serum;22;R_AIH_Serum;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
serum;22;R_PBC_Serum;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
serum;22;R_PSC_Serum;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Serum;radio
serum;22;R_PSC_Serum_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
serum;22;R_AIH_Serum_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
serum;22;R_PBC_Serum_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Serum;radio
serum;22;serum_obtained;Diagnosis Biobank;Rare Liver (Vascular);Serum sample obtained?;dropdown
serum;22;serum_date;Diagnosis Biobank;Rare Liver (Vascular);Serum sample date;date
serum;22;serum_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
serum;22;dia_lab_serum_albumin;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin;numeric
serum;22;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
serum;22;dia_lab_serum_gamma_globulins;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins IgG;numeric
serum;22;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
serum;22;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
serum;22;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
serum;22;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
serum;22;dia_lab_serum_ferritine;Diagnosis Laboratory data;Rare Liver (Vascular);Serum ferritin;numeric
serum;22;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
serum;22;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
serum;22;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
serum;22;dia_lab_serum_alfa_foetoprotein;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein;numeric
serum;22;Serum creatinine;Biochemistry;ERKNet;Â ;screa
setting;4;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
setting;4;immuno_setting;immunotherapy;EURACAN;Setting;1, neo-adjuvant | 2, concomitant | 3, adjuvant | 4, palliative | 9, unknown
setting;4;tt_setting;target_therapy;EURACAN;Setting;1, neo-adjuvant | 2, concomitant | 3, adjuvant | 4, palliative | 9, unknown
setting;4;setting;radiotherapy;EURACAN;Setting;1, Preoperative | 2, Postoperative | 3, Definitive | 4, Unknown
sever;14;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
sever;14;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
sever;14;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
sever;14;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
sever;14;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
sever;14;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
sever;14;fu_cli_bef_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity value;radio
sever;14;fu_cli_last_ascites_sever;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites severity;radio
sever;14;b. Severity of incontinence:;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
sever;14;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
sever;14;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
sever;14;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
sever;14;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
sever;14;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
severe;5;fu_severe_bacterial_infect;Follow-up Complications;Rare Liver (Vascular);Severe bacterial infection;radio
severe;5;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
severe;5;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
severe;5;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
severe;5;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
severity;7;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
severity;7;Change of severity in puberty;Diagnosis Fluctuation;EURO-NMD;;yesno
severity;7;Change of severity with menstrual cycle;Diagnosis Fluctuation;EURO-NMD;;yesno
severity;7;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
severity;7;Change of severity with pregnancy or childbirth;Diagnosis Fluctuation;EURO-NMD;;yesno
severity;7;b. Severity of incontinence:;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
severity;7;Severity of complication;Surgery;PaedCan;Grade according Clavien Dindo classification;I/II/III/IV/V (see below)
sex;8;R_AIH_Sex;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
sex;8;R_PBC_Sex;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
sex;8;R_PSC_Sex;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Sex;radio
sex;8;sex;Diagnosis General Information;Rare Liver (Vascular);Gender;radio
sex;8;Sex;subject;Genturis;What was the patient's sex at birth?;categorical
sex;8;Sex;Personal Information;PaedCan;Patient's Sex ;f/m/ud/unknown
sex;8;Sex at birth;Personal Information;EuRR-Bone & EuRRECa;Assigned sex at birth;Male/Female/Other/Unknown
sex;8;Sex chromosome disorder of sex development;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Sex chromosome disorder of sex development;
sf;11;SF EMG result;Diagnosis EMG;EURO-NMD;;
sf;11;Transfer from chair to bed;Mobility ;EURO-NMD;;single
sf;11;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
sf;11;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
sf;11;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
sf;11;clinical_dysfunction_angio;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
sf;11;hemodynamic_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
sf;11;radiological_dysfunc_angio;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
sf;11;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
sf;11;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
sf;11;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
sh;57;R_AIH_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Ishak score assessed;radio
sh;57;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sh;57;R_AIH_Additional_nash;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
sh;57;R_PBC_Ishak_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed?;radio
sh;57;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sh;57;R_PBC_Additional_nash;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
sh;57;R_PSC_Ishak_score_assessed_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Ishak score assessed;radio
sh;57;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sh;57;R_PSC_Additional_nash;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Additional signs of NASH?;radio
sh;57;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
sh;57;R_PSC_Ishak_Score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Ishak Score assessed;radio
sh;57;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sh;57;R_PSC_Additional_nash_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
sh;57;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
sh;57;R_AIH_Ishak_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Ishak score assessed?;radio
sh;57;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sh;57;R_AIH_Additional_nash_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Additional signs of NASH?;radio
sh;57;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
sh;57;R_PBC_Ishak_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Ishak score assessed?;radio
sh;57;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
sh;57;R_PBC_Additional_nash_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Additional signs of NASH?;radio
sh;57;hv_short_length_stenosis;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Short length stenosis (;radio
sh;57;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
sh;57;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
sh;57;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
sh;57;date_of_shunt;Follow-up Events;Rare Liver (Vascular);Date of shunt;date
sh;57;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
sh;57;date_of_evaluation_shunt;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
sh;57;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
sh;57;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
sh;57;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
sh;57;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
sh;57;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
sh;57;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
sh;57;Value (English);Anatomical Therapeutic Chemical Classification;ithaca;;string
sh;57;Description (English);Anatomical Therapeutic Chemical Classification;ithaca;;text
sh;57;Value (English);ICD-10: International Classification of Diseases and Related Health Problems;ithaca;;string
sh;57;Description (English);;ithaca;;text
sh;57;If Yes â€“ kinship of Carrier;;ithaca;;xref
sh;57;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
sh;57;TSH status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum TSH for local reference range;N/Low/High/Not Known
sh;57;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
sh;57;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
sh;57;PIK3R1 (Short Syndrome);GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;PIK3R1 (Short Syndrome);
sh;57;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
sh;57;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
sh;57;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
sh;57;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
sh;57;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
sh;57;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
sh;57;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
sh;57;Cushing disease;PITUITARY;EuRR-Bone & EuRRECa;Cushing disease;
sh;57;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
sh;57;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
sh;57;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
sh;57;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
sh;57;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
sh2b1;2;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
sh2b1;2;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
shared;1;Data can be shared for research purposes;Research;EuRR-Bone & EuRRECa;Patient's permission for the data to be shared internationally for research purpose;Y/N/NK - LOINC Code: 64292-6Â 
short;9;hv_short_length_stenosis;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Short length stenosis (;radio
short;9;PIK3R1 (Short Syndrome);GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;PIK3R1 (Short Syndrome);
short;9;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency;
short;9;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
short;9;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
short;9;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
short;9;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
short;9;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
short;9;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
shox-related;1;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
shunt;10;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
shunt;10;date_of_shunt;Follow-up Events;Rare Liver (Vascular);Date of shunt;date
shunt;10;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
shunt;10;date_of_evaluation_shunt;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
shunt;10;clinical_dysfunction_shunt;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
shunt;10;hemodynamic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
shunt;10;radiologic_dysfunct_shunt;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
shunt;10;salvage_procedure_shunt;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
shunt;10;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
shunt;10;date_salvage_proc_shunt;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
shwachman-diamond;1;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
side;6;Country of residence;;ithaca;;xref
side;6;residence_country;patient_management_at_the_hospital;EURACAN;Country of residence;1, Afghanistan | 2, Albania | 3, Algeria | 4, Andorra | 5, Angola | 6, Antigua and Barbuda | 7, Argentina | 8, Armenia | 9, Australia | 10, Austria | 11, Azerbaijan | 12, The Bahamas | 13, Bahrain | 14, Bangladesh | 15, Barbados | 16, Belarus | 17, Belgium | 18, Belize | 19, Benin | 20, Bhutan | 21, Bolivia | 22, Bosnia and Herzegovina | 23, Botswana | 24, Brazil | 25, Brunei | 26, Bulgaria | 27, Burkina Faso | 28, Burundi | 29, Cambodia | 30, Cameroon | 31, Canada | 32, Cape Verde | 33, Central African Republic | 34, Chad | 35, Chile | 36, China | 37, Colombia | 38, Comoros | 39, Congo | 40, Costa Rica | 41, Cote d'Ivoire | 42, Croatia | 43, Cuba | 44, Cyprus | 45, Czech Republic | 46, Denmark | 47, Djibouti | 48, Dominica | 49, Dominican Republic | 50, East Timor (Timor-Leste) | 51, Ecuador | 52, Egypt | 53, El Salvador | 54, Equatorial Guinea | 55, Eritrea | 56, Estonia | 57, Ethiopia | 58, Fiji | 59, Finland | 60, France | 61, Gabon | 62, The Gambia | 63, Georgia | 64, Germany | 65, Ghana | 66, Greece | 67, Grenada | 68, Guatemala | 69, Guinea | 70, Guinea-Bissau | 71, Guyana | 72, Haiti | 73, Honduras | 74, Hungary | 75, Iceland | 76, India | 77, Indonesia | 78, Iran | 79, Iraq | 80, Ireland | 81, Israel | 82, Italy | 83, Jamaica | 84, Japan | 85, Jordan | 86, Kazakhstan | 87, Kenya | 88, Kiribati | 89, Korea (North) | 90, Korea (South) | 91, Kosovo | 92, Kuwait | 93, Kyrgyzstan | 94, Laos | 95, Latvia | 96, Lebanon | 97, Lesotho | 98, Liberia | 99, Libya | 100, Liechtenstein | 101, Lithuania | 102, Luxembourg | 103, Macedonia | 104, Madagascar | 105, Malawi | 106, Malaysia | 107, Maldives | 108, Mali | 109, Malta | 110, Marshall Islands | 111, Mauritania | 112, Mauritius | 113, Mexico | 114, Micronesia | 115, Moldova | 116, Monaco | 117, Mongolia | 118, Montenegro | 119, Morocco | 120, Mozambique | 121, Myanmar (Burma) | 122, Namibia | 123, Nauru | 124, Nepal | 125, Netherlands | 126, New Zealand | 127, Nicaragua | 128, Niger | 129, Nigeria | 130, Norway | 131, Oman | 132, Pakistan | 133, Palau | 134, Panama | 135, Papua New Guinea | 136, Paraguay | 137, Peru | 138, Philippines | 139, Poland | 140, Portugal | 141, Qatar | 142, Romania | 143, Russia | 144, Rwanda | 145, Saint Kitts and Nevis | 146, Saint Lucia | 147, Saint Vincent and the Grenadines | 148, Samoa | 149, San Marino | 150, Sao Tome and Principe | 151, Saudi Arabia | 152, Senegal | 153, Serbia | 154, Seychelles | 155, Sierra Leone | 156, Singapore | 157, Slovakia | 158, Slovenia | 159, Solomon Islands | 160, Somalia | 161, South Africa | 162, South Sudan | 163, Spain | 164, Sri Lanka | 165, Sudan | 166, Suriname | 167, Swaziland | 168, Sweden | 169, Switzerland | 170, Syria | 171, Taiwan | 172, Tajikistan | 173, Tanzania | 174, Thailand | 175, Togo | 176, Tonga | 177, Trinidad and Tobago | 178, Tunisia | 179, Turkey | 180, Turkmenistan | 181, Tuvalu | 182, Uganda | 183, Ukraine | 184, United Arab Emirates | 185, United Kingdom | 186, United States of America | 187, Uruguay | 188, Uzbekistan | 189, Vanuatu | 190, Vatican City | 191, Venezuela | 192, Vietnam | 193, Yemen | 194, Zambia | 195, Zimbabwe
side;6;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
side;6;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
side;6;Body side ;Tumor's characteristics;PaedCan;Side of the primary tumor;right/left/bilateral/multifocal/not applicable/unknown
side;6;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
signs;3;R_PBC_Signs_of_cirrhosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Liver-related complications;radio
signs;3;esoph_varices_red_signs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophagel varices red color signs;radio
signs;3;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
silent;1;Silent pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;Silent pituitary adenoma;
silver-russell;7;Silver-Russell Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell Syndrome;
silver-russell;7;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
silver-russell;7;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
silver-russell;7;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
silver-russell;7;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
silver-russell;7;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
silver-russell;7;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
sim1;2;SIM1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1 deficiency;
sim1;2;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
sim1-related;1;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
simplified;6;R_AIH_Simplified_AIH_score_available;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
simplified;6;R_AIH_Simplified_AIH_score;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Simplified AIH score;numeric
simplified;6;R_PBC_Simplified_AIH_score_available;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
simplified;6;R_PBC_Simplified_AIH_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
simplified;6;R_PSC_Simplified_AIH_score_available;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Full simplified AIH score available;radio
simplified;6;R_PSC_Simplified_AIH_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Simplified AIH score;numeric
site;15;Website ERN/HCP;;ithaca;;hyperlink
site;15;other_hn_site;previous_cancer_genetic_syndromes;EURACAN;Site;999, Unknown | 1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS | 9, C11 nasopharynx | 10, C11.0  Superior wall of nasopharynx | 11, C11.1  Posterior wall of nasopharynx | 12, C11.2  Lateral wall of nasopharynx | 13, C11.3  Anterior wall of nasopharynx | 14, C11.8  Overlapping lesion of nasopharynx | 15, C11.9  Nasopharynx, NOS | 16, C12.9  Pyriform sinus | 17, C13 Hypopharynx | 18, C13.0  Postcricoid region | 19, C13.1  Hypopharyngeal aspect of aryepiglottic fold | 20, C13.2  Posterior wall of hypopharynx | 21, C13.8  Overlapping lesion of hypopharynx | 22, C13.9  Hypopharynx, NOS | 23, C01.9  Base of tongue, NOS | 24, C02.4  Lingual tonsil | 25, C05.1  Soft palate, NOS | 26, C05.2  Uvula | 27, C09 tonsil | 28, C09.0  Tonsillar fossa | 29, C09.1  Tonsillar pillar | 30, C09.8  Overlapping lesion of tonsil | 31, C09.9  Tonsil, NOS | 32, C10 oropharynx | 33, C10.0  Vallecula | 34, C10.2 Lateral wall of oropharynx | 35, C10.3 Posterior Pharyngeal wall | 36, C10.8 Overlapping lesions of oropharynx | 37, C10.9 Oropharynx, NOS | 38, C11.1 Pharyngeal tonsils | 39, C01.9  Base of tongue, NOS | 40, C02.4  Lingual tonsil | 41, C05.1  Soft palate, NOS | 42, C05.2  Uvula | 43, C09 tonsil | 44, C09.0  Tonsillar fossa | 45, C09.1  Tonsillar pillar | 46, C09.8  Overlapping lesion of tonsil | 47, C09.9  Tonsil, NOS | 48, C10 oropharynx | 49, C10.0  Vallecula | 50, C10.2 Lateral wall of oropharynx | 51, C10.3 Posterior Pharyngeal wall | 52, C10.8 Overlapping lesions of oropharynx | 53, C10.9 Oropharynx, NOS | 54, C11.1 Pharyngeal tonsils | 55, C10.1 Anterior (lingual) surface of epiglottis | 56, C32 Larynx | 57, C32.0  Glottis | 58, C32.1  Supraglottis | 59, C32.2  Subglottis | 60, C32.3  Laryngeal cartilage | 61, C32.8  Overlapping lesion of larynx | 62, C32.9  Larynx, NOS | 63, C02.0  Dorsal surface of tongue, NOS | 64, C02.1  Border of tongue | 65, C02.2  Ventral surface of tongue, NOS | 66, C02.3  Anterior 2/3 of tongue, NOS | 67, C02.8 Overlapping lesion of tongue | 68, C02.9  Tongue, NOS | 69, C03 gum | 70, C03.0  Upper gum | 71, C03.1  Lower gum | 72, C03.9  Gum, NOS | 73, C04 floor of mouth | 74, C04.0  Anterior floor of mouth | 75, C04.1  Lateral floor of mouth | 76, C04.8  Overlapping lesion of floor of mouth | 77, C04.9  Floor of mouth, NOS | 78, C05 palate | 79, C05.0  Hard palate | 80, C05.8  Overlapping lesion of palate | 81, C05.9  Palate, NOS | 82, C06 other and unspecified parts of mouth | 83, C06.0  Cheek mucosa | 84, C06.1  Vestibule of mouth | 85, C06.2  Retromolar area | 86, C06.8  Overlapping lesion of other  and unspecified parts of mouth | 87, C06.9  Mouth, NOS | 88, C00 lip (excludes skin of lip C44.0) | 89, C00.0  External upper lip | 90, C00.1  External lower lip | 91, C00.2  External lip, NOS | 92, C00.3  Mucosa of upper lip | 93, C00.4  Mucosa of lower lip | 94, C00.5  Mucosa of lip, NOS | 95, C00.6  Commissure of lip | 96, C00.8  Overlapping lesion of lip | 97, C00.9  Lip, NOS | 98, C30.1  Middle ear | 99, C07.9  Parotid gland | 100, C08 other and unspecified major salivary glands | 101, C08.0  Submandibular gland | 102, C08.1  Sublingual gland | 103, C08.8  Overlapping lesion of major salivary glands | 104, C08.9  Major salivary gland, NOS | 105, Minor salivary gland of the head & neck
site;15;site;primary_cancer;EURACAN;Site (AJCC);1, nasal cavity and paranasal sinuses | 2, nasopharynx | 3, major salivary glands | 4, salivary gland type tumours in any site of head and neck | 9, middle ear
site;15;site_nasal_cavity;primary_cancer;EURACAN;Subsite;1, C30.0 nasal cavity | 2, C31 accessory sinuses | 3, C31.0  Maxillary sinus | 4, C31.1  Ethmoid sinus | 5, C31.2  Frontal sinus | 6, C31.3  Sphenoid sinus | 7, C31.8  Overlapping lesion of accessory sinuses | 8, C31.9  Accessory sinus, NOS
site;15;site_nasopharynx;primary_cancer;EURACAN;Subsite;1, C11 nasopharynx | 2, C11.0  Superior wall of nasopharynx | 3, C11.1  Posterior wall of nasopharynx | 4, C11.2  Lateral wall of nasopharynx | 5, C11.3  Anterior wall of nasopharynx | 6, C11.8  Overlapping lesion of nasopharynx | 7, C11.9  Nasopharynx, NOS
site;15;site_maj_salivary;primary_cancer;EURACAN;Subsite;1, C07.9  Parotid gland | 2, C08 other and unspecified major salivary glands | 3, C08.0  Submandibular gland | 4, C08.1  Sublingual gland | 5, C08.8  Overlapping lesion of major salivary glands | 6, C08.9  Major salivary gland, NOS
site;15;site_salivary;primary_cancer;EURACAN;Subsite;1, nasal cavity and paranasal sinuses | 2, nasopharynx | 3, major salivary glands | 4, hypopharynx | 5, Oropharynx | 6, larynx | 7, oral cavity | 8, lip
site;15;site_squamous;primary_cancer;EURACAN;Squamous subtype;1, Keratinizing squamous cell carcinoma | 8071/3 | 2, Non-keratinizing squamous cell carcinoma | 8072/3 | 3, Spindle cell (sarcomatoid) squamous cell carcinoma | 8074/3 | 4, Lymphoepithelial carcinoma | 8082/3 | 5, Basaloid squamous cell carcinoma | 8083/3 | 6, Conventional squamous cell carcinoma | 8070/3 | 7, Verrucous squamous cell carcinoma | 8051/3 | 8, Papillary squamous cell carcinoma | 8052/3 | 9, Squamous cell carcinoma, HPV-positive | 8085/3 | 10, Squamous cell carcinoma, HPV-negative | 8086/3
site;15;site_squamous_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
site;15;site_adenocarcinoma;primary_cancer;EURACAN;Adenocarcinoma subtype;1, Intestinal-type adenocarcinoma | 8144/3 | 2, Non-intestinal-type adenocarcinoma  (adk, NOS) | 8140/3 | 3, Nasopharyngeal papillary adenocarcinoma | 8260/3 | 4, Adenoid cystic carcinoma | 8200/3 | 5, Mucoepidermoid carcinoma | 8430/3 | 6, Polymorphous adenocarcinoma | 8525/3 | 7, Acinic cell carcinoma | 8550/3 | 8, Clear cell carcinoma | 8310/3 | 9, Basal cell adenocarcinoma | 8147/3 | 10, Salivary duct carcinoma | 8500/3 | 11, Myoepithelial carcinoma |8982/3 | 12, Epithelial-myoepithelial carcinoma | 8562/3 | 13, Carcinoma ex pleomorphic adenoma | 8941/3 | 14, Secretory carcinoma | 8542/3 | 15, Sebaceous adenocarcinoma | 8410/3 | 16, Carcinosarcoma | 8980/3 | 17, Oncocytic carcinoma | 8290/3 | 18, Adenocarcinoma | 8420/3
site;15;site_neuroendocrine;primary_cancer;EURACAN;Neuroendocrine subtype;1, Small cell neuroendocrine carcinoma (SmCC) | 8041/3 | 2, Large cell neuroendocrine carcinoma (LCNEC) | 8013/3 | 3, Well-differentiated neuroendocrine carcinoma | 8240/3 | 4, Moderately differentiated neuroendocrine carcinoma | 8249/3 | 5, Sinonasal undifferentiated carcinoma | 8020/3
site;15;site_neuroend_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
site;15;surgery_fu_site;surgery;EURACAN;Surgery site;1, T | 2, N | 3, M
site;15;Site;Tumor's characteristics;PaedCan;Site of the primary tumor;ICD-O
site;15;Site of metastases;Tumor's characteristics;PaedCan;Definition of the site of metastases;Skin or soft tissues/CNS/Liver/Bone marrow/Lung/Distant nodes/Peritoneum or omentum/Bone/other/Unknown
sitffness;1;R_AIH_Liver_sitffness_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Liver stiffness;numeric
sitting;2;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
sitting;2;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
situ;1;Malignancies (invasive/ in situ);subject;Genturis;;compound
six;4;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
six;4;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
six;4;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
six;4;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
size;10;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
size;10;R_PBC_Spleen_size;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
size;10;R_PSC_Spleen_size;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size;numeric
size;10;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
size;10;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
size;10;R_AIH_Spleen_size_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Spleen size (diameter);numeric
size;10;waist_size;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Waist size;numeric
size;10;largest_nodule_size;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Largest nodule size;numeric
size;10;spleen_size;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Spleen size;radio
size;10;Tumor size;Tumor's characteristics;PaedCan;Maximum diameter of the tumor;a/b/x
skeletal;7;Skeletal muscle atrophy;Diagnosis Muscular;EURO-NMD;Muscle wasting;yesno
skeletal;7;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
skeletal;7;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
skeletal;7;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
skeletal;7;Primary bone dysplasia with disorganized development of skeletal components;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with disorganized development of skeletal components;
skeletal;7;Epimetaphyseal skeletal dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Epimetaphyseal skeletal dysplasia ;
skeletal;7;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
skin;4;skin_lesions;Diagnosis Aetiology;Rare Liver (Vascular);Skin lesions;radio
skin;4;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
skin;4;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
skin;4;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
skin-white;1;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
skin,;1;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
sla;18;R_AIH_SLA_LP;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sla;18;R_AIH_SLA_LP_value;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
sla;18;R_AIH_SLA_LP_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sla;18;R_PBC_SLA_LP;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sla;18;R_PBC_SLA_LP_units;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
sla;18;R_PBC_SLA_LP_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sla;18;R_PSC_SLA_LP;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sla;18;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
sla;18;R_PSC_SLA_LP_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sla;18;R_PSC_SLA_LP_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sla;18;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
sla;18;R_PSC_SLA_LP_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sla;18;R_AIH_SLA_LP_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sla;18;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
sla;18;R_AIH_SLA_LP_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sla;18;R_PBC_SLA_LP_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);radio
sla;18;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
sla;18;R_PBC_SLA_LP_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (Immunoblot);radio
sma;35;R_AIH_SMA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
sma;35;R_AIH_SMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sma;35;R_AIH_SMA_ELISA;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sma;35;R_AIH_SMA_Immunoblot;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sma;35;R_PBC_SMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
sma;35;R_PBC_Titer_SMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sma;35;R_PBC_SMA_ELISA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sma;35;R_PBC_SMA_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sma;35;R_PSC_SMA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA;radio
sma;35;R_PSC_SMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sma;35;R_PSC_SMA_ELISA;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sma;35;R_PSC_SMA_Immunoblot;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sma;35;R_PSC_SMA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
sma;35;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sma;35;R_PSC_SMA_ELISA_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sma;35;R_PSC_SMA_Immunoblot_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sma;35;R_AIH_SMA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
sma;35;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sma;35;R_AIH_SMA_ELISA_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sma;35;R_AIH_SMA_Immunoblot_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sma;35;R_PBC_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA;radio
sma;35;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
sma;35;R_PBC_SMA_ELISA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (ELISA);numeric
sma;35;R_PBC_SMA_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (Immunoblot);radio
sma;35;plasma_obtained;Diagnosis Biobank;Rare Liver (Vascular);Plasma sample obtained?;dropdown
sma;35;plasma_date;Diagnosis Biobank;Rare Liver (Vascular);Plasma sample date;date
sma;35;plasma_number;Diagnosis Biobank;Rare Liver (Vascular);Number;string
sma;35;plasma_crb;Diagnosis Biobank;Rare Liver (Vascular);CRB Number;string
sma;35;plasmalevel_homocy_fasting;Diagnosis Aetiology;Rare Liver (Vascular);Level of plasma homocysteine at fasting (umol/l);numeric
sma;35;"c.	Amount of HLA mismatches:";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
sma;35;"d.	HLA-DR mismatches: ";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
sma;35;site_squamous_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
sma;35;site_neuroend_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
sma;35;biom_plasma;tumour_material_available;EURACAN;Plasma;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
sma;35;Borjeson-Forssman-Lehmann syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Borjeson-Forssman-Lehmann syndromeÂ ;
smarcb1;2;site_squamous_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
smarcb1;2;site_neuroend_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
smith;4;Smith-Lemli-Opitz syndrome;ADRENAL;EuRR-Bone & EuRRECa;Smith-Lemli-Opitz syndrome;
smith;4;Smith-Magenis syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Smith-Magenis syndromeÂ ;
smith;4;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
smith;4;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
smith-lemli-opitz;1;Smith-Lemli-Opitz syndrome;ADRENAL;EuRR-Bone & EuRRECa;Smith-Lemli-Opitz syndrome;
smith-magenis;1;Smith-Magenis syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Smith-Magenis syndromeÂ ;
smoker;4;is_smoker;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
smoker;4;PBC_is_smoker;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
smoker;4;PSC_is_smoker;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);is_smoker;calculation
smoker;4;smoker;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Smoker;radio
smoking;13;R_AIH_Smoking;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
smoking;13;R_AIH_Smoking_amount;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
smoking;13;R_PBC_Smoking;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
smoking;13;R_PBC_Smoking_amount;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount;numeric
smoking;13;R_PSC_Smoking;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking;radio
smoking;13;R_PSC_Smoking_amount;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Smoking amount (pack years);numeric
smoking;13;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
smoking;13;smoking_status;patient_management_at_the_hospital;EURACAN;Smoking;1, Current tobacco smoker | 2, Former smoker | 3, Never smoker | 4, Unknown
smoking;13;smoking_habits;patient_management_at_the_hospital;EURACAN;Smoking habits;1, Cigarettes | 2, Cigar
smoking;13;smoking_per_day;patient_management_at_the_hospital;EURACAN;Cigarettes/cigars smoked per day;
smoking;13;smoking_years;patient_management_at_the_hospital;EURACAN;Number of years as a smoker;
smoking;13;smoking_pack_year_calc;patient_management_at_the_hospital;EURACAN;Pack/year;"if ([smoking_habits] = ""1"", ([smoking_per_day]/20)*[smoking_years], ([smoking_per_day]/4)*[smoking_years])"
smoking;13;smoking_pack_year_man;patient_management_at_the_hospital;EURACAN;Pack/year (manual);
smv;2;fu_ima_bef_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
smv;2;fu_ima_last_smv_patent;Follow-up Imaging data;Rare Liver (Vascular);Superior mesenteric vein patent;radio
sodium;3;dia_lab_sodium_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
sodium;3;fu_cli_bef_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
sodium;3;fu_cli_last_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
somatic;3;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
somatic;3;Tumour Types(Somatic);;ithaca;;string
somatic;3;Somatic Mutation as included in COSMIC;;ithaca;;text
somatomammotropinoma;1;Somatomammotropinoma;PITUITARY;EuRR-Bone & EuRRECa;Somatomammotropinoma;
sotos;1;Sotos syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Sotos syndrome;
source;2;Benign diagnosis source;benignNeoplasm;Genturis;What is level of evidence for the diagnosis?;xref
source;2;Diagnosis source;malignancy;Genturis;What is the level of evidence for the diagnosis?;xref
sp100;4;R_PBC_SP100;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
sp100;4;R_PBC_SP100_Immunoblot;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
sp100;4;R_PBC_SP100_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (ELISA);radio
sp100;4;R_PBC_SP100_Immunoblot_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SP100 (Immunoblot);radio
spahr;1;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
spastic;1;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
spc;1;SPC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
spec;46;R_PBC_PBC_specific_ANA_IFT;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
spec;46;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
spec;46;R_AIH_PBC_specific_treament;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC specific treatment;radio
spec;46;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
spec;46;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
spec;46;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
spec;46;ivc_aspect;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Aspect;radio
spec;46;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
spec;46;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
spec;46;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
spec;46;Please specify;;ithaca;;text
spec;46;prev_not_hn_spec;previous_cancer_genetic_syndromes;EURACAN;Please select the malignant cancers different from cancers of head and neck;99, Unknown | 1, Adrenal Glands | 2, Anal Canal & Anus | 3, Appendix | 4, Bones & Joints (Excl Skull And Face, Mandible) | 5, Bones Of Skull And Face | 6, Brain, & Cranial Nerves, & Spinal Cord, (Excl. Ventricle, Cerebellum) | 7, Breast | 8, Cerebellum | 9, Cervix Uteri | 10, Corpus Uteri | 11, Craniopharyngeal Duct | 12, Esophagus | 13, Eyeball | 14, Fallopian Tube | 15, Gallbladder & Extrahepatic Bile Ducts | 16, Heart | 17, Intrahepatic Bile Ducts | 18, Kidney | 19, Large Intestine (Excl. Appendix) | 20, Liver | 21, Lung & Bronchus | 22, Mandible | 23, Mediastinum | 24, Melanoma Skin | 25, Meninges (Cerebral, Spinal | 26, Orbit & Lacrimal Gland (Excl Ret, Eye, Nos) | 27, Ovary | 28, Pancreas | 29, Parathyroid Gland | 30, Penis | 31, Peripheral Nerves | 32, Peritoneum | 33, Pineal Gland | 34, Pituitary Gland | 35, Placenta | 36, Pleura | 37, Prostate Gland | 38, Rectum | 39, Renal Pelvis | 40, Retina | 41, Retroperitoneum | 42, Sarcoma | 43, Scrotum | 44, Small Intestine | 45, Stomach | 46, Testis | 47, Thymus | 48, Thyroid Gland | 49, Trachea | 50, Ureter | 51, Urinary Bladder | 52, Vagina & Labia | 53, Ventricle | 54, Vulva
spec;46;ctcae_spec;adverse_event;EURACAN;Please specify;
spec;46;ctcae_spec_2;adverse_event;EURACAN;Please specify;
spec;46;ctcae_spec_3;adverse_event;EURACAN;Please specify;
spec;46;ctcae_spec_4;adverse_event;EURACAN;Please specify;
spec;46;ctcae_spec_5;adverse_event;EURACAN;Please specify;
spec;46;if yes specify;Personal Information;PaedCan;;String
spec;46;Specify which malignancy;Patient's history;PaedCan;Description of any previous malignancy;ICCC3
spec;46;If other specify;Patient's history;PaedCan;;String
spec;46;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
spec;46;Specify which syndrome;Patient's history;PaedCan;Definition of the syndrome affecting the patient;String
spec;46;Specify the genetic abornalities found;Patient's history;PaedCan;;String
spec;46;Specify the disease;Family's history;PaedCan;Definition of disease affecting the patient's first degree relative;String
spec;46;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
spec;46;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
spec;46;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
spec;46;I yes, specify the most relevant;Pathology;PaedCan;;String
spec;46;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
spec;46;Specify complications;Surgery;PaedCan;Definition of complication;String
spec;46;if yes specify the drugs used;Chemotherapy;PaedCan;;String
spec;46;If yes specify;Chemotherapy;PaedCan;;String
spec;46;If other please specify;Radiotherapy;PaedCan;;String
spec;46;If yes specify;Radiotherapy;PaedCan;;String
spec;46;If yes, specify;Follow up (one form for each follow up visit);PaedCan;;String
spec;46;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
spec;46;In case of a second tumor please specify the type;Events;PaedCan;;String
spec;46;Specific diagnosis;Disease History;EuRR-Bone & EuRRECa;Orphacode for condition entered in 6.3;Drop down category
spec;46;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
spec;46;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
spec;46;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
spec;46;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
spec;46;Septo-optic dysplasia spectrum;PITUITARY;EuRR-Bone & EuRRECa;Septo-optic dysplasia spectrum;
spec;46;Non-specific;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Non-specific;
spec;46;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
spec;46;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
specialised;1;Date first contact specialised center;subject;Genturis;What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?;date
specialized;1;Date of first contact with specialized centre;Care pathway;PaedCan;Date in which the patient was firstly seen in a specialized centre;dd/mm/yyyy
specific;11;R_PBC_PBC_specific_ANA_IFT;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
specific;11;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
specific;11;R_AIH_PBC_specific_treament;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC specific treatment;radio
specific;11;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
specific;11;R_PBC_PBC_specific_ANA_IFT_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);PBC specific ANA on IFT;radio
specific;11;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
specific;11;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
specific;11;"d.	Specification other immunosuppressants at discharge:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
specific;11;Specific diagnosis;Disease History;EuRR-Bone & EuRRECa;Orphacode for condition entered in 6.3;Drop down category
specific;11;Condition-specific Outcomes;Patient Reported Outcomes;EuRR-Bone & EuRRECa;Questionnaires specific to diagnosis;
specific;11;Non-specific;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Non-specific;
specified;3;Other genetically specified MODY;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified MODY;
specified;3;Other genetically specified neonatal diabetes;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other genetically specified neonatal diabetes;
specified;3;Other specified genetic defects in insulin action;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other specified genetic defects in insulin action;
specify;22;Please specify;;ithaca;;text
specify;22;if yes specify;Personal Information;PaedCan;;String
specify;22;Specify which malignancy;Patient's history;PaedCan;Description of any previous malignancy;ICCC3
specify;22;If other specify;Patient's history;PaedCan;;String
specify;22;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
specify;22;Specify which syndrome;Patient's history;PaedCan;Definition of the syndrome affecting the patient;String
specify;22;Specify the genetic abornalities found;Patient's history;PaedCan;;String
specify;22;Specify the disease;Family's history;PaedCan;Definition of disease affecting the patient's first degree relative;String
specify;22;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
specify;22;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
specify;22;I yes, specify the most relevant;Pathology;PaedCan;;String
specify;22;In case of other metastases, specify;Tumor's characteristics;PaedCan;Definition of the site of metastases;String
specify;22;Specify complications;Surgery;PaedCan;Definition of complication;String
specify;22;if yes specify the drugs used;Chemotherapy;PaedCan;;String
specify;22;If yes specify;Chemotherapy;PaedCan;;String
specify;22;If other please specify;Radiotherapy;PaedCan;;String
specify;22;If yes specify;Radiotherapy;PaedCan;;String
specify;22;If yes, specify;Follow up (one form for each follow up visit);PaedCan;;String
specify;22;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
specify;22;In case of a second tumor please specify the type;Events;PaedCan;;String
specify;22;Please specify result of cytogenetic analysis ;Genetic diagnosis;ERKNet;Â ;gen_cyto_result
specify;22;Please specify genetic abnormality;Genetic diagnosis;ERKNet;If no gentetic specifications are given in diagnosis;gen_result
spectrum;1;Septo-optic dysplasia spectrum;PITUITARY;EuRR-Bone & EuRRECa;Septo-optic dysplasia spectrum;
speech;1;Speech following counting aloud from 1-50 (onset of dysarthria);QMG;EURO-NMD;;
spinal;1;Spinal rigidity;Diagnosis Skeletal;EURO-NMD;;yesno
spine;8;R_AIH_Lowest_T_Score_Lumber_spine;(AIH Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
spine;8;R_PBC_Lowest_T_score_lumber_spine;(PBC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
spine;8;R_PSC_Lowest_T_score_lumber_spine;(PSC Diagnosis) Bone mineral density (DXA);Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
spine;8;R_PSC_Lowest_T_score_lumber_spine_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
spine;8;R_AIH_T_Score_lumber_spine_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);T-Score (lumber spine, please add minus in case of negative value);numeric
spine;8;R_PBC_Lowest_T_Score_lumber_spine_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Lowest T-Score (lumber spine, please add minus in case of negative value);numeric
spine;8;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
spine;8;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
spleen;8;R_AIH_Spleen_size_diagnosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
spleen;8;R_PBC_Spleen_size;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size (diameter);numeric
spleen;8;R_PSC_Spleen_size;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Spleen size;numeric
spleen;8;R_PSC_Spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Spleen size (diameter);numeric
spleen;8;R_PSC_Date_spleen_size_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date spleen size;date
spleen;8;R_AIH_Spleen_size_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Spleen size (diameter);numeric
spleen;8;spleen_size;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Spleen size;radio
spleen;8;spleen_length;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Maximal spleen length;numeric
splen;5;splenic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenic vein;radio
splen;5;splenectomy;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenectomy;radio
splen;5;abd_interv_splen;Diagnosis Aetiology;Rare Liver (Vascular);Splenectomy;radio
splen;5;abd_interv_splen_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of Splenectomy;date
splen;5;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
splenectomy;1;splenectomy;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenectomy;radio
splenic;2;splenic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenic vein;radio
splenic;2;fu_end_splenic_infarction;Follow-up Endpoints;Rare Liver (Vascular);Splenic infarction;radio
splint;1;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
spondylodysplastic;1;Spondylodysplastic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Spondylodysplastic dysplasia ;
sporadic;2;Sporadic phaeochromocytoma/secreting paraganglioma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma/secreting paraganglioma;
sporadic;2;Sporadic phaeochromocytoma;ADRENAL;EuRR-Bone & EuRRECa;Sporadic phaeochromocytoma;
spot;2;Number of Cafe au lait spot known?;subject;Genturis;Is the maximal number of Cafe au lait spots ever observed in the patient known?;enum
spot;2;Number of Cafe au lait spot;subject;Genturis;What is the maximal number of cafe au lait spots ever observed in the patient?;int
squamous;2;site_squamous;primary_cancer;EURACAN;Squamous subtype;1, Keratinizing squamous cell carcinoma | 8071/3 | 2, Non-keratinizing squamous cell carcinoma | 8072/3 | 3, Spindle cell (sarcomatoid) squamous cell carcinoma | 8074/3 | 4, Lymphoepithelial carcinoma | 8082/3 | 5, Basaloid squamous cell carcinoma | 8083/3 | 6, Conventional squamous cell carcinoma | 8070/3 | 7, Verrucous squamous cell carcinoma | 8051/3 | 8, Papillary squamous cell carcinoma | 8052/3 | 9, Squamous cell carcinoma, HPV-positive | 8085/3 | 10, Squamous cell carcinoma, HPV-negative | 8086/3
squamous;2;site_squamous_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
srd5a2;1;5a-reductase def (SRD5A2);SEX DEVELOPMENT;EuRR-Bone & EuRRECa;5a-reductase def (SRD5A2);
stage;28;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
stage;28;R_AIH_Stage_liver_fibrosis;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
stage;28;R_AIH_Stage_of_liver_fibrosis_Ishak;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
stage;28;R_AIH_Tanner_stage;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
stage;28;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
stage;28;R_PBC_Stage_of_liver_fibrosis;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
stage;28;R_PBC_Stage_of_liver_fibrosis_ishak;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
stage;28;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
stage;28;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
stage;28;R_PSC_Fibrosis_stage_desmet;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
stage;28;R_PSC_Fibrosis_stage_Ishak;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
stage;28;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
stage;28;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
stage;28;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
stage;28;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
stage;28;R_PSC_Fibrosis_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
stage;28;R_PSC_Fibrosis_stage_ishak_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
stage;28;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
stage;28;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
stage;28;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
stage;28;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
stage;28;R_AIH_Fibrosis_stage_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
stage;28;R_AIH_Fibrosis_stage_Ishak_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
stage;28;R_PBC_Fibrosis_stage_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Desmet and Scheuer);numeric
stage;28;R_PBC_Fibrosis_stage_ishak_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Fibrosis stage (Ishak);numeric
stage;28;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
stage;28;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
stage;28;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
staging;9;R_PBC_Nakanuma_staging_score;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma staging score;calculation
staging;9;R_PSC_Nakanuma_staging_score;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Nakanuma grading score;calculation
staging;9;R_PSC_Nakanuma_staging_score_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
staging;9;R_AIH_Nakanuma_staging_score_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Nakanuma staging score;calculation
staging;9;R_PBC_Nakanuma_staging_score_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Nakanuma staging score;calculation
staging;9;staging_proc_req;stage_procedures;EURACAN;Staging procedures done/requested by;1, the hospital | 2, a different hospital
staging;9;clinical_staging_auto_0;stage_procedures;EURACAN;Clinical staging (automatic) = 0;
staging;9;clinical_staging_auto_1;stage_procedures;EURACAN;TESTING Clinical staging (automatic) = 0;
staging;9;staging_def_clin;stage_procedures;EURACAN;Clinical staging defined by;1, the hospital | 2, a different hospital
stairs;1;Climbing stairs;Mobility ;EURO-NMD;;single
standard;4;MuSK (standard, RIA);Diagnosis ;EURO-NMD;;single
standard;4;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
standard;4;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
standard;4;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
standard,;2;MuSK (standard, RIA);Diagnosis ;EURO-NMD;;single
standard,;2;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
star;30;Medication Date started;Medication ;EURO-NMD;;date
star;30;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
star;30;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
star;30;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
star;30;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
star;30;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
star;30;Start date medication;;ithaca;;date
star;30;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
star;30;ae_start;adverse_event;EURACAN;Adverse event starting date;
star;30;ae_start_mm;adverse_event;EURACAN;Adverse event starting month;
star;30;ae_start_yyyy;adverse_event;EURACAN;Adverse event starting year;
star;30;ae_start_2;adverse_event;EURACAN;Second adverse event starting date;
star;30;ae_start_mm_2;adverse_event;EURACAN;Second adverse event starting month;
star;30;ae_start_yyyy_2;adverse_event;EURACAN;Second adverse event starting year;
star;30;ae_start_3;adverse_event;EURACAN;Third adverse event starting date;
star;30;ae_start_mm_3;adverse_event;EURACAN;Third adverse event starting month;
star;30;ae_start_yyyy_3;adverse_event;EURACAN;Third adverse event starting year;
star;30;ae_start_4;adverse_event;EURACAN;Fourth adverse event starting date;
star;30;ae_start_mm_4;adverse_event;EURACAN;Fourth adverse event starting month;
star;30;ae_start_yyyy_4;adverse_event;EURACAN;Fourth adverse event starting year;
star;30;ae_start_5;adverse_event;EURACAN;Fifth adverse event starting date;
star;30;ae_start_mm_5;adverse_event;EURACAN;Fifth adverse event starting month;
star;30;ae_start_yyyy_5;adverse_event;EURACAN;Fifth adverse event starting year;
star;30;Start date;Chemotherapy;PaedCan;First day of chemoterapy;dd/mm/yyyy
star;30;Start date;Radiotherapy;PaedCan;First day of radiotherapy;dd/mm/yyyy
star;30;Start date;Other treatments;PaedCan;Date when therapy was started;dd/mm/yyyy or uk/uk/yyyy
star;30;StAR def;ADRENAL;EuRR-Bone & EuRRECa;StAR def;
star;30;StAR def;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;StAR def;
star;30;StAR def;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;StAR def;
star;30;StAR def;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;StAR def;
start;26;Medication Date started;Medication ;EURO-NMD;;date
start;26;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
start;26;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
start;26;contraceptives_start;Diagnosis Aetiology;Rare Liver (Vascular);Date start of use;date
start;26;pregnancy_start_date;Follow-up Events;Rare Liver (Vascular);Start date of pregnancy;date
start;26;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
start;26;Start date medication;;ithaca;;date
start;26;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
start;26;ae_start;adverse_event;EURACAN;Adverse event starting date;
start;26;ae_start_mm;adverse_event;EURACAN;Adverse event starting month;
start;26;ae_start_yyyy;adverse_event;EURACAN;Adverse event starting year;
start;26;ae_start_2;adverse_event;EURACAN;Second adverse event starting date;
start;26;ae_start_mm_2;adverse_event;EURACAN;Second adverse event starting month;
start;26;ae_start_yyyy_2;adverse_event;EURACAN;Second adverse event starting year;
start;26;ae_start_3;adverse_event;EURACAN;Third adverse event starting date;
start;26;ae_start_mm_3;adverse_event;EURACAN;Third adverse event starting month;
start;26;ae_start_yyyy_3;adverse_event;EURACAN;Third adverse event starting year;
start;26;ae_start_4;adverse_event;EURACAN;Fourth adverse event starting date;
start;26;ae_start_mm_4;adverse_event;EURACAN;Fourth adverse event starting month;
start;26;ae_start_yyyy_4;adverse_event;EURACAN;Fourth adverse event starting year;
start;26;ae_start_5;adverse_event;EURACAN;Fifth adverse event starting date;
start;26;ae_start_mm_5;adverse_event;EURACAN;Fifth adverse event starting month;
start;26;ae_start_yyyy_5;adverse_event;EURACAN;Fifth adverse event starting year;
start;26;Start date;Chemotherapy;PaedCan;First day of chemoterapy;dd/mm/yyyy
start;26;Start date;Radiotherapy;PaedCan;First day of radiotherapy;dd/mm/yyyy
start;26;Start date;Other treatments;PaedCan;Date when therapy was started;dd/mm/yyyy or uk/uk/yyyy
started;3;Medication Date started;Medication ;EURO-NMD;;date
started;3;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
started;3;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
starting;1;starting_management;patient_management_at_the_hospital;EURACAN;Patient management started at:;1, Diagnosis | 2, Treatment of primary tumor | 3, Treatment of local recurrence | 4, Treatment of regional recurrence | 5, Treatment of M+
stat3;1;STAT3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;STAT3;
stature;6;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
stature;6;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
stature;6;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
stature;6;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
stature;6;SHOX-related short stature ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;SHOX-related short stature ;
stature;6;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
stature-auditory;1;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
stature-brachydactyly-obesity-global;1;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
stature-intellectual;1;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
stature-skeletal;1;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
status;40;Current ambulatory status;Mobility ;EURO-NMD;;single
status;40;Patient_status;Base information;Rare Liver (Auto imune);Patient status;radio
status;40;R_PSC_IBD_status;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD Status;radio
status;40;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
status;40;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
status;40;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
status;40;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
status;40;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
status;40;ER receptor status;malignancy;Genturis;What is the Estrogen receptor status of the breast cancer?;categorical
status;40;PR receptor status;malignancy;Genturis;What is the Progesteron receptor status of the breast cancer?;categorical
status;40;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
status;40;MMR IHC status;malignancy;Genturis;What are the results of the IHC of the MMR proteins?;enum
status;40;MMR MSA status;malignancy;Genturis;What are the results of the MSA of the tumour DNA?;enum
status;40;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
status;40;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
status;40;Follow-up status;subject;Genturis;What is the patient's follow-up status?;categorical
status;40;Proband status;subject;Genturis;Is this a proband patient or relative?;enum
status;40;Malignancy status;subject;Genturis;Has this patient ever had a (invasive or in situ) malignancy?;enum
status;40;Benign status;subject;Genturis;Has this patient ever had a benign neoplasm/tumour?;enum
status;40;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
status;40;Variant status;subject;Genturis;Has any class 3, 4 of 5 variant been found?;enum
status;40;Patient StatusÂ ;;ithaca;;compound
status;40;Patient's Status;;ithaca;;categorical
status;40;Functional Status and or Disability;;ithaca;;mref
status;40;Status of diagnosis;;ithaca;;categorical
status;40;Other status of diagnosis;;ithaca;;text
status;40;marital_status;patient_management_at_the_hospital;EURACAN;Marital status;1, Married | 2, Not married | 3, Divorced | 4, Widowed/Widower | 5, Single
status;40;smoking_status;patient_management_at_the_hospital;EURACAN;Smoking;1, Current tobacco smoker | 2, Former smoker | 3, Never smoker | 4, Unknown
status;40;hpv_status;primary_cancer;EURACAN;HPV status;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
status;40;hpv_status_type;primary_cancer;EURACAN;HPV status detected by;1, FISH | 2, PCR | 9, Unknown
status;40;fu_status;clinical_update;EURACAN;Status at last clinical update;1, Alive, No Evidence of Disease (NED) | 2, Alive, With Disease (AWD) | 3, Dead of Disease (DOD) | 4, Dead of Other Cause (DOC) | 5, Dead of Unknown Cause (DUC) | 6, Unknown status | 7, Patients lost to follow-up | 8, New cancer diagnosis
status;40;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
status;40;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
status;40;Disease status;Follow up (one form for each follow up visit);PaedCan;If the patient is alive reports the status of the disease;on treatment/ in 1st complete remission/in 2nd complete remission/alive in 3rd or more complete remission/ alive with disease/unknown
status;40;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
status;40;T4 status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum free T4 for local reference range;N/Low/High/Not Known
status;40;T3 Status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Total T3 for local reference range;N/Low/High/Not Known
status;40;TSH status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum TSH for local reference range;N/Low/High/Not Known
status;40;Tg status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Tg (on thyroxin treatment) either TSH-suppressed < 0,2 ng/ml or TSH-stimulated < 1 ng/ml;Below/Above
status;40;Calcitonin status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Ct < 150 pg/ml;Below/Above
stenosed;1;ivc_obstructed_or_stenosed;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Level of obstruction;radio
stenosis;1;hv_short_length_stenosis;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Short length stenosis (;radio
stenting;1;date_of_stenting;Follow-up Events;Rare Liver (Vascular);Date of stenting;date
stents;1;pat_angioplasty_stents;Follow-up Events;Rare Liver (Vascular);Was a angioplasty/stenting performed in a previous f-u period;radio
steroid-resistant;1;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
stiffness;5;R_AIH_Liver_stiffness_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Liver stiffness (FibroScan);numeric
stiffness;5;R_PBC_Liver_stiffness;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
stiffness;5;R_PSC_Liver_stiffness;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
stiffness;5;R_PSC_Liver_stiffness_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
stiffness;5;R_PBC_Liver_stiffness_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver stiffness (Fibroscan);numeric
still;1;woman_still_menstruated;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Is she still menstruated?;radio
stimulation;1;EMG: repetitive nerve stimulation abnormality;Diagnosis EMG;EURO-NMD;Repetitive nerve stimulation result;
stoma;1;"catheterisableÂ stoma 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
stool;2;stool_yn;Diagnosis Biobank;Rare Liver (Vascular);Stool sample obtained?;dropdown
stool;2;stool_dt;Diagnosis Biobank;Rare Liver (Vascular);Stool sample date;date
stop;5;Medication Date stopped;Medication ;EURO-NMD;;date
stop;5;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
stop;5;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
stop;5;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
stop;5;anticoag_perm_stop;Follow-up Events;Rare Liver (Vascular);Anticoagulation was permanently stopped;radio
stopped;4;Medication Date stopped;Medication ;EURO-NMD;;date
stopped;4;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
stopped;4;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
stopped;4;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
stored;3;R_PSC_Biosamples_stored;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
stored;3;R_PSC_Biosamples_stored_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
stored;3;R_AIH_Biosamples_stored;AIH Follow-up Biobanking;Rare Liver (Auto imune);Biosamples stored;radio
stridor;1;Stridor;Diagnosis Respiratory;EURO-NMD;;yesno
study;1;country_study;Diagnosis General Information;Rare Liver (Vascular);Country of study;dropdown
subcaps;1;intrahep_subcaps_hv_collat;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Intrahepatic or subcapsular hepatic vein collaterals;radio
sudden;1;Sudden episodic apnea;Diagnosis Respiratory;EURO-NMD;Episodic apnoea;yesno
superior;1;superior_mesenteric_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Superior mesenteric vein;radio
supine;3;Head, lifted (45Â°, supine) Sec.;QMG;EURO-NMD;;
supine;3;Right leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
supine;3;Left leg outstretched (45Â° supine) Sec.;QMG;EURO-NMD;;
support;1;Learning support at school;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Requiring extra help at school with learning;Y/N/Not Known
sur1;3;Autosomal dominant hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal dominant hyperinsulinism due to SUR1 deficiency;
sur1;3;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency;
sur1;3;Autosomal recessive hyperinsulinism due to SUR1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autosomal recessive hyperinsulinism due to SUR1 deficiency;
surg;28;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
surg;28;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
surg;28;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
surg;28;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
surg;28;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
surg;28;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
surg;28;prev_non_onco_hn_surg_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of non-oncological head and neck surgery;
surg;28;surgery;surgery;EURACAN;Surgery performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done
surg;28;surgery_date;surgery;EURACAN;Surgery date;
surg;28;surgery_date_mm;surgery;EURACAN;Month of surgery;
surg;28;surgery_date_yyyy;surgery;EURACAN;Year of surgery;
surg;28;surgery_type;surgery;EURACAN;Tumor site, type of  surgery;1, External | 2, Endoscopic | 3, Robotic | 9, Unknown
surg;28;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
surg;28;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
surg;28;surgery_margins;surgery;EURACAN;Margins after surgery;0, R0 (microscopic negative) | 1, R1 (microscopic positive) | 2, R2 (macroscopic positive) | 9, Unknown
surg;28;surgery_nr_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
surg;28;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
surg;28;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
surg;28;surgery_fu_site;surgery;EURACAN;Surgery site;1, T | 2, N | 3, M
surg;28;Delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
surg;28;Date of delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surg;28;Further surgery;Surgery;PaedCan;A form to be completed if additional surgery has been perfomed;yes/no/unknown
surg;28;Date of further surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surg;28;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
surg;28;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surg;28;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
surg;28;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surg;28;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
surgcal;1;surgcal_shunt_constructed;Follow-up Events;Rare Liver (Vascular);Was a surgical shunt constructed in a previous f-u period;radio
surgery;24;"anti refluxÂ surgery 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
surgery;24;prev_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous oncological head and neck surgery;1, Yes | 2, No | 9, Unknown
surgery;24;prev_hn_surgery_diag_y;previous_cancer_genetic_syndromes;EURACAN;Year of oncological head and neck surgery;
surgery;24;prev_non_onco_hn_surgery;previous_cancer_genetic_syndromes;EURACAN;Previous non-oncological head and neck surgery ;1, Yes | 2, No | 9, Unknown
surgery;24;surgery;surgery;EURACAN;Surgery performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done
surgery;24;surgery_date;surgery;EURACAN;Surgery date;
surgery;24;surgery_date_mm;surgery;EURACAN;Month of surgery;
surgery;24;surgery_date_yyyy;surgery;EURACAN;Year of surgery;
surgery;24;surgery_type;surgery;EURACAN;Tumor site, type of  surgery;1, External | 2, Endoscopic | 3, Robotic | 9, Unknown
surgery;24;surgery_nr_lymphnodes;surgery;EURACAN;Number of lymph nodes removed;
surgery;24;surgery_nr_pos_lymphnodes;surgery;EURACAN;Number of positive lymph nodes;
surgery;24;surgery_margins;surgery;EURACAN;Margins after surgery;0, R0 (microscopic negative) | 1, R1 (microscopic positive) | 2, R2 (macroscopic positive) | 9, Unknown
surgery;24;surgery_nr_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
surgery;24;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
surgery;24;surgery_complications;surgery;EURACAN;Surgical complications (Clavien-Dindo Classification);1, Grade I | 2, Grade II | 3, Grade III | 4, Grade IIIa | 5, Grade IIIb | 6, Grade IV | 7, Grade IVa | 8, Grade IVb | 9, Grade V | 10, No complications | 99, Unknown
surgery;24;surgery_fu_site;surgery;EURACAN;Surgery site;1, T | 2, N | 3, M
surgery;24;Delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
surgery;24;Date of delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surgery;24;Further surgery;Surgery;PaedCan;A form to be completed if additional surgery has been perfomed;yes/no/unknown
surgery;24;Date of further surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surgery;24;Lymphnodes delayed surgery ;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/sampling/lymphadenectomy/unknown
surgery;24;Date of lymphnodes delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surgery;24;Metastases delayed surgery;Surgery;PaedCan;Surgery perfomed after initial treatment (chemo, radio,other);not perfomed/ complete tumor resection/ tumor macroscopically resected but surgical margins infiltrated/macroscopic residuals/unknown
surgery;24;Date of metastases delayed surgery;Surgery;PaedCan;Date of delayed surgery;dd/mm/yyyy
surgical;2;first_surgical_porto_shunt;Follow-up Events;Rare Liver (Vascular);First surgical portosystemic shunting;radio
surgical;2;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
survey;1;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
sv;2;fu_ima_bef_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
sv;2;fu_ima_last_sv_patent;Follow-up Imaging data;Rare Liver (Vascular);Splenic vein patent;radio
swallowing;2;Swallowing difficulties;Bulbar/Gi ;EURO-NMD;;single
swallowing;2;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
swanganz;1;swanganz;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Swan-Ganz;radio
sympt;12;Symptom fluctuation;Diagnosis Fluctuation;EURO-NMD;;yesno
sympt;12;asymptomatic;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Asymptomatic;radio
sympt;12;other_symptoms;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other symptoms;textarea
sympt;12;mo_prior_to_onset_sympt;Diagnosis Aetiology;Rare Liver (Vascular);;radio
sympt;12;fu_biliary_symptoms;Follow-up Complications;Rare Liver (Vascular);Biliary symptoms;radio
sympt;12;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
sympt;12;Age at first symptoms;subject;Genturis;At what age (years) did the patient have his/her first symptoms?;int
sympt;12;Period of first symptom onset;;ithaca;;categorical
sympt;12;Date of first symptoms onset;;ithaca;;date
sympt;12;Age at first symptoms onset;;ithaca;;int
sympt;12;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
sympt;12;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
symptom;11;Symptom fluctuation;Diagnosis Fluctuation;EURO-NMD;;yesno
symptom;11;asymptomatic;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Asymptomatic;radio
symptom;11;other_symptoms;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other symptoms;textarea
symptom;11;fu_biliary_symptoms;Follow-up Complications;Rare Liver (Vascular);Biliary symptoms;radio
symptom;11;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
symptom;11;Age at first symptoms;subject;Genturis;At what age (years) did the patient have his/her first symptoms?;int
symptom;11;Period of first symptom onset;;ithaca;;categorical
symptom;11;Date of first symptoms onset;;ithaca;;date
symptom;11;Age at first symptoms onset;;ithaca;;int
symptom;11;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
symptom;11;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
symptomatic;2;asymptomatic;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Asymptomatic;radio
symptomatic;2;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
symptoms;7;other_symptoms;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Other symptoms;textarea
symptoms;7;fu_biliary_symptoms;Follow-up Complications;Rare Liver (Vascular);Biliary symptoms;radio
symptoms;7;Age at first symptoms available?;subject;Genturis;Is the age (years) at which the patient had his/her first symptoms known?;enum
symptoms;7;Age at first symptoms;subject;Genturis;At what age (years) did the patient have his/her first symptoms?;int
symptoms;7;Date of first symptoms onset;;ithaca;;date
symptoms;7;Age at first symptoms onset;;ithaca;;int
symptoms;7;Specify symptoms and signs;Symptoms and signs;PaedCan;Definition of symptoms and signs caused by the tumor;String
syndrome;167;R_PSC_Hepatorenal_syndrome;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
syndrome;167;R_AIH_Hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Hepatorenal syndrome;radio
syndrome;167;R_AIH_Date_hepatorenal_syndrome_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date hepatorenal syndrome;date
syndrome;167;R_PSC_Hepatorenal_syndrome_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatorenal syndrome;radio
syndrome;167;R_AIH_Date_hepatorenal_syndrome_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date hepatorenal syndrome;date
syndrome;167;hepatorenal_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatorenal syndrome;radio
syndrome;167;hepatopulmonary_syndrome;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Hepatopulmonary syndrome;radio
syndrome;167;antphospol_syndrome_tested;Diagnosis Aetiology;Rare Liver (Vascular);Antiphospholipid syndrome tested;radio
syndrome;167;budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Budd-Chiari syndrome;radio
syndrome;167;date_budd_chiari_syndrome;Diagnosis Aetiology;Rare Liver (Vascular);Date;date
syndrome;167;Polyposis syndrome;benignNeoplasm;Genturis;What is the dominant polyp type?;xref
syndrome;167;Rare disease  syndrome;subject;Genturis;What is the classification (Orphanet) of the rare disease of the patients?;xref
syndrome;167;Cancer Syndrome;;ithaca;;string
syndrome;167;genetic_syndrome_ynu;previous_cancer_genetic_syndromes;EURACAN;Genetic syndrome;1, Yes | 2, No | 9, Unknown
syndrome;167;Syndrome;Patient's history;PaedCan;Presence or absence of any syndrome;yes/no/unknown
syndrome;167;Specify which syndrome;Patient's history;PaedCan;Definition of the syndrome affecting the patient;String
syndrome;167;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
syndrome;167;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
syndrome;167;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;ADRENAL;EuRR-Bone & EuRRECa;Familial steroid-resistant nephrotic syndrome with adrenal insufficiency;
syndrome;167;Kearns-Sayre syndrome;ADRENAL;EuRR-Bone & EuRRECa;Kearns-Sayre syndrome;
syndrome;167;Smith-Lemli-Opitz syndrome;ADRENAL;EuRR-Bone & EuRRECa;Smith-Lemli-Opitz syndrome;
syndrome;167;Triple A syndrome;ADRENAL;EuRR-Bone & EuRRECa;Triple A syndrome;
syndrome;167;Dahlberg-Borer-Newcomer syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Dahlberg-Borer-Newcomer syndrome;
syndrome;167;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
syndrome;167;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
syndrome;167;Sanjad-Sakati syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Sanjad-Sakati syndrome;
syndrome;167;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
syndrome;167;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
syndrome;167;Blue diaper syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Blue diaper syndrome;
syndrome;167;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
syndrome;167;PIK3R1 (Short Syndrome);GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;PIK3R1 (Short Syndrome);
syndrome;167;Autoimmune polyglandular syndrome I;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome I;
syndrome;167;Autoimmune polyglandular syndrome II;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Autoimmune polyglandular syndrome II;
syndrome;167;Hyperinsulinism-hyperammonaemia syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism-hyperammonaemia syndrome;
syndrome;167;Beckwith-Wiedemann syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome;
syndrome;167;Sotos syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Sotos syndrome;
syndrome;167;Kabuki syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Kabuki syndrome;
syndrome;167;Insulin-resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome;
syndrome;167;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
syndrome;167;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
syndrome;167;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
syndrome;167;Microcephalic primordial dwarfism-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Microcephalic primordial dwarfism-insulin resistance syndrome;
syndrome;167;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
syndrome;167;Short fifth metacarpals-insulin resistance syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Short fifth metacarpals-insulin resistance syndrome;
syndrome;167;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
syndrome;167;Silver-Russell Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell Syndrome;
syndrome;167;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
syndrome;167;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
syndrome;167;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
syndrome;167;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
syndrome;167;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
syndrome;167;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
syndrome;167;Beckwith-Wiedemann Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann Syndrome;
syndrome;167;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microdeletion;
syndrome;167;Beckwith-Wiedemann syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 microduplication;
syndrome;167;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
syndrome;167;Beckwith-Wiedemann syndrome due to CDKN1C mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to CDKN1C mutation;
syndrome;167;Beckwith-Wiedemann syndrome due to NSD1 mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to NSD1 mutation;
syndrome;167;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to imprinting defect of 11p15;
syndrome;167;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
syndrome;167;Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi Syndrome;
syndrome;167;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
syndrome;167;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
syndrome;167;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
syndrome;167;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
syndrome;167;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
syndrome;167;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
syndrome;167;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
syndrome;167;Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome;
syndrome;167;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
syndrome;167;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
syndrome;167;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
syndrome;167;Noonan Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan Syndrome;
syndrome;167;Neurofibromatosis-Noonan syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Neurofibromatosis-Noonan syndrome;
syndrome;167;Noonan syndrome and Noonan-related syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome and Noonan-related syndrome;
syndrome;167;Noonan syndrome with multiple lentigines;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome with multiple lentigines;
syndrome;167;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
syndrome;167;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
syndrome;167;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
syndrome;167;Laron syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Laron syndrome;
syndrome;167;Overgrowth Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth Syndrome;
syndrome;167;15q overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;15q overgrowth syndrome;
syndrome;167;CLOVES syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;CLOVES syndrome;
syndrome;167;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
syndrome;167;Malan overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Malan overgrowth syndrome;
syndrome;167;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Megalencephaly-severe kyphoscoliosis-overgrowth syndrome;
syndrome;167;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
syndrome;167;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
syndrome;167;Overgrowth-macrocephaly-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-macrocephaly-facial dysmorphism syndrome;
syndrome;167;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
syndrome;167;Overgrowth/obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth/obesity syndrome;
syndrome;167;PIK3CA-related overgrowth syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PIK3CA-related overgrowth syndrome;
syndrome;167;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Segmental progressive overgrowth syndrome with fibroadipose hyperplasia;
syndrome;167;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
syndrome;167;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
syndrome;167;Weaver syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Weaver syndrome;
syndrome;167;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency;
syndrome;167;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
syndrome;167;6q16 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;6q16 microdeletion syndrome;
syndrome;167;Prader-Willi syndrome due to imprinting mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to imprinting mutation;
syndrome;167;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
syndrome;167;Prader-Willi syndrome due to paternal 15q11q13 deletion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal 15q11q13 deletion;
syndrome;167;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
syndrome;167;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
syndrome;167;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
syndrome;167;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
syndrome;167;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a MAGEL2 or point mutation;
syndrome;167;Prader-Willi-like syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi-like syndrome due to a point mutation;
syndrome;167;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
syndrome;167;SIM1-related Prader-Willi-like syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;SIM1-related Prader-Willi-like syndrome;
syndrome;167;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
syndrome;167;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
syndrome;167;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
syndrome;167;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
syndrome;167;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
syndrome;167;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
syndrome;167;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
syndrome;167;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
syndrome;167;AlstrÃ¶m syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;AlstrÃ¶m syndromeÂ ;
syndrome;167;Bardet-Biedl syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Bardet-Biedl syndromeÂ ;
syndrome;167;Borjeson-Forssman-Lehmann syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Borjeson-Forssman-Lehmann syndromeÂ ;
syndrome;167;Carpenter syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Carpenter syndromeÂ ;
syndrome;167;Coffin-Lowry syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Coffin-Lowry syndromeÂ ;
syndrome;167;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome;
syndrome;167;Cohen syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Cohen syndromeÂ ;
syndrome;167;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
syndrome;167;Distal 16p11.2 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Distal 16p11.2 microdeletion syndrome;
syndrome;167;Fragile X syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Fragile X syndrome;
syndrome;167;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
syndrome;167;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome;
syndrome;167;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome;
syndrome;167;Intellectual disability-seizures-macrocephaly-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Intellectual disability-seizures-macrocephaly-obesity syndrome;
syndrome;167;MEHMO syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MEHMO syndrome;
syndrome;167;MOMO syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MOMO syndrome;
syndrome;167;MORM syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;MORM syndrome;
syndrome;167;ROHHAD syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;ROHHAD syndrome;
syndrome;167;Short stature-brachydactyly-obesity-global developmental delay syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short stature-brachydactyly-obesity-global developmental delay syndrome;
syndrome;167;Smith-Magenis syndromeÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Smith-Magenis syndromeÂ ;
syndrome;167;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
syndrome;167;Symptomatic form of Coffin-Lowry syndrome in female carriers;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Symptomatic form of Coffin-Lowry syndrome in female carriers;
syndrome;167;WAGR syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;WAGR syndrome;
syndrome;167;Wilson-Turner syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Wilson-Turner syndrome;
syndrome;167;Xq21 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Xq21 microdeletion syndrome;
syndrome;167;RHYNS syndrome;PITUITARY;EuRR-Bone & EuRRECa;RHYNS syndrome;
syndrome;167;Persistent mullerian duct syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Persistent mullerian duct syndrome;
syndrome;167;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
syndrome;167;Smith Lemli Opitz Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Smith Lemli Opitz Syndrome;
syndrome;167;Kallmann Syndrome;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Kallmann Syndrome;
syndrome;167;McCune-Albright syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;McCune-Albright syndrome ;
syndrome;167;Mazabraud syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mazabraud syndrome ;
syndrome;167;Maffucci syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Maffucci syndrome ;
syndrome;167;Ulna metaphyseal dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ulna metaphyseal dysplasia syndrome ;
syndrome;167;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome;
syndrome;167;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome ;
syndrome;167;Shwachman-Diamond syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Shwachman-Diamond syndrome ;
syndrome;167;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome ;
syndrome;167;Cleidorhizomelic syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Cleidorhizomelic syndrome ;
syndrome;167;Dyschondrosteosis-nephritis syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Dyschondrosteosis-nephritis syndrome ;
syndrome;167;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism-cleft palate-camptodactyly syndrome ;
syndrome;167;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
syndrome;167;Robinow syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Robinow syndrome ;
syndrome;167;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome ;
syndrome;167;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
syndrome;167;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
syndrome;167;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome ;
syndrome;167;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome ;
syndrome;167;Ehlers-Danlos/osteogenesis imperfecta syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ehlers-Danlos/osteogenesis imperfecta syndrome ;
syndrome-like;2;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
syndrome-like;2;Noonan syndrome-like disorder with loose anagen hair;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with loose anagen hair;
syndrome,;2;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
syndrome,;2;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
syndromic;10;Other syndromic form of CH;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other syndromic form of CH;
syndromic;10;Non syndromic limb overgrowth;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non syndromic limb overgrowth;
syndromic;10;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Congenital Leptin Resistance;
syndromic;10;Non-Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Non-Syndromic Genetic Obesity - Other;
syndromic;10;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Prader-Willi Syndrome;
syndromic;10;Syndromic Genetic Obesity â€“ PWS like Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PWS like Syndrome;
syndromic;10;Syndromic Genetic Obesity â€“ PHP with AHO;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ PHP with AHO;
syndromic;10;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
syndromic;10;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
syndromic;10;Syndromic Genetic Obesity - Other;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity - Other;
synthesis;1;Disorder of androgen synthesis;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Disorder of androgen synthesis;
sys;13;syst_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systolic blood pressue;numeric
sys;13;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
sys;13;sys_sarcoidosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Sarcoidosis;radio
sys;13;sys_con_tissue;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Connective Tissue Disease;radio
sys;13;sys_vasculitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Vasculitis;radio
sys;13;sys_celiac;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Celiac Disease;radio
sys;13;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
sys;13;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
sys;13;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
sys;13;Codesystem;Anatomical Therapeutic Chemical Classification;ithaca;;string
sys;13;Codesystem;;ithaca;;string
sys;13;Diagnosis Coding System;;ithaca;;mref
sys;13;Diagnosis Coding System;;ithaca;;mref
syst;8;syst_press;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systolic blood pressue;numeric
syst;8;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
syst;8;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
syst;8;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
syst;8;Codesystem;Anatomical Therapeutic Chemical Classification;ithaca;;string
syst;8;Codesystem;;ithaca;;string
syst;8;Diagnosis Coding System;;ithaca;;mref
syst;8;Diagnosis Coding System;;ithaca;;mref
system;7;system_dis_other_aq_proth;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Systemic disease (other than acquired prothrombotic);radio
system;7;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
system;7;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
system;7;Codesystem;Anatomical Therapeutic Chemical Classification;ithaca;;string
system;7;Codesystem;;ithaca;;string
system;7;Diagnosis Coding System;;ithaca;;mref
system;7;Diagnosis Coding System;;ithaca;;mref
systemic;2;portosystemic_collaterals;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portosystemic collaterals;radio
systemic;2;other_systemic_diseases;Diagnosis Aetiology;Rare Liver (Vascular);Condition(s);textarea
t3;2;T3 Status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Total T3 for local reference range;N/Low/High/Not Known
t3;2;STAT3;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;STAT3;
t4;1;T4 status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum free T4 for local reference range;N/Low/High/Not Known
tacrolimus;26;R_AIH_Tacrolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
tacrolimus;26;R_PBC_AIH_Tacrolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
tacrolimus;26;R_PSC_AIH_Tacrolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
tacrolimus;26;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
tacrolimus;26;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
tacrolimus;26;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
tacrolimus;26;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
tacrolimus;26;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
tacrolimus;26;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
tacrolimus;26;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
tacrolimus;26;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
tacrolimus;26;R_AIH_Tacrolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
tacrolimus;26;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
tacrolimus;26;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
tacrolimus;26;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
tacrolimus;26;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
tall;2;Overgrowth or tall stature syndrome with skeletal involvement;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth or tall stature syndrome with skeletal involvement;
tall;2;Tall stature-intellectual disability-facial dysmorphism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Tall stature-intellectual disability-facial dysmorphism syndrome;
tanner;15;R_AIH_Tanner_stage;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
tanner;15;R_AIH_Tanner_stage_pubic_hair;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
tanner;15;R_PBC_Tanner_stage_genital_breast;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
tanner;15;R_PBC_Tanner_stage_pubic_hair;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
tanner;15;R_PSC_Tanner_stage_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
tanner;15;R_PSC_Tanner_stage_pubic_hair_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
tanner;15;R_AIH_Tanner_stage_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
tanner;15;R_AIH_Tanner_stage_pubic_hair_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Tanner stage (1-5 pubic hair);numeric
tanner;15;R_PSC_Tanner_stage_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5 male genital or female breast);numeric
tanner;15;R_PSC_Tanner_stage_pubic_hair_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
tanner;15;R_AIH_Tanner_stage_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5 for male genital or female breast);numeric
tanner;15;R_AIH_Tanner_stage_hair_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
tanner;15;R_PBC_Tanner_stage_genital_breast_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, male genital or female breast);numeric
tanner;15;R_PBC_Tanner_stage_pubic_hair_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Tanner stage (1-5, pubic hair);numeric
tanner;15;Pubertal stage (Tanner scale);Clinical Status;ERKNet;Â ;"female: B1-5, P1-6; 
male: G1-5, P1-6"
target;1;Target area;Radiotherapy;PaedCan;Report the radiotherapy target;primary tumor/nodes/metastases
taybi;4;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Rubenstein Taybi Syndrome;
taybi;4;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to 16p13.3 microdeletionÂ ;
taybi;4;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to CREBBP mutationsÂ ;
taybi;4;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyÂ ;
tech;8;radio_photons_tech;radiotherapy;EURACAN;Photons treatment technique;1, 2D | 2, 3D | 3, IMRT conventional | 4, VMAT | 5, Thomotherapy | 6, SBRT
tech;8;radio_electrons_tech;radiotherapy;EURACAN;Electrons treatment technique;1, FLASH  therapy
tech;8;radio_protons_tech;radiotherapy;EURACAN;Protons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
tech;8;radio_carbons_tech;radiotherapy;EURACAN;Carbons treatment technique;1, Passive scattering modality | 2, Single beam optimization | 3, IMPT | 4, FLASH therapy
tech;8;radio_brachy_tech;radiotherapy;EURACAN;Brachytherapy treatment technique;1, Interstitial | 2, Endocavitary | 3, Contact
tech;8;radio_radionuc_tech;radiotherapy;EURACAN;Radionuclide treatment technique;
tech;8;radio_boron_tech;radiotherapy;EURACAN;Boron neutron capture therapy treatment technique;
tech;8;radio_others_tech;radiotherapy;EURACAN;Others treatment technique;
telomeropathy;2;telomeropathy;Diagnosis Aetiology;Rare Liver (Vascular);Telomeropathy;radio
telomeropathy;2;telomeropathy_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of telomeropathy;string
temple;4;Syndromic Genetic Obesity â€“ Temple Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Syndromic Genetic Obesity â€“ Temple Syndrome;
temple;4;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
temple;4;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 hypomethylationÂ ;
temple;4;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to paternal 14q32.2 microdeletionÂ ;
tendons;1;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
tensilon/prostigmine;1;Tensilon/Prostigmine test response;Diagnosis ;EURO-NMD;;single
term;6;eos_termination_reason;End of study End of study;Rare Liver (Vascular);Reason for Study Termination;radio
term;6;ctcae_term;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
term;6;ctcae_term_2;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
term;6;ctcae_term_3;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
term;6;ctcae_term_4;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
term;6;ctcae_term_5;adverse_event;EURACAN;Adverse event type (CTCAE Term);for later
termination;1;eos_termination_reason;End of study End of study;Rare Liver (Vascular);Reason for Study Termination;radio
test;12;Tensilon/Prostigmine test response;Diagnosis ;EURO-NMD;;single
test;12;gastro_intestinal_bleeding;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding;radio
test;12;gastro_intest_bleed_date;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding date;date
test;12;gastro_intest_bleed_origin;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastro-intestinal bleeding origin;radio
test;12;antphospol_syndrome_tested;Diagnosis Aetiology;Rare Liver (Vascular);Antiphospholipid syndrome tested;radio
test;12;methionine_tolerance_test;Diagnosis Aetiology;Rare Liver (Vascular);Methionine tolerance test;radio
test;12;pathergy_test;Diagnosis Aetiology;Rare Liver (Vascular);Pathergy test;radio
test;12;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
test;12;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
test;12;Testicular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Testicular DSD;
test;12;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
test;12;Testicular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Testicular DSD;
tested;1;antphospol_syndrome_tested;Diagnosis Aetiology;Rare Liver (Vascular);Antiphospholipid syndrome tested;radio
testicular;4;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
testicular;4;Testicular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Testicular DSD;
testicular;4;Ovotesticular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Ovotesticular DSD;
testicular;4;Testicular DSD;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Testicular DSD;
tg;10;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
tg;10;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tg;10;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
tg;10;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tg;10;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
tg;10;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tg;10;R_PBC_TGN_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
tg;10;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tg;10;dia_lab_fasting_tg_value;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum triglycerides value;numeric
tg;10;Tg status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Tg (on thyroxin treatment) either TSH-suppressed < 0,2 ng/ml or TSH-stimulated < 1 ng/ml;Below/Above
tgn;8;R_AIH_Six_TGN_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN;numeric
tgn;8;R_AIH_TGN_pmolml_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tgn;8;R_PSC_AIH_Six_TGN_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
tgn;8;R_PSC_AIH_TGN_pmolml_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tgn;8;R_AIH_Six_TGN_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
tgn;8;R_AIH_TGN_pmolml_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
tgn;8;R_PBC_TGN_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN;numeric
tgn;8;R_PBC_TGN_pmolml_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-TGN (pmol/0.2ml);numeric
therapy;12;Change of severity with hormonal therapy;Diagnosis Fluctuation;EURO-NMD;;yesno
therapy;12;Thymoma therapy:;Thymoma;EURO-NMD;;
therapy;12;R_PSC_Dilation_therapy_diagnosis;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Dilation therapy;radio
therapy;12;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
therapy;12;"a.	Induction therapy: ";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;[Tick-box, multiple selection]
therapy;12;"b.	Specification other induction therapy:	";4.Â Â Â Â Â Â  Immunosuppression:;Eurogen (Kid Transplantation);;String
therapy;12;Chemotherapy administered;Chemotherapy;PaedCan;;yes/no/unknown
therapy;12;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
therapy;12;Best response to chemotherapy;Chemotherapy;PaedCan;Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable);Complete Response/Partial Response/Stable Disease/Progression Disease/not evaluable/unknown
therapy;12;Major adverse effects to chemotherapy (grade IV);Chemotherapy;PaedCan;Please report Grade IV toxicity (excluding hematologic toxicity);yes/no/unknown
therapy;12;Radiotherapy administered;Radiotherapy;PaedCan;;yes/no/unknown
therapy;12;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
there;2;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
there;2;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
throm;12;portal_vein_thromb;Diagnosis General Information;Rare Liver (Vascular);For Portal vein thrombosis;radio
throm;12;prothrom_g20210a_mutation;Diagnosis Aetiology;Rare Liver (Vascular);Prothrombin (G20210A) mutation;radio
throm;12;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
throm;12;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
throm;12;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
throm;12;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
throm;12;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
throm;12;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
throm;12;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
throm;12;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
throm;12;fu_thrombotic_event;Follow-up Complications;Rare Liver (Vascular);Thrombotic event;radio
throm;12;thrombolysis;Follow-up Events;Rare Liver (Vascular);Thrombolysis;radio
thromb;10;portal_vein_thromb;Diagnosis General Information;Rare Liver (Vascular);For Portal vein thrombosis;radio
thromb;10;antithromb_deficiency_act;Diagnosis Aetiology;Rare Liver (Vascular);Antithrombin deficiency activity;numeric
thromb;10;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
thromb;10;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
thromb;10;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
thromb;10;dia_lab_prothrombin_normal;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time (normal value);numeric
thromb;10;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
thromb;10;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
thromb;10;fu_thrombotic_event;Follow-up Complications;Rare Liver (Vascular);Thrombotic event;radio
thromb;10;thrombolysis;Follow-up Events;Rare Liver (Vascular);Thrombolysis;radio
thrombolysis;1;thrombolysis;Follow-up Events;Rare Liver (Vascular);Thrombolysis;radio
thrombosis;2;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
thrombosis;2;arterial_thrombosis;Diagnosis Aetiology;Rare Liver (Vascular);Arterial thrombosis;radio
thrombotic;1;fu_thrombotic_event;Follow-up Complications;Rare Liver (Vascular);Thrombotic event;radio
thymectomy;4;Thymectomy?;Diagnosis ;EURO-NMD;;single
thymectomy;4;Thymectomy?;Thymoma;EURO-NMD;;yesno
thymectomy;4;Â­ Thymectomy date;Thymoma;EURO-NMD;;date
thymectomy;4;Time from onset to thymectomy:;Thymoma;EURO-NMD;;
thymoma;5;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
thymoma;5;If thymoma, WHO Classification:;Thymoma;EURO-NMD;;
thymoma;5;Thymoma therapy:;Thymoma;EURO-NMD;;
thymoma;5;If thymoma, relapse?;Thymoma;EURO-NMD;;
thymoma;5;Date of thymoma relapse:;Thymoma;EURO-NMD;;date
thymoma,;3;If thymoma, Masaoka stage:;Thymoma;EURO-NMD;;
thymoma,;3;If thymoma, WHO Classification:;Thymoma;EURO-NMD;;
thymoma,;3;If thymoma, relapse?;Thymoma;EURO-NMD;;
thymus;1;Thymus histology:;Thymoma;EURO-NMD;;
thyroid;39;Hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism;
thyroid;39;Autoimmune hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune hypoparathyroidism;
thyroid;39;Secondary hypoparathyroidism due to impaired parathormone secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Secondary hypoparathyroidism due to impaired parathormone secretion;
thyroid;39;Syndrome with hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Syndrome with hypoparathyroidism;
thyroid;39;Familial isolated hypoparathyroidism due to impaired PTH secretion;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to impaired PTH secretion;
thyroid;39;Genetic hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hypoparathyroidism;
thyroid;39;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypoparathyroidism-sensorineural deafness-renal disease syndrome;
thyroid;39;Familial isolated hypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism;
thyroid;39;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hypoparathyroidism due to agenesis of parathyroid gland;
thyroid;39;Pseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism;
thyroid;39;Pseudopseudohypoparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudopseudohypoparathyroidism;
thyroid;39;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
thyroid;39;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
thyroid;39;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
thyroid;39;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
thyroid;39;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism with Albright hereditary osteodystrophy;
thyroid;39;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
thyroid;39;Hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism;
thyroid;39;Familial isolated hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial isolated hyperparathyroidism;
thyroid;39;Familial primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial primary hyperparathyroidism;
thyroid;39;Genetic hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Genetic hyperparathyroidism;
thyroid;39;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
thyroid;39;Neonatal severe primary hyperparathyroidism;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Neonatal severe primary hyperparathyroidism;
thyroid;39;Nephropathy-deafness-hyperparathyroidism syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Nephropathy-deafness-hyperparathyroidism syndrome;
thyroid;39;Parathyroid carcinoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Parathyroid carcinoma;
thyroid;39;Familial parathyroid adenoma;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial parathyroid adenoma;
thyroid;39;Primary parathyroid hyperplasia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Primary parathyroid hyperplasia;
thyroid;39;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
thyroid;39;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
thyroid;39;PseudopseudohypoparathyroidismÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;PseudopseudohypoparathyroidismÂ ;
thyroid;39;Resistance to thyroid hormone alpha;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone alpha;
thyroid;39;Resistance to thyroid hormone beta;THYROID;EuRR-Bone & EuRRECa;Resistance to thyroid hormone beta;
thyroid;39;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
thyroid;39;Permanent congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Permanent congenital hypothyroidism;
thyroid;39;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
thyroid;39;Familial gestational hyperthyroidism;THYROID;EuRR-Bone & EuRRECa;Familial gestational hyperthyroidism;
thyroid;39;Papillary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Papillary thyroid carcinoma;
thyroid;39;Follicular thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Follicular thyroid carcinoma;
thyroid;39;Medullary thyroid carcinoma;THYROID;EuRR-Bone & EuRRECa;Medullary thyroid carcinoma;
time;12;Time from onset to thymectomy:;Thymoma;EURO-NMD;;
time;12;time_period_onset_diag;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Time period between onset of symptoms and diagnosis;radio
time;12;medics_at_time_diagnosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Medications;radio
time;12;pc_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time at testing;radio
time;12;ps_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
time;12;at_abnormal_pt_time;Diagnosis Aetiology;Rare Liver (Vascular);Abnormal prothrombin time;radio
time;12;dia_lab_prothrombin_time_sec;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
time;12;dia_lab_prothrombin_time_inr;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
time;12;dia_lab_prothrombin_time_quick;Diagnosis Laboratory data;Rare Liver (Vascular);Prothrombin time;numeric
time;12;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
time;12;"f.	Warm ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
time;12;"g.	Cold ischemia time (minutes):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
tipps;1;first_tipps;Follow-up Events;Rare Liver (Vascular);First TIPS;radio
tips;20;sh_ivc_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC Before TIPS;numeric
tips;20;sh_ivc_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Supra hepatic IVC After TIPS;numeric
tips;20;free_hv_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein Before TIPS;numeric
tips;20;free_hv_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Free hepatic vein After TIPS;numeric
tips;20;hv_gradient_before_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient Before TIPS;numeric
tips;20;hv_gradient_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venous pressure gradient After TIPS;numeric
tips;20;portal_pressure_bef_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure Before TIPS;numeric
tips;20;portal_pressure_after_tips;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal pressure After TIPS;numeric
tips;20;abd_interv_tips;Diagnosis Aetiology;Rare Liver (Vascular);TIPS;radio
tips;20;abd_interv_tips_dt;Diagnosis Aetiology;Rare Liver (Vascular);Date of TIPS;date
tips;20;date_of_tips;Follow-up Events;Rare Liver (Vascular);Date of TIPS;date
tips;20;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
tips;20;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
tips;20;date_of_evaluation_tips;Follow-up Events;Rare Liver (Vascular);Date of evaluation;date
tips;20;clinical_dysfunction_tips;Follow-up Events;Rare Liver (Vascular);Clinical dysfunction;radio
tips;20;hemodynamic_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Hemodynamic (but not clinical) dysfunction;radio
tips;20;radiological_dysfunc_tips;Follow-up Events;Rare Liver (Vascular);Radiological dysfunction;radio
tips;20;salvage_procedure_tips;Follow-up Events;Rare Liver (Vascular);Salvage procedure;radio
tips;20;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
tips;20;date_salvage_proc_tips;Follow-up Events;Rare Liver (Vascular);Date of salvage procedure;date
tissue;9;R_AIH_Liver_tissue;(AIH Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
tissue;9;R_PBC_Liver_tissue;(PBC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
tissue;9;R_PSC_Liver_tissue;(PSC Diagnosis) Biobanking;Rare Liver (Auto imune);Liver tissue;radio
tissue;9;R_PSC_Liver_tissue_followup;PSC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
tissue;9;R_AIH_Liver_tissue_followup;AIH Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
tissue;9;R_PBC_Liver_tissue_followup;PBC Follow-up Biobanking;Rare Liver (Auto imune);Liver tissue;radio
tissue;9;sys_con_tissue;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Connective Tissue Disease;radio
tissue;9;TissueType;;ithaca;;categoricalmref
tissue;9;Paraffin tumor tissue;Pathology;PaedCan;;yes/no/unknown
titer;30;Achromatopsia Titer;Diagnosis ;EURO-NMD;;
titer;30;AChR (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
titer;30;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
titer;30;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
titer;30;Titin Titer;Diagnosis ;EURO-NMD;;
titer;30;RYR1 Titer;Diagnosis ;EURO-NMD;;
titer;30;R_AIH_ANA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
titer;30;R_AIH_AMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
titer;30;R_AIH_SMA_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
titer;30;R_AIH_LKM_Titer;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
titer;30;R_PBC_ANA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
titer;30;R_PBC_Titer_SMA;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
titer;30;R_PBC_LKM_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
titer;30;R_PBC_AMA_IFT_titer;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
titer;30;R_PSC_ANA_IFT_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
titer;30;R_PSC_SMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
titer;30;R_PSC_LKM_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
titer;30;R_PSC_AMA_titer;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
titer;30;R_PSC_ANA_IFT_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
titer;30;R_PSC_SMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
titer;30;R_PSC_LKM_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
titer;30;R_PSC_AMA_titer_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
titer;30;R_AIH_ANA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
titer;30;R_AIH_AMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
titer;30;R_AIH_SMA_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
titer;30;R_AIH_LKM_Titer_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer:;numeric
titer;30;R_PBC_ANA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);ANA (IFT) titer 1:;numeric
titer;30;R_PBC_Titer_SMA_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SMA (IFT) titer 1:;numeric
titer;30;R_PBC_LKM_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);LKM (IFT) titer 1:;numeric
titer;30;R_PBC_AMA_IFT_titer_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);AMA (IFT) titer 1:;numeric
titin;2;Titin;Diagnosis ;EURO-NMD;;single
titin;2;Titin Titer;Diagnosis ;EURO-NMD;;
tnm;2;tnm_unk_clin;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
tnm;2;tnm_unk_pat;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
tolerance;1;methionine_tolerance_test;Diagnosis Aetiology;Rare Liver (Vascular);Methionine tolerance test;radio
tongue;1;Tongue atrophy;Diagnosis Muscular;EURO-NMD;Tongue wasting;yesno
topic;1;com_topic;Comments Comments;Rare Liver (Vascular);Topic of Comment;radio
total;19;MG-ADL total score;QoL;EURO-NMD;;int
total;19;Total QMG score if done;QMG;EURO-NMD;;
total;19;R_AIH_Total_bilirubin;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
total;19;R_AIH_Total_bilirubin_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
total;19;R_PBC_Total_bilirubin_mgdL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
total;19;R_PBC_Total_bilirubin_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
total;19;R_PSC_Total_bilirubin_mgdL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dl);numeric
total;19;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
total;19;R_AIH_Total_bilirubin_mgdL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
total;19;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
total;19;R_PSC_Total_bilirubin_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin;numeric
total;19;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
total;19;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
total;19;R_PBC_Total_bilirubin_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (mg/dL);numeric
total;19;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
total;19;b_fibroscan_total_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
total;19;fu_ima_fibro_scan_total_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Total number of measurements;numeric
total;19;cci_total_sc;charlson_index;EURACAN;Charlson comorbidity index (CCI) Total points:;if ([comorbid(1)] =1, 1, '') + if ([comorbid(2)] =1, 1, '') + if ([comorbid(3)] =1, 1, '') + if ([comorbid(4)] =1, 1, '') + if ([comorbid(5)] =1, 1, '') + if ([comorbid(6)] =1, 1, '') + if ([comorbid(7)] =1, 1, '') + if ([comorbid(8)] =1, 1, '') + if ([comorbid(9)] =1, 1, '') + if ([comorbid(10)] =1, 1, '') + if ([comorbid(11)] =1, 2, '') + if ([comorbid(12)] =1, 2, '') + if ([comorbid(13)] =1, 2, '') + if ([comorbid(14)] =1, 2, '') + if ([comorbid(15)] =1, 2, '') + if ([comorbid(16)] =1, 2, '') + if ([comorbid(17)] =1, 3, '') + if ([comorbid(18)] =1, 6, '') + if ([comorbid(19)] =1, 6, '')
total;19;caci_total_sc;charlson_index;EURACAN;Charlson age comorbidity index (CACI) Total points:;if([age]='','',if ([age] =1, 1, 0) + if ([age] =2, 2, 0) + if ([age] =3, 3, 0) + if ([age] =4, 4, 0) + if ([age] =5, 5, 0) + if ([comorbid(1)] =1, 1, 0) + if ([comorbid(2)] =1, 1, 0) + if ([comorbid(3)] =1, 1, 0) + if ([comorbid(4)] =1, 1, 0) + if ([comorbid(5)] =1, 1, 0) + if ([comorbid(6)] =1, 1, 0) + if ([comorbid(7)] =1, 1, 0) + if ([comorbid(8)] =1, 1, 0) + if ([comorbid(9)] =1, 1, 0) + if ([comorbid(10)] =1, 1, 0) + if ([comorbid(11)] =1, 2, 0) + if ([comorbid(12)] =1, 2, 0) + if ([comorbid(13)] =1, 2, 0) + if ([comorbid(14)] =1, 2, 0) + if ([comorbid(15)] =1, 2, 0) + if ([comorbid(16)] =1, 2, 0) + if ([comorbid(17)] =1, 3, 0) + if ([comorbid(18)] =1, 6, 0) + if ([comorbid(19)] =1, 6, 0))
totdose;8;radio_photons_totdose;radiotherapy;EURACAN;Photons total dose;
totdose;8;radio_electrons_totdose;radiotherapy;EURACAN;Electrons total dose;
totdose;8;radio_protons_totdose;radiotherapy;EURACAN;Protons total dose;
totdose;8;radio_carbons_totdose;radiotherapy;EURACAN;Carbons total dose;
totdose;8;radio_brachy_totdose;radiotherapy;EURACAN;Brachytherapy total dose;
totdose;8;radio_radionuc_totdose;radiotherapy;EURACAN;Radionuclide total dose;
totdose;8;radio_boron_totdose;radiotherapy;EURACAN;Boron neutron capture therapy total dose;
totdose;8;radio_others_totdose;radiotherapy;EURACAN;Others total dose;
toxicity;1;If dead for toxicity or other reasons please specify;Follow up (one form for each follow up visit);PaedCan;;String
tprot;1;dia_lab_ascites_tprot;Diagnosis Laboratory data;Rare Liver (Vascular);Total protein;numeric
tracheostomy;1;invasive (tracheostomy);Respiratory Myasthenic crisis;EURO-NMD;;yesno
tract;9;Recurrent acute respiratory tract infection;Diagnosis Respiratory;EURO-NMD;Recurrent respiratory tract infection;yesno
tract;9;Joint contractures;Diagnosis Skeletal;EURO-NMD;;single
tract;9;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
tract;9;Retractation for biobank use;;ithaca;;bool
tract;9;Date of retractation;;ithaca;;date
tract;9;Retractation for reuse;;ithaca;;bool
tract;9;Date of retractation;;ithaca;;date
tract;9;Retractation to be contacted for research;;ithaca;;bool
tract;9;Date of retractation;;ithaca;;date
transcript;1;Transcript;geneticVariant;Genturis;What is the transcript belonging to the cDNA variant? (HGVS nomenclature);string
transfer;1;Transfer from chair to bed;Mobility ;EURO-NMD;;single
transgender,;2;Transgender, male to female;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, male to female;
transgender,;2;Transgender, female to male;SEX DEVELOPMENT;EuRR-Bone & EuRRECa;Transgender, female to male;
transglut;1;transglut_antibodies;Diagnosis Aetiology;Rare Liver (Vascular);anti-transglutaminase antibodies;radio
transient;5;R_AIH_Transient_elastography_FibroScan;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Transient elastography (FibroScan);radio
transient;5;R_PBC_Transient_elastography;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
transient;5;R_PSC_Transient_elastography;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
transient;5;R_PSC_Transient_elastography_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Transient elastography (Fibroscan);radio
transient;5;Transient congenital hypothyroidism;THYROID;EuRR-Bone & EuRRECa;Transient congenital hypothyroidism;
translocation;4;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
translocation;4;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
translocation;4;Overgrowth syndrome with 2q37 translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth syndrome with 2q37 translocation;
translocation;4;Prader-Willi syndrome due to translocation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to translocation;
translocation/inversion;1;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion;
transpantation;1;R_PSC_Date_liver_transpantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
transplant;24;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
transplant;24;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
transplant;24;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
transplant;24;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
transplant;24;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
transplant;24;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
transplant;24;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
transplant;24;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
transplant;24;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
transplant;24;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
transplant;24;eos_liver_transplant;End of study End of study;Rare Liver (Vascular);Was a liver transplantation performed?;radio
transplant;24;eos_liver_transplant_date;End of study End of study;Rare Liver (Vascular);Date of liver transplantation;date
transplant;24;eos_liver_transplant_reason;End of study End of study;Rare Liver (Vascular);Why was no liver transplantation performed?;radio
transplant;24;eos_liver_transplant_other;End of study End of study;Rare Liver (Vascular);Other reason:;string
transplant;24;eos_liver_transplant_death;End of study End of study;Rare Liver (Vascular);Death after liver transplantation?;calculation
transplant;24;eos_liver_transplant_lifespan;End of study End of study;Rare Liver (Vascular);Lifespan after transplantation:;calculation
transplant;24;first_liver_transplant;Follow-up Events;Rare Liver (Vascular);First liver transplantation;radio
transplant;24;date_of_transplantation;Follow-up Events;Rare Liver (Vascular);Date of transplantation;date
transplant;24;"transplantation 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
transplant;24;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
transplant;24;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
transplant;24;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
transplant;24;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
transplant;24;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
transplantation;16;R_AIH_Liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation;radio
transplantation;16;R_AIH_Liver_transplantation_date_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Liver transplantation date;date
transplantation;16;R_AIH_Indication_liver_transplantation_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Indication of liver transplantation;radio
transplantation;16;R_PSC_Liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
transplantation;16;R_PSC_Indication_liver_transplantation_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Indication liver transplantation;radio
transplantation;16;R_AIH_Liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation;radio
transplantation;16;R_AIH_Liver_transplantation_date_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Liver transplantation date;date
transplantation;16;R_AIH_Indication_liver_transplantation_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Indication of liver transplantation;radio
transplantation;16;R_PBC_Liver_transplantation_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Liver transplantation;radio
transplantation;16;R_PBC_Liver_transplantation_date_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date of liver transplantation;date
transplantation;16;date_of_transplantation;Follow-up Events;Rare Liver (Vascular);Date of transplantation;date
transplantation;16;"transplantation 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
transplantation;16;a. Creatinine measurements performed prior to start of dialysis or transplantation: ;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[Radio button, one selection]
transplantation;16;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
transplantation;16;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
transplantation;16;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
transplants;1;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
trauma;2;abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal trauma;radio
trauma;2;date_abdominal_trauma;Diagnosis Aetiology;Rare Liver (Vascular);Date of abdominal trauma;date
treament;1;R_AIH_PBC_specific_treament;AIH Follow-up Treatment;Rare Liver (Auto imune);PBC specific treatment;radio
treat;63;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
treat;63;R_AIH_Treatment_other;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other;textarea
treat;63;R_PBC_Other_treatment;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
treat;63;R_PBC_Treatment_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
treat;63;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
treat;63;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
treat;63;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
treat;63;Current treatment;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
treat;63;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
treat;63;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
treat;63;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
treat;63;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
treat;63;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
treat;63;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
treat;63;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
treat;63;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
treat;63;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
treat;63;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
treat;63;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
treat;63;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
treat;63;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
treat;63;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
treat;63;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
treat;63;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
treat;63;"b. Constipation is treated with: 		";5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
treat;63;end_treatment_chem;chemotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treat;63;end_treat_res_chem;chemotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
treat;63;end_treatment_immuno;immunotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treat;63;end_treat_res_immuno;immunotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
treat;63;end_treatment_tt;target_therapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treat;63;end_treat_res_tt;target_therapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
treat;63;end_treatment_radio;radiotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treat;63;end_treat_res_radio;radiotherapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
treat;63;other_treatment;other_type_of_treatment;EURACAN;Other treatment performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
treat;63;other_treatment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of other treatment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{other_treatment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{other_treatment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{other_treatment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
treat;63;other_treatment_date;other_type_of_treatment;EURACAN;Date;
treat;63;other_treatment_date_mm;other_type_of_treatment;EURACAN;Month of other treatment;
treat;63;other_treatment_date_yyyy;other_type_of_treatment;EURACAN;Year of other treatment;
treat;63;other_treatment_type;other_type_of_treatment;EURACAN;Type;1, Local | 2, Systemic | 9, Unknown
treat;63;end_treatment_other;other_type_of_treatment;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treat;63;end_treat_res_other;other_type_of_treatment;EURACAN;Treatment response (based on imaging no defined criteria);1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
treat;63;end_treat_res_def_other;other_type_of_treatment;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
treat;63;end_treatment_note;imaging_available;EURACAN;Imaging after treatment available at the hospital?;
treat;63;end_treatment_us;imaging_available;EURACAN;US;1, Baseline | 2, After treatment
treat;63;end_treatment_ct;imaging_available;EURACAN;CT;1, Baseline | 2, After treatment
treat;63;end_treatment_mri;imaging_available;EURACAN;MRI;1, Baseline | 2, After treatment
treat;63;end_treatment_pet;imaging_available;EURACAN;PET;1, Baseline | 2, After treatment
treat;63;end_treatment_optical;imaging_available;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Baseline | 2, After treatment
treat;63;end_treatment_ctpet;imaging_available;EURACAN;CT/PET;1, Baseline | 2, After treatment
treat;63;overall_treat_res;overall_treatment_response;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
treat;63;overall_treat_res_def;overall_treatment_response;EURACAN;Treatment response defined/done:;1, At the hospital | 2, At a different hospital
treat;63;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
treat;63;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
treat;63;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
treat;63;Treatment line;Therapy;PaedCan;Please specifiy if this treatment has been given as first line treatment or after relapse or progression;1st line/2nd line/3rd line
treat;63;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
treat;63;Type of treatment;Other treatments;PaedCan;Immunotherapy, target agents, metabolic therapy, other/unknown;Drop down menu
treat;63;Please describe the treatment delivered;Other treatments;PaedCan;;String
treat;63;End of treatment date;End of treatment;PaedCan;Date of the last chemotherapy cycle or the last surgical procedure or the last day of radiotherapy or the last day of any other treatment whichever come last.;dd/mm/yyyy
treat;63;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
treat;63;Treatment of the event;Events;PaedCan;Event treated or not;yes,with curative intent/yes,with palliative intent/no/unknown
treat;63;Type of treatment of the event;Events;PaedCan;;surgery/chemotherapy/radiotherapy/other treatment/unknown
treat;63;Please give more details about the treatment of the event;Events;PaedCan;;String
treated;2;a. Present or being treated at time of survey:;5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
treated;2;"b. Constipation is treated with: 		";5. Constipation (independent of age): ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
treatment;53;Pyridostigmine treatment response;Diagnosis ;EURO-NMD;;single
treatment;53;R_AIH_Treatment_other;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Other;textarea
treatment;53;R_PBC_Other_treatment;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
treatment;53;R_PBC_Treatment_other;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
treatment;53;R_PSC_Other_treatment;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other treatment;radio
treatment;53;R_PSC_Treatment_other;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Other:;textarea
treatment;53;R_AIH_Change_of_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Change of treatment regimen (other than dose change);radio
treatment;53;Current treatment;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
treatment;53;R_AIH_No_standard_treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other immunosuppression;radio
treatment;53;R_AIH_Treatment_other_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Other;textarea
treatment;53;R_AIH_PSC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PSC specific treatment;radio
treatment;53;R_AIH_PBC_Treatment_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);PBC specific treatment;radio
treatment;53;R_PSC_Other_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
treatment;53;R_PSC_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
treatment;53;R_PSC_AIH_specific_treatment_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
treatment;53;R_PSC_AIH_Treatment_other_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
treatment;53;R_AIH_No_standard_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other immunosuppression;radio
treatment;53;R_AIH_Treatment_other_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
treatment;53;R_AIH_PSC_specific_treatment_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);PSC specific treatment;radio
treatment;53;R_PBC_Other_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other treatment;radio
treatment;53;R_PBC_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other:;textarea
treatment;53;R_PBC_AIH_specific_treatment_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);AIH specific treatment;radio
treatment;53;R_PBC_AIH_Treatment_other_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Other;textarea
treatment;53;end_treatment_chem;chemotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treatment;53;end_treatment_immuno;immunotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treatment;53;end_treatment_tt;target_therapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treatment;53;end_treatment_radio;radiotherapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treatment;53;other_treatment;other_type_of_treatment;EURACAN;Other treatment performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
treatment;53;other_treatment_date_emb;other_type_of_treatment;EURACAN;"<div class=""rich-text-field-label""><p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: auto; height: 21px; vertical-align: top;""><strong>Date of other treatment</strong></td> <td style=""width: 100px; vertical-align: top; text-align: left;"">{other_treatment_date}<br /> <div style=""text-align: center; font-size: 10px;"">(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=""margin-bottom: .0001pt; line-height: normal;"">Â </p> <p style=""margin-bottom: .0001pt; line-height: normal;""><strong>Â  If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=""border-collapse: collapse; width: 100%; height: 21px;"" border=""0""> <tbody> <tr style=""height: 21px;""> <td style=""width: 200px; height: 21px; vertical-align: top;"">month</td> <td style=""width: 150px; vertical-align: top; text-align: left;"">{other_treatment_date_mm}<br /> <div style=""text-align: center; font-size: 10px;"">(MM Format)</div> </td> <td style=""width: 200px; height: 21px; vertical-align: top; text-align: right;"">year</td> <td style=""width: 150px; text-align: left; vertical-align: top;"">{other_treatment_date_yyyy}<br /> <div style=""text-align: center; font-size: 10px;"">(YYYY Format)</div> </td> </tr> </tbody> </table> <p>Â </p></div>";
treatment;53;other_treatment_date;other_type_of_treatment;EURACAN;Date;
treatment;53;other_treatment_date_mm;other_type_of_treatment;EURACAN;Month of other treatment;
treatment;53;other_treatment_date_yyyy;other_type_of_treatment;EURACAN;Year of other treatment;
treatment;53;other_treatment_type;other_type_of_treatment;EURACAN;Type;1, Local | 2, Systemic | 9, Unknown
treatment;53;end_treatment_other;other_type_of_treatment;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
treatment;53;end_treatment_note;imaging_available;EURACAN;Imaging after treatment available at the hospital?;
treatment;53;end_treatment_us;imaging_available;EURACAN;US;1, Baseline | 2, After treatment
treatment;53;end_treatment_ct;imaging_available;EURACAN;CT;1, Baseline | 2, After treatment
treatment;53;end_treatment_mri;imaging_available;EURACAN;MRI;1, Baseline | 2, After treatment
treatment;53;end_treatment_pet;imaging_available;EURACAN;PET;1, Baseline | 2, After treatment
treatment;53;end_treatment_optical;imaging_available;EURACAN;Optical digital methods (e.g. narrow-band imaging);1, Baseline | 2, After treatment
treatment;53;end_treatment_ctpet;imaging_available;EURACAN;CT/PET;1, Baseline | 2, After treatment
treatment;53;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
treatment;53;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
treatment;53;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
treatment;53;Treatment line;Therapy;PaedCan;Please specifiy if this treatment has been given as first line treatment or after relapse or progression;1st line/2nd line/3rd line
treatment;53;Other treatment delivered;Other treatments;PaedCan;;yes/no/unknown
treatment;53;Type of treatment;Other treatments;PaedCan;Immunotherapy, target agents, metabolic therapy, other/unknown;Drop down menu
treatment;53;Please describe the treatment delivered;Other treatments;PaedCan;;String
treatment;53;End of treatment date;End of treatment;PaedCan;Date of the last chemotherapy cycle or the last surgical procedure or the last day of radiotherapy or the last day of any other treatment whichever come last.;dd/mm/yyyy
treatment;53;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
treatment;53;Treatment of the event;Events;PaedCan;Event treated or not;yes,with curative intent/yes,with palliative intent/no/unknown
treatment;53;Type of treatment of the event;Events;PaedCan;;surgery/chemotherapy/radiotherapy/other treatment/unknown
treatment;53;Please give more details about the treatment of the event;Events;PaedCan;;String
trial;5;clinical_trial;patient_included_in_clinical_trial;EURACAN;Patient included in a clinical trial;1, Yes | 2, No | 9, Unknown
trial;5;clinical_trial_enrol_data;patient_included_in_clinical_trial;EURACAN;Date of enrolment;DD-MM-YYY Format
trial;5;oth_clinical_trial;other_type_of_treatment;EURACAN;Patient included in a clinical trial;1, Yes | 2, No
trial;5;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
trial;5;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
trial/protocol;1;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
triple;1;Triple A syndrome;ADRENAL;EuRR-Bone & EuRRECa;Triple A syndrome;
tsh;3;TSH status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum TSH for local reference range;N/Low/High/Not Known
tsh;3;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
tsh;3;Familial hyperthyroidism due to mutations in TSH receptor;THYROID;EuRR-Bone & EuRRECa;Familial hyperthyroidism due to mutations in TSH receptor;
tsh-secreting;1;TSH-secreting pituitary adenoma;PITUITARY;EuRR-Bone & EuRRECa;TSH-secreting pituitary adenoma;
tt;44;Right arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
tt;44;Left arm outstretched (90Â° sitting) Sec.;QMG;EURO-NMD;;
tt;44;R_PBC_School_attendance;(PBC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance per year;radio
tt;44;R_PBC_IFT_pattern;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
tt;44;R_PSC_School_attendance;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
tt;44;R_PSC_School_attendance_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
tt;44;R_AIH_school_attendance_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);More than 75% school attendance over the year?;radio
tt;44;R_PBC_IFT_pattern_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);IFT pattern (nuclear rim or nuclear dots);checkbox
tt;44;R_PBC_School_attendance_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);More than 75% school attendance per year;radio
tt;44;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
tt;44;chemo_setting;chemotherapy;EURACAN;Setting;1, Neo-adjuvant | 2, Concomitant | 3, Adjuvant | 4, Palliative | 9, Unknown
tt;44;immuno_setting;immunotherapy;EURACAN;Setting;1, neo-adjuvant | 2, concomitant | 3, adjuvant | 4, palliative | 9, unknown
tt;44;tt;target_therapy;EURACAN;Target therapy performed?;1, Yes done at the hospital | 2, Yes done at a different hospital | 3, Not Done | 9, Unknown
tt;44;tt_setting;target_therapy;EURACAN;Setting;1, neo-adjuvant | 2, concomitant | 3, adjuvant | 4, palliative | 9, unknown
tt;44;tt_date_from;target_therapy;EURACAN;Start date;
tt;44;tt_date_from_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_date_to;target_therapy;EURACAN;End date;
tt;44;tt_date_to_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_cycle;target_therapy;EURACAN;Number of cycles;
tt;44;tt_cycle_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_drug_1;target_therapy;EURACAN;Drug 1;BIOPORTAL:ATC
tt;44;tt_drug_1_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_drug_2;target_therapy;EURACAN;Drug 2;BIOPORTAL:ATC
tt;44;tt_drug_2_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_drug_3;target_therapy;EURACAN;Drug 3;BIOPORTAL:ATC
tt;44;tt_drug_3_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_drug_4;target_therapy;EURACAN;Drug 4;BIOPORTAL:ATC
tt;44;tt_drug_4_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;tt_drug_5;target_therapy;EURACAN;Drug 5;BIOPORTAL:ATC
tt;44;tt_drug_5_unk;target_therapy;EURACAN;Unknown;1, Unknown
tt;44;end_treatment_tt;target_therapy;EURACAN;Reason for end of treatment;1, completion | 2, toxicity | 3, patient intolerance | 4, death | 5, other | 9, unknown
tt;44;end_treat_res_tt;target_therapy;EURACAN;Treatment response;1, complete response | 2, partial response | 3, stable disease | 4, progression | 9, unknown
tt;44;setting;radiotherapy;EURACAN;Setting;1, Preoperative | 2, Postoperative | 3, Definitive | 4, Unknown
tt;44;radio_photons_ott;radiotherapy;EURACAN;Photons OTT;"datediff([radio_photons_to],[radio_photons_from],""d"")"
tt;44;radio_electrons_ott;radiotherapy;EURACAN;Electrons OTT;"datediff([radio_electrons_to],[radio_electrons_from],""d"")"
tt;44;radio_protons_ott;radiotherapy;EURACAN;Protons OTT;"datediff([radio_protons_to],[radio_protons_from],""d"")"
tt;44;radio_carbons_ott;radiotherapy;EURACAN;Carbons OTT;"datediff([radio_carbons_to],[radio_carbons_from],""d"")"
tt;44;radio_brachy_ott;radiotherapy;EURACAN;Brachytherapy OTT;"datediff([radio_brachy_to],[radio_brachy_from],""d"")"
tt;44;radio_radionuc_ott;radiotherapy;EURACAN;Radionuclide OTT;"datediff([radio_radionuc_to],[radio_radionuc_from],""d"")"
tt;44;radio_boron_ott;radiotherapy;EURACAN;Boron neutron capture therapy OTT;"datediff([radio_boron_to],[radio_boron_from],""d"")"
tt;44;radio_others_ott;radiotherapy;EURACAN;Others OTT;"datediff([radio_others_to],[radio_others_from],""d"")"
tt;44;Educational attainment;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;International Standard Classification of Education (ISCED) 2011;Not Known/0/1/2/3/4/5/6/7/8
tt;44;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome;
tt;44;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
tube;6;Gastrostomy tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
tube;6;Gastrostomy tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
tube;6;Gastrostomy tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
tube;6;Nasogastric tube feeding;Bulbar/Gi ;EURO-NMD;;yesno
tube;6;Nasogastric tube feedingÂ­ date started;Bulbar/Gi ;EURO-NMD;;date
tube;6;Nasogastric tube feedingÂ­ date stopped;Bulbar/Gi ;EURO-NMD;;date
tuc;1;TUC Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
tumor;9;Paraffin tumor tissue;Pathology;PaedCan;;yes/no/unknown
tumor;9;Frozen tumor ;Pathology;PaedCan;;yes/no/unknown
tumor;9;Tumor size;Tumor's characteristics;PaedCan;Maximum diameter of the tumor;a/b/x
tumor;9;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
tumor;9;Tumor resection at diagnosis;Surgery;PaedCan;Result of resection (before any medical treatment, including primary re-excision) if perfomed ;not perfomed/ complete tumor resection/microscopic residuals/macroscopic residuals/unknown
tumor;9;Date of tumor resection;Surgery;PaedCan;Date of resection ;dd/mm/yyyy
tumor;9;Surgical complications of tumor resection;Surgery;PaedCan;Presence or absence of any surgical complication ;yes/no/unknown
tumor;9;Cumulative dose to primary tumor;Radiotherapy;PaedCan;Report the total dose of radiotherapy  in Gy (including any boost);String (numbers rounded to one decimal)
tumor;9;In case of a second tumor please specify the type;Events;PaedCan;;String
tumour;8;MMR tumour diagnostics;malignancy;Genturis;Has IHC of the MMR protein or microsatellite instability analyses been performed?;enum
tumour;8;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
tumour;8;Tumour Types(Somatic);;ithaca;;string
tumour;8;Tumour Types(Germline);;ithaca;;string
tumour;8;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
tumour;8;Hyperparathyroidism-jaw tumour syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hyperparathyroidism-jaw tumour syndrome;
tumour;8;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
tumour;8;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome;
tumoural;1;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome;
txt;1;com_txt;Comments Comments;Rare Liver (Vascular);Comment;textarea
typ;114;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
typ;114;R_AIH_Type_of_IBD;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Type of IBD;radio
typ;114;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
typ;114;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
typ;114;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
typ;114;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
typ;114;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
typ;114;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
typ;114;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
typ;114;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
typ;114;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
typ;114;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
typ;114;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
typ;114;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
typ;114;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
typ;114;pv_occlusion_type;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion type;radio
typ;114;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
typ;114;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
typ;114;pc_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
typ;114;ps_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
typ;114;type_of_mpd;Diagnosis Aetiology;Rare Liver (Vascular);Type of MPD;radio
typ;114;telomeropathy_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of telomeropathy;string
typ;114;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
typ;114;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
typ;114;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
typ;114;abd_inflammation_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of abdominal infection/inflamation;textarea
typ;114;extra_abd_inflam_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
typ;114;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
typ;114;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
typ;114;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
typ;114;med_typ;Medications Medication;Rare Liver (Vascular);Type of medication;radio
typ;114;med_typ_oth;Medications Medication;Rare Liver (Vascular);Other, please specify type of medication;string
typ;114;a. Type of malformation:;1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
typ;114;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
typ;114;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
typ;114;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
typ;114;Benign type;benignNeoplasm;Genturis;Where is the benign neoplasm located?;xref
typ;114;Variant type;geneticVariant;Genturis;What is the type of mutation?;xref
typ;114;Malignancy type;malignancy;Genturis;Where is the malignancy located?;xref
typ;114;Phenotypical Characteristics;subject;Genturis;;compound
typ;114;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
typ;114;Phenotypes;subject;Genturis;Multiple phenotypes can be entered;mref
typ;114;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
typ;114;Tumour Types(Somatic);;ithaca;;string
typ;114;Tumour Types(Germline);;ithaca;;string
typ;114;TissueType;;ithaca;;categoricalmref
typ;114;Full caryotype (if not inferred from CNV report);;ithaca;;string
typ;114;Locus Type (categorical);;ithaca;Hugo.owl.Locus_Type;categorical
typ;114;OMIM type (category);;ithaca;;categorical
typ;114;Semantic type UMLS property (URL);;ithaca;;hyperlink
typ;114;Phenotypic Abnormality (HPO);;ithaca;;mref
typ;114;Type of mutation;;ithaca;;mref
typ;114;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
typ;114;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
typ;114;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
typ;114;hpv_status_type;primary_cancer;EURACAN;HPV status detected by;1, FISH | 2, PCR | 9, Unknown
typ;114;surgery_type;surgery;EURACAN;Tumor site, type of  surgery;1, External | 2, Endoscopic | 3, Robotic | 9, Unknown
typ;114;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
typ;114;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
typ;114;other_treatment_type;other_type_of_treatment;EURACAN;Type;1, Local | 2, Systemic | 9, Unknown
typ;114;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
typ;114;Type of treatment;Other treatments;PaedCan;Immunotherapy, target agents, metabolic therapy, other/unknown;Drop down menu
typ;114;Type of event;Events;PaedCan;Definition of the type of event that has occured;local relapse/local relapse combined with regional nodal relapse/local relapse combined with metastatic relapse/regional nodal relapse/nodal relapse combined with metastatic relapse/metastatic relapse/progressive disease/second tumor/death for toxicity/death for other causes
typ;114;In case of a second tumor please specify the type;Events;PaedCan;;String
typ;114;Type of treatment of the event;Events;PaedCan;;surgery/chemotherapy/radiotherapy/other treatment/unknown
typ;114;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
typ;114;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
typ;114;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
typ;114;Familial hyperaldosteronism type I;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type I;
typ;114;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
typ;114;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
typ;114;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
typ;114;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
typ;114;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
typ;114;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
typ;114;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
typ;114;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
typ;114;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
typ;114;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
typ;114;Diabetes mellitus type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 1;
typ;114;Diabetes mellitus type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 2;
typ;114;Familial partial lipodystrophy Type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 1;
typ;114;Familial partial lipodystrophy Type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 2;
typ;114;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
typ;114;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
typ;114;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
typ;114;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
typ;114;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
typ;114;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
typ;114;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
typ;114;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
typ;114;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
typ;114;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
typ;114;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
typ;114;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
typ;114;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
typ;114;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
typ;114;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
typ;114;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
typ;114;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
typ;114;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
typ;114;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
typ;114;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
typ;114;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
typ;114;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
typ;114;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
typ;114;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
typ;114;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
typ;114;Mesomelic dysplasia, Savarirayan type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Savarirayan type ;
typ;114;OI type 1;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 1;
typ;114;OI type 2;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 2;
typ;114;OI type 3;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 3;
typ;114;OI type 4;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 4;
typ;114;OI type 5;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 5;
type;109;R_AIH_FDR_type_autoimmune_liver_disease;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease?;checkbox
type;109;R_AIH_Type_of_IBD;(AIH Diagnosis) Liver histology / Staging;Rare Liver (Auto imune);Type of IBD;radio
type;109;R_PBC_FDR_type_autoimmune_liver_disease;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
type;109;R_PSC_Type_bile_duct_affection;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of bile duct affection;radio
type;109;R_PSC_FDR_type_liver_disease;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Type of autoimmune liver disease;checkbox
type;109;R_PSC_Hepatobiliary_malignancy_type;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
type;109;R_AIH_type_hepatobiliary_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
type;109;R_AIH_Type_other_malignancy_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Type of other malignancy;string
type;109;R_PSC_Hepatobiliary_malignancy_type_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
type;109;R_PSC_Type_of_other_malignancy_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
type;109;R_AIH_Type_hepatobiliary_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of hepatobiliary malignancy;checkbox
type;109;R_AIH_Type_of_other_malignancy_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Type of other malignancy;string
type;109;R_PBC_Hepatobiliary_malignancy_type_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Hepatobiliary malignancy type;checkbox
type;109;R_PBC_Type_other_malignancy_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Type of other malignancy;string
type;109;budd_chiari_type_nodules;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Budd-Chiari type nodules or HNF like;radio
type;109;pv_occlusion_type;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion type;radio
type;109;liver_biopsy_type;Diagnosis Biobank;Rare Liver (Vascular);Liver biopsy type;dropdown
type;109;factor_v_leiden_mutation_type;Diagnosis Aetiology;Rare Liver (Vascular);Mutation type;radio
type;109;pc_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
type;109;ps_anticoag_type;Diagnosis Aetiology;Rare Liver (Vascular);type of anticoagulation;string
type;109;type_of_mpd;Diagnosis Aetiology;Rare Liver (Vascular);Type of MPD;radio
type;109;telomeropathy_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of telomeropathy;string
type;109;contrac_pri_diagn_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of Used Hormonal Contraception prior to diagnosis;radio
type;109;contraceptive_type;Diagnosis Aetiology;Rare Liver (Vascular);Type at onset of manifestations;radio
type;109;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
type;109;abd_inflammation_type;Diagnosis Aetiology;Rare Liver (Vascular);Type of abdominal infection/inflamation;textarea
type;109;extra_abd_inflam_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
type;109;fu_proc_type_tips;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
type;109;fu_proc_type_angio;Follow-up Events;Rare Liver (Vascular);Type of procedure;string
type;109;salvage_proc_shunt_type;Follow-up Events;Rare Liver (Vascular);Type of procedure;radio
type;109;a. Type of malformation:;1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
type;109;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
type;109;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
type;109;"b.	Type of most recent transplantation: 		";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Radio button, one selection]
type;109;Benign type;benignNeoplasm;Genturis;Where is the benign neoplasm located?;xref
type;109;Variant type;geneticVariant;Genturis;What is the type of mutation?;xref
type;109;Malignancy type;malignancy;Genturis;Where is the malignancy located?;xref
type;109;Phenotypes;subject;Genturis;Multiple phenotypes can be entered;mref
type;109;Genetic test type;subject;Genturis;What kind of genetic testing has been performed?;categoricalmref
type;109;Tumour Types(Somatic);;ithaca;;string
type;109;Tumour Types(Germline);;ithaca;;string
type;109;TissueType;;ithaca;;categoricalmref
type;109;Full caryotype (if not inferred from CNV report);;ithaca;;string
type;109;Locus Type (categorical);;ithaca;Hugo.owl.Locus_Type;categorical
type;109;OMIM type (category);;ithaca;;categorical
type;109;Semantic type UMLS property (URL);;ithaca;;hyperlink
type;109;Type of mutation;;ithaca;;mref
type;109;prev_anti_neoplastic_type;previous_cancer_genetic_syndromes;EURACAN;Previous anti neoplastic agents type;1, Target | 2, Immunotherapy
type;109;primer_type_baseline;primary_cancer;EURACAN;Primer type;1, BamH1 | 2, Other | 9, Unknown
type;109;primer_type_baseline_oth;primary_cancer;EURACAN;Please specify;
type;109;hpv_status_type;primary_cancer;EURACAN;HPV status detected by;1, FISH | 2, PCR | 9, Unknown
type;109;surgery_type;surgery;EURACAN;Tumor site, type of  surgery;1, External | 2, Endoscopic | 3, Robotic | 9, Unknown
type;109;primer_type_chemo;chemotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
type;109;primer_type_radio;radiotherapy;EURACAN;Primer type;1, BamH1 | 2, Other
type;109;other_treatment_type;other_type_of_treatment;EURACAN;Type;1, Local | 2, Systemic | 9, Unknown
type;109;Type of radiotherapy;Radiotherapy;PaedCan;Definition fo the type of radiotherapy administered;IMRTl (Intensity-modulated radiation therapy)/brachitherapy/proton therapy/other/unknown
type;109;Type of treatment;Other treatments;PaedCan;Immunotherapy, target agents, metabolic therapy, other/unknown;Drop down menu
type;109;Type of event;Events;PaedCan;Definition of the type of event that has occured;local relapse/local relapse combined with regional nodal relapse/local relapse combined with metastatic relapse/regional nodal relapse/nodal relapse combined with metastatic relapse/metastatic relapse/progressive disease/second tumor/death for toxicity/death for other causes
type;109;In case of a second tumor please specify the type;Events;PaedCan;;String
type;109;Type of treatment of the event;Events;PaedCan;;surgery/chemotherapy/radiotherapy/other treatment/unknown
type;109;Autoimmune polyendocrinopathy type 1;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
type;109;Autoimmune polyendocrinopathy type 2;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 2;
type;109;Autoimmune polyendocrinopathy type 4;ADRENAL;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 4;
type;109;Familial hyperaldosteronism type I;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type I;
type;109;Familial hyperaldosteronism type II;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type II;
type;109;Familial hyperaldosteronism type III;ADRENAL;EuRR-Bone & EuRRECa;Familial hyperaldosteronism type III;
type;109;Autoimmune polyendocrinopathy type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Autoimmune polyendocrinopathy type 1;
type;109;Pseudohypoparathyroidism type 1A;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
type;109;Pseudohypoparathyroidism type 1B;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1B;
type;109;Pseudohypoparathyroidism type 1C;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1C;
type;109;Pseudohypoparathyroidism type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 2;
type;109;Familial hypocalciuric hypercalcaemia type 1;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 1;
type;109;Familial hypocalciuric hypercalcaemia type 2;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 2;
type;109;Familial hypocalciuric hypercalcaemia type 3;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Familial hypocalciuric hypercalcaemia type 3;
type;109;Diabetes mellitus type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 1;
type;109;Diabetes mellitus type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 2;
type;109;Familial partial lipodystrophy Type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 1;
type;109;Familial partial lipodystrophy Type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Familial partial lipodystrophy Type 2;
type;109;Insulin-resistance syndrome type A;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type A;
type;109;Insulin-resistance syndrome type B;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Insulin-resistance syndrome type B;
type;109;Multiple endocrine neoplasia type 1;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 1;
type;109;Multiple endocrine neoplasia type 2;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2;
type;109;Multiple endocrine neoplasia type 2A;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2A;
type;109;Multiple endocrine neoplasia type 2B;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 2B;
type;109;Multiple endocrine neoplasia type 4;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Multiple endocrine neoplasia type 4;
type;109;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
type;109;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
type;109;Short rib-polydactyly syndrome, Saldino-Noonan type;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Short rib-polydactyly syndrome, Saldino-Noonan type;
type;109;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1;
type;109;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2;
type;109;Pseudohypoparathyroidism type 1A;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1A;
type;109;Pseudohypoparathyroidism type 1CÂ ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism type 1CÂ ;
type;109;Microcephalic osteodysplastic primordial dwarfism type II;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Microcephalic osteodysplastic primordial dwarfism type II;
type;109;Metaphyseal chondrodysplasia, Schmid type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Schmid type ;
type;109;Metaphyseal chondrodysplasia, Spahr type;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Spahr type;
type;109;Metaphyseal chondrodysplasia, Jansen type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Jansen type ;
type;109;Metaphyseal chondrodysplasia, Kaitila type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Metaphyseal chondrodysplasia, Kaitila type ;
type;109;Mesomelic dysplasia, Kantaputra type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Kantaputra type ;
type;109;Mesomelic dwarfism, Nievergelt type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Nievergelt type ;
type;109;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dwarfism, Reinhardt-Pfeiffer type ;
type;109;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
type;109;Rhizomelic dysplasia, Patterson-Lowry type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic dysplasia, Patterson-Lowry type ;
type;109;Atelosteogenesis type II ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Atelosteogenesis type II ;
type;109;Mesomelic dysplasia, Savarirayan type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Mesomelic dysplasia, Savarirayan type ;
type;109;OI type 1;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 1;
type;109;OI type 2;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 2;
type;109;OI type 3;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 3;
type;109;OI type 4;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 4;
type;109;OI type 5;BONE DYSPLASIA;EuRR-Bone & EuRRECa;OI type 5;
ucp2;1;Hyperinsulinism due to UCP2 deficiency;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Hyperinsulinism due to UCP2 deficiency;
udca;13;R_AIH_UDCA;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);UDCA;radio
udca;13;R_PBC_UDCA;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA;radio
udca;13;R_PBC_UDCA_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
udca;13;R_PBC_UDCA_dose_per_kg;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose mg / kg;calculation
udca;13;R_PSC_UDCA;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA;radio
udca;13;R_PSC_UDCA_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);UDCA dose;numeric
udca;13;R_AIH_UDCA_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA;radio
udca;13;R_AIH_UDCA_dose;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);UDCA dose;numeric
udca;13;R_PSC_UDCA_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
udca;13;R_PSC_UDCA_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
udca;13;R_AIH_UDCA_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
udca;13;R_PBC_UDCA_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA;radio
udca;13;R_PBC_UDCA_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);UDCA dose;numeric
ulc;1;rec_gen_ulc;Diagnosis Aetiology;Rare Liver (Vascular);Recurrent genital ulceration;radio
ulna;1;Ulna metaphyseal dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Ulna metaphyseal dysplasia syndrome ;
ultrasound;8;R_PSC_Ultrasound_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);Ultrasound;radio
ultrasound;8;ultrasound;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Ultrasound;radio
ultrasound;8;"a. Ultrasound kidney performed:	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
ultrasound;8;"b. Age first ultrasound kidney performed (in days):	";3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
ultrasound;8;"a. Ultrasound spine performed in the first 3 months of life:	";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
ultrasound;8;b. Age first ultrasound spine performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
ultrasound;8;Fetal ultrasound ;Imaging;ERKNet;Â ;Â 
ultrasound;8;(postnatal) ultrasound ;Imaging;ERKNet;Â ;Â 
umoll;14;R_AIH_Total_bilirubin_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
umoll;14;R_AIH_Creatinine_umolL;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
umoll;14;R_PBC_Total_bilirubin_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
umoll;14;R_PBC_Creatinine_umolL;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
umoll;14;R_PSC_Total_bilirubin_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
umoll;14;R_PSC_Creatinine_umolL;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);Creatinine;numeric
umoll;14;R_AIH_Total_bilirubin_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
umoll;14;R_AIH_Creatinine_umolL_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);Creatinine (Ã‚Âµmol/L);numeric
umoll;14;R_PSC_Total_bilirubin_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
umoll;14;R_PSC_Creatinine_umolL_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
umoll;14;R_AIH_Total_bilirubin2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (Ã‚Âµmol/L);numeric
umoll;14;R_AIH_Creatinine2_umolL_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);Creatinine  (Ã‚Âµmol/L);numeric
umoll;14;R_PBC_Total_bilirubin_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Total bilirubin (umol/L);numeric
umoll;14;R_PBC_Creatinine_umolL_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);Creatinine;numeric
underlying;1;a.Type of disease underlying kidney failure:;" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
undermodeling-spondylar;1;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome;
uniparental;6;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
uniparental;6;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
uniparental;6;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11;
uniparental;6;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
uniparental;6;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15;
uniparental;6;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Temple syndrome due to maternal uniparental disomy of chromosome 14Â ;
unique;2;PARTNER unique identifier;Identifiers;PaedCan;Patient's EUPID Pseudonym;String
unique;2;Registry unique identifier;Identifiers;EuRR-Bone & EuRRECa;Patient's ID;String
unit;12;R_PBC_SLA_LP_units;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
unit;12;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
unit;12;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
unit;12;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
unit;12;dia_lab_serum_bilirubin_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Bilirubin Unit;radio
unit;12;dia_lab_serum_creatinine_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Serum Creatinine Unit;radio
unit;12;dia_lab_fasting_glucose_unit;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting Serum Glucose Unit;radio
unit;12;fu_cli_bef_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
unit;12;fu_cli_bef_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
unit;12;fu_cli_last_bilirubin_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin unit;radio
unit;12;fu_cli_last_creat_unit;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine unit;radio
unit;12;med_unit;Medications Medication;Rare Liver (Vascular);Unit;radio
units;4;R_PBC_SLA_LP_units;(PBC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
units;4;R_PSC_SLA_LP_units;(PSC Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
units;4;R_PSC_SLA_LP_units_followup;PSC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (units);numeric
units;4;R_PBC_SLA_LP_units_followup;PBC Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP;numeric
unk;32;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
unk;32;unknown_pet;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
unk;32;unknown_meta;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
unk;32;tnm_unk_clin;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
unk;32;tnm_unk_pat;stage_procedures;EURACAN;If the information on cT,N,M is not available, please include directly the clinical staging here;0, 0 | 1, I | 2, II | 3, III | 4, IV | 5, IVA | 6, IVB | 7, IVC
unk;32;surgery_nr_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
unk;32;surgery_nr_pos_lymph_unk;surgery;EURACAN;Unknown;1, Unknown
unk;32;chemo_date_from_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_date_to_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_cycle_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_drug_1_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_drug_2_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_drug_3_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_drug_4_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;chemo_drug_5_unk;chemotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_date_from_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_date_to_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_admin_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_drug_1_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_drug_2_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_drug_3_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_drug_4_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;immuno_drug_5_unk;immunotherapy;EURACAN;Unknown;1, Unknown
unk;32;tt_date_from_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_date_to_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_cycle_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_drug_1_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_drug_2_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_drug_3_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_drug_4_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;tt_drug_5_unk;target_therapy;EURACAN;Unknown;1, Unknown
unk;32;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
unknown;4;unknown_primary;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
unknown;4;unknown_pet;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
unknown;4;unknown_meta;stage_procedures;EURACAN;Unknown;1, Yes | 2, No | 9, Unknown
unknown;4;Neonatal diabetes of unknown etiology;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Neonatal diabetes of unknown etiology;
unplanned;3;Unplanned hospitalization in the last 12 month;Hospitalization ;EURO-NMD;;yesno
unplanned;3;Unplanned hospitalization in the last 12 month (number);Hospitalization ;EURO-NMD;;int
unplanned;3;Unplanned hospitalization in the last 12 month (duration);Hospitalization ;EURO-NMD;;int
upload;2;UPLOAD OF PATHOLOGY REPORT (anonymized);Pathology;PaedCan;;
upload;2;UPLOAD OF RADIOLOGY REPORT (anonymized);Tumor's characteristics;PaedCan;;
upper;2;upper_endoscopy;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Upper endoscopy;radio
upper;2;Upper limb mesomelic dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Upper limb mesomelic dysplasia ;
upstream;1;hv_upstream;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic vein upstream from a short-length stenosis;numeric
upward;1;Ptosis (upward gaze) Sec.;QMG;EURO-NMD;;
urbach;1;Rhizomelic syndrome, Urbach type ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Rhizomelic syndrome, Urbach type ;
urban-rogers-meyer;2;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
urban-rogers-meyer;2;Urban-Rogers-Meyer syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Urban-Rogers-Meyer syndrome;
ureteral;2;e. Vesicoureteral reflux:;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
ureteral;2;Ureteral splint Duration of drainage (days);2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
ureterostomies;1;"openÂ ureterostomies 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
urethral;1;"b. Type of urethral or bladderneck fistula:	";1. Type of malformation: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]Â 
urin;55;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
urin;55;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
urin;55;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
urin;55;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
urin;55;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
urin;55;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
urin;55;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
urin;55;R_PSC_Pregnancy_during_last_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pregnancy during last 12 months;radio
urin;55;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
urin;55;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
urin;55;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
urin;55;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
urin;55;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
urin;55;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
urin;55;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
urin;55;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
urin;55;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urin;55;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
urin;55;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
urin;55;urine_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);Urine sample obtained?;dropdown
urin;55;urin_sample_date;Diagnosis Biobank;Rare Liver (Vascular);Urine sample date;date
urin;55;dia_lab_urine_na_24h;Diagnosis Laboratory data;Rare Liver (Vascular);urine sodium value - 24 hour;numeric
urin;55;a. Age during procedure (in days);1st surgical procedure performed to resect the valves: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
urin;55;b. Age during first control cystoscopy (in days):;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;
urin;55;c. Was there a re-excision performedÂ during the first control cystoscopy:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
urin;55;c. Left function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
urin;55;d. Right function during first renography (in %):;3. Renal function renography MAG 3Â / DMSA:Â ;Eurogen (Posterior urethral valves);;[Autocomplete with NumericÂ (Integer)=100-Left]
urin;55;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
urin;55;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
urin;55;"a.	Age during most recent transplantation (in days):	";2.Â Â Â Â Â Â  Transplantation surgery:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
urin;55;"c.	Lowest eGFR during admission after transplantation (in ml/min/1.73m2): ";3.Â Â Â Â Â Â  Graft function, eGFR calculated using Schwartz formula:;Eurogen (Kid Transplantation);;[Numeric (Integer)]
urin;55;"e.	EBV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;"f.	EBV prophylaxis during follow-up";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;"g.	CMV infection during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;"h.	CMV prophylaxis during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;"i.	BKV infection during follow-up:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
urin;55;biom_urine;tumour_material_available;EURACAN;Urine;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
urinary;1;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
urine;36;R_AIH_Mercaptopurine;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_AIH_Mercaptopurine_dose;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_AIH_Mercaptopurine_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
urine;36;R_PBC_AIH_Mercaptopurine;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_PBC_AIH_Mercaptourine_dose;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_PBC_AIH_Mercaptourine_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
urine;36;R_PSC_AIH_Mercaptopurine;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_PSC_AIH_Mercaptopurine_dose;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_PSC_AIH_Mercaptopurine_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
urine;36;R_AIH_Mercaptopurine_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_AIH_Mercaptopurine_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
urine;36;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
urine;36;R_AIH_Mercaptopurine_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_AIH_Mercaptopurine_dose_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_AIH_Mercaptopurine_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
urine;36;R_PSC_AIH_Mercaptopurine_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_PSC_AIH_Mercaptopurine_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
urine;36;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
urine;36;R_PSC_AIH_Mercaptopurine_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_PSC_AIH_Mercaptopurine_dose_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_PSC_AIH_Mercaptopurine_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
urine;36;R_AIH_Mercaptopurine_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_AIH_Mercaptopurine_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
urine;36;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
urine;36;R_AIH_Mercaptopurine_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_AIH_Mercaptopurine_dose_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_AIH_Mercaptopurine_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
urine;36;R_PBC_AIH_Mercaptopurine_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_PBC_AIH_Mercaptopurine_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
urine;36;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
urine;36;R_PBC_AIH_Mercaptopurine_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Mercaptopurine (6-MP);radio
urine;36;R_PBC_AIH_Mercaptopurine_dose_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);6-MP dose;numeric
urine;36;R_PBC_AIH_Mercaptopurine_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
urine;36;urine_sample_obtained;Diagnosis Biobank;Rare Liver (Vascular);Urine sample obtained?;dropdown
urine;36;dia_lab_urine_na_24h;Diagnosis Laboratory data;Rare Liver (Vascular);urine sodium value - 24 hour;numeric
urine;36;biom_urine;tumour_material_available;EURACAN;Urine;0, Before treatments | 1, After surgery | 2, During and/or after chemo therapy | 3, During and/or after immuno therapy | 4, During and/or after target therapy | 5, During and/or after radio therapy | 6, Available but unknown moment
us;190;Weakness of facial musculature;Diagnosis Muscular;EURO-NMD;Facial weakness;yesno
us;190;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
us;190;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
us;190;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
us;190;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
us;190;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
us;190;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
us;190;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
us;190;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
us;190;Neck muscle weakness;Diagnosis Muscular;EURO-NMD;Neck weakness;yesno
us;190;Skeletal muscle atrophy;Diagnosis Muscular;EURO-NMD;Muscle wasting;yesno
us;190;MuSK (standard, RIA);Diagnosis ;EURO-NMD;;single
us;190;MuSK (standard, RIA) Titer;Diagnosis ;EURO-NMD;;
us;190;MuSK (low-affinity, CBA);Diagnosis ;EURO-NMD;;single
us;190;MuSK (low-affinity, CBA) Titer;Diagnosis ;EURO-NMD;;
us;190;Current ambulatory status;Mobility ;EURO-NMD;;single
us;190;Facial Muscles;QMG;EURO-NMD;;
us;190;Thymus histology:;Thymoma;EURO-NMD;;
us;190;Patient_status;Base information;Rare Liver (Auto imune);Patient status;radio
us;190;Cause_of_death;Base information;Rare Liver (Auto imune);Cause of death;radio
us;190;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
us;190;R_AIH_Tacrolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_AIH_Tacrolimus_primary_indication;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_Everolimus;(AIH Diagnosis) Treatment within 12 weeks from diagnosis;Rare Liver (Auto imune);Everolimus;radio
us;190;R_PBC_Pruritus;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Pruritus;radio
us;190;R_PBC_AIH_Tacrolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_PBC_AIH_Tacrolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PBC_AIH_Everolimus;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
us;190;R_PBC_AIH_Everolimus_primary_indication;(PBC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_Brushing_biopsy;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);Brushing/biopsy;radio
us;190;R_PSC_IBD_status;(PSC Diagnosis) Liver histology / staging;Rare Liver (Auto imune);IBD Status;radio
us;190;R_PSC_Ustekinumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Ustekinumab;radio
us;190;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_AIH_Tacrolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_PSC_AIH_Tacrolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_AIH_Everolimus;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Everolimus;radio
us;190;R_PSC_AIH_Everolimus_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_Pruritus;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Pruritus;radio
us;190;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
us;190;R_AIH_Tacrolimus_change_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_AIH_Tacrolimus_change_reason_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Reason for change;radio
us;190;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
us;190;R_AIH_Tacrolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_AIH_Tacrolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_Everolimus_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Everolimus;radio
us;190;R_AIH_Everolimus_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
us;190;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_IBD_status_followup;PSC Follow-up Cancer surveillance;Rare Liver (Auto imune);IBD Status;radio
us;190;R_PSC_Pruritus_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
us;190;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
us;190;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_Brushing_biopsy_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
us;190;R_PSC_AIH_Tacrolimus_change_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_PSC_AIH_Tacrolimus_change_reason_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
us;190;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
us;190;R_PSC_AIH_Tacrolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_PSC_AIH_Tacrolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PSC_AIH_Everolimus_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
us;190;R_PSC_AIH_Everolimus_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_Tacrolimus_change_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_AIH_Tacrolimus_change_reason_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
us;190;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
us;190;R_AIH_Tacrolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_AIH_Tacrolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_Everolimus_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
us;190;R_AIH_Everolimus_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
us;190;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_AIH_PSC_Brushing_biopsy_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Brushing/Biopsy;radio
us;190;R_PBC_Pruritus_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Pruritus;radio
us;190;R_PBC_AIH_Tacrolimus_change_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_PBC_AIH_Tacrolimus_change_reason_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Reason for change;radio
us;190;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
us;190;R_PBC_AIH_Tacrolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Tacrolimus;radio
us;190;R_PBC_AIH_Tacrolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;R_PBC_AIH_Everolimus_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Everolimus;radio
us;190;R_PBC_AIH_Everolimus_primary_indication_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
us;190;abnormal_perfusion_pattern;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI);radio
us;190;pv_occlusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion;radio
us;190;pv_occlusion_type;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Portal vein occlusion type;radio
us;190;pleural_effusion;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Pleural effusion;radio
us;190;imaging_number_conclusive;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Number of conclusive abdominal imaging performed;radio
us;190;use_anticoagulants;Diagnosis Biobank;Rare Liver (Vascular);Use of anticoagulants;dropdown
us;190;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
us;190;use_antiplatlet;Diagnosis Biobank;Rare Liver (Vascular);Use antiplatelet;dropdown
us;190;lupus_anticoag;Diagnosis Aetiology;Rare Liver (Vascular);Lupus anticoagulant antibody;radio
us;190;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
us;190;eos_death_cause;End of study End of study;Rare Liver (Vascular);Cause of death;radio
us;190;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
us;190;tips_previous_f_u_period;Follow-up Events;Rare Liver (Vascular);Was a TIPS inserted during the previous FU period;radio
us;190;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
us;190;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
us;190;"b.	Previous therapy:";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
us;190;"d.	Number of previous kidney transplants received: 	";" 1.	Transplantation characteristics:";Eurogen (Kid Transplantation);;[Radio button, one selection]
us;190;"a.	CMV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
us;190;"b.	EBV serological status donor:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
us;190;"c.	CMV serological status recipient:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
us;190;"d.	EBV serological status recipient:	";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
us;190;Inclusion criteria;benignNeoplasm;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
us;190;Inclusion criteria;malignancy;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
us;190;ER receptor status;malignancy;Genturis;What is the Estrogen receptor status of the breast cancer?;categorical
us;190;PR receptor status;malignancy;Genturis;What is the Progesteron receptor status of the breast cancer?;categorical
us;190;Her2Neu receptor status;malignancy;Genturis;What is the Her2Neu receptor status of the breast cancer?;categorical
us;190;MMR IHC status;malignancy;Genturis;What are the results of the IHC of the MMR proteins?;enum
us;190;MMR MSA status;malignancy;Genturis;What are the results of the MSA of the tumour DNA?;enum
us;190;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
us;190;Somatic biallelic MMR mutation status;malignancy;Genturis;What are the results of the somatic MMR mutation analysis?;enum
us;190;Inclusion criteria;subject;Genturis;Which criteria does the patient fullfill to be included in the registry?;categorical
us;190;Follow-up status;subject;Genturis;What is the patient's follow-up status?;categorical
us;190;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
us;190;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
us;190;Proband status;subject;Genturis;Is this a proband patient or relative?;enum
us;190;Malignancy status;subject;Genturis;Has this patient ever had a (invasive or in situ) malignancy?;enum
us;190;Benign status;subject;Genturis;Has this patient ever had a benign neoplasm/tumour?;enum
us;190;Phenotypical characteristics status;subject;Genturis;Has the patient phenotypical characteristics?;enum
us;190;Variant status;subject;Genturis;Has any class 3, 4 of 5 variant been found?;enum
us;190;Locus Type (categorical);;ithaca;Hugo.owl.Locus_Type;categorical
us;190;Gene Locus;;ithaca;;string
us;190;Consent for usage of biobank material;;ithaca;;bool
us;190;Retractation for biobank use;;ithaca;;bool
us;190;Retractation for reuse;;ithaca;;bool
us;190;Patient StatusÂ ;;ithaca;;compound
us;190;Patient's Status;;ithaca;;categorical
us;190;Is this a repeat of a previous panel for the same patient at another age ?;;ithaca;;bool
us;190;Functional Status and or Disability;;ithaca;;mref
us;190;Status of diagnosis;;ithaca;;categorical
us;190;Other status of diagnosis;;ithaca;;text
us;190;marital_status;patient_management_at_the_hospital;EURACAN;Marital status;1, Married | 2, Not married | 3, Divorced | 4, Widowed/Widower | 5, Single
us;190;smoking_status;patient_management_at_the_hospital;EURACAN;Smoking;1, Current tobacco smoker | 2, Former smoker | 3, Never smoker | 4, Unknown
us;190;previous_cancer_history;previous_cancer_genetic_syndromes;EURACAN;Previous cancer;1, Yes | 2, No | 9, Unknown
us;190;site_squamous;primary_cancer;EURACAN;Squamous subtype;1, Keratinizing squamous cell carcinoma | 8071/3 | 2, Non-keratinizing squamous cell carcinoma | 8072/3 | 3, Spindle cell (sarcomatoid) squamous cell carcinoma | 8074/3 | 4, Lymphoepithelial carcinoma | 8082/3 | 5, Basaloid squamous cell carcinoma | 8083/3 | 6, Conventional squamous cell carcinoma | 8070/3 | 7, Verrucous squamous cell carcinoma | 8051/3 | 8, Papillary squamous cell carcinoma | 8052/3 | 9, Squamous cell carcinoma, HPV-positive | 8085/3 | 10, Squamous cell carcinoma, HPV-negative | 8086/3
us;190;site_squamous_smarcb1;primary_cancer;EURACAN;Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma;1, Yes | 2, No
us;190;hpv_status;primary_cancer;EURACAN;HPV status;1, Positive | 2, Negative | 3, Not tested | 9, Unknown
us;190;hpv_status_type;primary_cancer;EURACAN;HPV status detected by;1, FISH | 2, PCR | 9, Unknown
us;190;us_primary;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
us;190;us_neck;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
us;190;us_meta;stage_procedures;EURACAN;US;1, Yes | 2, No | 9, Unknown
us;190;fu_status;clinical_update;EURACAN;Status at last clinical update;1, Alive, No Evidence of Disease (NED) | 2, Alive, With Disease (AWD) | 3, Dead of Disease (DOD) | 4, Dead of Other Cause (DOC) | 5, Dead of Unknown Cause (DUC) | 6, Unknown status | 7, Patients lost to follow-up | 8, New cancer diagnosis
us;190;end_treatment_us;imaging_available;EURACAN;US;1, Baseline | 2, After treatment
us;190;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
us;190;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
us;190;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
us;190;Previous malignancy;Patient's history;PaedCan;Did the patient suffer from any malignancy before?;yes/no/unknown
us;190;Date of diagnosis of previous malignancy;Patient's history;PaedCan;Date of diagnosis of previous malignancy;dd/mm/yyyy or uk/uk/yyyy
us;190;Treatment of previous malignancy;Patient's history;PaedCan;;yes/no/unknown
us;190;Inclusion in a national or international treatment trial/protocol;Care pathway;PaedCan;Possible inclusion in a trial or protocol for treatment;yes/no/unknown
us;190;if yes specify the drugs used;Chemotherapy;PaedCan;;String
us;190;Disease status at the end of treatment;End of treatment;PaedCan;;Complete Remission/Presence of disease/Progressive disease/not evaluable
us;190;Patient's status at last follow up;Follow up (one form for each follow up visit);PaedCan;Patient alive or dead;alive/dead/lost to follow up/opted out/unknown
us;190;Disease status;Follow up (one form for each follow up visit);PaedCan;If the patient is alive reports the status of the disease;on treatment/ in 1st complete remission/in 2nd complete remission/alive in 3rd or more complete remission/ alive with disease/unknown
us;190;Cause of death;Follow up (one form for each follow up visit);PaedCan;if the patient is dead specfiy the cause of death;Dead of disease/dead for toxicity/dead for a second tumor/dead for other reason
us;190;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
us;190;Patient's follow up status;Patient Status;EuRR-Bone & EuRRECa;Current follow up;patient active/patient inactive/patient care suspended/patient care terminated/deceased/uk
us;190;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
us;190;T4 status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum free T4 for local reference range;N/Low/High/Not Known
us;190;T3 Status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Total T3 for local reference range;N/Low/High/Not Known
us;190;TSH status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum TSH for local reference range;N/Low/High/Not Known
us;190;Tg status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Tg (on thyroxin treatment) either TSH-suppressed < 0,2 ng/ml or TSH-stimulated < 1 ng/ml;Below/Above
us;190;Calcitonin status;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Serum Ct < 150 pg/ml;Below/Above
us;190;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour;
us;190;ACTH-independent Cushing syndrome;ADRENAL;EuRR-Bone & EuRRECa;ACTH-independent Cushing syndrome;
us;190;Diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus;
us;190;Diabetes mellitus type 1;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 1;
us;190;Diabetes mellitus type 2;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diabetes mellitus type 2;
us;190;Other diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Other diabetes mellitus;
us;190;Genetic diabetes mellitus;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Genetic diabetes mellitus;
us;190;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
us;190;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
us;190;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome;
us;190;Carney complex-trismus-pseudocamptodactyly syndrome;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Carney complex-trismus-pseudocamptodactyly syndrome;
us;190;Silver-Russell Syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell Syndrome;
us;190;Silver-Russell syndrome due to 11p15 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 11p15 microduplication;
us;190;Silver-Russell syndrome due to 7p11.2p13 microduplication;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to 7p11.2p13 microduplication;
us;190;Silver-Russell syndrome due to a point mutation;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to a point mutation;
us;190;Silver-Russell syndrome due to an imprinting defect of 11p15;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to an imprinting defect of 11p15;
us;190;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11;
us;190;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7;
us;190;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome;
us;190;Hydrocephalus-obesity-hypogonadism syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Hydrocephalus-obesity-hypogonadism syndrome;
us;190;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome;
us;190;Cushing disease;PITUITARY;EuRR-Bone & EuRRECa;Cushing disease;
us;190;Fibrous dysplasia of bone (incl MAS);BONE DYSPLASIA;EuRR-Bone & EuRRECa;Fibrous dysplasia of bone (incl MAS);
us;190;Polyostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Polyostotic fibrous dysplasia ;
us;190;Monostotic fibrous dysplasia ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Monostotic fibrous dysplasia ;
us;190;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Colobomatous microphthalmia-rhizomelic dysplasia syndrome ;
us;190;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome ;
us;190;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Primary bone dysplasia with progressive ossification of the skin, muscle and tendons ;
us;190; Progressive osseous heteroplasia (POH);BONE DYSPLASIA;EuRR-Bone & EuRRECa; Progressive osseous heteroplasia (POH);
us;190;Was a causative gene abnormality identified?;Genetic diagnosis;ERKNet;Â ;gen_diagnosis
use;18;Cause_of_death;Base information;Rare Liver (Auto imune);Cause of death;radio
use;18;Other_cause_of_death;Base information;Rare Liver (Auto imune);Cause;string
use;18;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
use;18;use_anticoagulants;Diagnosis Biobank;Rare Liver (Vascular);Use of anticoagulants;dropdown
use;18;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
use;18;use_antiplatlet;Diagnosis Biobank;Rare Liver (Vascular);Use antiplatelet;dropdown
use;18;eos_death_cause;End of study End of study;Rare Liver (Vascular);Cause of death;radio
use;18;eos_death_death_cause_other;End of study End of study;Rare Liver (Vascular);Other cause:;string
use;18;Consent for re-use of data;subject;Genturis;Has the patient signed informed consent for re-use of data for (other) research purposes?;enum
use;18;Consent for use of residual biomaterial;subject;Genturis;Has the patient signed informed consent for research using residual tissue?;enum
use;18;Retractation for biobank use;;ithaca;;bool
use;18;Retractation for reuse;;ithaca;;bool
use;18;To reuse data for research;Informed consent;PaedCan;Definition whether consent for reuse of patient's data for research was obtained;yes/no
use;18;if yes specify the drugs used;Chemotherapy;PaedCan;;String
use;18;Cause of death;Follow up (one form for each follow up visit);PaedCan;if the patient is dead specfiy the cause of death;Dead of disease/dead for toxicity/dead for a second tumor/dead for other reason
use;18;Primary Cause Of Death;Patient Status;EuRR-Bone & EuRRECa;Main cause of death;dropdown
use;18;Diazoxide-sensitive diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-sensitive diffuse hyperinsulinism;
use;18;Diazoxide-resistant diffuse hyperinsulinism;GLUCOSE & INSULIN;EuRR-Bone & EuRRECa;Diazoxide-resistant diffuse hyperinsulinism;
used;3;Drugs used and stopped during past 12 months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);remark;
used;3;other_anticoagulants_used;Diagnosis Biobank;Rare Liver (Vascular);Other anticoagulants used;string
used;3;if yes specify the drugs used;Chemotherapy;PaedCan;;String
ustekinumab;8;R_PSC_Ustekinumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Ustekinumab;radio
ustekinumab;8;R_PSC_Ustekinumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
ustekinumab;8;R_AIH_PSC_Ustekinumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Ustekinumab;radio
ustekinumab;8;R_AIH_PSC_Ustekinumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
ustekinumab;8;R_PSC_Ustekinumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
ustekinumab;8;R_PSC_Ustekinumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
ustekinumab;8;R_AIH_PSC_Ustekinumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Ustekinumab;radio
ustekinumab;8;R_AIH_PSC_Ustekinumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
usual;3;Country of usual residence;Personal Information;PaedCan;Country where patient lives most of his/her time;String
usual;3;Did the patient move from his usual place of residence to another country to receive treatment?;Personal Information;PaedCan;Any migration for health reasons;yes/no/unknown
usual;3;Country of usual residence;Personal Information;EuRR-Bone & EuRRECa;Country of residence at first presentation of condition;drop down/select
v600e;1;MLH1 promoter hypermethylation or tumour BRAF V600E status;malignancy;Genturis;Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?;enum
v617f;1;jak_2_mutation_v617f;Diagnosis Aetiology;Rare Liver (Vascular);JAK 2 Mutation (V617F);radio
valid;2;b_fibroscan_valid_measures;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
valid;2;fu_ima_last_fibro_valid_measures;Follow-up Imaging data;Rare Liver (Vascular);Fibroscan: Number of valid measurements;numeric
value;80;R_AIH_SLA_LP_value;(AIH Diagnosis) Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
value;80;R_AIH_SLA_LP_value_followup;AIH Follow-up Autoantibodies;Rare Liver (Auto imune);SLA/LP (ELISA);numeric
value;80;epo_value;Diagnosis Aetiology;Rare Liver (Vascular);EPO Value;numeric
value;80;dia_lab_antinuclear_antibodies_value;Diagnosis Laboratory data;Rare Liver (Vascular);Antinuclear antibodies value;numeric
value;80;dia_lab_alt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);ALT normal value;numeric
value;80;dia_lab_ast_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);AST normal value;numeric
value;80;dia_lab_alk_phosphat_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
value;80;dia_lab_ggt_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);GGT normal value;numeric
value;80;dia_lab_serum_albumin_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
value;80;dia_lab_serum_gamma_globulins_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum gamma-globulins normal value;numeric
value;80;dia_lab_serum_bilirubin_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
value;80;dia_lab_serum_bilirubin_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum bilirubin;numeric
value;80;dia_lab_serum_creatinine_value_mymol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
value;80;dia_lab_serum_creatinine_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Serum creatinine;numeric
value;80;dia_lab_sodium_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
value;80;dia_lab_fasting_glucose_value_mmol_l;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
value;80;dia_lab_fasting_glucose_value_mg_dl;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum glucose value;numeric
value;80;dia_lab_fasting_tg_value;Diagnosis Laboratory data;Rare Liver (Vascular);Fasting serum triglycerides value;numeric
value;80;dia_lab_alfa_foetoprotein_normal_value;Diagnosis Laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
value;80;fu_cli_bef_enceph_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Encephalopathy value;radio
value;80;fu_cli_bef_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
value;80;fu_cli_bef_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
value;80;fu_cli_bef_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
value;80;fu_cli_bef_platelet_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Platelet count value;numeric
value;80;fu_cli_bef_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
value;80;fu_cli_bef_pt_normal_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
value;80;fu_cli_bef_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
value;80;fu_cli_bef_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
value;80;fu_cli_bef_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
value;80;fu_cli_bef_pt_quick_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
value;80;fu_cli_bef_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
value;80;fu_cli_bef_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
value;80;fu_cli_bef_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
value;80;fu_cli_bef_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
value;80;fu_cli_bef_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
value;80;fu_cli_bef_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
value;80;fu_cli_bef_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
value;80;fu_cli_bef_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
value;80;fu_cli_bef_bilirubin_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
value;80;fu_cli_bef_bilirubin_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
value;80;fu_cli_bef_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
value;80;fu_cli_bef_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
value;80;fu_cli_bef_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
value;80;fu_cli_bef_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
value;80;fu_cli_bef_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
value;80;fu_cli_bef_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
value;80;fu_cli_bef_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
value;80;fu_cli_last_hb_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haemoglobin value;numeric
value;80;fu_cli_last_hto_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Haematocrit value;numeric
value;80;fu_cli_last_leuco_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Leukocytes value;numeric
value;80;fu_cli_last_pt_sec_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
value;80;fu_cli_last_pt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
value;80;fu_cli_last_pt_inr_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
value;80;fu_cli_last_pt_inr_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
value;80;fu_cli_last_pt_quick_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time value;numeric
value;80;fu_cli_last_pt_quic_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Prothrombin time normal value;numeric
value;80;fu_cli_last_alt_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT value;numeric
value;80;fu_cli_last_alt_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);ALT normal value;numeric
value;80;fu_cli_last_ast_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST value;numeric
value;80;fu_cli_last_ast_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);AST normal value;numeric
value;80;fu_cli_last_alkphos_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase value;numeric
value;80;fu_cli_last_alkphos_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Alkaline phosphatase normal value;numeric
value;80;fu_cli_last_albumin_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin value;numeric
value;80;fu_cli_last_albumin_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum albumin normal value;numeric
value;80;fu_cli_last_bilirub_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
value;80;fu_cli_last_bilirub_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum bilirubin value;numeric
value;80;fu_cli_last_factor_v_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Factor V value;numeric
value;80;fu_cli_last_creat_value_mymol_l;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
value;80;fu_cli_last_creat_value_mg_dl;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum creatinine value;numeric
value;80;fu_cli_last_sodium_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum sodium value;numeric
value;80;fu_cli_last_crp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);CRP;numeric
value;80;fu_cli_last_alfafp_value;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein value;numeric
value;80;fu_cli_last_alfafp_nvalue;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Serum alfa foetoprotein normal value;numeric
value;80;fu_ima_bef_fibroscan_value;Follow-up Imaging data;Rare Liver (Vascular);value;numeric
value;80;fu_ima_bef_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
value;80;fu_ima_last_fibro_value;Follow-up Imaging data;Rare Liver (Vascular);Liver fibroscan;numeric
value;80;fu_ima_last_iqr_value;Follow-up Imaging data;Rare Liver (Vascular);IQR;numeric
value;80;c. Lowest creatinine value (Âµmol/l):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
value;80;Value (English);Anatomical Therapeutic Chemical Classification;ithaca;;string
value;80;Value (English);ICD-10: International Classification of Diseases and Related Health Problems;ithaca;;string
variant;14;geneticVariantLabel;geneticVariant;Genturis;;string
variant;14;Variant at genomic reference sequence;geneticVariant;Genturis;What is the g. notation? (HGVS nomenclature);string
variant;14;Variant at coding DNA reference sequence;geneticVariant;Genturis;What is the coding DNA notation? (HGVS nomenclature);string
variant;14;Variant type;geneticVariant;Genturis;What is the type of mutation?;xref
variant;14;Zygosity of variant;geneticVariant;Genturis;What is the zygosity of the germline variant?;enum
variant;14;Variant classification;geneticVariant;Genturis;What is the class of the variant?;xref
variant;14;Variant status;subject;Genturis;Has any class 3, 4 of 5 variant been found?;enum
variant;14;Genetic variants;subject;Genturis;Genetic variants;mref
variant;14;Allelic variant of (link to other OMIM code);;ithaca;;xref
variant;14;Link to variant;;ithaca;;mref
variant;14;Link to Genomic variant;;ithaca;;mref
variant;14;Nucleotide variant description;;ithaca;;text
variant;14;Protein variant description;;ithaca;;text
variant;14;Class of variant;;ithaca;Clinical interperation for variant;mref
variants;1;Genetic variants;subject;Genturis;Genetic variants;mref
variceal;11;R_AIH_Variceal_bleeding_diagnosis;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_PBC_Variceal_diagnosis;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_PSC_Variceal_bleeding;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_AIH_Variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_AIH_Date_variceal_bleeding_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Date of variceal bleeding;date
variceal;11;R_PSC_Variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_PSC_Date_variceal_bleeding_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
variceal;11;R_AIH_Variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_AIH_Date_variceal_bleeding_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of variceal bleeding;date
variceal;11;R_PBC_Variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Variceal bleeding;radio
variceal;11;R_PBC_Date_of_variceal_bleeding_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date variceal bleeding;date
varices;14;R_AIH_Esophageal_or_gastric_varices;(AIH Diagnosis) Liver related complications;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_PBC_Esophageal_or_gastric_varices;(PBC Diagnosis) Liver-related complications / signs of cirrhosis;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_PSC_Esophageal_gastric_varices;(PSC Diagnosis) Malignancies / Liver-related outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_AIH_Esophageal_or_gastric_varices_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_PSC_Esophageal_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_PSC_Date_esophageal_or_gastric_varices_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
varices;14;R_AIH_Esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_AIH_Date_esophageal_or_gastric_varices_followup;AIH Follow-up Outcome II;Rare Liver (Auto imune);Date of esophageal or gastric varices;date
varices;14;R_PBC_Esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Esophageal or gastric varices;radio
varices;14;R_PBC_Date_of_esophageal_or_gastric_varices_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Date esophageal or gastric varices;date
varices;14;esophageal_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophageal varices;radio
varices;14;esophageal_varices_grade;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Grade;radio
varices;14;esoph_varices_red_signs;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Esophagel varices red color signs;radio
varices;14;gastric_varices;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Gastric varices;radio
vasc;2;vasc_oth;Diagnosis General Information;Rare Liver (Vascular);Specify Other Vascular Disease;string
vasc;2;sys_vasculitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Vasculitis;radio
vasculitis;1;sys_vasculitis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Vasculitis;radio
vci;1;infrahep_vci;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Infrahepatic IVC;numeric
vcug;2;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
vcug;2;d. AgeÂ first VCUG performedÂ (in days):;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
vedolizumab;8;R_PSC_Vedolizumab;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Vedolizumab;radio
vedolizumab;8;R_PSC_Vedolizumab_primary_indication;(PSC Diagnosis) Treatment within 12 weeks after diagnosis;Rare Liver (Auto imune);Primary indication;radio
vedolizumab;8;R_AIH_PSC_Vedolizumab_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Vedolizumab;radio
vedolizumab;8;R_AIH_PSC_Vedolizumab_primary_indication_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Primary indication;radio
vedolizumab;8;R_PSC_Vedolizumab_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
vedolizumab;8;R_PSC_Vedolizumab_primary_indication_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
vedolizumab;8;R_AIH_PSC_Vedolizumab_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Vedolizumab;radio
vedolizumab;8;R_AIH_PSC_Vedolizumab_primary_indication_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Primary indication;radio
vein;7;portal_vein_thromb;Diagnosis General Information;Rare Liver (Vascular);For Portal vein thrombosis;radio
vein;7;right_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Right portal vein branch;radio
vein;7;left_portal_vein_branch;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Left portal vein branch;radio
vein;7;splenic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Splenic vein;radio
vein;7;superior_mesenteric_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Superior mesenteric vein;radio
vein;7;hepatic_vein_catheter;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic Vein Catheterization;radio
vein;7;wedged_hepatic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged hepatic vein;numeric
ven;27;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
ven;27;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
ven;27;non-invasive ventilation;Respiratory Myasthenic crisis;EURO-NMD;;single
ven;27;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
ven;27;biopsie_proven_cirrhosis;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Biopsie proven cirrhosis;radio
ven;27;hepatic_venography;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venography;radio
ven;27;abdominal_intervention;Diagnosis Aetiology;Rare Liver (Vascular);Abdominal intervention;radio
ven;27;abd_intervention_date;Diagnosis Aetiology;Rare Liver (Vascular);Date of procedure;date
ven;27;abd_intervention_type;Diagnosis Aetiology;Rare Liver (Vascular);Type;textarea
ven;27;mesenterico_portal_ven_sys;Diagnosis Aetiology;Rare Liver (Vascular);Mesenterico-portal venous system;radio
ven;27;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
ven;27;history_throm_events_relat;Diagnosis Aetiology;Rare Liver (Vascular);History of thrombotic events in relatives;radio
ven;27;fu_thrombotic_event;Follow-up Complications;Rare Liver (Vascular);Thrombotic event;radio
ven;27;d. AdditionalÂ interventions:Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
ven;27;"j.	Culture-proven urinary tract infection with fever during follow-up:";"5.	Infections:";Eurogen (Kid Transplantation);;[Radio button, one selection]
ven;27;"a.	Biopsy proven rejection during follow-up	:";"6.	Rejection";Eurogen (Kid Transplantation);;[Radio button, one selection]
ven;27;Primary tumor local invasiveness (T);Tumor's characteristics;PaedCan;Local invasiveness according to clinical and radiology assessment (TNM system);T0/T1/T2/Tx
ven;27;Chemotherapy given according to a protocol or guidelines;Chemotherapy;PaedCan;;yes/no/unknown
ven;27;An event has occurred;Events;PaedCan;If any event has occurred ;yes/no/unknown
ven;27;Type of event;Events;PaedCan;Definition of the type of event that has occured;local relapse/local relapse combined with regional nodal relapse/local relapse combined with metastatic relapse/regional nodal relapse/nodal relapse combined with metastatic relapse/metastatic relapse/progressive disease/second tumor/death for toxicity/death for other causes
ven;27;Date of event;Events;PaedCan;Date when the event occurred;dd/mm/yyyy
ven;27;Treatment of the event;Events;PaedCan;Event treated or not;yes,with curative intent/yes,with palliative intent/no/unknown
ven;27;Type of treatment of the event;Events;PaedCan;;surgery/chemotherapy/radiotherapy/other treatment/unknown
ven;27;Please give more details about the treatment of the event;Events;PaedCan;;String
ven;27;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Noonan syndrome-like disorder with juvenile myelomonocytic leukemia;
ven;27;Juvenile Paget disease ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Juvenile Paget disease ;
ven;27;Idiopathic juvenile osteoporosis;BONE DYSPLASIA;EuRR-Bone & EuRRECa;Idiopathic juvenile osteoporosis;
venography;1;hepatic_venography;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Hepatic venography;radio
venous;1;venous_thrombosis_else;Diagnosis Aetiology;Rare Liver (Vascular);Venous thrombosis elsewhere;radio
ventilated;1;hours ventilated per 24-hr period;Respiratory Myasthenic crisis;EURO-NMD;;int
ventilation;3;Respiratory failure requiring assisted ventilation;Diagnosis Respiratory;EURO-NMD;Assisted ventilation required;yesno
ventilation;3;Assisted ventilation required;Respiratory Myasthenic crisis;EURO-NMD;;yesno
ventilation;3;non-invasive ventilation;Respiratory Myasthenic crisis;EURO-NMD;;single
vesicostomy;1;"vesicostomy 	Age (in days)	";2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);[Control];[NumericÂ (Integer)]
vesicoureteral;1;e. Vesicoureteral reflux:;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
vestibular;2;Number of vestibular schwannoma;benignNeoplasm;Genturis;What is the maximal number of vestibular schwannomas ever observed in this patient?;int
vestibular;2;Vestibular schwannoma laterality;benignNeoplasm;Genturis;What is the laterality of the vestibular schwannoma(s)?;enum
vii;2;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
vii;2;dia_lab_factor_vii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VII;numeric
viii;1;dia_lab_factor_viii;Diagnosis Laboratory data;Rare Liver (Vascular);Factor VIII;numeric
vis;10;Age at visit;Diagnosis Personal Information;EURO-NMD;Calculated age based on Date of Birth and Date of Visit;calculated
vis;10;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
vis;10;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
vis;10;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
vis;10;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
vis;10;vis_dt;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Date of visit;date
vis;10;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
vis;10;date_of_revision;Follow-up Events;Rare Liver (Vascular);Date of revision;date
vis;10;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
vis;10;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
vision;4;Double vision (lateral gaze) Sec.;QMG;EURO-NMD;;
vision;4;revision_tips_angioplasty;Follow-up Events;Rare Liver (Vascular);Revision of TIPS or angioplasty;radio
vision;4;date_of_revision;Follow-up Events;Rare Liver (Vascular);Date of revision;date
vision;4;Revision of record (authors);Audit History;EuRR-Bone & EuRRECa;For audit trail;dd/mm/yyyy
visit;5;Age at visit;Diagnosis Personal Information;EURO-NMD;Calculated age based on Date of Birth and Date of Visit;calculated
visit;5;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
visit;5;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
visit;5;Add Follow-up Visit;(AIH Follow-up (12 months/annual +/- 3 months)) Follow-up Visit;Rare Liver (Auto imune);add_report_button;
visit;5;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
vital;1;Vital capacity:;QMG;EURO-NMD;;
vitamin;3;vitamin_deficiency_excl;Diagnosis Aetiology;Rare Liver (Vascular);Vitamin deficiency/ folic acid excluded;radio
vitamin;3;Hypocalcaemic vitamin D-dependent rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-dependent rickets;
vitamin;3;Hypocalcaemic vitamin D-resistant rickets;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Hypocalcaemic vitamin D-resistant rickets;
voiding;1;c. Voiding Cystourethrogram (VCUG) performed: ;3. VisualisationÂ study of kidneys and bladder:Â ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
volume;2;fu_cli_bef_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
volume;2;fu_cli_last_ascites_volume;Follow-up Clinical and laboratory data;Rare Liver (Vascular);Ascites volume;radio
von;1;Von Hippel-Lindau disease;GENETIC ENDOCRINE TUMOURS;EuRR-Bone & EuRRECa;Von Hippel-Lindau disease;
vrt;1;Referral to VRT board (national or international) ;Care pathway;PaedCan;The case has been discussed within an official national or international VRT board for diagnosis and/or treatment;no/yes in the EXPERT Virtual consultation system/ yes in another tumor board
vur;3;"b. Age at first MCG VUR (in days):		";4. MCG VUR: ;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
vur;3;c. VUR present left during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
vur;3;d. VUR present right during first MCG VUR:  ;4. MCG VUR: ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
wagr;1;WAGR syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;WAGR syndrome;
waist;1;waist_size;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Waist size;numeric
water;1;Swallowing 4oz water (1/2 cup);QMG;EURO-NMD;;
weakness;10;Weakness of facial musculature;Diagnosis Muscular;EURO-NMD;Facial weakness;yesno
weakness;10;Fatigable weakness of bulbar muscles;Diagnosis Muscular;EURO-NMD;Bulbar weakness;yesno
weakness;10;Respiratory insufficiency due to muscle weakness;Diagnosis Muscular;EURO-NMD;Respiratory weakness;yesno
weakness;10;Limb muscle weakness location;Diagnosis Muscular;EURO-NMD;;single
weakness;10;Limb muscle weakness arms/legs;Diagnosis Muscular;EURO-NMD;;single
weakness;10;Limb muscle weakness severity;Diagnosis Muscular;EURO-NMD;;single
weakness;10;Limb muscle weakness fatigable;Diagnosis Muscular;EURO-NMD;;yesno
weakness;10;Limb muscle weakness fluctuacting;Diagnosis Muscular;EURO-NMD;;yesno
weakness;10;Limb muscle weakness age of onset;Diagnosis Muscular;EURO-NMD;;date
weakness;10;Neck muscle weakness;Diagnosis Muscular;EURO-NMD;Neck weakness;yesno
weaver;1;Weaver syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Weaver syndrome;
wedged;2;wedged_hepatic_vein;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged hepatic vein;numeric
wedged;2;wedged_pulm_art_press;Diagnosis Imaging / Haemodynamics / Fibroscan;Rare Liver (Vascular);Wedged pulmonary artery pressure;numeric
week;1;alcohol_grams_per_week;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Average grams of ethanol per week;radio
weight;14;Weight;Diagnosis General;EURO-NMD;;float
weight;14;R_AIH_Weight;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
weight;14;R_PBC_Weight;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
weight;14;R_PSC_Weight;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Weight;numeric
weight;14;R_AIH_Weight_6months;(AIH 6 months follow-up (+/- 6 weeks))Outcome / Follow-up during past 6 months;Rare Liver (Auto imune);Weight;numeric
weight;14;R_PSC_Weight_followup;PSC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
weight;14;R_AIH_Weight_followup;AIH Follow-up Outcome I;Rare Liver (Auto imune);Weight;numeric
weight;14;R_PBC_Weight_followup;PBC Follow-up Outcome;Rare Liver (Auto imune);Weight;numeric
weight;14;Weight;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Weight;numeric
weight;14;weight_w_o_ascites_oedema;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Estimated weight without ascites and oedema;numeric
weight;14;weight;patient_management_at_the_hospital;EURACAN;Weight (kg);
weight;14;Weight;Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Weight SDS to one decimal point;Not Known/number
weight;14;Weight (kg);Thyroid Clinical Outcome;EuRR-Bone & EuRRECa;Weight in kg;Not Known/number to one decimal point
weight;14;Weight;Clinical Status;ERKNet;Â ;weight
wenn;1;Age at menarche (only wenn premenarcheal in last visit);Clinical Status;ERKNet;Â ;"YYYY-MM;
premenarcheal"
when;2;b. Age when lowest creatinine was measured (in days):;5. Lowest creatinine;Eurogen (Posterior urethral valves);;[NumericÂ (Integer)]
when;2;Age when panel opened;;ithaca;;string
which;4;Specify which malignancy;Patient's history;PaedCan;Description of any previous malignancy;ICCC3
which;4;Specify which concomitant disease;Patient's history;PaedCan;Description of relevant concomitant disease;String
which;4;Specify which syndrome;Patient's history;PaedCan;Definition of the syndrome affecting the patient;String
which;4;Specify which trial or protocol;Care pathway;PaedCan;Definition of possible trial/protocol in which the patient was enrolled;String
who;2;If thymoma, WHO Classification:;Thymoma;EURO-NMD;;
who;2;WHODAS 2.0 Score (%);;ithaca;;int
wilson-turner;1;Wilson-Turner syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Wilson-Turner syndrome;
winging;1;Scapular winging;Diagnosis Skeletal;EURO-NMD;;yesno
withdrawal;28;R_AIH_Azathioprine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Prednisolone_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Budesonide_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Mercaptopurine_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Tacrolimus_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_MMF_withdrawal_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);MMF;radio
withdrawal;28;R_AIH_MMF_withdrawal_date_6months;(AIH 6 months follow-up (+/- 6 weeks)) Treatment at 6 months;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PSC_AIH_Azathioprine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PSC_AIH_Prednisolone_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PSC_AIH_Budesonide_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PSC_AIH_Mercaptopurine_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PSC_AIH_Tacrolimus_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PSC_AIH_MMF_withdrawal_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
withdrawal;28;R_PSC_AIH_MMF_withdrawal_date_followup;PSC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Azathioprine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Prednisolone_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Budesonide_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Mercaptopurine_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_Tacrolimus_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_AIH_MMF_withdrawal_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
withdrawal;28;R_AIH_MMF_withdrawal_date_followup;AIH Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PBC_AIH_Azathioprine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PBC_AIH_Prednisolone_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PBC_AIH_Budesonide_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PBC_AIH_Mercaptopurine_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PBC_AIH_Tacrolimus_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
withdrawal;28;R_PBC_AIH_MMF_withdrawal_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);MMF;radio
withdrawal;28;R_PBC_AIH_MMF_withdrawal_date_followup;PBC Follow-up Treatment;Rare Liver (Auto imune);Date of drug withdrawal;date
within;2;a. Was there aÂ control cystoscopyÂ performed within the first six months:Â Â ;2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Radio button, one selection]
within;2;Contact person within HCP;subject;Genturis;What is the name of the physician in charge of the patient's clinical management within the HCP?;string
without;1;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;Pseudohypoparathyroidism without Albright hereditary osteodystrophy;
woman;1;woman_still_menstruated;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Is she still menstruated?;radio
would;1;Patient would like access to Core registry;Research;EuRR-Bone & EuRRECa;Patient is provided with access to a read-only version of their record;Y/N/NK
x-linked;3;X-linked adrenoleukodystrophy;ADRENAL;EuRR-Bone & EuRRECa;X-linked adrenoleukodystrophy;
x-linked;3;X-linked hypophosphataemia;CALCIUM & PHOSPHATE;EuRR-Bone & EuRRECa;X-linked hypophosphataemia;
x-linked;3;X-linked osteoporosis with fractures ;BONE DYSPLASIA;EuRR-Bone & EuRRECa;X-linked osteoporosis with fractures ;
x-sacrum;2;"c. X-sacrum or US sacrum performed:		";4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
x-sacrum;2;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
x-sacrum/us;1;d. Age first X-sacrum/US Sacrum performed (in days):;4. Evaluation of spine and sacrum: ;Eurogen (Anorectal Malformations);;[Numeric (Integer)]
xq21;1;Xq21 microdeletion syndrome;GROWTH & OBESITY;EuRR-Bone & EuRRECa;Xq21 microdeletion syndrome;
year;16;R_AIH_Year_of_birth;(AIH Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
year;16;R_PBC_Year_of_birth;(PBC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
year;16;R_PSC_Year_of_birth;(PSC Diagnosis) Demographics;Rare Liver (Auto imune);Year of birth;year
year;16;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
year;16;a. Incontinent for feces (age > 4 years): ;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
year;16;Year of birth available?;subject;Genturis;Is the year of birth of the patient known?;enum
year;16;Year of Birth;subject;Genturis;What is patientâ€™s year of birth? (Specify using 4 digits);int
year;16;Year of death available?;subject;Genturis;Is the year of death of the patient known?;enum
year;16;Year of death;subject;Genturis;In what year did the patient die?;int
year;16;Year of lost to follow up available?;subject;Genturis;Is the year of lost to follow up of the patient known?;enum
year;16;Year of lost to follow up;subject;Genturis;In what year was the patient lost to follow up?;int
year;16;Year of opted-out available?;subject;Genturis;Is the year of opted-out of the patient known?;enum
year;16;Year of opted out;subject;Genturis;In what year has the patient opted out or revoked the GENTURIS registry consent?;int
year;16;smoking_years;patient_management_at_the_hospital;EURACAN;Number of years as a smoker;
year;16;smoking_pack_year_calc;patient_management_at_the_hospital;EURACAN;Pack/year;"if ([smoking_habits] = ""1"", ([smoking_per_day]/20)*[smoking_years], ([smoking_per_day]/4)*[smoking_years])"
year;16;smoking_pack_year_man;patient_management_at_the_hospital;EURACAN;Pack/year (manual);
years;3;smoking_number_pack_years;Diagnosis Clinical Manifestations;Rare Liver (Vascular);Number of pack years;numeric
years;3;a. Incontinent for feces (age > 4 years): ;6. Incontinence: ;Eurogen (Anorectal Malformations);;[Radio button, one selection]
years;3;smoking_years;patient_management_at_the_hospital;EURACAN;Number of years as a smoker;
yes,;3;(If yes, answer questionÂ 2e);2ndÂ surgical procedure performed to check for and resect valve remnants:Â ;Eurogen (Posterior urethral valves);;[Tick-box, multiple selection]
yes,;3;I yes, specify the most relevant;Pathology;PaedCan;;String
yes,;3;If yes, specify;Follow up (one form for each follow up visit);PaedCan;;String
yglobulins;7;R_AIH_yGlobulins;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
yglobulins;7;R_PBC_yGlobulins;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
yglobulins;7;R_PSC_yGlobulins;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
yglobulins;7;R_AIH_yGlobulins_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);yGlobulins;numeric
yglobulins;7;R_PSC_yGlobulins_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
yglobulins;7;R_AIH_yGlobulins_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
yglobulins;7;R_PBC_yGlobulins_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGlobulins;numeric
ygt;7;R_AIH_yGT;(AIH Diagnosis) Lab values;Rare Liver (Auto imune);y-GT;numeric
ygt;7;R_PBC_yGT;(PBC Diagnosis) Lab values;Rare Liver (Auto imune);y-GT;numeric
ygt;7;R_PSC_yGT;(PSC Diagnosis) Lab values;Rare Liver (Auto imune);yGT;numeric
ygt;7;R_AIH_yGT_6months;(AIH 6 months follow-up (+/- 6 weeks)) Lab values;Rare Liver (Auto imune);y-GT;numeric
ygt;7;R_PSC_yGT_followup;PSC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
ygt;7;R_AIH_yGT_followup;AIH Follow-up Lab values;Rare Liver (Auto imune);y-GT;numeric
ygt;7;R_PBC_yGT_followup;PBC Follow-up Lab values;Rare Liver (Auto imune);yGT;numeric
ynu;3;genetic_syndrome_ynu;previous_cancer_genetic_syndromes;EURACAN;Genetic syndrome;1, Yes | 2, No | 9, Unknown
ynu;3;prev_pre_canc_lesions_ynu;previous_cancer_genetic_syndromes;EURACAN;Previous pre cancer lesions;1, Yes | 2, No | 9, Unknown
ynu;3;comorbid_ynu;charlson_index;EURACAN;Comorbidity;1, Yes | 2, No | 9, Unknown
yyyy;14;fu_date_yyyy;clinical_update;EURACAN;Year of clinical update;
yyyy;14;ae_start_yyyy;adverse_event;EURACAN;Adverse event starting year;
yyyy;14;ae_end_yyyy;adverse_event;EURACAN;Adverse event ending year;
yyyy;14;ae_start_yyyy_2;adverse_event;EURACAN;Second adverse event starting year;
yyyy;14;ae_end_yyyy_2;adverse_event;EURACAN;Second adverse event ending year;
yyyy;14;ae_start_yyyy_3;adverse_event;EURACAN;Third adverse event starting year;
yyyy;14;ae_end_yyyy_3;adverse_event;EURACAN;Third adverse event ending year;
yyyy;14;ae_start_yyyy_4;adverse_event;EURACAN;Fourth adverse event starting year;
yyyy;14;ae_end_yyyy_4;adverse_event;EURACAN;Fourth adverse event ending year;
yyyy;14;ae_start_yyyy_5;adverse_event;EURACAN;Fifth adverse event starting year;
yyyy;14;ae_end_yyyy_5;adverse_event;EURACAN;Fifth adverse event ending year;
yyyy;14;surgery_date_yyyy;surgery;EURACAN;Year of surgery;
yyyy;14;other_treatment_date_yyyy;other_type_of_treatment;EURACAN;Year of other treatment;
yyyy;14;oth_enrolment_date_yyyy;other_type_of_treatment;EURACAN;Year of enrolment;
zygosity;2;Zygosity of variant;geneticVariant;Genturis;What is the zygosity of the germline variant?;enum
zygosity;2;Diagnosis - Zygosity;Genetic diagnosis;ERKNet;From Wiki: the degree to which both copies of a chromosome or gene have the same genetic sequence.;homozygous, heterozygous, hemizygous